PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MANCINI, JA; RIENDEAU, D; FALGUEYRET, JP; VICKERS, PJ; ONEILL, GP				MANCINI, JA; RIENDEAU, D; FALGUEYRET, JP; VICKERS, PJ; ONEILL, GP			ARGININE-120 OF PROSTAGLANDIN G/H SYNTHASE-1 IS REQUIRED FOR THE INHIBITION BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS CONTAINING A CARBOXYLIC-ACID MOIETY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE; CYCLOOXYGENASE; EXPRESSION; CATALYSIS; CDNA	The therapeutic action of nonsteroidal anti-inflammatory drugs (NSAIDs) is exerted through the inhibition of prostaglandin G/H synthase (PGHS), which is expressed as two isoenzymes, termed PGHS-1 and PGHS-2. From the crystal structure of sheep PGHS-1, it has been proposed that the carboxylic acid group of flurbiprofen is located in a favorable position for interacting with the arginine 120 residue of PGHS-1 (Picot, D., Loll, P. J., and Garavito, R. M. (1994) Nature 367, 243-249). Mutation of this Arg(120) residue to Glu was performed and expressed in COS-7 cells using a vaccinia virus expression system. Comparison of microsomal enzyme preparations show that the mutation results in a 20-fold reduction in the specific activity of PGHS-1 and in a 100-fold increase in the apparent K-m for arachidonic acid. Indomethacin, flurbiprofen, and ketoprofen, inhibitors of PGHS activity containing a free carboxylic acid group, do not exhibit any inhibitory effects against the activity of PGHS-1(Arg(120) --> Glu). Diclofenac and meclofenamic acid, other NSAIDS containing a free carboxylic acid group, were 50-100-fold less potent inhibitors of the activity of the mutant as compared with the wild type PGHS. In contrast, the nonacid PGHS inhibitors, 5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonyl)thiophene (DuP697) and a desbromo-sulfonamide analogue of DuP697 (L-746,483), were both more potent inhibitors of PGHS-1(Arg(120) --> Glu) than of the wild type PGHS-1. Inhibition of PGHS-1(Arg(120) --> Glu) was time-dependent for diclofenac and time-independent for DuP697, as observed for the wild type enzyme, indicating that the mutation does not alter the basic mechanism of inhibition. Aspirin is an acid NSAID that inhibits PGHS-1 through a unique covalent acetylation of the enzyme and also showed a reduced rate of inactivation of the mutated enzyme. These data provide biochemical evidence of the importance of the Arg(120) residue in PGHS-1 for interaction with arachidonic acid and NSAIDs containing a free carboxylic acid moiety			MANCINI, JA (corresponding author), MERCK FROSST CTR THERAPEUT RES, DEPT BIOCHEM & MOLEC BIOL, POB 1005, POINTE CLAIRE, PQ H9R 4P8, CANADA.							CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; ELROYSTEIN O, 1987, CURRENT PROTOCOLS MO; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GARAVITO RM, 1994, CURR OPIN STRUC BIOL, V4, P529, DOI 10.1016/S0959-440X(94)90215-1; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; KARGMAN SL, 1995, CANCER RES, V55, P2556; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LEBLANC Y, 1995, BIOORG MED CHEM LETT, V5, P2123, DOI 10.1016/0960-894X(95)00359-2; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LOLL PJ, 1994, EXPERT OPIN INV DRUG, V3, P1171; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; OTTO JC, 1993, J BIOL CHEM, V268, P18234; OUELLET M, 1995, BIOCHEM J, V306, P247, DOI 10.1042/bj3060247; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REID GK, 1990, J BIOL CHEM, V265, P19818; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; Sambrook J, 1989, MOL CLONING LABORATO; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928	33	124	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29372	29377		10.1074/jbc.270.49.29372	http://dx.doi.org/10.1074/jbc.270.49.29372			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493972	hybrid			2022-12-25	WOS:A1995TJ22700053
J	SU, ZZ; BLAZING, MA; FAN, D; GEORGE, SE				SU, ZZ; BLAZING, MA; FAN, D; GEORGE, SE			THE CALMODULIN-NITRIC OXIDE SYNTHASE INTERACTION - CRITICAL ROLE OF THE CALMODULIN LATCH DOMAIN IN ENZYME ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; CARDIAC TROPONIN-C; BINDING DOMAIN; CALCIUM-BINDING; PEPTIDE COMPLEX; RESOLUTION; RECOGNITION; PROTEINS	The neuronal isoform of nitric oxide synthase (nNOS) requires calmodulin for nitric oxide producing activity, Calmodulin functions as a molecular switch, allowing electron transport from the carboxyl-terminal reductase domain of nitric oxide synthase to its heme-containing amino-terminal domain. Available evidence suggests that calmodulin binds to a site between the two domains of nNOS, but it is not known how calmodulin then executes its snitch function. To study the calmodulin-nNOS interaction, we created a series of chimeras between calmodulin and cardiac troponin C (cTnC, a homologue of calmodulin that does not activate nNOS), Although a few chimeras showed good ability to activate nNOS, most failed to activate. A subset of the inactive chimeras retained the ability to bind to nNOS and therefore functioned as potent competitive inhibitors of nNOS activation by calmodulin (CaM). The observed inhibition was additive with the arginine antagonists N-G-monomethyl-L-arginine and 7-nitroindazole, indicating a distinct and independent mechanism of nNOS inhibition. To localize the calmodulin residues that account for impaired activation in the inhibitory CaM-cTnC chimeras, we conducted a detailed mutagenesis study, replacing CaM subdomains and individual amino acid residues with the corresponding residues from cTnC. This revealed that mutations in CaM helices 2 and 6 (its latch domain) have a disproportionate negative effect on nNOS activation. Thus, our evidence suggests that the CaM latch domain plays a critical role in its molecular switch function.	DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOVASC,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University; Duke University					NHLBI NIH HHS [HL48662] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048662] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRANDT PW, 1994, FEBS LETT, V353, P99, DOI 10.1016/0014-5793(94)01016-1; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KRETSINGER RH, 1992, SCIENCE, V258, P50, DOI 10.1126/science.1439768; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SU ZH, 1994, J BIOL CHEM, V269, P16761; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	32	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29117	29122		10.1074/jbc.270.49.29117	http://dx.doi.org/10.1074/jbc.270.49.29117			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493936				2022-12-25	WOS:A1995TJ22700017
J	ELHAYEK, R; LOKUTA, AJ; AREVALO, C; VALDIVIA, HH				ELHAYEK, R; LOKUTA, AJ; AREVALO, C; VALDIVIA, HH			PEPTIDE PROBE OF RYANODINE RECEPTOR FUNCTION - IMPERATOXIN-A, A PEPTIDE FROM THE VENOM OF THE SCORPION PANDINUS-IMPERATOR, SELECTIVELY ACTIVATES SKELETAL-TYPE RYANODINE RECEPTOR ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM RELEASE CHANNEL; CA-2+ RELEASE; CA2+ RELEASE; CARDIAC-MUSCLE; ADENINE-NUCLEOTIDE; MOLECULAR-CLONING; BINDING; MECHANISM; CAFFEINE	We have used [H-3]ryanodine binding experiments and single channel recordings to provide convergent descriptions of the effect of imperatoxin A (IpTx(a)), a similar to 5-kDa peptide from the venom of the scorpion Pandinus imperator (Valdivia, H. H., Kirby, M. S., Lederer, W. J., and Coronado, R. (1992) Proc. Ntl, Acad. Sc. U.S.A. 89, 12185-12189) on Ca2+ release channels/ryanodine receptors (RyR) of sarcoplasmic reticulum (SR). At nanomolar concentrations, IpTx(a) increased the binding of [H-3]ryanodine to skeletal SR and, to a lesser extent, to cerebellum microsomes. The activating effect of IpTx(a) on skeletal SR was Ca2+-dependent, synergized by caffeine, and independent of other modulators of RyRs. However, IpTx(a) had negligible effects on tissues where the expression of skeletal-type RyR isoforms (RyR1) is small or altogether absent, i.e. cardiac, cerebrum, and liver microsomes. Thus, IpTx(a) may be used as a ligand capable of discriminating between RyR isoforms with nanomolar affinity, IpTx(a) increased the open probability (P-o) of rabbit skeletal muscle RyRs by increasing the frequency of open events and decreasing the duration of the closed lifetimes. This activating effect was dose-dependent (ED(50) = 10 mM), had a fast onset, and was fully reversible, Purified RyR from solubilized skeletal SR displayed high affinity for [H-3]ryanodine with a K-D of 6.1 nM and B-max of similar to 30 pmol/mg of protein. IpTx(a) increased [H-3]ryanodine binding noncompetitively by increasing B-max to similar to 60 pmol/mg of protein. These results suggested the presence of an IpX(a)-binding site on the RyR or a closely associated regulatory protein, This site appears to be distinct from the caffeine- and adenine nucleotide-regulatory sites, IpTx(a) may prove a useful tool to identify regulatory domains critical for channel gating and to dissect the contribution of skeletal-type RyRs to intracellular Ca2+ waveforms generated by stimulation of different RyR isoforms.	UNIV WISCONSIN,SCH MED,DEPT PHYSIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BERS DM, 1991, EXCITATION CONTRACTI; BUCK E, 1992, J BIOL CHEM, V267, P23560; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CHENG HP, 1995, SCIENCE, V267, P2009, DOI 10.1126/science.7701326; CHU A, 1993, J MEMBRANE BIOL, V135, P49; CHU A, 1990, MOL PHARMACOL, V37, P735; CORONADO R, 1994, AM J PHYSIOL, V35, pC1485; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; ELHAYEK R, 1993, BIOPHYS J, V65, P779, DOI 10.1016/S0006-3495(93)81101-9; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FILL M, 1990, BIOPHYS J, V60, P471; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KNOX BE, 1986, P NATL ACAD SCI USA, V83, P2345, DOI 10.1073/pnas.83.8.2345; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAMB GD, 1993, J MUSCLE RES CELL M, V14, P554, DOI 10.1007/BF00141551; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LINDSAY ARG, 1994, J GEN PHYSIOL, V104, P425, DOI 10.1085/jgp.104.3.425; MCGARRY SJ, 1994, J MEMBRANE BIOL, V137, P169; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; OTSU K, 1990, J BIOL CHEM, V265, P13472; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; RARDON DP, 1992, ADV EXP MED BIOL, V311, P405; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SEINO A, 1991, J PHARMACOL EXP THER, V256, P861; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SMITH JS, 1989, J GEN PHYSIOL, V92, P1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; VALDIVIA HH, 1991, J BIOL CHEM, V266, P19135; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; VALDIVIA HH, 1994, J BIOCHEM, V116, P1383, DOI 10.1093/oxfordjournals.jbchem.a124691; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; VALDIVIA HH, 1991, AM J PHYSIOL, V261, pC237, DOI 10.1152/ajpcell.1991.261.2.C237; VALDIVIA HH, 1994, BIOPHYS J, V66, pA418; XU L, 1994, P NATL ACAD SCI USA, V91, P3294, DOI 10.1073/pnas.91.8.3294; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; ZYMANYI I, 1991, J PHARMACOL EXP THER, V256, P938	50	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28696	28704		10.1074/jbc.270.48.28696	http://dx.doi.org/10.1074/jbc.270.48.28696			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499390	hybrid			2022-12-25	WOS:A1995TH05600034
J	JOHNSTON, JA; WANG, LM; HANSON, EP; SUN, XJ; WHITE, MF; OAKES, SA; PIERCE, JH; OSHEA, JJ				JOHNSTON, JA; WANG, LM; HANSON, EP; SUN, XJ; WHITE, MF; OAKES, SA; PIERCE, JH; OSHEA, JJ			INTERLEUKIN-2, INTERLEUKIN-4, INTERLEUKIN-7, AND INTERLEUKIN-15 STIMULATE TYROSINE PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 AND SUBSTRATE-2 IN T-CELLS - POTENTIAL ROLE OF JAK KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IL-2 RECEPTOR; GAMMA-CHAIN	The signaling molecules insulin receptor substrate (IRS)-1 and the newly described IRS-2 (4PS) molecule are major insulin and interleukin 4 (IL-4)-dependent phosphoproteins. We report here that IL-2, IL-7, and IL-15, as well as IL-4, rapidly stimulate the tyrosine phosphorylation of IRS-1 and IRS-2 in human peripheral blood T cells, NK cells, and in lymphoid cell lines. In addition, we show that the Janus kinases, JAK1 and JAK3, associate with IRS-1 and IRS-2 in T cells. Coexpression studies demonstrate that these kinases can tyrosine-phosphorylate IRS-2, suggesting a possible mechanism by which cytokine receptors may induce the tyrosine phosphorylation of IRS-1 and IRS-2. We further demonstrate that the p85 subunit of phosphoinositol 3-kinase associates with IRS-1 in response to IL-2 and IL-4 in T cells. Therefore, these data indicate that IRS-1 and IRS-2 may have important roles in T lymphocyte activation not only in response to IL-4, but also in response to IL-2, IL-7, and IL-15.	NCI,CELL & MOLEC BIOL LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; NIH,HOWARD HUGHES MED INST,RES SCHOLARS PROGRAM,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA	JOHNSTON, JA (corresponding author), NIAMS,ARTHRIT & RHEUMATISM BRANCH,LYMPHOCYTE CELL BIOL SECT,BLDG 10,ROOM 9N262,BETHESDA,MD 20892, USA.		Hanson, Eric/AAE-5511-2022	Hanson, Eric/0000-0002-0318-4779				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AUSUBEL FM, 1992, SHORT PROTOCOLS MOL, P97; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FERRIS DK, 1989, J IMMUNOL, V143, P870; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5282; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MERIDA I, 1991, J IMMUNOL, V147, P2202; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PAUL WE, 1991, BLOOD, V77, P1859; RIDDERSTRALE M, 1994, J BIOL CHEM, V270, P3471; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7218; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; WANG LM, 1995, STEM CELLS, V13, P360, DOI 10.1002/stem.5530130407; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN T, 1994, J BIOL CHEM, P26614; ZHU XY, 1994, J BIOL CHEM, V269, P5518	37	128	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28527	28530		10.1074/jbc.270.48.28527	http://dx.doi.org/10.1074/jbc.270.48.28527			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499365	hybrid			2022-12-25	WOS:A1995TH05600009
J	TAMURA, S; NELSON, H; TAMURA, A; NELSON, N				TAMURA, S; NELSON, H; TAMURA, A; NELSON, N			SHORT EXTERNAL LOOPS AS POTENTIAL SUBSTRATE-BINDING SITE OF GAMMA-AMINOBUTYRIC-ACID TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN GABA TRANSPORTER; RAT-BRAIN; MOUSE-BRAIN; EXPRESSION; CLONING; PERMEASE	While the gamma-aminobutyric acid (GABA) transporter GAT1 exclusively transports GABA, GAT2, -3, and 4 also transport beta-alanine, Cross-mutations in the external loops IV, V, and VI among the various GABA transporters were performed by site-directed mutagenesis. The affinity of GABA transport as well as inhibitor sensitivity of the modified transporters was analyzed, Kinetic analysis revealed that a cross-mutation in which loop IV of GAT1 was modified to resemble GAT4 resulted in increased affinity to GABA from K-m = 8.7 to 2.0 mu M without changing the V-max. A cross mutation in loop VI, which swapped the amino acid sequence of GATE for GAT1, decreased the affinity to GABA (K-m, 35 mu M). These results suggest that loops TV and VI contribute to the binding affinity of GABA transporters, A substitution of three amino acids in loop V of GAT1 by the corresponding sequence of GAT3 resulted in beta-alanine sensitivity of its GABA uptake activity, These three amino acids in loop V seem to participate in the beta-alanine binding domain of GAT3. It is suggested that those three external loops (IV, V, and VI) form a pocket in which the substrate binds to the GABA transporters.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110; TEL AVIV UNIV,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL	Roche Holding; Tel Aviv University								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; GIROS B, 1994, J BIOL CHEM, V269, P15985; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Innis MA, 1990, PCR PROTOCOLS GUIDE; IVERSEN LL, 1975, BIOCHEM PHARMACOL, V24, P933, DOI 10.1016/0006-2952(75)90422-0; JURSKY F, 1994, J EXP BIOL, V196, P283; Kanner BI, 1989, CURR OPIN CELL BIOL, V1, P735, DOI 10.1016/0955-0674(89)90042-2; KANNER BI, 1990, P NATL ACAD SCI USA, V87, P2550, DOI 10.1073/pnas.87.7.2550; KLEINBERGERDORO.N, 1994, J BIOL CHEM, V269, P3063; LIU QR, 1993, J BIOL CHEM, V268, P2106; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; MARTIN D, 1976, GABA NERVOUS SYSTEM, P357; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; PUTTNER IB, 1988, P NATL ACAD SCI USA, V85, P1467, DOI 10.1073/pnas.85.5.1467; RADIAN R, 1990, J NEUROSCI, V10, P1319; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; WRIGHT EM, 1994, J EXP BIOL, V196, P197	24	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28712	28715		10.1074/jbc.270.48.28712	http://dx.doi.org/10.1074/jbc.270.48.28712			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499392	hybrid			2022-12-25	WOS:A1995TH05600036
J	HARUTA, T; MORRIS, AJ; ROSE, DW; NELSON, JG; MUECKLER, M; OLEFSKY, JM				HARUTA, T; MORRIS, AJ; ROSE, DW; NELSON, JG; MUECKLER, M; OLEFSKY, JM			INSULIN-STIMULATED GLUT4 TRANSLOCATION IS MEDIATED BY A DIVERGENT INTRACELLULAR SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLUCOSE-TRANSPORT; PLASMA-MEMBRANE; PROTEIN; RECEPTOR; PHOSPHORYLATION; ACTIVATION; MECHANISM; ONCOGENE; CELLS	Insulin stimulates glucose transport largely by mediating translocation of the insulin-sensitive glucose transporter (GLUT4) from an intracellular compartment to the plasma membrane. Using single cell microinjection of 3T3-L1 adipocytes, coupled with immunofluorescence detection of GLUT4 proteins, we have determined that inhibition of endogenous p21(ras) or injection of oncogenic p21(ras) has no effect on insulin-stimulated GLUT4 translocation. On the other hand, micro injection of anti-phosphotyrosine antibodies or inhibition of endogenous phosphatidylinositol 3-kinase by microinjection of a GST-p85 SH2 fusion protein markedly inhibits this biologic effect of insulin. These data suggest that the p21(ras)/mitogen-activated protein kinase pathway is not involved in this metabolic effect of insulin, whereas tyrosine phosphorylation and stimulation of phosphatidylinositol 3-kinase activity are critical components of this signaling pathway.	UNIV CALIF SAN DIEGO, DEPT MED 0673, LA JOLLA, CA 92093 USA; WASHINGTON UNIV, DEPT MED, ST LOUIS, MO 63110 USA; VET ADM RES SERV, SAN DIEGO, CA 92161 USA	University of California System; University of California San Diego; Washington University (WUSTL)			Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HELLERHARRISON R, 1995, DIABETES S1, V44, P31; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JHUN BH, 1994, MOL CELL BIOL, V14, P7486; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANCHESTER J, 1994, P NATL ACAD SCI USA, V91, P4644, DOI 10.1073/pnas.91.11.4644; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OLEFSKY JM, 1994, ELLENBERG RIFKINS DI, P121; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; STACEY DW, 1991, ONCOGENE, V6, P2297; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIAO S, 1994, J BIOL CHEM, V269, P21244	38	132	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					27991	27994						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499278				2022-12-25	WOS:A1995TG21000003
J	KATAGIRI, T; OGIMOTO, M; HASEGAWA, K; MIZUNO, K; YAKURA, H				KATAGIRI, T; OGIMOTO, M; HASEGAWA, K; MIZUNO, K; YAKURA, H			SELECTIVE REGULATION OF LYN TYROSINE KINASE BY CD45 IN IMMATURE B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LEUKOCYTE-COMMON ANTIGEN; PROTEIN-KINASE; LYMPHOCYTES-B; PHOSPHOTYROSINE PHOSPHATASE; MEMBRANE IMMUNOGLOBULIN; PHOSPHORYLATION; ACTIVATION; RECEPTOR; ASSOCIATION; EXPRESSION	It has been well established that protein-tyrosine phosphatase CD45 is critically involved in the regulation of initial tyrosine phosphorylation and effector functions of T and B cells, However, the signaling pathway governed by CD45 is not completely understood. In B cells, it has not been unequivocally resolved as to which protein-tyrosine kinases (PTKs) associated with B cell antigen receptor are regulated by CD45 in intact cells. As a first step toward the elucidation of CD45-initiated signaling events, we have tried to identify physiological substrates for CD45 by analyzing PTK activity in CD45-deficient clones recently generated from the immature B cell line WEHI-231. The results clearly demonstrated that among PTKs examined (Lyn, Lck, and Syk), only Lyn kinase is dysregulated in the absence of CD45 such that without B cell antigen receptor ligation, Lyn is hyperphosphorylated and activated in CD45-negative clones. Thus, Lyn seems to be a selective in vivo substrate for CD45 in immature B cells.	TOKYO METROPOLITAN INST NEUROSCI, DEPT MICROBIOL & IMMUNOL, FUCHU, TOKYO 183, JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science								BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1994, J IMMUNOL, V152, P42; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, ONCOGENE, V5, P809; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OGIMOTO M, 1995, EUR J IMMUNOL, V25, P2265, DOI 10.1002/eji.1830250823; OGIMOTO M, 1994, INT IMMUNOL, V6, P647, DOI 10.1093/intimm/6.4.647; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WECHSLER RJ, 1995, J IMMUNOL, V154, P1919; YAKURA H, 1994, CRIT REV IMMUNOL, V14, P311, DOI 10.1615/CritRevImmunol.v14.i3-4.50; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAO XR, 1993, IMMUNOL REV, V132, P163, DOI 10.1111/j.1600-065X.1993.tb00842.x	44	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					27987	27990						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499277				2022-12-25	WOS:A1995TG21000002
J	DICKINSON, JL; BATES, EJ; FERRANTE, A; ANTALIS, TM				DICKINSON, JL; BATES, EJ; FERRANTE, A; ANTALIS, TM			PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-2 INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA-INDUCED APOPTOSIS - EVIDENCE FOR AN ALTERNATE BIOLOGICAL FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-SUPEROXIDE-DISMUTASE; FACTOR-MEDIATED CYTOTOXICITY; CYTO-TOXICITY; VIRUS ENCODES; TNF RECEPTOR; UROKINASE; EXPRESSION; CELLS; PROTEASE; INTERLEUKIN-1-BETA	Plasminogen activator inhibitor type 2 (PAI-2) is a serine proteinase inhibitor or serpin that is a major product of macrophages in response to endotoxin and inflammatory cytokines. We have explored the role of PAI-2 in apoptotic cell death initiated by tumor necrosis factor alpha (TNF). HeLa cells stably transfected with PAI-2 cDNA were protected from TNF-induced apoptosis, whereas cells transfected with antisense PAI-2 cDNA, a control gene, or the plasmid vector alone remained susceptible, The level of PAI-2 expressed by different HeLa cell clones was inversely correlated with their sensitivity to TNF. Loss of TNF sensitivity was not a result of loss of TNF receptor binding. In contrast, PAI-2 expression did not confer protection against apoptosis induced by ultraviolet or ionizing radiation. The serine proteinase urokinase-type plasminogen activator was not demonstrated to be the target of PAI-2 action. The P-1-Arg amino acid residue of PAI-2 was determined to be required for protection, because cells expressing PAI-2 with an Ala in this position were not protected from TNF-mediated cell death. The results suggest that intracellular PAI-2 might be an important factor in regulating cell death in TNF-mediated inflammatory processes through inhibition of a proteinase involved in TNF-induced apoptosis.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND EXPTL ONCOL UNIT,BRISBANE,QLD 4029,AUSTRALIA; WOMENS & CHILDRENS HOSP,DEPT IMMUNOL,ADELAIDE,SA 5006,AUSTRALIA	QIMR Berghofer Medical Research Institute; Womens & Childrens Hospital Australia			Dickinson, Joanne/J-7728-2014	Dickinson, Joanne/0000-0003-4621-1703				ANTALIS TM, 1992, EUR J BIOCHEM, V205, P203, DOI 10.1111/j.1432-1033.1992.tb16769.x; ANTALIS TM, 1988, P NATL ACAD SCI USA, V85, P985, DOI 10.1073/pnas.85.4.985; BOSWELL DR, 1988, BIOESSAYS, V8, P83, DOI 10.1002/bies.950080209; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN RL, 1989, J BIOL CHEM, V264, P8375; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FUJII J, 1991, J BIOL CHEM, V266, P23142; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GOLDER JP, 1984, EUR J BIOCHEM, V139, P253; GYETKO MR, 1992, J LEUKOCYTE BIOL, V51, P256, DOI 10.1002/jlb.51.3.256; HENNET T, 1993, CANCER RES, V53, P1456; HIGUCHI M, 1991, MOL IMMUNOL, V28, P1039; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; KAWANO T, 1970, J BIOCHEM-TOKYO, V67, P333, DOI 10.1093/oxfordjournals.jbchem.a129257; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KETTNER C, 1979, BIOCHIM BIOPHYS ACTA, V569, P31, DOI 10.1016/0005-2744(79)90078-0; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KISO U, 1988, FEBS LETT, V230, P51, DOI 10.1016/0014-5793(88)80640-9; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LASTER SM, 1993, J IMMUNOL, V141, P2629; LOMAS DA, 1993, J BIOL CHEM, V268, P516; LYONSGIORDANO B, 1994, HISTOCHEMISTRY, V101, P105, DOI 10.1007/BF00269356; MIURA Y, 1994, J BIOL CHEM, V269, P542; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUIRA M, 1993, CELL, V75, P653; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; OLSSON I, 1993, EUR CYTOKINE NETW, V4, P169; POWERS JC, 1993, PROTEASES PROTEASE I, P3; PYTEL BA, 1990, J CELL PHYSIOL, V144, P416, DOI 10.1002/jcp.1041440308; RAGNO P, 1993, FEBS LETT, V323, P279, DOI 10.1016/0014-5793(93)81357-6; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SCHERRER A, 1991, LEUKEMIA, V5, P479; SCHLEUNING WD, 1987, MOL CELL BIOL, V12, P4564; SCHWARTZ BS, 1988, BLOOD, V71, P734; SHAW WV, 1984, METHOD ENZYMOL, V43, P2464; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SMITH DM, 1994, J BIOL CHEM, V269, P9898; SMITH GL, 1989, J GEN VIROL, V70, P2333, DOI 10.1099/0022-1317-70-9-2333; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUGARMAN BJ, 1987, CANCER RES, V47, P780; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; WALLACH D, 1984, J IMMUNOL, V132, P2464; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILSON KP, 1994, NATURE, V37, P270; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIEGLERHEITBROC.HW, 1987, INT J CANCER, V41, P456; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	68	221	227	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27894	27904		10.1074/jbc.270.46.27894	http://dx.doi.org/10.1074/jbc.270.46.27894			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499264	hybrid			2022-12-25	WOS:A1995TE73600075
J	JUCKER, M; FELDMAN, RA				JUCKER, M; FELDMAN, RA			IDENTIFICATION OF A NEW ADAPTER PROTEIN THAT MAY LINK THE COMMON BETA-SUBUNIT OF THE RECEPTOR FOR GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR, INTERLEUKIN (IL)-3, AND IL-5 TO PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; GM-CSF RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; SH2 DOMAIN; DEPENDENT TRANSFORMATION; EXPRESSION CLONING; CELLULAR PROTEINS; HIGH-AFFINITY; BINDING	Binding of human granulocyte/macrophage colony-stimulating factor (hGM-CSF) to its receptor induces the rapid activation of phosphatidylinositol-3 kinase (PI 3-kinase). As hGM-CSF receptor (hGMR) does not contain a consensus sequence for binding of PI 3-kinase, hGMR must use a distinct mechanism for its association with and activation of PI 3-kinase. Here, we describe the identification of a tyrosine phosphorylated protein of 76-85 kDa (p80) that associates with the common beta subunit of hGMR and with the SH2 domains of the p85 subunit of PI 3-kinase in hGM-CSF stimulated cells. Src/Yes and Lyn were tightly associated with the p80 PI 3-kinase complex, suggesting that p80 and other phosphotyrosyl proteins present in the complex were phosphorylated by Src family kinases. Tyrosine phosphorylation of p80 was only detected in hGM-CSF or human interleukin-3-stimulated cells, suggesting that activation of p80 might be specific for signaling via the common beta subunit. We postulate that p80 functions as an adapter protein that may participate in linking the hGM-CSF receptor to the PI 3-kinase signaling pathway.	UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore				Feldman, Ricardo A./0000-0001-6090-0439	NATIONAL CANCER INSTITUTE [R29CA055293] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA 55293-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; JUCKER M, UNPUB; KANAKURA Y, 1990, BLOOD, V76, P706; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TORIGOE T, 1992, BLOOD, V80, P617; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WATANABE Y, 1992, BLOOD, V80, P2215; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27817	27822						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499252				2022-12-25	WOS:A1995TE73600063
J	KISSIL, JL; DEISS, LP; BAYEWITCH, M; RAVEH, T; KHASPEKOV, G; KIMCHI, A				KISSIL, JL; DEISS, LP; BAYEWITCH, M; RAVEH, T; KHASPEKOV, G; KIMCHI, A			ISOLATION OF DAP3, A NOVEL MEDIATOR OF INTERFERON-GAMMA-INDUCED CELL-DEATH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; PROTEIN; GENE; PATHWAYS; ENCODES; TOOL; P53	Interaction of certain cytokines with their corresponding cell-surface receptors induces programed cell death. Interferon-gamma induces in HeLa cells a type of cell death with features characteristic of programed cell death. Here, we report the isolation of a novel gene, DAP3 (death-associated protein-3), involved in mediating interferon-gamma-induced cell death. The rescue of this gene was performed by a functional selection approach of gene cloning that is based on transfection with an antisense cDNA expression library, The antisense RNA-mediated inactivation of the DAPS gene protected the cells from interferon-gamma-induced cell death. This property endowed the cells expressing it with a growth advantage in an environment restrictive due to the continuous presence of interferon-gamma and thus provided the basis of its selection, The gene is transcribed into a single 1.7-kilobase mRNA, which is ubiquitously expressed in different tissues and codes for a 46-kDa protein carrying a potential P-loop motif. Ectopic expression of DAP3 in HeLa cells was not compatible with cell growth, resulting in a 16 fold reduction in the number of drug-resistant stable clones. The data presented suggest that DAP3 is a positive mediator of cell death induced by interferon-gamma.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHENCHIK AA, 1993, FEBS LETT, V324, P98; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALLACH D, 1984, J IMMUNOL, V132, P2464; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	31	83	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27932	27936		10.1074/jbc.270.46.27932	http://dx.doi.org/10.1074/jbc.270.46.27932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499268	hybrid			2022-12-25	WOS:A1995TE73600079
J	WENGER, RH; ROLFS, A; MARTI, HH; BAUER, C; GASSMANN, M				WENGER, RH; ROLFS, A; MARTI, HH; BAUER, C; GASSMANN, M			HYPOXIA, A NOVEL INDUCER OF ACUTE-PHASE GENE-EXPRESSION IN A HUMAN HEPATOMA-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ALZHEIMERS-DISEASE; ERYTHROPOIETIN GENE; MAMMALIAN-CELLS; IRON-ABSORPTION; MESSENGER-RNA; PROTEIN; TRANSCRIPTION; SEQUENCE; ALPHA-1-ANTICHYMOTRYPSIN	Transcriptional regulation of gene expression by hypoxia is an important, but yet only marginally characterized mechanism by which organisms adapt to low oxygen concentrations, The human hepatoma cell line HepG2 is a widely used model for studying hypoxic induction of the hematopoietic growth factor erythropoietin, In an attempt to identify additional genes expressed in HepG2 cells during hypoxia, we differentially screened a cDNA library derived from hypoxic (1% O-2) HepG2 cells using probes isolated from either normoxic (21% O-2) or hypoxic cells, Two genes were identified, one encoding aldolase, a member of the glycolytic enzymes, and the other encoding alpha(1)-antitrypsin which belongs to the family of the acute phase (AP) responsive proteins, Whereas hypoxic induction of glycolytic enzymes is well established, oxygen-dependent regulation of AP genes has not been reported so far, AP proteins are liver-derived plasma proteins whose production during inflammation is either up regulated (positive AP reactants) or down-regulated (negative AP reactants). In the present study, we demonstrate that on the mRNA level hypoxic stimulation of HepG2 cells led to (i) an induction of the positive AP reactants alpha(1)-antitrypsin, alpha(1)-antichymotrypsin, complement C3, haptoglobin, and alpha(1)-acid glycoprotein; (ii) a down-regulation of the negative AP reactant albumin; (iii) an up-regulation of the negative AP reactant transferrin; and (iv) unchanged levels of the positive AP reactants alpha- and beta-fibrinogen as well as hemopexin, Cycloheximide inhibited hypoxic up-regulation of AP mRNAs demonstrating that de novo protein synthesis is required for hypoxic induction, Nuclear run on assays indicate that the hypoxic increase in AP mRNAs is mainly due to transcriptional regulation, The hypoxic response was compared to AP stimulation by interleukin 6, The results suggest that the adaptive response to hypoxia overlaps with, but is not identical with, the AP response mediated by interleukin 6.			WENGER, RH (corresponding author), UNIV ZURICH, INST PHYSIOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.		Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; Marti, Hugo/0000-0002-8456-334X				ABRAHAM CR, 1992, RES IMMUNOL, V143, P631, DOI 10.1016/0923-2494(92)80047-O; ACKER H, 1994, RESP PHYSIOL, V95, P1, DOI 10.1016/0034-5687(94)90043-4; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; CABIN DE, 1990, SURGERY, V108, P902; CHALDAKOV GN, 1992, IMMUNOL TODAY, V13, P237, DOI 10.1016/0167-5699(92)90162-Z; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; COLAU B, 1984, DNA-J MOLEC CELL BIO, V3, P327, DOI 10.1089/dna.1.1984.3.327; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; ECKARDT KU, 1988, KLIN WOCHENSCHR, V66, P241, DOI 10.1007/BF01748163; EIKELENBOOM P, 1992, RES IMMUNOL, V143, P617, DOI 10.1016/0923-2494(92)80044-L; Fey G H, 1990, Prog Liver Dis, V9, P89; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FISHELSON Z, 1991, MOL IMMUNOL, V28, P545, DOI 10.1016/0161-5890(91)90169-K; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; GAULDIE J, 1990, J IMMUNOL, V144, P3804; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HELFMAN T, 1993, AM J MED SCI, V306, P37, DOI 10.1097/00000441-199307000-00010; HOLERS VM, 1992, IMMUNOL TODAY, V13, P231; HUBER P, 1990, J BIOL CHEM, V265, P5695; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; KURACHI K, 1981, P NATL ACAD SCI-BIOL, V78, P6826, DOI 10.1073/pnas.78.11.6826; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MITANI K, 1992, BLOOD, V79, P1255; NIELSEN OJ, 1987, BLOOD, V70, P1904; OSTERLOH KRS, 1987, BLUT, V55, P421, DOI 10.1007/BF00367458; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; POTTER H, 1992, PROG BRAIN RES, V94, P447; ROBIN ED, 1984, J CELL PHYSIOL, V118, P287, DOI 10.1002/jcp.1041180311; RUBIN H, 1992, BIOL CHEM H-S, V373, P497, DOI 10.1515/bchm3.1992.373.2.497; SAAD B, 1995, EUR J BIOCHEM, V229, P349, DOI 10.1111/j.1432-1033.1995.0349k.x; SAKAKIBARA M, 1985, BIOCHEM BIOPH RES CO, V131, P413, DOI 10.1016/0006-291X(85)91818-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIMPSON RJ, 1992, ANN HEMATOL, V65, P260, DOI 10.1007/BF01836070; VANDENABEELE P, 1991, IMMUNOL TODAY, V12, P217, DOI 10.1016/0167-5699(91)90032-O; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WENGER RH, 1993, J BIOL CHEM, V268, P23345; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463	61	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27865	27870		10.1074/jbc.270.46.27865	http://dx.doi.org/10.1074/jbc.270.46.27865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499259	hybrid, Green Accepted			2022-12-25	WOS:A1995TE73600070
J	MOSSIE, K; JALLAL, B; ALVES, F; SURES, I; PLOWMAN, GD; ULLRICH, A				MOSSIE, K; JALLAL, B; ALVES, F; SURES, I; PLOWMAN, GD; ULLRICH, A			COLON-CARCINOMA KINASE-4 DEFINES A NEW SUBCLASS OF THE RECEPTOR TYROSINE KINASE FAMILY	ONCOGENE			English	Note						RECEPTOR TYROSINE KINASE FAMILY; COLON CARCINOMA; SIGNAL TRANSDUCTION	GROWTH-FACTOR RECEPTOR; HUMAN INSULIN-RECEPTOR; SIGNAL TRANSDUCTION; STRUCTURAL BASIS; HUMAN-BREAST; CELLS; EXPRESSION; GENE; CDNA; SUPERFAMILY	Complementary DNA (cDNA) encoding a novel member of the receptor tyrosine kinase (RTK) family has been isolated from colon carcinoma tissue. Colon carcinoma kinase 4 (CCK-4) mRNA is highly expressed in human lung tissue and at lower levels in the thyroid gland and ovary. While no mRNA was found in human adult colon tissues, expression varied remarkably in colon carcinoma-derived cell lines. CCK-4 cDNA encodes a chicken KLG-related, 1071 amino acid-long transmembrane glycoprotein containing several genetic alterations within the RTK consensus sequences. These define CCK-4 as a catalytically inactive member of the RTK family of proteins and, in analogy to HER3, suggest a potentially tumor-characteristic role as a signal amplifier or modulator for an as yet unidentified kinase-competent partner.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063	Max Planck Society			PLOWMAN, Greg D/E-2012-2011					ALIMANDI M, 1995, ONCOGENE, V10, P1813; ALVES F, 1995, ONCOGENE, V10, P609; BROWN LF, 1993, CANCER RES, V553, P4727; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Faletto D L, 1993, EXS, V65, P107; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JALLAL B, 1992, J BIOL CHEM, V267, P4357; Kluftinger A M, 1992, Surg Oncol, V1, P97, DOI 10.1016/0960-7404(92)90062-P; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Mendelsohn J, 1992, J Natl Cancer Inst Monogr, P125; MORAN MF, 1988, ONCOGENE, V3, P665; MURGUE B, 1994, CANCER RES, V54, P5206; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; Plowman G. D., 1994, DRUG NEWS PERSPECT, V7, P334; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHIBUYA M, 1990, ONCOGENE, V5, P519; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TOYOTA M, 1993, TUMOR BIOL, V14, P295, DOI 10.1159/000217842; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yamori T, 1993, Gan To Kagaku Ryoho, V20, P393; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	127	137	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2179	2184						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478540				2022-12-25	WOS:A1995TF29700031
J	CARNERO, A; LIYANAGE, M; STABEL, S; LACAL, JC				CARNERO, A; LIYANAGE, M; STABEL, S; LACAL, JC			EVIDENCE FOR DIFFERENT SIGNALING PATHWAYS OF PKC-ZETA AND RAS-P21 IN XENOPUS OOCYTES	ONCOGENE			English	Article						OOCYTE MATURATION; PROTEIN KINASE C-ZETA; RAS-P21; MPF AND CDC2 KINASE; MAP KINASE; S6 KINASE II	PROTEIN-KINASE-C; MAP KINASE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION; ONCOGENE PRODUCT; LAEVIS OOCYTES; ACTIVATION; TRANSDUCTION; EXPRESSION	Considerable effort has been devoted to identifying critical steps in mitogenic signal transduction pathways. Recently, the atypical PKC zeta isoform has attracted great interest since it has been reported to induce GVBD in Xenopus oocytes and transformation of NIH3T3 fibroblasts, two processes closely linked with the regulation of cell division. Furthermore, PKC zeta has been proposed as an essential effector for ras-p21 function and therefore may be an essential component of the signalling pathway(s) activated by mitogens. In this study we have analysed the responses induced in Xenopus oocytes after microinjection of purified recombinant PKC zeta protein. Microinjection of PKC zeta induced the early activation of MPF which precedes GVBD and also induced the activation of MAP kinase and S6 kinase II. The activation of MPF, MAP kinase and S6 kinase II by PKC zeta was sensitive to cycloheximide, while induction of GVBD was independent of protein synthesis. These results indicate that PKC zeta induces the activation of at least two pathways, only one of them leading to the activation of MAP kinase. By contrast, neither the induction of GVBD nor the activation of MPF, MAPK and S6 kinase II induced by the ras-p21 protein were dependent on protein synthesis. Thus, the comparison of these responses suggests that PKC zeta most likely does not mediate the uas-induced signal transduction pathway in Xenopus laevis oocytes.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN; MAX PLANCK GESELL,MAX DELLBRUCK LAB,D-50829 COLOGNE,GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Max Planck Society			Lacal, Juan Carlos/AAL-2235-2020; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/N-9064-2015	Carnero, Amancio/0000-0003-4357-3979; Lacal, Juan Carlos/0000-0002-1908-2777				ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; CACACE AM, 1993, ONCOGENE, V8, P2095; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; CARNERO A, 1994, J CELL BIOCHEM, V55, P1; CARRERO A, 1994, J CELL BIOCHEM, V54, P478; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1995, BIOCHEM BIOPH RES CO, V213, P266, DOI 10.1006/bbrc.1995.2125; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MONTANER S, 1995, ONCOGENE, V10, P2213; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEBREDA AR, 1993, ONCOGENE, V8, P467; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PRICE BD, 1989, BIOCHEM J, V260, P157, DOI 10.1042/bj2600157; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; Stabel S., 1993, INTRACELLULAR MESSEN, P167; STABEL S, 1993, METH NEUROSCI, V18, P154; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1992, J BIOL CHEM, V267, P4799; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1992, NATURE, V355, P645	66	19	19	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1541	1547						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478578				2022-12-25	WOS:A1995TC53500012
J	FUKASAWA, K; ZHOU, RP; MATTEN, WT; ARMSTRONG, AJ; DAAR, I; OSKARSSON, M; SATHYANARAYANA, BK; MACLVOR, L; WOOD, TG; VANDEWOUDE, GF				FUKASAWA, K; ZHOU, RP; MATTEN, WT; ARMSTRONG, AJ; DAAR, I; OSKARSSON, M; SATHYANARAYANA, BK; MACLVOR, L; WOOD, TG; VANDEWOUDE, GF			MUTAGENIC ANALYSIS OF FUNCTIONAL DOMAINS OF THE MOS PROTOONCOGENE AND IDENTIFICATION OF THE SITES IMPORTANT FOR MAPK ACTIVATION AND DNA-BINDING	ONCOGENE			English	Article						MOS; MAP KINASE; TRANSFORMATION; OOCYTE MATURATION	XENOPUS-OOCYTES; V-MOS; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; KINASE-ACTIVITY; MEIOSIS-II; TUBULIN; INVITRO; CELLS; TRANSFORMATION	We constructed in-frame deletion/replacement mutations in the Xenopus mos proto-oncogene that lie within conserved Mos-specific codons, but outside of the regions that are conserved among the src kinase family of genes, All gene products were assayed in vine for kinase activity and in vivo for their ability to induce oocyte maturation, embryonic cleavage arrest and cellular transformation, Most mutations in Mos eliminated both kinase and biological activity, However, a mutation in Mos that removed two basic amino acid residues (R94 and K97) downstream from the lysine at the ATP binding site (K90) markedly enhanced autophosphorylation activity, Moreover, this mutant displayed markedly reduced biological activity, lacked transforming activity, and failed to activate mitogen activated protein kinase (MAPK), A second mutant Mos product, lacking amino acids R45-A54, displayed a five-fold increase in cellular transforming activity, This Mos mutant specifically localized to the cytoplasm; in contrast to wild-type (wt) Mos that localized to both the nucleus and the cytoplasm, These data indicate that Mos transforming activity is mediated via signalling exerted in the cytoplasm, presumably through MAPK, and that nuclear localization of the oncogene product interferes with transforming activity, We also show that amino acids R45-A54 are important for Mos DNA binding activity.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,RECOMBINANT DNA LAB,GALVESTON,TX 77555	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Texas System; University of Texas Medical Branch Galveston			Wood, Thomas/B-6172-2012; Wood, Thomas/GWZ-2481-2022	Wood, Thomas/0000-0001-8962-8571; Daar, Ira/0000-0003-2657-526X				BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1992, ONCOGENE, V7, P1757; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FUKASAWA K, 1995, ONCOGENE, V10, P1; FUKASAWA K, 1995, P NATL ACAD SCI USA, V92, P3430, DOI 10.1073/pnas.92.8.3430; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUCHON D, 1981, REPROD NUTR DEV, V21, P135, DOI 10.1051/rnd:19810112; JESSUS C, 1986, BIOL CELL, V56, P113, DOI 10.1111/j.1768-322X.1986.tb00448.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OKAZAKI K, 1995, JPN J CANCER RES, P1149; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RIEDER CL, 1993, MORPHOGENESIS MITOTI, P183; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SETH A, 1988, LOCALIZATION NUCLEIC, P82; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WANG XM, 1994, P NATL ACAD SCI USA, V91, P8329, DOI 10.1073/pnas.91.18.8329; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	52	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1447	1457						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478569				2022-12-25	WOS:A1995TC53500003
J	HALL, M; BATES, S; PETERS, G				HALL, M; BATES, S; PETERS, G			EVIDENCE FOR DIFFERENT MODES OF ACTION OF CYCLIN-DEPENDENT KINASE INHIBITORS - P15 AND P16 BIND TO KINASES, P21 AND P27 BIND TO CYCLINS	ONCOGENE			English	Article						CDKN1; CDKN2; CYCLINS; IN VITRO BINDING	SUBUNIT	A number of low molecular weight proteins have recently been identified that specifically inhibit the function of cyclin-dependent protein kinases in mammalian cells. These fall into two distinct families based on primary sequence comparisons and probable modes of action. Using a simple in vitro binding assay, we show that p21(CDKN1) and the related p27(KIP1) can efficiently interact with cyclins D1, D2, D3, E and A, and to a lesser extent with cyclin B. By generating a deleted form of cyclin D1 that binds to p21 and p27 but not to Cdks, we confirm that these interactions do not depend on stoichiometric amounts of the relevant kinase subunit. Moreover, p21 and p27 do not detectably associate with kinase subunits unless a cyclin is present. This is in sharp contrast to the properties of p16(CDKN2) and p15(MTS2/INK4b) which bind to Cdk4 and Cdk6 in the absence of any cyclin. These data suggest that p21 and p27 act as broad spectrum regulators of cyclin dependent kinase function by participating in ternary complexes whereas the p16 family specifically interfere with the formation of cyclin D-dependent kinase complexes.	IMPERIAL CANC RES FUND, ONCOL MOLEC LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Hall, marcia/0000-0003-0039-5041				BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEN J, 1994, CANCER RES, V54, P6353; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTSUKI T, 1995, CANCER RES, V55, P1436; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAHARA H, 1995, ONCOGENE, V10, P835; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668	52	190	200	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1581	1588						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478582				2022-12-25	WOS:A1995TC53500016
J	TIKHONENKO, AT; BLACK, DJ; LINIAL, ML				TIKHONENKO, AT; BLACK, DJ; LINIAL, ML			V-MYC IS INVARIABLY REQUIRED TO SUSTAIN RAPID PROLIFERATION OF INFECTED-CELLS BUT IN STABLE CELL-LINES BECOMES DISPENSABLE FOR OTHER TRAITS OF THE TRANSFORMED PHENOTYPE	ONCOGENE			English	Article						MYC; GLUCORTICOID RECEPTOR; TRANSFORMATION; PROLIFERATION	HUMAN C-MYC; AVIAN LEUKEMIA VIRUSES; EMBRYO FIBROBLASTS; DNA-BINDING; GLUCOCORTICOID RECEPTOR; N-MYC; NUCLEAR-LOCALIZATION; GENE; CHICKEN; EXPRESSION	The v-myc-containing retrovirus MC29 induces neoplastic transformation of avian embryo cells. To determine which traits of the transformed phenotype are directly controlled by v-Myc, we engineered a conditional MC29 mutant (GRIM) expressing v-Myc as a fusion protein with the glucocorticoid receptor and the retroviral Gag polyprotein. Only in the presence of glucocorticoids such as dexamethasone is GRIM capable of transforming embryo cells, from which six stable GRIM-lines have been derived. Although their survival in culture no longer requires functional v-Myc, hormone deprivation causes all six GRIM clones as web as acutely infected fibroblast cultures to either withdraw from cell cycle completely or to grow much more slowly and to much lower densities. However, removal of dexamethasone does not allow GRIM-transformed mass cultures and most of the clones to revert to normal shapes or to reconstruct actin cables. Furthermore, most clones do not require the hormone sustain anchorage-independent growth. We propose that certain secondary events have let the GRIM-clones sustain immortality, transformed morphology, and anchorage-independent growth independently of v-Myc. None of these events, however, has obliterated the requirement for v-Myc in cell division control. We thus conclude that enhanced proliferation is the primary effect of v-Myc expression.			TIKHONENKO, AT (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206	NATIONAL CANCER INSTITUTE [R01CA058809] Funding Source: NIH RePORTER; NCI NIH HHS [CA58809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BECKER D, 1977, J VIROL, V21, P1042, DOI 10.1128/JVI.21.3.1042-1055.1977; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIEGALKE BJ, 1987, J VIROL, V61, P2138, DOI 10.1128/JVI.61.7.2138-2142.1987; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; CROUCH DH, 1990, ONCOGENE, V5, P683; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DEHM P, 1971, BIOCHIM BIOPHYS ACTA, V240, P358, DOI 10.1016/0005-2787(71)90529-6; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ENRIETTO PJ, 1983, VIROLOGY, V124, P164, DOI 10.1016/0042-6822(83)90300-8; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; FRYKBERG L, 1987, ONCOGENE, V1, P415; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; MA A, 1993, ONCOGENE, V8, P1093; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHAW J, 1985, J VIROL, V56, P943, DOI 10.1128/JVI.56.3.943-950.1985; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1989, ONCOGENE, V4, P285; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1993, MOL CELL BIOL, V13, P3623, DOI 10.1128/MCB.13.6.3623; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG E, 1976, P NATL ACAD SCI USA, V73, P4065, DOI 10.1073/pnas.73.11.4065; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	52	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1499	1508						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478574				2022-12-25	WOS:A1995TC53500008
J	PIERCEALL, WE; WOODARD, AS; MORROW, JS; RIMM, D; FEARON, ER				PIERCEALL, WE; WOODARD, AS; MORROW, JS; RIMM, D; FEARON, ER			FREQUENT ALTERATIONS IN E-CADHERIN AND ALPHA-CATENIN AND BETA-CATENIN EXPRESSION IN HUMAN BREAST-CANCER CELL-LINES	ONCOGENE			English	Article						BREAST CANCER; E-CADHERIN; A-CATENIN; BETA-CATENIN; CYTOSKELETON; CELL-CELL INTERACTIONS	ADHESION MOLECULE; CYTOPLASMIC DOMAIN; COLORECTAL-CANCER; PROSTATE-CANCER; P-CADHERIN; CARCINOMAS; PROTEIN; PLAKOGLOBIN; ASSOCIATION; INVASIVENESS	Alterations in intercellular junction and membrane cytoskeletal proteins may underlie some of the morphological, invasive and metastatic properties of cancer. E-cadherin, a transmembrane protein that functions in epithelial cell-cell interactions at adherens junctions, is linked to the membrane cytoskeletal matrix through interactions with alpha- and beta-catenin. We have carried out studies of E-cadherin and alpha- and beta-catenin in 18 breast cancer cell lines to determine the prevalence and nature of alterations in these genes in breast cancer. Ten lines failed to express E-cadherin protein at detectable levels and seven failed to produce detectable levels of E-cadherin transcripts. In a line lacking E-cadherin expression (SK-BR-3) a homozygous deletion of a large portion of the E-cadherin gene was noted. Localized sequence alterations in E-cadherin transcripts were not identified in any lines. In contrast to the results of a previous study, no relationship was identified between E-caderin expression and HER-2/NEU expression. Two of the 18 lines had no detectable alpha-catenin protein and six others had reduced levels. The two lines lacking alpha-catenin protein had reduced or undetectable levels of alpha-catenin transcripts, while no consistent changes in alpha-catenin transcript levels were seen in the lines with reduced, but detectable, levels of alpha-catenin protein. Similarly, although two lines lacked beta-catenin protein, in most lines the levels of beta-catenin transcripts and protein were not well correlated with one another. Our findings suggest that alterations in E-cadherin and alpha- and beta-catenin expression are frequent in human breast cancer-derived cell lines, and that in some cases the decreased expression may result from mutations in the genes. Furthermore, the frequent alterations in the expression of these proteins argue that loss of function in the E-cadherin-catenin pathway may be critical in the development of many breast cancers.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT BIOL,NEW HAVEN,CT 06510	Yale University; Yale University				Rimm, David/0000-0001-5820-4397				BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BIRCHMEIER W, 1993, SEMIN CANCER BIOL, V4, P231; BRABANT G, 1993, CANCER RES, V53, P4987; BRINGUIER PP, 1993, CANCER RES, V5, P3241; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; CARTER BS, 1991, P NATL ACAD SCI USA, V87, P8751; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V16, P156; CROALL DE, 1986, BIOCHIM BIOPHYS ACTA, V882, P287, DOI 10.1016/0304-4165(86)90250-3; DOKI Y, 1993, CANCER RES, V53, P3421; DORUDI S, 1993, AM J PATHOL, V142, P981; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GAMALLO C, 1993, AM J PATHOL, V142, P987; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KADOWAKI T, 1994, CANCER RES, V54, P291; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; LINDBLOM A, 1993, CANCER RES, V53, P3707; MAYER B, 1993, CANCER RES, V53, P1690; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MOLL R, 1993, AM J PATHOL, V143, P1731; MORTON RA, 1993, CANCER RES, V53, P3585; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; OKA H, 1993, CANCER RES, V53, P1696; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PFIEFER M, 1990, CELL, V63, P1167; PRESS MF, 1993, CANCER RES, V53, P4960; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; REALE MA, 1994, CANCER RES, V54, P4493; RIMM DL, 1995, LAB INVEST, V72, P590; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SATO T, 1990, CANCER RES, V50, P7184; SCHIPPER JH, 1991, CANCER RES, V52, P2916; SHATKIN AJ, 1969, FUNDAMENTAL TECHNIQU, P231; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOMMERS CL, 1994, CANCER RES, V54, P3544; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; UMBAS R, 1992, CANCER RES, V52, P5104; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	66	132	136	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1319	1326						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478552				2022-12-25	WOS:A1995RY96700012
J	PRAML, C; FINKE, LH; HERFARTH, C; SCHLAG, P; SCHWAB, M; AMLER, L				PRAML, C; FINKE, LH; HERFARTH, C; SCHLAG, P; SCHWAB, M; AMLER, L			DELETION MAPPING DEFINES DIFFERENT REGIONS IN 1P34.2-PTER THAT MAY HARBOR GENETIC INFORMATION RELATED TO HUMAN COLORECTAL-CANCER	ONCOGENE			English	Article						CHROMOSOME 1; LOSS OF HETEROZYGOSITY (LOH); MICROSATELLITE; MOM1; TUMOR SUPPRESSOR-GENE	MULTIPLE INTESTINAL NEOPLASIA; FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN CHROMOSOME-1; COLON-CARCINOMA; CELL-LINE; SHORT ARM; IDENTIFICATION; TUMORS; MOUSE; LOCUS	Cytogenetic and molecular analyses of colorectal cancer cells have revealed deletions at 1p as prominent alterations, suggesting that genetic information on the short arm of chromosome 1 has a role in tumorigenesis. In this study we have used 33 microsatellite markers to fine map deletions at 1p in primary colorectal carcinomas. We found 1p-deletions in 84% of the cases (31/37). High frequencies of loss of heterozygosity (LOH), often the result of small independent interstitial deletions in the same tumor, defined three regions, that may harbor genetic information relevant for colorectal cancer: (i) region A between D1S243 and D1S468 (7cM; 1p36.3); (ii) region B between D1S436 and D1S199 (7cM; 1p35.1-36.31) and (iii) region C between D1S496 and D1S255 (1cM; 1p34.2-35). In addition we identified seven cell lines with LOH at 1p, all of which have deletions that span at least from the distal border of region A to the proximal border of region C.	MDC, UKVR ROBERT ROSSLE KLIN, CHIRURG ONKOL ABT, D-13122 BERLIN, GERMANY; UNIV HEIDELBERG, CHIRURG KLIN, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg	PRAML, C (corresponding author), GERMAN CANC RES CTR, DEPT CYTOGENET 0130, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							AMLER LC, 1995, ONCOGENE, V10, P1095; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARDI G, 1993, CANCER RES, V53, P1895; BARDI G, 1995, GENE CHROMOSOME CANC, V12, P97, DOI 10.1002/gcc.2870120204; BOMME L, 1994, GENE CHROMOSOME CANC, V10, P190, DOI 10.1002/gcc.2870100307; BRUDERLEIN S, 1990, GENE CHROMOSOME CANC, V2, P63, DOI 10.1002/gcc.2870020112; CHENG NC, 1995, ONCOGENE, V10, P291; COUTURIERTURPIN MH, 1992, HUM GENET, V88, P431, DOI 10.1007/BF00215678; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DRACOPOLI NC, 1994, CYTOGENET CELL GENET, V67, P143, DOI 10.1159/000133816; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEISTER I, 1990, CANCER RES, V50, P7232; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MIYAKI M, 1990, CANCER RES, V50, P7166; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NADEAU JH, 1991, MAMM GENOME, V1, P461; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TANAKA K, 1993, ONCOGENE, V8, P2253; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOLPI EV, 1994, CYTOGENET CELL GENET, V67, P187, DOI 10.1159/000133819; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; YANGFENG TL, 1985, AM J HUM GENET, V37, P1117; YANOSHITA R, 1992, CANCER RES, V52, P3965; YOUNG J, 1994, ONCOGENE, V9, P1053; YOUNG J, 1992, CANCER RES, V52, P285	42	101	104	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1357	1362						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478557				2022-12-25	WOS:A1995RY96700017
J	SIEGEL, J; FRITSCHE, M; MAI, S; BRANDNER, G; HESS, RD				SIEGEL, J; FRITSCHE, M; MAI, S; BRANDNER, G; HESS, RD			ENHANCED P53 ACTIVITY AND ACCUMULATION IN RESPONSE TO DNA-DAMAGE UPON DNA TRANSFECTION	ONCOGENE			English	Article						P53; P53 ACCUMULATION; P53 SENSITIZATION; DNA DAMAGE; DNA TRANSFECTION; CALICHEAMICIN GAMMA-1	CELLULAR TUMOR-ANTIGEN; DOUBLE-STRAND BREAKS; MONOCLONAL-ANTIBODIES; MAMMALIAN-CELLS; RESTRICTION ENDONUCLEASES; CHROMOSOMAL-ABERRATIONS; SUPPRESSOR PROTEIN; IONIZING-RADIATION; MOUSE CELLS; CHO CELLS	In response to DNA damage the wild-type tumor suppressor protein p53 accumulates in the nucleus of rodent and primate cells. To investigate the minimal requirement for this reaction the cellular DNA was restricted by two alternative ways: (i) by calicheamicin gamma 1, an enediyne, which causes direct, sequence-specific DNA damage, as shown by fluorimetric analysis of DNA unwinding and by poly(ADP-ribose) polymerase activation. The dose-dependent DNA damage correlated with the nuclear p53 accumulation. In addition, restriction was generated (ii) by the intracellular introduction of the restriction enzyme PvuII, which generates blunt-ended DNA breaks, applying a mild hypotonic shock (pellet method). Previous transfection of linear or circular, single- or ds, DNA, followed by mitomycin C-treatment, lead to a dramatic increase in nuclear p53 accumulation and p53 activity according to electrophoretic mobility shift analysis. The nature of transfected DNA was irrelevant for enhanced accumulation. The data suggest, that the cellular p53 response to DNA damage is sensitized by uptake of exogenous DNA.	UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,D-79104 FREIBURG,GERMANY; INST EXPTL KREBSFORSCH,TUMORBIOL KLIN,D-79106 FREIBURG,GERMANY; BASEL INST IMMUNOL,CH-4058 BASEL,SWITZERLAND	University of Freiburg			mai, sj/HGE-8908-2022					ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; AUER D, 1976, NATURWISSENSCHAFTEN, V63, P391, DOI 10.1007/BF00607946; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BHATTACHARYYA D, 1988, CARCINOGENESIS, V9, P683, DOI 10.1093/carcin/9.4.683; BIRNBOIM HC, 1981, CANCER RES, V41, P1889; BRAIN R, 1994, ONCOGENE, V9, P1775; BRYANT PE, 1989, MUTAT RES, V213, P233, DOI 10.1016/0027-5107(89)90155-3; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; COLEMAN WB, 1994, CARCINOGENESIS, V15, P145, DOI 10.1093/carcin/15.2.145; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; COSTA ND, 1990, INT J RADIAT BIOL, V57, P933, DOI 10.1080/09553009014551051; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1992, NATURE, V356, P79; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITSCHE M, 1991, THESIS FREIBURG; FRITSCHE M, 1991, J CANCER RES CLIN S, V117, pS30; GANNON JV, 1990, EMBO J, V9, P1591; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEHMANN AR, 1985, MUTAT RES, V150, P61, DOI 10.1016/0027-5107(85)90101-0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LJUNGMAN M, 1989, CARCINOGENESIS, V10, P447, DOI 10.1093/carcin/10.3.447; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCKEHUHLE C, 1989, MOL CELL BIOL, V9, P4812; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCWHIR J, 1993, NAT GENET, V3, P217; MESSMER UK, 1994, FEBS LETT, V355, P23; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MORTEN JEN, 1988, CARCINOGENESIS, V9, P45, DOI 10.1093/carcin/9.1.45; MOSNER J, 1995, J CANCER RES CLIN S2, V121, pB20; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOLAOU KC, 1992, SCIENCE, V256, P1172, DOI 10.1126/science.256.5060.1172; Nicolau K.C., 1991, ANGEW CHEM, V103, P1453; OBE G, 1985, MUTAT RES, V150, P359; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SCHMIDT RJ, 1995, J CANC RES CLIN O S2, V121, pA12; SCHULZELUTUM A, 1994, INT J ONCOL, V5, P1405; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SIEGEL J, 1993, J CANCER RES CLIN S2, V119, pS84; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; STEWART N, 1995, ONCOGENE, V10, P109; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WILSON RE, 1993, ONCOGENE, V8, P3229; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YAMAIZUMI M, 1994, ONCOGENE, V10, P2775; ZEIN N, 1988, SCIENCE, V240, P1198, DOI 10.1126/science.3240341; ZHAN QM, 1994, ONCOGENE, V9, P3743	72	42	42	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1363	1370						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478558				2022-12-25	WOS:A1995RY96700018
J	NIMPF, J; STIFANI, S; BILOUS, PT; SCHNEIDER, WJ				NIMPF, J; STIFANI, S; BILOUS, PT; SCHNEIDER, WJ			THE SOMATIC CELL-SPECIFIC LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN OF THE CHICKEN - CLOSE KINSHIP TO MAMMALIAN LOW-DENSITY-LIPOPROTEIN RECEPTOR GENE FAMILY MEMBERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; PREGNANCY ZONE PROTEIN; LDL-RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; HEYMANN NEPHRITIS; OOCYTE RECEPTOR; MESSENGER-RNA; PLASMINOGEN-ACTIVATOR; MEDIATED ENDOCYTOSIS; REGULATED EXPRESSION	Recently, the family of mammalian genes homologous to that for the low density lipoprotein (LDL) receptor has grown. One of the new family members, termed LDL receptor-related protein/alpha2-macroglobulin receptor (LRP/alpha2MR), is one of the largest cell surface proteins characterized to date. Its functions have been hypothesized to include the plasma clearance of chylomicron remnants and activated alpha2-macroglobulin, as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. Here we describe the molecular characterization of an LRP/alpha2MR expressed in chickens, which do not metabolize chylomicron remnants. This chicken protein is expressed in somatic tissues and is different from a second LRP/alpha2MR exclusively expressed in growing ovarian follicles. The sequence of the somatic cell-specific chicken LRP/alpha2MR, deduced from cloned full-length cDNA, shows 83% overall identity with human LRP/alpha2MR. Important characteristic features of the modular protein are completely conserved; in particular, all cysteine residues align perfectly. The avian LRP/alpha2MR is post-translationally cleaved in the same fashion as its human counterpart, and the resulting 515-kDa extracellular subunit binds Ca2+, alpha2-macroglobulin, and vitellogenin. The results indicate that avian LRP/alpha2MR genes have emerged from an ancestor designed to ensure a pivotal event in the reproduction of oviparous species, i.e. vitellogenesis, and that mammalian LRP/alpha2MRs have acquired features required for functioning in plasma clearance of certain non-yolk proteins.	BIOCTR,DEPT MOLEC GENET,DR BOHRGASSE 9-2,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,A-1030 VIENNA,AUSTRIA	University of Vienna				Nimpf, Johannes/0000-0002-9273-3492; Stifani, Stefano/0000-0002-2376-7701				AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARAKAT HA, 1985, J LIPID RES, V26, P1252; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BENSADOUN A, 1972, P SOC EXP BIOL MED, V41, P814; BORRAS T, 1985, EMBO J, V4, P445, DOI 10.1002/j.1460-2075.1985.tb03649.x; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; DEVRIENDT K, 1991, BIOCHIM BIOPHYS ACTA, V1088, P95, DOI 10.1016/0167-4781(91)90157-H; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; ESSER V, 1988, J BIOL CHEM, V263, P13282; GAFVELS ME, 1992, J BIOL CHEM, V267, P21230; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V883, P400, DOI 10.1016/0304-4165(86)90276-X; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HEINRICH P, 1989, CURRENT PROTOCOLS MO, V1; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KERJASCHKI D, 1990, VIRCHOWS ARCH B, V58, P253; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUVEN FV, 1986, J BIOL CHEM, V261, P11369; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGASE H, 1983, J BIOL CHEM, V258, P7481; NARDELLI D, 1987, BIOCHEMISTRY-US, V26, P6397, DOI 10.1021/bi00394a014; NIKAIDO T, 1981, NATURE, V292, P845, DOI 10.1038/292845a0; NIMPF J, 1989, P NATL ACAD SCI USA, V86, P906, DOI 10.1073/pnas.86.3.906; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NIMPF J, 1991, J NUTR, V121, P1471, DOI 10.1093/jn/121.9.1471; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OHLSSON K, 1971, ACTA PHYSIOL SCAND, V81, P269, DOI 10.1111/j.1748-1716.1971.tb04900.x; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RETZEK H, 1992, DNA CELL BIOL, V11, P661, DOI 10.1089/dna.1992.11.661; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOUTAR AK, 1989, NATURE, V341, P106, DOI 10.1038/341106a0; STENFLO J, 1988, J BIOL CHEM, V263, P21; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONDIJK MCM, 1991, BIOCHEM J, V279, P863; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	79	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					212	219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506255				2022-12-25	WOS:A1994MR21900040
J	PAN, CX; FUKUNAGA, R; YONEHARA, S; NAGATA, S				PAN, CX; FUKUNAGA, R; YONEHARA, S; NAGATA, S			UNIDIRECTIONAL CROSS-PHOSPHORYLATION BETWEEN THE GRANULOCYTE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-3 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; IL-6 SIGNAL TRANSDUCER; TYROSINE PHOSPHORYLATION; CELL-LINE; INTERMOLECULAR ASSOCIATION; ERYTHROPOIETIN RECEPTOR; EXPRESSION CLONING; BETA-SUBUNIT; GM-CSF; PROTEIN	The mouse interleukin-3 (IL-3)-dependent hemopoietic precursor cell line 32DCl3 responds to granulocyte colony-stimulating factor (G-CSF) for proliferation and differentiation. We established a subline (32D-FH) of the 32DCl3 cells which has lost the ability to respond to G-CSF. When murine G-CSF receptor cDNA was introduced into the 32D-FH cell line, the transformants responded to G-CSF as well as to IL-3 for proliferation. Adding G-CSF to the transformants rapidly induced tyrosine phosphorylation not only of the G-CSF receptor but also of both subtypes of the IL-3 receptor beta-chain (AIC2A and AIC2B molecules). On the other hand, stimulation of the transformants with IL-3 induced tyrosine phosphorylation of the AIC2A and AIC2B but not of the G-CSF receptor. These results indicate that the tyrosine kinase activated through the G-CSF receptor interacts with the IL-3 receptor beta-chains but not vice versa. This unidirectional cross-phosphorylation between the G-CSF and IL-3 receptors may play a role in granulopoiesis induced by G-CSF.	OSAKA BIOSCI INST, 6-2-4 FURUEDAI, SUITA, OSAKA 565, JAPAN; JT INC, PHARMACEUT BASIC RES LABS, KANAZAWA KU, YOKOHAMA 236, JAPAN				Fukunaga, Rikiro/CAG-2891-2022; Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CLEVELAND JL, 1989, MOL CELL BIOL, V264, P11699; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DURONIO V, 1992, J BIOL CHEM, V267, P21856; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LI W, 1991, J BIOL CHEM, V266, P6808; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NAGATA S, 1993, GROWTH FACTORS, V8, P99, DOI 10.3109/08977199309046930; NAGATA S, 1990, HDB EXPT PHARM, V95, P699; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHREURS J, 1991, INT IMMUNOL, V3, P1231, DOI 10.1093/intimm/3.12.1231; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	52	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25818	25823						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503988				2022-12-25	WOS:A1993MK10000079
J	STAYTON, PS; FISHER, MT; SLIGAR, SG				STAYTON, PS; FISHER, MT; SLIGAR, SG			DETERMINATION OF CYTOCHROME-B5 ASSOCIATION REACTIONS - CHARACTERIZATION OF METMYOGLOBIN AND CYTOCHROME-P-450CAM BINDING TO GENETICALLY ENGINEERED CYTOCHROME-B5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV ILLINOIS, DEPT CHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	SLIGAR, SG (corresponding author), UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA.		STAYTON, PATRICK/C-1975-2018	STAYTON, PATRICK/0000-0001-6939-6371	NCRR NIH HHS [RR03155-01] Funding Source: Medline; NIGMS NIH HHS [GM 31756, GM 33775] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033775, R37GM031756, R01GM031756] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONFILS C, 1981, J BIOL CHEM, V256, P9457; DAILEY HA, 1979, J BIOL CHEM, V254, P5388; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FISHER MT, 1986, J AM CHEM SOC, V108, P6835, DOI 10.1021/ja00281a079; GEREN LM, 1981, J BIOL CHEM, V256, P4851; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HACKETT CS, 1984, J BIOL CHEM, V259, P3275; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; KANG CH, 1978, J BIOL CHEM, V253, P6502; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; LIVINGSTON DJ, 1985, J BIOL CHEM, V260, P5699; LUDINGTON K, 1986, THESIS U ILLINOIS; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MATHEWS FS, 1972, J MOL BIOL, V64, P449, DOI 10.1016/0022-2836(72)90510-4; MATTHEW JB, 1983, NATURE, V301, P169, DOI 10.1038/301169a0; MAUK MR, 1986, BIOCHEMISTRY-US, V25, P7085, DOI 10.1021/bi00370a049; MAUK MR, 1982, BIOCHEMISTRY-US, V21, P4730, DOI 10.1021/bi00262a032; NG S, 1977, BIOCHEMISTRY-US, V16, P4975, DOI 10.1021/bi00642a006; OZOLS J, 1964, J BIOL CHEM, V239, P1018; POMPON D, 1984, J BIOL CHEM, V259, P5377; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1983, J BIOL CHEM, V258, P7369; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; RODGERS KK, 1988, SCIENCE, V240, P1657, DOI 10.1126/science.2837825; SALEMME FR, 1973, J BIOL CHEM, V248, P7701; SALEMME FR, 1976, J MOL BIOL, V102, P563, DOI 10.1016/0022-2836(76)90334-X; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; TAMBURINI PP, 1987, P NATL ACAD SCI USA, V84, P11, DOI 10.1073/pnas.84.1.11; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; UNGER BP, 1986, J BIOL CHEM, V261, P1158; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WENDOLOSKI JJ, 1987, SCIENCE, V238, P794, DOI 10.1126/science.2823387; Wittenberg J.B., 1981, Methods in Enzymology, V76, P29; [No title captured]	35	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13544	13548						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417673				2022-12-25	WOS:A1988Q159400016
J	WIESNER, W; VANPEE, KH; LINGENS, F				WIESNER, W; VANPEE, KH; LINGENS, F			PURIFICATION AND CHARACTERIZATION OF A NOVEL BACTERIAL NON-HEME CHLOROPEROXIDASE FROM PSEUDOMONAS-PYRROCINIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											WIESNER, W (corresponding author), UNIV HOHENHEIM,INST MIKROBIOL,GARBENSTR 30,D-7000 STUTTGART 70,FED REP GER.							AHERN TJ, 1980, BIOCHIM BIOPHYS ACTA, V616, P329, DOI 10.1016/0005-2744(80)90150-3; ALEXANDER NM, 1962, ANAL BIOCHEM, V4, P341, DOI 10.1016/0003-2697(62)90097-0; BADEN DG, 1980, BIOCHEM J, V187, P205, DOI 10.1042/bj1870205; BROWN FS, 1967, J AM CHEM SOC, V89, P719, DOI 10.1021/ja00979a061; CORBETT MD, 1979, BIOCHEM J, V183, P269, DOI 10.1042/bj1830269; FEHRNSTROM H, 1977, LKB306 APPL NOT, P12; GEIGERT J, 1983, APPL ENVIRON MICROB, V45, P1575, DOI 10.1128/AEM.45.5.1575-1581.1983; GEIGERT J, 1983, APPL ENVIRON MICROB, V45, P366, DOI 10.1128/AEM.45.2.366-374.1983; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HEWSON WD, 1980, J PHYCOL, V16, P340; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; ITOH N, 1986, J BIOL CHEM, V261, P5194; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBBY RD, 1982, J BIOL CHEM, V257, P5030; Liu T Y, 1972, Methods Enzymol, V25, P44, DOI 10.1016/S0076-6879(72)25006-6; LIU TNE, 1987, BIOCHEM BIOPH RES CO, V142, P329; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBBE C, 1983, H-S Z PHYSIOL CHEM, V364, P447, DOI 10.1515/bchm2.1983.364.1.447; MANTHEY JA, 1981, J BIOL CHEM, V256, P1232; MORRIS DR, 1966, J BIOL CHEM, V241, P1763; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SHANNON LM, 1966, J BIOL CHEM, V241, P2166; SHAW PD, 1961, J BIOL CHEM, V236, P1626; SPACKMAN DH, 1967, METHOD ENZYMOL, V11, P3; VANPEE KH, 1985, J BACTERIOL, V161, P1171; VANPEE KH, 1980, ANGEW CHEM INT EDIT, V19, P828, DOI 10.1002/anie.198008281; VANPEE KH, 1983, J ANTIBIOT, V36, P1735; VANPEE KH, 1987, BIOL CHEM H-S, V368, P1225, DOI 10.1515/bchm3.1987.368.2.1225; VANPEE KH, 1985, J GEN MICROBIOL, V131, P1911; WEVER R, 1985, BIOCHIM BIOPHYS ACTA, V830, P181, DOI 10.1016/0167-4838(85)90026-3; WIESNER W, 1986, FEBS LETT, V209, P321, DOI 10.1016/0014-5793(86)81135-8; WIESNER W, 1985, BIOL CHEM H-S, V366, P1085, DOI 10.1515/bchm3.1985.366.2.1085; WINTER A, 1977, LKB250 APPL NOT, P1; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	34	81	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13725	13732						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417677				2022-12-25	WOS:A1988Q159400041
J	KAKKAD, BP; ONG, DE				KAKKAD, BP; ONG, DE			REDUCTION OF RETINALDEHYDE BOUND TO CELLULAR RETINOL-BINDING PROTEIN (TYPE-II) BY MICROSOMES FROM RAT SMALL-INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032642] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32642] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN PL, 1974, BIOL DATA BOOK, V2, P1471; FIDGE NH, 1968, J LIPID RES, V9, P103; FIDGE NH, 1968, J BIOL CHEM, V243, P4372; FUTTERMAN S, 1977, INVEST OPHTH VIS SCI, V16, P768; FUTTERMAN S, 1965, BIOCHEMISTRY RETINA, P16; FUTTERMAN SIDNEY, 1963, JOUR BIOL CHEM, V238, P1145; Goodman DS, 1984, RETINOIDS, V2, P2; GOODMAN DWS, 1966, J CLIN INVEST, V45, P1615, DOI 10.1172/JCI105468; HELGERUD P, 1982, J LIPID RES, V23, P609; HUANG HS, 1965, J BIOL CHEM, V240, P2839; LEO MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P241, DOI 10.1016/0003-9861(87)90492-9; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; ONG DE, 1984, J BIOL CHEM, V259, P1476; ONG DE, 1987, J BIOL CHEM, V262, P2729; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X	18	89	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12916	12919						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417642				2022-12-25	WOS:A1988Q091700024
J	BASSOLS, A; MASSAGUE, J				BASSOLS, A; MASSAGUE, J			TRANSFORMING GROWTH FACTOR-BETA REGULATES THE EXPRESSION AND STRUCTURE OF EXTRACELLULAR-MATRIX CHONDROITIN DERMATAN SULFATE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											BASSOLS, A (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM,WORCESTER,MA 01655, USA.		Bassols, Anna/K-7961-2014	Bassols, Anna/0000-0003-4213-2274; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BRENNAN MJ, 1983, CANCER RES, V43, P4302; BRENNAN MJ, 1984, J BIOL CHEM, V259, P3742; CENTRELLA M, 1986, ENDOCRINOLOGY, V119, P2306, DOI 10.1210/endo-119-5-2306; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287, DOI 10.1073/pnas.84.15.5287; COSTER L, 1981, BIOCHEM J, V193, P143, DOI 10.1042/bj1930143; COSTER L, 1986, J BIOL CHEM, V261, P2079; CULP LA, 1979, J SUPRAMOL STR CELL, V11, P401, DOI 10.1002/jss.400110314; DAMLE SP, 1982, J BIOL CHEM, V257, P5523; FROESCH ER, 1976, P NATL ACAD SCI USA, V73, P2904, DOI 10.1073/pnas.73.8.2904; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; HEINEGARD D, 1984, EXTRACELLULAR MATRIX, P277; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; IOZZO R V, 1982, Journal of Biological Chemistry, V257, P11135; KATO Y, 1985, J CELL BIOL, V100, P477, DOI 10.1083/jcb.100.2.477; KATO Y, 1985, J BIOL CHEM, V260, P2364; KERL JH, 1985, CLIN RES, V33, P610; KRAEMER PM, 1972, J CELL BIOL, V55, P713, DOI 10.1083/jcb.55.3.713; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; Linker A., 1972, METHODS ENZYMOL, P902; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1985, J BIOL CHEM, V260, P7059; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; OEGEMA TR, 1979, J BIOL CHEM, V254, P1312; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; PEARSON CH, 1983, J BIOL CHEM, V258, P5101; RISTOW HJ, 1986, P NATL ACAD SCI USA, V83, P5531, DOI 10.1073/pnas.83.15.5531; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SALISBURY BGJ, 1981, J BIOL CHEM, V256, P8050; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SCOTT JE, 1984, BIOCHEM J, V218, P229, DOI 10.1042/bj2180229; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SILBERT JE, 1986, J BIOL CHEM, V261, P3397; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; STEVENS RL, 1981, J BIOL CHEM, V256, P2045; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; ULDBJERG N, 1983, BIOCHEM J, V209, P497, DOI 10.1042/bj2090497; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WAGNER WD, 1983, J BIOL CHEM, V258, P1136; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YANAGISHITA M, 1979, J BIOL CHEM, V254, P911	56	431	445	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1988	263	6					3039	3045						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M2161	3422640				2022-12-25	WOS:A1988M216100071
J	NESHEIM, ME; ABBOTT, T; JENNY, R; MANN, KG				NESHEIM, ME; ABBOTT, T; JENNY, R; MANN, KG			EVIDENCE THAT THE THROMBIN-CATALYZED FEEDBACK CLEAVAGE OF FRAGMENT 1.2 AT ARG154-SER155 PROMOTES THE RELEASE OF THROMBIN FROM THE CATALYTIC SURFACE DURING THE ACTIVATION OF BOVINE PROTHROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405	Queens University - Canada; University of Vermont	NESHEIM, ME (corresponding author), QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ONTARIO,CANADA.							ARONSON DL, 1977, J CLIN INVEST, V60, P1410, DOI 10.1172/JCI108902; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Lundblad R L, 1976, Methods Enzymol, V45, P156; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1983, CURRENT HEMATOLOGY, V2, P347; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; RABIET MJ, 1986, J BIOL CHEM, V261, P3210; TRACY PB, 1981, J BIOL CHEM, V256, P743	21	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1988	263	2					1037	1044						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	L7148	3422076				2022-12-25	WOS:A1988L714800065
J	LEWIS, RS; TAMIR, S; TANNENBAUM, SR; DEEN, WM				LEWIS, RS; TAMIR, S; TANNENBAUM, SR; DEEN, WM			KINETIC-ANALYSIS OF THE FATE OF NITRIC-OXIDE SYNTHESIZED BY MACROPHAGES IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED MACROPHAGES; L-ARGININE; SUPEROXIDE; NITRATE; PEROXYNITRITE; NITROSATION; OXIDATION	To investigate the fate of nitric oxide (NO) synthesized by activated macrophages, the concentrations of NO and its principal reaction products, nitrite (NO2-) and nitrate (NO3-), were measured as a function of time in suspension cultures of RAW264.7 macrophages attached to microcarrier beads. Synthesis of NO became evident 2-5 h after stimulation of the cells, and steady concentrations of NO were achieved after about 9 h. The appearance of NO in the extracellular fluid coincided with the appearance of NO2- and NO3-, which were formed thereafter at approximately equal and constant rates. Using a kinetic model based on rate constants measured previously in cell-free systems, only half of the NO2- formed could be accounted for by the reaction of NO with O-2. It is known that NO reacts with superoxide (O-2(.)) to give peroxynitrite and that NO also reacts with peroxynitrite to yield NO2-, so that the latter reaction may explain the ''excess'' NO2- formation, Adding superoxide dismutase to the medium markedly reduced the ratio of NO3- to NO2-, consistent with the hypothesis that NO3- in the medium results primarily from the extracellular reaction of NO with ((.)(2) over bar) The addition of morpholine, a model amine, resulted in formation of N-nitrosomorpholine, concurrent with the other products. Measured rates of nitrosomorpholine formation were 6-fold lower than predictions based on kinetics in simple solutions, suggesting that in the cell culture system there were additional reactions that lowered the concentration of nitrous anhydride, the principal nitrosating agent formed from NO and O-2.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,DIV TOXICOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NCI NIH HHS [P01-CA26731] Funding Source: Medline; NIEHS NIH HHS [ES 02109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA026731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; CROW JP, 1994, 1ST INT C BIOCH MOL, P75; DEROJASWALKER T, 1995, CHEM RES TOXICOL, V8, P473, DOI 10.1021/tx00045a020; FAN TY, 1973, J AGR FOOD CHEM, V21, P237, DOI 10.1021/jf60186a006; FIELDEN EM, 1974, BIOCHEM J, V139, P49, DOI 10.1042/bj1390049; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HETZER HB, 1966, J PHYS CHEM-US, V70, P2869, DOI 10.1021/j100881a024; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; LEWIS RS, 1995, J AM CHEM SOC, V117, P3933, DOI 10.1021/ja00119a006; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MIRVISH SS, 1975, TOXICOL APPL PHARM, V31, P325, DOI 10.1016/0041-008X(75)90255-0; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; MONCADA S, 1991, PHARMACOL REV, V43, P109; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RUBBO H, 1994, J BIOL CHEM, V269, P26066; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TANNENBAUM SR, 1993, 193 P AM CHEM SOC S, P120; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007	26	153	153	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29350	29355		10.1074/jbc.270.49.29350	http://dx.doi.org/10.1074/jbc.270.49.29350			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493969	hybrid			2022-12-25	WOS:A1995TJ22700050
J	RUSSO, T; ZAMBRANO, N; ESPOSITO, F; AMMENDOLA, R; CIMINO, F; FISCELLA, M; JACKMAN, J; OCONNOR, PM; ANDERSON, CW; APPELLA, E				RUSSO, T; ZAMBRANO, N; ESPOSITO, F; AMMENDOLA, R; CIMINO, F; FISCELLA, M; JACKMAN, J; OCONNOR, PM; ANDERSON, CW; APPELLA, E			A P53-INDEPENDENT PATHWAY FOR ACTIVATION OF WAF1/CIP1 EXPRESSION FOLLOWING OXIDATIVE STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; PROTEIN KINASE-C; IONIZING-RADIATION; TRANSCRIPTION FACTOR; GENE; DNA; BINDING; GROWTH; CELLS; WILD-TYPE-P53	Incubating human cells in diethylmaleate (DEM) depletes the intracellular pool of reduced glutathione (GSH) and increases the concentration of oxidative free radicals. We found that DEM-induced oxidative stress reduced the ability of p53 to bind its consensus recognition sequence and to activate transcription of a p53-specific reporter gene. Nevertheless, DEM treatment induced expression of WAF1/CIP1 but not GADD45 mRNA. The fact that N-acetylcysteine, a precursor of GSH that blocks oxidative stress, prevented WAF1/CIP1 induction by DEM suggests that WAF1/CIP1 induction probably was a consequence of the ability of DEM to reduce intracellular GSH levels. DEM induced WAF1/CIP1 expression in Saos-2 and T98G cells, both of which lack functional p53 protein. DEM treatment did not produce an increase in membrane-associated protein kinase C, but ERK2, a mitogen-activated protein kinase, was phosphorylated in a manner consistent with ERK2 activation. DEM treatment also produced a dose-dependent delay in cell cycle progression, which at low concentrations (0.25 mM) consisted of a G(2)/M arrest and at higher concentrations (1 mM) also involved G(1) and S phase delays. Our results indicate that oxidative stress induces WAF1/CIP1 expression and arrests cell cycle progression through a mechanism that is independent of p53. This mechanism may provide for cell cycle checkpoint control under conditions that inactivate p53.	NCI,CELL BIOL LAB,BETHESDA,MD 20892; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY; GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007; NCI,DIV CANC TREATMENT,MOLEC PHARMACOL LAB,BETHESDA,MD 20892; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Naples Federico II; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Brookhaven National Laboratory			Zambrano, Nicola/B-9352-2014; Esposito, Franca/K-2024-2016; Russo, Tommaso/K-1331-2016	Zambrano, Nicola/0000-0001-9395-3481; Esposito, Franca/0000-0001-9340-6875; Russo, Tommaso/0000-0003-4426-0106; AMMENDOLA, Rosario/0000-0003-1655-8028				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BOYLAND E, 1970, BIOCHEM PHARMACOL, V19, P1526, DOI 10.1016/0006-2952(70)90075-4; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESPOSITO F, 1995, BBA-GENE STRUCT EXPR, V1260, P308, DOI 10.1016/0167-4781(94)00209-L; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; FAN SJ, 1994, CANCER RES, V54, P5824; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FISCELLA M, 1993, ONCOGENE, V8, P1519; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAINAUT P, 1993, CANCER RES, V53, P4469; HARPER JW, 1993, CELL, V75, P805; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOMMA Y, 1988, CANCER RES, V48, P2744; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MCCLEAN S, 1992, BIOCHIM BIOPHYS ACTA, V1114, P107, DOI 10.1016/0304-419X(92)90010-V; MICHIELI P, 1994, CANCER RES, V54, P3391; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1993, CANCER RES, V53, P4776; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHIEVEN GL, 1994, TRENDS ENDOCRIN MET, V5, P383, DOI 10.1016/1043-2760(94)90106-6; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SIMIC MG, 1986, MECHANISMS DNA DAMAG, P39; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STEVENSON MA, 1994, CANCER RES, V54, P12; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P730; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZHANG W, 1995, CANCER RES, V55, P668	59	221	227	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29386	29391		10.1074/jbc.270.49.29386	http://dx.doi.org/10.1074/jbc.270.49.29386			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493974	hybrid			2022-12-25	WOS:A1995TJ22700055
J	FERRERAS, M; GAVILANES, JG; LOPEZOTIN, C; GARCIASEGURA, JM				FERRERAS, M; GAVILANES, JG; LOPEZOTIN, C; GARCIASEGURA, JM			THIOL-DISULFIDE EXCHANGE OF RIBONUCLEASE INHIBITOR BOUND TO RIBONUCLEASE-A - EVIDENCE OF ACTIVE INHIBITOR-BOUND RIBONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITION; LEUCINE-RICH REPEATS; HUMAN-PLACENTA; CIRCULAR-DICHROISM; RNASE INHIBITOR; PROTEIN; PURIFICATION; ANGIOGENIN; RESIDUES; SYSTEM	Ribonuclease Inhibitor (RI) has been purified from pig testis. It contains 30 half-cystines whose oxidation affects its ability to bind and inhibit ribonuclease (RNase), By N-terminal sequence analyses testis RI showed to be identical to that from porcine liver, for which a characteristic all-or-none type of SH-oxidation by 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) has been reported (Fominaya, J. M., and Hofsteenge, J. (1992) J. Biol. Chem. 257, 24655-24660), Under comparable reaction conditions, testis RI bound to RNase A did not exhibit this particular type of oxidation; instead, bound RI got intermediate oxidation degrees (up to 14 thiols oxidized per RI moiety) without dissociating from RNase. Moreover, RNase bound to partially oxidized RI was able to express some (15%) of its potential activity (active complex). Only when DTNB treatments accounted for complex dissociation (>14 thiols oxidized per RI moiety) the released RI molecules exhibited the all-or-none oxidation behavior. By both kinetic and circular dichroism analyses, conformational changes have been evidenced for the transition from the inactive to the active form of RI-RNase complex. Relaxation of RI-RNase binding without major alterations in RI structure is proposed as responsible for complex activation. The results are discussed in terms of a model for the reversible regulation of RNase activity mediated by the redox status of RI.	UNIV COMPLUTENSE MADRID, FAC QUIM, DEPT BIOQUIM & BIOL MOLEC, E-28040 MADRID, SPAIN; UNIV OVIEDO, DEPT BIOL FUNC, E-33006 OVIEDO, SPAIN	Complutense University of Madrid; University of Oviedo			López-Otín, Carlos/AAB-2106-2020; GARCIA-SEGURA, JUAN MANUEL/H-8215-2015; Gavilanes, Jose G./K-5307-2014	López-Otín, Carlos/0000-0001-6964-1904; GARCIA-SEGURA, JUAN MANUEL/0000-0003-2616-8154; Gavilanes, Jose G./0000-0002-6852-341X				BLACKBURN P, 1982, J BIOL CHEM, V257, P316; BLACKBURN P, 1980, J BIOL CHEM, V255, P959; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BLACKBURN P, 1979, J BIOL CHEM, V254, P2484; Blackburn P, 1982, ENZYMES, VXV, P317; BURTON LE, 1982, INT J PEPT PROT RES, V19, P372; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERRERAS M, 1993, ANAL BIOCHEM, V213, P206, DOI 10.1006/abio.1993.1410; FOMINAYA JM, 1988, BIOCHEM J, V253, P517, DOI 10.1042/bj2530517; FOMINAYA JM, 1992, J BIOL CHEM, V267, P24655; FOMINAYA JM, 1988, BIOCHIM BIOPHYS ACTA, V954, P216, DOI 10.1016/0167-4838(88)90074-X; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GLAZER AN, 1975, CHEM MODIFICATION PR, P113; GREIF RL, 1977, METABOLISM, V26, P851, DOI 10.1016/0026-0495(77)90003-8; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; HOFSTEENGE J, 1991, J BIOL CHEM, V266, P24198; JANATOVA J, 1968, J BIOL CHEM, V243, P3612; JOHNSON WC, 1992, METHOD ENZYMOL, V210, P426; KISS Z, 1979, FEBS LETT, V108, P185, DOI 10.1016/0014-5793(79)81206-5; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRAFT N, 1970, AUST J BIOL SCI, V23, P175, DOI 10.1071/BI9700175; KRAFT N, 1970, BIOCHIM BIOPHYS ACTA, V217, P164, DOI 10.1016/0005-2787(70)90133-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; LIU DK, 1975, BIOCHEM J, V148, P67, DOI 10.1042/bj1480067; Merril C.R., 1990, METHOD ENZYMOL, V182, P477; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; PIROTTE M, 1952, B SOC CHIM BELG, V61, P167; RICHARDS FM, 1971, ENZYMES, V4, P647; ROTH JS, 1967, METHOD CANCER RES, V3, P167; SAJDELSULKOWSKA EM, 1984, SCIENCE, V225, P947, DOI 10.1126/science.6206567; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SUZUKI Y, 1970, J NEUROCHEM, V17, P1521, DOI 10.1111/j.1471-4159.1970.tb00520.x; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WALTERS DW, 1986, J BIOL CHEM, V261, P5372; WALTERS DW, 1986, J BIOL CHEM, V261, P3135; WEAST RC, 1981, CRC HDB CHEM PHYSICS; YANG JT, 1986, METHOD ENZYMOL, V130, P208	46	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28570	28578		10.1074/jbc.270.48.28570	http://dx.doi.org/10.1074/jbc.270.48.28570			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499372	hybrid			2022-12-25	WOS:A1995TH05600016
J	KARKI, S; HOLZBAUR, ELF				KARKI, S; HOLZBAUR, ELF			AFFINITY-CHROMATOGRAPHY DEMONSTRATES A DIRECT BINDING BETWEEN CYTOPLASMIC DYNEIN AND THE DYNACTIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; VESICLE MOTILITY; MICROTUBULES; POLYPEPTIDE; PROTEIN; ACTIN; LOCALIZATION; COMPONENT; TRANSPORT; HOMOLOGY	We used affinity chromatography to probe for a direct binding interaction between cytoplasmic dynein and dynactin. Purified cytoplasmic dynein was found to bind to an affinity column of p150(Glued), the largest polypeptide in the dynactin complex. To test the specificity of the interaction, we loaded rat brain cytosol onto the p150(Glued) affinity column and observed that cytoplasmic dynein from cytosol was specifically retained on the column. Preincubation of the p150(Glued) affinity matrix with excess exogenous dynein intermediate chain resulted in a significant reduction of dynein binding, suggesting that p150(Glued) may be interacting with dynein via this polypeptide. Therefore we constructed an affinity column of recombinant dynein intermediate chain and observed that dynactin was retained from rat brain cytosol. These results demonstrate that the native dynein and dynactin complexes are capable of direct in. vitro interaction mediated by a direct binding of the dynein intermediate chain to the p150(Glued) component of the dynactin complex. We have mapped the site of this interaction to the amino-terminal region of p150(Glued) which is predicted to form an Lu helical coiled-coil. Regulation of the dynein-dynactin interaction may prove to be key in the control mechanism for cytoplasmic dynein-mediated vesicular transport.	UNIV PENN, SCH VET MED, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, CELL BIOL GRAD GRP, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048661] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48661] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ SFH, 1993, J CELL SCI, V106, P955; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; CLARK SW, 1994, J CELL BIOL, V127, P129, DOI 10.1083/jcb.127.1.129; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HARTE PJ, 1982, GENETICS, V101, P477; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; KING SM, 1990, J BIOL CHEM, V265, P19807; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; LACEY ML, 1992, J BIOL CHEM, V267, P4793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1993, J CELL SCI, V105, P579; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; SCHAFER DA, 1994, J CELL BIOL, V126, P402; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; [No title captured]	36	280	285	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28806	28811		10.1074/jbc.270.48.28806	http://dx.doi.org/10.1074/jbc.270.48.28806			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499404	hybrid			2022-12-25	WOS:A1995TH05600048
J	YEDNOCK, TA; CANNON, C; VANDEVERT, C; GOLDBACH, EG; SHAW, G; ELLIS, DR; LIAW, C; FRITZ, LC; TANNER, LI				YEDNOCK, TA; CANNON, C; VANDEVERT, C; GOLDBACH, EG; SHAW, G; ELLIS, DR; LIAW, C; FRITZ, LC; TANNER, LI			ALPHA(4)BETA(1) INTEGRIN-DEPENDENT CELL-ADHESION IS REGULATED BY A LOW-AFFINITY RECEPTOR POOL THAT IS CONFORMATIONALLY RESPONSIVE TO LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; MONOCLONAL-ANTIBODY; GPIIB-IIIA; PLASMA FIBRONECTIN; ENDOTHELIAL-CELLS; ACTIVATION; VCAM-1; VLA-4; RECOGNITION; SPECIFICITY	alpha(4) beta(1) integrin (VLA-4) appears to be unique among the leukocyte integrins in that it can initiate the adhesion of circulating lymphocytes without cellular activation, It is not known how lymphocytes or other cell types maintain constitutive levels of alpha(4) beta(1) integrin activity. The current report describes a monoclonal antibody, 15/7, that recognizes a high affinity or ligand-occupied conformation of beta(1) integrin. Studies with 15/7 revealed that alpha(4) beta(1) integrin-dependent adhesion of leukocytic cell lines is mediated by a population of low affinity receptors that is conformationally responsive to ligand; the 15/7 epitope could be induced by nanomolar concentrations of soluble VCAM-1 or by micromolar concentrations of a peptide derived from the type III connecting segment domain of fibronectin (as ligands for alpha(4) beta(1) integrin). The same receptors were also responsive to adhesion activating reagents, such as Mn2+, activating anti-beta(1) integrin antibodies, and phorbol myristate acetate, which induced the 15/7 epitope directly and/or decreased the concentration of ligand required for epitope induction. In addition to the responsive receptor pool, cells expressed a second population of alpha(4) beta(1) integrin that was conformationally restrained, failing to respond to ligand or to any of the activating reagents. The relative size of the responsive and inactive receptor pools, as well as the affinity of the responsive receptors, represented a stable phenotype of different cell types and played important roles in defining the cells' adhesive capacity and ligand specificity. Similar receptor populations were measured on lymphocyte subsets in whole blood, These studies provide insight into how cells maintain different constitutive levels of alpha(4) beta(1) integrin activity, and how the activity of beta(1) integrin can be modulated by activators of cell adhesion.	ATHENA NEUROSCI INC, San Francisco, CA 94080 USA; GENET INST INC, CAMBRIDGE, MA 02140 USA									ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BEAMES B, 1991, BIOTECHNIQUES, V11, P378; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAILIT J, 1988, J BIOL CHEM, V263, P12927; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HESSION C, 1991, J BIOL CHEM, V266, P6682; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKUBOWSKI A, 1995, J IMMUNOL, V155, P938; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KENT SJ, 1995, J NEUROIMMUNOL, V58, P1, DOI 10.1016/0165-5728(94)00165-K; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; LUSCINSKAS FW, 1995, J EXP MED, V181, P1179, DOI 10.1084/jem.181.3.1179; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MOULD AP, 1990, J BIOL CHEM, V265, P4020; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OVERLY CC, 1991, BIOCHEM BIOPH RES CO, V181, P513, DOI 10.1016/0006-291X(91)91218-2; PARKER CM, 1993, J BIOL CHEM, V268, P7028; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1981, J BIOL CHEM, V256, P9477; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321	49	144	155	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28740	28750		10.1074/jbc.270.48.28740	http://dx.doi.org/10.1074/jbc.270.48.28740			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499396	hybrid			2022-12-25	WOS:A1995TH05600040
J	TU, GC; CAO, QN; ISRAEL, Y				TU, GC; CAO, QN; ISRAEL, Y			INHIBITION OF GENE-EXPRESSION BY TRIPLE-HELIX FORMATION IN HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; T7 RNA-POLYMERASE; ANTISENSE OLIGONUCLEOTIDES; STEREOCONTROLLED SYNTHESIS; ALDEHYDE DEHYDROGENASES; FORMING OLIGONUCLEOTIDE; MOLECULAR ABNORMALITY; BINDING; TRANSCRIPTION; DNA	The aim of this study was to selectively inhibit human mitochondrial aldehyde dehydrogenase (ALDH(2)) gene expression by triple helix assembly. Eight 21-mer oligodeoxyribonucleotides were designed to bind to two purine-rich sequences in the 5'-flanking region of the human ALDH(2) gene. Gel mobility shift assays showed that tripler formation is sequence-specific for the target duplex and the third strand oligonucleotide, In the presence of Mg2+, but absence of K+, tripler-forming oligonucleotides bind to their target sites with apparent dissociation constants (K-d) in the 10(-7) to 10(-9) M range. Potassium cation virtually suppressed the tripler formation of G-C-rich duplex DNA with natural oligonucleotides, but did not prevent tripler formation with phosphorothioate-modified oligonucleotides. Phosphoro-thioate-modified oligonucleotides were delivered into human hepatoma Hep G2 cells by cationic liposomes. The reduction in ALDH(2) mRNA levels in the cells was determined by the competitive reverse transcription-polymerase chain reaction. One of the phosphorothioate-modified oligonucleotides designed to form an antiparallel tripler with a target in the 5'-flanking region of human ALDH(2) gene (-105 to -125 from the translation initiation codon ATG) reduced by 80-90% the ALDH(2) mRNA levels without affecting albumin mRNA levels. Data suggest that triple-helix formation may provide a means to selectively inhibit hepatic ALDH(2) gene expression for therapeutic use.			TU, GC (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT PATHOL ANAT & CELL BIOL, 1020 LOCUST ST, RM 275, PHILADELPHIA, PA 19107 USA.			Israel, Yedy/0000-0003-3468-7966				ADACHI J, 1989, ALCOHOL CLIN EXP RES, V13, P601, DOI 10.1111/j.1530-0277.1989.tb00389.x; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BLUME SW, 1992, NUCLEIC ACIDS RES, V20, P1777; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DURLAND RH, 1994, NUCLEIC ACIDS RES, V22, P3233, DOI 10.1093/nar/22.15.3233; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P275; GALLANT DM, 1987, ALCOHOLISM GUIDE DIA, P170; GAO X, 1993, NUCLEIC ACIDS RES, V21, P2867, DOI 10.1093/nar/21.12.2867; GEE JE, 1995, BIOCHEMISTRY-US, V34, P2042, DOI 10.1021/bi00006a026; GEE JE, 1992, J BIOL CHEM, V267, P11163; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; Gilman A., 1985, PHARM BASIS THERAPEU, Vseventh; GOEDDE HW, 1992, HUM GENET, V88, P344; GOEDDE HW, 1983, PHARMACOL BIOCHEM BE, V18, P161, DOI 10.1016/0091-3057(83)90165-X; GREENFIELD NJ, 1977, BIOCHIM BIOPHYS ACTA, V483, P35, DOI 10.1016/0005-2744(77)90005-5; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HACIA JG, 1994, BIOCHEMISTRY-US, V33, P5367, DOI 10.1021/bi00184a002; HARADA S, 1982, LANCET, V2, P827, DOI 10.1016/s0140-6736(82)92722-2; HEMPEL J, 1989, ENZYMOLOGY MOL BIOL, V2, P3; Hsu LC, 1988, GENOMICS, V2, P57, DOI 10.1016/0888-7543(88)90109-7; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; LAPLANCHE LA, 1986, NUCLEIC ACIDS RES, V14, P9081, DOI 10.1093/nar/14.22.9081; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P7587, DOI 10.1021/bi00148a021; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MCSHAN WM, 1992, J BIOL CHEM, V267, P5712; MILLIGAN JF, 1993, NUCLEIC ACIDS RES, V21, P327, DOI 10.1093/nar/21.2.327; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; OLIVAS WM, 1995, NUCLEIC ACIDS RES, V23, P1936, DOI 10.1093/nar/23.11.1936; OLIVAS WM, 1995, BIOCHEMISTRY-US, V34, P278, DOI 10.1021/bi00001a034; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PILCH DS, 1991, BIOCHEMISTRY-US, V30, P6083, DOI 10.1021/bi00239a001; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; QING NC, 1988, ALCOHOL CLIN EXP RES, V12, P720, DOI 10.1111/j.1530-0277.1988.tb00271.x; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; STEC WJ, 1991, NUCLEIC ACIDS RES, V19, P5883, DOI 10.1093/nar/19.21.5883; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SUSKA A, 1993, PURE APPL CHEM, V65, P707, DOI 10.1351/pac199365040707; SVANAS GW, 1985, ARCH BIOCHEM BIOPHYS, V236, P36, DOI 10.1016/0003-9861(85)90603-4; THOMASSON HR, 1991, AM J HUM GENET, V48, P677; TIPTON KF, 1985, ENZYMOLOGY CARBONYL, V2, P3; TU GC, 1993, EUR J CLIN CHEM CLIN, V31, P591; TU GC, 1995, BEHAV GENET, V25, P59, DOI 10.1007/BF02197242; WICKSTROM E, 1986, J BIOCHEM BIOPH METH, V13, P97, DOI 10.1016/0165-022X(86)90021-7; WILK A, 1995, NUCLEIC ACIDS RES, V23, P530, DOI 10.1093/nar/23.3.530; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Yaswen P, 1993, Antisense Res Dev, V3, P67; YOSHIDA A, 1985, ALCOHOL, V2, P103, DOI 10.1016/0741-8329(85)90024-2; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258	54	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28402	28407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499344				2022-12-25	WOS:A1995TG21000069
J	CODERRE, L; KANDROR, KV; VALLEGA, G; PILCH, PF				CODERRE, L; KANDROR, KV; VALLEGA, G; PILCH, PF			IDENTIFICATION AND CHARACTERIZATION OF AN EXERCISE-SENSITIVE POOL OF GLUCOSE TRANSPORTERS IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE ZUCKER RAT; INDUCED TRANSLOCATION; INSULIN; PROTEINS; MEMBRANES; VESICLES; GLUT4; CONTRACTIONS; STIMULATION; EXPRESSION	Augmentation of glucose transport into skeletal muscle by GLUT4 translocation to the plasma and T-tubule membranes can be mediated independently by insulin and by contraction/exercise. Available data suggest that separable pools of intracellular GLUT4 respond to these two stimuli. To identify and characterize these pools, we fractionated skeletal muscle membranes in a discontinuous sucrose density gradient, Fractions of 32 and 36% sucrose exhibited the highest enrichment of GLUT4 and were independently responsive to insulin and exercise, respectively. The combination of the two stimuli depleted both GLUT4 fractions simultaneously. Both vesicle populations contained the gp160 aminopeptidase, whose expression had previously been shown to be specific to muscle and fat and restricted to GLUT4 vesicles in the latter tissue. In muscle, gp160 translocates exactly as does GLUT4 in response to insulin and exercise. The contraction- and insulin sensitive GLUT4 pools also contained secretory component-associated membrane protein/glucose transporter vesicle triplet but not GLUT1 and caveolin, Immunoadsorption of the two pools followed by silver staining did not reveal any obvious difference in their major protein components. On the other hand, sedimentational analysis in sucrose velocity gradients revealed that the insulin sensitive GLUT4 vesicles had a larger sedimentation coefficient than the exercise-sensitive vesicles, Thus, the separation of the two intracellular GLUT4 pools should be useful in dissecting what are likely to be different signal transduction pathways that mediate their translocation to the cell surface.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Kandror, Konstantin/0000-0002-8601-9313; Pilch, Paul/0000-0003-1997-0499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044269] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAND SH, 1991, J BIOL CHEM, V266, P18949; BROZINICK JT, 1992, J APPL PHYSIOL, V73, P382, DOI 10.1152/jappl.1992.73.1.382; BROZINICK JT, 1994, AM J PHYSIOL, V267, pR236, DOI 10.1152/ajpregu.1994.267.1.R236; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CARTEE GD, 1990, AM J PHYSIOL, V258, pE390, DOI 10.1152/ajpendo.1990.258.2.E390; CODERRE L, 1992, ENDOCRINOLOGY, V131, P1821, DOI 10.1210/en.131.4.1821; CONSTABLE SH, 1988, J APPL PHYSIOL, V64, P2329, DOI 10.1152/jappl.1988.64.6.2329; DOLAN PL, 1993, BIOCHEM J, V289, P423, DOI 10.1042/bj2890423; DOUEN AG, 1989, ENDOCRINOLOGY, V124, P449, DOI 10.1210/endo-124-1-449; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FUSHIKI T, 1989, AM J PHYSIOL, V256, pE580, DOI 10.1152/ajpendo.1989.256.5.E580; GAO JP, 1994, J APPL PHYSIOL, V77, P1597, DOI 10.1152/jappl.1994.77.4.1597; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE795, DOI 10.1152/ajpendo.1991.261.6.E795; GRIMDITCH GK, 1985, AM J PHYSIOL, V249, pE398, DOI 10.1152/ajpendo.1985.249.4.E398; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HANDBERG A, 1992, AM J PHYSIOL, V262, pE721, DOI 10.1152/ajpendo.1992.262.5.E721; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KING PA, 1993, AM J PHYSIOL, V265, pR447, DOI 10.1152/ajpregu.1993.265.2.R447; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; PLOUG T, 1992, AM J PHYSIOL, V262, pE700, DOI 10.1152/ajpendo.1992.262.5.E700; PLOUG T, 1990, AM J PHYSIOL, V259, pE778, DOI 10.1152/ajpendo.1990.259.6.E778; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; TURINSKY J, 1987, ENDOCRINOLOGY, V121, P528, DOI 10.1210/endo-121-2-528; WALLBERGHENRIKS.H, 1988, J APPL PHYSIOL, V65, P909; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZORZANO A, 1989, J BIOL CHEM, V264, P12358; ZORZANO A, 1986, AM J PHYSIOL, V251, pE21, DOI 10.1152/ajpendo.1986.251.1.E21	36	155	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27584	27588		10.1074/jbc.270.46.27584	http://dx.doi.org/10.1074/jbc.270.46.27584			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499220	hybrid			2022-12-25	WOS:A1995TE73600031
J	TERADA, K; KAZIRO, Y; SATOH, T				TERADA, K; KAZIRO, Y; SATOH, T			RAS IS NOT REQUIRED FOR THE INTERLEUKIN 3-INDUCED PROLIFERATION OF A MOUSE PRO-B CELL-LINE, BAF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-2; RECEPTOR TYROSINE KINASES; HA-RAS; PROTEIN-KINASE; BETA-SUBUNIT; MAP KINASE; ACTIVATION; GROWTH; PHOSPHORYLATION; TRANSDUCTION	It has been demonstrated that Res is involved in interleukin 3 (IL-3)-stimulated signal transduction in various hematopoietic cultured cells (Satoh, T., Nakafuku, M., Miyajima, A., and Kaziro, Y. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3314-3318; Duronio, V., Welham, M. J., Abraham, S., Dryden, P., and Schrader, J. W. (1992) Proc. Natl. Acad. Sci. U.S. A. 89, 1587-1591). However, it has not been fully understood which of IL-3-promoted cellular responses, i.e. proliferation, survival, and differentiation, requires Ras function. We employed a system of inducible expression of the dominant-negative (S17N) or dominant-active (G12V) mutant of Ras in BaF3 mouse pro-B cell line to analyze the role of Ras in IL-3-stimulated signal transduction. Induction of the dominant-negative Ras(S17N) effectively inhibited the IL-3-induced activation of c-Raf-1 and mitogen activated protein kinase (MAPK). Furthermore, the activation of fos gene promoter following IL-3 stimulation was almost completely abolished when Ras(Sl7N) was induced. Under these conditions, Ras(S17N) exhibited no inhibitory effect on IL-3-dependent proliferation assessed by the increase of cell numbers and a mitochondrial enzyme activity. The results indicate that Ras-dependent pathways, including the Raf/MAPK/Fos pathway, are dispensable for IL-3 induced growth stimulation. When BaF3 cells were treated with a tyrosine kinase inhibitor, herbimycin A, IL-3 dependent proliferation of the cells was impaired, suggesting that tyrosine kinase-mediated pathways are critical for growth promotion. On the other hand, apoptotic cell death caused by deprivation of IL-3 was prevented by the induction of the activated mutant Ras(G12V), although the rate of cell number increase was markedly reduced. Thus, it is likely that Ras-independent pathways play important roles to facilitate the proliferation although they may not be essential for IL-3-stimulated antiapoptotic signal transduction.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			Satoh, Takaya/K-2628-2014; Terada, Koji/G-3049-2012					ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, MOL CELL BIOL, V15, P4125; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GOTOH Y, 1994, ONCOGENE, V9, P1891; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P2222; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKUDA K, 1994, J BIOL CHEM, V269, P24602; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REIF K, 1994, J BIOL CHEM, V269, P14081; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA T, 1985, P NATL ACAD SCI USA, V82, P3400, DOI 10.1073/pnas.82.10.3400; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	59	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27880	27886		10.1074/jbc.270.46.27880	http://dx.doi.org/10.1074/jbc.270.46.27880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499262	hybrid			2022-12-25	WOS:A1995TE73600073
J	BARLOW, PN; LISTER, MD; SIGLER, PB; DENNIS, EA				BARLOW, PN; LISTER, MD; SIGLER, PB; DENNIS, EA			PROBING THE ROLE OF SUBSTRATE CONFORMATION IN PHOSPHOLIPASE-A2 ACTION ON AGGREGATED PHOSPHOLIPIDS USING CONSTRAINED PHOSPHATIDYLCHOLINE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of Chicago; University of California System; University of California San Diego			Barlow, Paul N/G-2853-2011; Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22324] Funding Source: Medline; PHS HHS [20501] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMICH M, 1979, BIOCHEMISTRY-US, V18, P3308, DOI 10.1021/bi00582a017; BARLOW PN, 1988, CHEM PHYS LIPIDS, V46, P157, DOI 10.1016/0009-3084(88)90017-5; BONSEN PPM, 1972, BIOCHIM BIOPHYS ACTA, V270, P364, DOI 10.1016/0005-2760(72)90200-7; DARKE PL, 1980, BIOCHIM BIOPHYS ACTA, V626, P154, DOI 10.1016/0005-2795(80)90206-8; Deems R.A., 1981, Methods in Enzymology, V71, P703; Dennis EA, 1983, ENZYMES, P307; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DITTMER JC, 1964, J LIPID RES, V5, P126; Hancock A J, 1981, Methods Enzymol, V72, P640; HANCOCK AJ, 1982, J LIPID RES, V23, P183; HANCOCK AJ, 1975, J LIPID RES, V16, P300; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; HAZLETT TL, 1985, TOXICON, V23, P457, DOI 10.1016/0041-0101(85)90029-7; HAZLETT TL, 1985, BIOCHEMISTRY-US, V24, P6152, DOI 10.1021/bi00343a018; Hoult J.R.S., METHODS ENZYMOLOGY, P443, DOI [10.1016/0076-6879(94)34115-X, DOI 10.1016/0076-6879(94)34115-X, DOI 10.1016/0076-6879(67)10072-4]; KEITH C, 1981, J BIOL CHEM, V256, P8602; PIETERSON WA, 1974, BIOCHEMISTRY-US, V13, P1455, DOI 10.1021/bi00704a021; PLUCKTHUN A, 1985, BIOCHEMISTRY-US, V24, P4201, DOI 10.1021/bi00336a058; PLUCKTHUN A, 1986, BIOCHIM BIOPHYS ACTA, V856, P144, DOI 10.1016/0005-2736(86)90021-0; ROBERTS MF, 1978, BIOCHEMISTRY-US, V17, P935, DOI 10.1021/bi00598a030; ROBERTS MF, 1979, BIOCHEMISTRY-US, V18, P3301, DOI 10.1021/bi00582a016; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; TAUSK RJM, 1974, BIOPHYS CHEM, V2, P175, DOI 10.1016/0301-4622(74)80004-9; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WELLS MA, 1972, BIOCHEMISTRY-US, V11, P1030, DOI 10.1021/bi00756a013	25	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12954	12958						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417646				2022-12-25	WOS:A1988Q091700031
J	FUKUNAGA, BN; PROBST, MR; REISZPORSZASZ, S; HANKINSON, O				FUKUNAGA, BN; PROBST, MR; REISZPORSZASZ, S; HANKINSON, O			IDENTIFICATION OF FUNCTIONAL DOMAINS OF THE ARYL-HYDROCARBON RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOBIOTIC RESPONSIVE ELEMENTS; NUCLEAR TRANSLOCATOR PROTEIN; DNA-BINDING ACTIVITY; HEAT-SHOCK PROTEIN; AH-RECEPTOR; DIOXIN RECEPTOR; LIGAND; TRANSCRIPTION; CLONING; HSP90	Functional domains of the mouse aryl hydrocarbon receptor (Ahr) were investigated by deletion analysis. Ligand binding was localized to a region encompassing the PAS B repeat. The ligand-mediated dissociation of Ahr from the 90-kDa heat shock protein (HSP90) does not require the aryl hydrocarbon receptor nuclear translocator (Amt), but it is slightly enhanced by this protein. One HSP90 molecule appears to bind within the PBS region. The other molecule of HSP90 appears to require interaction at two sites: one over the basic helix-loop-helix region, and the other located within the PAS region. Each mutant was analyzed for dimerization with full-length mouse Amt and subsequent binding of the dimer to the xenobiotic responsive element (XRE). In order to minimize any artificial steric hindrances to dimerization and XRE binding, each Ahr mutant was also tested with an equivalently deleted Arnt mutant. The basic region of Ahr is required for XRE binding but not for dimerization. Both the first and second helices of the basic helix-loop-helix motif and the PAS region are required for dimerization. These last results are analogous to those previously obtained for Arnt (Reisz-Porszasz, S., Probst, M.R., Fukunaga, B. N., and Hankinson, O. (1994) Mol. Cell. Biol. 14, 6075-6086) compatible with the notion that equivalent regions of Ahr and Amt associate with each other. Deletion of the carboxyl-terminal half of Ahr does not affect dimerization or XRE binding but, in contrast to an equivalent deletion of Arnt, eliminates biological activity as assessed by an in vitro transcriptional activation assay, suggesting that this region of Ahr plays a more prominent role in transcriptional activation of the cyp1a1 gene than the corresponding region of Amt.	UNIV CALIF LOS ANGELES, STRUCT BIOL & MOLEC MED LAB, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NCI NIH HHS [CA 28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; BACSI SG, 1995, MOL PHARMACOL, V47, P432; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HS, 1994, J BIOL CHEM, V269, P27554; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1991, METHOD ENZYMOL, V206, P381; HENRY EC, 1989, BIOCHEMISTRY-US, V28, P6430, DOI 10.1021/bi00441a041; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1994, J BIOL CHEM, V269, P28098; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; POLAND A, 1994, MOL PHARMACOL, V46, P915; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHUE GL, 1994, J BIOL CHEM, V269, P2707; WATSON AJ, 1992, J BIOL CHEM, V267, P6874; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	40	234	243	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29270	29278		10.1074/jbc.270.49.29270	http://dx.doi.org/10.1074/jbc.270.49.29270			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493958	hybrid			2022-12-25	WOS:A1995TJ22700039
J	NICOLAS, JP; LAMBEAU, G; LAZDUNSKI, M				NICOLAS, JP; LAMBEAU, G; LAZDUNSKI, M			IDENTIFICATION OF THE BINDING DOMAIN FOR SECRETORY PHOSPHOLIPASES A(2) ON THEIR M-TYPE 180-KDA MEMBRANE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE MANNOSE RECEPTOR; HIGH-AFFINITY BINDING; CARBOHYDRATE-RECOGNITION DOMAINS; PANCREATIC-TYPE PHOSPHOLIPASE-A2; AMINO-ACID-SEQUENCE; TOXIC PHOSPHOLIPASES-A2; SKELETAL-MUSCLE; BLOOD-PLASMA; EXPRESSION; VENOM	The rabbit muscle (M)-type receptor for secretory phospholipases A(2) (sPLA(2)s) has a large extracellular domain of 1394 amino acids, composed of an N-terminal cysteine-rich domain, a fibronectin-like type II domain, and eight carbohydrate recognition domains (CRDs). It is thought to mediate some of the physiological effects of mammalian sPLA(2)s, including vascular smooth muscle contraction and cell proliferation, and is able to internalize sPLA(2)s. Here, we show by site directed mutagenesis that OS1, a snake venom sPLA(2), binds to the receptor via its CRDs and that deletion of CRD 5 completely abolishes the binding of sPLA(2)s. Moreover, a receptor lacking all CRDs but CRD 5 was still able to bind OS1 although with a lower affinity. Deletion of CRDs 4 and 6, surrounding the CRD 5, slightly reduced the affinity for OS1, thus suggesting that these CRDs are also involved in the binding of OS1. The M-type sPLA(2) receptor and the macrophage mannose receptor are homologous and are predicted to share the same tertiary structure. p-Aminophenyl-alpha-D-mannopyranoside bovine serum albumin, a known ligand of the macrophage mannose receptor, binds to the M-type sPLA(2) receptor essentially via CRDs 3-6.	CNRS, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE	Centre National de la Recherche Scientifique (CNRS)			Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X				ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ANCIAN P, 1995, IN PRESS BIOCHEMISTR; [Anonymous], 1994, PROGRAM MANUAL WISCO; ARITA H, 1991, J BIOL CHEM, V266, P19139; BOMALASKI JS, 1991, J IMMUNOL, V146, P3904; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENIS EA, 1994, J BIOL CHEM, V269, P13057; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FISHER AB, 1994, BBA-LIPID LIPID MET, V1211, P256, DOI 10.1016/0005-2760(94)90148-1; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; Hawgood B., 1991, HDB NATURAL TOXINS R, P3; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; INOUE S, 1991, J BIOL CHEM, V266, P1001; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, ADV SEC MESS PHOSPH, V28, P81; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; LAMBEAU G, 1991, FEBS LETT, V293, P29, DOI 10.1016/0014-5793(91)81145-X; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LAMBEAU G, 1991, NEUROCHEM RES, V16, P651, DOI 10.1007/BF00965551; LANGLAIS J, 1992, BIOCHEM BIOPH RES CO, V182, P208, DOI 10.1016/S0006-291X(05)80132-9; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; OHKURA N, 1993, J BIOCHEM-TOKYO, V113, P413, DOI 10.1093/oxfordjournals.jbchem.a124060; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; STRONG PN, 1987, CELLULAR MOL BASIS C, P534; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TOJO H, 1988, J BIOL CHEM, V263, P5724; VADAS P, 1989, AM J PATHOL, V134, P807; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WAITE M, 1987, HDB LIPID RES, P111; YING Z, 1993, EUR J BIOCHEM, V215, P91, DOI 10.1111/j.1432-1033.1993.tb18010.x	50	63	67	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28869	28873		10.1074/jbc.270.48.28869	http://dx.doi.org/10.1074/jbc.270.48.28869			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499413	hybrid			2022-12-25	WOS:A1995TH05600057
J	GETHER, U; LIN, SS; KOBILKA, BK				GETHER, U; LIN, SS; KOBILKA, BK			FLUORESCENT LABELING OF PURIFIED BETA(2) ADRENERGIC-RECEPTOR - EVIDENCE FOR LIGAND-SPECIFIC CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INTRINSIC ACTIVITY; ANTAGONISTS; COMPLEX; SYSTEM	The purpose of the present study was to develop an approach to directly monitor structural changes in a G protein coupled receptor in response to drug binding, Purified human beta(2) adrenergic receptor was covalently labeled with the cysteine-reactive, fluorescent probe N,N '-dimethyl-N-(iodoacetyl)-N '-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine (IANBD), IANBD is characterized by a fluorescence which is highly sensitive to the polarity of its environment, We found that the full agonist, isoproterenol, elicited a stereoselective and dose-dependent decrease in fluorescence from IANBD-labeled beta(2) receptor. The change in fluorescence could be plotted against the concentration of isoproterenol as a simple hyperbolic binding isotherm demonstrating interaction with a single binding site in the receptor, The ability of several adrenergic antagonists to reverse the response confirmed that this binding site is identical to the well described binding site in the beta(2) receptor, Comparison of the response to isoproterenol with a series of adrenergic agonists, having different biological efficacies, revealed a linear correlation between biological efficacy and the change in fluorescence, This suggests that the agonist-mediated decrease in fluorescence from IANBD-labeled beta(2) receptor is due to the same conformational change as involved in receptor activation and G protein coupling, In contrast to agonists, negative antagonists induced a small but significant increase in base line fluorescence. Despite the small amplitude of this response, it supports the notion that antagonists by themselves may alter receptor structure, In conclusion, our data provide the first direct evidence for ligand-specific conformational changes occurring in a G protein coupled receptor, Furthermore, the data demonstrate the potential of fluorescence spectroscopy as a tool for further delineating the molecular mechanisms of drug action at G protein-coupled receptors.	STANFORD UNIV, SCH MED, BECKMAN CTR B157, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DIV CARDIOVASC MED, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University				Gether, Ulrik/0000-0002-0020-3807; Kobilka, Brian/0000-0001-5958-3990	NINDS NIH HHS [R01 NS28471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADHAM N, 1993, MOL PHARMACOL, V43, P427; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; CERIONE RA, 1994, METHOD ENZYMOL, V237, P409; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CHIDIAC P, 1995, TRENDS PHARMACOL SCI, V16, P83, DOI 10.1016/S0165-6147(00)88986-5; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; DUNN SMJ, 1993, BIOCHEMISTRY-US, V32, P8608, DOI 10.1021/bi00084a031; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1995, BIOCHEM SOC T, V23, P96, DOI 10.1042/bst0230096; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; JASPER JR, 1992, BIOCHEM PHARMACOL, V43, P119, DOI 10.1016/0006-2952(92)90268-N; KENAKIN T, 1994, TRENDS PHARMACOL SCI, V15, P408, DOI 10.1016/0165-6147(94)90086-8; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; KOBILKA BK, 1995, IN PRESS ANAL BIOCH; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ J, 1983, PRINCIPLES FLUORESCE, P131; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; PHILLIPS WJ, 1991, J BIOL CHEM, V266, P11017; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SURYANARAYANA S, 1991, METHODS, V3, P193	33	258	266	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28268	28275						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499324				2022-12-25	WOS:A1995TG21000049
J	AARONSON, RM; GRAVEN, KK; TUCCI, M; MCDONALD, RJ; FARBER, HW				AARONSON, RM; GRAVEN, KK; TUCCI, M; MCDONALD, RJ; FARBER, HW			NONNEURONAL ENOLASE IS AN ENDOTHELIAL HYPOXIC STRESS PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLYCOLYTIC ENZYME ENOLASE; SEROTONIN UPTAKE; BINDING-PROTEIN; MESSENGER-RNAS; CELLS; GAMMA; LOCALIZATION; EXPRESSION; CENTROSOME	The hypoxia-associated proteins (HAPs) are five cell associated stress proteins (M(r) 34, 36, 39, 47, and 57) upregulated in cultured vascular endothelial cells (EC) exposed to hypoxia, While hypoxic exposure of other cell types induces heat shock and glucose-regulated proteins, EC preferentially up-regulate HAPs. In order to identify the 47 kDa HAP, protein from hypoxic bovine EC lysates was isolated, digested with trypsin, and sequenced. Significant identity was found with enolase, a glycolytic enzyme. Western analyses confirmed that non-neuronal enolase (NNE) is up-regulated in hypoxic EC. Western analysis of subcellular fractions localized NNE primarily to the cytoplasm and confirmed that it was up-regulated 2.3-fold by hypoxia. Interestingly, NNE also appeared in the nuclear fraction of EC but was unchanged by hypoxia. Northern analyses revealed that NNE mRNA hypoxic up-regulation began at 1-2 h, peaked at 18 h, persisted for 48 h, and returned to base line after return to 21% O-2 for 24 h, Hypoxia maximally up-regulated NNE mRNA levels 3.4-fold, While hypoxic up-regulation of NNE may have a protective effect by augmenting anaerobic metabolism, we speculate that enolase may contribute to EC hypoxia tolerance through one or more of its nonglycolytic functions.	BOSTON UNIV,SCH MED,CTR PULM,BOSTON,MA 02118	Boston University				Farber, Harrison/0000-0002-0297-7902	NHLBI NIH HHS [HL-03125, HL-45537] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045537] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALGIERY AG, BIOCHIM BIOPHYS ACTA, V1159, P134; ANG D, 1991, J BIOL CHEM, V266, P24233; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BRADY ST, 1981, CELL, V23, P515, DOI 10.1016/0092-8674(81)90147-1; CAMPISI J, 1984, CELL, V37, P241; DWYER BE, 1989, EXP NEUROL, V104, P28, DOI 10.1016/0014-4886(89)90005-8; FARBER HW, 1991, CIRC RES, V68, P1446, DOI 10.1161/01.RES.68.5.1446; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GERBITZ KD, 1986, J CLIN CHEM CLIN BIO, V24, P1009; GRAVEN KK, 1994, J BIOL CHEM, V269, P24446; GRAVEN KK, 1993, J CELL PHYSIOL, V157, P544, DOI 10.1002/jcp.1041570314; HAIMOTO H, 1985, LAB INVEST, V52, P257; HATTORI T, 1994, BIOCHEM BIOPH RES CO, V202, P25, DOI 10.1006/bbrc.1994.1888; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; IIDA H, 1985, NATURE, V315, P688, DOI 10.1038/315688a0; ISAWE K, 1986, J CLIN ENDOCR METAB, V63, P94; JOHNSTONE SA, 1992, EXP CELL RES, V202, P458, DOI 10.1016/0014-4827(92)90099-T; KATAGIRI T, 1993, MOL BRAIN RES, V19, P1, DOI 10.1016/0169-328X(93)90142-C; KELLER A, 1994, J NEUROSCI RES, V38, P493, DOI 10.1002/jnr.490380503; KNOWLTON AA, 1991, J CLIN INVEST, V87, P139, DOI 10.1172/JCI114963; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEE SL, 1986, AM J PHYSIOL, V250, pC766, DOI 10.1152/ajpcell.1986.250.5.C766; LEE SL, 1987, CIRC RES, V60, P653, DOI 10.1161/01.RES.60.5.653; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; MARANGOS PJ, 1980, BRAIN RES, V190, P185, DOI 10.1016/0006-8993(80)91168-3; MATHUR RL, 1992, EXP EYE RES, V54, P253, DOI 10.1016/S0014-4835(05)80215-5; MERTENS S, 1990, AM J PHYSIOL, V258, pH689, DOI 10.1152/ajpheart.1990.258.3.H689; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; PESHAVARIA M, 1990, BIOCHEM SOC T, V18, P254, DOI 10.1042/bst0180254; RATTNER JB, 1991, J IMMUNOL, V146, P2341; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; REDLITZ A, 1995, EUR J BIOCHEM, V227, P404; SCHMECHEL DE, 1985, LAB INVEST, V52, P239; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; TANAKA M, 1985, BIOCHEM BIOPH RES CO, V133, P868, DOI 10.1016/0006-291X(85)91215-X; TRETYAKOV AV, 1995, J CLIN INVEST, V95, P738, DOI 10.1172/JCI117721; TRETYAKOV AV, 1993, AM J PHYSIOL, V265, pC770, DOI 10.1152/ajpcell.1993.265.3.C770; VINORES SA, 1986, HISTOPATHOLOGY, V10, P891; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9; WALSH JL, 1988, BIOCHIM BIOPHYS ACTA, V952, P83, DOI 10.1016/0167-4838(88)90104-5; ZIMMERMAN LH, 1991, J CLIN INVEST, V87, P908, DOI 10.1172/JCI115097	42	122	129	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27752	27757		10.1074/jbc.270.46.27752	http://dx.doi.org/10.1074/jbc.270.46.27752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499243				2022-12-25	WOS:A1995TE73600054
J	SPARAGNA, GC; GUNTER, KK; SHEN, SS; GUNTER, TE				SPARAGNA, GC; GUNTER, KK; SHEN, SS; GUNTER, TE			MITOCHONDRIAL CALCIUM-UPTAKE FROM PHYSIOLOGICAL-TYPE PULSES OF CALCIUM - A DESCRIPTION OF THE RAPID UPTAKE MODE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-MITOCHONDRIA; INTRAMITOCHONDRIAL METABOLISM; OXIDATIVE-PHOSPHORYLATION; PYRUVATE-DEHYDROGENASE; HEART-MITOCHONDRIA; CARDIAC-MUSCLE; RAT-HEART; MEMBRANE; CA-2+; STIMULATION	A controversy in the field of bioenergetics has been whether mitochondria are capable of sequestering enough Ca2+ from cytosolic Ca2+ pulses to raise their intramitochondrial free Ca2+ level ([Ca2+](m)). This is significant because an increase in [Ca2+](m) has been linked to an increase in cellular metabolic rate through various mechanisms, To resolve this question, we exposed isolated liver mitochondria to physiological type pulses of Ca2+ produced using a pulse-generating system (Sparagna, G. C., Gunter, K. K., and Gunter, T. E. (1994) Anal. Biochem. 219, 96-103). We then measured the resulting mitochondrial Ca2+ uptake, The uniporter was previously thought to be the only specific Ca2+ uptake mechanism in mitochondria, Our studies have uncovered an additional uptake mechanism, the rapid mode of uptake or RaM, which functions at the beginning of each pulse and allows mitochondria to sequester a considerable amount of Ca2+ from short pulses, We have shown that the RaM is reset by decreasing the [Ca2+] between pulses for a very short time, making this uptake mode ideally suited for Ca2+ sequestration from Ca2+ pulse sequences, With rapid Ca2+ uptake occurring at the beginning of each pulse, liver mitochondria may be able to sequester sufficient Ca2+ from a short sequence of pulses to activate the cellular metabolic rate.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOPHYS, ROCHESTER, NY 14642 USA	University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35550] Funding Source: Medline; PHS HHS [27334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROWN GC, 1992, BIOCHEM J, V284, P1; CROMPTON M, 1990, BIOCHEM J, V266, P33, DOI 10.1042/bj2660033; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; GUNTER KK, 1991, J BIOL CHEM, V266, P21640; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1987, BIOCHEM J, V244, P159, DOI 10.1042/bj2440159; HALESTRAP AP, 1993, METHODS TOXICOL, V2, P365; HANSFORD RG, 1990, BIOCHIM BIOPHYS ACTA, V1018, P282, DOI 10.1016/0005-2728(90)90268-9; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; LEISEY JR, 1993, AM J PHYSIOL, V265, pH1203; MCCORMACK JG, 1984, BIOCHEM J, V218, P235, DOI 10.1042/bj2180235; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1985, BIOCHEM SOC T, V13, P664, DOI 10.1042/bst0130664; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MORAVEC CS, 1991, AM J PHYSIOL, V260, pH989, DOI 10.1152/ajpheart.1991.260.3.H989; MORAVEC CS, 1992, J BIOL CHEM, V267, P5310; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P4028; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P2554; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; SOMLYO AP, 1985, BIOCHEM BIOPH RES CO, V132, P1071, DOI 10.1016/0006-291X(85)91916-3; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; SOMLYO AP, 1984, NATURE, V309, P516, DOI 10.1038/309516b0; SPARAGNA GC, 1994, ANAL BIOCHEM, V219, P96, DOI 10.1006/abio.1994.1236; WAN B, 1993, AM J PHYSIOL, V265, pH453, DOI 10.1152/ajpheart.1993.265.2.H453; WENDTGALLITELLI MF, 1991, J PHYSIOL-LONDON, V435, P349, DOI 10.1113/jphysiol.1991.sp018514; WINGROVE DE, 1986, J BIOL CHEM, V261, P5159; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390; YAMADA EW, 1988, J BIOL CHEM, V263, P11498	33	248	253	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27510	27515		10.1074/jbc.270.46.27510	http://dx.doi.org/10.1074/jbc.270.46.27510			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499209	hybrid			2022-12-25	WOS:A1995TE73600020
J	THOMAS, RS; TYMMS, MJ; SETH, A; SHANNON, MF; KOLA, I				THOMAS, RS; TYMMS, MJ; SETH, A; SHANNON, MF; KOLA, I			ETS1 TRANSACTIVATES THE HUMAN GM-CSF PROMOTER IN JURKAT T-CELLS STIMULATED WITH PMA AND IONOMYCIN	ONCOGENE			English	Article						GRANULOCYTE-MACROPHAGE; COLONY-STIMULATING FACTOR; GM-CSF; ETS1; ELF1; TRANSCRIPTION	LONG TERMINAL REPEAT; VIRUS TYPE-I; DNA-BINDING; LEUKEMIA-VIRUS; INFLAMMATORY RESPONSES; TRANSCRIPTION FACTORS; C-ETS-1 PROTEIN; GENE PROMOTER; ACTIVATION; EXPRESSION	Activation of T helper cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one such cytokine whose increased expression results partly from increases in transcription. Cis-acting elements with NF kappa B, AP-1 and ETS-like motifs have been identified in the promoter region of the GM-CSF gene, which are important for transcriptional activity following PMA and ionomycin stimulation. A number of the ETS family of transcription factors are expressed in T cells, including ETS1 and ELF1. Here we describe the ability of these factors to interact with a site (GM5), located within the CLE0 element, -47 to -40 upstream of the GM-CSF transcription initiation site. Exogenous ETS1, but not ELF1, can transactivate GM-CSF, through the GM5 site, in a PMA/ionomycin dependent manner. Other unidentified ETS-like factors present in Jurkat cells are also capable of binding GM5. Mutation of the core ETS binding site from -GGAA- to -GGAT- prevents the binding of ETS-like factors with the exception of ETS1. The GM-CSF promoter, modified in this way to be ETS1 specific, is fully responsive to PMA/ionomycin induction, in addition to ETS1 transactivation in the presence of PMA and ionomycin. Together these data suggest that ETS1 may be involved in mediating the increased GM-CSF production associated with T cell activation.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,MOLEC GENET & DEV GRP,MELBOURNE,VIC 3168,AUSTRALIA; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; INST MED & VET SCI,HANSON CTR CANC RES,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Monash University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institute Medical & Veterinary Science Australia			Thomas, Ross/C-6434-2008; Kola, Ismail/C-5254-2013					ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASCIONE R, 1992, INT J ONCOL, V1, P631; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRORSON KA, 1991, J IMMUNOL, V147, P3601; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; FISHER CI, 1991, J IMMUNOL, V6, P1743; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1991, ONCOGENE, V6, P2249; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOYANONAKAGAWA N, 1993, INT IMMUNOL, V5, P345, DOI 10.1093/intimm/5.4.345; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; POGNONEC P, 1990, ONCOGENE, V5, P603; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAZANAJAONA D, 1992, CELL GROWTH DIFFER, V3, P299; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452	54	40	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2135	2143						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478534				2022-12-25	WOS:A1995TF29700025
J	BRUMMER, J; NEUMAIER, M; GOPFERT, C; WAGENER, C				BRUMMER, J; NEUMAIER, M; GOPFERT, C; WAGENER, C			ASSOCIATION OF PP60(C-SRC) WITH BILIARY GLYCOPROTEIN (CD66A), AN ADHESION MOLECULE OF THE CARCINOEMBRYONIC ANTIGEN FAMILY DOWN-REGULATED IN COLORECTAL CARCINOMAS	ONCOGENE			English	Article						SRC; TYROSINE KINASE; ONCOGENE; TUMOR-SUPPRESSOR; CELL ADHESION	GENE FAMILY; MONOCLONAL-ANTIBODIES; MODEL SYSTEM; ECTO-ATPASE; CELL-LINES; MEMBER; EXPRESSION; PP60C-SRC; CLONING; PROTEIN	CD66a, also known as 'biliary glycoprotein (BGP)', is the human homologue of a cell adhesion molecule (CAM) of the rat (Cell-CAM). CD66a, which belongs to the carcinoembryonic antigen family and the immunoglobulin superfamily, is expressed in cells of myeloid and epithelial origin. The cytoplasmic domain of the major isoform of CD66a (CD66a(cyt)) contains. two tyrosine residues in amino acid motifs potentially interacting with protein tyrosine kinases of the Src family. Here we provide evidence that CD66a is associated with pp60(c-src). From membrane fractions of granulocytes and the colonic cell line HT29, phosphokinase activity was co-immunoprecipitated with CD66a when monoclonal CD66 antibodies or an antiserum against the recombinant cytoplasmic domain of CD66a were used. From the dissociated immunecomplexes, a phosphokinase of M(r) 60 000 was reprecipitated using antibodies against pp60(c-src). In vitro, the recombinant cytoplasmic domain was a substrate and binding partner of pp60(c-src). Phosphopeptides corresponding to the tyrosine containing amino acid sequences of CD66a, activated the kinase activity of pp60(c-src) to a greater extent than a phosphopeptide containing Tyr(527) from the SH2-binding regulatory domain of pp60(c-src). The down-regulation of CD66a in about 80% of colorectal carcinomas may contribute to a dysregulation of pp60(c-src) in colorectal cancer.	UNIV HAMBURG, HOSP EPPENDORF, MED KLIN, KLIN CHEM ABT, D-20246 HAMBURG, GERMANY	University of Hamburg								AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; HARLOW E, 1988, ANTIBODIES LABORATOR; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HSIEH JT, 1995, CANCER RES, V55, P190; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; LIN SH, 1989, J BIOL CHEM, V264, P14408; NAGEL G, 1993, EUR J BIOCHEM, V214, P27, DOI 10.1111/j.1432-1033.1993.tb17892.x; NEUMAIER M, 1985, J IMMUNOL, V135, P3604; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; SKUBITZ KM, 1993, FEBS LETT, V318, P200, DOI 10.1016/0014-5793(93)80021-L; SKUBITZ KM, 1994, LEUKOCYTE TYPINE, V5; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STOCKS SC, 1993, BIOCHEM BIOPH RES CO, V195, P478, DOI 10.1006/bbrc.1993.2068; STOFFEL A, 1993, J IMMUNOL, V150, P4978; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; THOMPSON J, 1994, J BIOL CHEM, V269, P32924; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; WAGENER C, 1983, J IMMUNOL, V130, P2302; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	123	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1649	1655						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478590				2022-12-25	WOS:A1995TC53500024
J	VIGLIETTO, G; MAGLIONE, D; RAMBALDI, M; CERUTTI, J; ROMANO, A; TRAPASSO, F; FEDELE, M; IPPOLITO, P; CHIAPPETTA, G; BOTTI, G; FUSCO, A; PERSICO, MG				VIGLIETTO, G; MAGLIONE, D; RAMBALDI, M; CERUTTI, J; ROMANO, A; TRAPASSO, F; FEDELE, M; IPPOLITO, P; CHIAPPETTA, G; BOTTI, G; FUSCO, A; PERSICO, MG			UP-REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) AND DOWN-REGULATION OF PLACENTA GROWTH-FACTOR (PIGF) ASSOCIATED WITH MALIGNANCY IN HUMAN THYROID-TUMORS AND CELL-LINES	ONCOGENE			English	Article						HUMAN THYROID; P1GF; VEGF; TUMOR; ANGIOGENESIS	PERMEABILITY FACTOR; TYROSINE KINASE; DEVELOPMENTAL EXPRESSION; NUCLEOTIDE-SEQUENCE; STROMA GENERATION; ANGIOGENIC FACTOR; RIBONUCLEIC-ACID; MESSENGER-RNA; FACTOR-ALPHA; FACTOR GENE	Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells in vitro, promotes neoangiogenesis in vivo and increases the permeability of the vascular endothelium. VEGF overexpression occurs in several cultured tumor cell lines and in certain human malignancies, Placenta growth factor (PIGF) is a recently identified growth factor for endothelial cells (EC); PIGF strongly potentiates both the proliferative and the permeabilization effects exerted by VEGF on the vascular endothelium, To uncover the molecular mechanisms underlying neoangiogenesis in human thyroid tumors, we have analysed VEGF and PIGF expression in a panel of thyroid carcinoma cell lines with different tumorigenic potential as well as in human primary thyroid tumors, We show that a high tumorigenic potential is associated with an elevated VEGF expression in human thyroid tumor cell lines, Furthermore, VEGF overexpression occurs in 5/5 highly malignant anaplastic carcinomas, Papillary and follicular carcinomas express intermediate levels of VEGF mRNA. In contrast, PIGF expression is severely down regulated in the majority of thyroid tumor cell lines and in tumors, Furthermore, we show that both the VEGF receptors, FLT-1 and flk/KDR, are expressed in endothelial cells that line tumor-embedded microvascular vessels, suggesting that VEGF but not PIGF, contributes to thyroid tumor development.	FAC MED & CHIRURG,CNR,CTR ONCOL SPERIMENTALE,DIPARTIMENTO BIOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	VIGLIETTO, G (corresponding author), IST NAZL TUMORI,FDN SENATORE PASCALE,VIA M SEMMOLA,I-80131 NAPLES,ITALY.		Cerutti, Janete/D-3513-2014; Viglietto, Giuseppe/AAC-2852-2019; Fedele, Monica/C-1417-2015; Cerutti, Janete M/E-9121-2014	Viglietto, Giuseppe/0000-0003-2327-7515; Fedele, Monica/0000-0002-9171-1312; Botti, Gerardo/0000-0002-6287-733X; Cerutti, Janete/0000-0003-0156-8274; Fusco, Alfredo/0000-0003-3332-5197				BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BROWN LF, 1993, CANCER RES, V53, P4727; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FABIEN N, 1993, CANCER, V73, P2206; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KIESER A, 1994, ONCOGENE, V9, P963; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MONACCI WT, 1993, AM J PHYSIOL, V264, P995; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAKAMURA T, 1992, JPN J CANCER RES, V83, P1293, DOI 10.1111/j.1349-7006.1992.tb02761.x; OLSON TA, 1994, CANCER RES, V54, P276; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISHER E, 1991, J BIOL CHEM, V266, P11974; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WILSON JD, 1989, TXB ENDOCRINOLOGY; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; ZEKI K, 1991, J CLIN ENDOCR METAB, V76, P125	70	204	210	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1569	1579						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478581				2022-12-25	WOS:A1995TC53500015
J	HUANG, Y; SAEZ, R; CHAO, L; SANTOS, E; AARONSON, SA; CHAN, AML				HUANG, Y; SAEZ, R; CHAO, L; SANTOS, E; AARONSON, SA; CHAN, AML			A NOVEL INSERTIONAL MUTATION IN THE TC21 GENE ACTIVATES ITS TRANSFORMING ACTIVITY IN A HUMAN LEIOMYOSARCOMA CELL-LINE	ONCOGENE			English	Article						RAS; TC21; ONCOGENE; SSCP; MUTATION; LEIOMYOSARCOMA	RAS-RELATED GENE; MOLECULAR SWITCH; DIRECT REPEATS; DELETIONS; ONCOGENES; PROTEIN	TC21 is the fourth member of the pas gene family to exhibit oncogenic activation in human tumor cells. To assess the prevalence of activated TC21 oncogenes in human tumors, we have developed sensitive single-strand conformational polymorphism (SSCP) conditions and immunological reagents for the detection of both single base alterations and/or overt overexpression in a wide spectrum of human tumor cell lines and surgical samples. In an initial examination of 33 human tumor specimens, we observed a novel nine basepair three amino acids insertion at TC21 codon 24 in one human uterine leiomyosarcoma cell line, SK-UT-1. This mutant allele when transfected into NIH3T3 cells, displayed high transforming activity comparable to that of the Leu72 oncogenic mutant identified by expression cDNA cloning from a human ovarian carcinoma cell line. Comparing the level of GTP-binding by the mutant and normal TC21 products revealed that this novel lesion increases the GTP-bound form of the TC21 molecule. These findings imply that the mechanism by which mutations activate the oncogenic properties of this ras-related molecule is analogous to that of previously known ras family members.	MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; COX AD, 1994, ONCOGENE, V9, P3281; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GERNER RE, 1975, ANN SURG, V181, P803, DOI 10.1097/00000658-197506000-00007; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; JEGO N, 1993, ONCOGENE, V8, P209; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PATTERSON H, 1994, BRIT J CANCER, V69, P1052, DOI 10.1038/bjc.1994.207; PORRAS A, 1992, J BIOL CHEM, V267, P21124; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4648; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	26	46	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1255	1260						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478545				2022-12-25	WOS:A1995RY96700005
J	CALERO, M; ESCRIBANO, J; GRUBB, A; MENDEZ, E				CALERO, M; ESCRIBANO, J; GRUBB, A; MENDEZ, E			LOCATION OF A NOVEL TYPE OF INTERPOLYPEPTIDE CHAIN LINKAGE IN THE HUMAN PROTEIN HC-IGA COMPLEX (HC-IGA) AND IDENTIFICATION OF A HETEROGENEOUS CHROMOPHORE ASSOCIATED WITH THE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FORMING GLYCOPROTEIN; INTERNAL THIOLESTER; BINDING PROTEIN; CHARGE; ALPHA-1-MICROGLOBULIN; BOND; POLYPEPTIDE; COMPONENT; PLASMA	Protein HC (human complex-forming glycoprotein, heterogeneous in charge) is a member of the lipocalin superfamily of hydrophobic ligand-binding proteins. The quantitatively dominating blood plasma form of protein HC is a protein HC-IgA complex (HC-IgA), which is the fourth most abundant immunoglobulin species in plasma. A photodiode array detection system on-line with a high performance liquid chromatograph has allowed the identification of low amounts of a heterogeneous fluorescent chromophore covalently bound to HC-IgA, and displaying significant absorption in the visible region in resemblance to the free protein HC chromophore. Several structurally related chromophore-containing linked peptides, carrying 80% of the light absorption at 330 nm of HC-IgA, were isolated from a pepsin-produced protein HC-alpha1-nonapeptide. Sequence analysis of these linked peptides demonstrated that the bond between protein HC and IgA represents a novel type of reduction-resistant linkage between polypeptide chains and involves the cysteine residue 34 of protein HC and the penultimate cysteine residue of the carboxyl-terminal part of one of the IgA heavy chains, as well as the heterogeneous fluorescent chromophore. The light absorption and fluorescent spectra of the chromophore-linked peptides were similar to those of native free protein HC.	UNIV LUND HOSP, DEPT CLIN CHEM, S-22185 LUND, SWEDEN; CTR ESPECIAL RAMON & CAJAL, SERV ENDOCRINOL, MADRID 34, SPAIN	Lund University; Skane University Hospital			Calero, Miguel/H-5691-2015; Escribano, Julio/D-9742-2015	Calero, Miguel/0000-0001-5366-3324; Escribano, Julio/0000-0002-8919-8134; Grubb, Anders/0000-0002-0125-3662				AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; BABIKERMOHAMED H, 1990, SCAND J IMMUNOL, V32, P37, DOI 10.1111/j.1365-3083.1990.tb02889.x; BERNIER I, 1980, EXPERIENTIA, V36, P1419, DOI 10.1007/BF01960136; BIZZOZERO OA, 1990, J NEUROCHEM, V55, P1986, DOI 10.1111/j.1471-4159.1990.tb05786.x; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIEHANOVER A, 1980, P NATL ACAD SCI USA, V77, P1365; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EKSTROM B, 1977, J BIOL CHEM, V252, P8048; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ESCRIBANO J, 1991, J BIOL CHEM, V266, P15758; FALKENBERG C, 1990, J BIOL CHEM, V265, P16150; FERNANDEZLUNA JL, 1988, FEBS LETT, V236, P471, DOI 10.1016/0014-5793(88)80079-6; FERNANDEZLUNA JL, 1988, J CLIN PATHOL, V41, P1176, DOI 10.1136/jcp.41.11.1176; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; GAVILANES JG, 1984, BIOCHEMISTRY-US, V23, P1234, DOI 10.1021/bi00301a033; GEBHARD W, 1990, FEBS LETT, V269, P32, DOI 10.1016/0014-5793(90)81112-2; GRUBB A, 1986, J BIOL CHEM, V261, P14313; GRUBB A, 1992, CLIN NEPHROL, V38, pS20; GRUBB AO, 1983, J BIOL CHEM, V258, P4698; HAEFLIGER JA, 1987, BIOCHEM BIOPH RES CO, V149, P750, DOI 10.1016/0006-291X(87)90431-1; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; IMAI H, 1992, CLIN NEPHROL, V37, P169; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; ITOH Y, 1990, J CLIN LAB ANAL, V4, P376, DOI 10.1002/jcla.1860040511; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERCH K, 1982, J BIOL CHEM, V257, P6414; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MENDEZ E, 1986, P NATL ACAD SCI USA, V83, P1472, DOI 10.1073/pnas.83.5.1472; MENDEZ E, 1973, BIOCHEM BIOPH RES CO, V55, P1291, DOI 10.1016/S0006-291X(73)80034-8; MENDEZ E, 1982, ARCH BIOCHEM BIOPHYS, V213, P240, DOI 10.1016/0003-9861(82)90458-1; MESTECKY J, 1974, P NATL ACAD SCI USA, V71, P544, DOI 10.1073/pnas.71.2.544; MOORE S, 1963, J BIOL CHEM, V238, P235; OTIN CL, 1984, ARCH BIOCHEM BIOPHYS, V228, P544, DOI 10.1016/0003-9861(84)90021-3; PERVAIZ S, 1985, SCIENCE, V228, P335, DOI 10.1126/science.2580349; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; SJOBERG M, 1991, EUR J BIOCHEM, V197, P61, DOI 10.1111/j.1432-1033.1991.tb15882.x; SOTTRUPJENSEN L, 1982, BIOCHEM BIOPH RES CO, V107, P93, DOI 10.1016/0006-291X(82)91674-6; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; TEJLER L, 1976, BIOCHIM BIOPHYS ACTA, V439, P82, DOI 10.1016/0005-2795(76)90164-1; TRUEDSSON L, 1988, SCAND J IMMUNOL, V27, P201, DOI 10.1111/j.1365-3083.1988.tb02340.x; Vincent C, 1987, Adv Exp Med Biol, V216B, P1231; ZAGALSKY PF, 1991, BIOCHEM J, V274, P79, DOI 10.1042/bj2740079	44	22	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					384	389						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506257				2022-12-25	WOS:A1994MR21900065
J	TIEN, XY; BRASITUS, TA; KAETZEL, MA; DEDMAN, JR; NELSON, DJ				TIEN, XY; BRASITUS, TA; KAETZEL, MA; DEDMAN, JR; NELSON, DJ			ACTIVATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR BY CGMP IN THE HUMAN COLONIC-CANCER CELL-LINE, CACO-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTESTINAL GUANYLATE-CYCLASE; PROTEIN-KINASE; CHLORIDE CONDUCTANCE; ENDOGENOUS ACTIVATOR; CAMP; CHANNEL; CFTR; PHOSPHORYLATION; ENTEROTOXIN; EXPRESSION	Intestinal chloride (Cl-) secretion can be induced by the heat-stable enterotoxin (STa) from Escherichia coli via generation of cGMP. We investigated the regulatory pathway responsible for cGMP-mediated Cl- secretion in the human colonic carcinoma cell line Caco-2 using whole-cell voltage clamp techniques. Cyclic GMP or cAMP induced a 5-fold increase in Cl- conductance (g(Cl)) in the presence of intracellular ATP and 3-isobutyl-1-methylxanthine. Current activation by cGMP persisted in the presence of the type I cGMP-dependent protein kinase (PKG) inhibitor, KT5823, but was inhibited by the specific peptide inhibitor of the cAMP-dependent protein kinase A (PKA), PKI5-24. The stimulatory effects of cGMP and cAMP on g(Cl) were not additive. The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl- channel that is regulated by intracellular ATP and by cAMP-dependent phosphorylation. In order to determine whether CFTR was involved in the cGMP-dependent increase in g(Cl), we tested the effect of intracellularly injected anti-CFTR505-511 antibodies previously shown to inhibit CFTR function. Antibodies introduced into individual cells via the patch pipette completely inhibited cGMP-dependent current activation. Cyclic GMP also failed to activate g(Cl) in cystic fibrosis cells. Taken together, these studies demonstrate that activation of the CFTR via PKA-dependent phosphorylation accounts for the cGMP-mediated increase in Cl- secretion in Caco-2 cells.	UNIV CHICAGO,DEPT NEUROL,MC 2030,5841 S MARYLAND AVE,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,CINCINNATI,OH 45267	University of Chicago; University of Chicago; University System of Ohio; University of Cincinnati					NCI NIH HHS [CA36745] Funding Source: Medline; NIDDK NIH HHS [DK39573, P30DK42086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036745, R01CA036745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039573, P30DK042086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FESENKO EE, 1986, BIOCHIM BIOPHYS ACTA, V856, P661, DOI 10.1016/0005-2736(86)90162-8; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; FORTE LR, 1993, J CLIN INVEST, V91, P2423, DOI 10.1172/JCI116476; GARBERS DL, 1992, CELL, V71, P1; HUOTT PA, 1988, J CLIN INVEST, V82, P514, DOI 10.1172/JCI113626; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; MATESIC D, 1987, NATURE, V326, P600, DOI 10.1038/326600a0; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PINTO M, 1983, BIOL CELL, V47, P323; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; SCHULZ S, 1989, FASEB J, V3, P2026, DOI 10.1096/fasebj.3.9.2568301; SHABB JB, 1991, J BIOL CHEM, V266, P24320; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TIEN XY, 1993, AM J PHYSIOL, V256, pG143; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; WIEGAND RC, 1992, BIOCHEM BIOPH RES CO, V185, P812, DOI 10.1016/0006-291X(92)91699-Q; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862	30	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					51	54						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506258				2022-12-25	WOS:A1994MR21900014
J	BROWN, D; SIMONI, RD				BROWN, D; SIMONI, RD			MEVALONATE DEPRIVATION LEADS TO ANEUPLOIDY IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26502] Funding Source: Medline; NIGMS NIH HHS [GM07276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYTIA ED, 1976, ANNU REV BIOCHEM, V45, P113, DOI 10.1146/annurev.bi.45.070176.000553; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; BUCHER NLR, 1959, J BIOL CHEM, V234, P262; CHANG TY, 1981, J BIOL CHEM, V256, P6174; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; DEAVEN LL, 1973, CHROMOSOMA, V41, P129, DOI 10.1007/BF00319690; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; ENDO A, 1981, TRENDS BIOCHEM SCI, V6, P10, DOI 10.1016/0968-0004(81)90005-0; GAUST JR, 1983, P NATL ACAD SCI USA, V79, P5205; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOULD RG, 1957, BIOCHEM J, V66, pP51; HARDEMAN EC, 1983, P NATL ACAD SCI-BIOL, V80, P1516, DOI 10.1073/pnas.80.6.1516; HILL AB, 1985, CANCER RES, V45, P5050; KAO F, 1967, GENETICS, V55, P511; KAO FT, 1969, SCIENCE, V164, P313, DOI 10.1126/science.164.3877.312; KAO FT, 1969, J CELL PHYSIOL, V74, P245, DOI 10.1002/jcp.1040740305; KAO FT, 1968, P NATL ACAD SCI USA, V60, P1275, DOI 10.1073/pnas.60.4.1275; LUSKEY KL, 1983, J BIOL CHEM, V258, P8462; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; RYAN J, 1981, J BIOL CHEM, V256, P6762; SKALNIK DG, 1985, J BIOL CHEM, V260, P1991	25	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13497	13499						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417669				2022-12-25	WOS:A1988Q159400007
J	MAY, KM; JAY, FA; OESTERHELT, D				MAY, KM; JAY, FA; OESTERHELT, D			THE ORIENTATION OF HALORHODOPSIN IN THE CELL-MEMBRANE OF HALOBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									MAX PLANCK INST BIOCHEM,D-8033 MARTINSRIED,FED REP GER	Max Planck Society								BAMBERG E, 1984, BIOCHIM BIOPHYS ACTA, V773, P53, DOI 10.1016/0005-2736(84)90549-2; BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; BLAUROCK AE, 1976, J CELL BIOL, V71, P1, DOI 10.1083/jcb.71.1.1; BOGOMOLNI RA, 1982, P NATL ACAD SCI-BIOL, V79, P6250, DOI 10.1073/pnas.79.20.6250; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Lanyi J K, 1979, Methods Enzymol, V56, P398; LANYI JK, 1986, ANNU REV BIOPHYS BIO, V15, P11, DOI 10.1146/annurev.bb.15.060186.000303; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; Reichlin M, 1980, Methods Enzymol, V70, P159; SCHOBERT B, 1988, EMBO J, V7, P905, DOI 10.1002/j.1460-2075.1988.tb02895.x; SCHOBERT B, 1982, J BIOL CHEM, V257, P306; SPUDICH EN, 1982, P NATL ACAD SCI-BIOL, V79, P4308, DOI 10.1073/pnas.79.14.4308; STEINER M, 1983, EMBO J, V2, P1379, DOI 10.1002/j.1460-2075.1983.tb01595.x	13	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13623	13625						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417675				2022-12-25	WOS:A1988Q159400027
J	REGLINSKI, J; HOEY, S; SMITH, WE; STURROCK, RD				REGLINSKI, J; HOEY, S; SMITH, WE; STURROCK, RD			CELLULAR-RESPONSE TO OXIDATIVE STRESS AT SULFHYDRYL-GROUP RECEPTOR-SITES ON THE ERYTHROCYTE-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV GLASGOW,ROYAL INFIRM,DEPT MED,GLASGOW G4 0SF,SCOTLAND	Royal Infirmary of Edinburgh; University of Glasgow	REGLINSKI, J (corresponding author), UNIV STRATHCLYDE,DEPT PURE & APPL CHEM,GLASGOW G1 1XL,SCOTLAND.		reglinski, john/C-6397-2009					ABBOTT RE, 1986, AM J PHYSIOL, V250, pC853, DOI 10.1152/ajpcell.1986.250.6.C853; ABBOTT RE, 1976, J BIOL CHEM, V251, P7176; BANFORD JC, 1982, ANALYST, V107, P195, DOI 10.1039/an9820700195; BANFORD JC, 1982, RHEUMATOL INT, V2, P107, DOI 10.1007/BF00541162; BATT ER, 1976, J BIOL CHEM, V251, P7184; BROWN FF, 1977, FEBS LETT, V82, P12, DOI 10.1016/0014-5793(77)80875-2; BROWN FF, 1980, PHILOS T ROY SOC B, V289, P395, DOI 10.1098/rstb.1980.0056; BRUMMEL MC, 1985, MED HYPOTHESES, V18, P351, DOI 10.1016/0306-9877(85)90103-3; BULMER FMR, 1925, J BIOL CHEM, V83, P17; CAREY PR, 1978, ACCOUNTS CHEM RES, V11, P122, DOI 10.1021/ar50123a007; CLARK RJH, 1979, STRUCT BOND, V36, P1; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAMAEY JP, 1975, BIOCHEM PHARMACOL, V24, P1609, DOI 10.1016/0006-2952(75)90088-X; FISCHER TM, 1978, BIOCHIM BIOPHYS ACTA, V510, P270, DOI 10.1016/0005-2736(78)90027-5; FRASER R, 1950, J LAB CLIN MED, V35, P960; FRASER R, 1951, J LAB CLIN MED, V37, P119; GERBER DA, 1967, BIOCHEM PHARMACOL, V16, P115, DOI 10.1016/0006-2952(67)90192-X; GRIMALDI MG, 1980, J PHARM PHARMACOL, V32, P876, DOI 10.1111/j.2042-7158.1980.tb13103.x; HAEST CWM, 1978, BIOCHIM BIOPHYS ACTA, V509, P21, DOI 10.1016/0005-2736(78)90004-4; HAEST CWM, 1981, BIOCHIM BIOPHYS ACTA, V643, P319, DOI 10.1016/0005-2736(81)90077-8; HAEST CWM, 1977, BIOCHIM BIOPHYS ACTA, V469, P226, DOI 10.1016/0005-2736(77)90186-9; HALL ND, 1979, J PHARM PHARMACOL, V31, P676, DOI 10.1111/j.2042-7158.1979.tb13627.x; JOCELYN PC, 1958, BIOCHEM J, V70, P656, DOI 10.1042/bj0700656; JUNG CY, 1974, J BIOL CHEM, V249, P3568; KOSOWER EM, 1976, GLUTATHIONE METABOLI, P1; MCKAY CNN, 1986, BIOCHIM BIOPHYS ACTA, V888, P30, DOI 10.1016/0167-4889(86)90067-4; MELVILLE DB, 1959, VITAM HORM, V17, P155, DOI 10.1016/S0083-6729(08)60271-X; MIESTER A, 1984, FED PROC, V43, P3031; PINKOFSKY HB, 1985, ARCH BIOCHEM BIOPHYS, V240, P94, DOI 10.1016/0003-9861(85)90011-6; RABENSTEIN DL, 1980, FEBS LETT, V121, P61, DOI 10.1016/0014-5793(80)81267-1; RABENSTEIN DL, 1979, ANAL CHEM, V51, P1465, DOI 10.1021/ac50050a003; RABENSTEIN DL, 1985, ANAL CHEM, V57, P2294, DOI 10.1021/ac00289a028; RABENSTEIN DL, 1978, ANAL CHEM, V50, pA1265; REGLINSKI J, 1986, TRAC-TREND ANAL CHEM, V5, P190, DOI 10.1016/0165-9936(86)80032-2; REGLINSKI J, 1988, MAGNET RESON MED, V6, P217, DOI 10.1002/mrm.1910060210; RIDGWELL K, 1983, BIOCHEM J, V213, P267, DOI 10.1042/bj2130267; SMITH WE, 1985, SPECTROSCOPY BIOL MO, P452; SPIRO TG, 1975, ADV INFRARED RAMAN S, V1, P98; Tu A.T., 1982, RAMAN SPECTROSCOPY B	39	101	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1988	263	25					12360	12366						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P8611	3410845				2022-12-25	WOS:A1988P861100034
J	BERTHOLD, DA; SCHMIDT, CL; MALKIN, R				BERTHOLD, DA; SCHMIDT, CL; MALKIN, R			THE DELETION OF PETG IN CHLAMYDOMONAS-REINHARDTII DISRUPTS THE CYTOCHROME BF COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST GENOME; NUCLEOTIDE-SEQUENCE; GENE ORGANIZATION; RNA GENES; TRANSFORMATION; EXPRESSION; DNA	The 4-kDa protein encoded by chloroplast petG copurifies with the cytochrome bf complex of spinach and is found in a number of other photosynthetic organisms, including the eukaryotic alga Chlamydomonas reinhardtii. To determine whether petG is involved in the function or assembly of the cytochrome bf complex, the gene was cloned from C. reinhardtii, excised from the DNA fragment, and replaced with a spectinomycin resistance cassette. A petG deletion strain of C. reinhardtii was then obtained by biolistic transformation. The resulting homoplasmic petG deletion strains are unable to grow photosynthetically, and immunoblot analysis shows markedly decreased levels of cytochrome b(6), cytochrome f, the Rieske iron-sulfur protein, and subunit IV. To verify that this phenotype was due to the removal of petG, we also constructed a strain with a deletion in the open reading frame (ORF56), which is found 25 base pairs downstream of petG. The ORF56 deletion strain grew photosynthetically and had wild-type levels of the four major cytochrome bf subunits. We conclude that the absence of the PetG protein affects either the assembly or stability of the cytochrome bf complex in C. reinhardtii.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020571] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20571] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Berthold D. A., 1993, Plant Molecular Biology Reporter, V11, P338, DOI 10.1007/BF02905336; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BRANDT U, 1994, J BIOL CHEM, V269, P12947; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; FONG SE, 1992, CURR GENET, V21, P527, DOI 10.1007/BF00351664; FUKUZAWA H, 1988, J MOL BIOL, V203, P333, DOI 10.1016/0022-2836(88)90003-4; GOLDSCHMIDTCLER.M, 1991, NUCLEIC ACIDS RES, V19, P4083; HABERHAUSEN G, 1992, MOL GEN GENET, V232, P154, DOI 10.1007/BF00299148; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; HALLICK RB, 1993, NUCLEIC ACIDS RES, V21, P3537, DOI 10.1093/nar/21.15.3537; HARLOW E, 1988, ANTIBODIES LABORATOR; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; KUNSTNER P, 1995, J BIOL CHEM, V270, P9651; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; NEWMAN SM, 1990, GENETICS, V126, P875; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; RAN Z, 1995, IN PRESS THEOR APPL; REDSTON MS, 1994, BIOTECHNIQUES, V17, P286; ROFFEY RA, 1991, P NATL ACAD SCI USA, V88, P9122, DOI 10.1073/pnas.88.20.9122; Sambrook J, 1989, MOL CLONING LABORATO; SANFORD JC, 1993, METHOD ENZYMOL, V217, P483; SCHMIDT CL, 1993, PHOTOSYNTH RES, V38, P73, DOI 10.1007/BF00015063; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STIREWALT VL, 1989, NUCLEIC ACIDS RES, V17, P10095, DOI 10.1093/nar/17.23.10095; TAKAHASHI Y, 1994, PLANT MOL BIOL, V24, P779, DOI 10.1007/BF00029859; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TURMEL M, 1994, CURR GENET, V27, P54, DOI 10.1007/BF00326579; WAKASUGI T, 1994, P NATL ACAD SCI USA, V91, P9794, DOI 10.1073/pnas.91.21.9794; WHITELEGGE JP, 1995, J BIOL CHEM, V270, P225, DOI 10.1074/jbc.270.1.225	37	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29293	29298		10.1074/jbc.270.49.29293	http://dx.doi.org/10.1074/jbc.270.49.29293			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493961	hybrid			2022-12-25	WOS:A1995TJ22700042
J	JOVOV, B; ISMAILOV, II; BERDIEV, BK; FULLER, CM; SORSCHER, EJ; DEDMAN, JR; KAETZEL, MA; BENOS, DJ				JOVOV, B; ISMAILOV, II; BERDIEV, BK; FULLER, CM; SORSCHER, EJ; DEDMAN, JR; KAETZEL, MA; BENOS, DJ			INTERACTION BETWEEN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR AND OUTWARDLY RECTIFIED CHLORIDE CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL RECONSTITUTION; PROTEIN-KINASE; CL CHANNELS; CFTR; PURIFICATION; MEMBRANES	We have previously described a protocol for the simultaneous isolation and reconstitution of a protein kinase A (PKA)-sensitive outwardly rectified chloride channel (ORCC) and the cystic fibrosis transmembrane conductance regulator (CFTR) from bovine tracheal epithelium, immunoprecipitation of CFTR from this preparation prevented PKA activation of the ORCC, suggesting that CFTR regulated the ORCC and that this regulatory relationship was preserved throughout the purification procedure. We now report the purification of CFTR from bovine tracheal epithelia and the purification of a CFTR conduction mutant (G551D CFTR) from retrovirally transduced mouse L cells using a combination of alkali stripping, Triton-X extraction, and immunoaffinity chromatography. Immunopurified CFTR proteins were reconstituted in the absence and presence of ORCC. To test the hypothesis that only functional CFTR can support activation of ORCC by PKA and ATP, we used an inhibitory anti-CFTR(505-511) peptide antibody or G551D CFTR. When anti-CFTR(505-511) peptide antibodies were present prior to the addition of PKA and ATP, activation of both the ORCC and CFTR was prevented. If the antibody was added after activation of the ORCC and CFTR Cl- channels by PRA and ATP, only the CFTR Cl- channel was inhibited. When ORCC and G551D CFTR were co-incorporated into planar bilayers, only the ORCC was recorded and this channel could not be further activated by the addition of PRA and ATP. Thus, functional CFTR is required for activation of the ORCC by PKA and ATP. me also tested the hypothesis that PKA activation of ORCC was dependent-on the extracellular presence of ATP. We added ATP on the presumed extracellular side of the lipid bilayer under conditions where it was not possible to activate the ORCC, i.e. in the presence of inhibitory anti-CFTR(505-511) antibody or G551D CFTR. In both cases the ORCC regained PRA sensitivity, Moreover, the addition of hexokinase + glucose to the extracellular side prevented activation of the ORCCs by PKA and ATP in the presence of CFTR. These experiments confirm that both the presence of CFTR as well as the presence of ATP on the extracellular side is required for activation of the ORCC by PKA and ATP.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV CINCINNATI,DEPT MOLEC & CELLULAR PHYSIOL,CINCINNATI,OH 45267	University of Alabama System; University of Alabama Birmingham; University System of Ohio; University of Cincinnati			Fuller, Cathy/B-4046-2011	Sorscher, Eric J./0000-0001-9341-3354	NIDDK NIH HHS [DK48764] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048764] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ O, 1985, J ELECTROPHYSIOL TEC, V12, P159; ANDERSON PM, 1991, SCIENCE, V251, P269; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CHAN HC, 1992, J BIOL CHEM, V267, P8411; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FULLER CM, 1992, AM J PHYSIOL, V262, pC396, DOI 10.1152/ajpcell.1992.262.2.C396; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; HARTMAN J, 1992, BIOTECHNOL BIOENG, V39, P828, DOI 10.1002/bit.260390805; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; NELSON DJ, 1995, IN PRESS AM J PHYSL; ORIORDAN CR, 1995, J BIOL CHEM, V270, P17033, DOI 10.1074/jbc.270.28.17033; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RAN S, 1992, J BIOL CHEM, V267, P20630; RAN S, 1991, J BIOL CHEM, V266, P4782; REISIN IL, 1994, J BIOL CHEM, V269, P20584; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; TIEN XY, 1994, J BIOL CHEM, V269, P51; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253	25	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29194	29200		10.1074/jbc.270.49.29194	http://dx.doi.org/10.1074/jbc.270.49.29194			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493947	hybrid			2022-12-25	WOS:A1995TJ22700028
J	KHARITONENKOV, A; SCHNEKENBURGER, J; CHEN, ZJ; KNYAZEV, P; ALI, S; ZWICK, E; WHITE, M; ULLRICH, A				KHARITONENKOV, A; SCHNEKENBURGER, J; CHEN, ZJ; KNYAZEV, P; ALI, S; ZWICK, E; WHITE, M; ULLRICH, A			ADAPTER FUNCTION OF PROTEIN-TYROSINE-PHOSPHATASE 1D IN INSULIN-RECEPTOR INSULIN-RECEPTOR SUBSTRATE-1 INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY-2 DOMAINS; SIGNAL TRANSMISSION; KINASE; CORKSCREW; PHOSPHORYLATION; ASSOCIATION; IRS-1; SYP	Insulin signal transduction involves the multisite docking protein insulin receptor substrate-1 (IRS-1) and a number of Src homology-2 (SH2) domain factors, including p85/p110 phosphatidylinositol S-kinase, p110 GTPase-activating protein, and the phosphotyrosine-specific phosphatase PTP1D. In transfected baby hamster kidney cells, Rat1 fibroblasts, and normal IM9 lymphoblasts, PTP1D directly binds activated insulin receptor. This interaction is mediated by catalytic domain-proximal SH2 determinants of the phosphatase and phosphotyrosine 1146 of the activated insulin receptor. While the receptor and the phosphatase do not serve as substrates for each other, their interaction promotes IRS-1 binding to the receptor, indicating that PTP1D functions as an adapter for insulin receptor and IRS-1. The formation of a multiprotein signaling complex involving the insulin receptor, PTP1D, and IRS-1 enhances cellular glucose uptake, a critical process in the physiological action of insulin,	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY; JOSLIN DIABET CTR,BOSTON,MA 02115	Max Planck Society; Harvard University; Joslin Diabetes Center, Inc.				Schnekenburger, Juergen/0000-0002-0199-2908				ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; FENDLY BM, 1990, CANCER RES, V50, P1550; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MAEGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P208, DOI 10.1006/bbrc.1993.1805; MAEGAWA H, 1994, BIOCHEM BIOPH RES CO, V199, P780, DOI 10.1006/bbrc.1994.1297; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1987, P NATL ACAD SCI USA, V87, P3358; XIAO S, 1994, J BIOL CHEM, V269, P21244	30	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29189	29193		10.1074/jbc.270.49.29189	http://dx.doi.org/10.1074/jbc.270.49.29189			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493946	hybrid			2022-12-25	WOS:A1995TJ22700027
J	LEUNG, T; MANSER, E; TAN, L; LIM, L				LEUNG, T; MANSER, E; TAN, L; LIM, L			A NOVEL SERINE/THREONINE KINASE BINDING THE RAS-RELATED RHOA GTPASE WHICH TRANSLOCATES THE KINASE TO PERIPHERAL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; ACTIVATING PROTEINS; INVOLVEMENT; DYSTROPHY; REPEAT; GDI	We previously reported the cloning of a serine/threonine kinase, PAK (for p21 (Cdc42/Rac)-activated kinase), which binds to the Ras-related GTPases Cdc42Hs and Rac1 (Manser, E., Leung, T., Salihuddin, H., Zhao, Z-s., and Lim, L. (1994) Nature 367, 40-46), These p21 proteins together with RhoA comprise the Rho subfamily of proteins that are involved in morphological events. We now report the isolation of a rat cDNA encoding a 150-kDa protein, which specifically binds RhoA in its GTP form and contains an N-terminal serine/threonine kinase domain highly related to the human myotonic dystrophy kinase and a cysteine-rich domain toward the C terminus. The RhoA binding domain is unrelated to other p21 binding domains. Antibody raised against the kinase domain of the predicted protein, termed ROK alpha (for ROK alpha, RhoA-binding kinase), recognized a ubiquitous 150-kDa protein. The brain p150 purified by affinity chromatography with RhoA exhibited serine/threonine kinase activity. In cultured cells, immunoreactive p150 was recruited to membranes upon transfection with dominant positive RhoA(V14) mutant and was localized with actin microfilaments at the cell periphery. These results are consistent with a role for the kinase ROK alpha as an effector for RhoA.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,GLAXO IMCB GRP,SINGAPORE 0511,SINGAPORE; INST NEUROL,LONDON WC1N 1PJ,ENGLAND	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London			Manser, Edward/ABD-2301-2020					AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; JIMENEZ B, 1995, ONCOGENE, V10, P811; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEUNG T, 1994, J BIOL CHEM, V269, P12888; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MOUNSEY JP, 1995, J CLIN INVEST, V95, P2379, DOI 10.1172/JCI117931; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TIMCHENKO L, 1995, P NATL ACAD SCI USA, V92, P5366, DOI 10.1073/pnas.92.12.5366; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x	24	596	641	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29051	29054		10.1074/jbc.270.49.29051	http://dx.doi.org/10.1074/jbc.270.49.29051			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493923	hybrid			2022-12-25	WOS:A1995TJ22700004
J	SAHOO, T; MOHANTY, BK; LOBERT, M; MANNA, AC; BASTIA, D				SAHOO, T; MOHANTY, BK; LOBERT, M; MANNA, AC; BASTIA, D			THE CONTRAHELICASE ACTIVITIES OF THE REPLICATION TERMINATOR PROTEINS OF ESCHERICHIA-COLI AND BACILLUS-SUBTILIS ARE HELICASE-SPECIFIC AND IMPEDE BOTH HELICASE TRANSLOCATION AND AUTHENTIC DNA UNWINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN HELICASE; BINDING PROTEIN; FORK MOVEMENT; PLASMID R6K; TUS PROTEIN; SEQUENCE; PURIFICATION; CHROMOSOME; INVITRO; REGION	Replication forks are arrested at sequence-specific replication termini primarily, perhaps exclusively, by polar arrest of helicase-catalyzed DNA unwinding by the terminator protein. The mechanism of this arrest is of considerable interest. This paper presents experimental evidence in support of four major points pertaining to termination of DNA replication. First, the replication terminator proteins of both Escherichia coli and Bacillus subtilis are helicase-specific contrahelicases, i.e. the proteins specifically impede the activities of helicases that are involved in symmetric DNA replication but not of those involved in conjugative DNA transfer and rolling circle replication. Second, the terminator protein (Ter) of E. coli blocks not only helicase translocation but also authentic DNA unwinding. Third, the replication terminator protein of Gram-positive B. subtilis is a polar contrahelicase of the primosomal helicase PriA of Gram-negative E. coli. Finally, the blockage of PriA-catalyzed DNA unwinding was abrogated by the passage of an RNA transcript through the replication terminator protein-terminus complex. These results are significant because of their relevance to the mechanistic aspects of replication termination.	DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [GM 49264] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049264] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN AA, 1992, J BIOL CHEM, V267, P18612; BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BUSIERE DE, 1995, CELL, V80, P651; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; CROSA JH, 1976, J BACTERIOL, V126, P454, DOI 10.1128/JB.126.1.454-466.1976; DASH PK, 1992, MOL MICROBIOL, V6, P1163, DOI 10.1111/j.1365-2958.1992.tb01555.x; GAHN TA, 1989, CELL, V23, P681; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HERNANDEZ P, 1986, EMBO J, V7, P303; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOLTER R, 1978, J MOL BIOL, V124, P425, DOI 10.1016/0022-2836(78)90180-8; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; LOUARN J, 1977, J MOL BIOL, V115, P295, DOI 10.1016/0022-2836(77)90156-5; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MEHTA PP, 1992, J BIOL CHEM, V267, P18885; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; SMITH MT, 1992, J MOL BIOL, V227, P548	35	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29138	29144		10.1074/jbc.270.49.29138	http://dx.doi.org/10.1074/jbc.270.49.29138			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493939	hybrid			2022-12-25	WOS:A1995TJ22700020
J	KANG, JJ; YOKOI, TJ; HOLLAND, MJ				KANG, JJ; YOKOI, TJ; HOLLAND, MJ			BINDING-SITES FOR ABUNDANT NUCLEAR FACTORS MODULATE RNA-POLYMERASE I-DEPENDENT ENHANCER FUNCTION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III TRANSCRIPTION FACTOR; YEAST RIBOSOMAL DNA; SPACER REGION; 3'-END FORMATION; GENE-EXPRESSION; RDNA ENHANCER; PROTEIN; SEQUENCES; PROMOTER; ACTIVATION	The 190-base pair (bp) rDNA enhancer within the intergenic spacer sequences of Saccharomyces cerevisiae rRNA cistrons activates synthesis of the S-35-rRNA precursor about 20-fold in vivo (Mestel., R., Yip, M., Holland, J. P., Wang, E., Kang, J., and Holland, M. J. (1989) Mol. Cell. Biol. 9, 1243-1254). We now report identification and analysis of transcriptional activities mediated by three cis-acting sites within a 90-bp portion of the rDNA enhancer designated the modulator region. In vivo, these sequences mediated termination of transcription by RNA polymerase I and potentiated the activity of the rDNA enhancer element. Two trans acting factors, REB1 and REB2, bind independently to sites within the modulator region (Morrow, B. E., Johnson, S. P., and Warner, J. R. (1989) J. Biol. Chem. 264, 9061-9068). We show that REB2 is identical to the ABF1 protein, Site directed mutagenesis of REB1 and ABF1 binding sites demonstrated uncoupling of RNA polymerase I-dependent termination from transcriptional activation in vivo, We conclude that REB1 and ABF1 are required for RNA polymerase I-dependent termination and enhancer function, respectively. Since REB1 and ABF1 proteins also regulate expression of class II genes and other nuclear functions, our results suggest further similarities between RNA polymerase I and II regulatory mechanisms, Two rDNA enhancers flanking a rDNA minigene stimulated RNA polymerase I transcription in a ''multiplicative'' fashion, Deletion mapping analysis showed that similar cis-acting sequences were required for enhancer function when positioned upstream or down stream from a rDNA minigene.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030307] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07377, GM30307] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1986, CELL, V47, P839, DOI 10.1016/0092-8674(86)90795-6; BRINDLE PK, 1990, MOL CELL BIOL, V10, P4872, DOI 10.1128/MCB.10.9.4872; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; CARMEN AA, 1994, J BIOL CHEM, V269, P9790; CASSIDY BG, 1987, MOL CELL BIOL, V7, P2388, DOI 10.1128/MCB.7.7.2388; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWINTER RFJ, 1986, CELL, V44, P313, DOI 10.1016/0092-8674(86)90765-8; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GRIMALDI G, 1990, MOL CELL BIOL, V10, P4667, DOI 10.1128/MCB.10.9.4667; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HIGGUCHI R, 1990, PCR PROTOCOLS, P177; HOLLAND JP, 1990, MOL CELL BIOL, V10, P4863, DOI 10.1128/MCB.10.9.4863; HOLLAND MJ, 1987, MOL CELL BIOL, V7, P813, DOI 10.1128/MCB.7.2.813; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; KUHN A, 1987, EMBO J, V6, P3487, DOI 10.1002/j.1460-2075.1987.tb02673.x; KULKENS T, 1989, CURR GENET, V16, P351, DOI 10.1007/BF00340714; KULKENS T, 1992, EMBO J, V11, P4665, DOI 10.1002/j.1460-2075.1992.tb05568.x; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LABHART P, 1987, CELL, V50, P51, DOI 10.1016/0092-8674(87)90661-1; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LORCH Y, 1990, P NATL ACAD SCI USA, V87, P8202, DOI 10.1073/pnas.87.21.8202; MAGER WH, 1990, BIOCHIM BIOPHYS ACTA, V1050, P351, DOI 10.1016/0167-4781(90)90193-6; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARCZYNSKI GT, 1985, NUCLEIC ACIDS RES, V13, P8487, DOI 10.1093/nar/13.23.8487; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MCSTAY B, 1990, MOL CELL BIOL, V10, P2793, DOI 10.1128/MCB.10.6.2793; MESTEL R, 1989, MOL CELL BIOL, V9, P1243, DOI 10.1128/MCB.9.3.1243; MITCHELSON K, 1987, NUCLEIC ACIDS RES, V15, P9577, DOI 10.1093/nar/15.22.9577; MORROW BE, 1989, J BIOL CHEM, V264, P9061; MORROW BE, 1990, J BIOL CHEM, V265, P20778; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; PAPE LK, 1989, MOL CELL BIOL, V9, P5093, DOI 10.1128/MCB.9.11.5093; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; Reeder RH, 1989, CURR OPIN CELL BIOL, V1, P466, DOI 10.1016/0955-0674(89)90007-0; RHODE PR, 1989, GENE DEV, V3, P1926, DOI 10.1101/gad.3.12a.1926; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; SWANSON ME, 1983, J BIOL CHEM, V258, P3242; SWANSON ME, 1985, J BIOL CHEM, V260, P9905; TOWER J, 1989, MOL CELL BIOL, V9, P1513, DOI 10.1128/MCB.9.4.1513; VANDERSANDE CAFM, 1989, NUCLEIC ACIDS RES, V17, P9127, DOI 10.1093/nar/17.22.9127; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; YIP MT, 1989, J BIOL CHEM, V264, P4045	62	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28723	28732		10.1074/jbc.270.48.28723	http://dx.doi.org/10.1074/jbc.270.48.28723			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499394	hybrid			2022-12-25	WOS:A1995TH05600038
J	NEISH, AS; KHACHIGIAN, LM; PARK, A; BAICHWAL, VR; COLLINS, T				NEISH, AS; KHACHIGIAN, LM; PARK, A; BAICHWAL, VR; COLLINS, T			SP1 IS A COMPONENT OF THE CYTOKINE-INDUCIBLE ENHANCER IN THE PROMOTER OF VASCULAR CELL-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MONONUCLEAR LEUKOCYTE ADHESION; INTEGRIN VLA-4; EXPRESSION; VCAM-1; ACTIVATION; BINDING; PROTEIN; GENE; FIBRONECTIN	Transcription of the vascular cell adhesion molecule-1 (VCAM-1) gene in endothelial cells is induced by the inflammatory cytokines interleukin-1 beta, tumor necrosis factor-alpha, and lipopolysaccharide. Previous studies demonstrated that the cytokine-response region in the VCAM1 promoter contains binding sites for the transcription factors nuclear factor-kappa B (NF-kappa B) and interferon regulatory factor-1. Using a saturation mutagenesis approach, we report that the cytokine inducible enhancer consists of these previously characterized elements and a novel region located 3' of the NF-kappa B sites. Electrophoretic mobility shift assays and DNase I footprint studies with endothelial nuclear extracts and recombinant protein revealed that the transcriptional activator Sp1 interacts with this novel element in a specific manner. Transient transfection assays using vascular endothelial cells revealed that site-directed mutations in the Sp1 binding element decreased tumor necrosis factor-alpha-induced activity of the VCAM1 promoter. The cytokine-induced enhancer of the VCAM1 gene requires constitutively bound Sp1 and induced heterodimeric NF-kappa B for maximal promoter activity.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV VASC RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; TULARIK INC, San Francisco, CA 94080 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Neish, Andrew/B-3895-2009; Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035716, R37HL035716] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45462, HL03011-01, HL 35716] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAO XM, 1993, J BIOL CHEM, V268, P16949; CARLOS TM, 1994, BLOOD, V84, P2068; CARLOS TM, 1990, BLOOD, V76, P965; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; FRIES JWU, 1993, AM J PATHOL, V143, P725; GIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KOOPMAN G, 1991, J EXP MED, V173, P1297, DOI 10.1084/jem.173.6.1297; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; MINOWA T, 1994, J BIOL CHEM, V269, P11656; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RICE GE, 1991, AM J PATHOL, V138, P385; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5	37	111	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28903	28909		10.1074/jbc.270.48.28903	http://dx.doi.org/10.1074/jbc.270.48.28903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499419	hybrid			2022-12-25	WOS:A1995TH05600063
J	SAUS, J; WIESLANDER, J; LANGEVELD, JPM; QUINONES, S; HUDSON, BG				SAUS, J; WIESLANDER, J; LANGEVELD, JPM; QUINONES, S; HUDSON, BG			IDENTIFICATION OF THE GOODPASTURE ANTIGEN AS THE ALPHA-3(IV) CHAIN OF COLLAGEN-IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									BIOCARB,DEPT BIOCHEM,S-22370 LUND,SWEDEN; UNIV KANSAS,MED CTR,DEPT BIOCHEM,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center	SAUS, J (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MED,PISCATAWAY,NJ 08854, USA.			Saus, Juan/0000-0003-2082-1597; Hudson, Billy/0000-0002-5420-4100	NIDDK NIH HHS [DK 18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018381, R37DK018381] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSON DR, 1987, AM J PHYSIOL, V22, pF783; BABEL W, 1984, EUR J BIOCHEM, V143, P545, DOI 10.1111/j.1432-1033.1984.tb08404.x; BLUMBERG B, 1987, J BIOL CHEM, V262, P5947; BRINKER JM, 1985, P NATL ACAD SCI USA, V82, P3649, DOI 10.1073/pnas.82.11.3649; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; CECCHINI JP, 1987, EUR J BIOCHEM, V165, P587, DOI 10.1111/j.1432-1033.1987.tb11480.x; FISH AJ, 1984, CLIN EXP IMMUNOL, V55, P58; FOIDART JB, 1980, KIDNEY INT, V18, P136; FREYTAG JW, 1976, BIOCHEM BIOPH RES CO, V72, P796; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; HINGLAIS N, 1972, LAB INVEST, V27, P473; HOLDSWORTH SR, 1979, KIDNEY INT, V16, P797; HOSTIKKA SL, 1987, FEBS LETT, V216, P281, DOI 10.1016/0014-5793(87)80706-8; HUNT JS, 1982, BIOCHEM BIOPH RES CO, V104, P1025, DOI 10.1016/0006-291X(82)91352-3; KAYTES PS, 1987, GENE, V54, P141, DOI 10.1016/0378-1119(87)90356-8; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; KILLEN PD, 1987, HUM GENET, V77, P318, DOI 10.1007/BF00291418; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; KURKINEN M, 1987, J BIOL CHEM, V262, P8496; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; LANGEVELD JPM, 1987, RENAL BASEMENT MEMBR, P25; MAHIEU PM, 1973, EUR J BIOCHEM, V40, P599, DOI 10.1111/j.1432-1033.1973.tb03232.x; MARQUARDT H, 1973, KIDNEY INT, V3, P57, DOI 10.1038/ki.1973.12; MCINTOSH RM, 1971, ARCH PATHOL, V92, P329; MYERS JC, 1987, J BIOL CHEM, V262, P9231; OBERBAUMER I, 1985, EUR J BIOCHEM, V147, P217, DOI 10.1111/j.1432-1033.1985.tb08739.x; PECZON BD, 1982, EXP EYE RES, V35, P643, DOI 10.1016/S0014-4835(82)80076-6; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; RUMPELT HJ, 1980, CLIN NEPHROL, V13, P203; SAKURAI Y, 1986, J BIOL CHEM, V261, P6654; SARIOLA H, 1984, DEV BIOL, V101, P86, DOI 10.1016/0012-1606(84)90119-2; SCHUPPAN D, 1984, BIOCHEM J, V220, P227, DOI 10.1042/bj2200227; SCHUPPAN D, 1982, EUR J BIOCHEM, V123, P505; SCHWARZ U, 1986, EUR J BIOCHEM, V157, P49, DOI 10.1111/j.1432-1033.1986.tb09636.x; SCHWARZMAGDOLEN U, 1986, FEBS LETT, V208, P203, DOI 10.1016/0014-5793(86)81018-3; SHEER RL, 1964, ANN INTERN MED, V60, P1009; SPEAR GS, 1972, AM J PATHOL, V69, P213; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P1544, DOI 10.1073/pnas.81.5.1544; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WIESLANDER J, 1987, RENAL BASEMENT MEMBR, P305; WIESLANDER J, 1984, P NATL ACAD SCI USA, V81, P3833; YOSHIKAWA N, 1981, J PATHOL, V135, P199, DOI 10.1002/path.1711350305	45	404	425	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13374	13380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417661				2022-12-25	WOS:A1988Q091700090
J	HEKMAN, ACP; TRAPMAN, J; MULDER, AH; VANGAALEN, JLM; ZWARTHOFF, EC				HEKMAN, ACP; TRAPMAN, J; MULDER, AH; VANGAALEN, JLM; ZWARTHOFF, EC			INTERFERON EXPRESSION IN THE TESTES OF TRANSGENIC MICE LEADS TO STERILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									ERASMUS UNIV,DEPT PATHOL,POB 1738,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam								BELCHETZ PE, 1987, CLIN ENDOCRINOLOGY; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DODEMONT HJ, 1982, EMBO J, V1, P167, DOI 10.1002/j.1460-2075.1982.tb01142.x; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; FAWCETT DW, 1977, FRONTIERS REPRODUCTI, P302; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GORDON JW, 1986, MOL CELL BIOL, V6, P2158, DOI 10.1128/MCB.6.6.2158; HAMMER RE, 1984, NATURE, V311, P65, DOI 10.1038/311065a0; HAMMER RE, 1985, COLD SPRING HARB SYM, V50, P379, DOI 10.1101/SQB.1985.050.01.048; HOGAN B, 1986, MANIPULATING MOUSE E; LEBON P, 1982, J GEN VIROL, V59, P393, DOI 10.1099/0022-1317-59-2-393; LOW MJ, 1986, SCIENCE, V231, P1002, DOI 10.1126/science.2868526; MANIATIS T, 1982, MOL CLONING LABORATO; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PINKERT CA, 1985, EMBO J, V4, P2225, DOI 10.1002/j.1460-2075.1985.tb03918.x; SCHILSKY RL, 1987, CANCER TREAT REP, V71, P179; Stewart W E, 1981, INTERFERON SYSTEM; TAYLORPAPADIMITRIOU J, 1981, J INTERFERON RES, V1, P401, DOI 10.1089/jir.1981.1.401; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038; VANHEUVEL M, 1986, J GEN VIROL, V67, P2215, DOI 10.1099/0022-1317-67-10-2215; VANHEUVEL M, 1986, GENE, V45, P159, DOI 10.1016/0378-1119(86)90250-7; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1; ZWARTHOFF EC, 1985, J GEN VIROL, V66, P685, DOI 10.1099/0022-1317-66-4-685	28	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					12151	12155						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403564				2022-12-25	WOS:A1988P765000083
J	FOSTER, R; JAHROUDI, N; VARSHNEY, U; GEDAMU, L				FOSTER, R; JAHROUDI, N; VARSHNEY, U; GEDAMU, L			STRUCTURE AND EXPRESSION OF THE HUMAN METALLOTHIONEIN-IG GENE - DIFFERENTIAL PROMOTER ACTIVITY OF 2 LINKED METALLOTHIONEIN-I GENES IN RESPONSE TO HEAVY-METALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											FOSTER, R (corresponding author), UNIV CALGARY, DEPT BIOL SCI, 2500 UNIV DR NW, CALGARY T2N 1N4, ALBERTA, CANADA.		Varshney, Umesh/A-8062-2009; Varshney, Umesh/Q-6914-2019; Cheng, Sen/A-5722-2009	Cheng, Sen/0000-0002-6719-8029				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARTER AD, 1984, P NATL ACAD SCI-BIOL, V81, P7392, DOI 10.1073/pnas.81.23.7392; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; Favaloro J, 1980, Methods Enzymol, V65, P718; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HAGER LJ, 1981, NATURE, V291, P340, DOI 10.1038/291340a0; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HEGUY A, 1986, MOL CELL BIOL, V6, P2149, DOI 10.1128/MCB.6.6.2149; Kagi J.H.R., 1979, METALLOTHIONEIN; KAGI JHR, 1984, ENVIRON HEALTH PERSP, V54, P93, DOI 10.2307/3429795; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P5494, DOI 10.1073/pnas.81.17.5494; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; MANIATIS T, 1982, MOL CLONING LABORATO; Maxam A M, 1980, Methods Enzymol, V65, P499; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; OH SH, 1978, AM J PHYSIOL, V234, pE282, DOI 10.1152/ajpendo.1978.234.3.E282; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RICHARDS RI, 1984, CELL, V37, P263, DOI 10.1016/0092-8674(84)90322-2; SADHU C, 1988, J BIOL CHEM, V263, P2679; SCHMIDT CJ, 1984, SCIENCE, V224, P1104, DOI 10.1126/science.6719135; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; SCHMIDT CJ, 1985, J BIOL CHEM, V260, P7731; SHWORAK NW, 1983, BIOCHIM BIOPHYS ACTA, V763, P332, DOI 10.1016/0167-4889(83)90094-0; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; VARSHNEY U, 1984, GENE, V31, P135, DOI 10.1016/0378-1119(84)90204-X; VARSHNEY U, 1986, MOL CELL BIOL, V6, P26, DOI 10.1128/MCB.6.1.26; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291	38	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1988	263	23					11528	11535						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P6713	3403543				2022-12-25	WOS:A1988P671300083
J	MATSUZAKI, F; MATSUMOTO, S; YAHARA, I; YONEZAWA, N; NISHIDA, E; SAKAI, H				MATSUZAKI, F; MATSUMOTO, S; YAHARA, I; YONEZAWA, N; NISHIDA, E; SAKAI, H			CLONING AND CHARACTERIZATION OF PORCINE BRAIN COFILIN CDNA - COFILIN CONTAINS THE NUCLEAR TRANSPORT SIGNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN	University of Tokyo	MATSUZAKI, F (corresponding author), TOKYO METROPOLITAN INST MED SCI, DEPT CELL BIOL, TOKYO 113, JAPAN.		Yonezawa, Naoto/F-8300-2011					AMPE C, 1985, J BIOL CHEM, V260, P834; AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; BONNER WM, 1975, J CELL BIOL, V64, P421, DOI 10.1083/jcb.64.2.421; BONNER WM, 1975, J CELL BIOL, V64, P431, DOI 10.1083/jcb.64.2.431; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; IIDA K, 1986, EXP CELL RES, V164, P492, DOI 10.1016/0014-4827(86)90047-9; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LEWIS WG, 1983, FEBS LETT, V156, P269, DOI 10.1016/0014-5793(83)80511-0; MAEKAWA S, 1984, J BIOCHEM-TOKYO, V95, P377, DOI 10.1093/oxfordjournals.jbchem.a134618; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MUNEYUKI F, 1985, J BIOCHEM-TOKYO, V97, P563, DOI 10.1093/oxfordjournals.jbchem.a135091; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; NISHIDA E, 1985, CELL MOTILITY MECHAN, P201; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PRINGAULT E, 1986, EMBO J, V5, P3119, DOI 10.1002/j.1460-2075.1986.tb04618.x; RUIZOPAZO N, 1985, NATURE, V315, P67, DOI 10.1038/315067a0; SANDERS C, 1985, J BIOL CHEM, V260, P7264; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STONE D, 1978, J BIOL CHEM, V253, P1137; YAMAWAKIKATAOKA Y, 1985, J BIOL CHEM, V260, P4440; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443	36	99	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1988	263	23					11564	11568						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P6713	3403546				2022-12-25	WOS:A1988P671300089
J	BAE, HW; GEISER, AG; KIM, DH; CHUNG, MT; BURMESTER, JK; SPORN, MB; ROBERTS, AB; KIM, SJ				BAE, HW; GEISER, AG; KIM, DH; CHUNG, MT; BURMESTER, JK; SPORN, MB; ROBERTS, AB; KIM, SJ			CHARACTERIZATION OF THE PROMOTER REGION OF THE HUMAN TRANSFORMING GROWTH-FACTOR-BETA TYPE-II RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; SMOOTH-MUSCLE CELLS; EXPRESSION CLONING; FACTOR-BETA-1; PROTEOGLYCAN; INHIBITION; ACTIVIN; COMPLEX; FAMILY	Diminished cellular responsiveness to transforming growth factor-beta (TGF-beta) is frequently correlated with decreased transcription of the type II receptor for TGF-beta (TGF-beta RII). We have cloned and characterized the human TGF-beta RII promoter and, using S1 nuclease mapping and 5' rapid amplification of cDNA ends polymerase chain reaction, have identified five alternative transcription start sites within the region -33 to +57. DNA transfection experiments and electrophoretic mobility shift assays have revealed the existence of five distinct regulatory regions including two positive regulatory elements and two negative regulatory elements in addition to the core promoter region. The first positive regulatory element (-219 to -172) interacts with two distinct nuclear protein complexes, at least one of which appears to be a previously unidentified transcription factor. The second positive regulatory element (+1 to +35) also interacts with two separate protein complexes, both of which appear to be novel transcription factors. Deletion of either positive regulatory element markedly decreased expression of the target gene, suggesting that both positive regulatory elements are necessary for basal expression levels of TGF-beta RII.	NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BIRCHENALLROBER.MC, 1991, J BIOL CHEM, V266, P9617; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287, DOI 10.1073/pnas.84.15.5287; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KIM SJ, 1989, J BIOL CHEM, V264, P402; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAFYATIS R, 1989, J IMMUNOL, V143, P1142; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; SPORN MB, 1985, NATURE, V313, P747; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Wakefield L. M., 1990, TUMOR SUPPRESSOR GEN, P217; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	34	118	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29460	29468		10.1074/jbc.270.49.29460	http://dx.doi.org/10.1074/jbc.270.49.29460			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493985	hybrid			2022-12-25	WOS:A1995TJ22700066
J	DALLMANN, HG; THIMMIG, RL; MCHENRY, CS				DALLMANN, HG; THIMMIG, RL; MCHENRY, CS			DNAX COMPLEX OF ESCHERICHIA-COLI DNA-POLYMERASE-III HOLOENZYME - CENTRAL ROLE OF TAU IN INITIATION COMPLEX ASSEMBLY AND IN DETERMINING THE FUNCTIONAL ASYMMETRY OF HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SITE-SPECIFIC MUTAGENESIS; REPLICATION FACTOR-C; ACCESSORY PROTEINS; GAMMA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; PHENOTYPIC SELECTION; BETA-SUBUNIT; PRIMED DNA; GENE	The alternative forms of the DnaX protein found in Escherichia coli DNA polymerase III holoenzyme, tau and gamma, were purified from extracts of strains carrying overexpressing plasmids mutated in their frameshifting sequences such that they produced only one subunit or the other. The purified subunits were used to reconstitute the tau and gamma complexes which were characterized by functional assays. The gamma complex-reconstituted holoenzyme required a stoichiometric excess of DNA polymerase III core, beyond physiological levels, for activity. The gamma subunit stimulated the gamma complex 2-fold, but could not be used to reconstitute a holoenzyme with gamma complex and stoichiometric quantities of core. In the presence of adenosine 5'-O-(3'-thiotriphospate) (ATP gamma S), the DNA polymerase III holoenzyme behaves as an asymmetric dimer; it can form only initiation complexes with primed DNA in one-half of the enzyme (Johanson, K. O., and McHenry, C. S. (1984) J. Biol. Chem. 259, 4589-4595). An asymmetric distribution of two products of the dnaX gene, gamma and tau has been postulated to underlie the asymmetry of holoenzyme. To provide a direct test for this hypothesis, we reconstituted holoenzyme containing only the gamma or tau DnaX proteins. We observed that, although gamma could function in the presence of ATP and high concentrations of DNA polymerase III core, it was nearly inert in the presence of ATP gamma S. In contrast, tau-containing holoenzyme behaved exactly like native holoenzyme in the presence of ATP gamma S. These results implicate tau as a key component required to reconstitute holoenzyme with native behavior and show that tau plays a key role in initiation complex formation. These results also show that gamma is not a necessary component, since all of the known properties of native holoenzyme can be reproduced with a 9-subunit tau-holoenzyme.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOLEC BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; EDELHOCH H, 1967, BIOCHEMISTRY-US, V7, P1948; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; HUBSCHER U, 1992, TRENDS BIOCHEM SCI, V17, P55, DOI 10.1016/0968-0004(92)90499-Y; INGRAHAM J, 1983, GROWTH BACTERIAL CEL, P269; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; LEE SH, 1991, J BIOL CHEM, V266, P594; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY C, 1949, MOL MECHANISMS DNA R, P115; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, BIOCHIM BIOPHYS ACTA, V951, P240, DOI 10.1016/0167-4781(88)90092-9; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; MCHENRY CS, 1986, MECHANISMS DNA REPLI, P47; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; OBERFELDER R, 1987, J BIOL CHEM, V262, P4190; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1994, ANN NY ACAD SCI, V726, P144, DOI 10.1111/j.1749-6632.1994.tb52806.x; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; Reznikoff W, 1986, MAXIMIZING GENE EXPR; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; WU CA, 1992, J BIOL CHEM, V267, P4064; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; XIAO H, 1993, J BIOL CHEM, V268, P11779	54	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29555	29562		10.1074/jbc.270.49.29555	http://dx.doi.org/10.1074/jbc.270.49.29555			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493998	hybrid			2022-12-25	WOS:A1995TJ22700079
J	LUNDELL, I; BLOMQVIST, AG; BERGLUND, MM; SCHOBER, DA; JOHNSON, D; STATNICK, MA; GADSKI, RA; GEHLERT, DR; LARHAMMAR, D				LUNDELL, I; BLOMQVIST, AG; BERGLUND, MM; SCHOBER, DA; JOHNSON, D; STATNICK, MA; GADSKI, RA; GEHLERT, DR; LARHAMMAR, D			CLONING OF A HUMAN RECEPTOR OF THE NPY RECEPTOR FAMILY WITH HIGH-AFFINITY FOR PANCREATIC-POLYPEPTIDE AND PEPTIDE YY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PP-FOLD FAMILY; NEUROPEPTIDE-Y; BINDING-SITES; RAT-BRAIN; EXPRESSION; CELLS; IDENTIFICATION; LOCALIZATION; CLONING; MEMBRANES	Neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP) are structurally related peptides found in all higher vertebrates. NPY is expressed exclusively in neurons, whereas PYY and PP are produced primarily in gut endocrine cells. Several receptor subtypes have been identified pharmacologically, but only the NPY/PYY receptor of subtype Y1 has been cloned. This is a heptahelix receptor that couples to G proteins. We utilized Y1 sequence information from several species to clone a novel human receptor with 43% amino acid sequence identity to human Y1 and 53% identity in the transmembrane regions. The novel receptor displays a pharmacological profile that distinguishes it from all previously described NPY family receptors. It binds PP with an affinity (K-i) of 13.8 pM, PYY with 1.44 nM, and NPY with 9.9 nM. Because these data may identify the receptor as primarily a PP receptor, we have named it PPI. In stably transfected Chinese hamster ovary cells the PP1 receptor inhibits forskolin-stimulated cAMP synthesis. Northern hybridization detected mRNA in colon, small intestine, pancreas, and prostate. As all three peptides are present in the gut through either endocrine release or innervation, all three peptides may be physiological ligands to the novel NPY family receptor PP1.	UPPSALA UNIV, DEPT MED PHARMACOL, S-75124 UPPSALA, SWEDEN; ELI LILLY & CO, LILLY RES LABS, LILLY CORP CTR, INDIANAPOLIS, IN 46285 USA	Uppsala University; Eli Lilly				/0000-0002-8250-8152				BALLANTYNE GH, 1993, AM J PHYSIOL, V264, pG848, DOI 10.1152/ajpgi.1993.264.5.G848; BLOMQVIST AG, 1993, BIOCHIM BIOPHYS ACTA, V1261, P439; BOTTCHER G, 1993, REGUL PEPTIDES, V43, P115, DOI 10.1016/0167-0115(93)90146-Y; CASTAN I, 1992, ENDOCRINOLOGY, V131, P1970, DOI 10.1210/en.131.4.1970; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; ELSALHY M, 1983, HISTOCHEMISTRY, V77, P15, DOI 10.1007/BF00496632; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; GEHLERT DR, 1992, NEUROCHEM INT, V21, P45, DOI 10.1016/0197-0186(92)90067-2; GEHLERT DR, 1994, LIFE SCI, V55, P551, DOI 10.1016/0024-3205(94)00481-1; GILBERT WR, 1986, ENDOCRINOLOGY, V118, P2495, DOI 10.1210/endo-118-6-2495; GILBERT WR, 1988, P NATL ACAD SCI USA, V85, P4745, DOI 10.1073/pnas.85.13.4745; HAZELWOOD RL, 1993, P SOC EXP BIOL MED, V202, P44; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; INUI A, 1991, AM J PHYSIOL, V261, pR588, DOI 10.1152/ajpregu.1991.261.3.R588; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; JORGENSEN JC, 1990, EUR J PHARMACOL, V186, P105, DOI 10.1016/0014-2999(90)94065-6; KIMMEL JR, 1968, ENDOCRINOLOGY, V83, P1323, DOI 10.1210/endo-83-6-1323; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LABURTHE M, 1990, TRENDS ENDOCRIN MET, V1, P168, DOI 10.1016/1043-2760(90)90031-W; LARHAMMAR D, 1993, COMP BIOCHEM PHYS C, V106, P743, DOI 10.1016/0742-8413(93)90236-E; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LUNDBERG JM, 1982, P NATL ACAD SCI-BIOL, V79, P4471, DOI 10.1073/pnas.79.14.4471; SCHWARTZ TW, 1987, FEBS LETT, V225, P209, DOI 10.1016/0014-5793(87)81159-6; SCHWARTZ TW, 1990, ANN NY ACAD SCI, V611, P35; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245; WAHLESTEDT C, 1992, LIFE SCI, V50, pPL7, DOI 10.1016/0024-3205(92)90342-M; WALKER P, 1994, J BIOL CHEM, V269, P2863; WHITCOMB DC, 1992, AM J PHYSIOL, V262, pG532, DOI 10.1152/ajpgi.1992.262.3.G532; WHITCOMB DC, 1990, AM J PHYSIOL, V259, pG687, DOI 10.1152/ajpgi.1990.259.4.G687	31	282	296	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29123	29128		10.1074/jbc.270.49.29123	http://dx.doi.org/10.1074/jbc.270.49.29123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493937	hybrid			2022-12-25	WOS:A1995TJ22700018
J	NAGIEC, EE; BERNSTEIN, A; WHITEHEART, SW				NAGIEC, EE; BERNSTEIN, A; WHITEHEART, SW			EACH DOMAIN OF THE N-ETHYLMALEIMIDE-SENSITIVE FUSION PROTEIN CONTRIBUTES TO ITS TRANSPORT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; VESICLE FORMATION; GOLGI MEMBRANES; SNAP; YEAST; NSF; PURIFICATION; COMPONENT; RECEPTOR; PATHWAY	N-Ethylmaleimide-sensitive fusion protein (NSF) has been shown to be involved in numerous intracellular transport events. In an effort to understand the basic mechanism of NSF in vesicle-target membrane fusion events, we have examined the role that each of its three domains play in how NSF interacts with the SNAP SNARE: complex. Mutagenesis of the first ATP-binding domain (D2, amino acids 206-477) demonstrates that nucleotide binding by this domain is required for 20 S particle assembly, a second mutation, which permits ATP binding but not hydrolysis, yields a protein that can form 20 S particle but fails to mediate its disassembly. Similar mutations of the second ATP-binding domain (D2, amino acids 478-744) result in trimeric molecules that behave like wild type NSF. Domain rearrangement mutants were used to further probe the functional role of each domain. The amino-terminal domain (N, amino acids 1-205) is absolutely required for binding of NSF to the SNAP-SNARE complex, because the truncated mutant, D1D2, is unable to form 20 S particle. When tested as an isolated recombinant protein, the N domain is not sufficient for binding to the SNAP SNARE complex, but when adjacent to the D1 domain or in a trimeric molecule, the N domain does mediate binding to the SNAP-SNARE complex. Monomeric N-D1 and trimeric N-D2 could both participate in particle formation. Only the N-D1 mutant was able to facilitate MgATP-dependent release from the SNAP-SNARE complex. These data demonstrate that NSF binding to the SNAP-SNARE complex is mediated by the N domain and that both ATP binding and hydrolysis by the D1 domain are essential for 20 S particle dynamics. The intramolecular interactions outlined suggest a mechanism by which NSF may use ATP hydrolysis to facilitate the vesicle fusion process.	UNIV KENTUCKY,COLL MED,CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky				Bernstein, Audrey/0000-0002-2537-2594; Whiteheart, Sidney/0000-0001-5577-0473				BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HARLOW E, 1988, ANTIBODIES LABORATOR; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; INOUE A, 1992, J BIOL CHEM, V267, P10613; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MORGAN A, 1994, J BIOL CHEM, V269, P29347; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, METHOD ENZYMOL, V219, P309; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	30	119	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29182	29188		10.1074/jbc.270.49.29182	http://dx.doi.org/10.1074/jbc.270.49.29182			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493945	hybrid			2022-12-25	WOS:A1995TJ22700026
J	SABNIS, NA; YANG, HH; ROMEO, T				SABNIS, NA; YANG, HH; ROMEO, T			PLEIOTROPIC REGULATION OF CENTRAL CARBOHYDRATE-METABOLISM IN ESCHERICHIA-COLI VIA THE GENE CSRA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL GLYCOGEN-SYNTHESIS; RATE-DEPENDENT REGULATION; PHOSPHOENOLPYRUVATE CARBOXYKINASE; PYRUVATE-KINASE; ENZYME; BIOSYNTHESIS; EXPRESSION; PROTEINS; BINDING; SYSTEMS	The carbon storage regulator gene csrA has been shown previously to dramatically affect the biosynthesis of intracellular glycogen in Escherichia coli through its negative control of the expression of two glycogen biosynthetic operons and the gluconeogenic gene pckA (Romeo, T., Gong, M., Liu, M. Y., and Brun-Zinkernagel, A. M, (1993) J, Bacteriol, 175, 4744-4755). Examination of the effects of csrA on several enzymes, genes, and metabolites of central carbohydrate metabolism now estab lishes a more extensive role for csrA in directing intracellular carbon flux. Phosphoglucomutase and the gluconeogenic enzymes fructose 1,6-bisphosphatase and phosphoenolpyruvate synthetase were found to be under the negative control of csrA, and these enzyme activities were maximal during the early stationary phase of growth. The enzymes glucose-6-phosphate isomerase, triose-phosphate isomerase, and enolase were positively regulated by csrA. Thus, csrA exerts reciprocal effects on glycolysis versus gluconeogenesis and glycogen biosynthesis. The glycolytic isozymes pyruvate kinase F and A (encoded by pykF and pykA, respectively) and phosphofructokinase I and II (pfkA and pfkB, respectively) exhibited differential regulation via csrA. Since the individual members of these isozyme pairs are allosterically regulated by different cellular metabolites, csrA is also capable of fine-tuning the allosteric regulation of glycolysis. In contrast, the expression of genes of the pentose phosphate pathway was weakly or negligibly affected by csrA.	UNIV N TEXAS, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, FT WORTH, TX 76107 USA; UNIV N TEXAS, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, FT WORTH, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center								ADHYA S, 1971, J BACTERIOL, V108, P621, DOI 10.1128/JB.108.2.621-626.1971; BABUL J, 1978, J BIOL CHEM, V253, P4350; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; Cooper R. A., 1969, METHOD ENZYMOL, V13, P309; DALDAL F, 1983, J MOL BIOL, V168, P285, DOI 10.1016/S0022-2836(83)80019-9; DIETZLER DN, 1974, ARCH BIOCHEM BIOPHYS, V160, P14, DOI 10.1016/S0003-9861(74)80003-2; DOELLE HW, 1978, EUR J BIOCHEM, V83, P479, DOI 10.1111/j.1432-1033.1978.tb12114.x; FARRISH EE, 1982, J BACTERIOL, V152, P584; FRAENKEL DG, 1966, ARCH BIOCHEM BIOPHYS, V114, P4, DOI 10.1016/0003-9861(66)90298-0; FRAENKEL DG, 1967, J BACTERIOL, V93, P1571, DOI 10.1128/JB.93.5.1571-1578.1967; FRAENKEL DG, 1965, J BACTERIOL, V90, P837, DOI 10.1128/JB.90.4.837-842.1965; FRAENKEL DG, 1987, ESCHERICHIA COLI SAL, V1, P142; GARRIDOPERTIERR.A, 1977, J BACTERIOL, V129, P1208; GARRIDOPERTIERRA A, 1983, FEBS LETT, V162, P420, DOI 10.1016/0014-5793(83)80799-6; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOLDIE AH, 1980, J BIOL CHEM, V255, P1399; GOLDIE H, 1984, J BACTERIOL, V159, P832, DOI 10.1128/JB.159.3.832-836.1984; HOLLYWOOD N, 1976, MICROBIOS, V17, P23; KOTLARZ D, 1975, BIOCHIM BIOPHYS ACTA, V381, P257, DOI 10.1016/0304-4165(75)90232-9; KOTLARZ D, 1981, EUR J BIOCHEM, V117, P569; KREBS A, 1980, CAN J BIOCHEM CELL B, V58, P309, DOI 10.1139/o80-041; KREBS EG, 1975, MTP INT REV SCI CA 1, V5, P337; LIU MY, 1995, J BACTERIOL, V177, P2663, DOI 10.1128/jb.177.10.2663-2672.1995; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; MAITRA PK, 1971, J BIOL CHEM, V246, P475; MALCOVATI M, 1982, METHOD ENZYMOL, V90, P170; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V1, P3; PEASE AJ, 1994, J BACTERIOL, V176, P115, DOI 10.1128/JB.176.1.115-122.1994; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PREISS J, 1984, ANNU REV MICROBIOL, V38, P419, DOI 10.1146/annurev.mi.38.100184.002223; PREISS J, 1994, PROG NUCLEIC ACID RE, V47, P299, DOI 10.1016/S0079-6603(08)60255-X; PREISS J, 1989, ADV MICROB PHYSIOL, V30, P183; REICHELT JL, 1971, ANTON VAN LEE J M S, V37, P497, DOI 10.1007/BF02218520; ROMEO T, 1993, J BACTERIOL, V175, P5740, DOI 10.1128/JB.175.17.5740-5741.1993; ROMEO T, 1989, J BACTERIOL, V171, P2773, DOI 10.1128/jb.171.5.2773-2782.1989; ROMEO T, 1990, CURR MICROBIOL, V21, P131, DOI 10.1007/BF02091831; ROMEO T, 1993, J BACTERIOL, V175, P4744, DOI 10.1128/JB.175.15.4744-4755.1993; ROMEO T, 1988, GENE, V70, P363, DOI 10.1016/0378-1119(88)90208-9; ROWLEY DL, 1991, J BACTERIOL, V173, P4660, DOI 10.1128/jb.173.15.4660-4667.1991; ROZACKY EE, 1971, ARCH BIOCHEM BIOPHYS, V146, P312, DOI 10.1016/S0003-9861(71)80069-3; SCHWARTZ M, 1966, J BACTERIOL, V92, P1083, DOI 10.1128/JB.92.4.1083-1089.1966; SINGER M, 1989, MICROBIOL REV, V53, P1; SMITH MW, 1983, J BACTERIOL, V154, P336, DOI 10.1128/JB.154.1.336-343.1983; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THOMAS AD, 1972, J BACTERIOL, V112, P1099, DOI 10.1128/JB.112.3.1099-1105.1972; WAYGOOD EB, 1976, BIOCHEMISTRY-US, V15, P277, DOI 10.1021/bi00647a006; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	47	140	154	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29096	29104		10.1074/jbc.270.49.29096	http://dx.doi.org/10.1074/jbc.270.49.29096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493933	hybrid			2022-12-25	WOS:A1995TJ22700014
J	QUAITERANDALL, E; TRENT, JD; JOSEPHS, R; JOACHIMIAK, A				QUAITERANDALL, E; TRENT, JD; JOSEPHS, R; JOACHIMIAK, A			CONFORMATIONAL CYCLE OF THE ARCHAEOSOME, A TCP1-LIKE CHAPERONIN FROM SULFOLOBUS-SHIBATAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; CENTRAL CAVITY; HEAT-SHOCK; GROEL; ARCHAEBACTERIUM; PROTEINS	The major heat shock proteins in the archaeon Sulfolobus shibatae are similar to the cytosolic eukaryotic chaperonin and form an 18-subunit bitoroidal complex. Two sequence-related subunits constitute a functional complex, named the archaeosome. The archaeosome exists in two distinct conformational states that are part of chaperonin functional cycle. The closed archaeosome complex binds ATP and forms an open complex. Upon ATP hydrolysis, the open complex dissociates into subunits, Free subunits reassemble into a two-ring structure. The equilibrium between the complexes and free subunits is affected by ATP and temperature. Denatured proteins associate with both conformational states as well as with free subunits that form an intermediate complex. These unexpected observations suggest a new mechanism of archaeosome-mediated thermotolerance and protein folding.	ARGONNE NATL LAB,ARGONNE,IL 60439; UNIV CHICAGO,CHICAGO,IL 60637	United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago								AZEM A, 1994, NATURE, V265, P653; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRENNAN TV, 1993, PROTEIN SCI, V2, P331; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIOMETTI CS, 1994, J CHROMATOGR, V698, P341; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; ISHII N, 1995, FEBS LETT, V362, P121, DOI 10.1016/0014-5793(95)00222-U; JOACHIMIAK A, 1995, FASEB J, V9, P52; KAGAWA HK, 1995, J MOL BIOL, V253, P712, DOI 10.1006/jmbi.1995.0585; KNAPP S, 1994, J MOL BIOL, V242, P397; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1995, FEBS LETT, V361, P55, DOI 10.1016/0014-5793(95)00151-X; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; PHIPPS BM, 1993, NATURE, V361, P474; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1120, P267, DOI 10.1016/0167-4838(92)90247-B; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; THOMAS PD, 1993, PROTEIN SCI, V2, P2050, DOI 10.1002/pro.5560021206; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062	35	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28818	28823		10.1074/jbc.270.48.28818	http://dx.doi.org/10.1074/jbc.270.48.28818			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499406	hybrid			2022-12-25	WOS:A1995TH05600050
J	QUATTROCHI, LC; MILLS, AS; BARWICK, JL; YOCKEY, CB; GUZELIAN, PS				QUATTROCHI, LC; MILLS, AS; BARWICK, JL; YOCKEY, CB; GUZELIAN, PS			A NOVEL CIS-ACTING ELEMENT IN A LIVER CYTOCHROME-P450 3A GENE CONFERS SYNERGISTIC INDUCTION BY GLUCOCORTICOIDS PLUS ANTIGLUCOCORTICOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT HEPATOCYTES; RESPONSE ELEMENTS; PREGNENOLONE 16-ALPHA-CARBONITRILE; HEPATIC CYTOCHROME-P-450; PROGESTERONE INDUCTION; MESSENGER-RNAS; RETINOIC ACID; TRANSCRIPTION; HORMONE; DNA	The induction by dexamethasone of rat liver CYP3A1 differs from classical glucocorticoid gene regulation in part because both glucocorticoids and antiglucocorticoids such as pregnenolone 16 alpha-carbonitrile (PCN) induce CYP3A1 through transcriptional gene activation. In the present study, we transiently expressed in primary cultures of rat hepatocytes plasmids consisting of CYP3A1 5'-flanking sequences fused to a chloramphenicol acetyltransferase reporter plasmid. Deletional analysis identified a 78-base pair (bp) element located approximately 135 bp upstream of the transcriptional start site that was inducible by treatment of the cultures with dexamethasone or PCN and was induced synergistically by dexamethasone plus PCN. Nuclear extract from control rat liver protected two regions within the 78-bp sequence against digestion with DNase I. The same two regions were protected when nuclear extracts from dexamethasone-treated animals were used. Analysis of both of the ''footprints'' (FP1 and FP2) failed to reveal a classical sequence for the glucocorticoid-responsive element. A 33-bp element that includes FP1 sequences inserted into the chloramphenicol acetyltransferase reporter plasmid and transiently expressed in rat hepatocytes conferred a profile of dexamethasone and PCN induction similar to that of the 78-bp element. However, an Escherichia coli expressed glucocorticoid receptor protein failed to protect sequences within FP1 in DNase I footprinting experiments and failed to change its mobility in gel shift assays. Moreover, as judged by the gel shift assay, the specific protein binding to this fragment was the same whether nuclear extracts from the liver of untreated or dexamethasone treated rats were used. We conclude that the activation of CYP3A1 gene transcription by glucocorticoids may involve proteins already bound to the controlling element in the CYP3A1 gene through a mechanism in which GR in the presence of hormone does not bind directly to CYP3A1 DNA.	UNIV COLORADO, HLTH SCI CTR,DEPT MED,HEPATOBILIARY RES CTR, MED TOXICOL SECT, DENVER, CO 80262 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PATHOL, RICHMOND, VA 23298 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Virginia Commonwealth University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004238] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34914] Funding Source: Medline; NIEHS NIH HHS [ES04238, ES05744] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURGER HJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P204, DOI 10.1016/0003-9861(90)90433-Y; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ELSHOURBAGY NA, 1980, J BIOL CHEM, V255, P1279; FISHER RC, 1991, MOL CELL BIOL, V11, P1614, DOI 10.1128/MCB.11.3.1614; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; GRAHAM JM, 1990, ANAL BIOCHEM, V187, P318, DOI 10.1016/0003-2697(90)90463-J; GUERTIN M, 1983, BIOCHEMISTRY-US, V22, P4296, DOI 10.1021/bi00287a021; HEUMAN DM, 1982, MOL PHARMACOL, V21, P753; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOMORI M, 1994, J BIOCHEM-TOKYO, V116, P114, DOI 10.1093/oxfordjournals.jbchem.a124482; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LI D, 1991, METHOD ENZYMOL, V206, P335; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P224; Maxam A M, 1980, Methods Enzymol, V65, P499; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; MIYATA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P71, DOI 10.1006/abbi.1995.1206; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PEREIRA TM, 1995, EUR J BIOCHEM, V229, P171, DOI 10.1111/j.1432-1033.1995.0171l.x; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SCHUETZ EG, 1984, J BIOL CHEM, V259, P1999; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SIMMONS DL, 1987, J BIOL CHEM, V262, P326; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TELHADA MB, 1992, ARCH BIOCHEM BIOPHYS, V298, P715, DOI 10.1016/0003-9861(92)90471-8; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; WATKINS PB, 1985, P NATL ACAD SCI USA, V82, P6310, DOI 10.1073/pnas.82.18.6310; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WRIGHTON SA, 1985, MOL PHARMACOL, V28, P312	42	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28917	28923		10.1074/jbc.270.48.28917	http://dx.doi.org/10.1074/jbc.270.48.28917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499421	hybrid			2022-12-25	WOS:A1995TH05600065
J	WALSH, JP; SUEN, R; GLOMSET, JA				WALSH, JP; SUEN, R; GLOMSET, JA			ARACHIDONOYL-DIACYLGLYCEROL KINASE - SPECIFIC IN-VITRO INHIBITION BY POLYPHOSPHOINOSITIDES SUGGESTS A MECHANISM FOR REGULATION OF PHOSPHATIDYLINOSITOL BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ESCHERICHIA-COLI; PHOSPHATIDIC-ACID; HUMAN-PLATELETS; RAT-BRAIN; SN-1,2-DIACYLGLYCEROL KINASE; CULTURED FIBROBLASTS; RECEPTOR ACTIVATION; PHOSPHOLIPASE-C; 2ND MESSENGERS	We previously described the purification of a membrane-bound diacylglycerol kinase highly selective for sn-1-acyl-2-arachidonoyl diacylglycerols (Walsh, J. P., Suen, R., Lemaitre, R. N., and Glomset, J. A. (1994) J. Biol. Chem. 269, 21155-21164), This enzyme appears to be responsible for the rapid clearance of the arachidonate rich pool of diacylglycerols generated during stimulus-induced phosphoinositide turnover, We have now shown phosphatidylinositol 4,5-bisphosphate to be a potent and specific inhibitor of arachidonoyl-diacylglycerol kinase, Kinetic analyses indicated a K-i for phosphatidylinositol 4,5-bisphosphate of 0.04 mol %. Phosphatidic acid also was an inhibitor with a K-i of 0.7 mol %, Other phospholipids had only small effects at these concentrations, A series of multiply phosphorylated lipid analogs also inhibited the enzyme, indicating that the head group phosphomonoesters are the primary determinants of the polyphosphoinositide effect. However, these compounds were not as potent as phosphatidylinositol 4,5-bisphosphate, indicating some specificity for the polyphosphoinositide additional to its total charge, Five other diacylglycerol kinases were activated to varying degrees by phosphatidylinositol 4,5-bisphosphate and phosphatidic acid, suggesting that inhibition by acidic lipids may be specific for the arachidonoyl-DAG kinase isoform. Given the presumed role of arachidonoyl-diacylglycerol kinase in the phosphoinositide cycle, this inhibition may represent a mechanism for polyphosphoinositides to regulate their own synthesis.	UNIV WASHINGTON, HOWARD HUGHES MED INST, RES LABS, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, RES LABS, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, RES LABS, REG PRIMATE RES CTR, SEATTLE, WA 98195 USA; INDIANA UNIV, DEPT MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALSADEN A, 1977, J PHARM PHARMACOL, V29, pP23, DOI 10.1111/j.2042-7158.1977.tb11491.x; AUGERT G, 1989, J BIOL CHEM, V264, P2574; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CHEN Q, 1993, J NEUROCHEM, V60, P1212, DOI 10.1111/j.1471-4159.1993.tb03279.x; CLINT JH, 1975, J CHEM SOC FARAD T 1, V71, P1327, DOI 10.1039/f19757101327; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIXON M, 1979, ENZYMES, P79; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; GOLDFARB J, 1969, J COLLOID INTERF SCI, V31, P454, DOI 10.1016/0021-9797(69)90046-0; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; HELMS JB, 1991, J BIOL CHEM, V266, P21368; Holub B J, 1978, Adv Lipid Res, V16, P1; HUANG CF, 1990, J BIOL CHEM, V265, P17468; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KANOH H, 1978, EUR J BIOCHEM, V85, P225, DOI 10.1111/j.1432-1033.1978.tb12230.x; KANOH H, 1989, BIOCHEM J, V258, P455, DOI 10.1042/bj2580455; KATO M, 1990, J BIOL CHEM, V265, P794; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KERWIN JL, 1994, J LIPID RES, V35, P1102; LEE C, 1991, J BIOL CHEM, V266, P22837; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; LIN CH, 1986, LIPIDS, V21, P206, DOI 10.1007/BF02534823; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NGUYEN CM, 1986, J COLLOID INTERF SCI, V112, P438, DOI 10.1016/0021-9797(86)90112-8; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OSBORNELEE IW, 1985, J COLLOID INTERF SCI, V108, P60, DOI 10.1016/0021-9797(85)90236-X; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RENARD DC, 1982, BIOCHEM J, V281, P775; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Ribeiro A. A., 1987, NONIONIC SURFACTANTS, P971; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SERDAREVICH B, 1966, CAN J BIOCHEM CELL B, V44, P743, DOI 10.1139/o66-092; SHEARS SB, 1991, PHARMACOL THERAPEUT, V49, P79, DOI 10.1016/0163-7258(91)90023-F; SHOJI N, 1978, J AM OIL CHEM SOC, V55, P297, DOI 10.1007/BF02676947; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SOLING HD, 1989, J BIOL CHEM, V264, P10643; STATHOPOULOS VM, 1990, BIOCHEM J, V272, P569, DOI 10.1042/bj2720569; TERUI T, 1994, J BIOL CHEM, V269, P28130; TOKER A, 1994, J BIOL CHEM, V269, P32358; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALSH JP, 1990, J BIOL CHEM, V265, P4374; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WALSH JP, 1992, METHOD ENZYMOL, V209, P153; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YADA Y, 1990, J BIOL CHEM, V265, P19237; YAMADA K, 1988, BIOCHEM J, V255, P601; [No title captured]	72	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28647	28653		10.1074/jbc.270.48.28647	http://dx.doi.org/10.1074/jbc.270.48.28647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499383	hybrid			2022-12-25	WOS:A1995TH05600027
J	RICHARDON, RM; ALI, H; TOMHAVE, ED; HARIBABU, B; SNYDERMAN, R				RICHARDON, RM; ALI, H; TOMHAVE, ED; HARIBABU, B; SNYDERMAN, R			CROSS-DESENSITIZATION OF CHEMOATTRACTANT RECEPTORS OCCURS AT MULTIPLE LEVELS - EVIDENCE FOR A ROLE FOR INHIBITION OF PHOSPHOLIPASE-C ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED SIGNAL-TRANSDUCTION; POLYMORPHONUCLEAR LEUKOCYTES; DEPENDENT PHOSPHORYLATION; INOSITOL TRISPHOSPHATE; CELLS; FORMYLPEPTIDE; NEUTROPHILS; HYDROLYSIS; PEPTIDE; CALCIUM	To define the molecular mechanisms of cross-regulation among chemoattractant receptors, we stably coexpressed, in a rat basophilic leukemia (RBL-2H3) cell line, epitope tagged receptors for the chemoattractants formylmethionylleucylphenylalanine (fMLP), a peptide of the fifth component of the complement system (C5a), and interleukin-8 (IL-8), All the expressed receptors underwent homologous phosphorylation and desensitization upon agonist stimulation, When co-expressed, epitope-tagged C5a receptor (ET-C5aR) and epitope-tagged IL-8 receptor (ET-IL-8RA) were cross-phosphorylated by activation of the other. Activation of epitope-tagged fMLP receptor (ET-FR) also cross-phosphorylated ET-C5aR and ET-IL 8RA, but ET-FR was totally resistant to cross-phosphorylation. Similarly, C5a and IL-8 stimulation of [S-35]guanosine 5'-3-O-(thio) triphosphate (GTP gamma S) binding and Ca2+ mobilization were cross-desensitized by each other and by fMLP. Stimulation of [S-35]GTP gamma S binding by fMLP was also not cross-desensitized by C5a or IL-8, however, Ca2+ mobilization was, suggesting a site of inhibition distal to G protein activation, Consistent with this desensitization of Ca2+ mobilization, inositol 1,4,5-trisphosphate release in RBL-2H3 cells expressing both ET-C5aR and ET-FR revealed that fMLP and C5a cross-desensitized each other's ability to stimulate phosphoinositide hydrolysis, Taken together, these results indicate that receptor cross-phosphorylation correlates directly with desensitization at the level of G protein activation, The ET-FR was resistant to this process. Of note, cross desensitization of ET-FR at the level of phosphoinositide hydrolysis and Ca2+ mobilization was demonstrated in the absence of receptor phosphorylation, This suggests a new form of chemoattractant cross-regulation at a site distal to receptor/G; protein coupling, involving the activity of phospholipase C.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University; Duke University			Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-03738] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DOBOS GJ, 1992, J IMMUNOL, V149, P609; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LIGGETT SB, 1994, REGULATION CELLULAR, P71; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; PIKE MC, 1986, BLOOD, V67, P909; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TARDIF M, 1993, J IMMUNOL, V150, P3534; TOMHAVE E, 1994, J IMMUNOL, V154, P3267; WILDE MW, 1989, J BIOL CHEM, V264, P190; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	21	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27829	27833		10.1074/jbc.270.46.27829	http://dx.doi.org/10.1074/jbc.270.46.27829			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499254	hybrid			2022-12-25	WOS:A1995TE73600065
J	TOMINAGA, M; TOMINAGA, T; MIWA, A; OKADA, Y				TOMINAGA, M; TOMINAGA, T; MIWA, A; OKADA, Y			VOLUME-SENSITIVE CHLORIDE CHANNEL ACTIVITY DOES NOT DEPEND ON ENDOGENOUS P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; MONOCLONAL-ANTIBODIES; EPITHELIAL-CELLS; VINBLASTINE SECRETION; CONDUCTANCE; VERAPAMIL; CURRENTS; VINCRISTINE; MECHANISMS; EXPRESSION	To determine whether endogenous P-glycoprotein, the MDR1 gene product that functions as a drug transport pump, is a volume-sensitive Cl- channel molecule or a protein kinase C-mediated regulator of the Cl- channel, whole-cell patch clamp and molecular biological experiments were carried out in a human small intestinal epithelial cell line, Endogenous expression of P-glycoprotein was confirmed by Northern blot analysis, reverse transcription-polymerase chain reaction, Western blot analysis, and immunostaining, The P-glycoprotein expression was abolished by the antisense (but not sense) oligonucleotide for the MDR1 gene, whereas the magnitude of the Cl- current activated by osmotic swelling was not distinguishable between both antisense- and sense-treated cells, The volume-sensitive Cl- currents were not specifically affected by the anti-P-glycoprotein monoclonal antibodies, MRK16, C219, and UIC2, An inhibitor of P-glycoprotein-mediated pump activity, verapamil, was found to never affect the Cl- current, A substrate for the P-glycoprotein-mediated drug pump, vincristine or daunomycin, did not prevent swelling-induced activation of the Cl- current, Furthermore, the Cl- current was not affected by an activator of protein kinase C (12-O-tetradecanoylphorbol-13-acetate or 1-oleoyl-2-acetyl-sn-glycerol). Thus, it is concluded that the endogenous P-glycoprotein molecule is not itself a volume-sensitive Cl- channel nor a protein kinase C-mediated regulator of the channel in the human epithelial cells.			TOMINAGA, M (corresponding author), NATL INST PHYSIOL SCI,DEPT CELLULAR & MOLEC PHYSIOL,OKAZAKI,AICHI 444,JAPAN.							ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ALTENBERG GA, 1994, J BIOL CHEM, V269, P7145; BOTCHKIN LM, 1993, AM J PHYSIOL, V265, pC1037, DOI 10.1152/ajpcell.1993.265.4.C1037; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; DONG YJ, 1994, CANCER RES, V54, P5029; DOROSHENKO P, 1992, J PHYSIOL-LONDON, V449, P197, DOI 10.1113/jphysiol.1992.sp019082; EHRING GR, 1994, J GEN PHYSIOL, V104, P1129, DOI 10.1085/jgp.104.6.1129; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAN ES, 1994, J GEN PHYSIOL, V104, pA43; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HUNTER J, 1993, J BIOL CHEM, V268, P14991; INUI T, 1994, AM J PHYSIOL, V266, pL113, DOI 10.1152/ajplung.1994.266.2.L113; ITOH A, 1994, PFLUG ARCH EUR J PHY, V428, P468, DOI 10.1007/BF00374567; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; JENTSCH TJ, 1994, CURR OPIN CELL BIOL, V6, P600, DOI 10.1016/0955-0674(94)90082-5; JIRSCH JD, 1994, AM J PHYSIOL, V267, pC688, DOI 10.1152/ajpcell.1994.267.3.C688; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KUBO M, 1992, J PHYSIOL-LONDON, V456, P351, DOI 10.1113/jphysiol.1992.sp019340; LEWIS RS, 1993, J GEN PHYSIOL, V101, P801, DOI 10.1085/jgp.101.6.801; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; MA LD, 1991, J BIOL CHEM, V266, P5593; MACLEOD RJ, 1991, AM J PHYSIOL, V260, pG26, DOI 10.1152/ajpgi.1991.260.1.G26; MCEWAN GTA, 1992, FEBS LETT, V304, P233, DOI 10.1016/0014-5793(92)80626-R; MEEHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824; MINTENIG GM, 1992, RECEPTOR CHANNEL, V1, P305; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; OKADA Y, 1979, MEMBRANE BIOCHEM, V2, P339, DOI 10.3109/09687687909063871; OKADA Y, 1994, JPN J PHYSIOL, V44, pS31; OKADA Y, 1994, JPN J PHYSIOL, V44, P403, DOI 10.2170/jjphysiol.44.403; RASOLA A, 1994, J BIOL CHEM, V269, P1432; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RIVOLTINI L, 1990, INT J CANCER, V46, P727, DOI 10.1002/ijc.2910460429; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; STODDARD JS, 1993, AM J PHYSIOL, V265, pC156, DOI 10.1152/ajpcell.1993.265.1.C156; SUGAWARA I, 1992, JPN J CANCER RES, V83, P795, DOI 10.1111/j.1349-7006.1992.tb01982.x; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TOMINAGA M, 1995, CIRC RES, V77, P417, DOI 10.1161/01.RES.77.2.417; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; TSURUO T, 1981, CANCER RES, V41, P1967; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDENBERG JI, 1994, J GEN PHYSIOL, V104, P997, DOI 10.1085/jgp.104.6.997; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	53	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27887	27893		10.1074/jbc.270.46.27887	http://dx.doi.org/10.1074/jbc.270.46.27887			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499263	hybrid			2022-12-25	WOS:A1995TE73600074
J	FURUTA, Y; ILIC, D; KANAZAWA, S; TAKEDA, N; YAMAMOTO, T; AIZAWA, S				FURUTA, Y; ILIC, D; KANAZAWA, S; TAKEDA, N; YAMAMOTO, T; AIZAWA, S			MESODERMAL DEFECT IN LATE-PHASE OF GASTRULATION BY A TARGETED MUTATION OF FOCAL ADHESION KINASE, FAK	ONCOGENE			English	Article						MUTANT MOUSE; FAK; FOCAL ADHESION; CELL MOBILITY; MESODERM; CELL-EXTRACELLULAR MATRIX INTERACTION	PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; TUMOR-SUPPRESSOR; CELL-ADHESION; MOUSE EMBRYOS; GENE; EXPRESSION; FIBRONECTIN; BETA-1-INTEGRINS; PHOSPHORYLATION	FAK is a unique non-receptor protein tyrosine kinase that was found in cellular focal adhesions. An increasing number of in vitro observations has suggested that FAK mediates signaling through integrins brought about by interactions with extracellular matrix (ECM). It is highly tyrosine-phosphorylated in v-src-transformed cells and during embryogenesis. To clarify the function of FAK in cell-ECM interactions, embryonic phenotype of its mutant was analysed. FAK-deficient embryos could implant and initiate gastrulation normally, but showed abnormalities in. subsequent development. The abnormalities were characterized as a general deficiency in mesoderm, and the phenotype was quite similar to that caused by fibronectin-deficiency. The results suggest that FAK mediates fibronectin-integrin interactions uniquely at this stage of development, thereby playing an essential role in development of mesodermal cell lineages.	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT MORPHOGENESIS,KUMAMOTO 860,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	Kumamoto University; University of Tokyo				ILIC, DUSKO/0000-0003-1647-0026				BARRY ST, 1994, J CELL SCI, V107, P2033; BOLEN JB, 1993, ONCOGENE, V8, P2025; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAMSKY C, 1993, FASEB J, V7, P1320, DOI 10.1096/fasebj.7.14.8224605; DRAKE CJ, 1992, DEV DYNAM, V193, P83, DOI 10.1002/aja.1001930111; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GLUKHOVA MA, 1993, SEMIN CANCER BIOL, V4, P241; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; ILIC D, 1995, IN PRESS NATURE; KADOWAKI T, 1994, CANCER RES, V54, P291; KANAZAWA S, 1995, IN PRESS BIOCH BIOPH; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOHMURA N, 1994, MOL CELL BIOL, V14, P6915, DOI 10.1128/MCB.14.10.6915; LINASK KK, 1988, DEV BIOL, V129, P315, DOI 10.1016/0012-1606(88)90378-8; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NAKAMURA N, 1993, J CELL SCI, V106, P1057; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; STEPHENS LE, 1993, J CELL BIOL, V123, P1607, DOI 10.1083/jcb.123.6.1607; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; YAGI T, 1994, ANAL BIOCHEM, V214, P70; YANG JT, 1993, DEVELOPMENT, V119, P1093; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	40	182	187	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1989	1995						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478517				2022-12-25	WOS:A1995TF29700008
J	PENG, ZY; CARTWRIGHT, CA				PENG, ZY; CARTWRIGHT, CA			REGULATION OF THE SRC TYROSINE KINASE AND SYP TYROSINE PHOSPHATASE BY THEIR CELLULAR-ASSOCIATION	ONCOGENE			English	Article						SRC; SYP; TYROSINE KINASE; TYROSINE PHOSPHATASE	HUMAN-COLON-CARCINOMA; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PP60C-SRC PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; ACTIVATION; PHOSPHORYLATION; RECEPTOR; TRANSFORMATION; P60C-SRC; MITOSIS	The specific activity of the Src tyrosine kinase is elevated in human colon carcinoma cells. To identify Src-binding proteins that might upregulate Src activity in these cells, a human colon carcinoma lambda gt11 expression library was screened with purified, P-32-labeled Src. The SH-PTP2 (Syp) tyrosine phosphatase was isolated and shown to associate with Src. In vitro studies demonstrated that: (1) transforming F527 Src phosphorylates Syp, and (2) Syp dephosphorylates Src at Tyr 527. Both events are known to upregulate enzyme activity. Others have shown that overexpression of the receptor tyrosine phosphatase alpha in rat embryo fibroblasts results in Src activation by dephosphorylation of Tyr 527, cell transformation and tumorigenesis. Thus, transmembrane tyrosine phosphatases may be involved in cell transformation exerting at least some of their effects through activation of Src. To the best of our knowledge, this is the first identification of an intracellular tyrosine phosphatase which may activate Src by a similar mechanism.	STANFORD UNIV, SCH MED, DEPT MED, MED SCH LAB, STANFORD, CA 94305 USA	Stanford University					NIDDK NIH HHS [P30-DK38707, R29 DK43743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R29DK043743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DEMILIA JC, 1991, ONCOGENE, V6, P303; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; FANG KS, 1994, J BIOL CHEM, V269, P20194; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STONE RL, 1994, J BIOL CHEM, V269, P31323; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	57	76	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					1955	1962						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478513				2022-12-25	WOS:A1995TF29700004
J	ARTUSO, M; ESTEVE, A; BRESIL, H; VUILLAUME, M; HALL, J				ARTUSO, M; ESTEVE, A; BRESIL, H; VUILLAUME, M; HALL, J			THE ROLE OF THE ATAXIA-TELANGIECTASIA GENE IN THE P53, WAF1/CIP1(P21)- AND GADD45-MEDIATED RESPONSE TO DNA-DAMAGE PRODUCED BY IONIZING-RADIATION	ONCOGENE			English	Article						DNA DAMAGE; ATAXIA TELANGIECTASIA; P53 PROTEIN; WAF1/CIP1(P21); GADD45; CELL CYCLE	TUMOR-SUPPRESSOR PROTEIN; CYCLIN-DEPENDENT KINASES; IONIZING-RADIATION; GROWTH ARREST; HUMAN-CELLS; INDUCTION; SENSITIVITY; CANCER; ANTIGEN; UV	The inducible response of the tumour suppressor gene p53 has been examined following exposure to DNA-damaging agents in Ataxia telangiectasia (AT) cell lines, an autosomal recessive disorder with multiple clinical and biological abnormalities including sensitivity to ionising radiation. The p53 induction was significantly delayed and reduced in the 8 AT cell lines examined over the 6 h following irradiation with no dose response in p53 induction being observed compared to control cells, The increase of WAF1/CIP1(p21) and GADD45 mRNA, two genes transcriptionally activated by p53, was also reduced in the AT cell lines after such treatment. In contrast, the increase in p53 protein, WAF1/CIP1(p21) and GADD45 mRNA expression following exposure to the alkylating agent methylmethane sulphonate (25 and 100 mu g ml(-1)) was similar in both cell types, No alterations in the expression of EBNA-5, an EBV-encoded nuclear antigen which has been shown to bind p53 or mutations in the p53 gene (exons 4 to 8) were found in the AT cell lines studied, The AT gene product would thus appear to be involved upstream of p53, GADD45 and WAF1/CIP1 (p21) in the signalling of the presence of strand breaks produced by ionising radiation, with this defect in response contributing to the high cancer risk and radiosensitivity observed in this disorder.	INT AGCY RES CANC,MECH CARCINOGENESIS UNIT,F-69372 LYON 08,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC)			hall, janet/G-1372-2013	hall, janet/0000-0002-4397-6295				BALALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V54, P1169; ELDEIRY WS, 1994, CANCER RES, V54, P1174; ESTEVE A, 1993, MOL CARCINOGEN, V8, P306, DOI 10.1002/mc.2940080414; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRITSCHE M, 1993, ONCOGENE, V8, P307; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KEMP CJ, 1994, GENETICS, V8, P66; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACILWRATH AJ, 1994, CANCER RES, V54, P3718; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MORRELL D, 1986, J NATL CANCER I, V77, P89; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PIENTENPOL JA, 1993, NATURE, V211, P31; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SVITSKY K, 1995, SCIENCE, V268, P1749; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TROELSTRA C, 1994, CURR BIOL, V4, P1149, DOI 10.1016/S0960-9822(00)00260-8; VOGELSTEIN B, 1992, NATURE, V355, P209, DOI 10.1038/355209a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755	61	83	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1427	1435						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478567				2022-12-25	WOS:A1995TC53500001
J	CHEN, CY; FALLER, DV				CHEN, CY; FALLER, DV			DIRECTION OF P21(RAS)-GENERATED SIGNALS TOWARDS CELL-GROWTH OR APOPTOSIS IS DETERMINED BY PROTEIN-KINASE-C AND BCL-2	ONCOGENE			English	Article						PROGRAMMED CELL DEATH; T LYMPHOCYTE; ONCOGENE; PHOSPHOPROTEIN; SIGNAL TRANSDUCTION; CELL CYCLE	ANTIGEN RECEPTOR; T-CELLS; REGULATED KINASE-2; DNA FRAGMENTATION; RAS ONCOGENES; LYMPHOCYTES-T; HA-RAS; ACTIVATION; DEATH; MYC	Normal and activated Ras proteins are known to act as signal transducers, mediating mitogenic responses. Interactions of p21(ras) and protein kinase C (PKC) are required in a number of mitogenic or activation signaling pathways. The constitutive expression of activated v-Ha-ras in Jurkat cells, a human T lymphoblastoid cell line, renders the cells susceptible to apoptosis during transient down-regulation or inhibition of PKC. Similarly, the expression of v-Ki-ras in murine fibroblasts induces apoptosis during suppression of PKC activity. This Ras-specific cell death is dependent upon suppression of cellular PKC activity, and can be blocked by the survival-promoting bcl-2 gene product. In vivo phosphorylation studies indicate that Bcl-2 is a phosphoprotein, and the phosphorylation state of Bcl-2 is modulated in the setting of activated p21(Ha-ras) in response to inhibition of PKC. These findings suggest an interactive regulation of growth or apoptosis in cells which involves at least three molecules: p21(ras), PKC and Bcl-2.	BOSTON UNIV,SCH MED,CANC RES CTR,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University								ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BARBACID M, 1987, ANNU REV BIOCHEM, P779; BERRY N, 1990, EUR J BIOCHEM, V189, P204; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P678, DOI 10.1038/348678a0; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DEROSSI A, 1994, VIROLOGY, V198, P234, DOI 10.1006/viro.1994.1026; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FALLER DV, 1994, J BIOL CHEM, V269, P5022; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FERNANDEZSARABI.MJ, 1995, NATURE, V10, P768; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FU T, 1992, FEBS LETT, V307, P301, DOI 10.1016/0014-5793(92)80700-Q; FU T, 1991, EXP CELL RES, V203, P230; GRAVES JD, 1990, BIOCHEM J, V265, P407, DOI 10.1042/bj2650407; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOWE PH, 1993, J BIOL CHEM, V268, P21448; ILLERA VA, 1993, J IMMUNOL, V151, P2965; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOKA P, 1991, J IMMUNOL, V146, P2417; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOTEM J, 1994, CELL GROWTH DIFFER, V5, P321; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUCAS M, 1994, BIOCHEM PHARMACOL, V47, P667, DOI 10.1016/0006-2952(94)90129-5; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARVEL J, 1994, ONCOGENE, V9, P1117; MAUMOVSKI L, 1994, BLOOD, V83, P2261; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCDONNELL TJ, 1993, RADIAT RES, V136, P307, DOI 10.2307/3578541; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; POLVERINO AJ, 1990, BIOCHEM J, V271, P309, DOI 10.1042/bj2710309; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; RODEN RBS, 1993, CELL GROWTH DIFFER, V4, P957; SCHER CD, 1982, J CELL PHYSIOL, V113, P211, DOI 10.1002/jcp.1041130205; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SUGIMOTO Y, 1992, EXP CELL RES, V203, P230, DOI 10.1016/0014-4827(92)90059-H; TAMM I, 1990, J CELL PHYSIOL, V143, P494, DOI 10.1002/jcp.1041430314; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WALTON MI, 1993, CANCER RES, V53, P1853; WANG HG, 1994, ONCOGENE, V9, P2751; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YOSHINO T, 1994, BLOOD, V83, P1856; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	95	120	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1487	1498						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478573				2022-12-25	WOS:A1995TC53500007
J	ELIOPOULOS, AG; KERR, DJ; HEROD, J; HODGKINS, L; KRAJEWSKI, S; REED, JC; YOUNG, LS				ELIOPOULOS, AG; KERR, DJ; HEROD, J; HODGKINS, L; KRAJEWSKI, S; REED, JC; YOUNG, LS			THE CONTROL OF APOPTOSIS AND DRUG-RESISTANCE IN OVARIAN-CANCER - INFLUENCE OF P53 AND BCL-2	ONCOGENE			English	Article						BCL-2; BAX; P53; OVARIAN; CISPLATIN; DRUG-RESISTANCE	PROGRAMMED CELL-DEATH; WILD-TYPE P53; B-CELLS; GENE AMPLIFICATION; ANTICANCER AGENTS; LEUKEMIC-CELLS; CYCLE CONTROL; C-MYC; PROTEIN; DNA	Modulation of apoptosis may influence resistance to chemotherapy and therefore affect the outcome of cancer treatment. Ovarian cancer, one of the most fatal malignancies in women, is often associated with drug resistance but the cellular pathways contributing to this effect remain obscure. We have found that Bcl-2 and p53, two proteins implicated in the control of apoptosis, are frequently expressed in fresh biopsies of primary ovarian carcinoma. Examination of Bcl-2 and p53 protein levels in pairs of cis-platin sensitive and resistant ovarian cell lines demonstrated that the resistant variants over-express Bcl-2 and/or p53, apparently due to progressive expansion of Bcl-2 and/or p53 positive subpopulations during the in vitro development of resistance. Exogenous expression of Bcl-2 or a temperature sensitive mutant p53 (ts p53) in the ovarian cell line A2780 resulted in protection from drug-induced apoptosis and a delay in drug-mediated S-phase arrest. Interestingly, p53 accumulation in response to DNA damage induced by different agents was significantly delayed and reduced in the Bcl-2 transfectants compared to the control A2780 line, suggesting that Bcl-2 may act upstream of the p53 pathway. Similarly, the induction of Bax mRNA and protein was also found to be delayed in the presence of Bcl-2. Overall, our data provide further evidence for cross-talk between Bcl-2, p53 and Bax and suggest that these genes are important determinants of drug-induced apoptosis thereby modulating resistance to chemotherapy.	UNIV BIRMINGHAM, SCH MED, CRC, INST CANC STUDIES, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	University of Birmingham; Sanford Burnham Prebys Medical Discovery Institute			Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020	Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761	NCI NIH HHS [CA60138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA060138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENS BC, 1987, CANCER RES, V47, P414; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CAMPOS L, 1993, BLOOD, V81, P3091; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1987, CELL, V47, P2537; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DAWSON CW, 1995, ONCOGENE, V10, P69; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; DIVE C, 1993, FRONTIERS PHARM CANC, P21; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EASTMAN A, 1991, MOL CLIN ADV ANTICAN, P233; EASTMAN A, 1994, NEW MOL TARGETS CANC, P143; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGUE A, 1994, ONCOGENE, V9, P3367; HALDAR S, 1994, CANCER RES, V54, P2095; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLAND LR, 1992, CANCER RES, V52, P3857; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARKS JR, 1991, CANCER RES, V51, P2979; MASUDA H, 1990, CANCER RES, V50, P1863; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MONTENARH M, 1992, INT J ONCOL, V1, P37; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; Sambrook J, 1989, MOL CLONING LABORATO; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; SPANDIDOS DA, 1984, IN VITRO TRANSCRIPTI, P1; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TEYSSIER JR, 1989, CANCER GENET CYTOGEN, V39, P35, DOI 10.1016/0165-4608(89)90227-6; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; ZHAN QM, 1994, ONCOGENE, V9, P3743	74	288	301	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1217	1228						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478541				2022-12-25	WOS:A1995RY96700001
J	KIKUCHIYANOSHITA, R; TANAKA, K; MURAOKA, M; KONISHI, M; KAWASHIMA, I; TAKAMOTO, S; HIRAI, H; MIYAKI, M				KIKUCHIYANOSHITA, R; TANAKA, K; MURAOKA, M; KONISHI, M; KAWASHIMA, I; TAKAMOTO, S; HIRAI, H; MIYAKI, M			MALIGNANT TRANSFORMATION OF RAT EMBRYO FIBROBLASTS BY COTRANSFECTION WITH 11 HUMAN MUTANT P53 CDNAS AND ACTIVATED H-RAS GENE	ONCOGENE			English	Article						MUTANT P53 CDNAS; H-RAS GENE; REF; TRANSFORMATION; METASTASIS	FAMILIAL ADENOMATOUS POLYPOSIS; WILD-TYPE P53; TUMOR-ANTIGEN; CELLS; CARCINOMAS; ALLELES; DNA; IMMORTALIZATION; AMPLIFICATION; EXPRESSION	Eleven different missense and one nonsense mutant-type p53 cDNAs, which have been frequently detected in human colorectal carcinomas, were constructed and examined for their ability to cooperate with activated human H-ras genes, pSK2 and pHs49, in transfection of rat embryo fibroblasts (REF), Each missense mutant-type p53 cDNA with either of the two activated H-ras genes transformed REF with a different frequency of transformation depending on the different kind of mutation, whereas wild-type p53 (with ras), nonsense mutant-type p53 (with pas), as well as mutant-type p53 (alone) and ras (alone), did not transform REF, Six transformed REF cell lines were established from cotransfection with missense mutant-type p53 cDNA and ras gene; all of them exhibiting exogenous human p53 DNA, RNA, protein, and H-ras DNA and RNA, All six transformed cell lines showed both tumorigenicity and lung metastatic potential in nude mice, They also exhibited 92 kilodalton gelatinase activity, which was not detected in parental REF, These results suggest that missense mutations in p53 gene have a role in malignant transformation as well as metastatic potential.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT TUMOR IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT TRANSFUS MED,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; University of Tokyo								ADDISON C, 1990, ONCOGENE, V5, P423; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERNHARD EJ, 1990, CANCER RES, V550, P3872; BRISTOW RG, 1994, ONCOGENE, V9, P1527; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POLLACK R, 1974, P NATL ACAD SCI USA, V71, P4792, DOI 10.1073/pnas.71.12.4792; PONTA H, 1994, EUR J CANCER, V30A, P1995, DOI 10.1016/0959-8049(94)00393-J; ROVINSKI B, 1988, ONCOGENE, V2, P445; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; TAKAMOTO S, 1991, CYTOMETRY RES, V1, P77; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG JY, 1992, CANCER RES, V52, P6682	35	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1339	1345						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478555				2022-12-25	WOS:A1995RY96700015
J	LOPEZBARAHONA, M; MINANO, M; MIRA, E; IGLESIAS, T; STUNNENBERG, HG; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A				LOPEZBARAHONA, M; MINANO, M; MIRA, E; IGLESIAS, T; STUNNENBERG, HG; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A			RETINOIC ACID POSTTRANSCRIPTIONALLY UP-REGULATES PROTEOLIPID PROTEIN GENE-EXPRESSION IN C6 GLIOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; MYELIN-DEFICIENT RAT; MESSENGER-RNAS; RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; DEVELOPMENTAL EXPRESSION; BASIC-PROTEIN; BETA-GENE; PLP GENE; BRAIN	The proteolipid protein (PLP) gene codes for the major central nervous system myelin protein. We have studied the effects of different agents on the expression of the PLP gene in C6 glioma cells. Retinoic acid (RA), but not dexamethasone, estradiol, insulin, growth hormone, or vitamin D3, had a drastic effect, increasing 10-20-fold the level of PLP mRNA. Concomitantly, RA also induced the appearance of the corresponding immunoreactive protein. The increase in PLP RNA level showed a slow kinetics and was blocked by cycloheximide, suggesting a posttranscriptional regulation by RA. Nuclear run-on assays confirmed that the rate of PLP gene transcription was unchanged by RA. In contrast, we found that retinoic acid augmented PLP mRNA stability, causing a substantial increase in its half-life. RA action was independent of cell density, serum, or PDGF but was partially inhibited by bFGF. On the other hand, thyroid hormone caused a moderate increase in PLP mRNA levels in C6 cells but only when the low numbers of thyroid receptors in these cells were increased by retrovirally mediated expression of an exogenous c-erbA/TRalpha-1 gene. Our results indicate that RA specifically up-regulates PLP expression in glioma C6 cells at a posttranscriptional level by increasing PLP RNA half-life.	CSIC,INST INVEST BIOMED,ARTURO DUPERIER 4,E-28029 MADRID,SPAIN; ANTIBIOT FARMA SA,DEPT INVEST,E-28026 MADRID,SPAIN; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); European Molecular Biology Laboratory (EMBL)			Stunnenberg, Hendrik G./D-6875-2012; Bernal, Juan/J-6086-2014; Munoz, Alberto/O-6393-2014; MIRA, EMILIA/K-2456-2014	Stunnenberg, Hendrik G./0000-0002-0066-1576; Bernal, Juan/0000-0002-5867-4951; Munoz, Alberto/0000-0003-3890-4251; MIRA, EMILIA/0000-0002-4226-1829; Rodriguez-Pena, Angeles/0000-0002-2515-4626; Iglesias, Teresa/0000-0002-4326-9005				[Anonymous], MYELIN; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; BAHOUTH SW, 1991, J BIOL CHEM, V266, P15863; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOISON D, 1989, EMBO J, V8, P3295, DOI 10.1002/j.1460-2075.1989.tb08490.x; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BROCKES JP, 1989, NEURON, V2, P850; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DUBOISDALCQ M, 1987, EMBO J, V6, P2587, DOI 10.1002/j.1460-2075.1987.tb02549.x; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FAHIM S, 1986, J NEUROSCI RES, V16, P303, DOI 10.1002/jnr.490160125; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARDINIER MV, 1986, MOL CELL BIOL, V6, P3755, DOI 10.1128/MCB.6.11.3755; GELLERSEN B, 1992, ENDOCRINOLOGY, V131, P1017, DOI 10.1210/en.131.3.1017; GENCIC S, 1989, AM J HUM GENET, V45, P435; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUDSON LD, 1989, P NATL ACAD SCI USA, V86, P8128, DOI 10.1073/pnas.86.20.8128; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUMAR S, 1984, J NEUROCHEM, V43, P1455, DOI 10.1111/j.1471-4159.1984.tb05408.x; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOTAN R, 1991, CANCER BIOL, V2, P197; MACKLIN WB, 1991, J NEUROCHEM, V56, P163, DOI 10.1111/j.1471-4159.1991.tb02576.x; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MCMORRIS FA, 1977, P NATL ACAD SCI USA, V74, P4501, DOI 10.1073/pnas.74.10.4501; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; NAVE KA, 1991, J NEUROSCI, V11, P3060; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; Sambrook J, 1989, MOL CLONING LABORATO; SHAMBAUGH GE, 1969, J BIOL CHEM, V244, P5295; SHANKER G, 1985, NEUROCHEM RES, V10, P617, DOI 10.1007/BF00964401; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SHIOTA C, 1991, J NEUROCHEM, V56, P818, DOI 10.1111/j.1471-4159.1991.tb01997.x; SIMONS R, 1990, J NEUROCHEM, V54, P1079, DOI 10.1111/j.1471-4159.1990.tb02360.x; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TSUNEISHI S, 1991, DEV BRAIN RES, V61, P117, DOI 10.1016/0165-3806(91)90121-X; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VIVANCO RM, 1991, EMBO J, V10, P3829; YAMAMURA T, 1991, J NEUROCHEM, V57, P1671, DOI 10.1111/j.1471-4159.1991.tb06367.x	59	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25617	25623						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503983				2022-12-25	WOS:A1993MK10000050
J	MAY, JM				MAY, JM			REACTION OF AN EXOFACIAL SULFHYDRYL-GROUP ON THE ERYTHROCYTE HEXOSE CARRIER WITH AN IMPERMEANT MALEIMIDE - RELEVANCE TO THE MECHANISM OF HEXOSE-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											MAY, JM (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,CTR DIABET RES & TRAINING,NASHVILLE,TN 37232, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038794, K04DK001781] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-1781, DK-38794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT RE, 1986, AM J PHYSIOL, V250, pC853, DOI 10.1152/ajpcell.1986.250.6.C853; ABBOTT RE, 1976, J BIOL CHEM, V251, P7176; ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; BATT ER, 1976, J BIOL CHEM, V251, P7184; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLOCH R, 1974, J BIOL CHEM, V249, P1814; CARRUTHERS A, 1986, BIOCHEMISTRY-US, V25, P3592, DOI 10.1021/bi00360a018; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P339, DOI 10.1016/0005-2736(78)90034-2; DEZIEL MR, 1985, BIOCHIM BIOPHYS ACTA, V819, P83, DOI 10.1016/0005-2736(85)90198-1; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; HAEST CWM, 1977, BIOCHIM BIOPHYS ACTA, V469, P226, DOI 10.1016/0005-2736(77)90186-9; HOLMAN GD, 1986, BIOCHIM BIOPHYS ACTA, V855, P115, DOI 10.1016/0005-2736(86)90195-1; JACQUEZ JA, 1983, BIOCHIM BIOPHYS ACTA, V727, P367, DOI 10.1016/0005-2736(83)90422-4; KRUPKA RM, 1985, J MEMBRANE BIOL, V84, P35, DOI 10.1007/BF01871646; KRUPKA RM, 1985, J MEMBRANE BIOL, V83, P71, DOI 10.1007/BF01868739; KRUPKA RM, 1981, J BIOL CHEM, V256, P5410; KRUPKA RM, 1986, BIOCHEM CELL BIOL, V64, P1099, DOI 10.1139/o86-145; LACKO L, 1962, BIOCHEM J, V83, P622, DOI 10.1042/bj0830622; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENHARD GE, 1984, BIOCHIM BIOPHYS ACTA, V769, P404, DOI 10.1016/0005-2736(84)90324-9; LIN S, 1974, J BIOL CHEM, V249, P5778; LOWE AG, 1986, BIOCHIM BIOPHYS ACTA, V857, P146, DOI 10.1016/0005-2736(86)90342-1; MAY JM, 1986, J BIOL CHEM, V261, P2542; MAY JM, 1987, J BIOL CHEM, V262, P3140; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAFTALIN RJ, 1977, MEMBRANE TRANSPORT R, P257; RAMPAL AL, 1987, BIOCHIM BIOPHYS ACTA, V896, P287, DOI 10.1016/0005-2736(87)90189-1; ROBERTS SJ, 1982, BIOCHEM J, V205, P139, DOI 10.1042/bj2050139; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; VANSTEVENINCK J, 1965, J GEN PHYSIOL, V48, P617, DOI 10.1085/jgp.48.4.617; VIDAVER GA, 1966, J THEOR BIOL, V10, P301, DOI 10.1016/0022-5193(66)90128-7; WANG JF, 1986, P NATL ACAD SCI USA, V83, P3277, DOI 10.1073/pnas.83.10.3277; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	37	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13635	13640						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417676				2022-12-25	WOS:A1988Q159400029
J	SCHEPERS, L; CASTEELS, M; VAMECQ, J; PARMENTIER, G; VANVELDHOVEN, PP; MANNAERTS, GP				SCHEPERS, L; CASTEELS, M; VAMECQ, J; PARMENTIER, G; VANVELDHOVEN, PP; MANNAERTS, GP			BETA-OXIDATION OF THE CARBOXYL SIDE-CHAIN OF PROSTAGLANDIN-E2 IN RAT-LIVER PEROXISOMES AND MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									CATHOLIC UNIV LEUVEN, AFDELING FARMAKOL, CAMPUS GASTHUISBERG, B-3000 LOUVAIN, BELGIUM; CATHOLIC UNIV LOUVAIN, B-1200 BRUSSELS, BELGIUM; INT INST CELLULAR & MOLEC PATHOL, B-1200 BRUSSELS, BELGIUM; CATHOLIC UNIV LEUVEN, REGA INST MED RES, B-3000 LOUVAIN, BELGIUM	KU Leuven; Universite Catholique Louvain; KU Leuven			Vamecq, Joseph/M-4953-2018; , Van Veldhoven Paul/U-6359-2019	Vamecq, Joseph/0000-0002-4089-7663; , Van Veldhoven Paul/0000-0002-4478-2564				[Anonymous], [No title captured]; CASTEELS M, 1988, IN PRESS J BIOL CHEM, V263; CHEN RF, 1967, J BIOL CHEM, V242, P173; CHRISTENSEN E, 1986, BIOCHIM BIOPHYS ACTA, V879, P313, DOI 10.1016/0005-2760(86)90220-1; COOPER TG, 1969, J BIOL CHEM, V244, P3514; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; DICZFALUSY U, 1986, BIOCHIM BIOPHYS ACTA, V878, P387, DOI 10.1016/0005-2760(86)90247-X; DICZFALUSY U, 1987, BIOCHEM BIOPH RES CO, V144, P1206, DOI 10.1016/0006-291X(87)91439-2; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; EDWARDS NS, 1982, J BIOL CHEM, V257, P6339; EYSSEN H, 1972, BIOCHIM BIOPHYS ACTA, V273, P212, DOI 10.1016/0304-4165(72)90209-7; GRANSTRO.E, 1971, J BIOL CHEM, V246, P7470; GRANSTROM E, 1971, J BIOL CHEM, V246, P5254; GREEN K, 1971, BIOCHIM BIOPHYS ACTA, V231, P419, DOI 10.1016/0005-2760(71)90111-1; GREEN K, 1971, BIOCHEMISTRY-US, V10, P1072, DOI 10.1021/bi00782a022; HAMBERG M, 1968, EUR J BIOCHEM, V6, P135, DOI 10.1111/j.1432-1033.1968.tb00430.x; HAMBERG M, 1972, J BIOL CHEM, V247, P3495; HAMBERG M, 1971, J BIOL CHEM, V246, P6713; HILTUNEN JK, 1986, J BIOL CHEM, V261, P6484; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; JOHNSON M, 1972, J BIOL CHEM, V247, P5656; KERNER J, 1983, ANAL BIOCHEM, V134, P459, DOI 10.1016/0003-2697(83)90323-8; KINDAHL H, 1977, PROSTAGLANDINS, V13, P619, DOI 10.1016/0090-6980(77)90233-7; KOLVRAA S, 1986, BIOCHIM BIOPHYS ACTA, V876, P515, DOI 10.1016/0005-2760(86)90039-1; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; OSMUNDSEN H, 1982, ANN NY ACAD SCI, V386, P13, DOI 10.1111/j.1749-6632.1982.tb21404.x; OSUMI T, 1979, J BIOCHEM, V85, P131, DOI 10.1093/oxfordjournals.jbchem.a132302; PACEASCIAK CR, 1977, BIOCHEM BIOPH RES CO, V78, P115, DOI 10.1016/0006-291X(77)91228-1; PACEASCIAK CR, 1980, J BIOL CHEM, V255, P6106; PEDERSEN JJ, 1987, PEROXISOMES BIOL MED, P67; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROBERTS LJ, 1977, J BIOL CHEM, V252, P7415; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; STEFFENRUD S, 1984, BIOCHEM MED METAB B, V32, P161, DOI 10.1016/0006-2944(84)90070-X; SUN FF, 1978, BIOCHEMISTRY-US, V17, P4096, DOI 10.1021/bi00612a035; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; TULKENS P, 1974, J CELL BIOL, V63, P383, DOI 10.1083/jcb.63.2.383; VAMECQ J, 1985, BIOCHEM J, V230, P683, DOI 10.1042/bj2300683; VAMECQ J, 1984, BIOCHEM J, V221, P203, DOI 10.1042/bj2210203; VANHOOF F, 1968, EUR J BIOCHEM, V7, P34; VANVELDHOVEN P, 1985, BIOCHEM J, V227, P737, DOI 10.1042/bj2270737; WEBSTER LT, 1981, METHOD ENZYMOL, V77, P430; YAMADA J, 1984, BIOCHEM BIOPH RES CO, V125, P123, DOI 10.1016/S0006-291X(84)80343-5	48	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1988	263	6					2724	2731						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M2161	3422639				2022-12-25	WOS:A1988M216100026
J	BRASSEUR, G; COPPEE, JY; COLSON, AM; BRIVETCHEVILLOTTE, P				BRASSEUR, G; COPPEE, JY; COLSON, AM; BRIVETCHEVILLOTTE, P			STRUCTURE-FUNCTION-RELATIONSHIPS OF THE MITOCHONDRIAL BC(1) COMPLEX IN TEMPERATURE-SENSITIVE MUTANTS OF THE CYTOCHROME-B GENE, IMPAIRED IN THE CATALYTIC CENTER-N	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; SACCHAROMYCES-CEREVISIAE; RHODOBACTER-SPHAEROIDES; RESPIRATORY-CHAIN; BC1 COMPLEX; C REDUCTASE; MUTATIONAL ANALYSIS; DEFICIENT MUTANT; APOCYTOCHROME-B; SITE	Seven new structures of cytochrome b have been recently identified by isolating and sequencing revertants from cytochrome b respiratory deficient mutants (Coppee, J. Y., Brasseur, G., Brivet-Chevillotte, P., and Colson, A.M. (1994) J. Biol, Chem. 269, 4221-4226). These mutations are located in the center N domain (Q(N)). All the revertants exhibited a modified heme b(562) maximum, confirming that part of the NH2-terminal region is in the vicinity of the extramembranous loop between helices IV-V and heme b(562). Based on measurements performed on the maximal activities occurring in each segment of the respiratory chain, the decrease observed in the NADH oxidase activities of several revertants was correlated with some b(c1) complex activity impairments; this may also explain why a moderate decrease in b(c1) complex activity does not limit the succinate oxidase activity. The decrease in the rate of reduction of cytochrome b via the center N pathway is responsible for the impairment of the b(c1) complex activity of these revertants. The three double-mutated revertants (S206L/N208K or -Y; S206L/W30C) are temperature-sensitive in vivo, and their mitochondria like that of the original mutant S206L are thermosensitive in vitro. Isolating the W30C mutation does not yield a thermosensitive phenotype: the replacement of serine 206 by leucine is therefore responsible for the thermoinstability of these strains; this temperature sensitivity is reinforced by additional mutations N208K or N208Y, and not by W30C. These data suggest that serine 206 and asparagine 208 are involved in the thermostability of the protein. When b(c1) complex activity is lost after incubating mitochondria at a nonpermissive temperature (37 degrees C), heme b is still present, but can no longer be reduced by physiological substrate. The progressive loss of b(c1) complex activity seems to be initially linked to a change in the tertiary structure of cytochrome b, which occurs drastically at center N and much more slowly at center P, as shown by kinetic study on the two cytochrome b redox pathways.	CNRS, BIOENERGET & INGN PROT LAB, F-13402 MARSEILLE 20, FRANCE; UNIV CATHOLIQUE LOUVAIN, DEPT BIOL, GENET MICROBIENNE LAB, B-1348 LOUVAIN, BELGIUM	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Universite Catholique Louvain								ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BERTRAND P, 1991, STRUCT BOND, V75, P3; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BRASSEUR G, 1995, EUR J BIOCHEM, V230, P1118, DOI 10.1111/j.1432-1033.1995.tb20663.x; BRASSEUR G, 1994, FEBS LETT, V354, P23, DOI 10.1016/0014-5793(94)01077-3; BRASSEUR G, 1993, BIOCHEM SOC T, V22, pS60; BRASSEUR R, 1988, J BIOL CHEM, V263, P12571; BRIVET P, 1991, TRENDS BIOCH BIOENER, V1, P239; BRIVETCHEVILLOTTE P, 1989, FEBS LETT, V255, P5, DOI 10.1016/0014-5793(89)81050-6; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHEVILLOTTEBRIVET P, 1987, BIOCHIMIE, V69, P25, DOI 10.1016/0300-9084(87)90268-9; CHEVILLOTTEBRIVET P, 1980, EUR J BIOCHEM, V111, P161; CHEVILLOTTEBRIVET P, 1987, CURR GENET, V12, P111, DOI 10.1007/BF00434665; COPPEE JY, 1994, J BIOL CHEM, V269, P4221; CROFTS A, 1992, BIOCHIM BIOPHYS ACTA, V1101, P162, DOI 10.1016/S0005-2728(05)80009-X; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DEKOK J, 1975, BIOCHIM BIOPHYS ACTA, V387, P441, DOI 10.1016/0005-2728(75)90084-5; DIRAGO JP, 1995, J MOL BIOL, V248, P804, DOI 10.1006/jmbi.1995.0261; DIRAGO JP, 1990, FEBS LETT, V263, P93, DOI 10.1016/0014-5793(90)80713-S; DIRAGO JP, 1990, J BIOL CHEM, V265, P15750; DIRAGO JP, 1990, J BIOL CHEM, V265, P3332; FU W, 1990, J BIOL CHEM, V265, P16541; GATTI DL, 1990, J BIOL CHEM, V265, P21468; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014; GWAK SH, 1986, BIOCHEMISTRY-US, V25, P7675, DOI 10.1021/bi00371a059; HACKER B, 1994, BIOCHEMISTRY-US, V33, P13022, DOI 10.1021/bi00248a011; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; HAID A, 1979, EUR J BIOCHEM, V94, P451, DOI 10.1111/j.1432-1033.1979.tb12913.x; JOYET P, 1992, BIO-TECHNOL, V10, P1579, DOI 10.1038/nbt1292-1579; KOTYLAK Z, 1977, GENETICS BIOGENESIS, P83; KROGER A, 1973, EUR J BIOCHEM, V34, P358, DOI 10.1111/j.1432-1033.1973.tb02767.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; MATSUMURA M, 1986, NATURE, V923, P936; MEUNIER D, 1977, J THEOR BIOL, V64, P137, DOI 10.1016/0022-5193(77)90117-5; MEUNIERLEMESLE D, 1980, EUR J BIOCHEM, V111, P151; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; OHNISHI T, 1972, FEBS LETT, V24, P305, DOI 10.1016/0014-5793(72)80378-8; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; TRON T, 1991, FEBS LETT, V278, P26, DOI 10.1016/0014-5793(91)80075-E; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; YUN CH, 1992, J BIOL CHEM, V267, P5901	50	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29356	29364		10.1074/jbc.270.49.29356	http://dx.doi.org/10.1074/jbc.270.49.29356			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493970	hybrid			2022-12-25	WOS:A1995TJ22700051
J	BROWN, PM; TAGARI, P; ROWAN, KR; YU, VL; ONEILL, GP; MIDDAUGH, RC; SANYAL, G; FORDHUTCHINSON, AW; NICHOLSON, DW				BROWN, PM; TAGARI, P; ROWAN, KR; YU, VL; ONEILL, GP; MIDDAUGH, RC; SANYAL, G; FORDHUTCHINSON, AW; NICHOLSON, DW			EPITOPE-LABELED SOLUBLE HUMAN INTERLEUKIN-5 (IL-5) RECEPTORS - AFFINITY CROSS-LINK LABELING, IL-5 BINDING, AND BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHILS; SEQUENCES; PROTEINS; CLONING; SYSTEM; GROWTH	The human receptor for the potent eosinophilopoietic cytokine interleukin-5 (IL-5) consists of two components: a 60-kDa ligand-binding alpha chain (IL-5 alpha R) and a 130-kDa beta chain (IL-SPR). Three ectodomain constructs of the alpha chain (alpha RED) bearing C-terminal epitope tags were engineered and expressed in baculovirus-infected Sf9 cells. Each recombinant alpha chain was secreted into the medium, maximum expression occurring 72 h postinfection. The various soluble alpha chains were shown by affinity cross-link labeling and competition with unlabeled IL-5 to bind recombinant human (rh) I-125-IL-5 specifically with an ED(50) of 2-5 nM. The epitope tag provided a simple purification of the receptor from conditioned medium using immunoaffinity chromatography. The purified material had an apparent molecular mass of 43 kDa and was heterogeneously glycosylated. Sedimentation analysis revealed a 1:1 association of the purified epitope-tagged soluble receptor with its ligand, resulting in the formation of a 70-74-kDa complex. Circular dichroism analysis revealed that the soluble alpha chain existed with a significantly ordered structure consisting of 42% beta-sheet and 6% alpha-helix. Such analyses combined with fluorescence spectrometry suggested that ligand-receptor complex formation in solution resulted in minimal conformational changes, consistent with the suggestion that the membrane-associated form of the alpha chain itself has minimal signal transduction capability. Surface plasmon resonance studies of the interaction of the purified alpha RED with immobilized rhIL-5 revealed a specific, competable interaction with a dissociation constant of 9 nM. Preincubation of an IL-5-dependent cell Line with the epitope-tagged alpha RED also dose-dependently neutralized rhIL-5-induced proliferation. These data demonstrate that biologically active epitope-tagged recombinant soluble IL-5 receptors are facile to produce in large quantities and may have therapeutic utility in the modulation of IL-5-dependent eosinophilia in man.	MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA; MERCK & CO INC,DEPT PHARMACEUT RES,W POINT,PA 19486	Merck & Company; Merck & Company			SANYAL, GOUTAM/AAI-6613-2020					BROWN PM, 1995, PROTEIN EXPRES PURIF, V6, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; FISHKOFF SA, 1988, LEUKEMIA RES, V12, P679; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; Innis MA, 1990, PCR PROTOCOLS GUIDE; JONSSON U, 1991, BIOTECHNIQUES, V18, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUGERKRASAGAKES S, 1993, EUR J IMMUNOL, V23, P992, DOI 10.1002/eji.1830230438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHEID M, 1994, CAN J PHYSL PHARM, V72; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; TAGARI P, 1993, INT ARCH ALLERGY IMM, V101, P227, DOI 10.1159/000236450; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THOTAKURA NR, 1987, METHOD ENZYMOL, V138, P350; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	26	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29236	29243		10.1074/jbc.270.49.29236	http://dx.doi.org/10.1074/jbc.270.49.29236			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493953	hybrid			2022-12-25	WOS:A1995TJ22700034
J	COSS, MC; WINTERSTEIN, D; SOWDER, RC; SIMEK, SL				COSS, MC; WINTERSTEIN, D; SOWDER, RC; SIMEK, SL			MOLECULAR-CLONING, DNA-SEQUENCE ANALYSIS, AND BIOCHEMICAL-CHARACTERIZATION OF A NOVEL 65-KDA FK506-BINDING PROTEIN (FKBP65)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COMPLEXES; RAPAMYCIN-BINDING-PROTEIN; CIS-TRANS ISOMERASE; HEAT-SHOCK PROTEIN; CYCLOSPORINE-A; LYMPHOCYTES-T; IMMUNOSUPPRESSANT FK506; SIGNAL TRANSDUCTION; FK-506; IMMUNOPHILIN	We have identified a mouse gene encoding a 65-kDa protein (FKBP65) that shares homology with members of the FK506-binding protein (FKBP) class of immunophilins. Predicted amino acid sequence shows that this protein shares significant homology with FKBP12 (46%), FKBP13 (43%), FKBP25 (35%), and FKBP52 (26%). FKBP65 contains four predicted peptidylprolyl cis-trans-isomerase (PPIase) signature domains, and, although similar in size, is distinct from FKBP52 (also identified as FKBP59, hsp56, or HBI), which contains three FKBP12-like PPIase domains. With N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide as the substrate, recombinant FKBP65 is shown to accelerate the isomerization of the prolyl peptide bond with a catalytic efficiency similar to other family members. This isomerization activity is inhibited by FK506 and rapamycin, but is not sensitive to Cyclosporin A. Based on Northern blot analysis, FKBP65 mRNA transcripts are present in lung, spleen, heart, brain, and testis. A polyclonal antibody, raised against a COOH-terminal peptide (amino acid residues 566-581), was used to immunoprecipitate FKBP65 from NIH3T3 cells and demonstrate that FKBP65 is a glycoprotein. in addition, [P-32]orthophosphate labeling experiments show that FKBP65 is also a phosphoprotein. These results suggest that FKBP65 is a new FKBP family member.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,EXPTL IMMUNOL LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CAMERON AM, P NATL ACAD SCI USA, V92, P1784; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HARDING MW, 1989, NATURE, V341, P755; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; JIN YJ, 1992, J BIOL CHEM, V267, P10942; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; NIGAM SK, 1993, BIOCHEM J, V294, P511, DOI 10.1042/bj2940511; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PELHAM HRB, 1994, TRENDS BIOCHEM SCI, V15, P483; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; SIMEK SL, 1993, GENOMICS, V18, P407, DOI 10.1006/geno.1993.1485; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TIMERMAN AP, 1992, J BIOL CHEM, V268, P22992; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WIEDERRECHT G, 1992, BIOCHEM BIOPH RES CO, V185, P298, DOI 10.1016/S0006-291X(05)80990-8; YEM AW, 1992, J BIOL CHEM, V267, P2868	41	57	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29336	29341		10.1074/jbc.270.49.29336	http://dx.doi.org/10.1074/jbc.270.49.29336			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493967	hybrid			2022-12-25	WOS:A1995TJ22700048
J	KRAPIVINSKY, G; KRAPIVINSKY, L; WICKMAN, K; CLAPHAM, DE				KRAPIVINSKY, G; KRAPIVINSKY, L; WICKMAN, K; CLAPHAM, DE			G-BETA-GAMMA BINDS DIRECTLY TO THE G-PROTEIN-GATED K+ CHANNEL, I-KACH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SUBUNIT; ACTIVATION; EXPRESSION; MECHANISM; AFFINITY; HEART	The cardiac G protein-gated K+ channel, I-KACh, is activated by application of purified and recombinant beta and gamma subunits (G beta gamma) of heterotrimeric G proteins to excised inside-out patches from atrial membranes (Logothetis, D. E., Kurachi, Y., Galper, J., Neer, E., and Clapham, D. E., (1987) Nature 325, 321-326; Wickman, K., Iniguez-Lluhi, J., Davenport, P., Taussig, R. A., Krapivinsky, G. B., Linder, M. E., Gilman, A., and Clapham, D. E. (1994) Nature 368, 255-257). Cardiac I-KACh is composed of two inward rectifier K+ channel subunits, GIRK1 and CIR (Krapivinsky, G., Gordon, E., Wickman, K., Velimirovic, B., Krapivinsky, L., and Clapham, D. E. (1995) Nature 374, 135-141). We show that G beta gamma directly binds to immunoprecipitated cardiac I-KACh as well as to recombinant CIR and GIRK1 subunits, with dissociation constants (K-d) of 55, 50, and 125 nM, respectively. In each case, binding appeared specific as judged by competition of unlabeled G beta gamma with radiolabeled G beta gamma and inhibition of binding by antigenic peptide or G alpha-GDP, but not G alpha-GTP gamma S (guanosine 5'-3-O-(thio)triphosphate). In contrast, G alpha (GTP gamma S- or GDP-bound) did not bind to the native channel. We conclude that G beta gamma binds directly and specifically to I-KACh via interactions with both CIR and GIRK1 subunits to gate the channel.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; Wickman, Kevin/0000-0002-5179-9540	PHS HHS [53483] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NANAVATI C, 1990, PROTEINS SIGNAL TRAN, P30; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; UEDA N, 1994, J BIOL CHEM, V269, P4388; WICKMAN K, 1995, IN PRESS PHYSL REV, V75; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	21	199	203	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29059	29062		10.1074/jbc.270.49.29059	http://dx.doi.org/10.1074/jbc.270.49.29059			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493925				2022-12-25	WOS:A1995TJ22700006
J	FOGUEL, D; WEBER, G				FOGUEL, D; WEBER, G			PRESSURE-INDUCED DISSOCIATION AND DENATURATION OF ALLOPHYCOCYANIN AT SUBZERO TEMPERATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL DRIFT; REVERSIBLE DISSOCIATION; HYDROSTATIC-PRESSURE; QUATERNARY STRUCTURE; STABILITY; PROTEINS; ASSOCIATION; PHYCOCYANIN; EQUILIBRIUM; DILUTION	The thermodynamics of assembly of the allophycocyanin hexamer was examined employing hydrostatic pressures in the range of 1 bar to 2.4 kbar and temperatures of 20 to -12 degrees C, the latter made possible by the decrease of the freezing point of water under pressure. The existence of two processes, dissociation of the hexamer into dimers, (alpha beta)(3) --> 3 (alpha beta), and dissociation of the alpha beta dimers into monomers, (alpha beta)(3) --> alpha + beta have been recognized previously by changes in the absorbance and fluorescence of the tetrapyrrolic chromophores owing to added ligands. The same changes are observed in the absence of ligands at pressures of under 2.4 kbar and temperatures down to -12 degrees C. On decompression from 2.4 kbar at 0 degrees C, appreciable hysteresis and a persistent loss of 50% in the absorbance at 653 nm is observed, It results from the conformational drift of the isolated subunits and is reduced to 10% when the highest pressure is limited to 1.6 kbar, The thermodynamic parameters of the reaction alpha + beta --> alpha beta can be determined from pressure effects on perchlorate solutions of allophycocyanin, which consist of dimers alone, Their previous knowledge permits estimation, under suitable hypotheses, of the thermodynamic parameters of the reaction 3(alpha beta) --> (alpha beta(3) from the overall pressure effects on the hexamers. Both association reactions have positive enthalpy changes, and the whole hexamer assembly is made possible by the excess entropy.	UNIV ILLINOIS,SCH CHEM SCI,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign				Foguel, Debora/0000-0001-7312-7115	NIGMS NIH HHS [GM11223] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK WF, 1992, J PHYS CHEM-US, V96, P4658, DOI 10.1021/j100190a094; CANAANI OD, 1980, BIOCHEMISTRY-US, V19, P2950, DOI 10.1021/bi00554a021; CHEN CH, 1978, BIOPHYS CHEM, V8, P203, DOI 10.1016/0301-4622(78)87002-1; CHEN CH, 1977, BIOPHYS CHEM, V7, P81, DOI 10.1016/0301-4622(77)87018-X; COOPER A, 1988, J MOL LIQ, V39, P196; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CSATORDAY K, 1984, BIOCHEMISTRY-US, V23, P6466, DOI 10.1021/bi00321a029; ERIJMAN L, 1993, BIOCHEMISTRY-US, V32, P5187, DOI 10.1021/bi00070a030; EROKHINA L G, 1974, Molekulyarnaya Biologiya (Moscow), V8, P651; EVERETT DH, 1955, T FARADAY SOC, V51, P167; FOGUEL D, 1992, BIOPHYS J, V63, P1613, DOI 10.1016/S0006-3495(92)81756-3; GRIKO YV, 1988, J MOL BIOL, V202, P127, DOI 10.1016/0022-2836(88)90525-6; GURTIN ME, 1968, ARCH RATION MECH AN, V28, P40, DOI 10.1007/BF00281562; HOLZWARTH AR, 1990, BIOPHYS J, V57, P132; HUANG C, 1987, BIOCHEMISTRY-US, V26, P243, DOI 10.1021/bi00375a033; KING L, 1986, BIOCHEMISTRY-US, V25, P3632, DOI 10.1021/bi00360a023; LAUFFER MA, 1975, ENTROPYDRIVEN PROCES; MACCOLL R, 1983, ARCH BIOCHEM BIOPHYS, V223, P24, DOI 10.1016/0003-9861(83)90567-2; MACCOLL R, 1981, ARCH BIOCHEM BIOPHYS, V208, P42, DOI 10.1016/0003-9861(81)90121-1; MACCOLL R, 1980, BIOCHEMISTRY-US, V19, P2817, DOI 10.1021/bi00553a043; MACCOLL R, 1971, ARCH BIOCHEM BIOPHYS, V146, P477, DOI 10.1016/0003-9861(71)90151-2; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PALADINI AA, 1981, REV SCI INSTRUM, V52, P419, DOI 10.1063/1.1136596; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; RUAN K, 1989, BIOCHEMISTRY-US, V28, P2144, DOI 10.1021/bi00431a028; RUAN KC, 1993, BIOCHEMISTRY-US, V32, P6295, DOI 10.1021/bi00075a025; SCHEER H, 1977, Z NATURFORSCH C, V32, P513; SILVA JL, 1986, BIOCHEMISTRY-US, V25, P5780, DOI 10.1021/bi00367a065; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; TRUESDELL C, 1985, ELEMENTS CONTINUUM M, P199; WEBER G, 1995, J PHYS CHEM-US, V99, P1052, DOI 10.1021/j100003a031; WEBER G, 1986, BIOCHEMISTRY-US, V25, P3626, DOI 10.1021/bi00360a022; WEBER G, 1993, J PHYS CHEM-US, V97, P7108, DOI 10.1021/j100129a031; XU GJ, 1980, P NATL ACAD SCI USA, V79, P5268; ZILINSKAS BA, 1978, PHOTOCHEM PHOTOBIOL, V27, P587, DOI 10.1111/j.1751-1097.1978.tb07650.x	38	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28759	28766		10.1074/jbc.270.48.28759	http://dx.doi.org/10.1074/jbc.270.48.28759			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499398	hybrid			2022-12-25	WOS:A1995TH05600042
J	KHACHIGIAN, LM; WILLIAMS, AJ; COLLINS, T				KHACHIGIAN, LM; WILLIAMS, AJ; COLLINS, T			INTERPLAY OF SP1 AND EGR-1 IN THE PROXIMAL PLATELET-DERIVED GROWTH-FACTOR-A-CHAIN PROMOTER IN CULTURED VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR LOCUS; GENE; REGION; TRANSCRIPTION; SEQUENCE; PRODUCT; BINDING; CDNA; WT1; LOCALIZATION	The platelet-derived growth factor (PDGF) A-chain has been implicated in the initiation and progression of vascular occlusive lesions. The elements in the human PDGF-A promoter that mediate increased expression of the gene in vascular endothelial cells have not been identified. A potent inducer of PDGF-A expression in endothelial cells is phorbol 12-myristate 13-acetate (PMA). 5'-Deletion and transfection analysis revealed that a G+C-rich region in the proximal PDGF-A promoter is required for PMA-inducible gene expression. This region bears overlapping consensus recognition se quences for Sp1 and Egr-1. PMA induces Egr-1 mRNA expression within 1 h, whereas PDGF-A transcript levels increase after 2-4 h. Constitutive levels of Sp1 are not altered over 24 h. A specific nucleoprotein complex is formed when an oligonucleotide bearing the G+C-rich element is incubated with nuclear extracts from PMA-treated cells. The temporal appearance of this complex is consistent with the transient increase in Egr-1 transcripts. Antibodies to Egr-1 completely supershift the PMA-induced complex. Interestingly, increased nuclear levels of Egr-1 attenuate the ability of Sp1 to interact with the oligonucleotide, implicating competition between Egr-1 and Sp1 for the G+C-rich element. Binding studies with recombinant proteins demonstrate that Egr-1 can displace Sp1 from this region. Insertion of the G+C-rich element into a hybrid promoter-reporter construct confers PMA inducibility on the construct. Mutations that abolish Egr-1 binding also abrogate expression induced by PMA or overexpressed Egr-1. These findings demonstrate that PMA-induced Egr-1 displaces Sp1 from the G+C-rich element and activates expression driven by the PDGF-A proximal promoter in endothelial cells. The Sp1/Egr-1 displacement mechanism may be an important regulatory circuit in the control of inducible gene expression in vascular endothelial cells.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035716, R37HL035716] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35716, HL 45462] Funding Source: Medline; PHS HHS [P01 36028] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; BONTHRON D, 1992, GENOMICS, V13, P257, DOI 10.1016/0888-7543(92)90240-S; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CAO XM, 1993, J BIOL CHEM, V268, P16949; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; FAZIO MJ, 1991, J INVEST DERMATOL, V97, P281, DOI 10.1111/1523-1747.ep12480380; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; KANAZASHI S, 1994, MOL IMMUNOL, V31, P21; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KHACHIGIAN LM, 1993, PLATELETS, V4, P304, DOI 10.3109/09537109309013233; KIM SJ, 1989, J BIOL CHEM, V264, P402; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LARSEN FG, 1994, J INVEST DERMATOL, V102, P730, DOI 10.1111/1523-1747.ep12375840; LIN XH, 1992, J BIOL CHEM, V267, P25614; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MINOWA T, 1994, J BIOL CHEM, V269, P11656; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSS R, 1993, NATURE, V363, P801; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ A, 1991, GENE, V98, P295, DOI 10.1016/0378-1119(91)90189-I; SHNGU T, 1994, J BIOL CHEM, V269, P32551; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TAKIMOTO Y, 1995, BBA-GENE STRUCT EXPR, V1260, P176, DOI 10.1016/0167-4781(94)00197-B; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WILLIAMS T, 1989, GENE DEV, V3, P1507	48	270	275	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27679	27686		10.1074/jbc.270.46.27679	http://dx.doi.org/10.1074/jbc.270.46.27679			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499234	hybrid			2022-12-25	WOS:A1995TE73600045
J	KIM, MH; PETERSON, DO				KIM, MH; PETERSON, DO			OCT-1 PROTEIN PROMOTES FUNCTIONAL TRANSCRIPTION COMPLEX ASSEMBLY ON THE MOUSE MAMMARY-TUMOR VIRUS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; RNA POLYMERASE-II; NEGATIVE REGULATORY ELEMENT; HORMONE-RESPONSIVE PROMOTER; GLUCOCORTICOID RECEPTOR; ACTIVATION DOMAINS; DNA-SEQUENCES; POU DOMAIN; INITIATION; BINDING	The ubiquitous transcription factor Oct-1 stimulates basal transcription from the mouse mammary tumor virus (MMTV) promoter by binding to octamer-related sequences present in the proviral long terminal repeat. The mechanism of transcriptional activation by Oct-1 was investigated using in vitro transcription assays with a HeLa cell nuclear extract depleted of endogenous Oct-1. Oct-1-mediated transcriptional activation could be reconstituted by addition of bacterially expressed recombinant Oct-1 protein. The stimulatory effect of Oct-1 was observed only when the protein was present during formation of transcription preinitiation complexes and not when added to fully assembled complexes. Furthermore, assembled MMTV preinitiation complexes were resistant to inhibition by a competitor oligonucleotide containing MMTV octamer-related elements that could eliminate Oct-1-mediated stimulation when present during the assembly process. The time course of transcription complex assembly revealed that Oct-1 increases the number of templates an which functional transcription complexes form. Finally, experiments designed to exploit the sensitivity of discrete steps in transcription complex assembly to the anionic detergent Sarkosyl demonstrated that Oct-1 must be present during formation of an early intermediate in the assembly process.	TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station					NATIONAL CANCER INSTITUTE [R01CA032695] Funding Source: NIH RePORTER; NCI NIH HHS [CA32695] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNWEILER A, 1993, J BIOL CHEM, V268, P2525; ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; ASO T, 1994, J BIOL CHEM, V269, P26575; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1994, MOL CELL BIOL, V14, P1191, DOI 10.1128/MCB.14.2.1191; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GEISSE S, 1982, EMBO J, V1, P1613, DOI 10.1002/j.1460-2075.1982.tb01363.x; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; HUANG M, 1993, NUCLEIC ACIDS RES, V21, P5235, DOI 10.1093/nar/21.22.5235; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; KIM MH, 1995, J VIROL, V69, P4717, DOI 10.1128/JVI.69.8.4717-4726.1995; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LEE F, 1984, NUCLEIC ACIDS RES, V12, P4191, DOI 10.1093/nar/12.10.4191; LEE JW, 1991, J BIOL CHEM, V266, P24101; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MORLEY KL, 1987, NUCLEIC ACIDS RES, V15, P6973, DOI 10.1093/nar/15.17.6973; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PIERCE J, 1993, J VIROL, V67, P415, DOI 10.1128/JVI.67.1.415-424.1993; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	44	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27823	27828		10.1074/jbc.270.46.27823	http://dx.doi.org/10.1074/jbc.270.46.27823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499253	hybrid			2022-12-25	WOS:A1995TE73600064
J	KUMAR, S; MINNICH, MD; YOUNG, PR				KUMAR, S; MINNICH, MD; YOUNG, PR			ST2/T1 PROTEIN FUNCTIONALLY BINDS TO 2 SECRETED PROTEINS FROM BALB/C 3T3 AND HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS BUT DOES NOT BIND INTERLEUKIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1 RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; SOLUBLE RECEPTOR; GENE; EXPRESSION; PRODUCT; IDENTIFICATION; MECHANISM; ONCOGENE; VACCINIA	The ST2/T1 receptor, a homologue of the interleukin 1 receptor (IL-1R), was expressed in COS and Drosophila S2 cells as a human IgG-Fc fusion protein, While a type I IL-1RFc fusion protein bound human IL-1 in vitro, the ST2Fc fusion protein did not, Furthermore, IL-1 stimulated a synthetic interleukin-g promoter reporter gene that was cotransfected into Jurkat cells with a full-length IL-IR type I (IL-1RI) or a chimeric receptor composed of the IL-1RI extracellular domain and ST2 intracellular domain, In contrast, IL-1 did not stimulate the interleukin-8 promoter when cotransfected with a full-length ST2 or an ST2 extracellular/IL-1R intracellular domain fusion protein. Both IL-IRI and the IL-1R/ST2R chimeric receptor also activated a receptor-associated kinase and CSBP/p38 MAP kinase. Using ST2Fc receptor, we have identified, through receptor precipitation, receptor-dot blot and surface plasmon resonance, a putative ligand of ST2 secreted from Balb/c 3T3 and human umbilical vein endothelial cells. The putative ligand was also able to stimulate CSBP/p38 RAP kinase through the ST2 receptor, These results suggest that the ST2 is not an IL-1 receptor but rather has its own cognate ligand.	SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,DEPT MOLEC IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline								ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ANGELICHIO ML, 1991, NUCLEIC ACIDS RES, V19, P5037, DOI 10.1093/nar/19.18.5037; ASUBEL MF, 1987, CURRENT PROTOCOLS MO; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; EASTGATE JA, 1990, FEBS LETT, V260, P213, DOI 10.1016/0014-5793(90)80106-S; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GUIDA S, 1992, GENE, V111, P239, DOI 10.1016/0378-1119(92)90693-J; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; JOHANSSON B, 1991, ANAL BIOCHEM, V198, P268; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KUNO K, 1993, J BIOL CHEM, V268, P13510; LARSEN CG, 1989, BIOCHEM BIOPH RES CO, V160, P1403, DOI 10.1016/S0006-291X(89)80160-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REIKERSTORFER A, 1995, J BIOL CHEM, V270, P17645, DOI 10.1074/jbc.270.30.17645; ROBLER U, 1995, DEV BIOL, V168, P86; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; SYMONS JA, 1990, FEBS LETT, V272, P133, DOI 10.1016/0014-5793(90)80466-V; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x; WERENSKIOLD AK, 1995, CELL GROWTH DIFFER, V6, P171; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U	43	64	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27905	27913		10.1074/jbc.270.46.27905	http://dx.doi.org/10.1074/jbc.270.46.27905			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499265	hybrid			2022-12-25	WOS:A1995TE73600076
J	MAHADEVAN, D; YU, JC; SALDANHA, JW; THANKI, N; MCPHIE, P; UREN, A; LAROCHELLE, WJ; HEIDARAN, MA				MAHADEVAN, D; YU, JC; SALDANHA, JW; THANKI, N; MCPHIE, P; UREN, A; LAROCHELLE, WJ; HEIDARAN, MA			STRUCTURAL ROLE OF EXTRACELLULAR DOMAIN-1 OF ALPHA-PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTOR FOR PDGF-AA AND PDGF-BB BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-RECEPTOR; CRYSTAL-STRUCTURE; LIGAND-BINDING; DIMERIZATION; IDENTIFICATION; ACTIVATION; DEFINE; OCCURS; DIMER; AB	The purpose of this study was to bacterially express, purify, and refold combinations of the extracellular immunoglobulin (Ig)-like domains (2-3, 1-3, and 1-5) of the human alpha-platelet-derived growth factor receptor (alphaPDGFR) to characterize molecular interactions with its ligand, platelet-derived growth factor (PDGF). The far UV circular dichromism spectroscopy of the alpha-PDGFR extracellular domains (ECDs) revealed a predominantly beta-sheet protein, with a structure consistent with folded Ig-like domains. The addition of PDGF-BB to these ECD types changed the conformation of all three types with a decrease in mean residue ellipticity in the following rank order: 1-5=1-3 greater than 2-3. In striking contrast, addition of PDGF-AA to these ECD types markedly changed the conformation of ECD 2-3, by an increased mean residue ellipticity but no changes were observed for ECDs 1-3 and 1-5. PDGF-AA bound to the immobilized ECD types 2-3, 1-3, and 1-5 at concentrations of 20, 11, and 7.5nM, respectively. In contrast, PDGF-BB bound the ECD types 2-3, 1-3, and 1-5 at concentrations of 3,3, and 2.2 nM, respectively. Scatchard analysis of binding studies using labeled ECDs indicated that PDGF-BB bound ECD 1-3 and ECD 2-3 with K-D values of 74 and 72 nM, respectively. While, PDGF-AA bound ECD 1-3 and ECD 2-3 with K-D values of 33 and 87 nM, respectively. Therefore, our results indicated that the loss of ECD 1 impaired the binding affinity of alphaPDGFR ECD 1-3 toward PDGF-AA without having a similar effect on PDGF-BB binding. Together all of our data suggest that ECD 1 is differentially required for proper orientation of PDGF-AA but not PDGF-BB binding determinant within ECDs 2 and 3	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NIDDK,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892; MRC,CTR COLLABORAT,LONDON,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HERREN B, 1993, J BIOL CHEM, V268, P15088; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; MAHADEVAN D, 1994, BIOCHEMISTRY-US, V33, P746, DOI 10.1021/bi00169a016; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRASAD K, 1986, BIOCHEMISTRY-US, V25, P5214, DOI 10.1021/bi00366a035; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TIMM DE, 1992, PROTEIN SCI, V1, P236; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J BIOL CHEM, V269, P10668	32	21	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27595	27600		10.1074/jbc.270.46.27595	http://dx.doi.org/10.1074/jbc.270.46.27595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499222	hybrid			2022-12-25	WOS:A1995TE73600033
J	TOBIAS, KE; SHOR, J; KAHANA, C				TOBIAS, KE; SHOR, J; KAHANA, C			C-MYC AND MAX TRANSREGULATE THE MOUSE ORNITHINE DECARBOXYLASE PROMOTER THROUGH INTERACTION WITH 2 DOWNSTREAM CACGTG MOTIFS	ONCOGENE			English	Article						TRANSCRIPTION; ORNITHINE DECARBOXYLASE; C-MYC; MAX; USF	HAMSTER OVARY CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; LEUCINE ZIPPER; GENE; PROTEIN; SEQUENCE; EXPRESSION; DOMAINS; DIMERIZATION	Ornithine decarboxylase (ODC), the first enzyme in the biosynthesis of polyamines, is essential for the process of cellular proliferation. ODC is a typical delayed early gene, as its mitogenic activation requires ongoing protein synthesis in the stimulated cells. This study provides evidence that the immediate early c-Myc protein is a potential transactivator of the ODC gene. We demonstrate that overexpression of c-Myc results in efficient activation of the ODC promoter, whereas overexpression of Max exerts a repressive effect. Both effects depend on the presence of two evolutionary conserved CACGTG motifs found in the first intron of the ODC gene. Transactivation of the ODC promoter also requires the dimerization of c-Myc with Max. Interestingly, overexpression of USF, a member of the same family of proteins which efficiently binds these two CACGTG motifs, fails to transregulate the ODC promoter. Our data suggest that c-Myc and Max are potential transcriptional regulators of the ODC promoter.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FITZGERALD MC, 1989, DNA-J MOLEC CELL BIO, V8, P623, DOI 10.1089/dna.1.1989.8.623; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KATZ A, 1989, EMBO J, V8, P7604; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REDDY CD, 1992, ONCOGENE, V7, P2085; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WEN L, 1989, J BIOL CHEM, V264, P9016; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	56	55	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1721	1727						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478599				2022-12-25	WOS:A1995TD09400006
J	BOWTELL, DDL; LANGDON, WY				BOWTELL, DDL; LANGDON, WY			THE PROTEIN PRODUCT OF THE C-CBL ONCOGENE RAPIDLY COMPLEXES WITH THE EGF RECEPTOR AND IS TYROSINE-PHOSPHORYLATED FOLLOWING EGF STIMULATION	ONCOGENE			English	Article						TYROSINE KINASE; SRC HOMOLOGY; CBL ONCOGENE; CELL TRANSFORMATION; GROWTH FACTOR SIGNAL TRANSDUCTION	V-CBL; VULVAR INDUCTION; DOMAIN; SH2; IDENTIFICATION; TRUNCATION; RETROVIRUS; PATHWAY; BINDING; KINASES	The cbl oncogene was first identified as part of a transforming retrovirus which arose in a mouse pre-B cell lymphoma. Its protein product, p120(cbl): is cytoplasmic and has several distinctive domains including a highly basic region, a RING finger motif and a large proline-rich domain, A mutation to cbl in the 70Z/3 pre-B cell lymphoma produces an oncogenic protein which exhibits a marked enhancement of tyrosine phosphorylation, Parallel studies have demonstrated that p120(cbl) is a substrate of protein tyrosine kinases activated by engagement of the T cell antigen receptor and that cbl is phosphorylated by oncogenic forms of the Abl tyrosine kinase, A genetic analysis of the Caenorhabditis elegans c61 homologue, sli-1, demonstrates that sli-1 negatively regulates the LET-23 tyrosine kinase receptor, Here we show that p120(cbl) is rapidly phosphorylated on tyrosine residues following EGF stimulation and that it forms an inducible complex with the receptor, Our results also show that the oncogenic 70Z/3 form of cbl has enhanced binding to the EGF receptor and that peptides spanning the proline-rich region bind a range SH3 domains. These findings are consistent with a conserved role for cbl/sli-1 proteins in mammals and nematodes.	PETER MACCALLUM CANC INST,TRESCOWTHICK RES LABS,MELBOURNE,VIC 3000,AUSTRALIA; UNIV WESTERN AUSTRALIA,DEPT BIOCHEM,NEDLANDS,WA 6009,AUSTRALIA	Peter Maccallum Cancer Center; University of Western Australia			Bowtell, David/H-1007-2016	Bowtell, David/0000-0001-9089-7525				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GALISTEO ML, 1995, IN PRESS J BIOL CHEM; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILA A, 1995, J BIOL CHEM, V5270, P9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, IN PRESS SCIENCE; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	27	88	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1561	1567						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478580				2022-12-25	WOS:A1995TC53500014
J	GREVE, H; CULLY, Z; BLUMBERG, P; KRESSE, H				GREVE, H; CULLY, Z; BLUMBERG, P; KRESSE, H			INFLUENCE OF CHLORATE ON PROTEOGLYCAN BIOSYNTHESIS BY CULTURED HUMAN-FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV MUNSTER, DEPT PHYSIOL CHEM & PATHOBIOCHEM, WALDEYERSTR 15, D-4400 MUNSTER, FED REP GER	University of Munster								ARBOGAST B, 1975, BIOCHEM BIOPH RES CO, V67, P376, DOI 10.1016/0006-291X(75)90326-5; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Cantz M, 1972, METHOD ENZYMOL, V28, P884; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; DELFERT DM, 1985, J BIOL CHEM, V260, P4446; DONNELLY PV, 1984, CONNECT TISSUE RES, V13, P89, DOI 10.3109/03008208409152146; FRANSSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P5657, DOI 10.1073/pnas.81.18.5657; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GLOSSL J, 1986, J BIOL CHEM, V261, P1920; GLOSSL J, 1983, BIOCHEM J, V215, P295; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GORHAM LW, 1965, P SOC EXP BIOL MED, V119, P287; HABUCHI O, 1982, BIOCHIM BIOPHYS ACTA, V717, P414, DOI 10.1016/0304-4165(82)90282-3; HARPER GS, 1987, J BIOL CHEM, V262, P5637; HART GW, 1976, J BIOL CHEM, V251, P6513; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HOPPE W, 1985, EUR J BIOCHEM, V152, P91, DOI 10.1111/j.1432-1033.1985.tb09167.x; HUMPHRIES DE, 1986, J BIOL CHEM, V261, P9122; INOUE H, 1986, J BIOL CHEM, V261, P4470; ITO K, 1982, J BIOL CHEM, V257, P917; JANSSON L, 1975, BIOCHEM J, V149, P49, DOI 10.1042/bj1490049; KELLER JM, 1987, BIOCHIM BIOPHYS ACTA, V926, P139, DOI 10.1016/0304-4165(87)90230-3; KIMATA K, 1974, J BIOL CHEM, V249, P1646; KLEIN U, 1980, BIOCHIM BIOPHYS ACTA, V630, P10, DOI 10.1016/0304-4165(80)90131-2; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; RAUCH U, 1986, BIOCHEM J, V238, P465, DOI 10.1042/bj2380465; ROBINSON HC, 1969, J BIOL CHEM, V244, P348; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; RUTER ER, 1984, J BIOL CHEM, V259, P1771; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SILBERT JE, 1986, J BIOL CHEM, V261, P3397; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; SUGUMARAN G, 1986, J BIOL CHEM, V261, P2659; TIAN MY, 1986, ARCH BIOCHEM BIOPHYS, V247, P221, DOI 10.1016/0003-9861(86)90551-5; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; YAMASHINA I, 1983, MOL CELL BIOCHEM, V52, P107; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	47	99	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12886	12892						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417641				2022-12-25	WOS:A1988Q091700020
J	ROPSON, IJ; POWERS, DA				ROPSON, IJ; POWERS, DA			A NOVEL DEHYDROGENASE REACTION-MECHANISM FOR HEXOSE-6-PHOSPHATE DEHYDROGENASE ISOLATED FROM THE TELEOST FUNDULUS-HETEROCLITUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University								Ackers G. K., 1975, PROTEINS, V1, P1; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BEUTLER E, 1967, J BIOL CHEM, V242, P5289; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL DP, 1982, ARCH BIOCHEM BIOPHYS, V215, P289, DOI 10.1016/0003-9861(82)90307-1; CARPER WR, 1976, ARCH BIOCHEM BIOPHYS, V175, P312, DOI 10.1016/0003-9861(76)90513-0; CARPER WR, 1983, EXPERIENTIA, V39, P1295, DOI 10.1007/BF01990378; Dalziel K, 1975, ENZYMES, V11, P1; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fromm HJ, 1983, CONT ENZYME KINETICS, P233; GLASER L, 1955, J BIOL CHEM, V216, P67; Harrison DC, 1931, BIOCHEM J, V25, P1016, DOI 10.1042/bj0251016; HINO Y, 1982, J BIOCHEM, V92, P547, DOI 10.1093/oxfordjournals.jbchem.a133963; HINO Y, 1983, J BIOL CHEM, V258, P1415; HINO Y, 1982, J BIOL CHEM, V257, P2563; HINO Y, 1981, BIOCHEM BIOPH RES CO, V98, P1016, DOI 10.1016/0006-291X(81)91212-2; HORECKER BL, 1953, BIOCHIM BIOPHYS ACTA, V12, P98, DOI 10.1016/0006-3002(53)90128-0; HORI S H, 1974, Journal of the Faculty of Science Hokkaido University Series VI Zoology, V19, P515; HORI SH, 1977, BIOCHIM BIOPHYS ACTA, V496, P1, DOI 10.1016/0304-4165(77)90109-X; HORI SH, 1975, ISOZYMES GENETICS EV, P839; KIMURA K, 1979, J BIOCHEM-TOKYO, V85, P319, DOI 10.1093/oxfordjournals.jbchem.a132336; KULKARNI AP, 1982, BIOCHEM PHARMACOL, V31, P1131, DOI 10.1016/0006-2952(82)90353-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy H R, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P97; MANNERVIK B, 1983, CONT ENZYME KINETICS, P75; MANROW RE, 1982, ANAL BIOCHEM, V120, P181, DOI 10.1016/0003-2697(82)90334-7; MATSUOKA N, 1980, COMP BIOCHEM PHYS B, V65, P191, DOI 10.1016/0305-0491(80)90002-4; MATSUOKA N, 1977, Journal of the Faculty of Science Hokkaido University Series VI Zoology, V21, P12; MATSUOKA N, 1983, COMP BIOCHEM PHYS B, V76, P811, DOI 10.1016/0305-0491(83)90397-8; MOCHIZUKI Y, 1976, COMP BIOCHEM PHYS B, V54, P489, DOI 10.1016/0305-0491(76)90127-9; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; OKA KI, 1981, BIOCHIM BIOPHYS ACTA, V662, P318, DOI 10.1016/0005-2744(81)90045-0; RADIKA K, 1984, ANAL BIOCHEM, V141, P413, DOI 10.1016/0003-2697(84)90063-0; ROPSON IJ, 1988, IN PRESS MOL BIOL EV; SAWADA H, 1981, J BIOCHEM-TOKYO, V90, P1077, DOI 10.1093/oxfordjournals.jbchem.a133559; SAWADA H, 1980, J BIOCHEM-TOKYO, V87, P985, DOI 10.1093/oxfordjournals.jbchem.a132829; SEGEL IH, 1975, ENZYME KINETICS, P189; SHATTON JB, 1971, J BIOL CHEM, V246, P4878; Sokal R. R., 1981, BIOMETRY; STEGEMAN JJ, 1971, BIOCHEM GENET, V5, P579, DOI 10.1007/BF00485675; STEGEMAN JJ, 1972, COMP BIOCHEM PHYSIOL, V43, P241, DOI 10.1016/0305-0491(72)90282-9; STEGEMAN JJ, 1979, BIOCHEM BIOPH RES CO, V87, P410, DOI 10.1016/0006-291X(79)91811-4; STEGEMAN JJ, 1975, ISOZYMES GENETICS EV, P477; TAKAHASHI T, 1979, Journal of the Faculty of Science Hokkaido University Series VI Zoology, V22, P21; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMAUCHI T, 1975, ARCH BIOCHEM BIOPHYS, V167, P13, DOI 10.1016/0003-9861(75)90436-1; YOSHIDA A, 1975, ISOZYMES GENETICS EV, P853	47	14	14	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					11697	11703						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403551				2022-12-25	WOS:A1988P765000017
J	HELMAN, LJ; AHN, TG; LEVINE, MA; ALLISON, A; COHEN, PS; COOPER, MJ; COHN, DV; ISRAEL, MA				HELMAN, LJ; AHN, TG; LEVINE, MA; ALLISON, A; COHEN, PS; COOPER, MJ; COHN, DV; ISRAEL, MA			MOLECULAR-CLONING AND PRIMARY STRUCTURE OF HUMAN CHROMOGRANIN-A (SECRETORY PROTEIN-I) CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DIV ENDOCRINOL & METAB,BALTIMORE,MD 21205; UNIV LOUISVILLE,HLTH SCI CTR,DEPT ORAL BIOL & BIOCHEM,LOUISVILLE,KY 40292	Johns Hopkins University; University of Louisville	HELMAN, LJ (corresponding author), NCI,PEDIAT BRANCH,MOLEC GENET SECT,BETHESDA,MD 20892, USA.			Levine, Michael/0000-0003-0036-7809	NIDDK NIH HHS [DK-38990, DK-38296] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038296, R01DK038990] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN TG, 1987, P NATL ACAD SCI USA, V84, P5043, DOI 10.1073/pnas.84.14.5043; BAYLIN SB, 1978, SEMIN ONCOL, V5, P35; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BLASCHKO H, 1967, NATURE, V215, P58, DOI 10.1038/215058a0; CARNEY DN, 1985, CANCER RES, V45, P2913; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHN DV, 1982, P NATL ACAD SCI-BIOL, V79, P6056, DOI 10.1073/pnas.79.19.6056; DESTEPHANO DB, 1984, AM J PATHOL, V116, P464; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EIDEN LE, 1987, NATURE, V325, P301, DOI 10.1038/325301a0; EVANS AE, 1980, CANCER, V45, P833, DOI 10.1002/1097-0142(19800301)45:5<833::AID-CNCR2820450502>3.0.CO;2-U; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GENDELMAN HE, 1986, IN SITU HYBRIDIZATIO, P203; GORR S, 1987, CALCIUM REGULATION B, P49; GORR SU, 1987, BONE MINER, V2, P251; HAYASHI S, 1978, J HISTOCHEM CYTOCHEM, V26, P677, DOI 10.1177/26.8.99471; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; HUTTNER WB, 1987, NATURE, V325, P305, DOI 10.1038/325305b0; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LLOYD RV, 1983, SCIENCE, V222, P628, DOI 10.1126/science.6635661; LLOYD RV, 1984, AM J SURG PATHOL, V8, P607, DOI 10.1097/00000478-198408000-00004; MACMANUS JP, 1983, EUR J BIOCHEM, V136, P9, DOI 10.1111/j.1432-1033.1983.tb07698.x; MAPLES JA, 1985, AM J CLIN PATHOL, V83, P356, DOI 10.1093/ajcp/83.3.356; OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803; OCONNOR DT, 1983, J CLIN ENDOCR METAB, V57, P1084, DOI 10.1210/jcem-57-5-1084; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; ROSEN N, 1986, J BIOL CHEM, V261, P3754; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANCHEZPESCADOR R, 1984, DNA-J MOLEC CELL BIO, V3, P339, DOI 10.1089/dna.1.1984.3.339; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDAH NG, 1987, FEBS LETT, V211, P144, DOI 10.1016/0014-5793(87)81425-4; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; WILSON BS, 1984, AM J PATHOL, V115, P458; WINKLER H, 1976, NEUROSCIENCE, V1, P65, DOI 10.1016/0306-4522(76)90001-4; YOUNG WS, 1986, BRAIN RES, V387, P231	40	145	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1988	263	23					11559	11563						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P6713	3403545				2022-12-25	WOS:A1988P671300088
J	ASHIKARI, S; HABUCHI, H; KIMATA, K				ASHIKARI, S; HABUCHI, H; KIMATA, K			CHARACTERIZATION OF HEPARAN-SULFATE OLIGOSACCHARIDES THAT BIND TO HEPATOCYTE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; TUMOR CYTOTOXIC FACTOR; C-MET PROTOONCOGENE; FIBROBLAST GROWTH; RAT-LIVER; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; SCATTER FACTOR; CELL-SURFACE; IDENTIFICATION	Proteoglycans from rat liver had the ability to bind hepatocyte growth factor (HGF). Digestion of the proteoglycans with heparitinase resulted in the complete loss of the activity, while the digestion with chondroitinase ABC had no effect. Heparan sulfate (HS)-conjugated gel also bound HGF, and the binding was competitively inhibited by heparin and bovine liver HS, but not by Engelbreth-Holm-Swarm sarcoma HS, pig aorta HS, or other glycosaminoglycans, suggesting the specific structural domain in HS for the binding of HGF. Among limited digests with heparitinase I of bovine liver HS, octasaccharide is the minimal size to bind I-IGF. Comparison of the disaccharide unit compositions revealed a marked difference in IdoA(2SO(4))-GlcNSO(3)(GSO(4)) unit between the bound and unbound octasaccharides. The contents of this disaccharide unit were calculated to be 2 mol/mol for the bound octasaccharide but 1 mol/mol for the unbound one. Considering both the substrate specificity and properties of heparitinase I, the above results suggest that the bound octasaccharide should contain two units of IdoA(2SO(4))-GlcNSO(3)(GSO(4)) contiguously or alternately in the vicinity of the reducing end. The bound decasaccharide was more than 20 times as active as the unbound one with regard to the ability to release HGF bound to rat Liver HS proteoglycan. The ability was comparable to the one-fourth of that of heparin.	AICHI MED UNIV, INST MOLEC SCI MED, NAGAKUTE, AICHI 48011, JAPAN	Aichi Medical University								ARAKAKI N, 1992, J BIOL CHEM, V267, P7101; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; FUNAHASHI M, 1982, ANAL BIOCHEM, V126, P414, DOI 10.1016/0003-2697(82)90537-1; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KATO M, 1985, ANAL BIOCHEM, V148, P479, DOI 10.1016/0003-2697(85)90255-6; KATO S, 1994, EXP CELL RES, V211, P53, DOI 10.1006/excr.1994.1058; KATO Y, 1994, HEPATOLOGY, V20, P417; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; LIU KX, 1992, AM J PHYSIOL, V263, pG642, DOI 10.1152/ajpgi.1992.263.5.G642; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MASUMOTO A, 1993, BIOCHEM BIOPH RES CO, V191, P1218, DOI 10.1006/bbrc.1993.1347; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; MORITA H, 1994, LAB INVEST, V71, P528; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RESCAN PY, 1993, AM J PATHOL, V142, P199; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; ZARNEGAR R, 1990, BIOCHEM BIOPH RES CO, V173, P1179, DOI 10.1016/S0006-291X(05)80910-6; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZARNEGAR R, 1993, HEPATOCYTE GROWTH FA, P181	51	113	114	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29586	29593		10.1074/jbc.270.49.29586	http://dx.doi.org/10.1074/jbc.270.49.29586			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7494002	hybrid			2022-12-25	WOS:A1995TJ22700083
J	ELLIS, SW; HAYHURST, GP; SMITH, G; LIGHTFOOT, T; WONG, MMS; SIMULA, AP; ACKLAND, MJ; STERNBERG, MJE; LENNARD, MS; TUCKER, GT; WOLF, CR				ELLIS, SW; HAYHURST, GP; SMITH, G; LIGHTFOOT, T; WONG, MMS; SIMULA, AP; ACKLAND, MJ; STERNBERG, MJE; LENNARD, MS; TUCKER, GT; WOLF, CR			EVIDENCE THAT ASPARTIC-ACID-301 IS A CRITICAL SUBSTRATE-CONTACT RESIDUE IN THE ACTIVE-SITE OF CYTOCHROME-P450 2D6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CRYSTAL-STRUCTURE; INHIBITION; MUTAGENESIS; OXIDATION; PROTEINS; MODEL; YEAST	Model building studies have intimated a role for aspartic acid 301 in the substrate binding of cytochrome P450 2D6 (CYP2D6). We have tested this hypothesis by generating a range of CYP2D6 mutants substituting a variety of amino acids at this site. The mutant proteins, which included substitution with a negatively charged glutamic acid residue or neutral asparagine, alanine, or glycine residues, were expressed in Saccharomyces cerevisiae. In addition, a mutant where aspartic acid 301 was deleted was also tested. All the mutants expressed approximately equivalent amounts of recombinant apoprotein and, apart hom the alanine 301 and the aspartic acid 301 deletion mutants, gave carbon monoxide difference spectra of similar magnitude to the wild type. In the cases of the alanine and deletion mutants, the amount of holoprotein was significantly reduced or absent relative to the amount of apoprotein, indicating restricted heme incorporation. The glutamic acid mutant was shown to have similar catalytic properties to the wild type enzyme toward the substrates debrisoquine and metoprolol; however, some differences in regioselectivity and ligand binding were observed. The mutants containing neutral amino acids at position 301 exhibited marked reductions in catalytic activity. At low substrate concentrations little, if any, activity toward debrisoquine and metoprolol was measured. However, at a higher substrate concentration (2 mM) some activity was observed (about 10-20% of wild type levels). Consistent with the above findings, the debrisoquine-induced spin changes in the mutant proteins were markedly reduced These data collectively demonstrate that aspartic acid 301 plays an important role in determining the substrate specificity and activity of CYP2D6 and provide experimental evidence supporting the role of this amino acid in forming an electrostatic interaction between the basic nitrogen atom in CYP2D6 substrates and the carboxylate group of aspartic acid 301.	UPJOHN LABS EUROPE, CRAWLEY RH10 2LZ, W SUSSEX, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND	Cancer Research UK; University of Dundee	ELLIS, SW (corresponding author), UNIV SHEFFIELD, ROYAL HALLAMSHIRE HOSP, DEPT MED & PHARMACOL, GLOSSOP RD, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND.			Wolf, Charles Roland/0000-0002-6969-0113; Smith, Gillian/0000-0001-9288-7566; Sternberg, Michael/0000-0002-1884-5445	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; ELLIS SW, 1992, BIOCHEM PHARMACOL, V44, P617, DOI 10.1016/0006-2952(92)90394-X; ELLIS SW, 1994, BRIT J PHARMACOL, V112, pU124; FUKUDA T, 1993, J BIOCHEM-TOKYO, V113, P7, DOI 10.1093/oxfordjournals.jbchem.a124006; GOTOH O, 1992, J BIOL CHEM, V267, P83; GRAHAMLORENCE S, 1991, J BIOL CHEM, V266, P11939; GUENGERICH FP, 1995, ADV DRUG METABOLISM, P180; HANIOKA N, 1992, BIOCHEMISTRY-US, V31, P3364, DOI 10.1021/bi00128a009; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; ISLAM SA, 1991, CARCINOGENESIS, V12, P2211, DOI 10.1093/carcin/12.12.2211; Jefcoate C R, 1978, Methods Enzymol, V52, P258; KOYMANS L, 1992, CHEM RES TOXICOL, V5, P211, DOI 10.1021/tx00026a010; KOYMANS LMH, 1993, J COMPUT AID MOL DES, V7, P281, DOI 10.1007/BF00125503; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS DFV, 1995, XENOBIOTICA, V25, P333, DOI 10.3109/00498259509061857; MEYER UA, 1986, XENOBIOTICA, V16, P449, DOI 10.3109/00498258609050251; OMURA T, 1964, J BIOL CHEM, V239, P2370; OTTON SV, 1988, J PHARMACOL EXP THER, V247, P242; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Sambrook J, 1989, MOL CLONING LABORATO; STROBL GR, 1993, J MED CHEM, V36, P1136, DOI 10.1021/jm00061a004; TUCKER GT, 1994, J PHARM PHARMACOL, V46, P417; WOLFF T, 1985, CANCER RES, V45, P2116	27	115	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29055	29058		10.1074/jbc.270.49.29055	http://dx.doi.org/10.1074/jbc.270.49.29055			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493924	hybrid			2022-12-25	WOS:A1995TJ22700005
J	KANDASAMY, RK; YU, FH; HARRIS, R; BOUCHER, A; HANRAHAN, JW; ORLOWSKI, J				KANDASAMY, RK; YU, FH; HARRIS, R; BOUCHER, A; HANRAHAN, JW; ORLOWSKI, J			PLASMA-MEMBRANE NA+/H+ EXCHANGER ISOFORMS (NHE-1, NHE-2, AND NHE-3) ARE DIFFERENTIALLY RESPONSIVE TO 2ND MESSENGER AGONISTS OF THE PROTEIN-KINASE-A AND PROTEIN-KINASE-C PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; EPIDERMAL GROWTH-FACTOR; CELL-VOLUME REGULATION; OPOSSUM KIDNEY-CELLS; AORTIC SMOOTH-MUSCLE; CYCLIC-AMP; INTRACELLULAR PH; H EXCHANGE; FUNCTIONAL-PROPERTIES; PARATHYROID-HORMONE	Na+/H+ exchanger (NHE) activity is regulated by several types of receptors directly coupled to distinct classes (i.e. G(s), G(i), G(q), and G(12)) of heterotrimeric (alpha beta gamma) GTP-binding proteins (G proteins), which, upon activation, modulate production of various second messengers (e.g. cAMP, cGMP, diacylglycerol, inositol trisphosphate, and Ca2+). Recently, four isoforms of the rat Na+/H+ exchanger were identified by molecular cloning. To examine their intrinsic responsiveness to Gr protein and second messenger stimulation, three of these isoforms, NHE-1, -2, and -3, were stably expressed in mutant Chinese hamster ovary cells devoid of endogenous NHE activity (AP-1 cells). Incubation of cells with either AlF4-, a general agonist of G proteins, or cholera toxin, a selective activator of G alpha(s) that stimulates adenylate cyclase, accelerated the rates of amiloride-inhibitable Na-22(+) influx mediated by NHE-1 and 2, whereas they inhibited that by NHE-3. Similarly, short term treatment with phorbol 12-myristate 13-acetate, which mimics diacylglycerol activation of protein kinase C (PKC), or with agents (i.e. forskolin, 8-(4-chlorophenylthio)-cAMP, and isobutylmethylxanthine) that lead to activation of cAMP-dependent protein kinase (PKA) also stimulated transport by NHE-1 and NHE-2 but depressed that by NHE-3. The effects of phorbol 12-myristate 13-acetate were blocked by depleting cells of PKC or by inhibiting PKC using chelerythrine chloride, confirming a role for PHC in modulating NHE isoform activities. Likewise, the PKA antagonist, H-89, attenuated the effects of elevated cAMP(i) on NHE-1, -2, and -3, further demonstrating the regulation by PKA. Unlike cAMP(i), elevation of cGMP(i) by treatment with dibutyryl-cGMP or 8-bromo-cGMP had no influence on NHE isoform activities, thereby excluding the possibility of a role for cGMP-dependent protein kinase in these cells. These data support the concept that the NHE isoforms are differentially responsive to agonists of the PKA and PKC pathways.			KANDASAMY, RK (corresponding author), MCGILL UNIV,DEPT PHYSIOL,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL,PQ H3G 1Y6,CANADA.		Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039; Orlowski, John/0000-0001-7371-175X; Yu, Frank/0000-0001-9306-1731				AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; BORGESE F, 1994, P NATL ACAD SCI USA, V91, P5431, DOI 10.1073/pnas.91.12.5431; BRUNSKILL NJ, 1992, KIDNEY INT, V42, P11, DOI 10.1038/ki.1992.254; BURNS KD, 1991, AM J PHYSIOL, V261, pF607, DOI 10.1152/ajprenal.1991.261.4.F607; BUSCH S, 1995, J BIOL CHEM, V270, P17898, DOI 10.1074/jbc.270.30.17898; CANO A, 1993, J CLIN INVEST, V92, P1632, DOI 10.1172/JCI116748; CHANG EB, 1991, AM J PHYSIOL, V260, pC1264, DOI 10.1152/ajpcell.1991.260.6.C1264; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; DAVIS BA, 1992, AM J PHYSIOL, V262, pC533, DOI 10.1152/ajpcell.1992.262.2.C533; DEMAUREX N, 1995, J GEN PHYSIOL, V106, P85, DOI 10.1085/jgp.106.1.85; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; EMMER E, 1989, J MEMBRANE BIOL, V108, P207, DOI 10.1007/BF01871735; FLIEGEL L, 1992, BIOCHEM J, V282, P139, DOI 10.1042/bj2820139; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1987, J GEN PHYSIOL, V89, P185, DOI 10.1085/jgp.89.2.185; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HELMLEKOLB C, 1993, PFLUG ARCH EUR J PHY, V425, P34, DOI 10.1007/BF00374501; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V416, P615, DOI 10.1007/BF00370605; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HENDEY B, 1991, J CELL PHYSIOL, V146, P290, DOI 10.1002/jcp.1041460214; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KONG SK, 1989, BIOCHEM BIOPH RES CO, V165, P131, DOI 10.1016/0006-291X(89)91044-9; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LITTLE PJ, 1988, J BIOL CHEM, V263, P16780; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MANGANEL M, 1990, J BIOL CHEM, V265, P4284; MOULE SK, 1990, EUR J BIOCHEM, V187, P677, DOI 10.1111/j.1432-1033.1990.tb15353.x; MRKIC B, 1993, PFLUG ARCH EUR J PHY, V424, P377, DOI 10.1007/BF00374897; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ORLOV SN, 1993, BIOCHEM BIOPH RES CO, V191, P802, DOI 10.1006/bbrc.1993.1288; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PETROV V, 1994, EUR J BIOCHEM, V221, P195, DOI 10.1111/j.1432-1033.1994.tb18729.x; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SEMRAD CE, 1990, J CLIN INVEST, V86, P585, DOI 10.1172/JCI114748; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; SZPIRER C, 1994, MAMM GENOME, V5, P153, DOI 10.1007/BF00352346; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE M, 1993, J MEMBRANE BIOL, V135, P93; UEDA N, 1994, J BIOL CHEM, V269, P4388; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; WATSON AJM, 1991, AM J PHYSIOL, V261, pG229, DOI 10.1152/ajpgi.1991.261.2.G229; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WINKEL GK, 1993, J BIOL CHEM, V268, P3396; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; YU FH, 1993, J BIOL CHEM, V268, P25536	70	119	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29209	29216		10.1074/jbc.270.49.29209	http://dx.doi.org/10.1074/jbc.270.49.29209			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493949	hybrid			2022-12-25	WOS:A1995TJ22700030
J	MORISHITA, R; NAKAYAMA, H; ISOBE, T; MATSUDA, T; HASHIMOTO, Y; OKANO, T; FUKADA, Y; MIZUNO, K; OHNO, S; KOZAWA, O; KATO, K; ASANO, T				MORISHITA, R; NAKAYAMA, H; ISOBE, T; MATSUDA, T; HASHIMOTO, Y; OKANO, T; FUKADA, Y; MIZUNO, K; OHNO, S; KOZAWA, O; KATO, K; ASANO, T			PRIMARY STRUCTURE OF A GAMMA-SUBUNIT OF G-PROTEIN, GAMMA(12), AND ITS PHOSPHORYLATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; REGULATORY PROTEINS; PHORBOL ESTER; BOVINE BRAIN; IDENTIFICATION; CDNA; PURIFICATION; INHIBITION; SEQUENCE; ISOFORMS	We have determined the primary structure of a novel gamma subunit (gamma(12), previously designated gamma(S1)) of G protein purified from bovine spleen. The mature gamma(12) protein composed of 68 amino acids had acetylated serine at the N terminus and geranylgeranylated/carboxylmethylated cysteine at the C terminus. This was consistent with the C-terminal prenylation signal in the amino acid sequence, which was predicted from gamma(12) cDNA isolated from a bovine spleen cDNA library. Western blots with the specific antibody against gamma(12) showed that gamma(12) is present in all tissues examined. Among various gamma subunits (gamma(1), gamma(2), gamma(3), gamma(7), and gamma(12)), gamma(12) has a unique property to be phosphorylated by protein kinase C. The phosphorylated amino acid residue was Ser(1) (or Ser(2)). The phosphorylated beta gamma(12) associated with G(o) alpha more tightly than the unphosphorylated form. Exposure of Swiss 3T3 and aortic smooth muscle cells to phorbol 12-myristate 13-acetate and NaF induced phosphorylation of gamma(12). Stimulation of aortic smooth muscle cells with natural vasoactive agents such as angiotensin II and vasopressin also induced phosphorylation of gamma(12). The extent of phosphorylation of beta gamma(12) in vitro was suppressed by a complex formation with G(o) alpha, which was relieved by the addition of guanosine 5'-O-(3-thiotriphosphate) or aluminum fluoride. These results strongly suggest that gamma(12) is phosphorylated by protein kinase C during activation of receptor(s) and G protein(s) in living cells.	AICHI HUMAN SERV CTR,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN; TOKYO METROPOLITAN UNIV,FAC SCI,DEPT CHEM,HACHIOJI,TOKYO 19203,JAPAN; UNIV TOKYO,COLL ARTS & SCI,DEPT LIFE SCI,TOKYO 153,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL MOLEC,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Tokyo Metropolitan University; University of Tokyo; Yokohama City University			Ohno, Shigeo/B-1768-2010; Isobe, Toshiaki/Q-9279-2017; 吉孝, 深田/G-5090-2014	Ohno, Shigeo/0000-0002-1294-5269; Okano, Toshiyuki/0000-0001-6740-6265				ASANO T, 1990, FEBS LETT, V266, P41, DOI 10.1016/0014-5793(90)81501-E; ASANO T, 1988, J BIOCHEM-TOKYO, V103, P950, DOI 10.1093/oxfordjournals.jbchem.a122392; ASANO T, 1995, J NEUROCHEM, V64, P1267; ASANO T, 1993, J BIOL CHEM, V268, P20512; ASSENDER JW, 1994, FEBS LETT, V342, P76, DOI 10.1016/0014-5793(94)80588-1; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FUJISE A, 1994, J BIOL CHEM, V269, P31642; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUKADA Y, 1994, J BIOL CHEM, V268, P5163; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HAGA K, 1989, MOL PHARMACOL, V35, P286; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO Y, 1994, ATHEROSCLEROSIS, V110, P69, DOI 10.1016/0021-9150(94)90069-8; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; Kitano T, 1986, Methods Enzymol, V124, P349; MORISHITA R, 1992, EUR J BIOCHEM, V210, P1061, DOI 10.1111/j.1432-1033.1992.tb17512.x; MORISHITA R, 1993, BIOCHEM BIOPH RES CO, V194, P1221, DOI 10.1006/bbrc.1993.1953; MORISHITA R, 1994, FEBS LETT, V337, P23, DOI 10.1016/0014-5793(94)80622-5; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; RAHMATULLAH M, 1995, J BIOL CHEM, V270, P2946, DOI 10.1074/jbc.270.7.2946; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SANTELL L, 1992, BIOCHEM J, V284, P705, DOI 10.1042/bj2840705; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V66, P368; SOHMA H, 1993, BIOCHEM BIOPH RES CO, V190, P849, DOI 10.1006/bbrc.1993.1126; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; UEDA N, 1994, J BIOL CHEM, V269, P4388; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	51	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29469	29475		10.1074/jbc.270.49.29469	http://dx.doi.org/10.1074/jbc.270.49.29469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493986	hybrid			2022-12-25	WOS:A1995TJ22700067
J	ROTHERMEL, BA; SHYJAN, AW; ETHEREDGE, JL; BUTOW, RA				ROTHERMEL, BA; SHYJAN, AW; ETHEREDGE, JL; BUTOW, RA			TRANSACTIVATION BY RTG1P, A BASIC HELIX-LOOP-HELIX PROTEIN THAT FUNCTIONS IN COMMUNICATION BETWEEN MITOCHONDRIA AND THE NUCLEUS IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; GENE; TRANSCRIPTION; EXPRESSION; MYOGENESIS; MYOD; PEROXISOMES; ACTIVATION; SEQUENCE	Rtg1p is a basic helix-loop-helix transcription factor in the yeast Saccharomyces cerevisiae that is required for basal and regulated expression of CIT2, the gene encoding a peroxisomal isoform of citrate synthase. In respiratory incompetent rho degrees petite cells, CIT2 transcription is elevated as much as 30-fold compared with respiratory competent rho(+) cells. Here we provide evidence that Rtg1p interacts directly with a CIT2 upstream activation site (UAS(r)) and that the rho degrees/rho(+) regulation is not due to a change in the levels of Rtg1p. A fusion protein consisting of the DNA binding domain of Gal4p fused to the NH2 terminus of the full-length wild-type Rtg1p was able to transactivate an integrated LacZ reporter under control of the Gal4p-responsive GAL1 UAS(G) in a rho degrees/rho(+)-dependent manner. Other Gal4p fusions to deletions or mutations of Rtg1p indicate that the helix-loop-helix domain is essential for transactivation. Regulated expression of CIT2 also requires the RTG2 gene product. The GAl4-Rtg1p fusion was unable to transactivate the LacZ reporter gene in a strain deleted for RTG2, suggesting that the RTG2 product does not act independently of Rtg1p in the rho degrees/rho(+) transcriptional response.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM 22525] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022525, R37GM022525] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CHELSTOWSKA A, 1995, J BIOL CHEM, V270, P1811; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KOONIN EV, 1994, TRENDS BIOCHEM SCI, V19, P156, DOI 10.1016/0968-0004(94)90275-5; KUMAU WH, 1988, BIOCHEM SOC T, V16, P418; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARIKH VS, 1987, SCIENCE, V238, P576; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; Sambrook J, 1989, MOL CLONING LABORATO; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHYJAN AW, 1993, CURR BIOL, V3, P398, DOI 10.1016/0960-9822(93)90212-7; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; SUSEK RE, 1992, AUST J PLANT PHYSIOL, V19, P387, DOI 10.1071/PP9920387; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	39	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29476	29482		10.1074/jbc.270.49.29476	http://dx.doi.org/10.1074/jbc.270.49.29476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493987	hybrid			2022-12-25	WOS:A1995TJ22700068
J	YOUNG, KC; SHI, GY; CHANG, YF; CHANG, BI; CHANG, LC; LAI, MD; CHUANG, WJ; WU, HL				YOUNG, KC; SHI, GY; CHANG, YF; CHANG, BI; CHANG, LC; LAI, MD; CHUANG, WJ; WU, HL			INTERACTION OF STREPTOKINASE AND PLASMINOGEN - STUDIED WITH TRUNCATED STREPTOKINASE PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR COMPLEX; PURIFICATION; MICROPLASMIN; MECHANISM; FRAGMENTS; SEQUENCE; CLEAVAGE; PROTEINS; BINDING; GENE	The interaction of streptokinase (SK) with human plasminogen (HPlg) was investigated using truncated SK peptides prepared by gene cloning techniques, SK(16-414) and SK(16-378) could activate HPlg as efficiently as the authentic SK. SK(60-414), which had been preincubatd with SK(1-59), could also activate HPlg. SK(91-414), SK(127-414), and SK(158-414), at a concentration of one-tenth of HPlg, all failed to activate HPlg, However, the truncated SK peptides in complexes with equimolar HPlg could form amidolytically active virgin enzymes that slowly converted to human plasmin (HPlm) after a lag period of 15 min. SK(16-316) could not activate HPlg. No virgin enzyme was detected when SK(16-316) was incubated with equimolar HPlg, but the HPlg in the complex was modified to HPlm after reaction for 20 min. SK(220-414) and SK(16-251) had no ability to transform HPlg to virgin enzyme or to HPlm in equimolar complex with HPlg, although they could bind to HPlg. The functions of five regions in the SK molecule (a, Ile(1)-Lys(59); b, Ser(60)-Asn(9O); c, Val(158)-Arg(219); d, Tyr(252)- Ala(316); e, Ser(317)-Ala(378)) in interaction with HPlg are deduced. Region c is important in stabilizing the conformation of the SH molecule, and region b is essential for HPlg activation. Region c is required for induction of the conformational changes of HPlg to virgin enzyme. Regions c and d are required for the conversion of HPlg to HPlm in the HPlg . SK equimolar complex. Coordination of regions c, d, and e of SK is essential for a virgin enzyme formation, and coordination of regions b, c, d and e is required for an effective SK-type HPlg activator.	NATL CHENG KUNG UNIV,COLL MED,DEPT BIOCHEM,TAINAN 70101,TAIWAN; NATL CHENG KUNG UNIV,COLL MED,DEPT MED TECHNOL,TAINAN 70101,TAIWAN	National Cheng Kung University; National Cheng Kung University			Lai, Ming-Derg/M-8028-2014; Young, Kung-Chia/G-1529-2011					BAJAJ SP, 1977, J BIOL CHEM, V252, P492; BROCKWAY WJ, 1972, ARCH BIOCHEM BIOPHYS, V151, P194, DOI 10.1016/0003-9861(72)90488-2; BROCKWAY WJ, 1974, BIOCHEMISTRY-US, V13, P2063, DOI 10.1021/bi00707a010; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIBBER BAK, 1986, P NATL ACAD SCI USA, V83, P1237, DOI 10.1073/pnas.83.5.1237; DAMASCHUN G, 1992, EUR BIOPHYS J BIOPHY, V20, P355; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; GONZALEZGRONOW M, 1977, J BIOL CHEM, V252, P1090; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; JACKSON KW, 1986, BIOCHEMISTRY-US, V25, P108, DOI 10.1021/bi00349a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING CM, 1965, J BIOL CHEM, V240, P4213; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALKE H, 1985, GENE, V34, P357, DOI 10.1016/0378-1119(85)90145-3; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; MISSELWITZ R, 1992, INT J BIOL MACROMOL, V14, P107, DOI 10.1016/0141-8130(92)90007-U; RADEK JT, 1989, J BIOL CHEM, V264, P9915; REDDY K N N, 1974, Journal of Biological Chemistry, V249, P4851; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REDDY KNN, 1976, THROMB RES, V9, P407, DOI 10.1016/0049-3848(76)90140-7; RODRIGUEZ P, 1994, FIBRINOLYSIS, V8, P276, DOI 10.1016/0268-9499(94)90016-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHICK LA, 1973, BIOCHEMISTRY-US, V12, P4315, DOI 10.1021/bi00746a003; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SHI GY, 1994, BIOCHEM J, V304, P235, DOI 10.1042/bj3040235; SHI GY, 1993, BIOCHEM BIOPH RES CO, V195, P192, DOI 10.1006/bbrc.1993.2029; SHI GY, 1990, THROMB RES, V58, P317, DOI 10.1016/0049-3848(90)90101-H; SIEFRING GE, 1976, J BIOL CHEM, V251, P3913; SUMMARIA L, 1982, BIOCHEMISTRY-US, V21, P2056, DOI 10.1021/bi00538a012; TEUTEN AJ, 1993, BIOCHEM J, V290, P313, DOI 10.1042/bj2900313; Tillett WS, 1933, J EXP MED, V58, P485, DOI 10.1084/jem.58.4.485; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WU HL, 1992, BIOCHEM BIOPH RES CO, V188, P703, DOI 10.1016/0006-291X(92)91113-5; WU HL, 1990, J BIOL CHEM, V265, P19658; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; WULF RJ, 1969, CAN J BIOCHEM CELL B, V47, P927, DOI 10.1139/o69-145	37	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29601	29606		10.1074/jbc.270.49.29601	http://dx.doi.org/10.1074/jbc.270.49.29601			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7494004	hybrid			2022-12-25	WOS:A1995TJ22700085
J	CRATER, DL; DOUGHERTY, BA; VANDERIJN, I				CRATER, DL; DOUGHERTY, BA; VANDERIJN, I			MOLECULAR CHARACTERIZATION OF HASC FROM AN OPERON REQUIRED FOR HYALURONIC-ACID SYNTHESIS IN GROUP-A STREPTOCOCCI - DEMONSTRATION OF UDP-GLUCOSE PYROPHOSPHORYLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; ACETOBACTER-XYLINUM; ESCHERICHIA-COLI; RHEUMATIC-FEVER; POTATO-TUBER; GENE; EXPRESSION; SEQUENCE; PHOSPHOGLUCOMUTASE; BIOSYNTHESIS	Hyaluronic acid is a high molecular weight glycosaminoglycan composed of repeating subunits of glucuronic acid and N-acetylglucosamine. It is synthesized by the group A streptococcal membrane-associated enzyme hyaluronate synthase. In previous reports, the locus required for expression of hyaluronic acid, the has operon, was identified and found to consist of two genes, hasA and hasB encoding hyaluronate synthase and UDP-glucose dehydrogenase, respectively. Since a transcription terminator was not found at the end of hasB, it was the aim of this study to identify the remaining gene(s) in the has operon. By utilizing the Tn1000 method of DNA sequencing and inverse polymerase chain reaction, hasC, the third gene in the has operon was shown to be 915 base pairs in length (304 amino acids) and located 192 base pairs downstream of hasB. Sequence similarities to other genes suggested that hasC encodes UDP-glucose pyrophosphorylase. Overexpression of hasC using isopropyl-1-thio-beta-D-galactopyranoside induction of the T7 promoter in the pET translation system allowed for the production of bacterial extracts from Escherichia coli that possessed increased UDP-glucose pyrophosphorylase activity as compared to nondetectable levels in extracts with vector alone, In addition, expression of HasC resulted in a protein of approximately 36 kDa as shown by SDS-polyacrylamide gel electrophoresis. These data as well as complementation analysis of hasC in an E. coli galU mutant confirmed that hasC encodes UDP-glucose pyrophosphorylase. Finally, since sequence analysis identified a potential rho-independent transcription terminator at the 3-prime terminus of the gene, hasC is the third and probably the final gene in the has operon.	WAKE FOREST UNIV,MED CTR,WINSTON SALEM,NC 27157	Wake Forest University					NCI NIH HHS [CA12107] Funding Source: Medline; NIAID NIH HHS [AI37320, T32-AI-07401] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037320, T32AI007401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BREDE G, 1991, J BACTERIOL, V173, P7042, DOI 10.1128/jb.173.21.7042-7045.1991; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; FJAERVIK E, 1991, FEMS MICROBIOL LETT, V77, P325, DOI 10.1111/j.1574-6968.1991.tb04370.x; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; HOSSAIN SA, 1994, J BIOCHEM-TOKYO, V115, P965, DOI 10.1093/oxfordjournals.jbchem.a124446; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; JOSHI JG, 1982, METHOD ENZYMOL, V89, P599; KATSUBE T, 1991, BIOCHEMISTRY-US, V30, P8546, DOI 10.1021/bi00099a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; LUDWIG W, 1985, J GEN MICROBIOL, V131, P543; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P528, DOI 10.1093/oxfordjournals.jbchem.a122886; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; REMES B, 1980, J BACTERIOL, V143, P1054, DOI 10.1128/JB.143.2.1054-1056.1980; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VARON D, 1993, J BACTERIOL, V175, P3964; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WEISSBORN AC, 1994, J BACTERIOL, V176, P2611, DOI 10.1128/JB.176.9.2611-2618.1994; WESSELS MR, 1994, P NATL ACAD SCI USA, V91, P12238, DOI 10.1073/pnas.91.25.12238; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994	34	45	50	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28676	28680		10.1074/jbc.270.48.28676	http://dx.doi.org/10.1074/jbc.270.48.28676			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499387	hybrid			2022-12-25	WOS:A1995TH05600031
J	ENGLAND, SK; UEBELE, VN; KODALI, J; BENNETT, PB; TAMKUN, MM				ENGLAND, SK; UEBELE, VN; KODALI, J; BENNETT, PB; TAMKUN, MM			A NOVEL K+ CHANNEL BETA-SUBUNIT (HKV-BETA-1.3) IS PRODUCED VIA ALTERNATIVE MESSENGER-RNA SPLICINGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSIENT OUTWARD CURRENT; GUINEA-PIG ATRIAL; POTASSIUM CHANNELS; DELAYED RECTIFIER; VENTRICULAR MYOCYTES; SKELETAL-MUSCLE; RAT-BRAIN; XENOPUS-OOCYTES; MOLECULAR-BASIS; 2 COMPONENTS	Voltage-gated K+ channels can form multimeric complexes with accessory beta-subunits. We report here a novel K+ channel beta-subunit cloned from human heart, hKv beta 1.3, that has 74-83% overall identity with previously cloned beta-subunits. Comparison of hKv beta 1.3 with the previously cloned hKv beta 3 and rKv beta 1 proteins indicates that the carboxyl terminal 328 amino acids are identical, while unique variable length amino termini exist. Analysis of human beta-subunit cDNA and genomic nucleotide sequences confirm that these three beta-subunits are alternatively spliced from a common beta-subunit gene. Co-expression of hKv beta 1.3 in Xenopus oocytes with the delayed rectifier hKv1.5 indicated that hKv beta 1.3 has unique functional effects. This novel beta-subunit induced a time dependent inactivation during membrane voltage steps to positive potentials, induced a 13-mV hyperpolarizing shift in the activation curve, and slowed deactivation (tau = 13 +/- 0.5 ms versus 35 +/- 1.7 ms at -40 mV). Most notably, hKv beta 1.3 converted the Kv1.5 outwardly rectifying current voltage relationship to one showing strong inward rectification. These data suggest that Kv channel current diversity may arise from association with alternatively spliced Kv beta-subunits. A simplified nomenclature for the K+ channel beta-subunit subfamilies is suggested.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049330, P01HL046681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49330, HL 46681] Funding Source: Medline; NIGMS NIH HHS [GM 07628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALSER JR, 1990, J GEN PHYSIOL, V96, P835, DOI 10.1085/jgp.96.4.835; BENNDORF K, 1987, PFLUEGERS ARCH, V413, P127; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; BOYLE WA, 1991, AM J PHYSIOL, V260, pH1236, DOI 10.1152/ajpheart.1991.260.4.H1236; CASTELLINO RC, 1995, AM J PHYSIOL-HEART C, V38, pH385; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; ESCANDE D, 1985, AM J PHYSIOL, V252, pH142; HEIDBUCHEL H, 1990, CIRC RES, V66, P1277, DOI 10.1161/01.RES.66.5.1277; Heinemann Stefan H., 1995, Biophysical Journal, V68, pA361; Hille B., 1992, IONIC CHANNELS EXCIT; HUME JR, 1985, J PHYSIOL-LONDON, V368, P525, DOI 10.1113/jphysiol.1985.sp015874; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MAKITA N, 1994, J BIOL CHEM, V269, P7571; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MCHUGHSUTKOWSKI E, 1990, J BIOL CHEM, V265, P12393; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; MESSNER DJ, 1986, J BIOL CHEM, V261, P4882; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PO S, 1992, CIRC RES, V71, P732, DOI 10.1161/01.RES.71.3.732; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; POWERS PA, 1992, J BIOL CHEM, V267, P22967; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; TSENG GN, 1989, CIRC RES, V64, P633, DOI 10.1161/01.RES.64.4.633; WHITE MM, 1991, MOL PHARMACOL, V39, P604; YUE DT, 1988, PFLUG ARCH EUR J PHY, V413, P127, DOI 10.1007/BF00582522	43	107	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28531	28534		10.1074/jbc.270.48.28531	http://dx.doi.org/10.1074/jbc.270.48.28531			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499366	hybrid			2022-12-25	WOS:A1995TH05600010
J	SOUZA, GM; HIRAI, J; MEHTA, DP; FREEZE, HH				SOUZA, GM; HIRAI, J; MEHTA, DP; FREEZE, HH			IDENTIFICATION OF 2 NOVEL DICTYOSTELIUM-DISCOIDEUM CYSTEINE PROTEINASES THAT CARRY N-ACETYLGLUCOSAMINE-1-P MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR SLIME-MOLDS; AMINO-ACID SEQUENCE; SPORE COAT PROTEINS; LIVER CATHEPSIN-B; MOLECULAR-CLONING; PRESPORE; EXPRESSION; CELLS; CDNA; PROTEOGLYCAN	Dictyostelium discoideum makes multiple developmentally regulated lysosomal cysteine proteinases. One of these, a lysosomal enzyme called proteinase I, contains a cluster of GlcNAc-alpha-1-P-Ser residues. We call this phosphoglycosylation. To study its function, a cDNA library from vegetative cells was screened, and two novel cysteine proteinase clones were characterized (cprD and cprE). Each of them has highly conserved regions expected for cysteine proteinases, but unlike any other, each has a serine-rich domain containing three distinct motifs, poly-S, SGSQ, and SGSG, cprD and cprE cDNAs were overexpressed in Dictyostelium and the active enzymes identified, cprD codes for a protein of approximately 36 kDa (CP4), which is recognized by monoclonal antibodies against GlcNAc-1-P and fucose, cprE corresponds to a 29-kDa protein, which is recognized by antibodies against GlcNAc-1-P. mRNA for both enzymes is present in the vegetative phase and increases during growth on bacteria but decreases throughout development. When the formation of the fruiting body is complete the mRNA for both messages is detected again but in very low levels. Having cloned cDNAs for proteins that carry GlcNAc-1-P should allow us to probe the function of the carbohydrate in these putative lysosomal enzymes.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute			Souza, Glaucia/E-6780-2012	Souza, Glaucia/0000-0001-6903-9913; Freeze, Hudson/0000-0001-6316-0501	PHS HHS [32485] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BURDINE V, 1995, MOL BIOL CELL, V6, P311, DOI 10.1091/mbc.6.3.311; CARNE A, 1979, BIOCHEM J, V173, P73; DASILVA AM, 1990, DEV BIOL, V140, P139, DOI 10.1016/0012-1606(90)90061-M; DEVINE KM, 1982, P NATL ACAD SCI-BIOL, V79, P7361, DOI 10.1073/pnas.79.23.7361; DEVINE KM, 1983, DEV BIOL, V99, P437, DOI 10.1016/0012-1606(83)90293-2; EARLY AE, 1988, DEVELOPMENT, V103, P519; FONG D, 1978, J BACTERIOL, V134, P521, DOI 10.1128/JB.134.2.521-527.1978; FONG D, 1979, P NATL ACAD SCI USA, V76, P6481, DOI 10.1073/pnas.76.12.6481; FOSNAUGH KL, 1989, NUCLEIC ACIDS RES, V17, P9489, DOI 10.1093/nar/17.22.9489; FOSNAUGH KL, 1989, MOL CELL BIOL, V9, P5215, DOI 10.1128/MCB.9.11.5215; FREEZE HH, 1980, J BIOL CHEM, V255, P1081; FREEZE HH, 1995, BIOCHEM BIOPH RES CO, V208, P384, DOI 10.1006/bbrc.1995.1349; FREEZE HH, 1991, CELL SURFACE CARBOHY, P285; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; GOMER RH, 1986, J CELL BIOL, V103, P1999, DOI 10.1083/jcb.103.5.1999; GUSTAFSON GL, 1980, J BIOL CHEM, V255, P7208; GUSTAFSON GL, 1979, BIOCHEM BIOPH RES CO, V86, P667, DOI 10.1016/0006-291X(79)91765-0; GUSTAFSON GL, 1979, J BIOL CHEM, V254, P2471; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; ILG T, 1994, J BIOL CHEM, V269, P24073; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; JULIANI MH, 1990, J BIOL CHEM, V265, P9077; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOOMIS WF, 1995, GENETICS, V141, P147; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEHTA DP, 1995, ARCH BIOCHEM BIOPHYS, V321, P191, DOI 10.1006/abbi.1995.1385; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MITCHEL REJ, 1970, J BIOL CHEM, V245, P3485; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NELLEN W, 1987, METHOD CELL BIOL, V28, P87; NORTH MJ, 1988, BIOCHEM J, V254, P269, DOI 10.1042/bj2540269; NORTH MJ, 1991, DEV GENET, V12, P154, DOI 10.1002/dvg.1020120124; NORTH MJ, 1988, BIOCHEM J, V254, P261, DOI 10.1042/bj2540261; PEARS CJ, 1985, NUCLEIC ACIDS RES, V13, P8853, DOI 10.1093/nar/13.24.8853; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PRESSE F, 1986, MOL GEN GENET, V203, P324, DOI 10.1007/BF00333975; RITONJA A, 1985, FEBS LETT, V181, P169, DOI 10.1016/0014-5793(85)81136-4; Sambrook J, 1989, MOL CLONING LABORATO; SIEGEL LI, 1986, ANAL BIOCHEM, V159, P82, DOI 10.1016/0003-2697(86)90310-6; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; WEST C, UNPUB; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; WILLIAMS JG, 1985, EMBO J, V4, P999, DOI 10.1002/j.1460-2075.1985.tb03730.x	50	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28938	28945		10.1074/jbc.270.48.28938	http://dx.doi.org/10.1074/jbc.270.48.28938			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499424	hybrid			2022-12-25	WOS:A1995TH05600068
J	LLOYD, AR; BIRAGYN, A; JOHNSTON, JA; TAUB, DD; XU, LL; MICHIEL, D; SPRENGER, H; OPPENHEIM, JJ; KELVIN, DJ				LLOYD, AR; BIRAGYN, A; JOHNSTON, JA; TAUB, DD; XU, LL; MICHIEL, D; SPRENGER, H; OPPENHEIM, JJ; KELVIN, DJ			GRANULOCYTE-COLONY-STIMULATING FACTOR AND LIPOPOLYSACCHARIDE REGULATE THE EXPRESSION OF INTERLEUKIN-8 RECEPTORS ON POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PROPERTIES; TUMOR-NECROSIS-FACTOR; FUNCTIONAL EXPRESSION; CHEMOTACTIC FACTOR; CYTOKINE FAMILY; HIGH-AFFINITY; SEQUENCE; SECRETE; CLONING; ALPHA	Interleukin 8 (IL-8) is a potent chemoattractant and activating factor for human polymorphonuclear leukocytes (PMN) and hence plays a critical role in the pathogenesis of acute inflammation, Two unique but homologous receptors for IL-8 have been cloned (IL-8RA and -B), each of which binds the IL-8 ligand with high affinity, PMN stimulated by cytokines or lipopolysaccharide (LPS) exhibit changes in IL-8R mRNA and I-125-IL-8 binding, Granulocyte-colony stimulating factor (G-CSF) treatment of PMN enhances, and LPS inhibits, IL-8R mRNA expression, Similarly, I-125-IL-8 ligand binding to PMN is increased by G-CSF and decreased by LPS treatment, The stimulatory effect of G-CSF on IL-8R expression is transcriptional as it is inhibited by actinomycin D and is evident in nuclear run-on analyses. In contrast, LPS down-regulates IL-8R by both transcriptional and post-transcriptional mechanisms. The alterations in IL-8R expression are associated with similar changes in the IL-8-induced chemotactic responses of PMN. In conclusion, the two types of IL-8 receptor differ in their cellular distribution and are regulated in response to cytokines and LPS, Regulation of IL-8R expression by endogenous and exogenous immunomodulators may be important in the in vivo control of PMN effector functions in inflammation.	NCI, MOLEC IMMUNOREGULAT LAB, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; UNIV WESTERN ONTARIO, JOHN P ROBARTS RES INST, AUTOIMMUN GRP, LONDON, ON N6G 2V4, CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Western University (University of Western Ontario)			Lloyd, Andrew/E-7334-2017	Lloyd, Andrew/0000-0001-6277-8887				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; COLOTTA F, 1992, BLOOD, V80, P2012; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LEE J, 1992, J BIOL CHEM, V267, P16283; LLOYD A, 1993, CYTOGENET CELL GENET, V63, P238, DOI 10.1159/000133541; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; Maniatis T, 1989, MOL CLONING; MARUCHA PT, 1991, J IMMUNOL, V147, P2603; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRENGER H, 1994, J IMMUNOL, V153, P2524; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; TAUB DD, 1993, CYTOKINE, V5, P175, DOI 10.1016/1043-4666(93)90001-L; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; XU L, 1994, J LEUKOCYTE BIOL, V57, P335; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	30	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28188	28192						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499311				2022-12-25	WOS:A1995TG21000036
J	LORENZ, MC; HEITMAN, J				LORENZ, MC; HEITMAN, J			TOR MUTATIONS CONFER RAPAMYCIN RESISTANCE BY PREVENTING INTERACTION WITH FKBP12-RAPAMYCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; CYCLOSPORINE-A; SACCHAROMYCES-CEREVISIAE; IMMUNOSUPPRESSANT FK506; FK-506-BINDING PROTEIN; MACROLIDES FK-506; BINDING-PROTEIN; KINASE-ACTIVITY; CELL-LINE	The antifungal, immunosuppressive compound rapa mycin arrests the cell cycle in G(1) in both yeast cells and T-lymphocytes. Previous genetic studies in yeast identified mutations in three genes, FPR1 (FKBP12), TOR1, and TOR2, which confer rapamycin resistance, and genetic findings implicated the TOR proteins as direct targets of FKBP12-rapamycin. Consistent with this model, we find that modulating TORI and TOR2 expression alters rapamycin sensitivity. We describe several TOR2 mutations that confer rapamycin resistance, These mutations prevent FKBP12-rapamycin binding to TOR2, as assayed with the two-hybrid system, We find that TOR1 and the mammalian TOR homologue (mTOR) also bind FKBP12 rapamycin, and mutations corresponding to those in TOR2 similarly block FKBP12-rapamycin binding, We demonstrate that FKBP12 prolyl isomerase activity is not required for FKBP12-rapamycin binding to TOR and that a composite protein drug surface contacts the TOR proteins, These studies confirm that the TOR proteins are direct targets of FKBP12-rapamycin, reveal that drug-resistant mutations prevent this association, and define structural features of these complexes.	DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Heitman, Joseph/ABC-6006-2021	Lorenz, Michael/0000-0002-7881-8027	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07184-20] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN SJ, 1994, NATURE, V369, P758; CAFFERKEY R, 1994, GENE, V141, P133, DOI 10.1016/0378-1119(94)90141-4; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CARDENAS ME, 1995, IN PRESS EMBO J, V14; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARPER JW, 1993, CELL, V75, P805; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MORICE WG, 1993, J BIOL CHEM, V268, P22737; NORUSE J, 1994, NATURE, V372, P570; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROSEN MK, 1993, J AM CHEM SOC, V115, P821, DOI 10.1021/ja00055a082; ROTONDA J, 1993, J BIOL CHEM, V268, P7607; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SIKORSKI RS, 1989, GENETICS, V122, P19; STAN R, 1994, J BIOL CHEM, V269, P32027; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081	55	196	212	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27531	27537		10.1074/jbc.270.46.27531	http://dx.doi.org/10.1074/jbc.270.46.27531			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499212	hybrid			2022-12-25	WOS:A1995TE73600023
J	MORI, Y; FOLCO, E; KOREN, G				MORI, Y; FOLCO, E; KOREN, G			GH3 CELL-SPECIFIC EXPRESSION OF KV1.5 GENE - REGULATION BY A SILENCER CONTAINING A DINUCLEOTIDE REPETITIVE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNEL; K+ CHANNEL; RAT SKELETAL; DNA; CLONING; TRANSCRIPTION; SEQUENCES; BRAIN; HELIX	A silencer element (Kv1.5 repressor element; KRE) was characterized by deletion analyses in the promoter of Kv1.5, a voltage-gated potassium channel, The silencer element selectively decreases expression of Kv1.5- and thymidine kinase-chloramphenicol acetyltransferase reporter gene constructs in cell lines that do not express Kv1.5 polypeptide. It contains a dinucleotide repetitive element (poly(GT)(19)(GA)(1)(CA)(15)(GA)(16)), and self associates spontaneously in vitro to form complexes with slow electrophoretic mobility, Deletion of the repetitive element abolished self-association in vitro and the silencing activity in transient transfection experiments in vivo, Electromobility gel shift assays of KRE with GH3 cells nuclear extracts detected the formation of a unique DNA-protein complex, which was not detectable in Chinese hamster ovary and COS-7 cells. This complex does not react with an antibody against nonhistone high mobility group 1 protein, which binds KRE in gel retardation assays, These observations establish that a dinucleotide tandem repeat sequence, capable of self-association, forms part of a cell-specific silencer element in a mammalian gene.	BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046005, F32HL146005] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BROWN AM, 1993, ANNU REV BIOPH BIOM, V22, P173, DOI 10.1146/annurev.bb.22.060193.001133; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GAILLARD C, 1994, SCIENCE, V264, P433, DOI 10.1126/science.8153633; GE H, 1994, J BIOL CHEM, V269, P17136; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HERRERA VLM, 1990, J BIOL CHEM, V265, P9555; Hille B., 1992, IONIC CHANNELS EXCIT; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KOREN G, 1990, NEURON, V4, P39, DOI 10.1016/0896-6273(90)90442-I; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; MATSUBARA H, 1991, J BIOL CHEM, V266, P13324; MORI Y, 1993, J BIOL CHEM, V268, P26482; MURPHY KE, 1986, NUCLEIC ACIDS RES, V14, P7325, DOI 10.1093/nar/14.18.7325; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; STRONG M, 1993, MOL BIOL EVOL, V10, P221; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEBER JL, 1989, AM J HUM GENET, V44, P388	29	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27788	27796		10.1074/jbc.270.46.27788	http://dx.doi.org/10.1074/jbc.270.46.27788			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499248	hybrid			2022-12-25	WOS:A1995TE73600059
J	LUCA, M; XIE, SH; GUTMAN, M; HUANG, SY; BARELI, M				LUCA, M; XIE, SH; GUTMAN, M; HUANG, SY; BARELI, M			ABNORMALITIES IN THE CDKN2 (P16(INK4)/MTS-1) GENE IN HUMAN-MELANOMA CELLS - RELEVANCE TO TUMOR-GROWTH AND METASTASIS	ONCOGENE			English	Note						CDKN2 (P16(INK4)/MTS-1); HUMAN MELANOMA; METASTASIS	P53 MUTATIONS	The inhibitor of cyclin-dependent kinase 4, CDKN2 (also known as p16(INK4) Or MTS-1, multiple tumor suppressor gene 1), has been mapped to 9p21, The gene has been shown to be deleted or mutated in high frequency in human melanoma cell lines and familial melanoma patients, suggesting that it could be a melanoma suppressor gene. How these observations are related to tumorigenicity and metastasis of human melanoma is not clear however, To test the role of CDW2 in human melanoma metastasis, 14 human melanoma cell lines with different metastatic abilities in nude mice were analysed for possible abnormalities in the CDKN2 gene, Homozygous deletions that resulted in a lack of gene expression were found in six of 14 cell lines tested. SSCP-direct sequencing revealed point mutations in three other cell lines, One cell line displayed CC to TT transitions which constitute a hallmark of ultraviolet-induced DNA damage, Overall, abnormalities in the CDKN2 gene were found in nine of 14 (64%) cell lines tested, Homozygous deletion and lack of gene expression were found in several low tumorigenic and nonmetastatic melanoma lines, whereas other metastatic cells did not exhibit abnormalities in the CDKN2 gene, These data suggest that the absence of normal CDKN2 does not confer growth advantage to melanoma cells in vivo and that the production of metastasis by human melanoma cells can occur in the absence of CDKN2 gene abnormalities.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA041525] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; FIDLER IJ, 1991, CANCER METAST REV, V10, P229, DOI 10.1007/BF00050794; GUTMAN M, 1994, ANTICANCER RES, V14, P1759; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEEJACKSON D, 1993, BIOTECHNIQUES, V15, P363; LIU Q, 1995, ONCOGENE, V10, P1061; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUCA M, 1993, INT J ONCOL, V3, P19; NOBORI T, 1994, NATURE, V363, P753; OHTA M, 1994, CANCER RES, V54, P5269; RADINSKY R, 1994, ONCOGENE, V9, P1877; ROSTAD EK, 1994, BRIT J CANCER, V70, P804; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211	17	56	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1399	1402						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478563				2022-12-25	WOS:A1995RY96700023
J	FOO, NC; FUNKHOUSER, JM; CARTER, DA; MURPHY, D				FOO, NC; FUNKHOUSER, JM; CARTER, DA; MURPHY, D			A TESTIS-SPECIFIC PROMOTER IN THE RAT VASOPRESSIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR ANDROGEN BIOSYNTHESIS; MESSENGER-RNA; ARGININE-VASOPRESSIN; PROTO-ONCOGENE; LEYDIG-CELLS; VITAMIN-A; TRANSCRIPTION INITIATION; DIFFERENTIAL EXPRESSION; DIRECT INHIBITION; BINDING-PROTEIN	In the rat testis, the vasopressin gene is transcribed into precursor RNAs that are processed into a number of mature transcripts. One of these transcripts has a structure identical to that of the hypothalamic RNA that encodes the vasopressin prepropeptide, but is present at such low levels that it can only be detected by the polymerase chain reaction. Other vasopressin-like RNAs are derived from differential splicing events that join transcribed sequences between 3 and 9 kilobases upstream of the hypothalamic transcription start site to exons corresponding to II and III of the hypothalamic-type RNA. Here we describe the sequence of a testis-specific promoter and the exon structure of its transcription unit. We show that an in vitro synthesized RNA corresponding to the longer testicular vasopressin gene-derived transcript is not able to act as a template for protein synthesis in two different cell-free lysates. As attempts to localize the vasopressin-gene derived RNAs to particular cell types in the testis by in situ hybridization have consistently failed, we have used indirect methods. Three different procedures were used to effect germ cell depletion in adult male rats. Acute heat treatment of the testis, chronic ingestion of hydroxyurea, and chronic vitamin A deficiency all reduced the level of the aberrant testicular vasopressin-gene derived RNAs, indicating that their expression is closely associated with the integrity of germ cells and ongoing spermatogenesis.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,NEUROPEPTIDE LAB,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Carter, David/A-4479-2010; Murphy, David/C-3967-2012	Carter, David/0000-0002-8419-3975; Murphy, David/0000-0003-2946-0353				ADASHI EY, 1981, NATURE, V293, P650, DOI 10.1038/293650a0; ADASHI EY, 1981, ENDOCRINOLOGY, V109, P1793, DOI 10.1210/endo-109-5-1793; ADASHI EY, 1981, J BIOL CHEM, V257, P1301; AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AHLUWALIA B, 1971, J NUTR, V100, P715; ANG HL, 1991, ENDOCRINOLOGY, V128, P2110, DOI 10.1210/endo-128-4-2110; APPLING DR, 1981, ENDOCRINOLOGY, V108, P2120, DOI 10.1210/endo-108-6-2120; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; COLLINS P, 1969, PROC R SOC SER B-BIO, V172, P17, DOI 10.1098/rspb.1969.0009; COMB M, 1982, NATURE, V295, P663, DOI 10.1038/295663a0; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; FOO NC, 1991, ENDOCRINOLOGY, V128, P2118, DOI 10.1210/endo-128-4-2118; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUANG HFS, 1979, BIOL REPROD, V21, P891, DOI 10.1095/biolreprod21.4.891; HUANG HFS, 1983, ENDOCRINOLOGY, V112, P1163, DOI 10.1210/endo-112-4-1163; HUGGENVIK JI, 1987, ENDOCRINOLOGY, V120, P332, DOI 10.1210/endo-120-1-332; IVELL R, 1992, MOL CELL ENDOCRINOL, V89, P59, DOI 10.1016/0303-7207(92)90211-N; IVELL R, 1986, EMBO J, V5, P971, DOI 10.1002/j.1460-2075.1986.tb04311.x; IVELL R, 1992, INT J ANDROL, V15, P85, DOI 10.1111/j.1365-2605.1992.tb01117.x; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JEANNOTTE L, 1987, MOL ENDOCRINOL, V1, P749, DOI 10.1210/mend-1-10-749; KASSON BG, 1986, ENDOCRINOLOGY, V118, P23, DOI 10.1210/endo-118-1-23; KASSON BG, 1986, ENDOCR REV, V7, P156, DOI 10.1210/edrv-7-2-156; KASSON BG, 1985, J BIOL CHEM, V260, P5302; KATZ A, 1988, J BIOL CHEM, V263, P7604; KEIME S, 1990, EUR J BIOCHEM, V190, P200; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; LACAZEMASMONTEIL T, 1987, P NATL ACAD SCI USA, V84, P7261, DOI 10.1073/pnas.84.20.7261; LEFEBVRE DL, 1991, MOL ENDOCRINOL, V5, P645, DOI 10.1210/mend-5-5-645; MECKLENBURG RS, 1975, ENDOCRINOLOGY, V96, P564, DOI 10.1210/endo-96-3-564; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MORALES CR, 1989, MOL ENDOCRINOL, V3, P725, DOI 10.1210/mend-3-4-725; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; REEVES WB, 1992, WILLIAMS TXB ENDOCRI, P311; RENAUD LP, 1991, PROG NEUROBIOL, V36, P131, DOI 10.1016/0301-0082(91)90020-2; RICH KA, 1977, ENDOCRINOLOGY, V101, P959, DOI 10.1210/endo-101-3-959; RICHTER D, 1988, AM J PHYSIOL, V255, pF207, DOI 10.1152/ajprenal.1988.255.2.F207; Sambrook J, 1989, MOL CLONING LABORATO; SHARPE RM, 1987, J ENDOCRINOL, V113, P89, DOI 10.1677/joe.0.1130089; STALLARD BJ, 1990, MOL ENDOCRINOL, V4, P393, DOI 10.1210/mend-4-3-393; STALLARD BJ, 1991, MOL CELL BIOL, V11, P1448, DOI 10.1128/MCB.11.3.1448; STRUHL K, 1990, CURENT PROTOCOLS MOL, V2; TAHRIJOUTEI A, 1988, J REPROD FERTIL, V82, P247, DOI 10.1530/jrf.0.0820247; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; TREIZENBERG SJ, 1990, CURRENT PROTOCOLS MO, V1; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WIDMARK A, 1991, INT J ANDROL, V14, P58, DOI 10.1111/j.1365-2605.1991.tb01063.x; WILLIAMS TDM, 1985, ENDOCRINOLOGY, V116, P738, DOI 10.1210/endo-116-2-738; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; YOUNG WS, 1992, J NEUROENDOCRINOL, V4, P527, DOI 10.1111/j.1365-2826.1992.tb00201.x; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9	58	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					659	667						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506260				2022-12-25	WOS:A1994MR21900104
J	ODA, Y; KUO, MD; HUANG, SS; HUANG, JS				ODA, Y; KUO, MD; HUANG, SS; HUANG, JS			THE MAJOR ACIDIC FIBROBLAST GROWTH-FACTOR (AFGF)-STIMULATED PHOSPHOPROTEIN FROM BOVINE LIVER PLASMA-MEMBRANES HAS AFGF-STIMULATED KINASE, AUTOADENYLYLATION, AND ALKALINE NUCLEOTIDE PHOSPHODIESTERASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; GLYCOPROTEIN PC-1; HUMAN-PLATELETS; THREONINE; PEPTIDE; IDENTIFICATION; ADENYLYLATION; PURIFICATION; SEQUENCE; ANTIGEN	The major acidic fibroblast growth factor (aFGF)-stimulated phosphoprotein (MAFP) purified from bovine liver exhibits kinase, autoadenylylation, and alkaline nucleotide phosphodiesterase activities depending upon reaction conditions. In the presence of divalent ions, MAFP showed intrinsic and aFGF-stimulated kinase activities (autophosphorylation) using either [gamma-P-32]ATP or [gamma-P-32]GTP as a substrate. The autophosphorylation activity of MAFP was stimulated at low concentrations of Ca2+, Mg2+, or Mn2+ (0.2-2 muM). Depletion of the divalent ions by EDTA abolished the autophosphorylation activity but enhanced the autoadenylylation activity of MAFP. [Alpha-P-32]ATP as well as [alpha-P-32]NAD could serve as substrates for autoadenylylation activity of MAFP. aFGF appeared to enhance the autoadenylylation activity of MAFP with an optimal concentration (0.6-1.2 nM). P1,P3-di(adenosine-5')-triphosphate (AP3A) was found to be a potent inhibitor for the autophosphorylation and autoadenylylation activities of MAFP. Analyses by automated Edman degradation of the adenylylated and phosphorylated peptides derived from autoadenylylated and autophosphorylated MAFP revealed that both autoadenylylation and autophosphorylation occurred at residue Thr204. The kinase and autoadenylylation activities of MAFP had an optimal pH of 6.9-7.4. However, at pH 8.9, MAFP showed intrinsic and aFGF-stimulated phosphodiesterase activities. aFGF appeared to stimulate the phosphodiesterase activity of MAFP without altering the K(m) (approximately 0.2 mM) of its substrate.	ST LOUIS UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 1402 S GRAND BLVD, ST LOUIS, MO 63104 USA	Saint Louis University					NCI NIH HHS [CA 38808] Funding Source: Medline; NHLBI NIH HHS [HL 41782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CODINI M, 1992, BIOCHEM INT, V28, P989; CULP JS, 1985, J BIOL CHEM, V260, P8320; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EVANS WH, 1973, BIOCHEM J, V135, P819, DOI 10.1042/bj1350819; FLODGAARD H, 1982, BIOCHEM J, V208, P737, DOI 10.1042/bj2080737; HARTMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1136, P189, DOI 10.1016/0167-4889(92)90256-B; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUANG JS, 1982, J BIOL CHEM, V257, P8130; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JOSE ES, 1990, J BIOL CHEM, V265, P20653; KUO MD, 1990, J BIOL CHEM, V265, P16455; LUTHJE J, 1983, BIOCHEM BIOPH RES CO, V115, P253, DOI 10.1016/0006-291X(83)90997-X; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MARUYAMA E, 1993, BIOCHEM MOL BIOL INT, V29, P579; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; ODA Y, 1991, J BIOL CHEM, V266, P16791; PIROTTON S, 1992, BIOCHEM J, V285, P585, DOI 10.1042/bj2850585; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; SKUBITZ KM, 1991, BIOCHEM BIOPH RES CO, V174, P49, DOI 10.1016/0006-291X(91)90483-N; TAKAHASHI T, 1970, J EXP MED, V131, P1325, DOI 10.1084/jem.131.6.1325; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X	28	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27318	27326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7505270				2022-12-25	WOS:A1993MM26200070
J	SCHMIDT, J; BUBUNENKO, M; SUBRAMANIAN, AR				SCHMIDT, J; BUBUNENKO, M; SUBRAMANIAN, AR			A NOVEL OPERON ORGANIZATION INVOLVING THE GENES FOR CHORISMATE SYNTHASE (AROMATIC BIOSYNTHESIS PATHWAY) AND RIBOSOMAL GTPASE CENTER PROTEINS (L11, L1, L10, L12-RPLKAJL) IN CYANOBACTERIUM SYNECHOCYSTIS PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYDALIS-SEMPERVIRENS PERS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; EQUIVALENT; PURIFICATION; CLUSTER; CHLOROPLASTS; PRECURSOR	Many of the ribosomal protein (RP) genes in both bacterial and chloroplast genomes occur, for reasons not yet understood, in operons that include nonribosomal genes. Here we report such an operon organization in a cyanobacterium (Synechocystis PCC6803) involving the genes for four RPs that are important in the GTPase function of the ribosome and the aroC gene encoding chorismate synthase, a key enzyme in the shikimate pathway for biosynthesis of aromatic amino acids and cell wall components. The Synechocystis aroC encodes a 362-amino-acid residue protein which is 52, 60, and 68% identical to two eubacterial (both 52%), yeast, and a higher plant (Corydalis) chorismate synthase, respectively. The gene was overexpressed in Escherichia coli, and the gene product was shown to cross-react with antibodies to Corydalis chorismate synthase; it also complemented an aroC-lacking E. coli strain. The Synechocystis rpl1 and rpl11 genes encode polypeptides of 237 and 141 amino acid residues, respectively, also with high sequence identities to the corresponding RP sequences from other eubacteria and higher plant chloroplasts. The gene order is shown to be: rpl11-86bp spacer-rpl1-460bp spacer-rpl10-87-bp spacer-rpl12-206bp spacer-aroC. Southern and Northern blot analyses of Synechocystis DNA and RNA, respectively, revealed a single cluster of these genes per genome which is transcribed from a common promoter to an unusually long, approximately 9500-nucleotide transcript. Several constructs of the cyanobacterial aroC and rpl12 genes were made and expressed in E. coli to examine the mechanisms for their very differential expression from a polycistronic mRNA (e.g. four copies L12/ribosome; chorismate synthase, a non-abundant protein). These results present the first biochemical/molecular genetic evidence of shikimate pathway in the cyanobacterial group.	MAX PLANCK INST MOLEC GENET,IHNESTR 73,D-14195 BERLIN,GERMANY	Max Planck Society								ALLEN MM, 1968, J GEN MICROBIOL, V51, P199, DOI 10.1099/00221287-51-2-199; ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; ARNDT E, 1990, NUCLEIC ACIDS RES, V18, P1285, DOI 10.1093/nar/18.5.1285; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BAIER G, 1990, NUCLEIC ACIDS RES, V18, P719, DOI 10.1093/nar/18.4.719; BARTSCH M, 1982, P NATL ACAD SCI-BIOL, V79, P6871, DOI 10.1073/pnas.79.22.6871; BAUGHMAN G, 1984, P NATL ACAD SCI-BIOL, V81, P5389, DOI 10.1073/pnas.81.17.5389; BRAUER D, 1978, FEBS LETT, V96, P317, DOI 10.1016/0014-5793(78)80426-8; CHARLES IG, 1990, J GEN MICROBIOL, V136, P353, DOI 10.1099/00221287-136-2-353; CHRISTENSEN T, 1984, EMBO J, V3, P1609, DOI 10.1002/j.1460-2075.1984.tb02018.x; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DAVIS BD, 1992, ANNU REV MICROBIOL, V46, P1; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; DOGNIN MJ, 1980, EUR J BIOCHEM, V84, P342; DOUGLAS SE, 1984, NUCLEIC ACIDS RES, V12, P3373, DOI 10.1093/nar/12.7.3373; DOWNING WL, 1987, J MOL BIOL, V194, P609, DOI 10.1016/0022-2836(87)90238-5; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; HARDY SJS, 1975, MOL GEN GENET, V140, P253, DOI 10.1007/BF00334270; HASAN N, 1978, J BIOL CHEM, V251, P4993; HEIN J, 1989, MOL BIOL EVOL, V6, P649; JONES DGL, 1991, MOL MICROBIOL, V5, P2143, DOI 10.1111/j.1365-2958.1991.tb02144.x; KIMURA M, 1985, EUR J BIOCHEM, V150, P491, DOI 10.1111/j.1432-1033.1985.tb09049.x; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KROGER M, 1991, NUCLEIC ACIDS RES, V19, P2023, DOI 10.1093/nar/19.suppl.2023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI D, 1992, J BIOL CHEM, V267, P22787; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MOUSDALE DM, 1986, FEBS LETT, V205, P328, DOI 10.1016/0014-5793(86)80922-X; PITTARD AJ, 1987, ESCHERICHIA COLI SAL, P368; PUCCIARELLI MG, 1990, NUCLEIC ACIDS RES, V18, P4409, DOI 10.1093/nar/18.15.4409; Sambrook J, 1989, MOL CLONING LABORATO; SANDER G, 1983, J BIOL CHEM, V258, P98; SCHALLER A, 1991, J BIOL CHEM, V266, P21434; SCHALLER A, 1990, ARCH BIOCHEM BIOPHYS, V282, P437, DOI 10.1016/0003-9861(90)90141-K; SCHMIDT J, 1993, NUCLEIC ACIDS RES, V21, P2519, DOI 10.1093/nar/21.10.2519; SHIMMIN LC, 1989, EMBO J, V8, P1225, DOI 10.1002/j.1460-2075.1989.tb03496.x; SIBOLD C, 1990, BIOCHIM BIOPHYS ACTA, V1050, P61, DOI 10.1016/0167-4781(90)90142-O; SMOOKER PM, 1991, BIOCHIMIE, V73, P845, DOI 10.1016/0300-9084(91)90064-8; SOR F, 1987, MOL GEN GENET, V180, P52; STARK M, 1979, J MOL BIOL, V134, P767, DOI 10.1016/0022-2836(79)90485-6; SUBRAMANIAN AR, 1980, EUR J BIOCHEM, V112, P425, DOI 10.1111/j.1432-1033.1980.tb07222.x; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; SUBRAMANIAN AR, 1991, TRANSLATIONAL APPARA, P95; WADA KN, 1992, NUCLEIC ACIDS RES, V20, P2111, DOI 10.1093/nar/20.suppl.2111; WHITE PJ, 1988, BIOCHEM J, V251, P313, DOI 10.1042/bj2510313; WILSON EO, 1989, BIODIVERSITY, P3; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; XIE WQ, 1991, ARCH BIOCHEM BIOPHYS, V284, P22, DOI 10.1016/0003-9861(91)90256-I	51	19	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27447	27457						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7505271				2022-12-25	WOS:A1993MM26200086
J	HILBICH, C; MONNING, U; GRUND, C; MASTERS, CL; BEYREUTHER, K				HILBICH, C; MONNING, U; GRUND, C; MASTERS, CL; BEYREUTHER, K			AMYLOID-LIKE PROPERTIES OF PEPTIDES FLANKING THE EPITOPE OF AMYLOID PRECURSOR PROTEIN-SPECIFIC MONOCLONAL ANTIBODY-22C11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CONGO RED; BETA-A4 PEPTIDES; CONFORMATION; IDENTIFICATION; BINDING	Alzheimer's disease is one of the prevalent forms of human dementia. Its pathology is distinguished by proteinaceous deposits (''amyloid'') in the brain. They contain a peptide (betaA4) that is proteolytically derived from a larger transmembrane protein. To follow the different metabolic pathways of this Amyloid Precursor Protein (APP) may thus lead to the elucidation of the molecular basis of Alzheimer's disease. Specific antibodies are necessary tools for this task. Using synthetic peptides, we have characterized the epitope of the APP-specific monoclonal antibody 22C11; it is localized between residues 66 and 81 of APP. Some of the peptides flanking this site exhibited properties generally associated with amyloid, i.e. low solubility, filament formation, and birefringence after Congo Red staining. Exploiting differences in the peptides' aggregational properties, we present evidence that the two dyes Eosin and Direct Red 254, in conjunction with classical amyloid staining by Congo Red, can be used to characterize aggregating, amyloid-like peptides in vitro.	GERMAN CANC RES CTR,DEPT CELL BIOL,D-69120 HEIDELBERG,GERMANY; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	Helmholtz Association; German Cancer Research Center (DKFZ); University of Melbourne	HILBICH, C (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; CAPUTO CB, 1992, ARCH BIOCHEM BIOPHYS, V292, P199, DOI 10.1016/0003-9861(92)90068-8; CASTANO EM, 1988, LAB INVEST, V58, P122; COOPER JH, 1974, LAB INVEST, V31, P232; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1972, J HISTOCHEM CYTOCHEM, V20, P821, DOI 10.1177/20.10.821; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HILBICH C, 1991, EUR J BIOCHEM, V201, P61, DOI 10.1111/j.1432-1033.1991.tb16256.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARD J, 1967, J AM CHEM SOC, V89, P181, DOI 10.1021/ja00977a057; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNELL WG, 1992, J MOL BIOL, V227, P1205, DOI 10.1016/0022-2836(92)90532-O; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	24	132	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26571	26577						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7504673				2022-12-25	WOS:A1993MK42500081
J	KONISHI, K; FUJIOKA, M				KONISHI, K; FUJIOKA, M			RAT-LIVER GLYCINE METHYLTRANSFERASE - COOPERATIVE BINDING OF S-ADENOSYLMETHIONINE AND LOSS OF COOPERATIVITY BY REMOVAL OF A SHORT NH2-TERMINAL SEGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											KONISHI, K (corresponding author), TOYAMA MED & PHARMACEUT UNIV,FAC MED,DEPT BIOCHEM,SUGITANI,TOYAMA 93001,JAPAN.							FERDINAND W, 1966, BIOCHEM J, V98, P278, DOI 10.1042/bj0980278; FINKELSTEIN JD, 1986, J BIOL CHEM, V261, P1582; FRIEDEN C, 1967, J BIOL CHEM, V242, P4045; FUJIOKA M, 1986, J BIOL CHEM, V261, P6346; FUJIOKA M, 1987, BIOCHEMISTRY-US, V26, P5696, DOI 10.1021/bi00392a018; FUJIOKA M, 1981, J BIOL CHEM, V256, P1631; GOMI T, 1986, J BIOL CHEM, V261, P3422; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; KONISHI K, 1987, BIOCHEMISTRY-US, V26, P8496, DOI 10.1021/bi00399a069; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMOTO C, 1984, J BIOCHEM-TOKYO, V95, P287, DOI 10.1093/oxfordjournals.jbchem.a134596; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Neet K E, 1980, Methods Enzymol, V64, P139; NICHOL LW, 1967, BIOCHEMISTRY-US, V6, P2449, DOI 10.1021/bi00860a022; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; OGAWA H, 1982, J BIOL CHEM, V257, P3447; OGAWA H, 1982, BIOCHEM BIOPH RES CO, V108, P227, DOI 10.1016/0006-291X(82)91855-1; RABIN BR, 1967, BIOCHEM J, V102, pC22, DOI 10.1042/bj1020022C; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; THORNTON JM, 1983, J MOL BIOL, V167, P443, DOI 10.1016/S0022-2836(83)80344-1; WITTWER AJ, 1981, J BIOL CHEM, V256, P4109	23	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13381	13385						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417662				2022-12-25	WOS:A1988Q091700091
J	STECK, TL; KEZDY, FJ; LANGE, Y				STECK, TL; KEZDY, FJ; LANGE, Y			AN ACTIVATION-COLLISION MECHANISM FOR CHOLESTEROL TRANSFER BETWEEN MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									RUSH MED COLL,DEPT PATHOL,CHICAGO,IL 60612; RUSH MED COLL,DEPT BIOCHEM,CHICAGO,IL 60612	Rush University; Rush University	STECK, TL (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.		Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032466, R55HL028448, P50HL015062, R01HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 15062, HL 28448, HL 32466] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; ANIANSSON GEA, 1978, J PHYS CHEM-US, V82, P2805, DOI 10.1021/j100515a011; BACKER JM, 1981, BIOCHEMISTRY-US, V20, P3805, DOI 10.1021/bi00516a021; BAR LK, 1986, BIOCHEMISTRY-US, V25, P6701, DOI 10.1021/bi00369a056; BJORNSON LK, 1975, J LIPID RES, V16, P39; BOJESEN E, 1982, NATURE, V299, P276, DOI 10.1038/299276a0; BRUCKDORFER KR, 1984, BIOCHIM BIOPHYS ACTA, V769, P187, DOI 10.1016/0005-2736(84)90022-1; CHILD P, 1985, BIOCHIM BIOPHYS ACTA, V814, P237, DOI 10.1016/0005-2736(85)90441-9; DAINTY JACK, 1963, ADVAN BOT RES, V1, P279, DOI 10.1016/S0065-2296(08)60183-4; DAWIDOWICZ EA, 1987, CURR TOP MEMBR TRANS, V29, P175; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DEMPSEY ME, 1984, CURR TOP CELL REGUL, V24, P63; DHOLLANDER F, 1972, BIOCHIM BIOPHYS ACTA, V260, P110, DOI 10.1016/0005-2760(72)90080-X; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; DUCKWITZPETERLEIN G, 1978, BIOPHYS STRUCT MECH, V4, P315, DOI 10.1007/BF00537614; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; FUGLER L, 1985, J BIOL CHEM, V260, P4098; GIRAUD F, 1979, FEBS LETT, V103, P186, DOI 10.1016/0014-5793(79)81278-8; GOTTLIEB MH, 1980, BIOCHIM BIOPHYS ACTA, V600, P530, DOI 10.1016/0005-2736(80)90454-X; JONAS A, 1979, BIOCHEMISTRY-US, V18, P1722, DOI 10.1021/bi00576a014; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KREMER JMH, 1977, BIOCHIM BIOPHYS ACTA, V471, P177, DOI 10.1016/0005-2736(77)90248-6; LANGE Y, 1983, J BIOL CHEM, V258, P6920; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1981, J BIOL CHEM, V256, P5321; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1977, BIOCHEMISTRY-US, V16, P4339, DOI 10.1021/bi00639a002; LANGE Y, 1982, FED PROC, V41, P1280; LANGE Y, 1979, BIOCHIM BIOPHYS ACTA, V556, P388, DOI 10.1016/0005-2736(79)90127-5; LIEBER MR, 1982, J BIOL CHEM, V257, P1651; LIEBER MR, 1982, J BIOL CHEM, V257, P1660; LIEBER MR, 1984, J BIOL CHEM, V259, P9225; LUNDKATZ S, 1982, BIOCHEMISTRY-US, V21, P2964, DOI 10.1021/bi00541a025; MARTIN FJ, 1976, BIOCHEMISTRY-US, V15, P321, DOI 10.1021/bi00647a013; MASSEY JB, 1982, J BIOL CHEM, V257, P5444; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V794, P274, DOI 10.1016/0005-2760(84)90156-5; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MCLEAN LR, 1984, BIOCHEMISTRY-US, V23, P4624, DOI 10.1021/bi00315a017; MCLEAN LR, 1982, BIOCHEMISTRY-US, V21, P4053, DOI 10.1021/bi00260a022; MILLS JT, 1984, P NATL ACAD SCI-BIOL, V81, P1385, DOI 10.1073/pnas.81.5.1385; MOORE WJ, 1962, PHYSICAL CHEM, P278; MUTSCH B, 1986, BIOCHEMISTRY-US, V25, P2134; NAKAGAWA Y, 1979, BIOCHIM BIOPHYS ACTA, V553, P307, DOI 10.1016/0005-2736(79)90234-7; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; NICHOLS JW, 1983, J BIOL CHEM, V258, P5368; NICHOLS JW, 1985, BIOCHEMISTRY-US, V24, P6390, DOI 10.1021/bi00344a011; NICHOLS JW, 1981, BIOCHEMISTRY-US, V20, P2783, DOI 10.1021/bi00513a012; NICHOLS JW, 1987, BIOPHYS J, V51, P530; OWEN JS, 1984, TRENDS BIOCHEM SCI, V9, P238, DOI 10.1016/0968-0004(84)90076-8; PAPERMASTER D, 1984, BIOCHEMISTRY, V13, P2438; PETRIE GE, 1984, BIOCHEMISTRY-US, V23, P720, DOI 10.1021/bi00299a021; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; POWNALL HJ, 1982, BIOCHIM BIOPHYS ACTA, V712, P169, DOI 10.1016/0005-2760(82)90099-6; POWNALL HJ, 1983, J AM CHEM SOC, V105, P2440, DOI 10.1021/ja00346a055; POZNANSKY MJ, 1982, BIOCHIM BIOPHYS ACTA, V685, P182, DOI 10.1016/0005-2736(82)90096-7; POZNANSKY MJ, 1979, BIOCHEM J, V177, P989, DOI 10.1042/bj1770989; ROBERTSON DL, 1985, BIOCHEM J, V232, P553, DOI 10.1042/bj2320553; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; SLOTTE JP, 1983, BIOCHIM BIOPHYS ACTA, V750, P434, DOI 10.1016/0005-2760(83)90182-0; SOMERHARJU P, 1981, BIOCHIM BIOPHYS ACTA, V649, P521, DOI 10.1016/0005-2736(81)90155-3; Steck T. L., 1974, METHODS MEMBRANE BIO, V2, P245; TANFORD C, 1980, HYDROPHOBIC EFFECT; THILO L, 1977, BIOCHIM BIOPHYS ACTA, V469, P326, DOI 10.1016/0005-2736(77)90168-7; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WHARTON SA, 1982, BIOCHIM BIOPHYS ACTA, V711, P398, DOI 10.1016/0005-2760(82)90053-4; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5	74	87	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13023	13031						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417649				2022-12-25	WOS:A1988Q091700042
J	VALE, MGP				VALE, MGP			AFFINITY LABELING OF CALMODULIN-BINDING PROTEINS IN SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											VALE, MGP (corresponding author), UNIV COIMBRA,CTR CELL BIOL,DEPT ZOOL,P-3409 COIMBRA,PORTUGAL.							AGRE P, 1983, J BIOL CHEM, V258, P6258; ALFACE J S, 1982, Ciencia Biologica, V7, P115; ANDREASEN TJ, 1981, P NATL ACAD SCI-BIOL, V78, P2782, DOI 10.1073/pnas.78.5.2782; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1391; CAMPBELL KP, 1982, J BIOL CHEM, V257, P1238; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CAMPBELL KP, 1986, SARCOPLASMIC RETICUL, V1, P65; CARAFOLI E, 1981, CELL CALCIUM, V2, P353, DOI 10.1016/0143-4160(81)90025-7; CHIESI M, 1982, J BIOL CHEM, V257, P984; CHIESI M, 1983, BIOCHEMISTRY-US, V22, P985, DOI 10.1021/bi00273a043; DACOSTA AG, 1986, ARCH BIOCHEM BIOPHYS, V249, P199, DOI 10.1016/0003-9861(86)90575-8; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; GEORGOUSSI Z, 1986, BIOCHEM PHARMACOL, V35, P4571, DOI 10.1016/0006-2952(86)90780-X; GRUBBS RD, 1984, J BIOL CHEM, V259, P2184; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HASSELBACH W, 1964, PROG BIOPHYS MOL BIO, V14, P167, DOI 10.1016/S0079-6107(64)80006-7; HO MM, 1983, BIOCHIM BIOPHYS ACTA, V730, P64, DOI 10.1016/0005-2736(83)90317-6; KIM DH, 1986, J BIOL CHEM, V261, P1674; KIRCHBERGER MA, 1982, J BIOL CHEM, V257, P5685; KRISTENSEN BI, 1986, BIOCHIM BIOPHYS ACTA, V862, P457, DOI 10.1016/0005-2736(86)90251-8; KRISTENSEN BI, 1982, MOL PHYSIOL, V2, P99; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; LOPASCHUK G, 1980, BIOCHEMISTRY-US, V19, P5603, DOI 10.1021/bi00565a022; LOUIS CF, 1982, ARCH BIOCHEM BIOPHYS, V218, P109, DOI 10.1016/0003-9861(82)90326-5; LOUIS CF, 1985, EUR J BIOCHEM, V150, P271, DOI 10.1111/j.1432-1033.1985.tb09017.x; LOUIS CF, 1987, CELL CALCIUM, V8, P43, DOI 10.1016/0143-4160(87)90035-2; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; NAKAGAWA M, 1986, J CYCLIC NUCL PROT, V11, P237; PLANK B, 1983, BIOCHIM BIOPHYS ACTA, V732, P99, DOI 10.1016/0005-2736(83)90191-8; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SEILER S, 1984, J BIOL CHEM, V259, P8550; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TSAI MD, 1987, BIOCHEMISTRY-US, V26, P3635, DOI 10.1021/bi00386a057; TUANA BS, 1984, J BIOL CHEM, V259, P6979; VALE MGP, 1975, BIOCHIM BIOPHYS ACTA, V413, P202, DOI 10.1016/0005-2736(75)90104-2; VALE MGP, 1985, BIOCHEM PHARMACOL, V34, P4245, DOI 10.1016/0006-2952(85)90279-5; VALE MGP, 1986, CIENC BIOL COIMBRA, V11, P149; VANDERMEERS A, 1978, BIOCHEM BIOPH RES CO, V84, P1076, DOI 10.1016/0006-291X(78)91693-5; VOLPE P, 1987, ARCH BIOCHEM BIOPHYS, V253, P138, DOI 10.1016/0003-9861(87)90646-1; VOLPE P, 1984, ARCH BIOCHEM BIOPHYS, V233, P174, DOI 10.1016/0003-9861(84)90614-3; WATRAS J, 1985, BIOCHIM BIOPHYS ACTA, V812, P333, DOI 10.1016/0005-2736(85)90307-4; Williams R. J. P., 1980, CALCIUM BINDING PROT, P3	48	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12872	12877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417639				2022-12-25	WOS:A1988Q091700018
J	SILVER, G; KRAUTER, KS				SILVER, G; KRAUTER, KS			EXPRESSION OF CYTOCHROME-P-450C AND CYTOCHROME-P-450D MESSENGER-RNAS IN CULTURED RAT HEPATOCYTES - 3-METHYLCHOLANTHRENE INDUCTION IS REGULATED PRIMARILY AT THE POST-TRANSCRIPTIONAL LEVEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											SILVER, G (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461, USA.				NCI NIH HHS [CA31855, CA39553] Funding Source: Medline; NIEHS NIH HHS [ES05405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039553, P01CA031855] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DURRIN LK, 1987, MOL CELL BIOL, V7, P3008, DOI 10.1128/MCB.7.8.3008; ENAT R, 1984, P NATL ACAD SCI-BIOL, V81, P1411, DOI 10.1073/pnas.81.5.1411; FOLDES RL, 1985, ARCH BIOCHEM BIOPHYS, V239, P137, DOI 10.1016/0003-9861(85)90820-3; FREY AB, 1984, J CELL PHYSIOL, V120, P169, DOI 10.1002/jcp.1041200210; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GOLDSTEIN JA, 1984, MOL PHARMACOL, V25, P185; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; IKEDA T, 1983, EUR J BIOCHEM, V134, P13, DOI 10.1111/j.1432-1033.1983.tb07524.x; JAISWAL AK, 1985, BIOCHEM PHARMACOL, V34, P2721, DOI 10.1016/0006-2952(85)90573-8; JEFFERSON DM, 1984, MOL CELL BIOL, V4, P1929, DOI 10.1128/MCB.4.9.1929; JONES PBC, 1986, J BIOL CHEM, V261, P6647; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KIMURA S, 1984, J BIOL CHEM, V259, P705; KIMURA S, 1987, Journal of Experimental Pathology (New York), V3, P61; KIMURA S, 1984, NUCLEIC ACIDS RES, V12, P2917, DOI 10.1093/nar/12.6.2917; KRAUTER KS, 1986, DNA-J MOLEC CELL BIO, V5, P29, DOI 10.1089/dna.1986.5.29; LOOSE DS, 1986, P NATL ACAD SCI USA, V83, P5184, DOI 10.1073/pnas.83.14.5184; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORVILLE AL, 1983, J BIOL CHEM, V258, P3901; MURDOCH GH, 1982, NATURE, V300, P192, DOI 10.1038/300192a0; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1979, CRC CR REV BIOCH MOL, V6, P401, DOI 10.3109/10409237909105427; OKEY AB, 1979, J BIOL CHEM, V254, P1636; POWELL DJ, 1984, J MOL BIOL, V179, P21, DOI 10.1016/0022-2836(84)90304-8; ROBINSON JR, 1974, J BIOL CHEM, V249, P5851; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; STEWARD AR, 1985, ARCH BIOCHEM BIOPHYS, V241, P494, DOI 10.1016/0003-9861(85)90575-2; TUTEJA N, 1985, DEV BIOL, V112, P177, DOI 10.1016/0012-1606(85)90131-9; WHITLOCK JP, 1984, J BIOL CHEM, V259, P980; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; WILSON MC, 1981, J MOL BIOL, V148, P231, DOI 10.1016/0022-2836(81)90537-4; YABUSAKI Y, 1984, NUCLEIC ACIDS RES, V12, P2929, DOI 10.1093/nar/12.6.2929	43	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					11802	11807						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403555				2022-12-25	WOS:A1988P765000033
J	THEERASILP, S; KURIHARA, Y				THEERASILP, S; KURIHARA, Y			COMPLETE PURIFICATION AND CHARACTERIZATION OF THE TASTE-MODIFYING PROTEIN, MIRACULIN, FROM MIRACLE FRUIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									YOKOHAMA NATL UNIV,FAC EDUC,DEPT CHEM,YOKOHAMA,KANAGAWA 240,JAPAN	Yokohama National University								BROUWER JN, 1968, NATURE, V220, P373, DOI 10.1038/220373a0; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GIROUX EL, 1974, J AGR FOOD CHEM, V22, P594, DOI DOI 10.1021/JF60194A033; HENRIKSON RL, 1984, ANAL BIOCHEM, V136, P65; KURIHARA K, 1969, NATURE, V222, P1176, DOI 10.1038/2221176a0; KURIHARA K, 1968, SCIENCE, V161, P1241, DOI 10.1126/science.161.3847.1241; Kurihara K, 1969, OLFACTION TASTE, P450; KURIHARA Y, 1982, BIOCHIM BIOPHYS ACTA, V719, P444, DOI 10.1016/0304-4165(82)90232-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIKAMI H, 1983, BUNSEKI KAGAKU, V32, pE207; SCHOLZE H, 1985, J CHROMATOGR, V350, P453, DOI 10.1016/S0021-9673(01)93551-4; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7	13	103	110	3	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1988	263	23					11536	11539						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P6713	3403544				2022-12-25	WOS:A1988P671300084
J	GUBITS, RM; FAIRHURST, JL				GUBITS, RM; FAIRHURST, JL			C-FOS MESSENGER-RNA LEVELS ARE INCREASED BY THE CELLULAR STRESSORS, HEAT-SHOCK AND SODIUM ARSENITE	ONCOGENE			English	Article									NATHAN S KLINE INST,DIV MOLEC BIOL,ORANGEBURG,NY 10962	Nathan Kline Institute for Psychiatric Research					NIGMS NIH HHS [GM38202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; BARKA T, 1986, MOL CELL BIOL, V6, P2984, DOI 10.1128/MCB.6.8.2984; BARKA T, 1987, ONCOGENE, V1, P297; BESTERMAN JM, 1985, J BIOL CHEM, V260, P1155; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; DAVIS RJ, 1985, J BIOL CHEM, V260, P2543; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GUBITS RM, 1986, ENDOCRINOLOGY, V119, P1382, DOI 10.1210/endo-119-3-1382; GUBITS RM, 1984, J BIOL CHEM, V259, P2803; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HIGHTOWER LE, 1981, J CELL PHYSIOL, V108, P261, DOI 10.1002/jcp.1041080216; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; HUNT SP, 1987, NATURE, V328, P631; INGOLIA TD, 1980, CELL, V21, P669, DOI 10.1016/0092-8674(80)90430-4; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LI GC, 1985, CHANGES EUKARYOTIC G, P227; LIN CY, 1984, PLANT PHYSIOL, V74, P152, DOI 10.1104/pp.74.1.152; LOWE DG, 1986, J BIOL CHEM, V261, P2102; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; PELHAM H, 1985, TRENDS GENET, V1, P31, DOI 10.1016/0168-9525(85)90012-5; RENAN MJ, 1986, BIOSCIENCE REP, V6, P819, DOI 10.1007/BF01117105; RENAN MJ, 1985, BIOSCIENCE REP, V5, P739, DOI 10.1007/BF01119872; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; SCHLESINGER MJ, 1985, CHANGES EUKARYOTIC G, P183; SIMCOX AA, 1985, MOL CELL BIOL, V5, P3397, DOI 10.1128/MCB.5.12.3397; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	52	75	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					163	168						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412774				2022-12-25	WOS:A1988Q053400006
J	KAWASAKI, T; SNYDER, F				KAWASAKI, T; SNYDER, F			SYNTHESIS OF A NOVEL ACETYLATED NEUTRAL LIPID RELATED TO PLATELET-ACTIVATING FACTOR BY ACYL-COA-1-0-ALKYL-2-ACETYL-SN-GLYCEROL ACYLTRANSFERASE IN HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									OAK RIDGE ASSOC UNIV,DIV MED & HLTH SCI,OAK RIDGE,TN 37831	Oak Ridge Associated Universities					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035495, R01HL027109] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35495-02, HL-27109-07] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALONSO F, 1982, J BIOL CHEM, V257, P3376; BELL RM, 1983, ENZYMES, V16, P106; BILLAH MM, 1986, J BIOL CHEM, V261, P5824; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CAMUSSI G, 1982, BLOOD, V59, P16; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; LEE TC, 1986, J BIOL CHEM, V261, P5373; LEE TC, 1988, J BIOL CHEM, P1755; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAVIS RD, 1972, J BIOL CHEM, V256, P175; RECORD M, 1986, FASEB J, V45, P1529; RENOOIJ W, 1981, BIOCHIM BIOPHYS ACTA, V663, P545, DOI 10.1016/0005-2760(81)90182-X; SNYDER F, 1986, PHARMACOL RES, V18, P33, DOI 10.1016/0031-6989(86)90036-6; SNYDER F, 1966, LIPIDS, V1, P381, DOI 10.1007/BF02532540; SNYDER F, 1966, SEPARATION SCI, V1, P709; SNYDER F, 1987, PLATELET ACTIVATING; SPINKS NR, 1987, LANCET, V1, P106; Vargaftig B B, 1981, Ann N Y Acad Sci, V370, P119, DOI 10.1111/j.1749-6632.1981.tb29727.x; WOOD R, 1967, J LIPID RES, V8, P494; WOODARD DS, 1987, J BIOL CHEM, V262, P2520; [No title captured]	23	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1988	263	6					2593	2596						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M2161	3422635				2022-12-25	WOS:A1988M216100005
J	PING, DS; MOUNIER, CE; MAY, SW				PING, DS; MOUNIER, CE; MAY, SW			REACTION VERSUS SUBSITE STEREOSPECIFICITY OF PEPTIDYLGLYCINE ALPHA-MONOOXYGENASE AND PEPTIDYLAMIDOGLYCOLATE LYASE, THE 2 ENZYMES INVOLVED IN PEPTIDE AMIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTASE PREPHENATE DEHYDROGENASE; GLYCINE-EXTENDED PEPTIDES; ESCHERICHIA-COLI; MESSENGER-RNA; OXIDATION PROTEIN; XENOPUS-LAEVIS; PITUITARY; MECHANISM; CLONING; DOMAIN	Carboxyl-terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymatic action by peptidylglycine alpha-monooxygenase (PARS, EC 1.14.17.3) and peptidylamidoglycolate lyase (PGL, EC 4.3.2.5). The monooxygenase, PARS, first catalyzes conversion of a glycine-extended pro-peptide to the corresponding alpha-hydroxyglycine derivative, and the lyase, PGL, then catalyzes breakdown of this alpha-hydroxyglycine derivative to the amidated peptide plus glyoxylate. We have previously established that PAM and PGL exhibit tandem reaction stereospecificities, with PARS producing, and PGL being reactive toward, only alpha-hydroxyglycine derivatives of absolute configuration (S). We now demonstrate that PARS and PGL exhibit dramatically different subsite stereospecificities toward the residue at the penultimate position (the P-2 residue) in both substrates and inhibitors. Incubation of Ac-L-Phe Gly, Ac-L-Phe-L-Phe-Gly, or (S)-O-Ac-mandelyl-Gly with PAM results in complete conversion of these substrates to the corresponding alpha-hydroxylated products, whereas the corresponding X-D-Phe-Gly compounds undergo conversions of < 1%. The K-I of Ac-D-Phe-Gly is at least 700-fold higher than that of Ac-L-Phe-Gly, and the same pattern holds for other substrate stereoisomers. This S-2 subsite stereospecificity of PAM also holds for competitive inhibitors; thus, the K-I; of 45 mu M for Ac-L-Phe-OCH2CO2H increases to 2,247 mu M for the -D-Phe- enantiomer. In contrast, incubation of PGL with Ac-L-Phe-alpha-hydroxy-Gly, Ac-D-Phe-alpha-hydroxy-Gly, (S)-O-Ac-mandelyl-alpha-hydroxy-Gly, or (R)-O-Ac-mandelyl-alpha-hydroxy-Gly results in facile enzymatic conversion of each of these compounds to their corresponding amide products. The simultaneous expression of high reaction stereospecificity and low S-2 subsite stereospecificity in the course of PGL catalysis was illustrated by a series of experiments in which enzymatic conversion of the diastereomers of Ac-L-Phe-alpha-hydroxy-Gly and Ac-o-Phe-alpha-hydroxy-Gly was monitored directly by RPLC. Kinetic parameters were determined for both substrates and potent competitive inhibitors of PGL, and the results confirm that, in sharp contrast to PAM, the configuration of the chiral moiety at the P-2 position has virtually no effect on binding or catalysis. These results illustrate a case where catalytic domains, which must function sequentially (and with tandem reaction stereochemistry) in a given metabolic process, nevertheless exhibit sharply contrasting subsite stereospecificities toward the binding of substrates and inhibitors.	GEORGIA INST TECHNOL,SCH CHEM & BIOCHEM,ATLANTA,GA 30332	University System of Georgia; Georgia Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040540] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40540] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT PA, 1988, J ORG CHEM, V53, P3195, DOI 10.1021/jo00249a013; BEAUDRY GA, 1989, BIOCHEM BIOPH RES CO, V163, P959, DOI 10.1016/0006-291X(89)92315-2; BERTELSEN AH, 1990, ARCH BIOCHEM BIOPHYS, V279, P87, DOI 10.1016/0003-9861(90)90466-C; BILLICH A, 1987, BIOCHEMISTRY-US, V26, P8417, DOI 10.1021/bi00399a058; BISSWANGER H, 1980, MULTIFUNCTIONAL PROT; BRADBURY AF, 1983, BIOCHEM BIOPH RES CO, V112, P372, DOI 10.1016/0006-291X(83)91473-0; BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; FLOYD EE, 1985, J BIOL CHEM, V260, P9443; HEATHCOCK CH, 1987, ORG SYNTH, V66, P132; HENDRICK.JB, 1970, TETRAHEDRON LETT, P343; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; IWASAKI Y, 1991, EUR J BIOCHEM, V201, P551, DOI 10.1111/j.1432-1033.1991.tb16314.x; KATO I, 1990, FEBS LETT, V269, P319, DOI 10.1016/0014-5793(90)81184-P; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; KATOPODIS AG, 1988, BIOCHEM BIOPH RES CO, V151, P499, DOI 10.1016/0006-291X(88)90621-3; KIRSCHNER K, 1976, ANNU REV BIOCHEM, V45, P143, DOI 10.1146/annurev.bi.45.070176.001043; LI CZ, 1994, BIOCHEM J, V300, P31, DOI 10.1042/bj3000031; MERKLER DJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P594, DOI 10.1016/0003-9861(92)90730-K; MERKLER DJ, 1991, ARCH BIOCHEM BIOPHYS, V289, P192, DOI 10.1016/0003-9861(91)90461-Q; MIZUNO K, 1987, BIOCHEM BIOPH RES CO, V148, P546, DOI 10.1016/0006-291X(87)90911-9; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; PING DS, 1992, J AM CHEM SOC, V114, P3998, DOI 10.1021/ja00036a071; RAO CG, 1980, ORG PREP PROCED INT, V12, P225, DOI 10.1080/00304948009458553; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SKIADOPOULOS MH, 1993, VIROLOGY, V194, P509, DOI 10.1006/viro.1993.1289; STELAKATOS GC, 1966, J CHEM SOC C, P1191, DOI 10.1039/j39660001191; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; SUZUKI K, 1990, EMBO J, V9, P4259, DOI 10.1002/j.1460-2075.1990.tb07874.x; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TURNBULL J, 1990, BIOCHEMISTRY-US, V29, P10245, DOI 10.1021/bi00496a014; TURNBULL J, 1990, BIOCHEMISTRY-US, V29, P10255, DOI 10.1021/bi00496a015; VENKATARAMAN K, 1979, TETRAHEDRON LETT, P3037, DOI 10.1016/S0040-4039(00)71006-9; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023; ZOLLER U, 1975, TETRAHEDRON, V31, P863, DOI 10.1016/0040-4020(75)80092-5	43	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29250	29255		10.1074/jbc.270.49.29250	http://dx.doi.org/10.1074/jbc.270.49.29250			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493955	hybrid			2022-12-25	WOS:A1995TJ22700036
J	DIVITA, G; BAILLON, JG; RITTINGER, K; CHERMANN, JC; GOODY, RS				DIVITA, G; BAILLON, JG; RITTINGER, K; CHERMANN, JC; GOODY, RS			INTERFACE PEPTIDES AS STRUCTURE-BASED HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS RIBONUCLEOTIDE REDUCTASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SUBUNIT BINDING; HIV-1; DIMERIZATION; HETERODIMER; RESISTANCE; EXPRESSION	Reverse transcriptases from both human immunodeficiency viruses type 1 and 2 are obligatory dimers. A tryptophan-rich repeat motif that is highly conserved between these proteins, as well as in the reverse transcriptase from simian immunodeficiency virus, has been postulated to be involved in hydrophobic subunit interactions. A synthetic 19-mer peptide covering part of this tryptophan repeat motif was recently shown to inhibit human immunodeficiency viruses type 1 reverse transcriptase subunit dimerization (Divita, G., Restle, T., Goody, R. S., Chermann, J.-C., and Baillon, J. G. (1994) J. Biol. Chem. 269, 13080-13083). In the present study, we show that the same peptide can also inhibit human immunodeficiency virus type 2 reverse transcriptase subunit dimerization, suggesting that the same inhibitors might be used as agents against both viruses as well as against variants of human immunodeficiency virus type 1 that differ from the variant against which they were developed. Under appropriate experimental conditions, e.g. at acidic pH, this peptide is also able to induce the dissociation of the enzyme from human immunodeficiency virus type 1.	MAX PLANCK INST MOLEK PHYSIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, BIOPHYS ABT, D-69120 HEIDELBERG, GERMANY; INSERM, U322, F-13273 MARSEILLE 09, FRANCE	Max Planck Society; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm)			DIVITA, GILLES/AAV-9214-2021; Rittinger, Katrin/D-2586-2014; Rittinger, Katrin/N-3344-2019; Goody, Roger S/J-8845-2014	Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Goody, Roger S/0000-0002-0772-0444				BAILLON JG, 1991, NEW BIOL, V3, P1015; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA A, 1986, FEBS LETT, V200, P327, DOI 10.1016/0014-5793(86)81162-0; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DEVICO AL, 1989, AIDS RES HUM RETROV, V5, P51, DOI 10.1089/aid.1989.5.51; DIVITA G, 1993, FEBS LETT, V324, P153, DOI 10.1016/0014-5793(93)81383-B; DIVITA G, 1994, J BIOL CHEM, V269, P13080; DIVITA G, 1995, J MOL BIOL, V245, P508, DOI 10.1006/jmbi.1994.0042; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LIUZZI M, 1994, NATURE, V372, P695, DOI 10.1038/372695a0; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, J BIOL CHEM, V266, P14709; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	30	29	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28642	28646		10.1074/jbc.270.48.28642	http://dx.doi.org/10.1074/jbc.270.48.28642			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499382	hybrid			2022-12-25	WOS:A1995TH05600026
J	ICHIMURA, T; UCHIYAMA, J; KUNIHIRO, O; ITO, M; HORIGOME, T; OMATA, S; SHINKAI, F; KAJI, H; ISOBE, T				ICHIMURA, T; UCHIYAMA, J; KUNIHIRO, O; ITO, M; HORIGOME, T; OMATA, S; SHINKAI, F; KAJI, H; ISOBE, T			IDENTIFICATION OF THE SITE OF INTERACTION OF THE 14-3-3-PROTEIN WITH PHOSPHORYLATED TRYPTOPHAN-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE-DEPENDENT ACTIVATOR; TYROSINE	The 14-3-3 protein family plays a role in a wide variety of cell signaling processes including monoamine synthesis, exocytosis, and cell cycle regulation, but the structural requirements for the activity of this protein family are not known, We have previously shown that the 14-3-3 protein binds with and activates phosphorylated tryptophan hydroxylase (TPH, the rate-limiting enzyme in the biosynthesis of neurotransmitter serotonin) and proposed that this activity might be mediated through the COOH-terminal acidic region of the 14-3-3 molecules. In this report we demonstrate, using a series of truncation mutants of the 14-3-3 eta isoform expressed in Escherichia coli, that the COOH-terminal region, especially restricted in amino acids 171-213, binds indeed with the phosphorylated TPH. This restricted region, which we termed 14-3-3 box I, is one of the structural regions whose sequence is highly conserved beyond species, allowing that the plant 14-3-3 isoform (GF14) could also activate rat brain TPH. The 14-3-3 box I is the first functional region whose activity has directly been defined in the 14-3-3 sequence and may represent a common structural element whereby 14-3-3 interacts with other target proteins such as Raf-1 kinase, The result is consistent with the recently published crystal structure of this protein family, which suggests the importance of the negatively charged groove like structure in the ligand binding.	TOKYO METROPOLITAN UNIV, FAC SCI, DEPT CHEM, HACHIOJI 19203, TOKYO, JAPAN	Tokyo Metropolitan University	ICHIMURA, T (corresponding author), NIIGATA UNIV, FAC SCI, DEPT BIOCHEM, 2-IGARASHI, NIIGATA 95021, JAPAN.		Shinkai-ouchi, Fumiko/E-3207-2010; Isobe, Toshiaki/Q-9279-2017; Kaji, Hiroyuki/L-7122-2018	Shinkai-ouchi, Fumiko/0000-0002-0095-941X; Kaji, Hiroyuki/0000-0002-0910-9999				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LU GH, 1994, PLANT MOL BIOL, V25, P659, DOI 10.1007/BF00029604; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Sambrook J, 1989, MOL CLONING LABORATO; TANJI M, 1994, J NEUROCHEM, V63, P1908; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404	17	76	77	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28515	28518		10.1074/jbc.270.48.28515	http://dx.doi.org/10.1074/jbc.270.48.28515			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499362	hybrid			2022-12-25	WOS:A1995TH05600006
J	PITTMAN, N; SHUE, GL; LELEIKO, NS; WALSH, MJ				PITTMAN, N; SHUE, GL; LELEIKO, NS; WALSH, MJ			TRANSCRIPTION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR REQUIRES A CCAAT-LIKE ELEMENT FOR BOTH BASAL AND CAMP-MEDIATED REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ENHANCER BINDING-PROTEIN; EPITHELIAL-CELLS; GENE-EXPRESSION; DOWN-REGULATION; LEUCINE ZIPPER; RESPONSE ELEMENT; PROMOTER REGION; C/EBP ISOFORMS; PHORBOL ESTER	The cystic fibrosis transmembrane conductance regulator (CFTR) gene in man is controlled by a tightly regulated and weak promoter. The architecture of the CFTR promoter suggests regulatory characteristics that are consistent with the absence of a TATA-like sequence, including the ability to initiate RNA transcription at numerous positions. Detailed investigation of the most proximal region of the human CFTR gene promoter through deletion and mutational analysis reveals that expression is contingent on the conservation of the inverted CCAAT sequence. Basal expression of CFTR transcription and cAMP-mediated transcriptional regulation require the presence of an imperfect and inverted CCAAT element recognized as 5'-AATTGGAAGCAAAT-3', located between 132 and 119 nucleotides upstream of the translational start site. RNA isolated from a transfected pancreatic cell line carrying integrated wild-type and mutant CFTR-directed transgenes was used to map the 5' termini of the transgenic transcripts. Analysis of the transcript termini by ribonuclease protection analysis reflects the direct association of the conserved inverted CCAAT sequence in promoting transcript initiation. Because of the requirement for the inverted CCAAT sequence for promoting transcription of CFTR, the involvement of CCAAT-binding factors is suspected in the regulation of CFTR gene transcription. To test this, we used electrophoretic mobility shift assays to demonstrate that the majority of the binding to the inverted CCAAT element, between -135 and -116, was easily competed for by binding to cognate nucleotide sequences for CCAAT-enhancer binding protein (C/EBP). An antibody specific for the C/EBP-related protein, C/EBP delta, detected C/EBP delta as part of a nuclear protein complex bound to the inverted CCAAT sequence of the CFTR gene. Also, the detection of specific activating transcription factor/cyclic-AMP response element binding protein antigens by antibody supershift analysis of nuclear complexes suggest that species of this family of transcription factors could be involved in the formation of complexes with C/EBP delta within the CFTR gene inverted CCAAT-like element. These studies raise the possibility of interactions between individual members of the C/EBP and activating transcription factor/cyclic-AMP response element binding protein families potentially contribute to the tight transcriptional control rendered by the CFTR gene promoter.	CUNY MT SINAI SCH MED,DEPT PEDIAT,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			LeLeiko, Neal/GRJ-6855-2022	leleiko, neal/0000-0001-7699-1400				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BARGON J, 1992, J BIOL CHEM, V267, P16056; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; BREUER W, 1993, J BIOL CHEM, V268, P13935; BREUER W, 1992, J BIOL CHEM, V267, P10465; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHENKIANG S, 1993, CURR OPIN IMMUNOL, V5, P124, DOI 10.1016/0952-7915(93)90091-6; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOU JL, 1991, J BIOL CHEM, V266, P24471; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DIEHL AM, 1994, HEPATOLOGY, V19, P447; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P7863; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KINANE TB, 1992, J BIOL CHEM, V268, P24669; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOH J, 1993, J BIOL CHEM, V268, P15912; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1989, SCIENCE, V243, P681; LEVINE A, 1992, P NATL ACAD SCI USA, V89, P10119, DOI 10.1073/pnas.89.21.10119; LUND J, 1990, J BIOL CHEM, V265, P3304; MCKNIGHT S, 1987, CELL, V46, P795; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1986, P NATL ACAD SCI USA, V86, P56; MURO AF, 1992, J BIOL CHEM, V267, P12767; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARK EA, 1992, J BIOL CHEM, V268, P613; PARK K, 1993, J BIOL CHEM, V268, P17811; PITTMAN N, 1994, PEDIATR RES, V35, pA904; QUITON PM, 1990, FASEB J, V4, P2709; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIERRA F, 1990, LABORATORY GUIDE IN, P30; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SOOD R, 1992, EMBO J, V11, P2487, DOI 10.1002/j.1460-2075.1992.tb05313.x; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VELLEJO M, 1994, TRANSCRIPTION MECHAN, P353; VINSON CR, 1988, SCIENCE, V246, P911; WALSH MJ, 1992, J BIOL CHEM, V267, P7026; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	60	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28848	28857		10.1074/jbc.270.48.28848	http://dx.doi.org/10.1074/jbc.270.48.28848			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499410	hybrid			2022-12-25	WOS:A1995TH05600054
J	SHAW, P; KNEZ, J; CAPONE, JP				SHAW, P; KNEZ, J; CAPONE, JP			AMINO-ACID SUBSTITUTIONS IN THE HERPES-SIMPLEX VIRUS TRANSACTIVATOR VP16 UNCOUPLE DIRECT PROTEIN-PROTEIN INTERACTION AND DNA-BINDING FROM COMPLEX ASSEMBLY AND TRANSACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-ACTIVATOR; HOMEO DOMAIN; TRANSCRIPTION COMPLEX; MUTATIONAL ANALYSIS; REGULATORY PROTEIN; CELLULAR PROTEINS; POSITIVE CONTROL; GENE-EXPRESSION; FACTOR VMW65; OCT-1	The herpes simplex virus transactivator VP16 directs the assembly of a multicomponent protein-DNA complex that requires the participation of two cellular factors, the POU homeodomain protein Oct-1, which binds independently to response elements, and VCAF-1 (VP16 complex assembly factor; also called HCF, C1), a factor that binds directly to VP16. A number of distinct properties of VP16 have been implicated in the assembly of the VP16-induced complex (VIC). These include its independent association with VCAF-1 and, under appropriate conditions, its ability to bind to DNA or to DNA-bound Oct-1 in the absence of VCAF-1, In order to probe the requirements of these individual interactions in the functional asembly of VIC, we mutated selected charged amino acids in two subdomains of VP16 previously shown to be important in protein-DNA complex formation, Purified VP16 proteins were analyzed for their ability to direct protein-DNA complex formation and to interact directly with VCAF-1. Several classes of mutants that were differentially compromised in VCAF-1 interaction, direct DNA binding, and/or association with DNA-bound Oct-1 were obtained. Interestingly, all of the derivatives were still capable of generating the VIC complex in vitro and activating transcription in vivo, Our findings indicate that the cooperative assembly of functional VP16-containing complexes can occur by pathways that do not necessarily require the prior interaction of VP16 with VCAF-1 or the ability of VP16 to bind directly to DNA or associate with DNA-bound Oct-1.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University								ACE CI, 1988, J GEN VIROL, V69, P2595, DOI 10.1099/0022-1317-69-10-2595; APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; DOUVILLE P, 1995, VIROLOGY, V207, P107, DOI 10.1006/viro.1995.1056; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GREAVES R, 1989, J VIROL, V63, P1642; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HAYES S, 1993, J VIROL, V67, P852, DOI 10.1128/JVI.67.2.852-862.1993; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POPOVA B, 1995, VIROLOGY, V209, P19, DOI 10.1006/viro.1995.1227; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; ROIZMAN B, 1991, HERPESVIRUS TRANSCRI, P17; SMIBERT CA, 1994, J VIROL, V68, P2239; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; WERSTUCK G, 1989, GENE, V75, P213, DOI 10.1016/0378-1119(89)90267-9; WERSTUCK G, 1993, THESIS MCMASTER U ON; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WU TJ, 1994, MOL CELL BIOL, V14, P3484, DOI 10.1128/MCB.14.5.3484; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974	43	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29030	29037		10.1074/jbc.270.48.29030	http://dx.doi.org/10.1074/jbc.270.48.29030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499437	hybrid			2022-12-25	WOS:A1995TH05600081
J	GARWICZ, D; LINDMARK, A; GULLBERG, U				GARWICZ, D; LINDMARK, A; GULLBERG, U			HUMAN CATHEPSIN-G LACKING FUNCTIONAL GLYCOSYLATION SITE IS PROTEOLYTICALLY PROCESSED AND TARGETED FOR STORAGE IN GRANULES AFTER TRANSFECTION TO THE RAT BASOPHILIC/MAST CELL-LINE RBL OR THE MURINE MYELOID CELL-LINE 32D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL ELASTASE; DIPEPTIDYL PEPTIDASE-I; SERINE PROTEASE; MAST-CELL; MEMBRANE ASSOCIATION; LYSOSOMAL-ENZYMES; PROGENITOR-CELL; PROCATHEPSIN-L; HEPG2 CELLS; ACTIVATION	The neutral protease cathepsin G belongs to a family of hematopoietic serine proteases stored in the azurophil granules of the neutrophil granulocyte. To investigate the function of asparagine-linked carbohydrates in neutrophil serine proteases, we constructed a mutant cDNA, coding for human cathepsin G deficient of a functional glycosylation site, for use in a transgenic cellular model. Wild type and mutant cDNA were stably expressed in the rat basophilic/mast cell line RBL and in the murine myeloblast-like cell line 32D. Biosynthetic labeling, followed by immunoprecipitation, SDS-polyacrylamide gel electrophoresis, and fluorography, showed that carbohydrate-deficient cathepsin G was synthesized as a 29-kDa preform in both cell lines. The preform was proteolytically processed into a stable form with an apparent molecular mass of 27.5 kDa, indicating removal of the carboxyl-terminal prodomain. The mutant cathepsin G was enzymatically activated as determined by acquisition of affinity to aprotinin, a serine protease inhibitor. As for wild type cathepsin G, small amounts of the unprocessed form of the mutated enzyme were released from the cells, while the major part was transferred to a granular compartment as demonstrated by subcellular fractionation. Thus, neither processing leading to enzymatic activation nor granular sorting was obviously affected by the lack of oligosaccharides on the mutant cathepsin G. Our results therefore indicate that glycosylation is not essential for these processes. In addition to the previously utilized cell line RBL, we propose the 32D cell line as a suitable cellular model for transgenic expression of human neutrophil serine proteases.	LUND UNIV, DEPT MED, DIV HEMATOL, LUND, SWEDEN	Lund University								BAINTON DF, 1992, INFLAMMATION BASIC P, P303; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; BROWN GR, 1993, J IMMUNOL, V150, P4733; BURGE V, 1991, BIOCHEM J, V275, P797, DOI 10.1042/bj2750797; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; CAUGHEY GH, 1994, AM J RESP CRIT CARE, V150, pS138, DOI 10.1164/ajrccm/150.6_Pt_2.S138; ELBEIN AD, 1991, TRENDS BIOTECHNOL, V9, P346, DOI 10.1016/0167-7799(91)90117-Z; ELSBACH P, 1992, INFLAMMATION BASIC P; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GRACE ME, 1990, BIOCHEM BIOPH RES CO, V168, P771, DOI 10.1016/0006-291X(90)92388-G; GRASSEL S, 1992, BIOCHEM BIOPH RES CO, V182, P276, DOI 10.1016/S0006-291X(05)80141-X; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; KIDO H, 1986, J IMMUNOL, V136, P1061; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LEHRER RI, 1990, BLOOD, V76, P2169; LINDMARK A, 1990, BLOOD, V76, P2374; LIU L, 1995, BLOOD, V85, P1095, DOI 10.1182/blood.V85.4.1095.bloodjournal8541095; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; POHL J, 1990, FEBS LETT, V272, P200, DOI 10.1016/0014-5793(90)80484-Z; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; SHIVER JW, 1991, CELL, V64, P1175, DOI 10.1016/0092-8674(91)90272-Z; URATA H, 1993, J BIOL CHEM, V268, P24318; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VERNET T, 1990, J BIOL CHEM, V265, P16661; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; WATOREK W, 1993, BIOL CHEM H-S, V374, P385, DOI 10.1515/bchm3.1993.374.1-6.385	48	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28413	28418						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499346				2022-12-25	WOS:A1995TG21000071
J	LEE, Y; MELEKHOVETS, YF; NAZAR, RN				LEE, Y; MELEKHOVETS, YF; NAZAR, RN			TERMINATION AS A FACTOR IN QUALITY-CONTROL DURING RIBOSOME BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA STABILITY; SACCHAROMYCES-CEREVISIAE; 5S RNA; TRANSCRIPTION TERMINATION; YEAST; DROSOPHILA; PRECURSOR; MATURATION	In eukaryotes, nascent rDNA and 5 S rRNA gene transcripts undergo 3'-end processing after termination. Mutations in which terminator sequences in these ribosomal RNA genes are deleted completely result in highly unstable transcripts, which are not properly processed and integrated into stable ribosome structure. Mutations that retard RNA processing by extending the 3' external transcribed spacer or by introducing additional secondary structure in the spacers have a similar effect on stable transcript integration. The results indicate that proper termination coupled with efficient rRNA processing acts as a ''quality control'' process, which helps to ensure that only normal rRNA precursors are effectively processed and assembled into active ribosomes.			LEE, Y (corresponding author), UNIV GUELPH, DEPT MOLEC BIOL & GENET, GUELPH, ON N1G 2W1, CANADA.							ABOUELELA S, 1995, BBA-GENE STRUCT EXPR, V1262, P164, DOI 10.1016/0167-4781(95)00074-Q; ABOUELELA S, 1994, NUCLEIC ACIDS RES, V22, P668; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HAMADA H, 1979, CELL, V17, P163, DOI 10.1016/0092-8674(79)90304-0; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; JACQ B, 1977, J MOL BIOL, V117, P785, DOI 10.1016/0022-2836(77)90069-9; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; KUHN A, 1988, EMBO J, V7, P1497, DOI 10.1002/j.1460-2075.1988.tb02968.x; LABHART P, 1990, GENE DEV, V4, P269, DOI 10.1101/gad.4.2.269; LEE Y, 1995, NUCLEIC ACIDS RES, V23, P634, DOI 10.1093/nar/23.4.634; LOSSON R, 1983, CELL, V32, P371, DOI 10.1016/0092-8674(83)90456-7; MELEKHOVETS YF, 1994, J MOL BIOL, V239, P170, DOI 10.1006/jmbi.1994.1361; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; NAZAR RN, 1982, CELL NUCLEUS, V11, P1; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RUBIN GM, 1975, CELL, V6, P207, DOI 10.1016/0092-8674(75)90011-2; VANDERSANDE CAFM, 1989, NUCLEIC ACIDS RES, V17, P9127, DOI 10.1093/nar/17.22.9127; VANRYK DI, 1990, J BIOL CHEM, V265, P8377; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008	24	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28003	28005						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499281				2022-12-25	WOS:A1995TG21000006
J	FAVOT, P; YUE, X; HUME, DA				FAVOT, P; YUE, X; HUME, DA			REGULATION OF THE C-FMS PROMOTER IN MURINE TUMOR-CELL LINES	ONCOGENE			English	Article						MACROPHAGE; C-FMS; TRANSCRIPTION; CSF-1; TUMOR PROGRESSION	COLONY-STIMULATING FACTOR; MACROPHAGE GROWTH-FACTOR; CSF RECEPTOR EXPRESSION; FACTOR-I RECEPTOR; PLASMINOGEN-ACTIVATOR; CARCINOMAS INVIVO; PROTO-ONCOGENE; BONE-MARROW; MOUSE; GENE	Macrophage colony-stimulating factor (CSF-1) mRNA was detected in a wide range of murine tumour cell lines. Stable transfection with a CSF-1 receptor (c-fms) expression plasmid increased the number and size of colonies formed in soft agar by tumour cell lines that were already clonogenic, but did not induce transformation in non-clonogenic lines. To identify mechanisms that might lead to ectopic expression of c-fms, the regulation of the exon 2 promoter of the gene, which flanks the transcription start sites in macrophages, was examined. In transient and stable transfections this promoter was as active in non-macrophage tumour cell lines as it was in RAW264 macrophages. Promoter activity in non-macrophage lines was serum-dependent and was activated further in lines stably transfected with c-fms. Cis-acting elements required for serum-dependent activity lay outside the 300 bp proximal promoter that was sufficient for maximal activity in RAW264 macrophages, but the c-fms-responsive elements were retained in the proximal promoter. Exon 2 promoter activity was selectively suppressed in non-macrophage fines inclusion of intron 2, which has been implicated transcription attenuation. Lewis lung carcinoma cells were able to partly bypass this block and expressed c-fms mRNA when grown in limiting serum. The finding that c-fms promoter activity and c-fms mRNA levels are responsive to growth factor signalling pathways provides an insight into mechanisms that may lead to ectopic c-fms expression in tumour cells.	UNIV QUEENSLAND, CTR CELLULAR & MOLEC BIOL, ST LUCIA, QLD 4072, AUSTRALIA	University of Queensland			Hume, David A/C-7695-2013	Hume, David/0000-0002-2615-1478				AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BAIOCCHI G, 1991, CANCER, V67, P990, DOI 10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO;2-8; BAUKNECHT T, 1994, CANCER DETECT PREV, V18, P231; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BERTRAM JS, 1980, CANCER LETT, V11, P63, DOI 10.1016/0304-3835(80)90130-5; BRUCKNER A, 1992, CANCER RES, V52, P3043; BURTHEM J, 1994, BLOOD, V83, P1381, DOI 10.1182/blood.V83.5.1381.bloodjournal8351381; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; EVANS R, 1990, BIOTECHNIQUES, V8, P357; FILDERMAN AE, 1992, CANCER RES, V52, P3661; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANKS LM, 1978, J PATHOL, V124, P35, DOI 10.1002/path.1711240108; GLINIAK BC, 1992, MOL BIOL CELL, V3, P535, DOI 10.1091/mbc.3.5.535; HUME DA, 1983, J CELL PHYSIOL, V117, P189, DOI 10.1002/jcp.1041170209; JIN DI, 1995, MOL CELL BIOL, V15, P693; KACINSKI BM, 1990, INT J RADIAT ONCOL, V19, P619, DOI 10.1016/0360-3016(90)90488-6; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KAUMA SW, 1991, J CLIN ENDOCR METAB, V73, P746, DOI 10.1210/jcem-73-4-746; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEISEROWITZ GS, 1993, GYNECOL ONCOL, V49, P190, DOI 10.1006/gyno.1993.1106; PAIETTA E, 1990, CANCER RES, V50, P2049; PATEK PQ, 1978, NATURE, V276, P510, DOI 10.1038/276510a0; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROBERTS WM, 1992, BLOOD, V79, P586; ROSS IL, 1994, ONCOGENE, V9, P121; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SARIBAN E, 1989, BLOOD, V74, P123; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHERR CJ, 1990, BLOOD, V75, P1; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STORGA D, 1992, INT J EXP PATHOL, V73, P527; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TILL KJ, 1993, BRIT J HAEMATOL, V83, P223, DOI 10.1111/j.1365-2141.1993.tb08276.x; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	54	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1371	1381						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478559				2022-12-25	WOS:A1995RY96700019
J	KACZMAREK, E; MCDONAGH, J				KACZMAREK, E; MCDONAGH, J			THROMBIN BINDING TO THE A-ALPHA-CHAINS, B-BETA-CHAINS, AND GAMMA-CHAINS OF FIBRINOGEN AND TO THEIR REMNANTS CONTAINED IN FRAGMENT-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									BETH ISRAEL HOSP,DEPT PATHOL,330 BROOKLINE AVE,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; CHARLES A DANA RES INST,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER LJ, 1977, BIOCHEMISTRY-US, V16, P4622, DOI 10.1021/bi00640a015; BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038; BETTELHEIM FR, 1956, BIOCHIM BIOPHYS ACTA, V19, P121, DOI 10.1016/0006-3002(56)90393-6; BETTELHEIM FR, 1952, BIOCHIM BIOPHYS ACTA, V9, P578, DOI 10.1016/0006-3002(52)90213-8; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BLOMBACK B, 1977, CHEM BIOL THROMBIN, P275; DOOLITTLE RF, 1976, FED PROC, V35, P2145; DOOLITTLE RF, 1983, ANN NY ACAD SCI, V408, P13, DOI 10.1111/j.1749-6632.1983.tb23231.x; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; DOOLITTLE RF, 1979, CHEM PHYSL HUMAN PLA, P77; FURIE B, 1982, J BIOL CHEM, V257, P3875; GERSHONI JM, 1982, ANAL BIOCHEM, V124, P396, DOI 10.1016/0003-2697(82)90056-2; GRIFFITH MJ, 1979, J BIOL CHEM, V254, P3401; HAGEMAN TC, 1977, ARCH BIOCHEM BIOPHYS, V179, P506, DOI 10.1016/0003-9861(77)90139-4; HAGEMAN TC, 1974, ARCH BIOCHEM BIOPHYS, V164, P707, DOI 10.1016/0003-9861(74)90083-6; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN A, 1980, PROTIDES BIOL FLUIDS, V28, P47; KACZMAREK E, 1987, BIOCHIM BIOPHYS ACTA, V914, P275, DOI 10.1016/0167-4838(87)90286-X; KAMINSKI M, 1983, J BIOL CHEM, V258, P530; KAMINSKI M, 1987, BIOCHEM J, V242, P881, DOI 10.1042/bj2420881; KAYE NMC, 1978, MOL CELL BIOCHEM, V20, P173, DOI 10.1007/BF00243764; KLOCZEWIAK M, 1987, BIOCHEMISTRY-US, V26, P6152, DOI 10.1021/bi00393a031; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEM RKH, 1973, ARCH BIOCHEM BIOPHYS, V158, P387, DOI 10.1016/0003-9861(73)90635-8; LIEM RKH, 1974, ARCH BIOCHEM BIOPHYS, V160, P333, DOI 10.1016/S0003-9861(74)80041-X; LIEM RKH, 1971, ARCH BIOCHEM BIOPHYS, V147, P201, DOI 10.1016/0003-9861(71)90328-6; Liu C Y, 1981, Ann N Y Acad Sci, V370, P545, DOI 10.1111/j.1749-6632.1981.tb29762.x; LIU CY, 1979, J BIOL CHEM, V254, P421; LORAND L, 1952, BIOCHIM BIOPHYS ACTA, V9, P581, DOI 10.1016/0006-3002(52)90215-1; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MARSH HC, 1985, BIOCHEMISTRY-US, V24, P2806, DOI 10.1021/bi00332a031; MARSH HC, 1982, BIOCHEMISTRY-US, V21, P6167, DOI 10.1021/bi00267a022; MARSH HC, 1983, BIOCHEMISTRY-US, V22, P4170, DOI 10.1021/bi00287a002; MARTINELLI RA, 1980, BIOCHEMISTRY-US, V19, P2343, DOI 10.1021/bi00552a010; MCDONAGH J, 1987, HEMOSTASIS THROMBOSI, P301; NAGY JA, 1985, BIOCHEMISTRY-US, V24, P882, DOI 10.1021/bi00325a011; NAGY JA, 1982, BIOCHEMISTRY-US, V21, P1794, DOI 10.1021/bi00537a015; OLEXA SA, 1981, BIOCHEMISTRY-US, V20, P6139, DOI 10.1021/bi00524a035; REBER P, 1985, THROMB HAEMOSTASIS, V54, P390; SAITO Y, 1983, ANN NY ACAD SCI, V408, P288, DOI 10.1111/j.1749-6632.1983.tb23252.x; SLADE CL, 1976, J BIOL CHEM, V251, P1591; STRONG DD, 1982, BIOCHEMISTRY-US, V21, P1414, DOI 10.1021/bi00535a048; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANNISPEN JW, 1977, ARCH BIOCHEM BIOPHYS, V182, P227, DOI 10.1016/0003-9861(77)90303-4	46	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13896	13900						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417681				2022-12-25	WOS:A1988Q159400068
J	KUCERA, GL; MILLER, C; SISSON, PJ; WILCOX, RW; WIEMER, Z; WAITE, M				KUCERA, GL; MILLER, C; SISSON, PJ; WILCOX, RW; WIEMER, Z; WAITE, M			HYDROLYSIS OF THIOESTER ANALOGS BY RAT-LIVER PHOSPHOLIPASE-A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27103; SALEM COLL,DEPT CHEM & NUTR,WINSTON SALEM,NC 27108	Wake Forest University; Wake Forest Baptist Medical Center					NCI NIH HHS [CA-12197] Funding Source: Medline; NHLBI NIH HHS [HL-31338] Funding Source: Medline; NIDDK NIH HHS [DK-11799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK011799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARSMAN AJ, 1976, BIOORG CHEM, V5, P241, DOI 10.1016/0045-2068(76)90033-X; AHESSON B, 1976, FEBS LETT, V71, P241; BAMBERGER M, 1983, J LIPID RES, V24, P869; BELCHER JD, 1985, BIOCHEM J, V229, P343, DOI 10.1042/bj2290343; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROCKERHOFF H, 1979, LIPIDS, V14, P88, DOI 10.1007/BF02533575; BUGAUT M, 1985, BIOCHIM BIOPHYS ACTA, V835, P304, DOI 10.1016/0005-2760(85)90286-3; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; COX JW, 1981, J LIPID RES, V22, P496; DEHAAS GH, 1971, BIOCHIM BIOPHYS ACTA, V239, P252, DOI 10.1016/0005-2760(71)90171-8; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Dixon M., 1979, ENZYMES, Vthird; FAROOQUI AA, 1984, J LIPID RES, V25, P1555; GLASER CB, 1970, J CHROMATOGR, V50, P151, DOI 10.1016/S0021-9673(00)97936-6; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; Hauser H., 1975, WATER COMPREHENSIVE, V4, P209; HENDRICKSON HS, 1983, J LIPID RES, V24, P1532; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; JANSEN H, 1980, BIOCHEM BIOPH RES CO, V92, P53, DOI 10.1016/0006-291X(80)91518-1; JENSEN GL, 1981, ANAL BIOCHEM, V113, P246, DOI 10.1016/0003-2697(81)90073-7; KREGER AS, 1987, INFECT IMMUN, V55, P3209, DOI 10.1128/IAI.55.12.3209-3212.1987; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; MILLER CH, 1981, BIOCHIM BIOPHYS ACTA, V665, P385, DOI 10.1016/0005-2760(81)90250-2; OFLAHERTY JT, 1984, BIOCHEM BIOPH RES CO, V123, P64, DOI 10.1016/0006-291X(84)90380-2; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROGOZINSKI M, 1964, J GAS CHROMATOGR, V2, P328, DOI 10.1093/chromsci/2.10.328; VANTOL A, 1980, BIOCHEM BIOPH RES CO, V94, P101, DOI 10.1016/S0006-291X(80)80193-8; WAITE M, 1967, BIOCHIM BIOPHYS ACTA, V137, P498, DOI 10.1016/0005-2760(67)90131-2; WAITE M, 1973, J BIOL CHEM, V248, P7985; WELLS MA, 1971, BIOCHIM BIOPHYS ACTA, V248, P80, DOI 10.1016/0005-2760(71)90077-4	31	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12964	12969						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417647				2022-12-25	WOS:A1988Q091700033
J	OPPLIGER, T; THONY, B; NAR, H; BURGISSER, D; HUBER, R; HEIZMANN, CW; BLAU, N				OPPLIGER, T; THONY, B; NAR, H; BURGISSER, D; HUBER, R; HEIZMANN, CW; BLAU, N			STRUCTURAL AND FUNCTIONAL CONSEQUENCES OF MUTATIONS IN 6-PYRUVOYLTETRAHYDROPTERIN SYNTHASE CAUSING HYPERPHENYLALANINEMIA IN HUMANS - PHOSPHORYLATION IS A REQUIREMENT FOR IN-VIVO ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE; CDNA CLONING; TETRAHYDROBIOPTERIN; EXPRESSION; BIOSYNTHESIS; PURIFICATION; DEFICIENCY	Four naturally occurring mutants with single amino acid alterations in human 6-pyruvoyltetrahydropterin synthase (PTPS) were overexpressed and characterized in vitro. The corresponding DNA mutations were found in patients with hyperphenylalaninemia and monoamine neurotransmitter insufficiency due to lack of the tetrahydrobiopterin biosynthetic enzyme PTPS. To predict the structure of the mutant enzymes, computer modeling was performed based on the solved three-dimensional structure of the homohexameric rat enzyme. One mutant (Delta V57) is incorrectly folded and thus unstable in vitro and in vivo, while a second mutant (P87L) has substantial activity but enhanced sensitivity to local unfolding. Two other mutants, R16C and R25Q, form stable homomultimers and exhibit significant activity in vitro but no activity in COS-1 cells, In vivo P-32 labeling showed that nild-type PTPS, P87L, and R25Q are phosphorylated, while R16C is not modified. This strongly suggests that the serine 19 within the consensus sequence for various kinases, RXXS, is the site of modification, Our results demonstrate that PTPS undergoes protein phosphorylation and requires additional, not yet identified post-translational modification(s) for its in vivo function.	UNIV ZURICH, DEPT PEDIAT, DIV CLIN CHEM, CH-8032 ZURICH, SWITZERLAND; MAX PLANCK INST BIOCHEM, STRUKT FORSCH ABT, D-82152 MARTINSRIED, GERMANY	University of Zurich; Max Planck Society				Blau, Nenad/0000-0003-4347-3230; Nar, Herbert/0000-0002-3878-6964				BALU N, 1995, J PEDIATR, V126, P401; Blau N., 1993, PTERIDINES, V4, P1; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BURGISSER DM, 1995, J MOL BIOL, V253, P358, DOI 10.1006/jmbi.1995.0558; BURGISSER DM, 1994, EUR J BIOCHEM, V219, P497, DOI 10.1111/j.1432-1033.1994.tb19964.x; DHONDT JL, 1984, J PEDIATR-US, V104, P501, DOI 10.1016/S0022-3476(84)80537-5; DUCH DS, 1991, J NUTR BIOCHEM, V2, P411, DOI 10.1016/0955-2863(91)90110-Q; HARLOW E, 1988, ANTIBODIES LABORATOR; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; IMAMURA T, 1994, PTERIDINES, V5, P31; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; INCHINOSE H, 1995, J BIOL CHEM, V270, P10062; INOUE Y, 1991, J BIOL CHEM, V266, P20791; JOHNES TA, 1990, CRYSTALLOGRAPHY MODE, P189; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KATOH S, 1994, FEBS LETT, V341, P227, DOI 10.1016/0014-5793(94)80462-1; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAR H, 1994, EMBO J, V13, P1255, DOI 10.1002/j.1460-2075.1994.tb06377.x; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OPPLIGER T, 1995, PTERIDINES, V6, P141; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SAMBOOK J, 1989, MOL CLONING LABORATO; Scriver C.R., 1995, METABOLIC MOL BASIS, V7th ed, P1015; SMOOKER PM, 1993, BIOCHEMISTRY-US, V32, P6443, DOI 10.1021/bi00076a018; TAKIKAWA SI, 1986, EUR J BIOCHEM, V161, P295, DOI 10.1111/j.1432-1033.1986.tb10446.x; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; THONY B, 1994, AM J HUM GENET, V54, P782; THONY B, 1992, BIOCHEM BIOPH RES CO, V189, P1437, DOI 10.1016/0006-291X(92)90235-D; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WRAY W, 1981, ANAL BIOCHEM, V72, P248; ZHU M, 1994, J BIOL CHEM, V269, P11325	33	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29498	29506		10.1074/jbc.270.49.29498	http://dx.doi.org/10.1074/jbc.270.49.29498			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493990	hybrid			2022-12-25	WOS:A1995TJ22700071
J	LEWIS, BA; ORKIN, SH				LEWIS, BA; ORKIN, SH			A FUNCTIONAL INITIATOR ELEMENT IN THE HUMAN BETA-GLOBIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA-LESS PROMOTER; TRANSCRIPTION INITIATION; ACCURATE TRANSCRIPTION; TFIID COMPLEX; BOX; THALASSEMIA; MUTATION; BINDING; DNA	Core promoters are defined by the presence of either a TATA box at approximately 30 base pairs upstream of the transcriptional start site (+1) and/or an initiator element centered around the +1 site. The prevalence, function, and significance of the various combinations of core promoter elements are as yet unclear, We describe here the identification and characterization of an initiator element in the TATA-containing human beta-globin promoter, Mutagenesis of the beta-globin initiator element at positions +2/+3 and +4/+5 abrogates transcription in a heterologous construct, Interestingly, we have found a beta-globin initiator binding activity in nuclear extracts whose presence or absence correlates with function of the beta-globin initiator. Accordingly, this binding activity may be part of the machinery required for beta-globin initiator-dependent transcription, Our analysis further describes a previously uncharacterized beta-thalassemia mutation at the +1 site as a mutation that decreases beta-globin initiator activity, Finally, consistent with other initiator elements, the beta-globin initiator requires a TFIID-containing fraction for in vitro activity, Thus, the human beta-globin promoter contains an initiator element whose function, as revealed by a beta-thalassemia mutation, is of physiological relevance.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	LEWIS, BA (corresponding author), HARVARD UNIV, CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,ENDERS, RM 750, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.			Lewis, Brian/0000-0002-8321-0665				ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P1154, DOI 10.1073/pnas.81.4.1154; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAI SP, 1989, AM J HUM GENET, V45, P112; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; ORKIN SH, 1984, ANNU REV GENET, V18, P131; ORKIN SH, 1983, NUCLEIC ACIDS RES, V11, P4727, DOI 10.1093/nar/11.14.4727; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAKIHARA Y, 1986, BLOOD, V67, P547; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	40	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28139	28144						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499303				2022-12-25	WOS:A1995TG21000028
J	CHAOUCHI, N; ARVANITAKIS, L; AUFFREDOU, MT; BLANCHARD, DA; VAZQUEZ, A; SHARMA, S				CHAOUCHI, N; ARVANITAKIS, L; AUFFREDOU, MT; BLANCHARD, DA; VAZQUEZ, A; SHARMA, S			CHARACTERIZATION OF TRANSFORMING GROWTH-FACTOR-BETA-1 INDUCED APOPTOSIS IN NORMAL HUMAN B-CELLS AND LYMPHOMA B-CELL LINES	ONCOGENE			English	Article						TGF-BETA; APOPTOSIS; CELL CYCLE; BURKITT; BCL-2; C-MYC	FACTOR-BETA; C-MYC; BCL-2 EXPRESSION; LYMPHOCYTES-B; DEATH; INDUCTION; PROTEIN; INHIBITION; SURVIVAL; GENE	Transforming growth factor beta 1 (TGF beta 1) has been shown to inhibit growth stimulation in normal human B cells as well as in Epstein Barr virus (EBV)-negative Burbitt's lymphoma (BL) cell lines. The mechanisms for this potent growth inhibition are not completely defined. Here me show that a number of EBV-negative lymphoma B cell lines (BL-41, Ramos and CAPA-2), when exposed in vitro to TGF beta 1, undergo apoptosis. Maximum apoptosis was observed at 48 h following TGF beta 1 treatment, with no apparent effect on the expression of c-myc and bcl-2 proteins. Similar induction of apoptosis was observed when these lymphoma cell lines were treated with aphidicolin, a DNA synthesis inhibitor. In contrast, various preparations (14 out of 17) of normal human tonsilar B cells showed no significant apoptosis, although both TGF beta 1 and aphidicolin inhibited anti-mu/IL-4 induced DNA synthesis in all preparations. Furthermore, another TGF beta 1 sensitive EBV-negative BL cell line, CA46, exhibited no apoptosis in response to TGF beta 1 and aphidicolin, corroborating the findings in normal human B cells. Taken together, these data support the hypothesis that exposure to TGF beta 1, which results in cell cycle arrest and DNA synthesis inhibition, may not be obligatory or sufficient for the induction of apoptosis. Rather, induction of apoptosis or lack of-it may be intrinsically determined by an interplay between extracellular and intracellular regulators of cellular growth.	INSERM,U131,F-92140 CLAMART,FRANCE; BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT PATHOL,EXPTL PATHOL SECT,PROVIDENCE,RI 02908	Institut National de la Sante et de la Recherche Medicale (Inserm); Brown University; Roger Williams Medical Center					NCI NIH HHS [CA 55910, CA 54763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055910, R01CA054763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427; ARVANITAKIS L, 1995, IN PRESS J IMMUNOL; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAOUCHI N, 1994, CLIN IMMUNOL IMMUNOP, V73, P197, DOI 10.1006/clin.1994.1188; DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FERNANDEZRUIZ E, 1989, J IMMUNOL, V143, P4146; FINKE J, 1992, BLOOD, V80, P459; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HANNON GJ, 1994, NATURE, V371, P534; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLDER MJ, 1992, EUR J IMMUNOL, V22, P2725, DOI 10.1002/eji.1830221037; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KUMAR A, 1991, J IMMUNOL, V147, P998; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LEE G, 1987, J EXP MED, V166, P1290, DOI 10.1084/jem.166.5.1290; LI L, 1990, J BIOL CHEM, V265, P1556; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOMO J, 1995, J IMMUNOL, V154, P1634; LOTZ M, 1994, J EXP MED, V179, P999, DOI 10.1084/jem.179.3.999; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; ROUACH EY, 1991, NATURE, V352, P345; Sambrook J, 1989, MOL CLONING LABORATO; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; TAIEB J, 1994, EUR J IMMUNOL, V24, P480, DOI 10.1002/eji.1830240233; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VAZQUEZ A, 1991, EUR J IMMUNOL, V21, P2311, DOI 10.1002/eji.1830211004; WELLER M, 1994, EUR J IMMUNOL, V24, P1293, DOI 10.1002/eji.1830240608; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIE AH, 1980, NATURE, V284, P555; WILLY AH, 1987, INT REV CYTOL S, V17, P755	57	81	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1615	1622						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478586				2022-12-25	WOS:A1995TC53500020
J	MAHER, J; BAKER, DA; MANNING, M; DIBB, NJ; ROBERTS, IAG				MAHER, J; BAKER, DA; MANNING, M; DIBB, NJ; ROBERTS, IAG			EVIDENCE FOR CELL-SPECIFIC DIFFERENCES IN TRANSFORMATION BY N-RAS, H-RAS AND K-RAS	ONCOGENE			English	Article						N-RAS; H-RAS; K-RAS; TRANSFORMATION	MURINE SARCOMA-VIRUS; GENE FAMILY; PROTO-ONCOGENE; HARVEY-RAS; LINE; P21; EXPRESSION; DIFFERENTIATION; INDEPENDENCE; PROTEINS	Although Ras plays a fundamental role in cellular proliferation, differentiation and transformation, clear functional differences between the three major Ras proteins (N-, H- and K-Ras) have not as yet been demonstrated. In this study, chimeric constructs were used to compare directly transformation by N-, H- and E-vas oncogenes. In Rat-2 and MH3T3 fibroblasts, transformation assays (anchorage independence, focus-formation and growth in 1% FCS) showed that H-12-Ras was more transforming than N-12-Ras or K-12-Ras. By contrast, in the human multipotent haemopoietic cell line, TF-1, N-12-Ras exhibited greater biological activity. Northern blotting and protein analyses indicated that these findings were not the result of differences in expression or stability of p21Ras. Using further H-ras/N-ras chimeric constructs, we found that the greater transforming activity of H-12-Ras in fibroblasts was not due to the hypervariable-CAAX region, but rather to unique sequences between amino acids 84 and 143. These data demonstrate cell specific differences in the intrinsic transforming potential of N-ras, H-ras and K-ras oncogenes.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0NN, ENGLAND; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT OBSTET & GYNAECOL, LONDON W12 0NN, ENGLAND	Imperial College London; Imperial College London				Maher, John/0000-0001-8275-8488				ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BAKER DA, 1994, LEUKEMIA, V8, P1970; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CARBONE A, 1991, ONCOGENE, V6, P731; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DELGADO MD, 1992, CANCER RES, V52, P5979; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FIORUCCI G, 1988, BIOCHIM BIOPHYS ACTA, V950, P81, DOI 10.1016/0167-4781(88)90076-0; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MAHER J, 1994, EXP HEMATOL, V22, P8; MAHER J, 1994, IN PRESS LEUKEMIA, V84; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; TOKSOZ D, 1989, BRIT J HAEMATOL, V71, P1, DOI 10.1111/j.1365-2141.1989.tb06265.x; UEMURA N, 1992, BLOOD, V80, P3198; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	45	73	73	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1639	1647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478589				2022-12-25	WOS:A1995TC53500023
J	GANDARILLAS, A; WATT, FM				GANDARILLAS, A; WATT, FM			CHANGES IN EXPRESSION OF MEMBERS OF THE FOS AND JUN FAMILIES AND MYC NETWORK DURING TERMINAL DIFFERENTIATION OF HUMAN KERATINOCYTES	ONCOGENE			English	Note						AP-1; NDK; SQUAMOUS CELL CARCINOMA; SUSPENSION CULTURE	HUMAN INVOLUCRIN GENE; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; PROTEIN; GROWTH; MAX; PROLIFERATION; PROMOTER; CELL; PROTOONCOGENE	Normal human epidermal keratinocytes are induced to undergo terminal differentiation when disaggregated and placed in suspension: commitment occurs at about 5 h and overt differentiation by 24 h. In contrast, the squamous cell carcinoma line SCC12B2 does not initiate terminal differentiation until 75 h in suspension and the ndk strain of keratinocytes undergoes growth arrest but does not differentiate at all. In order to identify genes that may regulate terminal differentiation we have examined mRNA levels of members of the fos and jun gene families and myc gene network in suspension cultures of normal keratinocytes, SCC12B2 and ndk. The major changes observed were an up-regulation of c-Fos and Fra-1 and a decrease in c-Myc at the time of commitment, followed by an increase in Mad, Mxi1, Fra-2 and JunB expression at the onset of differentiation. The sequence of events shows a striking similarity to that which occurs during myeloid differentiation and suggests a role for AP-1 complexes and Myc and Mad complexes in regulating keratinocyte differentiation.	IMPERIAL CANC RES FUND,KERATINOCYTE LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154				ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; ADAMS JC, 1991, J CELL BIOL, V115, P8829; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GANDARILLAS A, 1995, IN PRESS MAMMALIAN G; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; HASHIRO M, 1991, BIOCHEM BIOPH RES CO, V174, P287, DOI 10.1016/0006-291X(91)90518-C; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LARSSON LG, 1994, ONCOGENE, V9, P1247; MATSUI M, 1990, ONCOGENE, V5, P249; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; READ J, 1988, J INVEST DERMATOL, V90, P739, DOI 10.1111/1523-1747.ep12560940; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; Sambrook J, 1989, MOL CLONING LABORATO; SONOBE MH, 1995, ONCOGENE, V10, P689; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YAAR M, 1993, EXP CELL RES, V206, P235, DOI 10.1006/excr.1993.1143; YONEDA K, 1992, J BIOL CHEM, V267, P18060; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	41	76	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1403	1407						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478564				2022-12-25	WOS:A1995RY96700024
J	LEVIN, WJ; PRESS, MF; GAYNOR, RB; SUKHATME, VP; BOONE, TC; REISSMANN, PT; FIGLIN, RA; HOLMES, EC; SOUZA, LM; SLAMON, DJ				LEVIN, WJ; PRESS, MF; GAYNOR, RB; SUKHATME, VP; BOONE, TC; REISSMANN, PT; FIGLIN, RA; HOLMES, EC; SOUZA, LM; SLAMON, DJ			EXPRESSION PATTERNS OF IMMEDIATE-EARLY TRANSCRIPTION FACTORS IN HUMAN NONSMALL CELL LUNG-CANCER	ONCOGENE			English	Article						C-JUN; C-FOS; EGR1; NON-SMALL CELL LUNG; CANCER	C-FOS GENE; DNA-BINDING; PROTO-ONCOGENE; FACTOR EGR-1; RESPONSE ELEMENT; JUN ENCODES; 3T3 CELLS; GROWTH; DIFFERENTIATION; AP-1	In 1995, there will be 172 000 new cases of lung cancer diagnosed and 153 000 deaths from this disease in the United States. While the pathogenesis of the disease profess is poorly understood, a growing body of evidence suggests that abnormalities in cellular regulatory genes may play an important role in the induction, maintenance and/or progression of some tumor types. These genes include both growth promoting oncogenes as well as growth inhibitory or suppressor genes. Included among these genetic sequences are several cellular transcription factor. A group of these factors including c-jun, c-fos and EGR1 are members of a class of genes known as immediate early genes whose expression are inducible by a variety of stimuli including mitogenic and differentiation inducing growth factors, indicating a potential important role for these genes in normal growth processes. Since these genes are involved in early regulation of cellular growth properties and at least two (c-jun and c-fos) can act as oncogenes, we wished to determine whether their expression levels were altered in human non-small cell lung cancers (NSCLC) compared to normal lung tissue. To address this, Northern blot analyses were performed using c-fos, c-jun and EGR1 probes on RNA extracted from 101 NSCLC tumor specimens and adjacent uninvolved lung tissue. Analysis of this cohort revealed that 72% of the normal tissues demonstrate significantly greater expression of these transcription factors as compared to adjacent malignant tissue. Moreover, this expression pattern appeared to be coordinate for all three genes in the majority of cases. This differential expression pattern was confirmed at the protein level using an immunohistochemical approach with antibodies directed against the c-jun, c-fos and EGR1 gene products. Southern blot analyses demonstrated no gross alterations of these sequences at the DNA level, indicating that the observed differential expression pattern was not due to gross structural changes in the genes. These data suggest that downregulation of these genes may be involved in the pathogenesis of lung cancer.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG, LOS ANGELES, CA 90024 USA; UNIV SO CALIF, SCH MED, DEPT PATHOL, LOS ANGELES, CA 90033 USA; UNIV TEXAS, SW MED CTR, DEPT MED, DALLAS, TX 75235 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Amgen			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [R01 CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1990, CELL, V59, P979; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GINSBERG RJ, 1993, CHEST S4, V104, pS356; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILBERG F, 1992, ONCOGENE, V7, P2371; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IP YT, 1990, MOL CELL BIOL, V10, P3782, DOI 10.1128/MCB.10.7.3782; JOISHY SK, 1977, ANN INTERN MED, V87, P447, DOI 10.7326/0003-4819-87-4-447; KORNUC M, 1990, J VIROL, V64, P2004, DOI 10.1128/JVI.64.5.2004-2013.1990; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINNA JD, 1989, INT J CANCER, P32; MOLINARRODE R, 1993, MOL CELL BIOL, V13, P3213, DOI 10.1128/MCB.13.6.3213; MOOLGAVKAR SH, 1989, J NATL CANCER I, V81, P415, DOI 10.1093/jnci/81.6.415; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PRESS MF, 1990, ONCOGENE, V5, P953; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOLM M, 1992, ANTICANCER RES, V12, P11; VOLM M, 1993, CLIN EXP METASTAS, V11, P325, DOI 10.1007/BF00058052; WATSON WL, 1966, CANCER, V19, P776, DOI 10.1002/1097-0142(196606)19:6<776::AID-CNCR2820190606>3.0.CO;2-J; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	67	118	125	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1261	1269						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478546				2022-12-25	WOS:A1995RY96700006
J	SALVATI, PD; RANFORD, PR; FORD, J; KEES, UR				SALVATI, PD; RANFORD, PR; FORD, J; KEES, UR			HOX11 EXPRESSION IN PEDIATRIC ACUTE LYMPHOBLASTIC-LEUKEMIA IS ASSOCIATED WITH T-CELL PHENOTYPE	ONCOGENE			English	Article						HOX11; 10Q24; T-ALL; PEDIATRIC ALL	DNA-BINDING MOTIF; HOMEOBOX GENE; CHROMOSOMAL TRANSLOCATION; MYELOID-LEUKEMIA; PRE-B; PROTEIN; CHILDHOOD; ONCOGENE; ENCODES; DIFFERENTIATION	Based on cytogenetic analysis, chromosomal translocations involving band 10q24 occur in 4-7% of T-cell acute lymphoblastic leukemia (T-ALL). The HOX11 gene is located in this chromosomal band and is activated by translocations t(10;14) (q24;q11) and t(7;10) (q35;q24). Ectopic expression of the HOX11 gene appears to be involved in the development of T-cell tumors. The aim of this study was to determine the frequency of HOX11 activation in pediatric ALL patients and to correlate gene expression with ALL immunophenotype. None of 53 B-lineage ALLs was positive for HOX11 expression, however, Northern blot and RT-PCR analysis revealed that four out of 12 T-ALLs (33%) showed expression of the gene. In order to assess whether HOX11 expression is present in other pediatric malignancies we examined a panel of 20 tumor cell lines established from solid tumors and leukemias, but none of them showed expression of HOX11. Using our RT-PCR method we confirmed that HOX11 expression is not detectable in normal T-cells. These findings indicate that HOX11 expression in pediatric ALL is exclusive to T-ALL and does not occur in B-lineage ALL. The frequency detected by molecular techniques was significantly higher than the frequency reported in the literature based on cytogenetic analysis. These results support the notion that ectopic expression of the HOX11 homeobox gene is a crucial step in T-cell tumorigenesis.	TVW TELETHON INST CHILD HLTH RES, DIV CHILDRENS LEUKAEMIA & CANC RES, PERTH, WA 6872, AUSTRALIA	Telethon Kids Institute; University of Western Australia								ADAMS JM, 1992, CANCER SURV, V15, P119; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1991, ONCOGENE, V6, P695; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DUBE ID, 1991, BLOOD, V78, P2996; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1994, CANCER RES, V54, P226; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEES UR, 1989, BLOOD, V74, P369; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; LARSON RC, 1994, ONCOGENE, V9, P3675; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MING L, 1992, ONCOGENE, V7, P1325; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; RAIMONDI SC, 1993, BLOOD, V81, P2237; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCHNEIDER EL, 1975, IN VITRO CELL DEV B, V11, P20; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	38	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1333	1338						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478554				2022-12-25	WOS:A1995RY96700014
J	HU, L; GUDAS, LJ				HU, L; GUDAS, LJ			ACTIVATION OF KERATIN-19 GENE-EXPRESSION BY A 3' ENHANCER CONTAINING AN AP1 SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR AP-1; F9 TERATOCARCINOMA CELLS; MAMMARY EPITHELIAL-CELLS; C-JUN; TERMINAL DIFFERENTIATION; VITAMIN-A; EPIDERMAL-KERATINOCYTES; REGULATORY ELEMENTS	We previously reported that the human keratin 19 (K19) gene was expressed in nonkeratinizing oral epithelial subtypes, and that the steady state K19 mRNA levels in different normal epithelial subtypes correlated with the levels of the retinoic acid receptor (RAR) beta-mRNA (Hu, L., Crowe, D. L., Rheinwald, J. G., Chambon, P., and Gudas, L. J. (1991) Cancer Res. 51, 3972-3981). To elucidate the mechanisms by which the K19 gene is differentially expressed in various epithelial subtypes, we isolated phage containing human K19 genomic DNA from a human placental library. Through transient transfection assays with various K19/CAT constructs that contain different portions of K19 genomic DNA, an enhancer sequence has been identified in the K19 3'-flanking region. In normal human epithelial cell strains, the activity of this enhancer correlates with K19 mRNA abundance. This enhancer activates both the K19 and TK basal promoters in HeLa cells. A high level of K19/CAT fusion mRNA was detected when this K19 3' enhancer sequence was present at the 3' end of the fusion gene whereas no K19/CAT fusion transcript was detected if this 3' K19 enhancer sequence was absent, suggesting that the 3' K19 enhancer is crucial for the positive regulation of K19 expression. Deletion analysis has permitted the localization of the enhancer to a 19-base pair sequence which contains an AP1 binding site (AGTCATCT). Point mutations within this AP1 site completely abolished K19 enhancer activity in HeLa cells. Co-transfections of a c-jun expression vector with K19/CAT reporter constructs demonstrated that c-jun was able to activate the K19 promoter via the 3' K19 enhancer. Collectively, these data indicate that a cis-acting AP1 element and its associated trans-acting effector proteins regulate expression of lineage-specific genes in epithelial cells.	CORNELL UNIV,MED CTR,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Cornell University					NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010389] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01DE10389] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLAUSEN H, 1986, J ORAL PATHOL MED, V15, P36, DOI 10.1111/j.1600-0714.1986.tb00561.x; CREMISI C, 1987, NUCLEIC ACIDS RES, V15, P6105, DOI 10.1093/nar/15.15.6105; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DORAN TI, 1980, CELL, V22, P17, DOI 10.1016/0092-8674(80)90150-6; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; ECKERT RL, 1988, P NATL ACAD SCI USA, V85, P1114, DOI 10.1073/pnas.85.4.1114; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; ECKERT RL, 1984, P NATL ACAD SCI-BIOL, V81, P4321, DOI 10.1073/pnas.81.14.4321; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; ERMICH T, 1988, BIOMED BIOCHIM ACTA, V47, P737; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GARCIA J, 1987, NUCLEIC ACIDS RES, V15, P8367, DOI 10.1093/nar/15.20.8367; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HU L, 1991, CANCER RES, V51, P3972; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JIANG CK, 1990, NUCLEIC ACIDS RES, V18, P247, DOI 10.1093/nar/18.2.247; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENSTRA JA, 1983, EUR J BIOCHEM, V130, P419, DOI 10.1111/j.1432-1033.1983.tb07168.x; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LINDBERG K, 1990, DIFFERENTIATION, V45, P230, DOI 10.1111/j.1432-0436.1990.tb00477.x; LINDBERG K, 1989, AM J PATHOL, V134, P89; LOCKETT TJ, 1987, EXP CELL RES, V173, P370, DOI 10.1016/0014-4827(87)90277-1; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSSIER M, 1989, GENE, V85, P435, DOI 10.1016/0378-1119(89)90437-X; LUSSIER M, 1990, GENE, V95, P203, DOI 10.1016/0378-1119(90)90363-V; Maniatis T., 1982, MOL CLONING; MASON I, 1985, DIFFERENTIATION, V30, P76, DOI 10.1111/j.1432-0436.1985.tb00516.x; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORGAN PR, 1987, EPITHELIA, V1, P31; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OGUIN WM, 1987, CURR TOP DEV BIOL, V22, P97; OHTSUKI M, 1992, J INVEST DERMATOL, V99, P206, DOI 10.1111/1523-1747.ep12650436; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; OSHIMA RG, 1988, GENE DEV, V2, P505, DOI 10.1101/gad.2.5.505; PAN LY, 1992, NUCLEIC ACIDS RES, V20, P3105, DOI 10.1093/nar/20.12.3105; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REIBEL J, 1989, DIFFERENTIATION, V41, P237, DOI 10.1111/j.1432-0436.1989.tb00752.x; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAVENTCHO ES, 1988, AM J HUM GENET, V43, P630; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; STASIAK PC, 1987, NUCLEIC ACIDS RES, V15, P10058, DOI 10.1093/nar/15.23.10058; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; STELLMACH V M, 1989, New Biologist, V1, P305; TAKAHASHI N, 1991, BIOCHEM BIOPH RES CO, V180, P393, DOI 10.1016/S0006-291X(05)81306-3; TAKEMOTO Y, 1991, NUCLEIC ACIDS RES, V19, P2761, DOI 10.1093/nar/19.10.2761; TOMIC M, 1990, CELL REGUL, V1, P965, DOI 10.1091/mbc.1.12.965; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; YANG-YEN H-F, 1990, New Biologist, V2, P351	84	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					183	191						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506253				2022-12-25	WOS:A1994MR21900036
J	WORMAN, HJ; LAZARIDIS, I; GEORGATOS, SD				WORMAN, HJ; LAZARIDIS, I; GEORGATOS, SD			NUCLEAR LAMINA HETEROGENEITY IN MAMMALIAN-CELLS - DIFFERENTIAL EXPRESSION OF THE MAJOR LAMINS AND VARIATIONS IN LAMIN-B PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University	WORMAN, HJ (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021, USA.			Georgatos, Spyros/0000-0002-2078-7467	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001790] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 K11 DK01790] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON RP, 1975, P NATL ACAD SCI USA, V72, P1007, DOI 10.1073/pnas.72.3.1007; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BENAVENTE R, 1985, CELL, V41, P177, DOI 10.1016/0092-8674(85)90072-8; BENAVENTE R, 1985, P NATL ACAD SCI USA, V82, P6176, DOI 10.1073/pnas.82.18.6176; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FAWCETT DW, 1966, AM J ANAT, V119, P129, DOI 10.1002/aja.1001190108; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FORBES DJ, 1983, CELL, V34, P13, DOI 10.1016/0092-8674(83)90132-0; FRANKE WW, 1981, J CELL BIOL, V91, pS39, DOI 10.1083/jcb.91.3.39s; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1988, P NATL ACAD SCI USA, V85, P4325, DOI 10.1073/pnas.85.12.4325; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Gerace L, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P967; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1984, J CELL SCI S, V1, P137; GUILLY MN, 1987, EMBO J, V6, P3795, DOI 10.1002/j.1460-2075.1987.tb02715.x; KROHNE G, 1987, EMBO J, V6, P3801, DOI 10.1002/j.1460-2075.1987.tb02716.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL S, 1987, J CELL BIOL, V105, P1099, DOI 10.1083/jcb.105.3.1099; LEHNER CF, 1987, J CELL BIOL, V105, P577, DOI 10.1083/jcb.105.1.577; LEHNER CF, 1986, J BIOL CHEM, V261, P13292; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MOON RT, 1983, NATURE, V305, P62, DOI 10.1038/305062a0; Nevins J R, 1980, Methods Enzymol, V65, P768; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; REEVES WH, 1987, J EXP MED, V165, P750, DOI 10.1084/jem.165.3.750; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; STICK R, 1985, CELL, V41, P191, DOI 10.1016/0092-8674(85)90073-X; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ZAK R, 1971, EXCERPTA MED INT C S, V240, P163	45	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					12135	12141						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403563				2022-12-25	WOS:A1988P765000080
J	CASTELEIJN, E; KUIPER, J; VANROOIJ, HCJ; KAMPS, JAAM; KOSTER, JF; VANBERKEL, TJC				CASTELEIJN, E; KUIPER, J; VANROOIJ, HCJ; KAMPS, JAAM; KOSTER, JF; VANBERKEL, TJC			HORMONAL-CONTROL OF GLYCOGENOLYSIS IN PARENCHYMAL LIVER-CELLS BY KUPFFER AND ENDOTHELIAL LIVER-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									STATE UNIV LEIDEN,SYLVIUS LABS,CTR BIOPHARMACEUT SCI,DIV BIOPHARMACEUT,POB 9503,2312 AV LEIDEN,NETHERLANDS; ERASMUS UNIV,DEPT BIOCHEM 1,3000 DR ROTTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam			Van Berkel, Theo/ABD-7677-2021					ANDERSON FL, 1976, AM J PHYSIOL, V231, P426, DOI 10.1152/ajplegacy.1976.231.2.426; BIRMELIN M, 1984, EUR J BIOCHEM, V142, P219, DOI 10.1111/j.1432-1033.1984.tb08274.x; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BUXTON DB, 1984, J BIOL CHEM, V259, P3758; BUXTON DB, 1984, J BIOL CHEM, V259, P1468; CASTELEIJN E, 1986, FEBS LETT, V201, P193, DOI 10.1016/0014-5793(86)80607-X; CORVERA S, 1984, BIOCHEM BIOPH RES CO, V119, P1128, DOI 10.1016/0006-291X(84)90892-1; DECKER K, 1985, PROSTAGLANDINS MEMBR, P113; FAHIMI HD, 1970, J CELL BIOL, V47, P247, DOI 10.1083/jcb.47.1.247; FAIN JN, 1984, BIOCHEM BIOPH RES CO, V119, P88, DOI 10.1016/0006-291X(84)91622-X; FISHER RA, 1984, J BIOL CHEM, V259, P8685; GARCIASAINZ JA, 1985, BIOCHEM BIOPH RES CO, V132, P204, DOI 10.1016/0006-291X(85)91008-3; GARRITY MJ, 1983, CLIN RES, V32, P47; HARKES L, 1984, BIOCHEM J, V224, P21, DOI 10.1042/bj2240021; HASHIMOTO S, 1985, CANCER IMMUNOL IMMUN, V20, P117; KOSS LG, 1979, DIAGNOSTIC CYTOLOGY, P1211; KUIPER J, 1988, IN PRESS BIOCH BIOPH; MENDLOVIC F, 1984, BIOCHEM BIOPH RES CO, V123, P507, DOI 10.1016/0006-291X(84)90259-6; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; OKUMURA T, 1985, BIOCHIM BIOPHYS ACTA, V837, P197; OSBORNE DJ, 1979, PROSTAGLANDINS, V17, P863, DOI 10.1016/0090-6980(79)90058-3; OUWENDIJK J, 1986, IN PRESS PROSTAGLAND; PAUL P, 1984, EXP HEMATOL, V12, P825; Penefsky H S, 1979, Methods Enzymol, V56, P527; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHUKLA SD, 1983, J BIOL CHEM, V258, P212; STALMANS W, 1975, EUR J BIOCHEM, V54, P341, DOI 10.1111/j.1432-1033.1975.tb04144.x; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2203; VANDERWERVE G, 1984, BIOCH J, V231, P511; WERNER W, 1970, Z ANAL CHEM FRESENIU, V252, P224	30	110	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1988	263	6					2699	2703						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M2161	3422638				2022-12-25	WOS:A1988M216100022
J	GORDON, DA; SHELNESS, GS; NICOSIA, M; WILLIAMS, DL				GORDON, DA; SHELNESS, GS; NICOSIA, M; WILLIAMS, DL			ESTROGEN-INDUCED DESTABILIZATION OF YOLK PRECURSOR PROTEIN MESSENGER-RNAS IN AVIAN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											GORDON, DA (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018171, R37DK018171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18171] Funding Source: Medline; NIGMS NIH HHS [GM 07518] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLIN CM, 1965, MOL PHARMACOL, V1, P149; BLUE ML, 1981, BIOCHEM BIOPH RES CO, V98, P785, DOI 10.1016/0006-291X(81)91180-3; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CAPONY F, 1981, ENDOCRINOLOGY, V108, P1862, DOI 10.1210/endo-108-5-1862; CAPONY F, 1980, BIOCHEMISTRY-US, V19, P2219, DOI 10.1021/bi00551a035; CAPONY F, 1978, MOL CELL ENDOCRINOL, V11, P181, DOI 10.1016/0303-7207(78)90006-0; CHAN L, 1976, J CLIN INVEST, V58, P368, DOI 10.1172/JCI108481; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; COX RF, 1977, BIOCHEMISTRY-US, V16, P3433, DOI 10.1021/bi00634a022; DARNELL J, 1986, MOL CELL BIOL, P490; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; ELBRECHT A, 1984, SCIENCE, V225, P639, DOI 10.1126/science.6740331; EVANS MI, 1981, CELL, V25, P187, DOI 10.1016/0092-8674(81)90243-9; HARRIS SE, 1975, BIOCHEMISTRY-US, V14, P2072, DOI 10.1021/bi00681a006; HYNES NE, 1979, BIOCHEMISTRY-US, V18, P616, DOI 10.1021/bi00571a011; JOST JP, 1978, EUR J BIOCHEM, V84, P355, DOI 10.1111/j.1432-1033.1978.tb12175.x; KATZENELLENBOGEN BS, 1980, ANNU REV PHYSIOL, V42, P17, DOI 10.1146/annurev.ph.42.030180.000313; KIRSCHGESSNER TG, 1987, IN PRESS GENE AMST; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; PALMITER RD, 1974, P NATL ACAD SCI USA, V71, P2357, DOI 10.1073/pnas.71.6.2357; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PALMITER RD, 1973, J BIOL CHEM, V248, P8260; PROTTER AA, 1982, NUCLEIC ACIDS RES, V10, P4935, DOI 10.1093/nar/10.16.4935; SCHIP ADVH, 1983, NUCLEIC ACIDS RES, V11, P2529; SHAPIRO DJ, 1985, BIOCHEM ACTION HORM, V12, P139; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; SHELNESS GS, 1985, J BIOL CHEM, V260, P8637; SHELNESS GS, 1984, J BIOL CHEM, V259, P9929; SHELNESS GS, 1987, IN PRESS MOL BIOL RN; SHEPHERD JH, 1980, J CELL BIOL, V87, P142, DOI 10.1083/jcb.87.1.142; STRIJKER R, 1986, GENE, V45, P27, DOI 10.1016/0378-1119(86)90128-9; SUTHERLAND R, 1977, NATURE, V267, P434, DOI 10.1038/267434a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WATSON G, 1981, J BIOL CHEM, V256, P3005; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WIERINGA B, 1981, NUCLEIC ACIDS RES, V9, P489, DOI 10.1093/nar/9.3.489; WILLIAMS DL, 1978, P NATL ACAD SCI USA, V75, P5974, DOI 10.1073/pnas.75.12.5974; WILLIAMS DL, 1986, METHOD ENZYMOL, V128, P671; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474	42	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1988	263	6					2625	2631						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M2161	3422636				2022-12-25	WOS:A1988M216100010
J	EBERT, BL; FIRTH, JD; RATCLIFFE, PJ				EBERT, BL; FIRTH, JD; RATCLIFFE, PJ			HYPOXIA AND MITOCHONDRIAL INHIBITORS REGULATE EXPRESSION OF GLUCOSE TRANSPORTER-1 VIA DISTINCT CIS-ACTING SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; ERYTHROPOIETIN GENE; GROWTH-FACTOR; OXIDATIVE-PHOSPHORYLATION; ENDOTHELIAL-CELLS; HEPATOMA-CELLS; PHORBOL ESTER; ENHANCER; PROTEIN; MECHANISMS	Studies of gene regulation by oxygen have recently defined the existence of a widely operative system that responds to hypoxia but not mitochondrial inhibitors and involves the induction of a DNA-binding complex termed hypoxia-inducible factor 1. This system has been implicated in the regulation of erythropoietin, certain angiogenic growth factors, and particular glycolytic isoenzymes. The glucose transporter Glut-1 is induced by both hypoxia and mitochondrial inhibitors, implying the operation of a different mechanism of oxygen sensing. To explore that possibility, we analyzed the cis-acting sequences that convey these responses. An enhancer lying 5' to the mouse Glut-1 gene was found to convey responses both to hypoxia and to the mitochondrial inhibitors, azide and rotenone. However, detailed analysis of this enhancer demonstrated that distinct elements responded to hypoxia and the mitochondrial inhibitors. The response to hypoxia was mediated by sequences that contained a functionally critical, although atypical, hypoxia-inducible factor 1 binding site, whereas sequences lying approximately 100 nucleotides 5' to this site, which contained a critical serum response element, conveyed responses to the mitochondrial inhibitors. Thus, rather than reflecting an entirely different mechanism of oxygen sensing, regulation of Glut-1 gene expression by hypoxia and mitochondrial inhibitors arises from the function of two different sensing systems. One of these responds to hypoxia alone and resembles that involved in erythropoietin regulation, while the other responds to mitochondrial inhibitors and involves activation of a serum response element.	JOHN RADCLIFFE HOSP,INST MOLEC MED,ERYTHROPOIETIN GRP,OXFORD OX3 9DU,ENGLAND	University of Oxford				Ratcliffe, Peter/0000-0002-2853-806X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCHER SL, 1993, CIRC RES, V73, P1100, DOI 10.1161/01.RES.73.6.1100; BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; BASHAN N, 1993, AM J PHYSIOL, V264, pC430, DOI 10.1152/ajpcell.1993.264.2.C430; BECK I, 1993, BLOOD, V82, P704; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAQUIN WC, 1993, EXP HEMATOL, V21, P420; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDWASSER E, 1958, BLOOD, V13, P55, DOI 10.1182/blood.V13.1.55.55; GONZALEZ C, 1994, PHYSIOL REV, V74, P829, DOI 10.1152/physrev.1994.74.4.829; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; JELKMANN W, 1991, BIOCHEM BIOPH RES CO, V179, P1441, DOI 10.1016/0006-291X(91)91734-T; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KURTZ A, 1992, AM J PHYSIOL, V262, pC1204, DOI 10.1152/ajpcell.1992.262.5.C1204; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; NECAS E, 1972, AM J PHYSIOL, V222, P1187, DOI 10.1152/ajplegacy.1972.222.5.1187; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; SHETTY M, 1993, J BIOL CHEM, V268, P17225; SIVITZ WI, 1992, AM J PHYSIOL, V263, pE562, DOI 10.1152/ajpendo.1992.263.3.E562; SUN MK, 1994, J PHYSIOL-LONDON, V476, P101; TAN CC, 1991, AM J PHYSIOL, V261, pF982, DOI 10.1152/ajprenal.1991.261.6.F982; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	37	431	447	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29083	29089		10.1074/jbc.270.49.29083	http://dx.doi.org/10.1074/jbc.270.49.29083			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493931	hybrid			2022-12-25	WOS:A1995TJ22700012
J	GROSSMANN, M; SZKUDLINSKI, MW; TROPEA, JE; BISHOP, LA; THOTAKURA, NR; SCHOFIELD, PR; WEINTRAUB, BD				GROSSMANN, M; SZKUDLINSKI, MW; TROPEA, JE; BISHOP, LA; THOTAKURA, NR; SCHOFIELD, PR; WEINTRAUB, BD			EXPRESSION OF HUMAN THYROTROPIN IN CELL-LINES WITH DIFFERENT GLYCOSYLATION PATTERNS COMBINED WITH MUTAGENESIS OF SPECIFIC GLYCOSYLATION SITES - CHARACTERIZATION OF A NOVEL ROLE FOR THE OLIGOSACCHARIDES IN THE IN-VITRO AND IN-VIVO BIOACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; ASPARAGINE-LINKED OLIGOSACCHARIDES; FRTL-5 THYROID-CELLS; HAMSTER OVARY CELLS; HUMAN TSH RECEPTORS; GLYCOPROTEIN HORMONES; ALPHA-SUBUNIT; SIALYLATED OLIGOSACCHARIDES; CARBOHYDRATE MOIETY; STIMULATING-HORMONE	We used a novel approach to study the role of the Asn-linked oligosaccharides for human thyrotropin (hTSH) activity. Mutagenesis of Asn (N) within individual glycosylation recognition sequences to Gln (Q) was combined with expression of wild type and mutant hTSH in cell Lines with different glycosylation patterns. The in vitro activity of hTSH lacking the Asn(alpha 52) oligosaccharide (alpha Q52/TSH beta) expressed in CHO-K1 cells (sialylated oligosaccharides) was increased 6-fold compared with wild type, whereas the activities of alpha Q78/TSH beta and alpha/TSH beta Q23 were increased 2-3-fold. Deletion of the Asn(alpha 52) oligosaccharide also increased the thyrotropic activity of human chorionic gonadotropin, in contrast to previous findings at its native receptor. The in vitro activity of wild type hTSH expressed in CHO-LEC2 cells (sialic acid-deficient oligosaccharides), CHO-LEC1 cells (Man(5)GlcNAc(2) intermediates), and 293 cells (sulfated oligosaccharides) was 5-8-fold higher than of wild type from CHO-K1 cells. In contrast to CHO-K1 cells, there was no difference in the activity between wild type and selectively deglycosylated mutants expressed in these cell lines. Thus, in hTSH, the oligosaccharide at Asn(alpha 52) and, specifically, its terminal sialic acid residues attenuate in vitro activity, in contrast to the previously reported stimulatory role of this chain for human chorionic gonadotropin and human follitropin activity. The increased thyrotropic activity of alpha Q52/CG beta suggests that receptor-related mechanisms may be responsible for these differences among the glycoprotein hormones. Despite their increased in vitro activity, alpha Q52/TSH beta, and alpha Q78/TSH beta from CHO-K1 cells had a faster serum disappearance rate and decreased effect on T-4 production in mice. These findings highlight the importance of individual oligosaccharides in maintaining circulatory half-life and hence in vivo activity of hTSH.	GARVAN INST MED RES,SYDNEY,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research	GROSSMANN, M (corresponding author), NIDDK,MOLEC & CELLULAR ENDOCRINOL LAB,BLDG 10,ROOM 8D14,BETHESDA,MD 20892, USA.		Schofield, Peter/C-9669-2011	Schofield, Peter/0000-0003-2967-9662				AMBESIIMPIOMBAT.FS, 1980, P NATL ACAD SCI USA, V77, P3455; AMIR SM, 1987, ENDOCRINOLOGY, V120, P345, DOI 10.1210/endo-120-1-345; BERMAN MI, 1985, BIOCHEM BIOPH RES CO, V133, P680, DOI 10.1016/0006-291X(85)90958-1; BISHOP LA, 1995, ENDOCRINOLOGY, V136, P2635, DOI 10.1210/en.136.6.2635; BISHOP LA, 1994, MOL ENDOCRINOL, V8, P722, DOI 10.1210/me.8.6.722; COLE ES, 1993, BIO-TECHNOL, V11, P1014, DOI 10.1038/nbt0993-1014; COSTAGLIOLA S, 1992, J CLIN ENDOCR METAB, V75, P1540, DOI 10.1210/jc.75.6.1540; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; EASTPALMER J, 1995, THYROID, V5, P55, DOI 10.1089/thy.1995.5.55; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; FLACK MR, 1994, J BIOL CHEM, V269, P14015; GALWAY AB, 1990, ENDOCRINOLOGY, V127, P93, DOI 10.1210/endo-127-1-93; GREEN ED, 1988, J BIOL CHEM, V263, P25; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; HOERMANN R, 1991, ENDOCRINOLOGY, V128, P1129; HOERMANN R, 1994, J CLIN ENDOCR METAB, V78, P933, DOI 10.1210/jcem.78.4.8157724; JI I, 1990, P NATL ACAD SCI USA, V87, P4396, DOI 10.1073/pnas.87.11.4396; JOSHI L, 1995, ENDOCRINOLOGY, V136, P3839, DOI 10.1210/en.136.9.3839; KALYAN NK, 1983, J BIOL CHEM, V258, P67; KEENE JL, 1989, MOL ENDOCRINOL, V3, P2011, DOI 10.1210/mend-3-12-2011; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LASH RW, 1992, J ENDOCRINOL INVEST, V15, P225; MAGNER JA, 1990, ENDOCR REV, V11, P345; MANN K, 1993, J ENDOCRINOL INVEST, V16, P378, DOI 10.1007/BF03348862; MATZUK MM, 1988, J BIOL CHEM, V264, P2409; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MEIER CA, 1994, J CLIN ENDOCR METAB, V78, P188, DOI 10.1210/jc.78.1.188; MILLER RL, 1982, J BIOL CHEM, V257, P7574; MOYLE WR, 1975, J BIOL CHEM, V250, P9163; NISSIM M, 1987, ENDOCRINOLOGY, V121, P1278, DOI 10.1210/endo-121-4-1278; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAIRAM MR, 1985, SCIENCE, V229, P65, DOI 10.1126/science.2990039; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1990, J BIOL CHEM, V265, P874; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3423; STRICKLAND TW, 1982, ENDOCRINOLOGY, V111, P95, DOI 10.1210/endo-111-1-95; SZKUDLINSKI MW, 1993, ENDOCRINOLOGY, V133, P1490, DOI 10.1210/en.133.4.1490; THOTAKURA NR, 1992, ENDOCRINOLOGY, V131, P82, DOI 10.1210/en.131.1.82; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; THOTAKURA NR, 1994, GLYCOBIOLOGY, V4, P525, DOI 10.1093/glycob/4.4.525; TOMER Y, 1992, J CLIN ENDOCR METAB, V74, P1477, DOI 10.1210/jc.74.6.1477; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YOSHIMURA M, 1993, J CLIN ENDOCR METAB, V77, P1009, DOI 10.1210/jc.77.4.1009	47	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29378	29385		10.1074/jbc.270.49.29378	http://dx.doi.org/10.1074/jbc.270.49.29378			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493973	hybrid			2022-12-25	WOS:A1995TJ22700054
J	HATCH, LP; COX, GB; HOWITT, SM				HATCH, LP; COX, GB; HOWITT, SM			THE ESSENTIAL ARGININE RESIDUE AT POSITION-210 IN THE ALPHA-SUBUNIT OF THE ESCHERICHIA-COLI ATP SYNTHASE CAN BE TRANSFERRED TO POSITION-252 WITH PARTIAL RETENTION OF ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-SUBUNIT; OXIDATIVE-PHOSPHORYLATION; PROTON PERMEABILITY; H+-ATPASE; PROTEOLIPID SUBUNIT; F0F1-ATPASE; MUTATION; PORE; F1F0; PHOTOPHOSPHORYLATION	The substitution of arginine at position 210 in the a subunit of Escherichia coli F0F1-ATPase by either lysine or alanine causes dominance in complementation tests with a chromosomal c subunit mutation. Reversal of dominance was achieved for the a R210K mutation but not for the a R210A mutation by the presence of an aspartic acid residue at position 50 or at position 252 in the a subunit. It was concluded that position 210 in putative helix 4 of a previously proposed model of the a subunit is close to position 252 in putative helix 5 and to position 50 in putative helix 1. The juxtaposition of residues 252 and 210 was also indicated by the observation that the double mutant a R210Q/Q252R was partially functional. A revertant of the partially functional double mutant, isolated on succinate medium, was found to contain a third mutation resulting in Pro-204 in the a subunit being replaced by threonine. That the revertant phenotype was due to the a P204T change was confirmed by site-directed mutagenesis. ATP synthesis in the revertant strain was at near normal levels as judged by growth yield experiments, but the revertant strain was unable to pump protons in response to ATP hydrolysis.			HATCH, LP (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOLEC BIOL,MEMBRANE BIOCHEM GRP,CANBERRA,ACT 2601,AUSTRALIA.		Howitt, Susan M/C-9308-2009	Howitt, Susan M/0000-0002-2192-2317				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V1, P1513; BJORBAEK C, 1990, FEBS LETT, V260, P31, DOI 10.1016/0014-5793(90)80058-Q; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; COX GB, 1983, BIOCHEM J, V216, P143, DOI 10.1042/bj2160143; COX GB, 1970, BIOCHEM J, V117, P551, DOI 10.1042/bj1170551; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; CROSS RL, 1984, CURR TOP CELL REGUL, V24, P335; DOWNIE JA, 1979, J BACTERIOL, V137, P711, DOI 10.1128/JB.137.2.711-718.1979; EYA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P71, DOI 10.1016/0003-9861(91)90265-K; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P346; FRAGA D, 1994, J BIOL CHEM, V269, P2562; GIBSON F, 1977, BIOCHEM J, V164, P193, DOI 10.1042/bj1640193; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HATCH L, 1993, BIOCHIM BIOPHYS ACTA, V1141, P183, DOI 10.1016/0005-2728(93)90041-D; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; HOPPE J, 1980, FEBS LETT, V109, P107, DOI 10.1016/0014-5793(80)81321-4; HOPPE J, 1982, FEBS LETT, V145, P21, DOI 10.1016/0014-5793(82)81198-8; HOWITT SM, 1988, BIOCHIM BIOPHYS ACTA, V936, P74, DOI 10.1016/0005-2728(88)90253-8; HOWITT SM, 1990, BIOCHIM BIOPHYS ACTA, V1015, P264, DOI 10.1016/0005-2728(90)90030-8; HOWITT SM, 1992, P NATL ACAD SCI USA, V89, P9799, DOI 10.1073/pnas.89.20.9799; JANS DA, 1984, J BACTERIOL, V160, P764, DOI 10.1128/JB.160.2.764-770.1984; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MITCHELL P, 1985, FEBS LETT, V181, P1; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; VIK SB, 1994, J BIOL CHEM, V269, P30364; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P192; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X	41	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29407	29412		10.1074/jbc.270.49.29407	http://dx.doi.org/10.1074/jbc.270.49.29407			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493977	hybrid			2022-12-25	WOS:A1995TJ22700058
J	CHEN, QL; OLASHAW, N; WU, J				CHEN, QL; OLASHAW, N; WU, J			PARTICIPATION OF REACTIVE OXYGEN SPECIES IN THE LYSOPHOSPHATIDIC ACID-STIMULATED MITOGEN-ACTIVATED PROTEIN-KINASE KINASE ACTIVATION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IDENTIFICATION; GENE; STRESS; EGF	Recent evidence suggests that reactive oxygen species (ROS) may function as second messengers in intracellular signal transduction pathways. We explored the possibility that ROS were involved in lysophosphatidic acid (LPA)-induced mitogen-activated protein (MAP) kinase signaling pathway in HeLa cells. Antioxidant N-acetylcysteine inhibited the LPA stimulated MAP kinase kinase activity. Direct exposure of HeLa cells to hydrogen peroxide resulted in a concentration- and time-dependent activation of MAP kinase kinase. Inhibition of catalase with aminotriazole enhanced the effect of LPA on induction of MAP kinase kinase. Further, LPA stimulated ROS production in HeLa cells. These findings suggest that ROS participate in the LPA-elicited MAP kinase signaling pathway.	UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,MOLEC ONCOL PROGRAM,TAMPA,FL 33612; UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,CELL BIOL PROGRAM,TAMPA,FL 33612; UNIV S FLORIDA,DEPT MED MICROBIOL & IMMUNOL,TAMPA,FL 33612; UNIV S FLORIDA,DEPT ANAT,TAMPA,FL 33612	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida			Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606				BASUMODAK S, 1993, CANCER RES, V53, P4505; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BUTTKE TM, 1994, IMMUNOL TODAY, V7, P7; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; RIZZO MT, 1994, EXP HEMATOL, V22, P87; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUBINEK T, 1993, BIOCHIM BIOPHYS ACTA, V1176, P51, DOI 10.1016/0167-4889(93)90176-P; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	33	172	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28499	28502		10.1074/jbc.270.48.28499	http://dx.doi.org/10.1074/jbc.270.48.28499			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499358	hybrid			2022-12-25	WOS:A1995TH05600002
J	EARP, HS; HUCKLE, WR; DAWSON, TL; LI, X; GRAVES, LM; DY, R				EARP, HS; HUCKLE, WR; DAWSON, TL; LI, X; GRAVES, LM; DY, R			ANGIOTENSIN-II ACTIVATES AT LEAST 2 TYROSINE KINASES IN RAT-LIVER EPITHELIAL-CELLS - SEPARATION OF THE MAJOR CALCIUM-REGULATED TYROSINE KINASE FROM P125(FAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; SMOOTH-MUSCLE CELLS; EPIDERMAL GROWTH-FACTOR; BOMBESIN STIMULATION; SIGNAL TRANSDUCTION; MAP KINASE; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; VASOPRESSIN	In rat liver epithelial cell lines (WB or GN4), angiotensin II (Ang II) stimulates cytosolic tyrosine kinase activity, in part, through a calcium-dependent mechanism. In other cell types, selected hormones that activate G(i)- or G(q)-coupled receptors stimulate the soluble tyrosine kinase, p125(FAK). Immunoprecipitation of p125(FAK) from Ang II-activated GN4 cells demonstrated a doubling of p125(FAK) kinase activity. However, an additional Ang II-activated tyrosine kinase (or kinases) representing the majority of the total activity was detected when the remaining cell lysate, immunodepleted of p125(FAK), was reimmunoprecipitated with an anti phosphotyrosine antibody. Cytochalasin D pretreatment blocks G-protein receptor-dependent tyrosine phosphorylation in Swiss 3T3 cells. While cytochalasin D decreased the Tyr(P) content of 65-75-kDa substrates in Ang II-treated GN4 cells, it did not diminish tyrosine phosphorylation of 115-130-kDa substrates, again suggesting activation of at least two tyrosine kinase pathways in GN4 cells. To search for additional Ang II-activated enzymes, we used molecular techniques to identify 20 tyrosine kinase sequences in these cell lines. None was the major cytosolic enzyme activated by Ang II. Specifically, JAK2, which had been shown by others to be stimulated by Ang II in smooth muscle cells, was not activated by Ang II in GN4 cells. Finally, we purified Tyr(P)-containing tyrosine kinases from Ang II-treated cells, using anti-Tyr(P) and ATP affinity resins; 80% of the tyrosine kinase activity migrated as a single 115-120-kDa tyrosine-phosphorylated protein immunologically distinct from p125(FAK). In summary, Ang II activates at least two separate tyrosine kinases in rat liver epithelial cells; p125(FAK) and a presumably novel, cytosolic 115-120-kDa protein referred to as the calcium-dependent tyrosine kinase.	UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; MERCK & CO INC, W POINT, PA 19486 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Merck & Company	EARP, HS (corresponding author), UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA.		Graves, Lee/AAG-5470-2021	Huckle, William/0000-0001-7838-329X; Dawson, Thomas/0000-0003-3878-1722	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031683] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31683] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HARPUR AG, 1992, ONCOGENE, V7, P1347; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; Huckle William R., 1994, Progress in Growth Factor Research, V5, P177, DOI 10.1016/0955-2235(94)90004-3; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LETWIN K, 1988, ONCOGENE, V3, P621; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MARI B, 1994, J BIOL CHEM, V269, P8517; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; SADOSHIMA J, 1995, CIRC RES, V76, P1; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	53	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28440	28447						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499350				2022-12-25	WOS:A1995TG21000075
J	KAGAN, J; STEIN, J; BABAIAN, RJ; JOE, YS; PISTERS, LL; GLASSMAN, AB; VONESCHENBACH, AC; TRONCOSO, P				KAGAN, J; STEIN, J; BABAIAN, RJ; JOE, YS; PISTERS, LL; GLASSMAN, AB; VONESCHENBACH, AC; TRONCOSO, P			HOMOZYGOUS DELETIONS AT 8P22 AND 8P21 IN PROSTATE-CANCER IMPLICATE THESE REGIONS AS THE SITES FOR CANDIDATE TUMOR-SUPPRESSOR GENES	ONCOGENE			English	Article						CHROMOSOME 8P; LOH; MICROSATELLITE; PROSTATE CANCER; TUMOR SUPPRESSOR GENE (TSG)	DINUCLEOTIDE REPEAT POLYMORPHISM; ALLELIC LOSS; CHROMOSOME REARRANGEMENTS; ADENOCARCINOMA; LOCALIZATION; CARCINOMA; LOCUS	Frequent loss of an allele at specific chromosomal regions implicates these regions as sites of tumor suppressor genes (TSG) that become inactivated during tumor progression. We have studied chromosome 8p allele losses in 32 primary human prostate carcinomas with 16 polymorphic microsatellite sequences. Overall, 22 of 32 (69%) informative specimens showed loss of allele in at least one locus. The most frequent losses of heterozygosity (LOH) occurred at the LPL locus (46%) on chromosome 8p22 and at the DSS360 (45%) and NEFL (43%) loci on chromosome 8p21. Homozygous deletions were detected at the LPL and NEFL loci at 8p22 and 8p21, respectively. The minimal region with frequent LOH and homozygous deletion, around the LPL locus, was restricted between the MSR locus and the D8S258 marker, separated by less than 9 cM. The second region was restricted between markers D8S1128 and D8S131 separated by 12 cM. The results suggest the existence of two chromosome 8p sites for candidate TSGs in prostate cancer.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	KAGAN, J (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HEMATOPATHOL PROGRAM,BOX 72,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ARPS S, 1993, CANCER GENET CYTOGEN, V66, P93, DOI 10.1016/0165-4608(93)90234-D; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1994, GENOMICS, V24, P317, DOI 10.1006/geno.1994.1622; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOVA GS, 1993, CANCER RES, V53, P3869; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHANG M, 1994, AM J PATHOL, V144, P1; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GIBAS Z, 1985, CANCER GENET CYTOGEN, V16, P301, DOI 10.1016/0165-4608(85)90237-7; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; ICHIKAWA T, 1994, CANCER RES, V54, P2299; KAGAN J, 1994, INT J ONCOL, V5, P921; KAMINO K, 1993, HUM MOL GENET, V2, P1751, DOI 10.1093/hmg/2.10.1751; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LUNDGREN R, 1988, CANCER GENET CYTOGEN, V35, P103, DOI 10.1016/0165-4608(88)90128-8; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MURRAY JE, 1993, COMMUNICATION; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; Rogaev E., 1992, Human Molecular Genetics, V1, P781, DOI 10.1093/hmg/1.9.781; SADLER LA, 1991, NUCLEIC ACIDS RES, V19, P6058, DOI 10.1093/nar/19.21.6058-a; THOMFOHRDE J, 1992, GENOMICS, V14, P144; TRAPMAN J, 1994, CANCER RES, V54, P6061; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WEBBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Wood S, 1993, Cytogenet Cell Genet, V64, P134; WOOD S, 1992, GENOMICS, V13, P232, DOI 10.1016/0888-7543(92)90230-P; YU CE, 1994, HUM MOL GENET, V3, P211; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	40	105	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2121	2126						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478532				2022-12-25	WOS:A1995TF29700023
J	KORTENJANN, M; SHAW, PE				KORTENJANN, M; SHAW, PE			RAF-1 KINASE AND ERK2 UNCOUPLED FROM MITOGENIC SIGNALS IN RAT FIBROBLASTS	ONCOGENE			English	Article						C-FOS; CELL PROLIFERATION; SIGNAL CASCADE; MAP KINASES	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; MAP KINASE; C-FOS; GROWTH-FACTOR; TRANSDUCTION PATHWAY; IN-VITRO; V-RAF; CELLS; PHOSPHORYLATION	The MAP kinase pathway impinging on ERK2 has been shown to be integrally associated with mitogenic signalling in many cell types. Previously, we and others have demonstrated that oncogenic forms of Raf-1 kinase, when expressed in fibroblasts, lead to the constitutive activation of ERK2, the de-regulation of c-fos expression and increased cell proliferation. Here we describe an exception to this scenario. In Rat6 cells, although both ERK1 and ERK2 are activated in response to mitogens that induce c-fos expression, such as Epidermal Growth Factor (EGF), lysophosphatidic acid (LPA) or serum, expression of v-Raf fails to induce c-fos expression and increase proliferation. However, ERK2 is activated by v-Raf expression. The co-transfection of an interfering mutant of ERK2 has no effect on the level of c-fos reporter expression in Rat6 cells whereas the analogous ERK1 mutant reduces its expression. Furthermore, the spontaneous focus formation observed in Rat6 cells is susceptible to the interfering mutant of ERK1 but resistant to that of ERK2. Thus, not only do mitogenic signals appear to by-pass both Raf-1 kinase and ERK2, the Raf-1-ERK2 pathway seems to be functionally compromised in Rat6 cells as its activation leads neither to c-fos expression nor to increased proliferation.	MAX PLANCK INST IMMUNBIOL,SPEMANN LABS,D-79108 FREIBURG,GERMANY	Max Planck Society				SHAW, Peter/0000-0002-2598-4283				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CHOI KY, 1994, CELL, V78, P499; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GILLE H, 1995, UNPUB; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAGGI R, 1986, EMBO J, V55, P2609; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V113, P3003; PAPIN C, 1995, ONCOGENE, V10, P1647; PERKINS LM, 1994, NUCLEIC ACIDS RES, V22, P450, DOI 10.1093/nar/22.3.450; PHAM CD, 1995, ONCOGENE, V10, P1683; PRINTEN JA, 1994, GENETICS, V138, P609; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROZAKISADOCK M, 1992, NATURE, V260, P689; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WU J, 1993, ADV SEC MESS PHOSPH, V28, P219; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	71	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2105	2112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478530				2022-12-25	WOS:A1995TF29700021
J	FELIX, CA; WASSERMAN, R; CESANO, A; NOWELL, PC; HOSLER, MR; MASTERSON, M; POPLACK, DG; SANTOLI, D				FELIX, CA; WASSERMAN, R; CESANO, A; NOWELL, PC; HOSLER, MR; MASTERSON, M; POPLACK, DG; SANTOLI, D			CLONAL EXPANSION OF GERMLINE B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA IN SEVERE COMBINED IMMUNODEFICIENT MICE	ONCOGENE			English	Article						CDR3; POLYMERASE CHAIN REACTION; SOUTHERN BLOT ANALYSIS; DIFFERENTIATION; SUBCLONE	IMMUNOGLOBULIN HEAVY-CHAIN; T-CELL; GENE REARRANGEMENT; RESIDUAL DISEASE; ALL-1 GENE; CHILDHOOD; DIFFERENTIATION; EXPRESSION; PATTERNS; ORIGIN	CD19(+) B lineage acute lymphoblastic leukemias (ALLs) with unrearranged Ig and TCR genes are designated germline B lineage ALLS. We used CDR3 PCR to determine whether pediatric germline B lineage ALLs contain minor subclones with rearranged Ig H V genes. In six of seven cases there were no PCR detectable CDR3 rearrangements. One case with a smear pattern on CDR3 PCR contained multiple unique CDR3 sequences at frequencies of 1-2 per 2 600, suggesting that polyclonal B cells were present at low frequency. To verify that the germline patterns were from leukemic cells and evaluate in vivo subclone differentiation, a germline B lineage ALL with the t(4;11) translocation was propagated in severe combined immunodeficient (SCID) mice. The Ig and TCR genes in the leukemic cells recovered from mouse tissues were germline by Southern blot analysis except for single rearrangements that suggested subclone evolution at the Ig H and lambda loci in addition to the germline population. No CDR3 sequences were detected, indicating that the observed Ig H gene rearrangement most likely was a DJ joining. This study suggests that the transformed cell ingermline B lineage ALL represents an early pro-B cell with limited tendency to further differentiate.	UNIV PENN,SCH MED,WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV CINCINNATI,CHILDRENS HOSP,MED CTR,DEPT PEDIAT,CINCINNATI,OH 45229; TEXAS CHILDRENS HOSP,BAYLOR COLL MED,HEMATOL ONCOL SERV,HOUSTON,TX 77030	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Baylor College of Medicine	FELIX, CA (corresponding author), UNIV PENN,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV ONCOL,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA-42232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANVRET M, 1984, NUCLEIC ACIDS RES, V12, P1149, DOI 10.1093/nar/12.2.1149; BEISHUIZEN A, 1994, BLOOD, V83, P2238, DOI 10.1182/blood.V83.8.2238.bloodjournal8382238; BEISHUIZEN A, 1991, LEUKEMIA, V5, P657; BEISHUIZEN A, 1992, LEUKEMIA, V6, P60; BIONDI A, 1989, BLOOD, V73, P2133; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; BORIES JC, 1991, BLOOD, V78, P2053, DOI 10.1182/blood.V78.8.2053.bloodjournal7882053; CESANO A, 1991, BLOOD, V77, P2463; CESANO A, 1992, ONCOGENE, V7, P827; DAVEY MP, 1986, P NATL ACAD SCI USA, V83, P8759, DOI 10.1073/pnas.83.22.8759; DEANE M, 1991, LEUKEMIA, V5, P832; EHRLICH A, 1993, CELL, V72, P695; FELIX CA, 1993, CANCER RES, V53, P2954; FELIX CA, 1987, J CLIN INVEST, V80, P545, DOI 10.1172/JCI113103; FELIX CA, 1987, BLOOD, V70, P536; FELIX CA, 1990, J CLIN ONCOL, V8, P431, DOI 10.1200/JCO.1990.8.3.431; FELIX CA, 1994, LEUKEMIA, V8, P963; FOA R, 1984, J CLIN INVEST, V74, P1756, DOI 10.1172/JCI111594; GREENBERG JM, 1986, J IMMUNOL, V137, P2043; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HARA J, 1988, J CLIN INVEST, V82, P1974, DOI 10.1172/JCI113817; HUNGER SP, 1993, BLOOD, V81, P3197; JANSEN B, 1992, CANCER RES, V52, P406; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; KITCHINGMAN GR, 1986, BLOOD, V67, P698; KITCHINGMAN GR, 1993, BLOOD, V81, P775; KIYOI H, 1992, J CLIN INVEST, V89, P739, DOI 10.1172/JCI115650; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; LEBIEN TW, 1990, HEMATOL ONCOL CLIN N, V4, P835, DOI 10.1016/S0889-8588(18)30470-2; MIRRO J, 1986, BLOOD, V67, P689; NADLER LM, 1984, J CLIN INVEST, V74, P332, DOI 10.1172/JCI111428; RAIMONDI SC, 1993, BLOOD, V81, P2237; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; STEENBERGEN EJ, 1993, BLOOD, V82, P581, DOI 10.1182/blood.V82.2.581.bloodjournal822581; TYCKO B, 1992, BLOOD, V79, P481; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1988, BLOOD, V71, P13; VANDONGEN JJM, 1987, J IMMUNOL, V138, P1260; WASSERMAN R, 1992, BLOOD, V79, P223; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123; YAMADA M, 1991, J EXP MED, V173, P395, DOI 10.1084/jem.173.2.395; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705; YONEDA N, 1993, BLOOD, V82, P207, DOI 10.1182/blood.V82.1.207.bloodjournal821207	43	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1753	1759						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478603				2022-12-25	WOS:A1995TD09400010
J	MIRZAYANS, R; FAMULSKI, KS; ENNS, L; FRASER, M; PATERSON, MC				MIRZAYANS, R; FAMULSKI, KS; ENNS, L; FRASER, M; PATERSON, MC			CHARACTERIZATION OF THE SIGNAL-TRANSDUCTION PATHWAY MEDIATING GAMMA-RAY-INDUCED INHIBITION OF DNA-SYNTHESIS IN HUMAN-CELLS - INDIRECT EVIDENCE FOR INVOLVEMENT OF CALMODULIN BUT NOT PROTEIN-KINASE-C NOR P53	ONCOGENE			English	Article						RADIORESISTANT DNA SYNTHESIS; ATAXIA-TELANGIECTASIA; LI-FRAUMENI SYNDROME; CALMODULIN; PROTEIN KINASE C; P53	ATAXIA-TELANGIECTASIA CELLS; LI-FRAUMENI SYNDROME; WILD-TYPE P53; IONIZING-RADIATION; 4-NITROQUINOLINE 1-OXIDE; MUTANT P53; STAUROSPORINE; HYPERSENSITIVITY; COMPLEMENTATION; REPLICATION	Cultured cells from patients inheriting the rare cancer-prone and radiotherapy-sensitive disorder ataxia-telangiectasia (A-T) exhibit anomalies in cell. cycle control and protein kinase C (PKC)-mediated upregulation of p53 protein following exposure to ionizing radiation. It remains unclear, however, as to whether this irregularity in a p53-dependent signal transduction pathway controlling the G(1)/S checkpoint is causally linked to the most consistent molecular hallmark. of A-T - namely, marked attenuation in the inhibition of replicative DNA synthesis at early times (less than or equal to 2 h) after irradiation [radioresistant DNA synthesis (RDS)]. We report here that treatment of normal human fibroblast strains with inhibitors of calmodulin (CaM) (i.e. W7 and W13) and CaM-dependent protein kinases II and IV (i.e. KN62) prior to radiation exposure elicits an 'A-T-like' RDS phenotype, whereas treatment with PKC inhibitors (e.g. staurosporine) does not produce this response. Moreover, at 1 h post-gamma irradiation A-T fibroblasts undergo normal induction of p53 protein while exhibiting the RDS trait. At later times (e.g. 4 h) following irradiation, however, these A-T cells contain abnormally low levels of p53 protein, as do their lymphoblastoid cell line counterparts during the entire post-gamma ray incubation period. On the other hand, human cells which either lack the p53 gene completely (i.e. HL60 leukemia cells) or harbor a germline mutation in the gene (i.e. Li-Frauneni syndrome cells) shut down their DNA replication machinery normally upon sustaining radiation damage. We thus conclude that the transitory delay in DNA; synthesis routinely experienced by human cells in the face of radiation injury is mediated through a CaM-dependent regulatory cascade which involves neither PKC nor p53 protein. Accordingly, A-T cells appear to be malfunctional in at least two distinct radiation-responsive signalling pathways, one regulating the G(1)/S checkpoint and governed by p53 and PKC and another controlling passage through S phase and requiring CaM.	CROSS CANC INST,ONCOL MOLEC PROGRAM,EDMONTON,AB T6G 1Z2,CANADA; UNIV ALBERTA,DEPT ONCOL,EDMONTON,AB T6G 1Z2,CANADA	University of Alberta; University of Alberta			Famulski, Konrad/J-8685-2012					BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; CHAFOULEAS JG, 1984, SCIENCE, V224, P1346, DOI 10.1126/science.6203171; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CLEAVER JE, 1990, RADIAT RES, V124, P294, DOI 10.2307/3577842; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GANGULY A, 1992, BIOCHEM BIOPH RES CO, V182, P254, DOI 10.1016/S0006-291X(05)80138-X; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; HANAWALT P, 1985, ATAXIA TELANGIECTASI, P67; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1979, MOL PHARMACOL, V15, P49; HIDAKA H, 1984, P NATL ACAD SCI USA, V78, P4354; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; LAVIN MF, 1993, NATO ASI SERIES H, V77, P235; LEHMANN AR, 1979, CANCER RES, V39, P4237; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARX J, 1994, SCIENCE, V266, P1321, DOI 10.1126/science.7973719; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MIRZAYANS R, 1989, CANCER RES, V49, P5523; MIRZAYANS R, 1991, CARCINOGENESIS, V12, P19, DOI 10.1093/carcin/12.1.19; MIRZAYANS R, 1995, 86TH ANN M AM ASS CA, P172; MURNANE JP, 1982, P NATL ACAD SCI-BIOL, V79, P1960, DOI 10.1073/pnas.79.6.1960; Murray A, 1993, CELL CYCLE INTRO; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1990, J NATL CANCER I, V82, P1734, DOI 10.1093/jnci/82.22.1734; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PALCIC B, 1990, BIOINSTRUMENTATION D, P923; PATERSON MC, 1994, 3RD MCGILL U C REG E; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHNEIDE.EL, 1974, EXP CELL RES, V84, P311, DOI 10.1016/0014-4827(74)90411-X; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHUNG B, 1994, MUTAT RES, V307, P43, DOI 10.1016/0027-5107(94)90276-3; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; WANG Y, 1993, CANCER RES, V53, P1213; WRIGHT CD, 1986, BIOCHEM BIOPH RES CO, V135, P749, DOI 10.1016/0006-291X(86)90992-7; YOUNG BR, 1989, HUM GENET, V82, P113, DOI 10.1007/BF00284040; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	50	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1597	1605						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478584				2022-12-25	WOS:A1995TC53500018
J	MULLERHUSMANN, G; GLOOR, S; SCHACHNER, M				MULLERHUSMANN, G; GLOOR, S; SCHACHNER, M			FUNCTIONAL-CHARACTERIZATION OF BETA-ISOFORMS OF MURINE NA,K-ATPASE - THE ADHESION MOLECULE ON GLIA (AMOG/BETA-2), BUT NOT BETA-1, PROMOTES NEURITE OUTGROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; 2ND MESSENGER SYSTEMS; (NA+ + K+)-ATPASE; N-CAM; MOUSE CEREBELLUM; CELL-MIGRATION; SODIUM-PUMP; SUBUNIT; EXPRESSION; PROTEIN	We have previously provided evidence for a dual function of the adhesion molecule on glia (AMOG/beta2), the beta2 subunit of the murine Na,K-ATPase, both as neural recognition molecule mediating neuron-glia interactions and as functional beta subunit of the sodium pump. To analyze the functional role of AMOG/beta2 in neurite outgrowth, AMOG/beta2-expressing L-cells were generated by transfection and used as substrates for neurite outgrowth of cerebellar and hippocampal neurons. AMOG/beta2-transfected L-cells led to an increase in neurite length after 6 h, which was specifically inhibited by antibodies to AMOG/beta2 and a neuronal membrane fraction. Moreover, the extracellular domain of AMOG/beta2 generated as a soluble recombinant protein in Chinese hamster ovary cells partially inhibited the increase in neurite outgrowth on AMOG/beta2-transfected L-cells. L-cells transfected with the mouse beta1 subunit had no effect on neurite extension. Our observations show for the first time differences in functional properties for different beta isoforms of the Na,K-ATPase and suggest that AMOG/beta2 but not beta1 is able to interact with an unknown neuronal receptor leading to increased neurite outgrowth, most likely via signal transduction.			MULLERHUSMANN, G (corresponding author), SWISS FED INST TECHNOL,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND.							ALTMAN J, 1982, EXP BRAIN RES S, V6, P8; ANTONICEK H, 1987, J CELL BIOL, V104, P1587, DOI 10.1083/jcb.104.6.1587; ANTONICEK H, 1988, J NEUROSCI, V8, P2961; APPEL F, 1993, IN PRESS J NEUROSCI; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; BIXBY JL, 1989, NEURON, V3, P287, DOI 10.1016/0896-6273(89)90253-5; BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CLAUSS G, 1977, GRUNDLAGEN STATISTIK, P224; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; Doherty P, 1989, CURR OPIN CELL BIOL, V1, P1102, DOI 10.1016/S0955-0674(89)80057-2; FAHRIG T, 1990, EUR J NEUROSCI, V2, P153, DOI 10.1111/j.1460-9568.1990.tb00407.x; FISCHER G, 1982, NEUROSCI LETT, V28, P325, DOI 10.1016/0304-3940(82)90079-9; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; GLOOR S, 1989, NUCLEIC ACIDS RES, V17, P10117; GLOOR S, 1992, GENE, V120, P307, DOI 10.1016/0378-1119(92)90111-2; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORVEL GP, 1984, CELL TISSUE RES, V238, P253; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LANDER AD, 1985, P NATL ACAD SCI USA, V82, P2183, DOI 10.1073/pnas.82.7.2183; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; PAGLIUSI S, 1989, J NEUROSCI RES, V22, P113, DOI 10.1002/jnr.490220202; POLLERBERG GE, 1986, NATURE, V324, P462, DOI 10.1038/324462a0; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; ROGERS SL, 1985, J NEUROSCI, V5, P369; Sambrook J, 1989, MOL CLONING LABORATO; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SCHNITZER J, 1981, J NEUROIMMUNOL, V1, P429, DOI 10.1016/0165-5728(81)90022-9; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425	57	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26260	26267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7504672				2022-12-25	WOS:A1993MK42500040
J	LIN, G; NOEL, J; LOFFREDO, W; STABLE, HZ; TSAI, MD				LIN, G; NOEL, J; LOFFREDO, W; STABLE, HZ; TSAI, MD			USE OF SHORT-CHAIN CYCLOPENTANO-PHOSPHATIDYLCHOLINES TO PROBE THE MODE OF ACTIVATION OF PHOSPHOLIPASE-A2 FROM BOVINE PANCREAS AND BEE VENOM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA; CASE WESTERN RESERVE UNIV, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Ohio State University; Case Western Reserve University			Tsai, Ming-Daw/G-4689-2019; Noel, Joseph P/A-9459-2009	Tsai, Ming-Daw/0000-0003-1374-0414; 	NCRR NIH HHS [RR 01458] Funding Source: Medline; NIGMS NIH HHS [GM 30327, GM 27431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030327] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLGYER TT, 1979, BIOCHEMISTRY-US, V18, P4354, DOI 10.1021/bi00587a014; BARLOW PN, 1988, CHEM PHYS LIPIDS, V46, P157, DOI 10.1016/0009-3084(88)90017-5; BARLOW PN, 1988, IN PRESS J BIOL CHEM; BONSEN PPM, 1972, BIOCHIM BIOPHYS ACTA, V270, P364, DOI 10.1016/0005-2760(72)90200-7; BRUZIK K, 1983, BIOCHEMISTRY-US, V22, P2478, DOI 10.1021/bi00279a026; BRUZIK KS, 1986, J ORG CHEM, V51, P2368, DOI 10.1021/jo00362a035; BURNS RA, 1982, J AM CHEM SOC, V104, P430, DOI 10.1021/ja00366a010; BURNS RA, 1981, BIOCHEMISTRY-US, V20, P5945, DOI 10.1021/bi00524a004; COHEN H, 1976, J COLLOID INTERF SCI, V56, P240, DOI 10.1016/0021-9797(76)90249-6; DEHAAS GH, 1971, BIOCHIM BIOPHYS ACTA, V239, P252, DOI 10.1016/0005-2760(71)90171-8; Dennis EA, 1983, ENZYMES, P307; DRAINAS D, 1978, EUR J BIOCHEM, V91, P131, DOI 10.1111/j.1432-1033.1978.tb20945.x; DRAINAS D, 1978, FEBS LETT, V86, P49, DOI 10.1016/0014-5793(78)80096-9; DUTILH CE, 1975, EUR J BIOCHEM, V53, P91, DOI 10.1111/j.1432-1033.1975.tb04045.x; Hancock A J, 1981, Methods Enzymol, V72, P640; HANCOCK AJ, 1982, J LIPID RES, V23, P183; HANCOCK AJ, 1977, J LIPID RES, V18, P81; HAUSER H, 1980, BIOCHEMISTRY-US, V19, P366, DOI 10.1021/bi00543a018; HERSHBERG RD, 1976, BIOCHIM BIOPHYS ACTA, V424, P73, DOI 10.1016/0005-2760(76)90051-5; IUPAC-IUB Commission on Biochemical Nomenclature, 1977, European Journal of Biochemistry, V79, P11, DOI 10.1111/j.1432-1033.1977.tb11778.x; JAIN MK, 1984, BIOCHIM BIOPHYS ACTA, V774, P199, DOI 10.1016/0005-2736(84)90292-X; LAWRENCE AJ, 1975, FEBS LETT, V49, P287, DOI 10.1016/0014-5793(75)80768-X; LIN TL, 1987, J AM CHEM SOC, V109, P2321, DOI 10.1021/ja00242a013; LISTER MD, 1985, THESIS U MISSOURI; MAO SY, 1986, BIOCHEMISTRY-US, V25, P2781, DOI 10.1021/bi00358a007; PAJOUHESH H, 1983, J LIPID RES, V24, P645; PAJOUHESH H, 1984, J LIPID RES, V25, P294; PIETERSON WA, 1974, BIOCHEMISTRY-US, V13, P1455, DOI 10.1021/bi00704a021; PIETERSON WA, 1973, THESIS RIJKSUNIVERSI; ROBERTS MF, 1978, BIOCHEMISTRY-US, V17, P935, DOI 10.1021/bi00598a030; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROHOLT OA, 1961, ARCH BIOCHEM BIOPHYS, V94, P364, DOI 10.1016/0003-9861(61)90063-7; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SUNDARAL, 1972, ANN NY ACAD SCI, V195, P324; TAUSK RJM, 1974, BIOPHYS CHEM, V2, P53, DOI 10.1016/0301-4622(74)80024-4; TAUSK RJM, 1974, BIOPHYS CHEM, V2, P175, DOI 10.1016/0301-4622(74)80004-9; TSAI TC, 1985, BIOCHEMISTRY-US, V24, P3180, DOI 10.1021/bi00334a016; UPRETI GC, 1978, ARCH BIOCHEM BIOPHYS, V188, P364, DOI 10.1016/S0003-9861(78)80021-6; VANEIJK JH, 1983, EUR J BIOCHEM, V132, P183; VANEIJK JH, 1984, EUR J BIOCHEM, V139, P51; VERGER R, 1973, J BIOL CHEM, V248, P4023; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; VOLWERK JJ, 1986, BIOCHEMISTRY-US, V25, P1726, DOI 10.1021/bi00355a042; VOLWERK JJ, 1982, LIPID PROTEIN INTERA, V1, P69; Wells M A, 1978, Adv Prostaglandin Thromboxane Res, V3, P39; WELLS MA, 1974, BIOCHEMISTRY-US, V13, P2248, DOI 10.1021/bi00708a002; WILSCHUT JC, 1978, BIOCHIM BIOPHYS ACTA, V508, P185, DOI 10.1016/0005-2736(78)90324-3; 1968, ARCH BIOCH BIOPHYS, V128, P269	48	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13208	13214						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417654				2022-12-25	WOS:A1988Q091700069
J	SIMONET, WS; NESS, GC				SIMONET, WS; NESS, GC			TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF RAT HEPATIC 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE BY THYROID-HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612	State University System of Florida; University of South Florida					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 18094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACK DW, 1986, J BIOL CHEM, V261, P2555; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE CF, 1985, J BIOL CHEM, V260, P4363; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; DIAMOND DJ, 1985, J MOL BIOL, V181, P41, DOI 10.1016/0022-2836(85)90323-7; DUGAN RE, 1974, ARCH BIOCHEM BIOPHYS, V161, P499, DOI 10.1016/0003-9861(74)90332-4; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; HAMBLIN PS, 1987, MOL ENDOCRINOL, V1, P397, DOI 10.1210/mend-1-6-397; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; ICHIKAWA K, 1987, P NATL ACAD SCI USA, V84, P3420, DOI 10.1073/pnas.84.10.3420; JUMP DB, 1984, J BIOL CHEM, V259, P2789; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; LARSEN PR, 1986, J BIOL CHEM, V261, P4373; LEE YP, 1965, J BIOL CHEM, V240, P1427; LOOSE DS, 1985, BIOCHEMISTRY-US, V24, P4509, DOI 10.1021/bi00338a004; MANIATIS T, 1982, MOL CLONING LABORATO; MARKHAM BE, 1987, J BIOL CHEM, V262, P12856; NESS GC, 1973, P NATL ACAD SCI USA, V70, P3839, DOI 10.1073/pnas.70.12.3839; NESS GC, 1986, BIOCHEM J, V233, P167, DOI 10.1042/bj2330167; OPPENHEIMER JH, 1972, J CLIN ENDOCR METAB, V35, P330, DOI 10.1210/jcem-35-2-330; OPPENHEIMER JH, 1974, ENDOCRINOLOGY, V95, P897, DOI 10.1210/endo-95-3-897; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; Rodwell V W, 1976, Adv Lipid Res, V14, P1; SAMPLE CE, 1987, BIOCHEMISTRY-US, V26, P727, DOI 10.1021/bi00377a011; SAMUELS HH, 1979, J CLIN INVEST, V63, P1229, DOI 10.1172/JCI109418; SANTOS A, 1987, J BIOL CHEM, V262, P16880; SCHMICKE RT, 1970, ANNU REV BIOCHEM, V39, P929; SCHMIKE RT, 1973, ADV ENZYMOL, V37, P135; SIMONET WS, 1987, BIOCHEM BIOPH RES CO, V146, P1033, DOI 10.1016/0006-291X(87)90751-0; TOWLE HC, 1986, FASEB J, V45, P2406; WONG NCW, 1986, J BIOL CHEM, V261, P387	32	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1988	263	25					12448	12453						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P8611	3410847				2022-12-25	WOS:A1988P861100046
J	BLAKE, MJ; BUCKLEY, AR; ZHANG, MY; BUCKLEY, DJ; LAVOI, KP				BLAKE, MJ; BUCKLEY, AR; ZHANG, MY; BUCKLEY, DJ; LAVOI, KP			A NOVEL HEAT-SHOCK RESPONSE IN PROLACTIN-DEPENDENT NB2 NODE LYMPHOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HSP70 PROMOTER; BINDING PROTEINS; GENE; TRANSCRIPTION; EXPRESSION; CULTURES; CLONING; GROWTH	Virtually all cells respond to heat stress by increased expression or induction of one or more of the highly conserved cellular stress response proteins, heat shock proteins (HSPs). Here, we report the unusual property of rat Nb2-11 cells, a prolactin-dependent pre-T cell line, to display reduced HSP expression following exposure to elevated temperature. After heat stress (41 degrees C, 1 h), there was no evidence of inducible members of the 70 kDa HSP family, a response common to other cell culture and tissue systems. Moreover, expression of constitutive members of the HSP70 and HSP90 families decreased during the heat stress, apparently reflecting a decrease in mRNA stability. Gel shift assays revealed that heat shock factor (HSF) was activated in spite of the lack of expression of inducible HSP70 transcripts, although its DNA binding rapidly deteriorated. Immunoblotting, using an antibody specific to HSF1, indicated that proteolysis of HSF1 may be responsible for this rapid termination of heat shock element binding. CCAAT binding, a component of constitutive HSP70 expression, was also reduced by heat stress in Nb2-11 cells and may account for the decline in constitutive HSP70 expression. Prolactin pretreatment prevented the fragmentation of HSF1, protected heat shock element and CCAAT binding, prevented the decline in constitutive HSP70 and HSP90 expression, and restored a modest expression of inducible HSP70 following heat treatment. Results of this study describe a unique regulatory defect in HSP expression in Nb2-11 cells, possibly a common characteristic of other hormone-dependent tumors.			BLAKE, MJ (corresponding author), UNIV N DAKOTA,SCH MED,DEPT PHARMACOL & TOXICOL,501 N COLUMBIA RD,GRAND FORKS,ND 58203, USA.				NIDDK NIH HHS [DK44439] Funding Source: Medline; NINDS NIH HHS [NS30493] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030493] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLAKE MJ, 1990, J BIOL CHEM, V265, P15275; BUCKLEY AR, 1994, BIOCHEM BIOPH RES CO, V204, P1158, DOI 10.1006/bbrc.1994.2584; BUCKLEY AR, 1993, MOL CELL ENDOCRINOL, V98, P17, DOI 10.1016/0303-7207(93)90231-8; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORNACE AJ, 1989, EXP CELL RES, V182, P61, DOI 10.1016/0014-4827(89)90279-6; GOUT PW, 1980, CANCER RES, V40, P2433; GOUT PW, 1994, ANTICANCER RES, V14, P2485; GOUT PW, 1987, CANCER RES, V47, P1751; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; HOLMGREN R, 1981, P NATL ACAD SCI-BIOL, V78, P3775, DOI 10.1073/pnas.78.6.3775; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MORIMOTO RI, 1994, COLD SPRING HARBOR M, V26, P1; MORIMOTO RI, 1994, COLD SPRING HARBOR M, V26, P417; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; PELLHAM HRB, 1982, CELL, V30, P517; RAO YP, 1995, CELL GROWTH DIFFER, V6, P1235; RUI H, 1994, J BIOL CHEM, V269, P5364; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6910; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; WU C, 1994, COLD SPRING HARBOR M, V26, P395	37	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29614	29620		10.1074/jbc.270.49.29614	http://dx.doi.org/10.1074/jbc.270.49.29614			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7494006	hybrid			2022-12-25	WOS:A1995TJ22700087
J	URICH, M; ELSHEMERLY, MYM; BESSER, D; NAGAMINE, Y; BALLMERHOFER, K				URICH, M; ELSHEMERLY, MYM; BESSER, D; NAGAMINE, Y; BALLMERHOFER, K			ACTIVATION AND NUCLEAR TRANSLOCATION OF MITOGEN-ACTIVATED PROTEIN-KINASES BY POLYOMAVIRUS MIDDLE-T OR SERUM DEPEND ON PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIZED TUMOR-ANTIGEN; GROWTH-FACTORS; CELL-TRANSFORMATION; MAP KINASES; VIRUS; EXPRESSION; MUTANTS; PHOSPHORYLATION; PHOSPHATASE-2A; FIBROBLASTS	Several cellular signal transduction pathways activated by middle-T in polyomavirus-transformed cells are required for viral oncogenicity. Here we focus on the role of phosphatidylinositol 3-kinase (PI 3-kinase) and Ras and address the question how these signaling molecules cooperate during cell cycle activation. Ras activation is mediated through association with SHC GRB2 . SOS and leads to increased activity of several members of the mitogen-activated protein (MAP) kinase family, while activation of PI 3-kinase results in the generation of D3-phosphorylated phosphatidylinositides whose downstream targets remain elusive. PI 3-kinase activation might also ensue as a direct consequence of Ras activation. Oncogenicity of middle-T requires stimulation of both Ras- and PI 3-kinase-dependent pathways. Mutants of middle-T incapable to bind either SHC . GRB2 . SOS or PI 3-kinase are not oncogenic, Sustained activation and nuclear localization of one of the MAP kinases, ERK-1, was observed in wild type but not in mutant middle-T-expressing cells. Wortmannin, an inhibitor of PI 3-kinase, prevented MAP kinase activation and nuclear localization in middle-T-transformed cells. PI 3-kinase activity was also required for activation of the MAP kinase pathway in normal serum-stimulated cells, generalizing the concept that signaling through MAP kinases requires not only Ras- but also PI 3-kinase-mediated signals.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624; Ballmer-Hofer, Kurt/0000-0002-3800-9129				CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HATTORI J, 1979, CELL, V16, P505, DOI 10.1016/0092-8674(79)90025-4; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; MAGNUSSON G, 1981, J VIROL, V39, P673, DOI 10.1128/JVI.39.3.673-683.1981; MARKLAND W, 1986, J VIROL, V59, P384, DOI 10.1128/JVI.59.2.384-391.1986; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTE BM, 1995, ONCOGENE, V10, P167; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MESSERSCHMITT A, IN PRESS J GEN VIROL; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PEREZ L, 1993, P NATL ACAD SCI USA, V90, P8113, DOI 10.1073/pnas.90.17.8113; POWIS G, 1994, CANCER RES, V54, P2419; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAMEH LE, 1991, ONCOGENE, V6, P1049; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHAFFHAUSEN BS, 1985, VIROLOGY, V143, P671, DOI 10.1016/0042-6822(85)90410-6; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; STRAUSS M, 1990, ONCOGENE, V5, P1223; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TALMAGE DA, 1994, ONCOGENE, V9, P3557; Tooze J, 1980, DNA TUMOR VIRUSES; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	60	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29286	29292		10.1074/jbc.270.49.29286	http://dx.doi.org/10.1074/jbc.270.49.29286			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493960	hybrid			2022-12-25	WOS:A1995TJ22700041
J	HURD, C; KHATTREE, N; ALBAN, P; NAG, K; JHANWAR, SC; DINDA, S; MOUDGIL, VK				HURD, C; KHATTREE, N; ALBAN, P; NAG, K; JHANWAR, SC; DINDA, S; MOUDGIL, VK			HORMONAL-REGULATION OF THE P53 TUMOR-SUPPRESSOR PROTEIN IN T47D HUMAN BREAST-CARCINOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA-BINDING; PROGESTERONE RECEPTORS; CANCER-CELLS; PHOSPHORYLATION	Under normal culturing conditions, the T47D human breast cancer cell line expresses progesterone receptor constitutively and is responsive to estrogen. Because the tumor suppressor protein p53 plays a central role in determining genetic stability and cell proliferation, we have examined the effects of 17 beta-estradiol, the synthetic progestin R5020, and the antiprogestin RU486 on the levels of this protein in T47D cells. Western blot analysis of cellular extracts, performed with a monoclonal antibody capable of quantitatively supershifting a specific p53-p53 response element complex in a gel mobility shift assay, detected a single immunoreactive band representing p53. When cells were grown for 4-5 days in culture medium containing charcoal-treated fetal calf serum, p53 levels declined to 10% of the level seen in the control (no charcoal treatment) group. Supplementation of culture medium containing charcoal-treated calf serum with 0.1-1 nM 17 beta-estradiol restored p53 to its normal levels. A 4-day treatment of cells with R5020 or RU486 lowered the p53 levels in cells grown in normal culturing conditions to 15 and 30% of control levels, respectively. R5020 and RU486 treatments also caused down regulation and/or hyperphosphorylation of the progesterone receptor, which correlated with the down regulation of p53. These observations indicate that in T47D cells, p53 is up-regulated by estradiol while R5020 down-regulates this protein. Since estradiol is known to promote cell proliferation, the induction of p53 observed in this study leads us to propose that estradiol stimulates p53 to regulate proliferation of T47D cells in culture.	OAKLAND UNIV,DEPT BIOL SCI,ROCHESTER,MI 48309; OAKLAND UNIV,INST BIOCHEM & BIOTECHNOL,ROCHESTER,MI 48309; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Oakland University; Oakland University; Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BANERJEE PP, 1995, P ANN M ENDOCRINE SO; BARTEK J, 1991, ONCOGENE, V6, P1699; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELASHRYSTOWERS D, 1988, CANCER RES, V48, P6662; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; GRONEMEYER H, 1992, J STEROID BIOCHEM, V41, P217, DOI 10.1016/0960-0760(92)90347-L; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HORWITZ KB, 1986, J STEROID BIOCHEM, V25, P911, DOI 10.1016/0022-4731(86)90323-7; HORWITZ KB, 1994, J STEROID BIOCHEM, V49, P295, DOI 10.1016/0960-0760(94)90271-2; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWASAKI K, 1994, MAY P AM SOC BIOCH M; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; SCHUCHARD M, 1993, ENDOCR REV, V14, P659, DOI 10.1210/er.14.6.659; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; ZAVA DT, 1978, ENDOCRINOLOGY, V103, P624, DOI 10.1210/endo-103-2-624	28	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28507	28510		10.1074/jbc.270.48.28507	http://dx.doi.org/10.1074/jbc.270.48.28507			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499360	hybrid			2022-12-25	WOS:A1995TH05600004
J	MORI, S; SATOH, T; KOIDE, H; NAKAFUKU, M; VILLAFRANCA, E; KAZIRO, Y				MORI, S; SATOH, T; KOIDE, H; NAKAFUKU, M; VILLAFRANCA, E; KAZIRO, Y			INHIBITION OF RAS/RAF INTERACTION BY ANTI-ONCOGENIC MUTANTS OF NEUROFIBROMIN, THE NEUROFIBROMATOSIS TYPE-1 (NF1) GENE-PRODUCT, IN CELL-FREE SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GAP-RELATED DOMAIN; SACCHAROMYCES-CEREVISIAE; RAS GTPASE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; KINASE KINASE; CDNA CLONING; HA-RAS; EXPRESSION; ENCODES	The neurofibromatosis type 1 (NF1) gene encodes a protein, neurofibromin, containing GTPase-activating protein-related domain (GRD) that stimulates intrinsic GTPase activity of Ras protein, By screening a randomly mutagenized NF1-GRD library in Saccharomyces cerevisiae, we isolated two NF1-GRD mutants (NF201 and NF204) with single amino acid substitutions, which suppress the heat shock sensitive phenotype of the RAS2(G19V) mutant. The NF1-GRD mutants also suppress the oncogenic Res-induced transformation of NIH 3T3 mouse fibroblasts (Nakafuku, M., Nagamine, M., Ohtoshi, A., Tanaka, K., Toh-e, A., and Kaziro, Y. (1993) Proc. Natl. Acad, Sci. U. S. A. 90, 6706-6710), In this paper, we investigated the molecular mechanism of inhibition of the transforming Ras-specific function by the NF1-GRD mutants in mammalian cells. In human embryonic kidney (HEK) 293 cells, the mutant NF1-GRDs attenuated the stimulation of mitogen-activated protein kinase by Ras(G12V), but not by platelet-derived growth factor. In cell-free systems, purified recombinant NF1-GRD mutants showed ale inhibitory effect on the association of Ras . guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) with Raf at several times lower concentrations than the wild type. Furthermore, it was revealed that the binding affinity of the mutant NF1-GRDs toward Ras . GTP gamma S is approximately 5-10 times higher than the wild type. These results suggest that the mutant NF1-GRDs tightly bind to an oncogenic Res in its GTP-bound active conformation and block the interaction between Ras and its effector, Raf.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; INST ADV SCI & TECHNOL,NARA 63001,JAPAN; AGOURON PHARMACEUT INC,SAN DIEGO,CA 92121	Tokyo Institute of Technology; Pfizer			Koide, Hiroshi/E-9000-2011; Satoh, Takaya/K-2628-2014; Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005; Mori, Sadao/0000-0003-4723-726X; Koide, Hiroshi/0000-0001-5916-3179				ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; GOTOH Y, 1994, ONCOGENE, V9, P1891; GUTMANN DH, 1992, ANN NEUROL, V31, P555, DOI 10.1002/ana.410310515; GUTMANN DH, 1993, ONCOGENE, V8, P761; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LI Y, 1992, CELL, V69, P215; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MIURA K, 1986, JPN J CANCER RES, V77, P45; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NISHI T, 1991, ONCOGENE, V6, P1555; NURKEKAMAL MSA, 1993, J BIOL CHEM, V268, P22331; POULLET P, 1994, MOL CELL BIOL, V14, P815, DOI 10.1128/MCB.14.1.815; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P27; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; White R, 1991, Curr Opin Neurobiol, V1, P462, DOI 10.1016/0959-4388(91)90070-N; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28834	28838		10.1074/jbc.270.48.28834	http://dx.doi.org/10.1074/jbc.270.48.28834			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499408	hybrid			2022-12-25	WOS:A1995TH05600052
J	PATRIE, KM; KUDLA, AJ; OLWIN, BB; CHIU, IM				PATRIE, KM; KUDLA, AJ; OLWIN, BB; CHIU, IM			CONSERVATION OF LIGAND SPECIFICITY BETWEEN THE MAMMALIAN AND AMPHIBIAN FIBROBLAST GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FGF RECEPTOR; SIGNAL-TRANSDUCTION; DEVELOPMENTAL EXPRESSION; TERMINAL DIFFERENTIATION; BINDING SPECIFICITY; LIMB REGENERATION; MESSENGER-RNA; GENE; FAMILY; MOUSE	We have previously cloned and sequenced a newt keratinocyte growth factor receptor (KGFR) cDNA which exhibited a unique spatial and temporal expression pattern in the regenerating newt limb. In this report, we further characterize the biochemical and functional properties of this newt KGFR. A stable Chinese hamster ovary transfectant overexpressing the newt KGFR was capable of binding both I-125-fibroblast growth factor-1 (FGF-1) and I-125-FGF-7 but not I-125-FGF-2, indistinguishable from the human KGFR. Scatchard analysis and cross-linking studies further support the conclusion that FGF-1 and FGF-7 are the ligands for the newt KGFR. In addition to their ability to bind to FGFs, both the human and the newt KGFR are also capable of repressing differentiation in mouse MM14 myoblasts. MM14 cells express FGFR1 and are repressed from differentiation by FGF-1, FGF-2, and FGF-4 but not FGF-7. Co-transfection of MM14 cells with either a human or newt KGFR expression construct conferred a response to FGF-7 as determined by a human alpha-cardiac actin/ luciferase reporter construct. The response to FGF-7 was similar to the endogenous FGF response as FGF-7 prevented MM14 myoblasts from undergoing terminal differentiation. Thus, both the human and the newt KGFRs transduce signals similar to those transduced via the endogenous mouse FGFR1. Together these data indicate that this newly isolated newt KGFR is a functional receptor as it binds two FGF family members with high affinity and mediates signaling in skeletal muscle myoblasts. Because the binding pattern of the newt KGFR is similar to the pattern observed for its mammalian counterpart, it emphasizes the strict conservation that this ligand/receptor system has undergone through evolution.	OHIO STATE UNIV, DAVIS MED RES CTR, MOLEC CELLULAR & DEV BIOL PROGRAM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DAVIS MED RES CTR, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA; WALTHER CANC INST, INDIANAPOLIS, IN 46208 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Walther Cancer Institute			Chiu, Ing-Ming/B-1534-2008; Olwin, Bradley B/A-1333-2014		NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047506] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45611] Funding Source: Medline; NIAMS NIH HHS [R01AR39467] Funding Source: Medline; NIDDK NIH HHS [R01DK47506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOILLY B, 1991, DEV BIOL, V145, P302, DOI 10.1016/0012-1606(91)90128-P; CASTILLA M, 1992, MG DEVEL B, V23, P116; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU IM, 1989, TROPHIC FACTORS NERV, P57; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Gospodarowicz D, 1980, Ann N Y Acad Sci, V339, P151, DOI 10.1111/j.1749-6632.1980.tb15976.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LINKHART TA, 1980, J SUPRAMOL STR CELL, V14, P483, DOI 10.1002/jss.400140407; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ONDA H, 1991, DEV BIOL, V148, P219, DOI 10.1016/0012-1606(91)90331-V; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; POULIN ML, 1994, BBA-MOL CELL RES, V1220, P209, DOI 10.1016/0167-4889(94)90137-6; POULIN ML, 1993, DEVELOPMENT, V119, P353; POULIN ML, 1995, DEV DYNAM, V202, P378, DOI 10.1002/aja.1002020407; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; Sambrook J, 1989, MOL CLONING LABORATO; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; Singer M., 1961, GROWTH LIVING SYSTEM, P277; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANNAHILL D, 1992, DEVELOPMENT, V115, P695; TASSAVA RA, 1986, J EXP ZOOL, V239, P229, DOI 10.1002/jez.1402390210; TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WHIMAN M, 1989, ANN REV CELL BIOL, V5, P93	56	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29018	29024		10.1074/jbc.270.48.29018	http://dx.doi.org/10.1074/jbc.270.48.29018			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499435	hybrid			2022-12-25	WOS:A1995TH05600079
J	WEISKIRCHEN, R; PINO, JD; MACALMA, T; BISTER, K; BECKERLE, MC				WEISKIRCHEN, R; PINO, JD; MACALMA, T; BISTER, K; BECKERLE, MC			THE CYSTEINE-RICH PROTEIN FAMILY OF HIGHLY RELATED LIM-DOMAIN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER MOTIF; C-MYC; TRANSGENIC MICE; GROWTH-FACTOR; INSULIN GENE; SEQUENCE; FIBROBLASTS; LEUKEMIA; CLONING; MEMBER	Here we describe a family of closely related LIM do main proteins in avian cells, The LlM motif defines a zinc binding domain that is found in a variety of transcriptional regulators, proto-oncogene products, and proteins associated with sites of cell substratum con tact, One type of LIM-domain protein, called the cysteine-rich protein (CRP), is characterized by the presence of two LIM domains linked to short glycine-rich repeats and a potential nuclear localization signal, We have identified and characterized two evolutionarily conserved members of the CRP family, CRP1 and CRP2, in chicken and quail, Expression of the genes encoding both CRP1 and CRP2 is differentially regulated in normal versus transformed cells, raising the possibility that members of the CRP family may function in control of cell growth and differentiation.	UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA; UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA	University of Innsbruck; Utah System of Higher Education; University of Utah			Bister, Klaus/AFA-9400-2022; Weiskirchen, Ralf/O-1734-2018	Weiskirchen, Ralf/0000-0003-3888-0931; Bister, Klaus/0000-0001-6545-5653	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHUURMAN R, 1991, BIOTECHNIQUES, V10, P185; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WANG XK, 1992, GENOMICS, V14, P391, DOI 10.1016/S0888-7543(05)80231-9; WANG XK, 1992, J BIOL CHEM, V267, P9176; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WU RY, 1994, J BIOL CHEM, V269, P25085	49	101	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28946	28954		10.1074/jbc.270.48.28946	http://dx.doi.org/10.1074/jbc.270.48.28946			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499425	hybrid			2022-12-25	WOS:A1995TH05600069
J	LIEVENEMA, H; LABRUYERE, WT; VANROON, MA; DEBOER, PAJ; MOORMAN, AFM; BERNS, AJM; LAMERS, WH				LIEVENEMA, H; LABRUYERE, WT; VANROON, MA; DEBOER, PAJ; MOORMAN, AFM; BERNS, AJM; LAMERS, WH			THE SPATIOTEMPORAL CONTROL OF THE EXPRESSION OF GLUTAMINE-SYNTHETASE IN THE LIVER IS MEDIATED BY ITS 5'-ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT LIVER; HETEROGENEOUS DISTRIBUTION; ENZYMIC ZONATION; GENE-EXPRESSION; MOUSE-LIVER; HEPATOCYTES; AMMONIA; RNA; ARCHITECTURE; EXTRACTION	In previous studies of the glutamine synthetase gene, the promoter and two enhancer elements, one in the upstream region and one within the first intron, were identified, To analyze the role of the far-upstream enhancer element in the regulation of the expression of the glutamine synthetase gene, two classes of transgenic mice were generated, In GSK mice, the basal promoter directs the expression of the chloramphenicol acetyltransferase reporter gene, In GSL mice reporter gene expression is driven, in addition, by the upstream regulatory region, including the far-upstream enhancer, Whereas chloramphenicol acetyltransferase expression was barely detectable in GSK mice, high levels were detected in GSL mice, By comparing chloramphenicol acetyltransferase expression with that of endogenous glutamine synthetase in GSL mice, three groups of organs were distinguished in which the effects of the upstream regulatory region on the expression of glutamine synthetase were quantitatively different, The chloramphenicol acetyltransferase mRNA in the GSL mice was shown to be localized in the pericentral hepatocytes of the liver, The developmental changes in chloramphenicol acetyltransferase enzyme activity in the liver were similar to those in endogenous glutamine synthetase, These results show that the upstream region is a major determinant for three characteristics of glutamine synthetase expression: its organ specificity, its pericentral expression pattern in the liver, and its developmental appearance in the liver.	UNIV AMSTERDAM, ACAD MED CTR, DEPT ANAT & EMBRYOL, 1105 AZ AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DEPT MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute			Lamers, Wouter H./D-2965-2012					Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENNETT AL, 1987, J CELL BIOL, V105, P1073, DOI 10.1083/jcb.105.3.1073; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT CJ, 1987, BIOCHIM BIOPHYS ACTA, V908, P231, DOI 10.1016/0167-4781(87)90103-5; FAHRNER J, 1993, EUR J BIOCHEM, V213, P1067, DOI 10.1111/j.1432-1033.1993.tb17854.x; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; GEBHARDT R, 1994, HEPATOLOGY, V20, P684, DOI 10.1016/0270-9139(94)90105-8; GEBHARDT R, 1986, DIFFERENTIATION, V33, P45, DOI 10.1111/j.1432-0436.1986.tb00409.x; HAUSSINGER D, 1992, ENZYME, V46, P72; HOGAN B, 1986, MANIPULATION MOUSE E; Janzen JWG, 1987, J HISTOCHEM CYTOCHEM, V35, P49, DOI 10.1177/35.1.2878950; JANZEN JWG, 1984, J HISTOCHEM CYTOCHEM, V32, P557, DOI 10.1177/32.6.6373912; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; KUO CF, 1988, MOL CELL BIOL, V8, P4966, DOI 10.1128/MCB.8.11.4966; KUO CF, 1989, J MOL BIOL, V208, P45, DOI 10.1016/0022-2836(89)90086-7; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMERS WH, 1987, DIFFERENTIATION, V35, P228, DOI 10.1111/j.1432-0436.1987.tb00173.x; LAMERS WH, 1988, ANAT EMBRYOL, V178, P175, DOI 10.1007/BF02463651; LEVINTOW L, 1954, J NATL CANCER I, V15, P347; LOUIE M, 1978, J BIOL CHEM, V253, P6119; MOORMAN AFM, 1988, J HISTOCHEM CYTOCHEM, V36, P751, DOI 10.1177/36.7.2898495; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; MOORMAN AFM, 1994, FEBS LETT, V356, P76, DOI 10.1016/0014-5793(94)01230-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHRODE W, 1990, EUR J CELL BIOL, V53, P35; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIKES ML, 1994, HUM GENE THER, V5, P837, DOI 10.1089/hum.1994.5.7-837; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; VANDENHOFF MJB, 1993, NUCLEIC ACIDS RES, V21, P4987, DOI 10.1093/nar/21.21.4987; VANDENHOFF MJB, 1995, EUR J BIOCHEM, V228, P351; VANDEZANDE L, 1990, GENE, V87, P225, DOI 10.1016/0378-1119(90)90306-C; WAGENAAR GTM, 1993, HEPATOLOGY, V18, P1144; WAGENAAR GTM, 1993, J HEPATOL, V17, P397, DOI 10.1016/S0168-8278(05)80224-7	35	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28251	28256						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499322				2022-12-25	WOS:A1995TG21000047
J	TEBOUL, L; GAILLARD, D; STACCINI, L; INADERA, H; AMRI, EZ; GRIMALDI, PA				TEBOUL, L; GAILLARD, D; STACCINI, L; INADERA, H; AMRI, EZ; GRIMALDI, PA			THIAZOLIDINEDIONES AND FATTY-ACIDS CONVERT MYOGENIC CELLS INTO ADIPOSE-LIKE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; AP2 GENE-EXPRESSION; CLONAL LINE; DIFFERENTIATION; INSULIN; GROWTH; MUSCLE; MOUSE; 3T3-CELLS; INDUCTION	Fatty acids and thiazolidinediones act as potent activators of the adipose differentiation program in established preadipose cell lines, In this report, the effects of these agents on the differentiation pathway of myoblasts have been investigated, Exposure of C2C12N myoblasts (a subclone of the C2C12 cell line) to thiazolidinediones or fatty acids prevents the expression of myogenin, cy-actin, and creatine kinase, thus abolishing the formation of multinucleated myotubes, These treatments lead in parallel to the expression of a typical adipose differentiation program including acquisition of adipocyte morphology and activation of adipose-related genes, A similar transition toward the adipose differentiation pathway also occurs in mouse muscle satellite cells maintained in primary culture, Thiazolidinediones exert their adipogenic effects only in non-terminally differentiated myoblasts; myotubes are insensitive to the compounds, Continuous exposure to inducers after growth arrest is not required to maintain the adipose phenotype, but proliferation of adipose-like C2C12N cells leads to a complete reversion toward undifferentiated cells able to undergo either myogenic or adipogenic differentiation depending on the composition of culture medium, These results indicate that adipogenic inducers, such as thiazolidinediones or fatty acids, specifically convert the differentiation pathway of myoblasts into that of adipoblasts.	UNIV NICE, FAC SCI, CTR BIOCHIM, CNRS, UMR 134, F-06108 NICE 2, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Teboul, Lydia/P-2428-2019	Teboul, Lydia/0000-0002-2789-8637; amri, Ez-Zoubir/0000-0001-8426-5396				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; AMRI EZ, 1994, J LIPID RES, V35, P930; AMRI EZ, 1991, J LIPID RES, V32, P1457; AMRI EZ, 1991, J LIPID RES, V32, P1449; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; AMRI EZ, 1986, BIOCHEM J, V238, P115, DOI 10.1042/bj2380115; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CAWTHORNE MA, 1993, DIABETES, V42, pA204; CHANG AY, 1983, DIABETES, V32, P839, DOI 10.2337/diabetes.32.9.839; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARMON M, 1981, EXP CELL RES, V132, P313, DOI 10.1016/0014-4827(81)90107-5; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GRIGORIADIIS AE, 1990, J CELL BIOL, V106, P2139; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; HIRAGUN A, 1988, J CELL PHYSIOL, V134, P124, DOI 10.1002/jcp.1041340115; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; IKEDA H, 1990, ARZNEIMITTEL-FORSCH, V40-1, P156; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; LIN CH, 1969, LIFE SCI PT 1 PHYSI, V8, P21, DOI 10.1016/0024-3205(69)90112-X; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORGANHUGHES JA, 1986, MYOLOGY, V2, P1709; MUNSON R, 1982, J CELL BIOL, V92, P350, DOI 10.1083/jcb.92.2.350; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; REINILA A, 1984, DIABETOLOGIA, V27, P397, DOI 10.1007/BF00304857; ROSEN DM, 1988, J CELL PHYSIOL, V134, P337, DOI 10.1002/jcp.1041340304; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yaffe D, 1973, TISSUE CULTURE METHO, P106; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681	41	188	198	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28183	28187						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499310	hybrid			2022-12-25	WOS:A1995TG21000035
J	BRIATA, P; VANDEWERKEN, B; AIROLDI, I; ILENGO, C; DIBLAS, E; BONCINELLI, E; CORTE, G				BRIATA, P; VANDEWERKEN, B; AIROLDI, I; ILENGO, C; DIBLAS, E; BONCINELLI, E; CORTE, G			TRANSCRIPTIONAL REPRESSION BY THE HUMAN HOMEOBOX PROTEIN EVX1 IN TRANSFECTED MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EVEN-SKIPPED PROTEIN; PANCREATIC-ISLET CELLS; TATA-BINDING PROTEIN; DNA-BINDING; SYNERGISTIC ACTIVATION; HOMEODOMAIN PROTEINS; DROSOPHILA EMBRYOS; GENE-TRANSCRIPTION; TRANSGENIC MICE; GLUCAGON GENE	The human homeobox protein EVX1 (EVX1) is thought to play an important role during embryogenesis. In this study, the effect of EVX1 on gene transcription has been investigated in transfected mammalian cells. EVX1 expression represses transcription of a reporter gene directed by either cell-specific or viral promoter/enhancer sequences in a variety of mammalian cell lines and in a concentration-dependent manner. Transcriptional repression is independent of the presence of DNA-binding sites for EVX1 in all the promoters we tested. Furthermore, repression by EVX1 is evident also using a TATA-less minimal promoter in the reporter construct. A carboxyl-terminal proline/alanine-rich region of EVX1 seems to be responsible for the transcriptional repression activity, as suggested by transfection of EVX1 mutants. We speculate that the repressor function of EVX1 contributes to its proposed role in embryogenesis.	DIBIT HS RAFFAELE,I-20132 MILAN,ITALY; UNIV GENOA,SCH MED,INST BIOCHEM,I-16132 GENOA,ITALY	University of Genoa	BRIATA, P (corresponding author), ADV BIOTECHNOL CTR,IMMUNOBIOL LAB,IST,VIALE R BENZI 10,I-16132 GENOA,ITALY.		airoldi, irma/I-6169-2017; Briata, Paola/AAC-6039-2020	airoldi, irma/0000-0002-4352-8396; Briata, Paola/0000-0003-3470-0454				ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; CORTE G, 1981, EUR J IMMUNOL, V11, P162, DOI 10.1002/eji.1830110220; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DESPOSITO M, 1991, GENOMICS, V10, P43, DOI 10.1016/0888-7543(91)90482-T; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FAIELLA A, 1992, NUCLEIC ACIDS RES, V23, P6541; FEHMANN HC, 1982, ENDOCRINOLOGY, V130, P159; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GEHRING WJ, 1993, GENE, V135, P215, DOI 10.1016/0378-1119(93)90068-E; GHERZI R, 1995, FEBS LETT, V369, P335, DOI 10.1016/0014-5793(95)00778-8; GHERZI R, 1994, EXP CELL RES, V213, P20, DOI 10.1006/excr.1994.1168; GHERZI R, 1995, EXP CELL RES, V218, P460, DOI 10.1006/excr.1995.1179; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INOSTROZA JA, 1992, CELL, V70, P477; Jackle H, 1993, CURR OPIN CELL BIOL, V5, P505, DOI 10.1016/0955-0674(93)90017-K; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPYROPOULOS DD, 1994, GENE DEV, V8, P1949, DOI 10.1101/gad.8.16.1949; STERN S, NATUR, V345, P783; Summers MD, 1987, TEXAS AGR EXPT STATI; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	67	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27695	27701		10.1074/jbc.270.46.27695	http://dx.doi.org/10.1074/jbc.270.46.27695			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499236	hybrid			2022-12-25	WOS:A1995TE73600047
J	HO, GY; CHEN, TLL; CHISHOLM, RL				HO, GY; CHEN, TLL; CHISHOLM, RL			BOTH THE AMINO AND CARBOXYL TERMINI OF DICTYOSTELIUM MYOSIN ESSENTIAL LIGHT-CHAIN ARE REQUIRED FOR BINDING TO MYOSIN HEAVY-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE MYOSIN; CENTRAL HELIX; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; SECONDARY STRUCTURE; PEPTIDE COMPLEX; TROPONIN-C; CALMODULIN; DISCOIDEUM; EVOLUTION	Dictyostelium myosin deficient in the essential light chain (ELC) does not function normally either in vivo or in vitro (Pollent, R. S., Chen, T. L., Trivinos-Lagos, L., and Chisholm, R. L. (1992) Cell 69, 951-962). Since normal myosin function requires association of ELC, we investigated the domains of ELC that are necessary for binding to the myosin heavy chain (MHC), Deleting the NH2-terminal 11 or 28 amino acid residues (Delta N11 or Delta N28) or the COOH terminal 15 amino acid residues (Delta C15) abolished binding of the ELC to the MHC when the mutants were expressed in wild-type (WT) cells, In contrast, the ELC carrying deletion or insertion of four amino acid residues (D4 or I4) in the central linker segment bound the MHC in WT cells, although less efficient competition with WT ELC suggested that the affinity for the MHC is reduced, When these mutants were ex pressed in ELC-minus (mlcE(-)) cells, where the binding to the heavy chain is not dependent on efficient competition with the endogenous ELC, Delta N28 and Delta N11 bound to the MHC at 15% of WT levels and Delta C15 did not bind to a significant degree, 14 and D4, however, bound with normal stoichiometry. These data indicate that residues at both termini of the ELC are required for association with the MHC, while the central linker domain appears to be less critical for binding, When the mutants were analyzed for their ability to complement the cytokinesis defect displayed by mlcE(-) cells, a correlation to the level of ELC carried by the MHC was observed, indicating that a stoichiometric ELC MHC association is necessary for normal myosin function in vivo.	NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOLEC BIOL, CHICAGO, IL 60611 USA	Northwestern University			Chisholm, Rex L/B-3418-2009	Chisholm, Rex L/0000-0002-5638-3990	NIGMS NIH HHS [GM-39264] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039264] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECHET JJ, 1989, BIOCHIM BIOPHYS ACTA, V996, P199, DOI 10.1016/0167-4838(89)90248-3; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; CHISHOLM RL, 1988, J MOL BIOL, V86, P209; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIFFARD RG, 1983, J MUSCLE RES CELL M, V4, P115, DOI 10.1007/BF00711962; HAILSTONES DL, 1990, MOL CELL BIOL, V10, P1095, DOI 10.1128/MCB.10.3.1095; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATCH T, 1989, J CELL BIOL, V109, P1549; KING SM, 1986, METHOD ENZYMOL, V134, P291; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; OSTROW BD, 1994, J CELL BIOL, V127, P1945, DOI 10.1083/jcb.127.6.1945; PAABO S, 1990, J BIOL CHEM, V265, P4718; PERIASAMY M, 1989, NUCLEIC ACIDS RES, V17, P7723, DOI 10.1093/nar/17.19.7723; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLENZ RS, 1992, CELL, V69, P951, DOI 10.1016/0092-8674(92)90614-I; POLLENZ RS, 1991, CELL MOTIL CYTOSKEL, V20, P83, DOI 10.1002/cm.970200202; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; Stryer L., 1988, BIOCHEMISTRY-US, P15; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; UENO H, 1985, J BIOCHEM-TOKYO, V97, P1785, DOI 10.1093/oxfordjournals.jbchem.a135237; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	40	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27977	27981		10.1074/jbc.270.46.27977	http://dx.doi.org/10.1074/jbc.270.46.27977			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499275	hybrid			2022-12-25	WOS:A1995TE73600086
J	ROYAL, I; PARK, M				ROYAL, I; PARK, M			HEPATOCYTE GROWTH FACTOR-INDUCED SCATTER OF MADIN-DARBY CANINE KIDNEY-CELLS REQUIRES PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PROCESSES; EPITHELIAL-CELLS; FACTOR-RECEPTOR; MET PROTOONCOGENE; TYROSINE KINASE; SIGNAL TRANSDUCTION; PROTEIN-KINASE; POLYMORPHONUCLEAR NEUTROPHILS; DESMOPLAKIN ORGANIZATION; EXTRACELLULAR CALCIUM	Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional cytokine that induces mitogenesis, motility, invasion, and morphogenesis of several epithelial and endothelial cell lines in culture. The receptor for HGF/SF has been identified as the Met tyrosine kinase. To investigate the signaling pathways that are involved in these events, we have generated chimeric receptors containing the extracellular domain of the colony stimulating factor-1 (CSF-1) receptor fused to the transmembrane and intracellular domains of the Met receptor (MET). Madin-Darby canine kidney (MDCK) epithelial cells expressing the CSF-MET chimera dissociate and scatter in response to CSF-1. However, cells expressing a mutant CSF-MET receptor containing a phenylalanine substitution for tyrosine 1356 were unable to scatter or form branching tubules following stimulation with CSF-1. Tyrosine 1356 is essential for the recruitment of multiple substrates including the p85 subunit of PI3-kinase, phospholipase C gamma, and Grb2. In this study, we have investigated the role of PI3-kinase and a downstream target of PI3-kinase, pp70(S6K), in the induction of MDCK cell scatter in response to HGF/SF. Our results demonstrate that following stimulation with HGF/SF, activation of PI3-kinase but not pp70(S6K) is essential for MDCK cell scatter.	ROYAL VICTORIA HOSP, ONCOL MOLEC LAB, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3A 1A1, CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University				Royal, Isabelle/0000-0002-7548-1182				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BIZXXON D, 1995, J  IOL HDM, V270, P5225; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DOWRICK PG, 1991, EXP SUPPL, V59, P89; FALETTO DL, 1993, HEPATOCYTE GROWTH FA, P108; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FIXMAN ED, 1995, ONCOGENE, V10, P237; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GHERARDI E, 1991, EUR J CANCER, V27, P403, DOI 10.1016/0277-5379(91)90370-S; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1983; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HALABAN R, 1992, ONCOGENE, V7, P2195; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LIU C, 1992, ONCOGENE, V7, P181; LONGATI P, 1994, ONCOGENE, V9, P49; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MATSUMOTO K, 1993, HEPATOCYTE GROWTH FA, P226; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NOBES CD, 1995, J CELL SCI, V108, P225; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1990, J CELL SCI, V96, P639; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; STEVENSON BR, 1988, MOL CELL BIOCHEM, V83, P129; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKEICHI M, 1991, SCIENCE, V251, P14551; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	82	233	242	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27780	27787		10.1074/jbc.270.46.27780	http://dx.doi.org/10.1074/jbc.270.46.27780			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499247	hybrid			2022-12-25	WOS:A1995TE73600058
J	LENNY, N; MEYERS, S; HIEBERT, SW				LENNY, N; MEYERS, S; HIEBERT, SW			FUNCTIONAL DOMAINS OF THE T(8-21) FUSION PROTEIN, AML-1/ETO	ONCOGENE			English	Article						AML-1; TRANSCRIPTION; REPRESSION; TRANSLOCATION	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; E2F TRANSCRIPTION FACTOR; DNA-BINDING; AML1 GENE; SECONDARY-STRUCTURE; TRANSLOCATION; RUNT; IDENTIFICATION; EXPRESSION	The AML-1/ETO fusion protein is created by the (8;21) translocation, the second most frequent chromosomal abnormality associated with acute myeloid leukemia. In the fusion protein the AML-1 rant homology domain, which is responsible for DNA binding and CBF beta interaction, is linked to ETO, a gene of unknown function. The primary sequences of the rant homology domain indicates no known DNA binding motifs, but is predicted to contain six beta-strands, two alpha-helices and a nucleotide binding motif, Mutagenesis of AML-1/ETO was performed to delimit the functional domains of the chimeric protein. Most mutations in the runt homology domain that resulted in reduced CBF beta binding also inhibited DNA binding, indicating that the DNA and CBF beta binding sequences are tightly linked. However, these activities were separated by a point mutation of residue 144, within the putative ATP binding motif, which nearly eliminated DNA binding, but did not affect CBF beta binding, Random mutagenesis identified the hydrophobic face of the amphipathic fifth beta-strand, adjacent to the putative ATP binding motif, as critical for both DNA and CBF beta binding. C-terminal deletion mutants of AML-1/ETO indicated that ETO sequences are essential for interference with AML-1B-mediated transcriptional activation, and that residue 540 defines the C-terminal boundary of a potential repression domain. Thus, these mutational analyses define the regions of AML-1/ETO which regulate its function and that may be important in promoting leukemia.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital			Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA 21765] Funding Source: Medline; PHS HHS [R01-64140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DOWNING JR, 1993, BLOOD, V81, P2860; ERICKSON P, 1992, BLOOD, V80, P1825; FRANK R, 1995, IN PRESS ONCOGENE; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Leung DW, 1989, TECHNIQUE, V1, P11; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MADDEN SL, 1993, ONCOGENE, V8, P1713; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; WANG S, 1993, EMBO J, V13, P3324; WOLIN M, 1993, ONCOGENE, V8, P1905; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	39	99	104	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1761	1769						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478604				2022-12-25	WOS:A1995TD09400011
J	BARLAT, I; HENGLEIN, B; PLET, A; LAMB, N; FERNANDEZ, A; MCKENZIE, F; POUYSSEGUR, J				BARLAT, I; HENGLEIN, B; PLET, A; LAMB, N; FERNANDEZ, A; MCKENZIE, F; POUYSSEGUR, J			TGF-BETA-1 AND CAMP ATTENUATE CYCLIN-A GENE-TRANSCRIPTION VIA A CAMP-RESPONSIVE ELEMENT THROUGH INDEPENDENT PATHWAYS	ONCOGENE			English	Article						TGF-BETA; CYCLIN-A; CAMP; INHIBITION OF PROLIFERATION	GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; TGF-BETA; SIGNAL TRANSDUCTION; NEGATIVE REGULATION; CATALYTIC SUBUNIT; DNA-REPLICATION; A EXPRESSION; CROSS-TALK; PHOSPHORYLATION	Transforming growth factor beta (TGF-beta) is a potent inhibitor of the proliferation of many cell lines. The expression of Cyclin A is down-regulated by TGF-beta 1 in Chinese hamster lung fibroblasts and most of this effect is mediated at the transcriptional level through a cAMP-reponsive element (CRE), but does not require a functional cAMP-dependent protein kinase. However, activation of the cAMP pathway in these cells gives rise to a strong inhibition of proliferation, paralleled by a down-regulation of Cyclin A promoter activity. This effect requires the integrity of the CRE, suggesting a role for CRE-binding proteins in late G1/S controls.	CNRS,CTR GENET MOLEC,UPR 2420,F-91198 GIF SUR YVETTE,FRANCE; CNRS,INSERM,CRBM,CELL BIOL UNIT,F-34033 MONTPELLIER 1,FRANCE; UNIV NICE,CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	BARLAT, I (corresponding author), INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,BP 5051,1919 ROUTE MENDE,F-34033 MONTPELLIER 1,FRANCE.							ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DARBON JM, 1994, ONCOGENE, V9, P3127; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FERNANDEZPOL JA, 1987, BIOCHEM BIOPH RES CO, V144, P1197, DOI 10.1016/0006-291X(87)91438-0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MCCORMICK F, 1993, CURRENT OP GENET DEV, V4, P71; MECHTA F, 1989, New Biologist, V1, P297; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PINES J, 1993, BIOCHEM SOC T, V18, P921; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROGERS KV, 1990, P NATL ACAD SCI USA, V87, P8975, DOI 10.1073/pnas.87.22.8975; ROSKOSKI R, 1993, METHOD ENZYMOL, V99, P3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCOTTO L, 1990, J BIOL CHEM, V265, P2203; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	79	55	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1309	1318						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478551				2022-12-25	WOS:A1995RY96700011
J	SEELIG, GF; PROSISE, WW; TAREMI, SS				SEELIG, GF; PROSISE, WW; TAREMI, SS			SYNTHETIC MIMICS OF JUXTAPOSED AMINO-TERMINAL AND CARBOXYL-TERMINAL PEPTIDE DOMAINS OF HUMAN GAMMA-INTERFERON BLOCK LIGAND-BINDING TO HUMAN GAMMA-INTERFERON RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; BIOLOGICAL-ACTIVITY; ANTIPEPTIDE ANTIBODIES; ANTIGENIC STRUCTURE; IMMUNE INTERFERON; NATIVE PROTEIN; C-TERMINUS; IFN-GAMMA; MACROPHAGE; MYOGLOBIN	The epitopes of two neutralizing antibodies (47N3-6 and 47N30A35) raised against rhuIFN-gamma each mapped both to amino-terminal regions (22-29 and 12-19, respectively) and to a carboxyl-terminal region 131-139, suggesting the juxtaposition of these two domains in the native protein. Three novel peptides were designed to mimic a conformation of rhuIFN-gamma that places the two regions in close proximity (discontinuous peptides 1 (15-21-GGG-132-138), 2 (15-29...111-118...130-138), and 3 (15-21-CGPGC-130-138)), by bridging the amino- and carboxyl-terminal regions of gamma interferon. Each discontinuous peptide inhibits biological or receptor binding activities with an IC50 of 15-50 muM and produces a neutralizing antibody when used as an immunogen. Neutralizing rabbit polyclonal antibody (P616) raised against discontinuous peptide 1 was used as immunogen to generate an anti-idiotypic response. This anti-idiotypic antibody inhibits receptor binding and recognizes soluble gamma interferon receptor on direct enzyme-linked immunosorbent assay. The anti-idiotypic response suggests that juxtaposed regions at the amino and carboxyl termini serve as the receptor-ligand binding site of human gamma interferon.			SEELIG, GF (corresponding author), SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033, USA.							ARAKAWA T, 1986, J BIOL CHEM, V261, P8534; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BILLIAU A, 1988, IMMUNOL TODAY, V9, P37, DOI 10.1016/0167-5699(88)91256-X; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON LE, 1985, BIOL INTERFERON SYST, P403; CARUSO A, 1992, J INTERFERON RES, V12, P49, DOI 10.1089/jir.1992.12.49; CZARNIECKI CW, 1985, TNO ISIR M INTERFERO; DELAMAZA LM, 1987, INFECT IMMUN, V55, P2727, DOI 10.1128/IAI.55.11.2727-2733.1987; DEPLA E, 1991, MOL IMMUNOL, V28, P743, DOI 10.1016/0161-5890(91)90117-3; DOBELI H, 1988, J BIOTECHNOL, V7, P199, DOI 10.1016/0168-1656(88)90052-1; DOROW DS, 1985, MOL IMMUNOL, V22, P1255, DOI 10.1016/0161-5890(85)90044-6; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; EPSTEIN LB, 1984, INTERFERONS IMMUNE S, P185; EPSTEIN LB, 1977, INTERFERONS THEIR AC, P91; GEORGIADES JA, 1984, INTERFERONS THEIR AP, V71, P305; GETZOFF ED, 1987, SCIENCE, V235, P1191, DOI 10.1126/science.3823879; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GIBSON UEM, 1989, J IMMUNOL METHODS, V125, P105, DOI 10.1016/0022-1759(89)90083-5; GRAY PW, 1983, P S BIOL BASIS NEW D, P35; ICHIMORI Y, 1987, HYBRIDOMA, V6, P173, DOI 10.1089/hyb.1987.6.173; ICHIMORI Y, 1985, J IMMUNOL METHODS, V80, P55, DOI 10.1016/0022-1759(85)90164-4; JOHNSON HM, 1982, J IMMUNOL, V129, P2357; LANDO G, 1982, J IMMUNOL, V129, P212; LEINIKKI PO, 1987, J IMMUNOL, V139, P3360; LEIST T, 1985, MOL IMMUNOL, V22, P929, DOI 10.1016/0161-5890(85)90079-3; LORD SC, 1989, MOL IMMUNOL, V26, P637, DOI 10.1016/0161-5890(89)90045-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; LUNN CA, 1992, J BIOL CHEM, V267, P17920; LYDON NB, 1985, BIOCHEMISTRY-US, V24, P4131, DOI 10.1021/bi00336a048; MAGAZINE HI, 1991, BIOCHEMISTRY-US, V30, P5784, DOI 10.1021/bi00237a022; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NAGABHUSAN TL, 1989, Patent No. 4751078; NAGABHUSHAN TL, 1985, INTERFERON ALPHA 2 P, P1; NICOLETTI F, 1990, LANCET, V336, P319, DOI 10.1016/0140-6736(90)91860-D; OZMEN L, 1988, LYMPHOKINE RES, V7, P328; PACE JL, 1983, P NATL ACAD SCI-BIOL, V80, P3782, DOI 10.1073/pnas.80.12.3782; RAYMOND CA, 1986, JAMA-J AM MED ASSOC, V256, P685, DOI 10.1001/jama.256.6.685; ROSE K, 1983, BIOCHEM J, V215, P273, DOI 10.1042/bj2150273; SAKAGUCHI M, 1988, FEBS LETT, V230, P201, DOI 10.1016/0014-5793(88)80671-9; SEELIG GF, 1988, BIOCHEMISTRY-US, V27, P1981, DOI 10.1021/bi00406a026; SEELIG GF, 1992, J CELL BIOCHEM, V16, P101; SEELIG GF, 1989, J INTERFERON RES, V4, P184; SIMS JM, 1985, BIOL INTERFERON SYST, P411; SONNENFELD G, 1980, LYMPHOKINE REPORTS, V1, P113; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; TROTTA PP, 1986, INTERFERONS CELL GRO, P497; WETZEL R, 1990, PROTEIN ENG, V3, P611, DOI 10.1093/protein/3.7.611; WONG GHW, 1983, J IMMUNOL, V131, P788	50	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					358	363						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506256				2022-12-25	WOS:A1994MR21900060
J	GERL, L; SUMPER, M				GERL, L; SUMPER, M			HALOBACTERIAL FLAGELLINS ARE ENCODED BY A MULTIGENE FAMILY - CHARACTERIZATION OF 5 FLAGELLIN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV REGENSBURG,INST BIOCHEM GENET & MIKROBIOL,UNIV STR 31,D-8400 REGENSBURG,FED REP GER	University of Regensburg								ALAM M, 1984, J MOL BIOL, V176, P459, DOI 10.1016/0022-2836(84)90172-4; ALAM M, 1987, J MOL BIOL, V194, P495, DOI 10.1016/0022-2836(87)90677-2; BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; DELANGE RJ, 1976, J BIOL CHEM, V251, P705; DUNN R, 1981, P NATL ACAD SCI-BIOL, V78, P6744, DOI 10.1073/pnas.78.11.6744; EMERSON SU, 1970, SCIENCE, V169, P190, DOI 10.1126/science.169.3941.190; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILL PR, 1983, J BIOL CHEM, V258, P7395; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOMMA M, 1984, J BACTERIOL, V159, P1056, DOI 10.1128/JB.159.3.1056-1059.1984; JOYS TM, 1985, J BIOL CHEM, V260, P5758; KAGRAMANOVA VK, 1982, FEBS LETT, V144, P177, DOI 10.1016/0014-5793(82)80595-4; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; KUWAJIMA G, 1986, J BACTERIOL, V168, P1479, DOI 10.1128/jb.168.3.1479-1483.1986; LECHNER J, 1987, J BIOL CHEM, V262, P9724; LECHNER J, 1986, SYST APPL MICROBIOL, V7, P286; LECHNER J, 1985, J BIOL CHEM, V260, P8984; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOEWY ZG, 1987, GENE DEV, V1, P626, DOI 10.1101/gad.1.6.626; MANIATIS T, 1982, MOL CLONING LABORATO; MASUI Y, 1984, BIO-TECHNOL, V2, P81, DOI 10.1038/nbt0184-81; MESCHER MF, 1976, J BIOL CHEM, V251, P2005; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Steiner A L, 1974, Methods Enzymol, V38, P96; SUMPER M, 1987, BIOCHIM BIOPHYS ACTA, V906, P69, DOI 10.1016/0304-4157(87)90005-0; SUMPER M, 1978, EUR J BIOCHEM, V89, P229, DOI 10.1111/j.1432-1033.1978.tb20917.x; THOMASHOW LS, 1985, J BACTERIOL, V163, P1047, DOI 10.1128/JB.163.3.1047-1054.1985; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIELAND F, 1985, J BIOL CHEM, V260, P5180	32	93	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13246	13251						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417656				2022-12-25	WOS:A1988Q091700073
J	LINHARDT, RJ; RICE, KG; KIM, YS; ENGELKEN, JD; WEILER, JM				LINHARDT, RJ; RICE, KG; KIM, YS; ENGELKEN, JD; WEILER, JM			HOMOGENEOUS, STRUCTURALLY DEFINED HEPARIN-OLIGOSACCHARIDES WITH LOW ANTICOAGULANT ACTIVITY INHIBIT THE GENERATION OF THE AMPLIFICATION PATHWAY C-3 CONVERTASE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; VET ADM MED CTR,IOWA CITY,IA 52240	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	LINHARDT, RJ (corresponding author), UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242, USA.				NHLBI NIH HHS [HL29797] Funding Source: Medline; NIAID NIH HHS [AI22350] Funding Source: Medline; NIGMS NIH HHS [GM38060] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CAUGHMAN GB, 1982, MOL IMMUNOL, V19, P287, DOI 10.1016/0161-5890(82)90342-X; COFRANCESCO E, 1979, THROMB RES, V14, P179, DOI 10.1016/0049-3848(79)90036-7; Comper W.D., 1981, HEPARIN RELATED POLY, V7; Ecker EE, 1929, J INFECT DIS, V44, P250, DOI 10.1093/infdis/44.3.250; EKRE HPT, 1985, INT J IMMUNOPHARMACO, V7, P271; FEARON DT, 1973, J EXP MED, V138, P1305, DOI 10.1084/jem.138.6.1305; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; GALLIHER PM, 1981, APPL ENVIRON MICROB, V41, P360, DOI 10.1128/AEM.41.2.360-365.1981; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; HARRISON RA, 1986, HDB EXPT IMMUNOLOGY, pCH39; HUNSICKE.LG, 1973, J IMMUNOL, V110, P128; JACQUES LB, 1979, SCIENCE, V206, P528; KAZATCHKINE MD, 1981, J CLIN INVEST, V67, P223, DOI 10.1172/JCI110017; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINHARDT RJ, 1986, J BIOL CHEM, V261, P4448; LINHARDT RJ, 1982, J BIOL CHEM, V257, P7310; LINKER A, 1972, BIOCHEMISTRY-US, V11, P563, DOI 10.1021/bi00754a013; LOOS M, 1976, IMMUNOCHEMISTRY, V13, P257, DOI 10.1016/0019-2791(76)90224-X; LOOS M, 1976, IMMUNOCHEMISTRY, V13, P789, DOI 10.1016/0019-2791(76)90202-0; MERCHANT ZM, 1986, ATHEROSCLEROSIS, V62, P151, DOI 10.1016/0021-9150(86)90061-4; MERCHANT ZM, 1985, BIOCHEM J, V229, P369, DOI 10.1042/bj2290369; RAEPPLE E, 1976, IMMUNOCHEMISTRY, V13, P251, DOI 10.1016/0019-2791(76)90223-8; RICE KG, 1985, ANAL BIOCHEM, V150, P325, DOI 10.1016/0003-2697(85)90518-4; RICE KG, 1987, BIOCHEM J, V244, P515, DOI 10.1042/bj2440515; SACHE E, 1982, THROMB RES, V25, P443, DOI 10.1016/0049-3848(82)90086-X; SHARATH MD, 1985, IMMUNOPHARMACOLOGY, V9, P73, DOI 10.1016/0162-3109(85)90002-5; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TAYLOR RL, 1973, BIOCHEMISTRY-US, V12, P3633, DOI 10.1021/bi00743a010; WEILER JM, 1978, J EXP MED, V147, P409, DOI 10.1084/jem.147.2.409; WEILER JM, 1983, IMMUNOPHARMACOLOGY, V6, P245, DOI 10.1016/0162-3109(83)90024-3; YANG VC, 1985, J BIOL CHEM, V260, P1849	36	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13090	13096						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417651				2022-12-25	WOS:A1988Q091700051
J	STENMARK, H; OLSNES, S; SANDVIG, K				STENMARK, H; OLSNES, S; SANDVIG, K			REQUIREMENT OF SPECIFIC RECEPTORS FOR EFFICIENT TRANSLOCATION OF DIPHTHERIA TOXIN-A FRAGMENT ACROSS THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									NORWEGIAN CANC SOC,OSLO 3,NORWAY		STENMARK, H (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,OSLO 3,NORWAY.		Stenmark, Harald/B-8868-2008					BACHA P, 1983, J BIOL CHEM, V258, P1565; Bayer E A, 1979, Methods Enzymol, V62, P308; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLOMBATTI M, 1986, J BIOL CHEM, V261, P3030; DIDSBURY JR, 1983, MOL CELL BIOL, V3, P1283, DOI 10.1128/MCB.3.7.1283; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILLILAND DG, 1980, P NATL ACAD SCI USA, V78, P4950; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MONTECUCCO C, 1985, BIOCHEM J, V231, P123, DOI 10.1042/bj2310123; MOOLTEN FL, 1970, SCIENCE, V169, P68, DOI 10.1126/science.169.3940.68; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2815; MURPHY JR, 1986, P NATL ACAD SCI USA, V83, P8258, DOI 10.1073/pnas.83.21.8258; OLSNES S, 1986, J BIOL CHEM, V261, P1562; OLSNES S, 1985, ENDOCYTOSIS, P195; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1982, J BIOL CHEM, V257, P7495; SANDVIG K, 1986, J BIOL CHEM, V261, P1570; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; THORPE PE, 1978, NATURE, V271, P752, DOI 10.1038/271752a0	34	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13449	13455						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417666				2022-12-25	WOS:A1988Q091700102
J	MORAND, OH; ZOELLER, RA; RAETZ, CRH				MORAND, OH; ZOELLER, RA; RAETZ, CRH			DISAPPEARANCE OF PLASMALOGENS FROM MEMBRANES OF ANIMAL-CELLS SUBJECTED TO PHOTOSENSITIZED OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison				Zoeller, Raphael/0000-0002-6560-0993	NIDDK NIH HHS [DK 21722] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRIGHT FR, 1973, J BIOL CHEM, V248, P3968; ANSELL GB, 1982, NEW COMPREHENSIVE BI, V4, P1; ASVELD EWH, 1980, J AM CHEM SOC, V102, P3644, DOI 10.1021/ja00530a065; BARTLETT PD, 1978, HETEROCYCLES, V11, P419; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P3543, DOI 10.1021/bi00556a020; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BORCH RF, 1975, ANAL CHEM, V47, P2437, DOI 10.1021/ac60364a037; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; BRECKENR.WC, 1968, LIPIDS, V3, P291, DOI 10.1007/BF02530927; BRUCHOVSKY N, 1968, J BIOL CHEM, V243, P2012; COREY EJ, 1987, SCIENCE, V236, P68, DOI 10.1126/science.3563489; CORR PB, 1984, CIRC RES, V55, P135, DOI 10.1161/01.RES.55.2.135; DAHL TA, 1987, PHOTOCHEM PHOTOBIOL, V46, P345, DOI 10.1111/j.1751-1097.1987.tb04779.x; DAVIS PA, 1979, J BIOL CHEM, V254, P4760; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ENOCH HG, 1975, J BIOL CHEM, V250, P6693; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FIBACH E, 1986, J CELL SCI, V85, P149; Foote C.S, 1976, FREE RADICALS BIOL, P85, DOI DOI 10.1016/B978-0-12-566502-5.50010-X; FOOTE CS, 1984, METHOD ENZYMOL, V105, P36; FRIDOVICH SE, 1981, J BIOL CHEM, V256, P260; Frimer A. H., 1983, CHEM FUNCTIONAL GROU, P201; FRIMER AA, 1979, CHEM REV, V79, P359, DOI 10.1021/cr60321a001; GATT S, 1988, BIOCHIM BIOPHYS ACTA, V958, P130, DOI 10.1016/0005-2760(88)90254-8; GRAY GM, 1967, LIPID CHROMATOGRAPHI, V1, P401; HOCK H, 1957, ANGEW CHEM INT EDIT, V69, P313, DOI 10.1002/ange.19570691002; KALYANARAMAN B, 1987, P NATL ACAD SCI USA, V84, P2999, DOI 10.1073/pnas.84.9.2999; KANOFSKY JR, 1984, J AM CHEM SOC, V106, P4277, DOI 10.1021/ja00327a042; LABEQUE R, 1988, IN PRESS BIOCHEMISTR; LIANG T, 1984, J BIOL CHEM, V259, P734; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; MAN RYK, 1983, LIPIDS, V18, P677, DOI 10.1007/BF02534533; MANGOLD HK, 1960, J AM OIL CHEM SOC, V37, P383, DOI 10.1007/BF02672641; MARMER WN, 1986, LIPIDS, V21, P648, DOI 10.1007/BF02537215; MARTIN JP, 1987, J BIOL CHEM, V262, P7213; Marver H. S., 1972, METABOLIC BASIS INHE, P1087; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MIDDEN WR, 1983, J AM CHEM SOC, V105, P4129, DOI 10.1021/ja00351a001; MORAND O, 1982, BIOCHIM BIOPHYS ACTA, V711, P539, DOI 10.1016/0005-2760(82)90070-4; NAQUI A, 1986, ANNU REV BIOCHEM, V55, P137, DOI 10.1146/annurev.biochem.55.1.137; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; OWENS K, 1966, BIOCHEM J, V100, P354, DOI 10.1042/bj1000354; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHAAP AP, 1979, SINGLET OXYGEN, P173; VANCE DE, 1985, BIOCH LIPIDS MEMBRAN, P271; YAVIN E, 1972, EUR J BIOCHEM, V25, P437, DOI 10.1111/j.1432-1033.1972.tb01713.x; YAVIN E, 1972, EUR J BIOCHEM, V25, P431, DOI 10.1111/j.1432-1033.1972.tb01712.x; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	51	180	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1988	263	23					11597	11606						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P6713	3403548				2022-12-25	WOS:A1988P671300094
J	MAJIMA, E; IKAWA, K; TAKEDA, M; HASHIMOTO, M; SHINOHARA, Y; TERADA, H				MAJIMA, E; IKAWA, K; TAKEDA, M; HASHIMOTO, M; SHINOHARA, Y; TERADA, H			TRANSLOCATION OF LOOPS REGULATES TRANSPORT ACTIVITY OF MITOCHONDRIAL ADP-ATP CARRIER DEDUCED FROM FORMATION OF A SPECIFIC INTERMOLECULAR DISULFIDE BRIDGE CATALYZED BY COPPER-O-PHENANTHROLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-HEART MITOCHONDRIA; ADENINE-NUCLEOTIDE CARRIER; ADP/ATP CARRIER; CONFORMATIONAL STATE; UNCOUPLING PROTEIN; SH-GROUPS; MEMBRANE; CROSSLINKING; DETERGENT; SEQUENCE	The cross-linking reagent copper-o-phenanthroline complex (Cu(OP)(2)) specifically caused a decrease in the amount of the 3O-kDa ADP/ATP carrier in bovine submitochondrial particles associated predominantly with formation of a 60-kDa protein consisting of a cross-linked dimer of the carrier. However, Cu(OP)(2) had no effect on mitochondria. The transport of ADP via the carrier through submitochondrial particle membranes was found to be inhibited in parallel with the progress of intermolecular cross-linking. Analysis of the cross-linked site showed that a disulfide bridge was formed only between two Cys(56) residues in a pair of the first loops facing the matrix space. The transport inhibitor bongkrekic acid, which locks the m-state conformation of the carrier, had no effect on disulfide bridge formation catalyzed by Cu(OP)(2), but carboxyatractyloside, which locks the c-state conformation by acting from the cytosolic side, completely inhibited the cross-linking. These results show that the ADP/ATP carrier functions as a dimer form, and a pair of the first loops protrudes into the matrix space in the m-state, but possibly intrudes into the membrane in the c-state. Thus, it is suggested that a pair of the first loops acts as a gate and that its opening and closing are regulated by their translocation.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN; APRO LIFE SCI INST,NARUTO 772,JAPAN	Tokushima University								AQUILA H, 1982, EUR J BIOCHEM, V122, P141, DOI 10.1111/j.1432-1033.1982.tb05859.x; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; BAUMERT HG, 1981, FEBS LETT, V132, P308, DOI 10.1016/0014-5793(81)81186-6; BLOCK MR, 1984, BIOCHIM BIOPHYS ACTA, V767, P369, DOI 10.1016/0005-2728(84)90207-X; BLOCK MR, 1986, BIOCHEMISTRY-US, V25, P374, DOI 10.1021/bi00350a015; BLOCK MR, 1982, BIOCHEM BIOPH RES CO, V109, P471, DOI 10.1016/0006-291X(82)91745-4; BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; DUNCAN DD, 1988, CHEM-BIOL INTERACT, V68, P137, DOI 10.1016/0009-2797(88)90012-9; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; JOSHI S, 1984, J BIOL CHEM, V259, P2742; KLINGENBERG M, 1989, EUR J BIOCHEM, V180, P123, DOI 10.1111/j.1432-1033.1989.tb14622.x; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; KLINGENBERG M, 1985, BIOCHEMISTRY-US, V24, P3650, DOI 10.1021/bi00335a038; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; KRAMER R, 1979, BIOCHEMISTRY-US, V18, P4209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJIMA E, 1994, BIOCHEMISTRY-US, V33, P9530, DOI 10.1021/bi00198a019; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MARTY I, 1992, BIOCHEMISTRY-US, V31, P4058, DOI 10.1021/bi00131a023; NELSON DR, 1993, J MOL BIOL, V230, P1171, DOI 10.1006/jmbi.1993.1234; RICCIO P, 1975, FEBS LETT, V56, P133, DOI 10.1016/0014-5793(75)80127-X; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SHINOHARA Y, 1987, BIOCHIM BIOPHYS ACTA, V890, P387, DOI 10.1016/0005-2728(87)90167-8; SIMON S, 1994, NATURE, V371, P103, DOI 10.1038/371103a0; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; STECK TL, 1972, J MOL BIOL, V66, P295, DOI 10.1016/0022-2836(72)90481-0; TAKEGUCHI N, 1983, J BIOL CHEM, V258, P3094; TOROK K, 1985, FEBS LETT, V182, P340, DOI 10.1016/0014-5793(85)80329-X; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; ZIMMER G, 1982, FEBS LETT, V150, P207, DOI 10.1016/0014-5793(82)81335-5	32	95	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29548	29554		10.1074/jbc.270.49.29548	http://dx.doi.org/10.1074/jbc.270.49.29548			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493997	hybrid			2022-12-25	WOS:A1995TJ22700078
J	MCCORMICK, ML; BUETTNER, GR; BRITIGAN, BE				MCCORMICK, ML; BUETTNER, GR; BRITIGAN, BE			THE SPIN TRAP ALPHA-(4-PYRIDYL-L-OXIDE)-N-TERT-BUTYLNITRONE STIMULATES PEROXIDASE-MEDIATED OXIDATION OF DEFEROXAMINE - IMPLICATIONS FOR PHARMACOLOGICAL USE OF SPIN-TRAPPING AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYL RADICALS; HUMAN NEUTROPHILS; NITRONE PBN; DESFERRIOXAMINE; SUPEROXIDE; NITROXIDE; MYELOPEROXIDASE; RAT	The iron chelator deferoxamine (Desferal; DSFL) reacts with peroxidases and H2O2 to form the DSFL radical (DSFL(.)), which can be detected by EPR spectroscopy. We have found that DSFL(.) formation resulting from exposure to H2O2 and any of a number of different peroxidases is greatly enhanced in the presence of the nitrone spin trap alpha-(4-pyridyl-1-oxide)-N-tert-butylnitro (4-POBN). This enhancement was seen at 4-POBN concentrations as low as 200 mu M. We observed a modest enhancement of DSFL(.) formation with 2-methyl-2-nitrosopropane. However, no enhancement was seen with 5,5-dimethyl-1-pyrroline 1-oxide (DMPO) or phenyl-tert-butylnitrone. A modest enhancement was also seen with the nitrone compound pyridine N-oxide. 2-Methyl-2-nitrosopropane and pyridine N-oxide were additionally capable of increasing enzymatic peroxidase activity as measured by o-dianisidine and/or tetramethylbenzidine oxidation. Furthermore, at high concentrations of 4-POBN (50 mM) in the absence of DSFL, we detected a peroxidase/H2O2-dependent 12-line EPR spectrum that Likely represents a 4-POBN/(.)4-POBN nitrogen-centered spin adduct. In the presence of both 4-POBN (10 mM) and DMPO (100 mM), an 18-line EPR spectrum was observed consistent with formation of a DMPO/(.)4-POBN nitrogen-centered spin adduct. Thus, the nitrone spin trap 4-POBN can enhance the peroxidase-mediated formation of DSFL(.), possibly via the formation of a transient 4-POBN radical species. These data suggest the importance of assessing the potential for nitrone spin traps to both inhibit and enhance biological oxidation prior to their use as potential pharmacological agents.	VET ADM MED CTR,RES SERV,IOWA CITY,IA 52246; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT MED,ELECTR SPIN RESONANCE FACIL,IOWA CITY,IA 52242	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa; University of Iowa				Buettner, Garry/0000-0002-5594-1903	NHLBI NIH HHS [HL-44275] Funding Source: Medline; NIAID NIH HHS [AI-28412, AI-34954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034954, P01AI028412] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V; BRADAMANTE S, 1992, J MOL CELL CARDIOL, V24, P375, DOI 10.1016/0022-2828(92)93192-M; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; BYNOE LA, 1991, BIOCHEM BIOPH RES CO, V179, P1305, DOI 10.1016/0006-291X(91)91715-O; DAVIES MJ, 1987, BIOCHEM J, V246, P725, DOI 10.1042/bj2460725; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; GUTTERIDGE JMC, 1979, BIOCHEM J, V184, P469, DOI 10.1042/bj1840469; HEARSE DJ, 1987, CIRC RES, V60, P373; MCCORMICK ML, 1994, J BIOL CHEM, V269, P27914; MODELL B, 1982, BRIT MED J, V284, P1081, DOI 10.1136/bmj.284.6322.1081; MOREHOUSE KM, 1987, FEBS LETT, V222, P246, DOI 10.1016/0014-5793(87)80379-4; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PEDRAZACHAVERRI J, 1992, RENAL FAILURE, V14, P467, DOI 10.3109/08860229209047654; RAMOS CL, 1992, J BIOL CHEM, V267, P8307; ROBERTS RL, 1985, BLOOD, V65, P433; SORIANI M, 1993, FREE RADICAL BIO MED, V14, P589, DOI 10.1016/0891-5849(93)90140-P; SUMMERS MR, 1979, BRIT J HAEMATOL, V42, P547, DOI 10.1111/j.1365-2141.1979.tb01167.x; 1972, WORTHINGTON ENZYME M, P43	18	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29265	29269		10.1074/jbc.270.49.29265	http://dx.doi.org/10.1074/jbc.270.49.29265			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493957	hybrid			2022-12-25	WOS:A1995TJ22700038
J	MILES, AJ; KNUTSON, JB; SKUBITZ, APN; FURCHT, LT; MCCARTHY, JB; FIELDS, GB				MILES, AJ; KNUTSON, JB; SKUBITZ, APN; FURCHT, LT; MCCARTHY, JB; FIELDS, GB			A PEPTIDE MODEL OF BASEMENT-MEMBRANE COLLAGEN ALPHA-1(IV)531-543 BINDS THE ALPHA(3)BETA(1) INTEGRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MELANOMA CELL-ADHESION; IV-COLLAGEN; IN-VITRO; SYNTHETIC PEPTIDE; LAMININ; MIGRATION; RECEPTORS; ALPHA-2-BETA-1; FIBRONECTIN; IDENTIFICATION	Tumor cell adhesion to the triple-helical domain of basement membrane (type IV) collagen occurs at several different regions. Cellular recognition of the sequence spanning alpha 1(IV)531-543 has been proposed to be independent of triple-helical conformation (Miles, A. J., Skubitz, A. P. N., Furcht, L. T., and Fields, G. B. (1994) J. Biol. Chem. 269, 30939-30945). In the present study, integrin interactions with a peptide analog of the alpha 1(TV)531-543 sequence have been analyzed. Tumor cell adhesion (melanoma, ovarian carcinoma) to the alpha 1(IV)531-543 chemically synthesized peptide was inhibited by a monoclonal antibody against the alpha(3) integrin subunit, and to a lesser extent by monoclonal antibodies against the beta(1) and alpha(2) integrin subunits. An anti-alpha(5) monoclonal antibody and normal mouse IgG were ineffective as inhibitors of tumor cell adhesion to the peptide. Two cell surface proteins of 120 and 150 kDa bound to an alpha 1(IV)531-543 peptide affinity column and were eluted with 20 mM EDTA. When the eluted proteins were incubated with monoclonal antibodies against either the alpha(3) or beta(1) integrin subunit, proteins corresponding in molecular weight to alpha(3) and beta(1) integrin subunits were precipitated. No proteins were immunoprecipated with monoclonal antibodies against the alpha(2) or alpha(5) integrin subunits. Thus, the alpha(3) beta(1) integrin from two tumor cell types has been shown to bind directly to the alpha(1)(IV)531-543 peptide. The alpha 1(IV)531-543 peptide is the first collagen-like sequence that has been shown to bind the alpha(3) beta(1) integrin.	UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR BIOMED ENGN,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	MILES, AJ (corresponding author), UNIV MINNESOTA,DEPT LAB MED & PATHOL,BOX 107,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.			Skubitz, Amy/0000-0003-4672-3450	NCI NIH HHS [CA 21463] Funding Source: Medline; NIAMS NIH HHS [AR 01929] Funding Source: Medline; PHS HHS [KD 44494] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021463, R01CA021463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CAMERON JD, 1991, INVEST OPHTH VIS SCI, V32, P2766; CARMELIET G, 1994, J CELL SCI, V107, P3379; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHELBERG MK, 1989, CANCER RES, V49, P4796; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; DEDHAR S, 1993, CLIN EXP METASTAS, V11, P391, DOI 10.1007/BF00132982; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ETOH T, 1993, J INVEST DERMATOL, V100, P640, DOI 10.1111/1523-1747.ep12472299; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; HIMELSTEIN BP, 1994, J CELL SCI, V107, P477; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KAWAHARA E, 1993, JPN J CANCER RES, V84, P409, DOI 10.1111/j.1349-7006.1993.tb00151.x; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KIM JP, 1994, LAB INVEST, V71, P401; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; MALDONADO BA, 1995, INVEST OPHTH VIS SCI, V36, P364; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MORELLI JG, 1993, J INVEST DERMATOL, V101, P605, DOI 10.1111/1523-1747.ep12366064; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; OLIVERO DK, 1993, INVEST OPHTH VIS SCI, V34, P2825; PERRIS R, 1993, J CELL SCI, V1046, P1357; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Ruoslahti E., 1991, CELL BIOL EXTRACELLU, P343; SANTALA P, 1994, J BIOL CHEM, V269, P1276; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TUCKWELL DS, 1994, J CELL SCI, V107, P993; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VINK J, 1994, PIGM CELL RES, V7, P339, DOI 10.1111/j.1600-0749.1994.tb00637.x; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILKE MS, 1990, J INVEST DERMATOL, V95, P264, DOI 10.1111/1523-1747.ep12484883; YOSHINAGA IG, 1993, MELANOMA RES, V3, P435, DOI 10.1097/00008390-199311000-00006	48	75	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29047	29050		10.1074/jbc.270.49.29047	http://dx.doi.org/10.1074/jbc.270.49.29047			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493922				2022-12-25	WOS:A1995TJ22700003
J	PENG, ZH; VERMA, DPS				PENG, ZH; VERMA, DPS			A RICE HAL2-LIKE GENE ENCODES A CA2+-SENSITIVE 3'(2'),5'-DIPHOSPHONUCLEOSIDE 3'(2')-PHOSPHOHYDROLASE AND COMPLEMENTS YEAST MET22 AND ESCHERICHIA-COLI CYSQ MUTATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INOSITOL MONOPHOSPHATASE; SULFATE ASSIMILATION; METABOLISM; SULFUR; ACTIVATION; TOXICITY; PLANTS; RNAS	A plant homolog of yeast HAL2 gene (RHL) was cloned from rice (Orizya sativa L.). The RHL cDNA complemented an Escherichia coli cysteine auxotrophic mutant, cysQ, and the yeast HBL2 mutant, met22. The latter is a methionine auxotroph and cannot use sulfate, sulfite, or sulfide as sulfur sources but exhibits wild-type activities of the enzymes necessary to assimilate sulfate and has normal sulfur uptake system. These results demonstrated that HAL2, cysQ, and RHL genes encode proteins with similar function in sulfur assimilatory pathway. The RHL cDNA expressed a 40-kDa protein that was shown to catalyze the conversion of adenosine 5'-phosphate 5'-phosphosulfate (PAPS) to adenosine 5'-phosphosulfate (APS) and 3'(2')-phosphoadenosine 5'-phosphate (PAP) to AMP. The enzyme activity is Mg2+-dependent, sensitive to Ca2+, Li+, and Na+ and activated by K+. The inhibition by Ca2+ depends on the Mg2+/Ca2+ ratio and is reversible by high Mg2+ concentration. The substrate specificity and kinetics of RHL enzyme are very similar to the Chlorella 3'(2'),5'-diphosphonucleoside 3'(2')-phosphohydrolase (DPNPase). Our evidence suggests that this enzyme regulates the flux of sulfur in the sulfur-activation pathway by converting PAPS to APS. Several residues that are essential for the activity of this enzyme were identified by site-directed mutagenesis, and the possible role of DPNPase in salt tolerance is discussed.	OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT PLANT BIOL,CTR PLANT BIOTECHNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University								ALBERTS B, 1989, MOL BIOL CELL, P114; BERGLIN EH, 1985, INFECT IMMUN, V49, P538, DOI 10.1128/IAI.49.3.538-543.1985; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; BRUNNGRABER EG, 1958, J BIOL CHEM, V233, P472; GILLESPI.D, 1968, GENETICS, V59, P433; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; GOLDSCHMIDT EE, 1975, PLANT SCI LETT, V4, P293, DOI 10.1016/0304-4211(75)90101-7; GUMBER SC, 1984, PLANT PHYSIOL, V76, P40, DOI 10.1104/pp.76.1.40; HANDSON AD, 1994, P NATL ACAD SCI USA, V91, P306; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HODSON RC, 1971, PLANT PHYSIOL, V47, P300, DOI 10.1104/pp.47.2.300; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LASH LH, 1987, MOL PHARMACOL, V32, P549; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MARZLUF GA, 1993, ANNU REV MICROBIOL, V47, P31, DOI 10.1146/annurev.micro.47.1.31; MATSUHISA A, 1995, J BACTERIOL, V177, P200, DOI 10.1128/jb.177.1.200-205.1995; MURGUIA JR, 1995, SCIENCE, V267, P232; NEUWALD AF, 1992, J BACTERIOL, V174, P415, DOI 10.1128/jb.174.2.415-425.1992; NEUWALD AF, 1991, FEBS LETT, V294, P16, DOI 10.1016/0014-5793(91)81332-3; Newsholme E A, 1976, Biochem Soc Symp, P61; NEWSHOLME EA, 1984, TRENDS BIOCHEM SCI, V9, P277, DOI 10.1016/0968-0004(84)90165-8; POLLACK SJ, 1994, P NATL ACAD SCI USA, V91, P5766, DOI 10.1073/pnas.91.13.5766; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10044; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; SAIDHA T, 1987, MODELS PLANT PHYSL B, V2, P37; SATISHCHANDRAN C, 1989, J BIOL CHEM, V264, P15012; SCHIFF JA, 1987, METHOD ENZYMOL, V143, P329; SCHIMIT A, 1978, PLANT SCI LETT, V13, P193; SCHIMZ KL, 1980, ARCH MICROBIOL, V125, P89, DOI 10.1007/BF00403203; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SHUSTER L, 1953, J BIOL CHEM, V201, P535; SRIVASTAVA A, 1989, PHYSIOL PLANTARUM, V77, P320, DOI 10.1111/j.1399-3054.1989.tb05648.x; THOMAS D, 1990, J BIOL CHEM, V265, P15518; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; TSANG MLS, 1976, EUR J BIOCHEM, V65, P113; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; VOET D, 1990, BIOCHEMISTRY-US, P450; WATAD AEA, 1991, PLANT PHYSIOL, V95, P1265, DOI 10.1104/pp.95.4.1265	40	52	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29105	29110		10.1074/jbc.270.49.29105	http://dx.doi.org/10.1074/jbc.270.49.29105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493934	hybrid			2022-12-25	WOS:A1995TJ22700015
J	TOKER, A; BACHELOT, C; CHEN, CS; FALCK, JR; HARTWIG, JH; CANTLEY, LC; KOVACSOVICS, TJ				TOKER, A; BACHELOT, C; CHEN, CS; FALCK, JR; HARTWIG, JH; CANTLEY, LC; KOVACSOVICS, TJ			PHOSPHORYLATION OF THE PLATELET P47 PHOSPHOPROTEIN IS MEDIATED BY THE LIPID PRODUCTS OF PHOSPHOINOSITIDE 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; BLOOD-PLATELETS; BOVINE BRAIN; THROMBIN; PLECKSTRIN; WORTMANNIN; CELLS; POLYPHOSPHOINOSITIDES; ACTIVATION	Platelet stimulation by thrombin or the thrombin receptor activating peptide (TRAP) results in the activation of phosphoinositide 3-kinase and the production of the novel polyphosphoinositides phosphatidylinositol 3,4-bisphosphate (PtdIns-3,CP2) and phosphatidylinositol 3,4,5-trisphosphate (PtdIns-3,4,5-P-3). We have shown previously that these lipids activate calcium-independent protein kinase C (PKC) isoforms in vitro (Toker, A, Meyer, M., Reddy, K. K, Falck, J. R., Aneja, R., Aneja, S., Parra, A., Burns, D. J., Ballas, L. M. and Cantley, L. C. (1994) J. Biol. Chem. 269, 32358-32367). Activation of platelet PRC in response to TRAP is detected by the phosphorylation of the major PKC substrate in platelets, the p47 phosphoprotein, also known as pleckstrin. Here we provide evidence for two phases of pleckstrin phosphorylation in response to TRAP. A rapid phase of pleckstrin phosphorylation (<1 min) precedes the peak of PtdIns-3,4-P-2 production and is unaffected by concentrations of wortmannin (10-100 nw) that block production of this lipid. However prolonged phosphorylation of pleckstrin (>2 min) is inhibited by wortmannin concentrations that block PtdIns-3,4-P-3 production. Phorbol ester-mediated pleckstrin phosphorylation was not affected by wortmannin and wortmannin had no effect on purified platelet PKC activity. Phosphorylation of pleckstrin could be induced using permeabilized platelets supplied with exogenous gamma-P-32[ATP] and synthetic dipalmitoyl PtdIns-3,4,5-P-3 and dipalmitoyl PtdIns-3,4-P-2 micelles, but not with dipalmitoyl phosphatidylinositol 3-phosphate or phosphatidylinositol 4,5-bisphosphate. These results suggest two modes of stimulating pleckstrin phosphorylation: a rapid activation of PKC (via diacylglycerol and calcium) followed by a slower activation of calcium-independent PKCs via PtdIns-3,4-P-2.	BETH ISRAEL HOSP,DEPT MED,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT ANAT & CELL BIOL,BOSTON,MA 02115; UNIV PARIS 05,FAC SCI PHARMACEUT & BIOL,INSERM,U428,F-75270 PARIS,FRANCE; UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40536; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Kentucky; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Falck, John/0000-0002-9219-7845; Bachelot-Loza, Christilla/0000-0002-6264-902X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47874] Funding Source: Medline; NIGMS NIH HHS [GM 41890, R01 GM041890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUTHI KS, 1986, BIOCHEM J, V233, P707, DOI 10.1042/bj2330707; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTER AN, 1994, BIOCHEM J, V3012, P415; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; FRANKE TF, 1995, CELL, V81, P1; FUKAMI MH, 1995, EUR J BIOCHEM, V228, P579, DOI 10.1111/j.1432-1033.1995.tb20297.x; GAILANI D, 1990, BRIT J HAEMATOL, V74, P192, DOI 10.1111/j.1365-2141.1990.tb02565.x; GOU DM, 1994, J CHEM SOC CHEM COMM, P2125, DOI 10.1039/c39940002125; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; GRABAREK J, 1993, J BIOL CHEM, V268, P5543; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1222, P56, DOI 10.1016/0167-4889(94)90024-8; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KROLL MH, 1993, J BIOL CHEM, V268, P3520; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NISHIZUKA Y, 1995, FASEB J, V9, P485; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; PELECH SL, 1991, J BIOL CHEM, V266, P8696; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; POWIS G, 1994, CANCER RES, V54, P2419; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1989, J CELL BIOCHEM, V40, P133, DOI 10.1002/jcb.240400202; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745	44	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29525	29531		10.1074/jbc.270.49.29525	http://dx.doi.org/10.1074/jbc.270.49.29525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493994	Green Published, hybrid			2022-12-25	WOS:A1995TJ22700075
J	EVANS, GA; GOLDSMITH, MA; JOHNSTON, JA; XU, WD; WEILER, SR; ERWIN, R; HOWARD, OMZ; ABRAHAM, RT; OSHEA, JJ; GREENE, WC; FARRAR, WL				EVANS, GA; GOLDSMITH, MA; JOHNSTON, JA; XU, WD; WEILER, SR; ERWIN, R; HOWARD, OMZ; ABRAHAM, RT; OSHEA, JJ; GREENE, WC; FARRAR, WL			ANALYSIS OF INTERLEUKIN-2 DEPENDENT SIGNAL-TRANSDUCTION THROUGH THE SHC/GRB2 ADAPTER PATHWAY - INTERLEUKIN-2-DEPENDENT MITOGENESIS DOES NOT REQUIRE SHC PHOSPHORYLATION OR RECEPTOR ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; IL-2 RECEPTOR; CELL LINE; PROTEIN; ACTIVATION; GROWTH; RAF-1; GRB2; DOMAIN	The interleukin (IL)-2 receptor system has previously been shown to signal through the association and tyrosine phosphorylation of Shc. This study demonstrates that the IL-2 receptor beta (IL-2R beta) chain is the critical receptor component required to mediate this effect. The use of IL-2R beta chain deletion mutants transfected into a Ba/F3 murine cell model describes a requirement for the IL-2R beta ''acid-rich'' domain between amino acids 315 and 384 for Shc tyrosine phosphorylation and receptor association. COS cell co-transfection studies of IL-BR beta chain constructs containing point mutations of tyrosine to phenylalanine along with the tyrosine kinase Jak-1 and a hemagglutinin-tagged Shc revealed that the motif surrounding phosphorylated tyrosine 338 within the acid-rich domain of the IL-2R beta is a binding site for Shc. Deletion of this domain has previously been shown to abrogate the ability of IL-2 to activate Ras but does not affect IL-2-dependent mitogenesis in the presence of serum. Proliferation assays of Ba/F3 cells containing IL-2R beta chain deletion mutants in serum-free medium with or without insulin shows that deletion of the acid-rich domain does not affect IL-2-driven mitogenesis regardless of the culture conditions. This study thus defines the critical domain within the IL-2R beta chain required to mediate Shc binding and Shc tyrosine phosphorylation and further shows that Shc binding and phosphorylation are not required for IL-2-dependent mitogenesis. Neither serum nor insulin is required to supplement the loss of induction of the Shc adapter or Ras pathways, which therefore suggests a novel mechanism for mitogenic signal transduction mediated by this hematopoietin receptor.	SCI APPLICAT INT CORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, MOLEC IMMUNOREGULAT LAB, CYTOKINE MECH SECT, FREDERICK, MD 21702 USA; UNIV CALIF SAN FRANCISCO, SCH MED, GLADSTONE INST VIROL & IMMUNOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MED, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT IMMUNOL & MICROBIOL, SAN FRANCISCO, CA 94141 USA; NIAMSD, ARTHRITIS & RHEUMATISM BRANCH, LYMPHOCYTE CELL BIOL SECT, BETHESDA, MD 20892 USA; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA	Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Mayo Clinic			Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052				[Anonymous], 1994, PROGRAM MANUAL WISCO; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; EVANS GA, 1994, J BIOL CHEM, V269, P23407; EVANS GA, 1992, BIOCHEM J, V282, P759, DOI 10.1042/bj2820759; GAULTON GN, 1994, CHEM IMMUNOL, V59, P91; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; GOLDSMITH MA, 1995, IN PRESS J VIROL; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HOWARD OMZ, 1995, BIOCHEM J, V306, P217, DOI 10.1042/bj3060217; IHLE JN, 1982, J IMMUNOL, V129, P1377; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LEONARD WJ, 1994, ADV EXP MED BIOL, V365, P225; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MILLS GB, 1985, J BIOL CHEM, V260, P2500; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUI H, 1992, J BIOL CHEM, V267, P24076; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAKAMAKI K, 1994, FEBS LETT, V353, P133, DOI 10.1016/0014-5793(94)01024-2; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WLODZIMIERZ M, 1992, J BIOL CHEM, V267, P15281; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHU XY, 1994, J BIOL CHEM, V269, P5518	50	68	68	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28858	28863		10.1074/jbc.270.48.28858	http://dx.doi.org/10.1074/jbc.270.48.28858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499411	hybrid			2022-12-25	WOS:A1995TH05600055
J	LESAGE, F; GUILLEMARE, E; FINK, M; DUPRAT, F; HEURTEAUX, C; FOSSET, M; ROMEY, G; BARHANIN, J; LAZDUNSKI, M				LESAGE, F; GUILLEMARE, E; FINK, M; DUPRAT, F; HEURTEAUX, C; FOSSET, M; ROMEY, G; BARHANIN, J; LAZDUNSKI, M			MOLECULAR-PROPERTIES OF NEURONAL G-PROTEIN-ACTIVATED INWARDLY RECTIFYING K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANOMALOUS RECTIFICATION; EXPRESSION CLONING; POTASSIUM CHANNEL; BINDING PROTEIN; CARDIAC-CELLS; STARFISH EGG; ION CHANNELS; BRAIN; SOMATOSTATIN; MUSCLE	Four cDNA-encoding G-activated inwardly rectifying K+ channels have been cloned recently (Kubo, Y., Reuveny, E., Slesinger, P. A., Jan, Y. N., and Jan, L. Y. (1993) Nature 364, 802-806; Lesage, F., Duprat, F., Fink, M., Guillemare, E., Coppola, T., Lazdunski, M., and Hugnot, J. P. (1994) FEES Lett. 353, 37-42; Krapivinsky, G., Gor don, E. A., Wickman, K., Velimirovic, B., Krapivinsky, L., and Clapham, D. E. (1995) Nature 374, 135-141). We report the cloning of a mouse GIRK2 splice variant, noted mGIRK2A. Both channel proteins are functionally expressed in Xenopus oocytes upon injection of their cRNA, alone or in combination with the GIRK1 cRNA. Three GIRK channels, mGIRK1-3, are shown to be present in the brain. Colocalization in the same neurons of mGIRK1 and mGIRK2 supports the hypothesis that native channels are made by an heteromeric subunit assembly. GIRK3 channels have not been expressed successfully, even in the presence of the other types of subunits. However, GIRK3 chimeras with the amino and carboxyl-terminal of GIRK2 are functionally expressed in the presence of GIRK1. The expressed mGIRK2 and mGIRK1, -2 currents are blocked by Ba2+ and Cs+ ions. They are not regulated by protein kinase A and protein kinase C. Channel activity runs down in inside-out excised patches, and ATP is required to prevent this rundown. Since the nonhydrolyzable ATP analog AMP-PCP is also active and since addition of kinases A and C as well as alkaline phosphatase does not modify the ATP effect, it is concluded that ATP hydrolysis is not required. An ATP binding process appears to be essential for maintaining a functional state of the neuronal inward rectifier K+ channel. A Na+ binding site on the cytoplasmic face of the membrane acts in synergy with the ATP binding site to stabilize channel activity.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Duprat, Fabrice/D-1221-2013; HEURTEAUX, Catherine/M-4947-2016; Lesage, Florian/D-5097-2011; Lesage, Florian/P-9780-2019	Duprat, Fabrice/0000-0001-8774-1220; HEURTEAUX, Catherine/0000-0002-9741-9777; Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AMOROSO S, 1990, SCIENCE, V247, P852, DOI 10.1126/science.2305257; ASHFORD MLJ, 1988, PFLUG ARCH EUR J PHY, V412, P297, DOI 10.1007/BF00582512; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; DEWEILLE JR, 1989, P NATL ACAD SCI USA, V86, P2971; DRYER SE, 1994, TRENDS NEUROSCI, V17, P155, DOI 10.1016/0166-2236(94)90093-0; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HAGIWARA S, 1979, J PHYSIOL-LONDON, V292, P251, DOI 10.1113/jphysiol.1979.sp012849; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HARTZELL HC, 1981, NATURE, V291, P539, DOI 10.1038/291539a0; HEURTEAUX C, 1993, MOL BRAIN RES, V18, P17, DOI 10.1016/0169-328X(93)90169-P; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; KAMEYAMA M, 1984, NATURE, V309, P354, DOI 10.1038/309354a0; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; KATZ B, 1949, ARCH SCI PHYSIOL, V3, P285; KOBAYASHI T, 1995, BIOCHEM BIOPH RES CO, V208, P1166, DOI 10.1006/bbrc.1995.1456; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1994, TRENDS CARDIOVAS MED, V4, P64, DOI 10.1016/1050-1738(94)90011-6; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; LUK HN, 1990, PFLUG ARCH EUR J PHY, V416, P766, DOI 10.1007/BF00370627; MA GH, 1995, MOL PHARMACOL, V47, P1035; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; MIYAKE M, 1989, P NATL ACAD SCI USA, V86, P3419, DOI 10.1073/pnas.86.9.3419; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; QUAST U, 1993, TRENDS PHARMACOL SCI, V14, P332, DOI 10.1016/0165-6147(93)90006-6; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	46	228	234	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28660	28667		10.1074/jbc.270.48.28660	http://dx.doi.org/10.1074/jbc.270.48.28660			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499385	hybrid			2022-12-25	WOS:A1995TH05600029
J	NELSON, WC; HOWARD, MT; SHERMAN, JA; MATSON, SW				NELSON, WC; HOWARD, MT; SHERMAN, JA; MATSON, SW			THE TRAY GENE-PRODUCT AND INTEGRATION HOST FACTOR STIMULATE ESCHERICHIA-COLI DNA HELICASE I-CATALYZED NICKING AT THE F-PLASMID ORIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNWINDING ENZYME; SEX FACTOR; PROTEIN; ORIGIN; BINDING; PURIFICATION; SYSTEM	F plasmid conjugative transfer is initiated by the introduction of a site- and strand-specific nick within the plasmid origin of transfer (oriT), Genetic studies have shown nick formation to be dependent on both the traI and traY genes, However, highly purified TraIp, the traI gene product, nicks oriT in a site- and strand-specific manner in the absence of the traY gene product (TraYp) in vitro (Matson, S. W., and Morton, B. S. (1991) J. Biol, Chem. 266, 16232-16237). Analysis of the oriT region has revealed binding sites for TraYp and the host protein integration host factor (IHF). To explore possible interactions occurring at oriT, highly purified TraIp, TraYp, and IHF were incubated with a supercoiled oriT-containing DNA substrate, A marked enhancement of the nicking reaction catalyzed by TraIp was observed in a reaction that required both TraYp and IHF, In addition, TraIp was able to nick a linear oriT-containing double-stranded DNA substrate when IHF and TraYp were present in the reaction; such a substrate is not nicked by TraIp alone, Individual protein concentration requirements for the supercoiled and linear nicking reactions were similar, and the reactions occurred at equal velocity, suggesting that they are biochemically identical, Concentrations of TraYp and IHF that yield half-maximal activity in the nicking assays compare well with the reported K-D values for the IHF and TraYp binding sites in oriT, These data, coupled with data presented in the accompanying report, suggest that TraYp and IHF bind independent of one another, forming a nucleo-protein complex with oriT that can be recognized and nicked by TraIp.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Nelson, William C/E-9263-2016	Nelson, William C/0000-0002-1873-3929	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33476] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1977, J MOL BIOL, V110, P667, DOI 10.1016/S0022-2836(77)80083-1; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; BENZ I, 1990, EUR J BIOCHEM, V189, P267, DOI 10.1111/j.1432-1033.1990.tb15486.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CLEWELL DB, 1993, BACTERIAL CONJUGATIO, P23; DILAURENZIO L, 1992, MOL MICROBIOL, V6, P2951; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; EVERETT R, 1982, EMBO J, V1, P747, DOI 10.1002/j.1460-2075.1982.tb01241.x; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FU YHF, 1991, J BACTERIOL, V173, P1012, DOI 10.1128/jb.173.3.1012-1020.1991; GAMAS P, 1987, MOL GEN GENET, V207, P302, DOI 10.1007/BF00331593; GAO Q, 1994, MOL MICROBIOL, V11, P449, DOI 10.1111/j.1365-2958.1994.tb00326.x; INAMOTO S, 1994, J BIOCHEM-TOKYO, V116, P838, DOI 10.1093/oxfordjournals.jbchem.a124604; IPPENIHLER KA, 1986, ANNU REV GENET, V20, P593, DOI 10.1146/annurev.ge.20.120186.003113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE EE, 1990, J BACTERIOL, V172, P1385, DOI 10.1128/jb.172.3.1385-1391.1990; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; LUO Y, 1994, MOL MICROBIOL, V11, P459, DOI 10.1111/j.1365-2958.1994.tb00327.x; MATSON SW, 1991, J BIOL CHEM, V266, P16232; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; NELSON WC, 1993, J BACTERIOL, V175, P2221, DOI 10.1128/JB.175.8.2221-2228.1993; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SHERMAN JA, 1994, J BIOL CHEM, V269, P26620; TRAXLER BA, 1988, J MOL BIOL, V204, P205, DOI 10.1016/0022-2836(88)90609-2; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; WILLETTS N, 1980, ANNU REV GENET, V14, P41, DOI 10.1146/annurev.ge.14.120180.000353	32	81	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28374	28380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499339				2022-12-25	WOS:A1995TG21000064
J	KUNO, K; ISHIKAWA, Y; ERNST, MK; OGATA, M; RICE, NR; MUKAIDA, N; MATSUSHIMA, K				KUNO, K; ISHIKAWA, Y; ERNST, MK; OGATA, M; RICE, NR; MUKAIDA, N; MATSUSHIMA, K			IDENTIFICATION OF AN I-KAPPA-B-ALPHA-ASSOCIATED PROTEIN-KINASE IN A HUMAN MONOCYTIC CELL-LINE AND DETERMINATION OF ITS PHOSPHORYLATION SITES ON I-KAPPA-B-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; ACTIVATION; PRECURSOR; P105; MACROPHAGES; INVITRO; P50	Nuclear factor kappa B (NF-kappa B) is stored in the cytoplasm as an inactive form through interaction with I kappa B, Stimulation of cells leads to a rapid phosphorylation of I kappa B alpha, which is presumed to be important for the subsequent degradation, We have recently reported the establishment of a lipopolysaccharide (LPS)-dependent cell free activation system of NF-kappa B in association with the induction of I kappa B alpha phosphorylation, In this study, we have identified a kinase in cell extracts from the LPS stimulated human monocytic cell line, THP-1, that specifically binds and phosphorylates I kappa B alpha. LPS stimulation transiently enhanced the I kappa B alpha-bound kinase activity in THP-1 cells, Mutational analyses of I kappa B alpha and competition experiments with the synthetic peptides identified major phosphorylation sites by the bound kinase as Ser and Thr residues in the C-terminal acidic domain of I kappa B alpha, Moreover, we show that the peptide, corresponding to the C-terminal acidic domain of I kappa B alpha, blocked the LPS induced NF-kappa B activation as well as inducible phosphorylation of endogenous I kappa B alpha in a cell-free system using THP-1 cells. These results suggested that the bound kinase is involved in the signaling pathway of LPS by inducing the phosphorylation of the C terminal region of I kappa B alpha and subsequent dissociation of the NF-kappa B . I kappa B alpha complex.	KANAZAWA UNIV,CANC RES INST,DEPT PHARMACOL,KANAZAWA,ISHIKAWA 920,JAPAN; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD 21702	Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			KUNO, Kouji/D-8439-2015; Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1994, MOL CELL BIOL, V13, P3301; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; COOPER JA, 1982, METHOD ENZYMOL, V99, P387; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GENG Y, 1993, J IMMUNOL, V151, P6692; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOHMANN HP, 1991, MOL CELL BIOL, V11, P2315, DOI 10.1128/MCB.11.4.2315; ISHIKAWA Y, 1995, J BIOL CHEM, V270, P4158, DOI 10.1074/jbc.270.8.4158; KERR JD, 1991, GENE DEV, V5, P1464; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leonardo MJ, 1998, CELL, V58, P227; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MUKAIDA N, 1991, J BIOL CHEM, V265, P21128; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NAUMANN M, 1994, EMBO J, V13, P4595; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955	41	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27914	27919		10.1074/jbc.270.46.27914	http://dx.doi.org/10.1074/jbc.270.46.27914			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499266	hybrid			2022-12-25	WOS:A1995TE73600077
J	SALERNO, JC; FREY, C; MCMILLAN, K; WILLIAMS, RF; MASTERS, BSS; GRIFFITH, OW				SALERNO, JC; FREY, C; MCMILLAN, K; WILLIAMS, RF; MASTERS, BSS; GRIFFITH, OW			CHARACTERIZATION BY ELECTRON-PARAMAGNETIC-RESONANCE OF THE INTERACTIONS OF L-ARGININE AND L-THIOCITRULLINE WITH THE HEME COFACTOR REGION OF NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-PRESSURE; RE-EXAMINATION; BRAIN; INTERMEDIATE; CALMODULIN; COMPLEXES; EPR	Nitric oxide synthase (NOS) catalyzes sequential NADPH- and O-2-dependent mono-oxygenase reactions converting L-arginine to N-omega-hydroxy-L-arginine and N-omega-hydroxy-L-arginine to citrulline and nitric oxide, The homodimeric enzyme contains one heme/monomer, and that cofactor is thought to mediate both partial reactions, Here we show by electron paramagnetic resonance spectroscopy that binding of substrate L-arginine to neuronal NOS perturbs the heme cofactor binding pocket without directly interacting as a sixth axial heme ligand; heme iron is exclusively high spin, In contrast, binding of L-thiocitrulline, a NOS inhibitor, produces both high and low spin iron spectra; L-thiocitrulline sulfur is a sixth axial heme ligand in one, but not all, of the low spin forms, The high spin forms of the L-thiocitrulline NOS complex display a distortion in the opposite direction to that caused by L-arginine binding, The findings elucidate the binding interactions of L-arginine and L-thiocitrulline to neuronal NOS and demonstrate that each causes a unique perturbation to the heme cofactor pocket of NOS.	MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA; RENSSELAER POLYTECH INST, DEPT BIOL, TROY, NY 12180 USA; RENSSELAER POLYTECH INST, CTR BIOCHEM & BIOPHYS, TROY, NY 12180 USA; UNIV TEXAS, HLTH SCI CTR, CTR RES IMAGING, SAN ANTONIO, TX 78284 USA; UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	Medical College of Wisconsin; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio			salerno, john c/A-2595-2014		NHLBI NIH HHS [HL30050] Funding Source: Medline; NIDDK NIH HHS [DK48423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030050, R01HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; BOHAN TL, 1977, J MAGN RESON, V26, P109, DOI 10.1016/0022-2364(77)90240-2; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; EISENBER.P, 1966, J CHEM PHYS, V45, P2832, DOI 10.1063/1.1728035; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; FREY C, 1994, J BIOL CHEM, V269, P26083; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; KLATT P, 1993, J BIOL CHEM, V268, P14781; KOTANI M, 1969, ANN NY ACAD SCI, V158, P20, DOI 10.1111/j.1749-6632.1969.tb56212.x; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PEISACH J, 1973, ANN NY ACAD SCI, V206, P310, DOI 10.1111/j.1749-6632.1973.tb43219.x; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; SALERNO JC, 1979, J BIOL CHEM, V254, P4828; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SLAPPENDEL S, 1981, BIOCHIM BIOPHYS ACTA, V667, P77, DOI 10.1016/0005-2795(81)90068-4; SONO M, 1982, J BIOL CHEM, V257, P5496; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; VAANGARD T, 1985, BIOCHEM SOC T, V13, P619; WANG JL, 1993, J BIOL CHEM, V268, P22255	37	60	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27423	27428		10.1074/jbc.270.46.27423	http://dx.doi.org/10.1074/jbc.270.46.27423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499198	hybrid			2022-12-25	WOS:A1995TE73600009
J	JUNG, JM; BRUNER, JM; RUAN, SB; LANGFORD, LA; KYRITSIS, AP; KOBAYASHI, T; LEVIN, VA; ZHANG, W				JUNG, JM; BRUNER, JM; RUAN, SB; LANGFORD, LA; KYRITSIS, AP; KOBAYASHI, T; LEVIN, VA; ZHANG, W			INCREASED LEVELS OF P21(WAF1/CIP1) IN HUMAN BRAIN-TUMORS	ONCOGENE			English	Article						GLIOMA; P21(WAF1/CIP1); CELL CYCLE; IMMUNOHISTOCHEMISTRY	HUMAN GLIOMAS; AMPLIFICATION; GENE; EXPRESSION; RECEPTORS	The cdk inhibitor p21(WAF1/Cip1) (p21), which can be transcriptionally activated by p53, functions to block cell cycle progression. In this study, we analysed the expression of p21 in normal and reactive brain and in gliomas of various malignancy grades. Southern blotting showed no p21 gene deletion. Western blotting and immunohistochemical assay showed that the levels of p21 protein in normal and reactive brain tissue were very low; however, p21 was elevated in a majority of gliomas tested, regardless of their malignancy grades. In glioblastoma multiforme, marked elevation of p21 was observed in samples harboring either wild-type or mutant p53. But, in anaplastic astrocytomas, the level of p21 was not elevated in samples harboring mutant-type p53. Immunohistochemical staining of paraffin-embedded astrocytomas and glioblastomas showed that tumor cells and not contaminating normal cells were positive for p21. Therefore, overexpression of p21 appears to be an early event in the development of glial neoplasms and p53-dependent p21 expression appears to be tumor grade specific.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P33; CHOZICK BS, 1994, CANCER, V73, P406, DOI 10.1002/1097-0142(19940115)73:2<406::AID-CNCR2820730228>3.0.CO;2-S; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FLEMING TP, 1992, CANCER RES, V52, P4550; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; JEN J, 1994, CANCER RES, V54, P6353; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KORNBLAU SM, 1994, BLOOD, V84, P256; KUN LE, 1994, MOSS RAD ONCOLOGY RA, P737; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LI YJ, 1995, ONCOGENE, V10, P599; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LOUIS DN, 1994, J NEUROPATH EXP NEUR, V53, P11, DOI 10.1097/00005072-199401000-00002; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MORRISON RS, 1990, CANCER RES, V50, P2524; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PATCHELL RA, 1992, CHEMOTHERAPY SOURCE, P908; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Russell D., 1989, PATHOLOGY TUMORS NER; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VAN MEIR EG, 1994, CANCER RES, V54, P649; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x; YUNG WKA, 1990, CANCER COMMUN, V2, P201, DOI 10.3727/095535490820874416; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, LEUKEMIA LYMPHOMA, V16, P191, DOI 10.3109/10428199509049757; Zhang W, 1995, CLIN CANCER RES, V1, P1051; ZHANG W, 1995, CANCER RES, V55, P668	41	162	166	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2021	2028						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478521				2022-12-25	WOS:A1995TF29700012
J	MALIK, KTA; WALLACE, JI; IVINS, SM; BROWN, KW				MALIK, KTA; WALLACE, JI; IVINS, SM; BROWN, KW			IDENTIFICATION OF AN ANTISENSE WT1 PROMOTER IN INTRON-1 - IMPLICATIONS FOR WT1 GENE-REGULATION	ONCOGENE			English	Article						WT1 AUTOREGULATION; ANTISENSE PROMOTER	WILMS-TUMOR GENE; FACTOR-A-CHAIN; GROWTH-FACTOR; GENITOURINARY DEVELOPMENT; TRANSCRIPTION FACTORS; GENOMIC ORGANIZATION; UROGENITAL SYSTEM; SUPPRESSOR WT1; EXPRESSION; DELETION	Expression of the Wilms' tumour suppressor gene, WT1, is tightly regulated during nephrogenesis, and loss of function of its gene product correlates with malignancy. By using luciferase reporter gene constructs containing DNA sequences from the first intron of the WT1 gene, we have identified an antisense WT1 promoter operational in the opposite direction relative to the 5' promoter. Transcription directed by the promoter is negatively regulated by upstream elements, but is activated by expression of WT1. This effect of WT1 is reciprocal to that observed on the 5' promoter, suggesting that antisense promoter activity is involved in WT1 gene regulation. By mimicking expression of the transcript regulated by the antisense promoter, we demonstrate that cellular levels of WT1 can be effectively down-regulated by antisense mRNA complementary to sequences in the first exon of WT1.			MALIK, KTA (corresponding author), UNIV BRISTOL, SCH MED SCI, DEPT PATHOL & MICROBIOL, CLIC RES UNIT, UNIV WALK, BRISTOL BS8 1TD, AVON, ENGLAND.		Brown, Keith/C-3355-2009	Brown, Keith/0000-0002-4258-5129; Malik, Karim/0000-0002-8965-200X				BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BENNINGTON JL, 1975, ATLAS TUMOR PATHOLOG; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BRENNER B, 1992, ONCOGENE, V7, P1431; BROWN KW, 1992, ONCOGENE, V7, P763; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1994, ONCOGENE, V9, P583; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1994, ONCOGENE, V9, P2059; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HOFMANN W, 1993, ONCOGENE, V8, P3123; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; MATSUNAGA E, 1981, HUM GENET, V57, P231; MIWA H, 1992, LEUKEMIA, V6, P405; MIYAGI T, 1993, LEUKEMIA, V7, P970; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Sambrook J., 1989, MOL CLONING, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA PM, 1992, CANCER RES, V52, P6407; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; TADOKORO K, 1992, JPN J CANCER RES, V83, P1198, DOI 10.1111/j.1349-7006.1992.tb02745.x; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	56	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1589	1595						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478583				2022-12-25	WOS:A1995TC53500017
J	GAO, X; ZACHAREK, A; GRIGNON, DJ; SAKR, W; POWELL, IJ; PORTER, AT; HONN, KV				GAO, X; ZACHAREK, A; GRIGNON, DJ; SAKR, W; POWELL, IJ; PORTER, AT; HONN, KV			LOCALIZATION OF POTENTIAL TUMOR-SUPPRESSOR LOCI TO A LESS-THAN-2 MB REGION ON CHROMOSOME 17Q IN HUMAN PROSTATE-CANCER	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; DELETION MAPPING; TUMOR SUPPRESSOR GENE; POLYMERASE CHAIN REACTION; PROSTATIC CARCINOMA	BREAST-OVARIAN-CANCER; FAMILIAL BREAST; REPEAT POLYMORPHISM; ESOPHAGEAL CANCERS; LINKAGE ANALYSIS; ALLELIC LOSS; GENES; P53; CARCINOMA; DELETION	We recently demonstrated a high frequency of loss of heterozygosity (LOH) at the D17S856 and D17S855 (within the BRCA1 gene) loci in primary prostate cancer, suggesting that the BRCA1, gene and/or other tumor suppressor gene(s) located within the interval of the D17S856 and D17S855 loci and/or within the vicinity of this interval may be important in prostate cancer (Cancer Res., 55: 1002-1005, 1995). To further define the exact boundary of the deleted region (i.e., D17S856/D17S855) and to detect other possible LOH regions on the long arm of chromosome 17, we analysed 23 matched normal and tumor DNAs with 15 polymorphic microsatellite markers spanning chromosome 17q12-21. Eleven of 22 (50%) informative tumors showed allelic deletion at one or more of the loci studied. A minimal area of LOH was identified to extend from the proximal boundary at the D17S776 locus to the distal boundary at the D17S855 locus, spanning an estimated <2 Mb segment on chromosome 17q21. Our results suggest that a potential tumor suppressor gene(s) may reside in the <2 Mb region centromeric (inclusive) to the BRCA1 gene and that this tumor suppressor gene(s) may be involved in the formation of prostate cancer.	WAYNE STATE UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT UROL,DETROIT,MI 48202	Wayne State University; Wayne State University; Wayne State University								ANDERSON LA, 1993, GENOMICS, V17, P618, DOI 10.1006/geno.1993.1381; ARASON A, 1993, AM J HUM GENET, V52, P711; BAQUET CR, 1991, J NATL CANCER I, V83, P551, DOI 10.1093/jnci/83.8.551; BERGERHEIM USR, 1993, GENE CHROMOSOME CANC, V3, P215; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOVA GS, 1993, CANCER RES, V53, P3869; BRAWN PN, 1993, CANCER, V71, P2569, DOI 10.1002/1097-0142(19930415)71:8<2569::AID-CNCR2820710822>3.0.CO;2-R; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; CHIARODO A, 1991, CANCER RES, V51, P2498; CROPP CS, 1993, CANCER RES, V53, P5617; CROPP CS, 1994, CANCER RES, V54, P2548; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; EASTON DF, 1993, AM J HUM GENET, V52, P678; EFFERT PJ, 1993, J UROLOGY, V150, P257, DOI 10.1016/S0022-5347(17)35458-7; FLEJTER WL, 1993, HUM MOL GENET, V2, P1080, DOI 10.1093/hmg/2.7.1080; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1995, INT J ONCOL, V6, P111; GAO X, 1993, CANCER RES, V53, P2723; GAO X, 1995, IN PRESS PATHOL ONCO; GAO X, 1995, CANCER MOL BIOL, V2, P475; GAO X, 1995, IN PRESS UROL; GAO X, 1994, CANCER MOL BIOL, V1, P297; GAO X, 1995, IN PRESS ONCOGENE; GAO XA, 1994, ONCOGENE, V9, P2999; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUANG Y, 1992, CANCER RES, V52, P6525; ILES DE, 1993, HUM MOL GENET, V2, P863; ISAACS WB, 1991, CANCER RES, V51, P4716; ISSHIKI K, 1994, ONCOGENE, V9, P1649; JACOBS IJ, 1993, CANCER RES, V53, P1218; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V26, P436; KEEN AJ, 1994, ONCOGENE, V9, P2083; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORI T, 1994, CANCER RES, V54, P3396; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; PEEHL DM, 1993, CANCER, V71, P1159, DOI 10.1002/1097-0142(19930201)71:3+<1159::AID-CNCR2820711439>3.0.CO;2-U; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V20, P1961; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; ROACH M, 1992, INT J RADIAT ONCOL, V24, P441, DOI 10.1016/0360-3016(92)91058-U; SAITO H, 1993, CANCER RES, V53, P3382; SIMARD J, 1994, NAT GENET, V8, P393; TARMIN L, 1994, CANCER RES, V54, P6094; TRAPMAN J, 1994, CANCER RES, V54, P6061; UCHIDA T, 1995, ONCOGENE, V10, P1019; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	71	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1241	1247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478543				2022-12-25	WOS:A1995RY96700003
J	OH, Y; MULLER, HL; PHAM, H; ROSENFELD, RG				OH, Y; MULLER, HL; PHAM, H; ROSENFELD, RG			DEMONSTRATION OF RECEPTORS FOR INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-3 ON HS578T HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IGF-I; MOLECULAR-CLONING; FIBROBLASTS; IDENTIFICATION; MECHANISMS; SEQUENCE; SERUM	Hs578T human breast cancer cells are from an estrogen receptor-negative breast cell line derived from a highly aggressive mammary tumor. Our previous insulin-like growth factor binding protein-3 (IGFBP-3) binding studies (Oh, Y., Muller, H. L., Lamson, G., and Rosenfeld, R. G. (1993) J. Biol. Chem. 268, 14964-14971) have demonstrated specific binding of IGFBP-3 on the Hs578T cell surface and a significant inhibitory effect of IGFBP-3, itself, on monolayer growth. In this study, we have demonstrated cell surface association proteins that are specific for IGFBP-3 by showing: 1) detection of 20-, 26-, and 50-kDa proteins by affinity cross-linking with I-125-IGFBP-3E. coli and immunoprecipitation of cell monolayers and cell lysates with anti-IGFBP-3 antibodies; 2) dose-dependent competition of I-125-IGFBP-3E. coli by unlabeled IGFBP-3E. coli; 3) inhibition of IGFBP-3 binding to these cell surface proteins by EDTA and by coincubation with native insulin-like growth factor II (IGF-II), but not by coincubation with [Gln6,Ala7,Tyr18, Leu19,Leu27]IGF-II, an IGF-II analog with decreased affinity for IGFBP-3; and 4) partial purification of 20- and 26-kDa species by IGFBP-3-anti-IGFBP-3 antibody immunoaffinity membranes. Characteristics of these specific IGFBP-3 cell surface association proteins are identical to those observed in our previous monolayer binding assay and monolayer growth assay experiments. The specificity of binding and the inhibitory effect of IGFBP-3 binding on Hs578T cell growth suggest that these cell surface proteins are IGFFBP-3-specific receptors or receptor subunits mediating the direct inhibitory effect of IGFBP-3 on monolayer growth of Hs578T cells.			OH, Y (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV PEDIAT ENDOCRINOL,RM S306,STANFORD,CA 94305, USA.		müller, Hermann l/AAC-1637-2020	Muller, Hermann L./0000-0003-4929-9966	NCI NIH HHS [CA58110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BINOUX M, 1988, J CLIN ENDOCR METAB, V67, P509, DOI 10.1210/jcem-67-3-509; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; CONOVER CA, 1990, ENDOCRINOLOGY, V126, P3139, DOI 10.1210/endo-126-6-3139; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; DELBE J, 1991, BIOCHEM BIOPH RES CO, V179, P495, DOI 10.1016/0006-291X(91)91398-V; FURLANETTO RW, 1984, CANCER RES, V44, P2122; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3041; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; OH Y, 1992, ENDOCRINOLOGY, V131, P3123, DOI 10.1210/en.131.6.3123; OH Y, 1993, GROWTH REGULAT, V3, P84; OH YM, 1993, J BIOL CHEM, V268, P14964; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SMITH EP, 1992, ENDOCRINOLOGY, V131, P2733, DOI 10.1210/en.131.6.2733; Spratt SK, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037503; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176	23	291	293	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26045	26048						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7504671				2022-12-25	WOS:A1993MK42500004
J	YANO, H; NAKANISHI, S; KIMURA, K; HANAI, N; SAITOH, Y; FUKUI, Y; NONOMURA, Y; MATSUDA, Y				YANO, H; NAKANISHI, S; KIMURA, K; HANAI, N; SAITOH, Y; FUKUI, Y; NONOMURA, Y; MATSUDA, Y			INHIBITION OF HISTAMINE-SECRETION BY WORTMANNIN THROUGH THE BLOCKADE OF PHOSPHATIDYLINOSITOL 3-KINASE IN RBL-2H3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; MYOSIN LIGHT CHAIN; PROTEIN-KINASE-C; RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; GROWTH-FACTOR; 2H3 CELLS; MEDIATED HISTAMINE; HUMAN NEUTROPHIL	The surface engagement of high affinity immunoglobulin E receptor (FcepsilonRI) of rat basophilic leukemia 2H3 (RBL-2H3) cells induced histamine secretion and leukotriene release following activation of the tyrosine kinase Lyn together with phosphatidylinositol 3-kinase (PI3-kinase). Wortmannin inhibited the activity of partially purified PI3-kinase from calf thymus, as well as the PI3-kinase activity in anti-PI3-kinase p85 immunoprecipitates from RBL-2H3 cells, at a concentration as low as 1.0 nM and with IC50 values of 3.0 nM, but did not inhibit P14-kinase activity. The inhibition of PI3-kinase by wortmannin was irreversible. Wortmannin inhibited both FcepsilonRI-mediated histamine secretion and leukotriene release up to 80% with IC50 values of 2.0 and 3.0 nM, respectively. Wortmannin inhibited PI3-kinase activity in intact cells up to 80% with an IC50 value of 2.0 nM, which is almost equal to those for PI3-kinase in vitro and for histamine secretion and leukotriene release. With anti-wortmannin antibody, we have shown that wortmannin binds to the 110-kDa protein, but not to P13-kinase 85-kDa regulatory subunit both in vitro and in whole cells. Furthermore, there was a positive correlation between the potencies of wortmannin derivatives as inhibitors of P13-kinase and as inhibitors of histamine secretion. Wortmannin had no effect on the activation of the tyrosine kinase Lyn. These results suggest that P13-kinase is involved in the signal transduction pathway responsible for histamine secretion following stimulation of FcepsilonRI and that wortmannin blocks these responses through direct interaction with the catalytic subunit of this enzyme.	KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,3-6-6 ASAHIMACHI,MACHIDA,TOKYO 194,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,BIOCHEM LAB,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL 1,BUNKYOU KU,TOKYO 113,JAPAN	Kyowa Kirin Ltd; University of Tokyo; University of Tokyo			Fukui, Yasuhisa/E-8806-2010; Kimura, Koutarou D./T-9645-2019	Kimura, Koutarou D./0000-0002-3359-1578				ABBAS HK, 1988, APPL ENVIRON MICROB, V54, P1268, DOI 10.1128/AEM.54.5.1268-1274.1988; ATKINSON TP, 1992, J IMMUNOL, V148, P2194; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; BRAIN PW, 1957, T BR MYCOL SOC, V40, P365; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CREWS FT, 1980, BIOCHEM BIOPH RES CO, V93, P42, DOI 10.1016/S0006-291X(80)80243-9; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; DEWALD B, 1988, J BIOL CHEM, V263, P16179; EISEMAN E, 1992, NATURE, V355, P78; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GOLD MR, 1992, J IMMUNOL, V148, P2012; GUNTHER R, 1989, IMMUNOPHARM IMMUNOT, V11, P559, DOI 10.3109/08923978909005385; HAEFLIGER W, 1975, HELV CHIM ACTA, V58, P1620, DOI 10.1002/hlca.19750580616; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P17078; HATTORI Y, 1987, IMMUNOLOGY, V60, P573; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLGATE ST, 1988, IMMUNOLOGY MED SERIE, P129; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KITANI S, 1992, BIOCHEM BIOPH RES CO, V183, P48, DOI 10.1016/0006-291X(92)91607-R; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MACMILLAN J, 1972, J CHEM SOC PERK T 1, P2898, DOI 10.1039/p19720002898; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MORITZ A, 1992, METHOD ENZYMOL, V209, P202; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OHARAIMAIZUMI M, 1992, BIOCHEM BIOPH RES CO, V185, P1016, DOI 10.1016/0006-291X(92)91728-9; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OKADA T, 1992, SEIKAGAKU, V64, P1040; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARK DJ, 1991, J BIOL CHEM, V266, P24237; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHMITTVERHULST AM, 1978, J EXP MED, V147, P352, DOI 10.1084/jem.147.2.352; SCHNEIDER H, 1992, INT IMMUNOL, V4, P447, DOI 10.1093/intimm/4.4.447; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SIEGEL PD, 1990, ANAL BIOCHEM, V188, P416, DOI 10.1016/0003-2697(90)90629-N; SIEGHART W, 1978, NATURE, V275, P329, DOI 10.1038/275329a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TESHIMA R, 1989, MOL IMMUNOL, V26, P641; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WARNER JA, 1987, J IMMUNOL, V139, P161; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WIESINGE.D, 1974, EXPERIENTIA, V30, P135, DOI 10.1007/BF01927691; YAMADA K, 1992, J IMMUNOL, V149, P1031; YAMAKAWA A, 1988, J BIOL CHEM, V263, P17555; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	77	739	773	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25846	25856						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503989				2022-12-25	WOS:A1993MK10000082
J	SAWADOGO, M				SAWADOGO, M			MULTIPLE FORMS OF THE HUMAN GENE-SPECIFIC TRANSCRIPTION FACTOR USF .2. DNA-BINDING PROPERTIES AND TRANSCRIPTIONAL ACTIVITY OF THE PURIFIED HELA USF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											SAWADOGO, M (corresponding author), ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038212] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38212] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CLOS J, 1986, P NATL ACAD SCI USA, V83, P604, DOI 10.1073/pnas.83.3.604; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONCINO MF, 1984, NUCLEIC ACIDS RES, V12, P7423, DOI 10.1093/nar/12.19.7423; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CROTHERS DM, 1987, NATURE, V325, P464, DOI 10.1038/325464a0; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOUGH PVC, 1987, P NATL ACAD SCI USA, V84, P4826, DOI 10.1073/pnas.84.14.4826; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KMIEC EB, 1986, J CELL BIOL, V103, P673, DOI 10.1083/jcb.103.3.673; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENNARD AC, 1987, EMBO J, V6, P3027, DOI 10.1002/j.1460-2075.1987.tb02608.x; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LOGAN J, 1986, NUCLEIC ACIDS RES, V14, P6327; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MANIATIS T, 1982, MOL CLONING LABORATO, P468; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P8779, DOI 10.1093/nar/12.23.8779; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; TRAVERS A, 1983, NATURE, V303, P755, DOI 10.1038/303755a0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; UCKER DS, 1984, J BIOL CHEM, V259, P7416; von Hippel P.H., 1975, PROTEIN LIGAND INTER, P270; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V83, P1608; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG LH, 1987, J BIOL CHEM, V262, P16080; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; YU YT, 1984, NUCLEIC ACIDS RES, V12, P9309, DOI 10.1093/nar/12.24.9309; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	67	151	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					11994	12001						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403559				2022-12-25	WOS:A1988P765000061
J	TABAS, I; ROSOFF, WJ; BOYKOW, GC				TABAS, I; ROSOFF, WJ; BOYKOW, GC			ACYL COENZYME-A CHOLESTEROL ACYL TRANSFERASE IN MACROPHAGES UTILIZES A CELLULAR POOL OF CHOLESTEROL OXIDASE-ACCESSIBLE CHOLESTEROL AS SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											TABAS, I (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.				NHLBI NIH HHS [HL 21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALASUBRAMANIAM S, 1978, BIOCHEM J, V174, P863, DOI 10.1042/bj1740863; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1975, P NATL ACAD SCI USA, V72, P2925, DOI 10.1073/pnas.72.8.2925; DREVON CA, 1980, J BIOL CHEM, V255, P9128; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HASHIMOTO S, 1980, J BIOL CHEM, V255, P8678; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1984, J BIOL CHEM, V259, P4624; POZNANSKY MJ, 1982, BIOCHIM BIOPHYS ACTA, V685, P182, DOI 10.1016/0005-2736(82)90096-7; REINHART MP, 1987, J BIOL CHEM, V262, P9649; SPECTOR A A, 1979, Progress in Lipid Research, V18, P31, DOI 10.1016/0163-7827(79)90003-1; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1985, P NATL ACAD SCI USA, V82, P416, DOI 10.1073/pnas.82.2.416; TABAS I, 1986, J BIOL CHEM, V261, P3147	18	116	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1988	263	3					1266	1272						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	L7728	3422077				2022-12-25	WOS:A1988L772800028
J	NAKABAYASHI, H; HUANG, KP				NAKABAYASHI, H; HUANG, KP			MONOCLONAL-ANTIBODIES AGAINST TYPE-II RAT-BRAIN PROTEIN KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											NAKABAYASHI, H (corresponding author), NICHHD,METAB REGULAT SECT,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892, USA.							ASHENDEL CL, 1983, CANCER RES, V43, P4333; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; GIRARD PR, 1985, P NATL ACAD SCI USA, V82, P3030, DOI 10.1073/pnas.82.9.3030; GIRARD PR, 1986, J BIOL CHEM, V261, P370; HOSHIJIMA M, 1986, CANCER RES, V46, P3000; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; HUANG KP, 1976, ANAL BIOCHEM, V72, P593, DOI 10.1016/0003-2697(76)90571-6; HUANG KP, 1986, J BIOL CHEM, V261, P4781; HUANG KP, 1986, J BIOL CHEM, V261, P2134; INOUE M, 1977, J BIOL CHEM, V252, P7610; JUAREZ-SALINAS H, 1984, Biotechniques, V2, P164; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOHLER G, 1975, NATURE, V256, P496; KUO JF, 1980, P NATL ACAD SCI-BIOL, V77, P7039, DOI 10.1073/pnas.77.12.7039; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEE MH, 1986, J BIOL CHEM, V261, P4867; Mage M G, 1980, Methods Enzymol, V70, P142; MINAKUCHI R, 1981, J BIOCHEM-TOKYO, V89, P1651, DOI 10.1093/oxfordjournals.jbchem.a133362; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; WELDON SL, 1985, J BIOL CHEM, V260, P4203; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85	46	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1988	263	1					298	304						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	L5047	3422075				2022-12-25	WOS:A1988L504700048
J	BROSH, N; STERNBERG, D; HONIGWACHSSHAANANI, J; LEE, BC; SHAV-TAL, Y; TZEHOVAL, E; SHULMAN, LM; TOLEDO, J; HACHAM, Y; CARMI, P; JIANG, W; SASSE, J; HORN, F; BURSTEIN, Y; ZIPORI, D				BROSH, N; STERNBERG, D; HONIGWACHSSHAANANI, J; LEE, BC; SHAV-TAL, Y; TZEHOVAL, E; SHULMAN, LM; TOLEDO, J; HACHAM, Y; CARMI, P; JIANG, W; SASSE, J; HORN, F; BURSTEIN, Y; ZIPORI, D			THE PLASMACYTOMA GROWTH INHIBITOR RESTRICTIN-P IS AN ANTAGONIST OF INTERLEUKIN-6 AND INTERLEUKIN-11 - IDENTIFICATION AS A STROMA-DERIVED ACTIVIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; TUMOR-NECROSIS-FACTOR; HEMATOPOIETIC STEM-CELLS; BONE-MARROW CELLS; INTERFERON-GAMMA; FIBROBLASTOID CELLS; INVITRO GROWTH; FACTOR-BETA; FACTOR EDF; PROLIFERATION	A stromal protein, designated restrictin-P, that specifically kills plasma-like cells was purified to homogeneity and shown to be identical with activin A. The specificity 60 plasma-like cells stemmed from the ability of restrictin-P/activin A to competitively antagonize the proliferation-inducing effects of interleukin (IL) 6 and IL-11. Restrictin-P further interfered with the IL-6-induced secretion of acute phase proteins by HepGB human hepatoma cells and with the IL-6-mediated differentiation of M1 myeloblasts. A competition binding assay indicated that restrictin-P did not interfere with the binding of IL-6 to its receptor on plasma-like cells, suggesting that it may act by intervening in the signal transduction pathway of the growth factor. Indeed, concomitant addition of restrictin-P and IL-6 to cytokine-deprived B9 hybridoma cells was followed by sustained overexpression of junB gene until cell death occurred, while IL-6 alone caused a transient increase only, This altered response to IL-6 stimulation was accompanied by a moderate increase in STAT protein activation. Thus, in this study, we identified the plasmacytoma growth inhibitor, restrictin-P, as being activin A of stromal origin. It is shown that activin A is an antagonist of IL-6 induced functions and that it modifies the IL-6 signaling pattern.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL; CHAIM SHEBA MED CTR, IL-52621 TEL HASHOMER, ISRAEL; RHEIN WESTFAL TH AACHEN, INST BIOCHEM, D-52057 AACHEN, GERMANY	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center; RWTH Aachen University			Shulman, Lester M./AAU-4372-2021	Shulman, Lester M./0000-0002-6385-894X; Shav-Tal, Yaron/0000-0002-8017-948X; Burstein, Yigal/0000-0003-0494-7739				BAUMANN H, 1993, J IMMUNOL, V151, P1456; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOT FJ, 1989, BLOOD, V73, P435; BRETON J, 1995, EUR J BIOCHEM, V227, P573, DOI 10.1111/j.1432-1033.1995.tb20427.x; BREUNINGER L, 1994, CLIN IMMUNOL IMMUNOP, V72, P264, DOI 10.1006/clin.1994.1140; BROXMEYER HE, 1988, P NATL ACAD SCI USA, V85, P9052, DOI 10.1073/pnas.85.23.9052; BURGER R, 1993, J IMMUNOL METHODS, V158, P147, DOI 10.1016/0022-1759(93)90266-A; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; CRAIG RW, 1989, J CELL PHYSIOL, V141, P46, DOI 10.1002/jcp.1041410108; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FUNKHOUSER SW, 1994, ENVIRON RES, V66, P77, DOI 10.1006/enrs.1994.1045; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; HELLE M, 1988, EUR J IMMUNOL, V18, P1535, DOI 10.1002/eji.1830181010; HOANG T, 1988, BLOOD, V72, P823; HONIGWACHSSHAANANI J, 1991, ANN NY ACAD SCI, V628, P287, DOI 10.1111/j.1749-6632.1991.tb17259.x; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; KADOURI A, 1992, INT J CELL CLONING, V10, P299, DOI 10.1002/stem.5530100508; KASUKABE T, 1994, CANCER RES, V54, P592; KASUKABE T, 1992, LEUKEMIA RES, V16, P1191, DOI 10.1016/0145-2126(92)90118-Q; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; LAOUAR A, 1993, EUR J BIOCHEM, V215, P825, DOI 10.1111/j.1432-1033.1993.tb18098.x; LASKOV R, 1970, Journal of Experimental Medicine, V131, P515, DOI 10.1084/jem.131.3.515; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; LOTEM J, 1989, LEUKEMIA, V3, P804; MALIK Z, 1992, MICRON MICROSCOPIA A, V23, P369; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; NAKAO K, 1991, EXP HEMATOL, V19, P1090; ORITANI K, 1992, BLOOD, V80, P2298; RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528; ROBERTSON DM, 1992, ENDOCRINOLOGY, V130, P1680, DOI 10.1210/en.130.3.1680; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; RUHL S, 1993, BLOOD, V82, P2641; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SKLAR MD, 1975, NATURE, V253, P550, DOI 10.1038/253550a0; SPORENO E, 1994, J BIOL CHEM, V269, P10991; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SRIVASTAVA MD, 1994, RES COMMUN CHEM PATH, V83, P145; STERNBERG D, 1995, IN PRESS GROWTH FACT; STOECK M, 1989, J CELL PHYSIOL, V141, P65, DOI 10.1002/jcp.1041410111; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TWIGG HI, 1994, J LAB CLIN MED, V124, P283; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARNER NL, 1969, J NATL CANCER I, V43, P963; WARREN DJ, 1990, EUR J HAEMATOL, V45, P158; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5; YAMASHITA T, 1992, BLOOD, V79, P304; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0; ZIPORI D, 1985, J CELL PHYSIOL, V122, P81, DOI 10.1002/jcp.1041220113; ZIPORI D, 1979, EXP HEMATOL, V7, P206; ZIPORI D, 1990, CANCER CELL-MON REV, V2, P205; ZIPORI D, 1992, FASEB J, V6, P2691, DOI 10.1096/fasebj.6.9.1612293; ZIPORI D, 1988, NAT IMMUN CELL GROW, V7, P185; ZIPORI D, 1981, CELL TISSUE KINET, V14, P479, DOI 10.1111/j.1365-2184.1981.tb00554.x; ZIPORI D, 1980, CELL TISSUE KINET, V13, P287, DOI 10.1111/j.1365-2184.1980.tb00467.x; ZIPORI D, 1986, P NATL ACAD SCI USA, V83, P4547, DOI 10.1073/pnas.83.12.4547; ZIPORI D, 1989, EUR J HAEMATOL, V42, P225; ZIPORI D, 1984, J CELL PHYSIOL, V118, P143, DOI 10.1002/jcp.1041180206	69	83	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29594	29600		10.1074/jbc.270.49.29594	http://dx.doi.org/10.1074/jbc.270.49.29594			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7494003	hybrid			2022-12-25	WOS:A1995TJ22700084
J	SHISHIDO, Y; SHARMA, KD; HIGASHIYAMA, S; KLAGSBRUN, M; MEKADA, E				SHISHIDO, Y; SHARMA, KD; HIGASHIYAMA, S; KLAGSBRUN, M; MEKADA, E			HEPARIN-LIKE MOLECULES ON THE CELL-SURFACE POTENTIATE BINDING OF DIPHTHERIA-TOXIN TO THE DIPHTHERIA-TOXIN RECEPTOR MEMBRANE-ANCHORED HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERO CELLS; MONOCLONAL-ANTIBODY; CD9 ANTIGEN; SULFATE; EGF; PROTEIN; BIOSYNTHESIS; ASSOCIATION; EXPRESSION; MUTANTS	Diphtheria toxin receptor (DTR), which is identical to the membrane-anchored form of heparin-binding EGF-like growth factor (proHB-EGF), has a high affinity for heparin. We studied the effect of heparin-like molecules on the binding of diphtheria toxin (DT) to DTWproHB-EGF. Mutant Chinese hamster ovary (CHO) cells deficient in heparan sulfate (HS) proteoglycans were about 15 times less sensitive to DT than wild type CHO-K1 cells. When free heparan sulfate or heparin was added to the culture medium, DT sensitivity of the mutant cells was fully restored. Studies of binding of I-125-labeled DT to HS-deficient CHO cells transfected with human DTR/ proHB-EGF cDNA indicated that the increased sensitivity to DT after addition of heparin is due to increased binding of DT to cells. Vero cells display a relatively large amount of heparan sulfate residues compared to CHO-K1 cells or L cells. Enhancement of DT binding by the addition of heparin was also observed with CHO-K1 cells and L cells that had been transfected with human DTR/proHB-EGF cDNA, but the degree of enhancement was less than that observed with the HS-deficient CHO cells. Addition of heparin did not affect DT binding or DT sensitivity of Vero cells. Heparin-dependent binding was observed when intact Vero cells were treated with heparitinase or when the cell membrane was solubilized with a neutral detergent. Scatchard plot analysis for the binding of DT to a recombinant HB-EGF in vitro and to L cells expressing human DTR/proHB-EGF revealed that heparin increases the affinity of DTR/proHB-EGF for DT but does not change the number of binding sites. Although DRAP27/CD9 is known to enhance DT binding to DTR/proHB-EGF, the results indicate that heparin and DRAP27/CD9 increase DT binding by independent mechanisms. Thus, heparin-like molecules, probably in the form of heparan sulfate proteoglycan on the cell surface, are a third factor required for maximal DT binding activity of cells.	KURUME UNIV, INST LIFE SCI, DIV CELL BIOL, KURUME, FUKUOKA 830, JAPAN; OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Kurume University; Osaka University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School				Mekada, Eisuke/0000-0001-8858-4781				AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BROWN JG, 1993, P NATL ACAD SCI USA, V90, P8184, DOI 10.1073/pnas.90.17.8184; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; GABLIKS J, 1962, J IMMUNOL, V88, P505; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HAYAKAWA S, 1983, J BIOL CHEM, V258, P4311; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; KOHNO K, 1985, SOMAT CELL MOLEC GEN, V11, P421, DOI 10.1007/BF01534836; KURE S, 1986, J IMMUNOL, V137, P3900; LENNOX ES, 1957, P SOC EXP BIOL MED, V95, P700, DOI 10.3181/00379727-95-23335; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MEKADA E, 1982, BIOCHEM BIOPH RES CO, V109, P792, DOI 10.1016/0006-291X(82)92009-5; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; ONO M, 1994, J BIOL CHEM, V269, P31315; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAEFER EM, 1988, J CELL PHYSIOL, V135, P407, DOI 10.1002/jcp.1041350307; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; UMATA T, 1990, J BIOL CHEM, V265, P21940; WALKER A, 1994, J BIOL CHEM, V269, P931; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	40	52	54	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29578	29585		10.1074/jbc.270.49.29578	http://dx.doi.org/10.1074/jbc.270.49.29578			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7494001	hybrid			2022-12-25	WOS:A1995TJ22700082
J	TARANTINI, F; GAMBLE, S; JACKSON, A; MACIAG, T				TARANTINI, F; GAMBLE, S; JACKSON, A; MACIAG, T			THE CYSTEINE RESIDUE RESPONSIBLE FOR THE RELEASE OF FIBROBLAST GROWTH-FACTOR-I RESIDES IN A DOMAIN-INDEPENDENT OF THE DOMAIN FOR PHOSPHATIDYLSERINE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-C; FACTOR-I; PHOSPHOLIPID-BINDING; FACTOR FAMILY; CELLS; SITE; PHOSPHORYLATION; TRANSLOCATION; SECRETION; SUBSTRATE	Fibroblast growth factor (FGF)-1 lacks a classical signal sequence to direct its secretion yet utilizes high affinity cell surface receptors to signal its heparin-dependent angiogenic and neurotrophic activities. We have previously reported that FGF-1 is released in response to temperature stress as a latent homodimer through a pathway that is potentiated by the Golgi inhibitor, brefeldin A (Jackson, A., Tarantini, F., Gamble, S., Friedman, S., and Maciag, T. (1995) J. Biol Chem. 270, 33-36). In an attempt to further characterize this unconventional secretion mechanism, we sought to define the Cys residue(s) critical for FGF-1 dimer formation and release and to determine whether FGF-1 can associate with known phospholipid components of organelle or plasma membranes, which may be disturbed by brefeldin A. Utilizing FGF-1 Cys mutants, we were able to demonstrate that residue Cys(30) is critical for FGF-1 release in response to heat shock. In addition, using solid phase phospholipid binding assays we demonstrate that FGF-1 is able to specifically associate with phosphatidylserine (PS). Heparin inhibits the association between FGF-1 and PS, and synthetic peptide competition assays suggest that the PS-binding domain of FGF-1 lies between residues 114 and 137. These observations indicate that FGF-1 may be able to associate with the PS component of organelle and/or plasma membranes and that the domains responsible for FGF-1 homodimer formation and PS binding are structurally distinct.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855	American Red Cross			Tarantini, Francesca/I-6332-2012	TARANTINI, FRANCESCA/0000-0002-1390-2965	NHLBI NIH HHS [HL44336, HL32348] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUDIER J, 1991, J BIOL CHEM, V266, P229; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; LIPPINCOTTSCHWARTZ, 1989, CELL, V56, P801; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; MACH H, 1993, BIOCHEMISTRY-US, V32, P7703, DOI 10.1021/bi00081a015; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SHING Y, 1990, ANAL BIOCHEM, V185, P108, DOI 10.1016/0003-2697(90)90263-9; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VOROTNIKOV AV, 1992, BIOCHEM J, V284, P911, DOI 10.1042/bj2840911; ZHAG JZ, 1994, CELL, V78, P751; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	25	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29039	29042		10.1074/jbc.270.49.29039	http://dx.doi.org/10.1074/jbc.270.49.29039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493920	hybrid			2022-12-25	WOS:A1995TJ22700001
J	YOU, GF; LEE, WS; BARROS, EJG; KANAI, Y; HUO, TL; KHAWAJA, S; WELLS, RG; NIGAM, SK; HEDIGER, MA				YOU, GF; LEE, WS; BARROS, EJG; KANAI, Y; HUO, TL; KHAWAJA, S; WELLS, RG; NIGAM, SK; HEDIGER, MA			MOLECULAR CHARACTERISTICS OF NA+-COUPLED GLUCOSE TRANSPORTERS IN ADULT AND EMBRYONIC RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COTRANSPORTER; CLONING; EXPRESSION; HETEROGENEITY; NA+/GLUCOSE; SIMILARITY; VESICLES; CDNA	Two distinct Na+-coupled glucose transporters (SGLTs) with either a high or a low affinity for glucose were shown to provide reabsorption of filtered glucose in the kidney. We have previously reported the characteristics of the high affinity Na+/glucose cotransporter SGLT1 hom rabbit, rat, and human kidney and the low affinity Na+/glucose cotransporter SGLT2 from human kidney. Because the molecular identity of SGLT2 as the kidney cortical low affinity Na+/glucose cotransporter has been recently challenged based on studies of the porcine low affinity Na+/glucose cotransporter SAAT-pSGLT2 (Mackenzie, B., Panayotova-Heiermann, M., Loo, D. D. F., Lever, J. E., and Wright, E. M. (1994) J. Biol. Chem. 269, 22488-22491), we have reevaluated the properties of SGLT2 in greater detail. We furthermore report new data on the regulation of SGLT1 and SGLT2 during kidney development. To analyze and compare SGLT1 and SGLT2 in adult and embryonic kidney, we have cloned and characterized SGLT2 from rat kidney and determined its tissue distribution based on Northern analysis and in situ hybridization. When expressed in Xenopus oocytes, rat SGLT2 stimulated transport of cu-methyl-D-glucopyranoside (2 mM) in oocytes up to 4.5-fold over controls with an apparent K-m of 3.0 mM. The transport properties (i.e. a Na+ to glucose coupling of 1:1 and lack of galactose transport) generally matched those of the kidney cortical low affinity system. We show that expression of rat SGLT2 mRNA is kidney specific and that it is strongly and exclusively expressed in proximal tubule Si segments. Hybrid-depletion studies were performed to conclusively determine whether SGLT2 corresponds to the kidney cortical low affinity system, injection of rat kidney superficial cortex mRNA into oocytes stimulated the uptake of alpha-methyl-D-glucopyranoside (2 mM) 2-3-fold. We show that hybrid depletion of this kidney RNA using an SGLT2 antisense oligonucleotide completely suppresses the uptake. These data strongly indicate that SGLT2 is the major kidney cortical low affinity glucose transporter. We therefore propose that SAAT-pSGLT2 be renamed SGLT3. Experiments addressing the expression of SGLT1 and SGLT2 mRNAs in embryonic rat kidneys reveal that the two Na+/glucose cotransporters are developmentally regulated and that there may be a different splice variant for SGLT2 in embryonic kidney compared to the adult.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Barros, Elvino José Guardão/M-8612-2014	Hediger, Matthias/0000-0003-1946-027X	NIDDK NIH HHS [DK 43632] Funding Source: Medline; PHS HHS [43171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043632] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARFUSS DW, 1981, AM J PHYSIOL, V240, pF322; BROWN D, 1990, P NATL ACAD SCI USA, V89, P7457; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; KONG CT, 1993, J BIOL CHEM, V268, P1509; LEE WS, 1994, J BIOL CHEM, V269, P12032; MACKENZIE B, 1994, J BIOL CHEM, V269, P22488; NIGAM SK, 1995, KIDNEY, V1, P72; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; SABOLIC I, 1992, AM J PHYSIOL, V262, pF217, DOI 10.1152/ajprenal.1992.262.2.F217; THORENS B, 1990, AM J PHYSIOL, V259, pC286; TURNER RJ, 1977, P NATL ACAD SCI USA, V74, P2825, DOI 10.1073/pnas.74.7.2825; TURNER RJ, 1982, J MEMBRANE BIOL, V67, P73, DOI 10.1007/BF01868649; TURNER RJ, 1982, J MEMBRANE BIOL, V70, P37, DOI 10.1007/BF01871587; TURNER RJ, 1982, AM J PHYSIOL, V242, pF406, DOI 10.1152/ajprenal.1982.242.4.F406; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459	21	160	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29365	29371		10.1074/jbc.270.49.29365	http://dx.doi.org/10.1074/jbc.270.49.29365			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493971	hybrid			2022-12-25	WOS:A1995TJ22700052
J	KRAPIVINSKY, G; KRAPIVINSKY, L; VELIMIROVIC, B; WICKMAN, K; NAVARRO, B; CLAPHAM, DE				KRAPIVINSKY, G; KRAPIVINSKY, L; VELIMIROVIC, B; WICKMAN, K; NAVARRO, B; CLAPHAM, DE			THE CARDIAC INWARD RECTIFIER K+ CHANNEL SUBUNIT, CIR, DOES NOT COMPRISE THE ATP-SENSITIVE K+ CHANNEL, I-KATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; GAMMA-SUBUNIT; ACTIVATION; MECHANISM; MYOCYTES; MEMBRANE; HEART	Cardiac I-KACh is comprised of two inwardly rectifying K+ channel subunits, CIR and GIRK1 (Krapivinsky, G., Gordon, E. G., Wickman, K., Velimirovic, B., Krapivinsky, L., and Clapham, D. E. (1995) Nature 374, 135-141). A cardiac protein virtually identical to CIR, termed rcKATP-1 (Ashford, M. L. J., Bond, C. T., Blair, T. A., and Adelman, J. P. (1994) Nature 370, 456-459), was reported to form an ATP-sensitive inwardly rectifying K+ channel, I-KATP. We attempted to determine whether CIR alone or together with an unknown protein(s) participated in the formation of cardiac I-KATP. Expression of CIR in insect, oocyte, and mammalian cell systems did not increase the appearance of ATP-sensitive currents, but rather gave rise to unique strongly inwardly rectifying, G protein-regulated K+ currents. CIR protein is found exclusively in atria, in contrast to the predominance of I-KATP functional activity in ventricle. Also, CIR was completely depleted from heart membrane after immunodepletion of GLRK1. We conclude that CIR/rcK-ATP-1 is not a subunit of cardiac I-KATP and that GIRK1 is the only channel protein coassociating with CIR in heart.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Wickman, Kevin/0000-0002-5179-9540; Clapham, David/0000-0002-4459-9428	PHS HHS [54873] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KURACHI Y, 1992, PROG NEUROBIOL, V39, P229, DOI 10.1016/0301-0082(92)90017-9; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; NICHOLS CG, 1990, J PHYSIOL-LONDON, V423, P91, DOI 10.1113/jphysiol.1990.sp018013; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; VANWAGONER DR, 1993, CIRC RES, V72, P973, DOI 10.1161/01.RES.72.5.973; WICKMAN K, 1995, IN PRESS PHYSL REV, V75; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	20	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28777	28779		10.1074/jbc.270.48.28777	http://dx.doi.org/10.1074/jbc.270.48.28777			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499400	hybrid			2022-12-25	WOS:A1995TH05600044
J	TAYLOR, V; WELCHER, AA; SUTER, U				TAYLOR, V; WELCHER, AA; SUTER, U			EPITHELIAL MEMBRANE PROTEIN-1, PERIPHERAL MYELIN PROTEIN-22, AND LENS MEMBRANE-PROTEIN-20 DEFINE A NOVEL GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOOTH DISEASE TYPE-1A; ARREST-SPECIFIC GENE; TREMBLER-J MOUSE; POINT MUTATION; GROWTH ARREST; PMP22 GENE; NERVOUS-SYSTEM; SCHWANN-CELLS; BOVINE LENS; EXPRESSION	Peripheral myelin protein 22 (PMP22) is expressed in many tissues but mainly by Schwann cells as a component of compact myelin of the peripheral nervous system (PNS). Mutations affecting PMP22 are associated with hereditary motor and sensory neuropathies. Although these phenotypes are restricted to the PNS, PMP22 is thought to play a dual role in myelin formation and in cell proliferation. We describe the cloning and characterization of epithelial membrane protein-1 (EMP-1), a putative four-transmembrane protein of 160 amino acids with 40% amino acid identity to PMP22. EMP-1 and PMP22 are co-expressed in most tissues but with differences in relative expression levels. EMP-1 is most prominently found in the gastrointestinal tract, skin, lung, and brain but not in liver. In the corpus gastricum, EMP-1 protein can be detected in epithelial cells of the gastric pit and isthmus of the gastric gland in a pattern consistent with plasma membrane association, EMP-1 and PMP22 mRNA levels are inversely regulated in the degenerating rat sciatic nerve after injury and by growth arrest in NIH 3T3 fibroblasts. The discovery of EMP-1 as the second member of a novel gene family led to the identification of the lens-specific membrane protein 20 (MP20) as a third but distant relative. The proteins of this family are likely to serve similar functions possibly related to cell proliferation and differentiation in a variety of cell types.	ETH HONGGERBERG,INST CELL BIOL,DEPT CELL BIOL,CH-8093 ZURICH,SWITZERLAND; AMGEN INC,THOUSAND OAKS,CA 91320	Swiss Federal Institutes of Technology Domain; ETH Zurich; Amgen			Suter, Ueli/A-1624-2010					ADLKOFER K, 1995, IN PRESS NAT GENET; BAECHNER D, 1995, IN PRESS J NEUROSCI; BANSAL R, 1987, J NEUROCHEM, V49, P1902, DOI 10.1111/j.1471-4159.1987.tb02453.x; BOSSE F, 1994, J NEUROSCI RES, V37, P529, DOI 10.1002/jnr.490370412; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CHANCE PF, 1994, HUM MOL GENET, V3, P223, DOI 10.1093/hmg/3.2.223; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELEON M, 1991, J NEUROSCI RES, V29, P437; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GALVAN A, 1989, J BIOL CHEM, V264, P19974; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GUTEKUNST KA, 1990, CURR EYE RES, V9, P955, DOI 10.3109/02713689009069931; JARVIS LJ, 1993, INVEST OPHTH VIS SCI, V34, P613; KITAMURA K, 1981, 6TH P INT S GLYC, P273; KUHN G, 1993, GLIA, V8, P256, DOI 10.1002/glia.440080406; KUMAR NM, 1993, EXP EYE RES, V56, P35, DOI 10.1006/exer.1993.1006; LEMKE G, 1988, DEVELOPMENT, V102, P499; LOUIS CF, 1989, J BIOL CHEM, V264, P19967; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MULDERS JWM, 1988, CURR EYE RES, V7, P207, DOI 10.3109/02713688808995750; PAREEK S, 1993, J BIOL CHEM, V268, P10372; PARMANTIER E, 1995, EUR J NEUROSCI, V7, P1080, DOI 10.1111/j.1460-9568.1995.tb01095.x; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; ROA BB, 1993, NAT GENET, V5, P189, DOI 10.1038/ng1093-189; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; ROA BB, 1993, NAT GENET, V5, P269, DOI 10.1038/ng1193-269; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; SUTER U, 1994, HUM MUTAT, V3, P95, DOI 10.1002/humu.1380030203; SUTER U, 1993, TRENDS NEUROSCI, V16, P50, DOI 10.1016/0166-2236(93)90015-E; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1995, ANNU REV NEUROSCI, V18, P45, DOI 10.1146/annurev.ne.18.030195.000401; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; SUTER U, 1995, J NEUROSCI RES, V40, P145, DOI 10.1002/jnr.490400202; SUTER U, 1994, J BIOL CHEM, V269, P1; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; TENBROEK E, 1992, J CELL SCI, V103, P245; TIMMERMAN V, 1992, J NEUROL SCI, V109, P41, DOI 10.1016/0022-510X(92)90091-X; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; ZOIDL G, 1995, EMBO J, V14, P1122, DOI 10.1002/j.1460-2075.1995.tb07095.x	48	133	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28824	28833		10.1074/jbc.270.48.28824	http://dx.doi.org/10.1074/jbc.270.48.28824			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499407	hybrid			2022-12-25	WOS:A1995TH05600051
J	THOMAS, D; PATTERSON, SD; BRADSHAW, RA				THOMAS, D; PATTERSON, SD; BRADSHAW, RA			SRC HOMOLOGOUS AND COLLAGEN (SHC) PROTEIN BINDS TO F-ACTIN AND TRANSLOCATES TO THE CYTOSKELETON UPON NERVE GROWTH-FACTOR STIMULATION IN PG12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; RAPID REORGANIZATION; SIGNAL TRANSDUCTION; MEMBRANE SKELETON; TYROSINE KINASES; FACTOR RECEPTOR; V-SRC; IDENTIFICATION; CALCIUM; PHOSPHORYLATION	Immunoprecipitates of metabolically labeled PC12 cells consistently contained a 43-kDa protein that was associated with Shc, a signal-transducing protein with a single SH2 domain. Following affinity chromatography with immobilized recombinant glutathione S-transferase (GST)-Shc fusion protein, the 43-kDa protein was identified as actin by mass spectrometry and immunoblotting. Cosedimentation experiments using purified actin and GST Shc showed that Shc binds directly to F-actin, confirming Shc actin interaction in vivo. Various GST-truncated Shc fusion proteins were prepared and used in actin cosedimentation assays. Constructs containing the SH2 and collagen homology domains were not precipitated, and those containing the aminoterminal domain were. Thus, Shc-actin interactions do not occur in the region of tyrosine phosphorylation and leave the SH2 domain free to bind to other tyrosine-phosphorylated molecules. Although the major pool of Shc in unstimulated PC12 cells is soluble, two other pools are associated with the cytoskeleton and the submembranous cytoskeleton. Upon nerve growth factor stimulation, approximately 50% of the soluble Shc translocates to both cytoskeleton environments within 2 min, decreasing thereafter. When cells were pretreated with cytochalasin D, a drug that disrupts actin filaments, Shc translocation to the cytoskeleton was abolished. However, in the submembranous fraction, the Shc level was elevated in resting cells following cytochalasin D treatment. The kinetics of translocation, compared to mitogen-activated protein kinase activation, and the nature of the Shc-actin interaction suggest that the cytoskeletal association of Shc, induced by growth factors, may be related to membrane ruffling and actin fiber reorganization.	AMGEN INC, THOUSAND OAKS, CA 91320 USA	Amgen	THOMAS, D (corresponding author), UNIV CALIF IRVINE, COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA.		Patterson, Scott/A-7404-2009; Bradshaw, Ralph A/K-1515-2013		NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER; NIA NIH HHS [AG09735] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BASU T, 1994, ONCOGENE, V9, P3483; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; FOX GM, 1988, J BIOL CHEM, V263, P18452; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; GUINEBAULT C, 1994, CELL MOL BIOL, V40, P687; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HABIB T, 1994, J BIOL CHEM, V269, P25243; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HENKE RC, 1991, NEUROCHEM RES, V16, P675, DOI 10.1007/BF00965554; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM UH, 1991, J BIOL CHEM, V266, P1359; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; KUMAR G, 1995, BIOCHEM J, V307, P215, DOI 10.1042/bj3070215; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKAMURA H, 1994, ONCOGENE, V9, P2293; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; PATTERSON SD, 1994, ANAL BIOCHEM, V221, P1, DOI 10.1006/abio.1994.1371; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P1104, DOI 10.1002/elps.11501601187; PAVES H, 1990, EXP CELL RES, V186, P218, DOI 10.1016/0014-4827(90)90299-P; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, J CELL SCI, P127; RIJKEN PJ, 1991, J CELL SCI, V100, P491; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SAXTON TM, 1994, J IMMUNOL, V153, P623; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHANG WZ, 1994, PROTEIN SCI, V3, P677	79	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28924	28931		10.1074/jbc.270.48.28924	http://dx.doi.org/10.1074/jbc.270.48.28924			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499422	hybrid			2022-12-25	WOS:A1995TH05600066
J	WANG, D; SUL, HS				WANG, D; SUL, HS			UPSTREAM STIMULATORY FACTORS BIND TO INSULIN-RESPONSE SEQUENCE OF THE FATTY-ACID SYNTHASE PROMOTER - USF1 IS REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; HELIX-LOOP-HELIX; MAJOR LATE PROMOTER; GROWTH-HORMONE GENE; RNA POLYMERASE-II; DEHYDROGENASE GENE; MULTIPLE FORMS; RAT-LIVER; ELEMENT; EXPRESSION	Fatty acid synthase (FAS) plays a central role in de novo lipogenesis in mammals, The concentration or activity of FAS in liver and adipose tissue changes dramatically when animals are subjected to nutritional and hormonal manipulations. We previously reported that due to changes in transcription, FAS synthesis declines and increases in an insulin-dependent manner during fasting and refeeding, respectively, and that insulin administration of streptozotocin-diabetic mice stimulates FAS transcription. We previously mapped the FAS insulin response sequence (IRS) to the proximal promoter region from position -71 to position -50, which contains an E-box DNA binding motif, Here, using competition gel shift assays and specific upstream stimulatory factor (USF) antibodies, we identified USF1 and USF2 as major components of complexes that bind to the FAS IRS, W-cross-linking experiments further supported that USFs bind the FAS IRS, We also found that the amount of the 43-kDa USF1 was dramatically increased in liver of refed rats, In contrast, the amount of USF2 remained the same in liver of fasted or refed rats, Moreover, a 17-kDa protein in both fasted and refed rat liver was recognized by anti-USF1 antibodies, and this 17-kDa USF1 related protein was expressed in a manner opposite to that of the 43-kDa USF1, i.e. high in liver of fasted rats and decreased in liver of refed rats. These data suggest that the regulation of USF expression mayplay an important role in the regulation of FAS transcription.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [DK-36264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GREAVES RF, 1991, J VIROL, V65, P6705, DOI 10.1128/JVI.65.12.6705-6713.1991; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOZLOWSKI MT, 1991, DEV BIOL, V148, P625, DOI 10.1016/0012-1606(91)90280-G; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; MILLIPORE, 1990, PROTEIN BLOTTING PRO; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; OSBORN L, 1988, J BIOL CHEM, V263, P16519; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCOTTO KW, 1989, GENE DEV, V3, P651, DOI 10.1101/gad.3.5.651; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; ZWARTKRUIS F, 1991, MECH DEVELOP, V33, P179, DOI 10.1016/0925-4773(91)90026-3	48	105	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28716	28722		10.1074/jbc.270.48.28716	http://dx.doi.org/10.1074/jbc.270.48.28716			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499393	hybrid			2022-12-25	WOS:A1995TH05600037
J	HANSEN, SH; OLSSON, A; CASANOVA, JE				HANSEN, SH; OLSSON, A; CASANOVA, JE			WORTMANNIN, AN INHIBITOR OF PHOSPHOINOSITIDE 3-KINASE, INHIBITS TRANSCYTOSIS IN POLARIZED EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDCK CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; BREFELDIN-A; RECEPTOR; COMPLEX; ENDOCYTOSIS; TRANSPORT; SECRETION; SURFACE	Wortmannin, an inhibitor of phosphoinositide 3-kinase, inhibits both basolateral to apical and apical to basolateral transcytosis of ricin in Fisher rat thyroid (FRT) cells by 50% at 100 nM in a continuous transcytosis assay. In MDCK cells, a similar effect of wortmannin on basolateral to apical transcytosis of ricin was found, whereas apical to basolateral transcytosis was inhibited to a lesser degree. Transcytosis of dimeric IgA in MDCK cells expressing the polymeric immunoglobulin receptor was also reduced to 50% of controls, suggesting that wortmannin inhibits membrane translocation rather than sorting of specific proteins in the transcytotic pathway. This effect of wortmannin is selective, however, in that endocytosis at the basolateral domain and recycling at both the basolateral and apical membrane domains are unaffected, and apical endocytosis and apical secretion are only moderately reduced. We have shown previously that cAMP stimulates a late stage in basolateral to apical transcytosis in MDCK cells through activation of protein kinase A (Hansen, S. H., and Casanova, J. E. (1994) J. Cell Biol. 126, 677-687). Elevation of cellular cAMP still induced a 100% increase in transcytosis in wortmannin-treated cells, but transcytosis was no longer increased when compared to cells which received no drugs. In contrast, in experiments using a 17 degrees C block to accumulate ricin internalized from the basolateral surface in the apical compartment of MDCK cells, wortmannin had little effect on the stimulation of transcytosis by activators of protein kinase A observed under these conditions. The data thus suggest the existence of a wortmannin sensitive step in the transcytotic pathway, positioned after endocytosis but prior to translocation into the protein kinase A-sensitive apical compartment, implying a role for phosphoinositide 3-kinase in an intermediate step in transcytosis in polarized epithelial cells.			HANSEN, SH (corresponding author), MASSACHUSETTS GEN HOSP E, DEPT PEDIAT, 149 13TH ST, BOSTON, MA 02129 USA.			Hansen, Steen/0000-0002-9408-4676	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32291] Funding Source: Medline; NIDDK NIH HHS [DK33506] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1994, J BIOL CHEM, V269, P19005; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BRANTZAEG P, 1977, CLIN EXP IMMUNOL, V30, P77; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EKER P, 1994, J BIOL CHEM, V269, P18607; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAM K, 1994, J BIOL CHEM, V269, P20648; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MATLIN KS, 1983, CELL, V233; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; POWIS G, 1994, CANCER RES, V54, P2419; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANDEURS B, 1990, EUR J CELL BIOL, V51, P96; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	58	101	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28425	28432						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499348				2022-12-25	WOS:A1995TG21000073
J	MYERS, SM; ENG, C; PONDER, BAJ; MULLIGAN, LM				MYERS, SM; ENG, C; PONDER, BAJ; MULLIGAN, LM			CHARACTERIZATION OF RET PROTOONCOGENE 3'-SPLICING VARIANTS AND POLYADENYLATION SITES - A NOVEL C-TERMINUS FOR RET	ONCOGENE			English	Article						RET; 3' SPLICING; UTR; POLYADENYLATION	NEUROBLASTOMA CELL-LINES; MYOTONIC-DYSTROPHY; MESSENGER-RNA; TYROSINE KINASE; EXPRESSION; PROTOONCOGENE; GENE; MUTATIONS; ISOFORMS; SEQUENCE	The RET proto-oncogene, which encodes a receptor tyrosine kinase, displays multiple alternative splicing variants. Splicing of sequences 3' of exon 19 to generate several coding and untranslated region (UTR) sequences has been previously reported. We have sequenced the full length RET coding region and characterized the transcripts and 3' UTRs generated by alternative splicing of the RET 3' terminus. These analyses were performed using both RET cDNA cloned from a pheochromocytoma library and reverse transcriptase PCR products generated using RNA from a neuroblastoma cell line (LA-N-2). Three different carboxyl termini were identified. In addition to the nine and 51 terminal amino acid forms already known, we identified a third with 43 terminal amino acids predicted to encode a novel RET protein isoform. A total of 3621 base pairs of DNA 3' of exon 19, which spans the alternatively spliced exons and RET UTRs, was sequenced. Four polyadenylation sites were identified. The observed combinations of polyadenylation sites and 3' coding sequence suggest that RET transcripts with up to 10 different 3' sequences and up to 40 different full length RET transcripts may exist.	QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA; UNIV CAMBRIDGE,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115	Queens University - Canada; Queens University - Canada; University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Eng, Charis/0000-0002-3693-5145				ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Borson N D, 1992, PCR Methods Appl, V2, P144; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GARDNER E, 1994, HUM MOL GENET, V3, P1771, DOI 10.1093/hmg/3.10.1771; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOPPENER J, 1994, 5TH INT WORKSH MULT, P70; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; JHIANG SM, 1991, NUCLEIC ACIDS RES, V19, P4303, DOI 10.1093/nar/19.15.4303; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MOQADAM F, 1994, CLONTECHNIQUES, V9, P6; MULLIGAN L, 1995, IN PRESS J INT MED; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PESOLE G, 1994, GENE, V140, P219, DOI 10.1016/0378-1119(94)90547-9; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; ROMANO A, 1994, ONCOGENE, V9, P2923; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Sambrook J, 1989, MOL CLONING LABORATO; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SINGH IN, 1990, J NEUROSCI RES, V25, P476, DOI 10.1002/jnr.490250405; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WEST GJ, 1977, CANCER RES, V37, P1372	50	132	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2039	2045						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478523				2022-12-25	WOS:A1995TF29700014
J	DARVILLE, MI; ANTOINE, IV; MERTENSSTRIJTHAGEN, JR; DUPRIEZ, VJ; ROUSSEAU, GG				DARVILLE, MI; ANTOINE, IV; MERTENSSTRIJTHAGEN, JR; DUPRIEZ, VJ; ROUSSEAU, GG			AN E2F-DEPENDENT LATE-SERUM-RESPONSE PROMOTER IN A GENE THAT CONTROLS GLYCOLYSIS	ONCOGENE			English	Article						CELL CYCLE; E2F; FRUCTOSE-2,6-BISPHOSPHATE; GLYCOLYSIS; SRC; ETS	TRANSCRIPTION FACTOR E2F; EPIDERMAL GROWTH-FACTOR; THYMIDINE KINASE; MESSENGER-RNA; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; CELL-PROLIFERATION; BINDING-SITE; STIMULATION; ASSOCIATION; FIBROBLASTS	The F-type mRNA of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is found in proliferating, but not in quiescent, cells. This bifunctional enzyme catalyses the synthesis and degradation of fructose-2,6-bisphosphate, a potent stimulator of glycolysis. F-type mRNA concentration decreased upon differentiation of rat rhabdomyosarcoma cells; it increased in Rat-1. fibroblasts stimulated to proliferate by serum, by epidermal growth factor, or by the v-src oncogene product. This increase resulted, at least in part, from a stimulation of F promoter activity. The stimulation occurred at the G(1)/S transition of the cell cycle. It depended on a binding site for the oncogenic transcription factor E2F located in the first exon of F-type mRNA, This effect was inhibited by agents that increase cAMP concentration. The data provide the first evidence that a gene involved in the control of glycolysis can be regulated by a late-serum-response promoter in an E2F-dependent way.	UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; DIAMOND I, 1978, J BIOL CHEM, V253, P866; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EIGENBRODT E, 1985, REGULATION CARBOHYDR, V2, P141; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GAUTRON S, 1991, NUCLEIC ACIDS RES, V19, P767, DOI 10.1093/nar/19.4.767; GERHARZ CD, 1989, CANCER RES, V49, P7132; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUE L, 1993, ADV ENZYME REGUL, V33, P97; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MARCHAND MJ, 1992, BIOCHEM J, V285, P413, DOI 10.1042/bj2850413; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEIENHOFER MC, 1983, BIOCHEM J, V214, P195, DOI 10.1042/bj2140195; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; ROUSSEAU GG, 1993, PROG NUCLEIC ACID RE, V45, P99, DOI 10.1016/S0079-6603(08)60868-5; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; WEINHOUSE S, 1976, Z KREBSFORSCH KLIN O, V87, P115; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	47	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1509	1517						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478575				2022-12-25	WOS:A1995TC53500009
J	PROSCHEL, C; BLOUIN, MJ; GUTOWSKI, NJ; LUDWIG, R; NOBLE, M				PROSCHEL, C; BLOUIN, MJ; GUTOWSKI, NJ; LUDWIG, R; NOBLE, M			LIMK1 IS PREDOMINANTLY EXPRESSED IN NEURAL TISSUES AND PHOSPHORYLATES SERINE, THREONINE AND TYROSINE RESIDUES IN-VITRO	ONCOGENE			English	Article						LIMK1; LIM-DOMAIN; PROTEIN KINASE; CHROMOSOME 5; MOUSE	CYSTEINE-RICH PROTEIN; POLYMERASE CHAIN-REACTION; ZINC-FINGER MOTIF; T-CELL ONCOGENE; KINASE FAMILY; DEVELOPMENTAL REGULATION; CONSERVED FEATURES; POINT MUTATIONS; INSULIN GENE; KIT RECEPTOR	We have isolated the murine Limk1 gene, which is a single copy gene located at the distal end of mouse chromosome 5. Limk1 exhibits a 95% homology to the human homologue, LIMK, which contains two LIM domains and a putative protein kinase domain. Although Limk1 and LIMK contain all motifs found in catalytic kinase domains, amino acids previously described to be diagnostic of either serine/threonine- or tyrosine-kinases are not present. It is demonstrated that GST-Limk1-fusion protein can autophosphorylate on serine, tyrosine and threonine residues in vitro and that mutation of residue D460 within the IHRDL motif abolishes kinase activity. Northern blot showed preferential expression of a 3.5 kb message in adult spinal cord and brain. In situ hybridisation confirmed high expression levels in the nervous system, particularly in the spinal cord and the cranial nerve and dorsal root ganglia. Limk1 also contains two tandem LIM-domains. These zinc-finger like domains can mediate protein-protein interactions and have been described in nuclear and cytoskeletal proteins. The combination of LIM- and kinase domains may provide a novel route by which intracellular signalling can be integrated.			PROSCHEL, C (corresponding author), LUDWIG INST CANC RES, 91 RIDING HOUSE ST, LONDON W1P 8BT, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DAVIES AH, 1993, BIO-TECHNOL, V11, P933, DOI 10.1038/nbt0893-933; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONG JL, 1991, MOL ENDOCRINOL, V5, P1633, DOI 10.1210/mend-5-11-1633; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FISCH P, 1992, ONCOGENE, V7, P2389; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MORAN MF, 1988, ONCOGENE, V3, P665; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; ORKIN SH, 1992, BLOOD, V80, P575; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PEREZALVARADO GC, 1994, STRUCT BIOL, V1, P388; PLACZEK M, 1991, DEVELOPMENT, P105; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; ROWE LB, 1994, MAMMALIAN GENOME, V5; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAMBROOK KJ, 1989, MOL CLONING LABORATO; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Scott J D, 1992, Curr Opin Neurobiol, V2, P289, DOI 10.1016/0959-4388(92)90117-4; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAYLOR SS, 1992, CURR OPIN STRUC BIOL, V2, P743; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; TURNER CE, 1994, J CELL SCI, V107, P1583; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WILKINSON DG, 1992, IN SITU HYBRIDSATION; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WOODGETT JR, 1989, RECEPTORS PRACTICAL, P133; WU RY, 1994, J BIOL CHEM, V269, P25085; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	82	97	99	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1271	1281						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478547				2022-12-25	WOS:A1995RY96700007
J	HOOPS, TC; IVANOV, I; CUI, Z; COLOMERGOULD, V; RINDLER, MJ				HOOPS, TC; IVANOV, I; CUI, Z; COLOMERGOULD, V; RINDLER, MJ			INCORPORATION OF THE PANCREATIC MEMBRANE-PROTEIN GP-2 INTO SECRETORY GRANULES IN EXOCRINE BUT NOT ENDOCRINE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; PITUITARY-TUMOR-CELLS; CELLULAR SECRETION; MESSENGER-RNA; GENE-TRANSFER; RAT PANCREAS; PHOSPHATIDYLINOSITOL; GLYCOPROTEIN; BIOSYNTHESIS; EXPRESSION	The pancreatic zymogen granule membrane protein GP-2 was introduced into cells of exocrine or endocrine origin by transfection of its cDNA in order to investigate the mechanisms by which proteins are specifically incorporated into the membranes of secretory granules. Permanent transformants expressing GP-2 were isolated from exocrine pancreatic-derived AR42J cells as well as AtT20 cells of anterior pituitary origin and insulinoma-derived Rin5F cells. In AR42J cells, GP-2 was localized by immunofluorescence and immunoelectron microscopy to the endogenous zymogen-like granules as well as to the plasma membrane. In experiments supporting the localization data, incubation of the AR42J transformants with the secretagogue cholecystokinin (CCK8) resulted in enhanced release of a shed form of GP-2 into the medium in parallel with amylase, suggesting that the two proteins were secreted from the same compartment. By contrast, when expressed in AtT20 cells, the protein was found by immunofluorescence microscopy on the plasma membrane as well as in intracellular vesicles that differed in size and location from the endogenous secretory vesicles. By electron microscopy, large (approximately 5 mum) multivesicular structures were observed. Single- and double-label immunoelectron microscopy demonstrated that these large organelles labeled with anti-GP-2 antibodies, whereas the smaller adrenocorticotropic hormone (ACTH)-containing secretory vesicles did not. In permanent transformants of Rin5F cells, GP-2 was also excluded from the insulin-containing granules and found in multivesicular bodies similar to those in the AtT20 cells and containing the endosomal/lysosomal marker endolyn-78. Despite the apparent accumulation of GP-2 in lysosome-like structures, it turned over slowly and did not undergo rapid endocytosis from the cell surface. We conclude that GP-2 is targeted to secretory granule membranes by cell type-specific mechanisms that likely involve its interaction with other membrane or content proteins expressed only in the exocrine cells.	NYU MED CTR,DEPT CELL BIOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,DEPT ENVIRONM MED,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	New York University; New York University; New York University; University of Pennsylvania					NIA NIH HHS [AG01461] Funding Source: Medline; NIDDK NIH HHS [DK44238] Funding Source: Medline; NIEHS NIH HHS [ES00136] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K12ES000136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001461] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DITTIE A, 1992, EUR J CELL BIOL, V58, P243; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; HAVINGA JR, 1985, EUR J CELL BIOL, V39, P70; HAVINGA JR, 1983, EUR J BIOCHEM, V133, P449, DOI 10.1111/j.1432-1033.1983.tb07484.x; HE HT, 1987, J CELL BIOL, V105, P2489, DOI 10.1083/jcb.105.6.2489; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAETZEL DM, 1990, J BIOL CHEM, V265, P15932; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P1350, DOI 10.1073/pnas.89.4.1350; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LEBEL D, 1989, BIOCHEM CELL BIOL, V67, P281, DOI 10.1139/o89-042; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; LOGSDON CD, 1985, J CELL BIOL, V100, P1200, DOI 10.1083/jcb.100.4.1200; MAINS RE, 1976, J BIOL CHEM, V251, P4115; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONACO ME, 1988, BIOCHEM BIOPH RES CO, V151, P717, DOI 10.1016/S0006-291X(88)80339-5; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; NODA T, 1992, J CELL BIOL, V119, P85, DOI 10.1083/jcb.119.1.85; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RINDLER MJ, 1990, EUR J CELL BIOL, V53, P154; RIVAS RJ, 1989, J CELL BIOL, V109, P51, DOI 10.1083/jcb.109.1.51; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SWAROVSKY B, 1988, EUR J CELL BIOL, V47, P101; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TOUTANT JP, 1990, EUR J BIOCHEM, V187, P31, DOI 10.1111/j.1432-1033.1990.tb15274.x; VOORBERG J, 1993, EMBO J, V12, P749, DOI 10.1002/j.1460-2075.1993.tb05709.x; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I	53	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25694	25705						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503984				2022-12-25	WOS:A1993MK10000061
J	NUDELMAN, ED; LEVERY, SB; STROUD, MR; SALYAN, MEK; ABE, K; HAKOMORI, S				NUDELMAN, ED; LEVERY, SB; STROUD, MR; SALYAN, MEK; ABE, K; HAKOMORI, S			A NOVEL TUMOR-ASSOCIATED, DEVELOPMENTALLY REGULATED GLYCOLIPID ANTIGEN DEFINED BY MONOCLONAL-ANTIBODY ACFH-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98119; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98119; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98119	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	NUDELMAN, ED (corresponding author), UNIV WASHINGTON,INST BIOMEMBRANE,SEATTLE,WA 98119, USA.				NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE K, 1983, J BIOL CHEM, V258, P1793; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; CHIA D, 1985, CANCER RES, V45, P435; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DABROWSKI J, 1981, ARCH BIOCHEM BIOPHYS, V210, P405, DOI 10.1016/0003-9861(81)90203-4; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; EGGE H, 1987, MASS SPECTROM REV, V6, P331, DOI 10.1002/mas.1280060302; FUKUDA MN, 1986, J BIOL CHEM, V261, P5145; FUKUDA MN, 1986, J BIOL CHEM, V261, P2376; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHI Y, 1984, J BIOL CHEM, V259, P4681; Hakomori S, 1970, Biochim Biophys Acta, V202, P225, DOI 10.1016/0005-2760(70)90244-4; HAKOMORI S, 1983, BIOCHEM BIOPH RES CO, V113, P791, DOI 10.1016/0006-291X(83)91069-0; HAKOMORI S, 1983, J BIOL CHEM, V258, P1819; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HANFLAND P, 1981, BIOCHEMISTRY-US, V20, P5310, DOI 10.1021/bi00521a034; HANFLAND P, 1984, EUR J BIOCHEM, V145, P531, DOI 10.1111/j.1432-1033.1984.tb08589.x; HOLMES EH, 1985, J BIOL CHEM, V260, P7619; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KANNAGI R, 1982, J BIOL CHEM, V257, P4438; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KANNAGI R, 1983, CANCER RES, V43, P4997; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; LEVERY SB, 1986, CARBOHYD RES, V151, P311, DOI 10.1016/S0008-6215(00)90351-3; LEVERY SB, 1988, CARBOHYD RES, V178, P121, DOI 10.1016/0008-6215(88)80106-X; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; NUDELMAN E, 1986, J BIOL CHEM, V261, P1247; RAUVALA H, 1976, J BIOL CHEM, V251, P7517; Skipski V P, 1975, Methods Enzymol, V35, P396, DOI 10.1016/0076-6879(75)35178-1; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P21, DOI 10.1515/bchm2.1973.354.1.21; TAI T, 1975, J BIOCHEM-TOKYO, V78, P679, DOI 10.1093/oxfordjournals.jbchem.a130955; URDAL DL, 1983, BLOOD, V62, P1022; YANG HJ, 1971, J BIOL CHEM, V246, P1192; YOUNG WW, 1981, J BIOL CHEM, V256, P967; 1977, LIPIDS, V12, P455	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13942	13951						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417685				2022-12-25	WOS:A1988Q159400075
J	LOMBARDO, YB; MORSE, EL; ADIBI, SA				LOMBARDO, YB; MORSE, EL; ADIBI, SA			SPECIFICITY AND MECHANISM OF INFLUENCE OF AMINO-ACID RESIDUES ON HEPATIC-CLEARANCE OF OLIGOPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									MONTEFIORE HOSP,CLIN NUTR UNIT,PITTSBURGH,PA 15213; MONTEFIORE HOSP,DEPT MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015861] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-15861] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADIBI SA, 1975, J CLIN INVEST, V56, P1355, DOI 10.1172/JCI108215; ADIBI SA, 1977, J CLIN INVEST, V60, P1008, DOI 10.1172/JCI108851; ADIBI SA, 1971, J CLIN INVEST, V50, P2266, DOI 10.1172/JCI106724; ADIBI SA, 1986, METABOLISM, V35, P830, DOI 10.1016/0026-0495(86)90224-6; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; CARO JF, 1982, J BIOL CHEM, V257, P8459; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; HEADING RC, 1977, CLIN SCI MOL MED, V52, P607, DOI 10.1042/cs0520607; HEMS R, 1966, BIOCHEM J, V101, P284, DOI 10.1042/bj1010284; HO S, 1984, J LAB CLIN MED, V103, P152; KIM YS, 1979, GASTROENTEROLOGY, V78, P82; LANE AE, 1975, J PHYSIOL-LONDON, V248, P143, DOI 10.1113/jphysiol.1975.sp010966; Little G H, 1976, Methods Enzymol, V45, P495; LOCHS H, 1986, J BIOL CHEM, V261, P4976; LOMBARDO YB, 1984, HORM METAB RES, V16, P183, DOI 10.1055/s-2007-1014738; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MISBIN RI, 1982, AM J PHYSIOL, V243, pG103, DOI 10.1152/ajpgi.1982.243.2.G103; QUINLAN DC, 1982, BIOCHEM J, V208, P685, DOI 10.1042/bj2080685; RAJENDRAN VM, 1987, AM J PHYSIOL, V252, pG281, DOI 10.1152/ajpgi.1987.252.2.G281; ROSENTHAL NR, 1985, AM J PHYSIOL, V248, pE581, DOI 10.1152/ajpendo.1985.248.5.E581; RUBINO A, 1971, J BIOL CHEM, V246, P3542; SILBERNAGL S, 1987, AM J PHYSIOL, V253, pF448, DOI 10.1152/ajprenal.1987.253.3.F448; SIPS HJ, 1980, EUR J BIOCHEM, V105, P217, DOI 10.1111/j.1432-1033.1980.tb04492.x; STARNES WL, 1974, BIOCHEMISTRY-US, V13, P3221, DOI 10.1021/bi00713a004; STEINHARDT HJ, 1984, GASTROENTEROLOGY, V86, P1562; VANAMELSVOORT JMM, 1978, BIOCHEM J, V174, P1083, DOI 10.1042/bj1741083; VAZQUEZ JA, 1986, AM J CLIN NUTR, V44, P24, DOI 10.1093/ajcn/44.1.24; VAZQUEZ JA, 1985, AM J PHYSL, V249, pE563; WALDMAN RH, 1963, AM J PHYSIOL, V204, P749, DOI 10.1152/ajplegacy.1963.204.5.749; WIDNELL CC, 1968, P NATL ACAD SCI USA, V61, P1050, DOI 10.1073/pnas.61.3.1050; ZAR JH, 1974, BIOSTAT ANAL, V12, P151	32	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12920	12926						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417643				2022-12-25	WOS:A1988Q091700025
J	BARBARAT, B; PODEVIN, RA				BARBARAT, B; PODEVIN, RA			STOICHIOMETRY OF THE RENAL SODIUM-L-LACTATE COTRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									FAC MED XAVIER BICHAT,DEPT PHYSIOL,16 RUE HENRI HUCHARD,F-75018 PARIS,FRANCE; INSERM,U251,F-75018 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			Barbarat, Bernadette/R-2881-2016	Barbarat, Bernadette/0000-0002-8578-980X				BARACNIETO M, 1980, AM J PHYSIOL, V239, pF496, DOI 10.1152/ajprenal.1980.239.5.F496; BARBARAT B, 1986, J BIOL CHEM, V261, P4455; BARBARAT B, 1987, J BIOL CHEM, V262, P13102; BECK JC, 1978, J BIOL CHEM, V253, P7158; BECK JC, 1975, J BIOL CHEM, V250, P8674; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EVERS J, 1976, BIOCHIM BIOPHYS ACTA, V426, P598, DOI 10.1016/0005-2736(76)90124-3; GUGGINO SE, 1983, AM J PHYSIOL, V244, pF612, DOI 10.1152/ajprenal.1983.244.6.F612; HILDEN S, 1982, AM J PHYSIOL, V242, pF340, DOI 10.1152/ajprenal.1982.242.4.F340; HILDMANN B, 1980, BIOCHEM J, V186, P169, DOI 10.1042/bj1860169; JORGENSEN KE, 1984, BIOCHEM J, V223, P803, DOI 10.1042/bj2230803; KINNE R, 1975, J MEMBRANE BIOL, V21, P375, DOI 10.1007/BF01941077; KRAGHHANSEN U, 1982, BIOCHEM J, V208, P359, DOI 10.1042/bj2080359; MENGUAL R, 1983, J BIOL CHEM, V258, P5071; MENGUAL R, 1983, J MEMBRANE BIOL, V71, P163, DOI 10.1007/BF01875457; NORD E, 1982, AM J PHYSIOL, V243, pF456, DOI 10.1152/ajprenal.1982.243.5.F456; NORD EP, 1983, J MEMBRANE BIOL, V72, P213, DOI 10.1007/BF01870588; SAMARZIJA I, 1981, KIDNEY BODY FLUIDS, V11, P419; Segel I.H., 1975, ENZYME KINETICS; TURNER RJ, 1984, AM J PHYSIOL, V247, pF793, DOI 10.1152/ajprenal.1984.247.5.F793; ULLRICH KJ, 1982, PFLUG ARCH EUR J PHY, V395, P227, DOI 10.1007/BF00584814; ULLRICH KJ, 1982, PFLUG ARCH EUR J PHY, V395, P220, DOI 10.1007/BF00584813; WAGGONER A, 1976, J MEMBRANE BIOL, V27, P317, DOI 10.1007/BF01869143	23	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1988	263	25					12190	12193						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P8611	3410840				2022-12-25	WOS:A1988P861100008
J	SAWADOGO, M; VANDYKE, MW; GREGOR, PD; ROEDER, RG				SAWADOGO, M; VANDYKE, MW; GREGOR, PD; ROEDER, RG			MULTIPLE FORMS OF THE HUMAN GENE-SPECIFIC TRANSCRIPTION FACTOR USF .1. COMPLETE PURIFICATION AND IDENTIFICATION OF USF FROM HELA-CELL NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											SAWADOGO, M (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.		Van Dyke, Michael W./AAY-6751-2020	Van Dyke, Michael W./0000-0003-0306-4002	NCI NIH HHS [CA 42567] Funding Source: Medline; NIGMS NIH HHS [GM 09949, GM 38212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038212, F32GM009949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CADENA WS, 1987, J BIOL CHEM, V262, P12468; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CONCINO M, 1983, J BIOL CHEM, V258, P8493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; HOUGH PVC, 1987, P NATL ACAD SCI USA, V84, P4826, DOI 10.1073/pnas.84.14.4826; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNARD AC, 1987, EMBO J, V6, P3027, DOI 10.1002/j.1460-2075.1987.tb02608.x; LEVENS D, 1985, MOL CELL BIOL, V5, P2307, DOI 10.1128/MCB.5.9.2307; LOGAN J, 1986, NUCLEIC ACIDS RES, V14, P6327; MANIATIS T, 1982, MOL CLONING LABORATO, P468; MATSUI T, 1980, J BIOL CHEM, V255, P1992; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P9309; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SAKATO N, 1975, J EXP MED, V141, P1411, DOI 10.1084/jem.141.6.1411; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SAWADOGO M, 1986, CANCER CELL, V4, P147; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; WOOD WI, 1976, ANAL BIOCHEM, V73, P250, DOI 10.1016/0003-2697(76)90165-2; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975	44	244	244	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					11985	11993						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403558				2022-12-25	WOS:A1988P765000060
J	CALAMITA, G; BISHAI, WR; PRESTON, GM; GUGGINO, WB; AGRE, P				CALAMITA, G; BISHAI, WR; PRESTON, GM; GUGGINO, WB; AGRE, P			MOLECULAR-CLONING AND CHARACTERIZATION OF AQPZ, A WATER CHANNEL FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							XENOPUS-OOCYTES; RAT-KIDNEY; PROTEIN	The aquaporin family of molecular water channels is widely expressed throughout the plant and animal kingdoms. No bacterial aquaporins are known; however, sequence-related bacterial genes have been identified that encode glycerol facilitators (glpF), By homology cloning, a novel aquaporin-related DNA (aqpZ) was identified that contained no surface N-glycosylation consensus.The aqpZ RNA was not identified in mammalian mRNA by Northern analysis and exhibited bacterial codon usage preferences. Southern analysis failed to demonstrate aqpZ in mammalian genomic DNA, whereas a strongly reactive DNA was present in chromosomal DNA from Escherichia coli and other bacterial species and did not correspond to glpF. The aqpZ DNA isolated from E. coli contained a 693-base pair open reading frame encoding a polypeptide 28-38% identical to known aquaporins. When compared with other aquaporins, aqpZ encodes a 10-residue insert preceding exofacial loop C, truncated NR(2) and COOH termini, and no cysteines at known mercury-sensitive sites. Expression of aqpZ cRNA conferred Xenopus oocytes with a 15-fold increase in osmotic water permeability, which was maximal after 5 days of expression, was not inhibited with HgCl2, exhibited a low activation energy (E(a) = 3.8 kcal/mol), and failed to transport nonionic solutes such as urea and glycerol. In contrast, oocytes expressing glpF transported glycerol but exhibited limited osmotic water permeability. Phylogenetic comparison of aquaporins and homologs revealed a large separation between aqpZ and glpF, consistent with an ancient gene divergence.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOLEC MICROBIOL & IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Calamita, Giuseppe/0000-0003-4666-9546	NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048268, R01HL033991, R01HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P13052; JUNG JS, 1994, J BIOL CHEM, V269, P14648; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; MA TH, 1994, J BIOL CHEM, V269, P21845; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MAUREL C, 1994, J BIOL CHEM, V269, P11869; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V269, P1668; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; VANAELST L, 1991, EMBO J, V10, P2095, DOI 10.1002/j.1460-2075.1991.tb07742.x; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WEAVER CD, 1991, PLANT PHYSIOL, V95, P222, DOI 10.1104/pp.95.1.222	25	176	178	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29063	29066		10.1074/jbc.270.49.29063	http://dx.doi.org/10.1074/jbc.270.49.29063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493926	hybrid			2022-12-25	WOS:A1995TJ22700007
J	HERNANDEZSANCHEZ, C; BLAKESLEY, V; KALEBIC, T; HELMAN, L; LEROITH, D				HERNANDEZSANCHEZ, C; BLAKESLEY, V; KALEBIC, T; HELMAN, L; LEROITH, D			THE ROLE OF THE TYROSINE KINASE DOMAIN OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR IN INTRACELLULAR SIGNALING, CELLULAR PROLIFERATION AND TUMORIGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; PHOSPHORYLATION SITES; BINDING-SITE; IRS-1; AUTOPHOSPHORYLATION; TRANSDUCTION; CELLS; SUBSTRATE-1; PROTEIN; SPECIFICITY	Insulin and insulin-like growth factor (IGF-I) receptors are heterotetrameric proteins consisting of two alpha- and two beta-subunits and members of the transmembrane tyrosine kinase receptors. Specific ligand binding to the receptor triggers a cascade of intracellular events, which begins with autophosphorylation of several tyrosine residues of the beta-subunit of the receptor. The triple cluster in the tyrosine kinase domain of the beta-subunit is the earliest and major autophosphorylation site. Previous studies have shown that substitutions of these three tyrosines by phenylalanines of both insulin and IGF-I receptors practically abolish any activation of cellular signaling pathways. We have studied the effect of double tyrosine mutations on IGF-I-induced receptor autophosphorylation, activation of Shc and IRS-1 pathways, and cell proliferation and tumorigenicity. Substitution of tyrosines 1131/1135 blocks any detectable autophosphorylation, whereas substitution of tyrosines 1131/1136 or 1135/1136 only reduces autophosphorylation levels in some clones by similar to 50%. Nevertheless, all the cells expressing IGF-I receptors with double tyrosine substitutions demonstrated markedly reduced signaling through Shc and IRS-1 pathways. In addition, they were unable to respond to IGF-I-stimulated cell growth in culture, and tumor formation in nude mice was abrogated. These data suggest that the presence of tyrosine 1131 or 1135 essential for receptor autophosphorylation, whereas the presence of each of these tyrosines is necessary for a fully functional receptor.	NIDDK,DIABET BRANCH,MOLEC & CELLULAR PHYSIOL SECT,BETHESDA,MD 20892; NCI,PEDIAT BRANCH,MOLEC ONCOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Hernández-Sánchez, Catalina/N-1737-2014	Hernández-Sánchez, Catalina/0000-0002-0846-5019				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ISSAD T, 1991, BIOCHEM J, V275, P15, DOI 10.1042/bj2750015; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V1992, P1303; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI CH, 1993, P NATL ACAD SCI USA, V90, P11713; LI SW, 1994, J BIOL CHEM, V269, P32558; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STANNARD B, 1995, IN PRESS ENDOCRINOLO; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YONEZAWA K, 1991, ADV EXP MED BIOL, V293, P227; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	48	79	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29176	29181		10.1074/jbc.270.49.29176	http://dx.doi.org/10.1074/jbc.270.49.29176			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493944	hybrid			2022-12-25	WOS:A1995TJ22700025
J	MORI, S; TANAKA, K; OMURA, S; SAITO, Y				MORI, S; TANAKA, K; OMURA, S; SAITO, Y			DEGRADATION PROCESS OF LIGAND-STIMULATED PLATELET-DERIVED GROWTH-FACTOR BETA-RECEPTOR INVOLVES UBIQUITIN-PROTEASOME PROTEOLYTIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE MUTANT TS85; MICROBIAL METABOLITE; MEDIATED ENDOCYTOSIS; PROTEIN-DEGRADATION; NEUROBLASTOMA-CELLS; PDGF RECEPTOR; SH3 DOMAINS; IDENTIFICATION; ESTABLISHES; LACTACYSTIN	The platelet-derived growth factor beta-receptor undergoes polyubiquitination as a consequence of ligand binding. We have previously reported that ligand-induced ubiquitination of the receptor plays a negative regulatory role in its mitogenic signaling possibly by promoting the efficient degradation of the ligand-activated receptor (Mori, S., Heldin, C.-H., and Claesson-Welsh, L. (1993) J. Biol. Chem. 268, 577-583). In the present study, we have examined effects of different kinds of cell-penetrating proteasome inhibitors, including substrate-related peptidyl aldehydes, Cbz-Ile-Glu(O-t-Bu)Ala-leucinal (where Bu is butyl and Cbz is benzyloxycarbonyl) (PSI) and Cbz-Leu-Leu-norvalinal (MG115), and a Streptomyces metabolite lactacystin, on degradation of the receptor in intact cells with the aim of evaluating the role of the receptor ubiquitination in the proteasome-dependent proteolytic process. These proteasome inhibitors were found to considerably inhibit ligand-stimulated degradation of the wild-type beta-receptor; however, their inhibitory effect was not observed when the cells expressing the ubiquitination-deficient mutant beta-receptor were analyzed. These data suggest that the degradation process of the ligand-stimulated beta-receptor involves the ubiquitin-proteasome proteolytic pathway.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; KITASATO INST,BIOL FUNCT RES CTR,MINATO KU,TOKYO 108,JAPAN	Tokushima University	MORI, S (corresponding author), CHIBA UNIV,SCH MED,DEPT INTERNAL MED 2,1-8-1 INOHANA,CHIBA 260,JAPAN.							BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; MORI S, 1993, J BIOL CHEM, V268, P577; MORI S, 1994, J BIOL CHEM, V269, P4917; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; TANAKA K, 1992, NEW BIOL, V4, P173; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	37	127	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29447	29452		10.1074/jbc.270.49.29447	http://dx.doi.org/10.1074/jbc.270.49.29447			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493983	hybrid			2022-12-25	WOS:A1995TJ22700064
J	OLSON, MW; DALLMANN, HG; MCHENRY, CS				OLSON, MW; DALLMANN, HG; MCHENRY, CS			DNAX COMPLEX OF ESCHERICHIA-COLI DNA-POLYMERASE-III HOLOENZYME - THE (CHI-CENTER-DOT-PSI) COMPLEX FUNCTIONS BY INCREASING THE AFFINITY OF (TAU) AND (GAMMA) FOR DELTA-CENTER-DOT-DELTA TO A PHYSIOLOGICALLY RELEVANT RANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; ACCESSORY PROTEINS; BETA-SUBUNIT; REPLICATION FORK; MECHANISM; IDENTIFICATION; PURIFICATION; COMPONENTS; CLONING; PRODUCT	An artificial operon that contains tandem holC-holD genes was used to overproduce a complex of the chi and psi subunits of the DNA polymerase III holoenzyme. Normally insoluble by itself, psi forms a tight soluble complex with chi. A purification procedure that yields pure, active chi .psi complex in 100-mg quantities suitable for biophysical studies is reported. Sedimentation equilibrium studies demonstrate that chi .psi is a 1:1 heterodimer. The presence of chi .psi dramatically lowers the level of delta .delta' required to reconstitute holoenzyme to levels expected in vivo. That chi .psi accomplishes this by binding to gamma or tau and increasing their affinity for delta .psi' was demonstrated by surface plasmon resonance using a Pharmacia BIA-core(TM) instrument. In the absence of delta .delta', chi .psi binds to core(TM) instrument. In the absence of delta .delta, chi .psi binds to either the gamma or tau DnaX protein with K-d = 2 nM.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOLEC BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARTER JR, 1993, MOL GEN GENET, V241, P399, DOI 10.1007/BF00284693; CARTER JR, 1993, J BACTERIOL, V175, P5406; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; EDELHOCH H, 1967, BIOCHEMISTRY-US, V7, P1948; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HAWKER J, 1985, THESIS U TEXAS GRADU; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; INGRAHAM J, 1983, GROWTH BACTERIAL CEL, P269; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MAKI S, 1988, J BIOL CHEM, V263, P6555; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1986, MECHANISMS DNA REPLI, P47; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1993, J BIOL CHEM, V268, P11766; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; WU YH, 1984, J BIOL CHEM, V259, P2117; XIAO H, 1993, J BIOL CHEM, V268, P11779; XIAO H, 1993, J BIOL CHEM, V268, P11773	35	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29570	29577		10.1074/jbc.270.49.29570	http://dx.doi.org/10.1074/jbc.270.49.29570			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7494000	hybrid			2022-12-25	WOS:A1995TJ22700081
J	BONNARDEL, JA; DAVIS, RA				BONNARDEL, JA; DAVIS, RA			IN HEPG2 CELLS, TRANSLOCATION, NOT DEGRADATION, DETERMINES THE FATE OF THE DE-NOVO SYNTHESIZED APOLIPOPROTEIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; DISULFIDE ISOMERASE; OLEIC-ACID; G2 CELLS; SECRETION; HEP-G2; LIVER; LINE	Previous studies show that translocation and degradation of apolipoprotein B (apoB), two processes occurring on or within the endoplasmic reticulum, determine how much de novo synthesized apoB is secreted. We determined which of these processes regulates the intracellular fate of apoB by examining whether degradation determines how much apoB is translocated or if translocation determines how much apoB is degraded. HepG2 cells, treated with the cysteine active site protease inhibitor ALLN, previously shown to block the degradation of translocation-arrested apoB in Chinese hamster ovary cells (Du, E., Kurth, J., Wang, S.-L., Humiston, P., and Davis, R. A. (1994) J. Biol. Chem. 269, 24169-24176), showed a 10-fold increase in the accumulation of de novo synthesized [S-35] methionine-labeled apoB. The majority (80%) of the apoB accumulated in response to ALLN was in the microsomal fraction, In contrast, ALLN did not effect apoB secretion, Since ALLN did not effect the intracellular accumulation of [S-35]methionine-labeled albumin and other proteins (trichloroacetic acid precipitable [S-35]methionine-labeled proteins), its effect on apoB was specific. Pulse-chase studies showed that ALLN dramatically reduced the first-order rate of removal of [S-35]methionine-labeled apoB from the cell but did not effect its rate of secretion. The finding that ALLN caused the intracellular accumulation of incompletely translated chains of apoB suggests that at least some of the degradation occurs at the ribosomal level. Moreover, 85% of the apoB that accumulated in isolated microsomes in response to ALLN was accessible to exogenous trypsin, indicating this pool of apoB was incompletely translocated. The combined data suggest that translocation, not degradation, determines the intracellular fate of de novo synthesized apoB.	SAN DIEGO STATE UNIV,DEPT BIOL,MAMMALIAN CELL & MOLEC BIOL LAB,SAN DIEGO,CA 92182	California State University System; San Diego State University					NHLBI NIH HHS [HL51643] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORNSSON OG, 1994, EUR J CLIN INVEST, V24, P137, DOI 10.1111/j.1365-2362.1994.tb00979.x; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; Davis R.A., 1991, BIOCH LIPIDS LIPOPRO, P403; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; ERICKSON SK, 1986, J LIPID RES, V27, P875; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; HARTMANN E, 1994, NATURE, V37, P654; HAVEL RJ, 1992, SEMINARS LIVER DISEA, P356; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1994, J BIOL CHEM, V269, P29138; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALAM WH, 1988, BIOCHEM J, V251, P809, DOI 10.1042/bj2510809; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1986, J LIPID RES, V27, P236; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VANCE JE, 1990, ANNU REV NUTR, V10, P337, DOI 10.1146/annurev.nu.10.070190.002005; WANG HX, 1994, J BIOL CHEM, V269, P18514; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WETTERAU JR, 1908, J BIOL CHEM, V259, P10863; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; YAO Z, 1901, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	40	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28892	28896		10.1074/jbc.270.48.28892	http://dx.doi.org/10.1074/jbc.270.48.28892			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499417	hybrid			2022-12-25	WOS:A1995TH05600061
J	GADDYKURTEN, D; VALE, WW				GADDYKURTEN, D; VALE, WW			ACTIVIN INCREASES PHOSPHORYLATION AND DECREASES STABILITY OF THE TRANSCRIPTION FACTOR PIT-1 IN MTTW15 SOMATOTROPE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SERINE KINASE; GLOBIN GENE-EXPRESSION; BETA FAMILY MEMBER; GROWTH-HORMONE; TGF-BETA; II RECEPTOR; PROTEIN; CLONING; BINDING; IDENTIFICATION	Activin is a polypeptide growth factor which exerts endocrine, paracrine, and autocrine effects in a variety of tissues. In the pituitary somatotrope, activin represses proliferation and growth hormone (GH) biosynthesis and secretion. We previously demonstrated that decreases in GH biosynthesis in MtTW15 somatotrope cells are due at least in part to decreased binding of the tissue specific transcription factor, Pit-1, to the GH promoter, resulting in decreased transcription of the GH gene. The objective of the current study was to determine the extent to which activin-mediated decreases in GH transcription were the result of decreased Pit-1 activity and/or decreased Pit-1 protein content in MtTW15 cells. Activin caused rapid increases in Pit-1 phosphorylation, which were temporally correlated with de creases in GH DNA binding. Pit-1 phosphorylation preceded marked decreases in steady-state levels of Pit-1 protein. The rate of Pit-1 synthesis was only moderately decreased by activin, with a time course similar to that observed for decreases in GH biosynthesis. However, Pit-1 stability was markedly decreased after more than 4 h of activin treatment. These data demonstrate that activin decreases GH expression in MtTW15 cells through multilevel regulation of Pit-1, which may represent a more general mechanism whereby activin and other transforming growth factor beta family members modulate gene expression through regulation of transcription factor activity as well as content.	SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA	Salk Institute					NICHD NIH HHS [HD 13527] Funding Source: Medline; NIDDK NIH HHS [DK 26741] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BILEZIKJIAN LM, 1990, ENDOCRINOLOGY, V126, P2369, DOI 10.1210/endo-126-5-2369; BILLESTRUP N, 1990, MOL ENDOCRINOL, V4, P356, DOI 10.1210/mend-4-2-356; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; DEPAOLO LV, 1991, P SOC EXP BIOL MED, V198, P500; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FISCHBERG DJ, 1994, MOL ENDOCRINOL, V8, P1566, DOI 10.1210/me.8.11.1566; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIGON NL, 1992, BLOOD, V79, P765; GUTIERREZHARTMANN A, 1994, MOL ENDOCRINOL, V8, P1447, DOI 10.1210/me.8.11.1447; HOWARD PW, 1994, J BIOL CHEM, V269, P28662; ICHIJO H, 1993, BIOCHEM BIOPH RES CO, V194, P1508, DOI 10.1006/bbrc.1993.1995; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JUDD AM, 1984, BRAIN RES, V308, P137, DOI 10.1016/0006-8993(84)90924-7; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MEISENHELDER J, 1991, METHOD ENZYMOL, V197, P288; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; ROBERTS V, 1989, ENDOCRINOLOGY, V124, P552, DOI 10.1210/endo-124-1-552; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAO LE, 1992, BLOOD, V79, P773; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STRUTHERS RS, 1992, P NATL ACAD SCI USA, V89, P11451, DOI 10.1073/pnas.89.23.11451; SU JGJ, 1994, ENDOCRINE, V2, P715; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; TSUCHIDA K, 1995, IN PRESS ENDOCRINOLO, V136; VALE W, 1983, METHOD ENZYMOL, V103, P565; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; VOSS JW, 1991, J BIOL CHEM, V266, P12832; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	61	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28733	28739		10.1074/jbc.270.48.28733	http://dx.doi.org/10.1074/jbc.270.48.28733			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499395	hybrid			2022-12-25	WOS:A1995TH05600039
J	JIMENEZRUIZ, A; ZHANG, QY; SHEN, CKJ				JIMENEZRUIZ, A; ZHANG, QY; SHEN, CKJ			IN-VIVO BINDING OF TRIMETHYLPSORALEN DETECTS DNA STRUCTURAL ALTERATIONS ASSOCIATED WITH TRANSCRIBING REGIONS IN THE HUMAN BETA-GLOBIN CLUSTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; CHROMATIN STRUCTURE; GENE-EXPRESSION; LOCUS; CELLS; TRANSCRIPTION; HEMOGLOBIN; ACTIVATION; DROSOPHILA; DELETION	In order to increase our knowledge about the mechanisms that regulate expression of human beta-like globin genes, we have used a novel technique to analyze the chromatin structure in living cells. This approach allowed us to detect specific DNA regions in vivo where nucleosome folding or unconstrained DNA supercoiling in erythroid cells differs from that in non-erythroid cells, In this method, we use 4,5',8-trimethylpsoralen (TMP) as a probe capable of detecting altered chromatin conformations, Our results show that TMP binds to DNA with a higher affinity over the regions in the locus that are actively expressed, including both the promoter and the transcribed region. This higher affinity detected when comparing erythroid cells with non-erythroid cells does not extend to other regions inside the beta-globin cluster, Our data suggest that the observed effect is likely due to nucleosome displacement. Alternatively, it could result from localized DNA supercoiling, but not from widespread torsional stress across the entire beta-like globin locus as hypothesized previously,	UNIV CALIF DAVIS, MOL & CELLULAR BIOL SECT, DAVIS, CA 95616 USA; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	University of California System; University of California Davis; Academia Sinica - Taiwan			Jimenez-Ruiz, Antonio/K-2991-2014	Jimenez-Ruiz, Antonio/0000-0001-8238-3081	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK29800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; CECH T, 1977, CELL, V11, P631, DOI 10.1016/0092-8674(77)90080-0; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; COOK DN, 1989, J BACTERIOL, V171, P4836, DOI 10.1128/jb.171.9.4836-4843.1989; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; ELDER JT, 1990, MOL CELL BIOL, V10, P1382, DOI 10.1128/MCB.10.4.1382; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; GROUDINE M, 1983, DEV ASPECTS CHROMATI, P159; HYDE JE, 1978, BIOCHEMISTRY-US, V17, P1251, DOI 10.1021/bi00600a019; JUPE ER, 1993, EMBO J, V12, P1067, DOI 10.1002/j.1460-2075.1993.tb05748.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; Sambrook J, 1989, MOL CLONING LABORATO; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; YOAKUM GH, 1978, BIOCHIM BIOPHYS ACTA, V521, P529, DOI 10.1016/0005-2787(78)90295-2; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	24	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28978	28981		10.1074/jbc.270.48.28978	http://dx.doi.org/10.1074/jbc.270.48.28978			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499429	hybrid			2022-12-25	WOS:A1995TH05600073
J	NADEL, Y; WEISMANSHOMER, P; FRY, M				NADEL, Y; WEISMANSHOMER, P; FRY, M			THE FRAGILE-X SYNDROME SINGLE-STRAND D(CGG)(N) NUCLEOTIDE REPEATS READILY FOLD BACK TO FORM UNIMOLECULAR HAIRPIN STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIETHYL PYROCARBONATE; TELOMERIC SEQUENCES; CGG REPEAT; FMR1 GENE; DNA; INSTABILITY; METHYLATION; SITES; EXPRESSION; GUANINE	Expansion of a d(CGG)(n) run within the 5'-untranslated region of the X-linked human gene FMR1 blocks FMR1 transcription, delays its replication, and precipitates the fragile X syndrome, We showed previously that d(CGG)(n) tracts aggregate into interstrand tetrahelical complexes (Fry, M,, and Loeb, L, A, (1994) Proc. Natl. Acad. Sci, U. S. A. 91, 4950-4954), Here we show that these sequences also form under physiological conditions in in vitro unimolecular hairpin structures, Folding is demonstrated by temperature-dependent mobility of d(CGG)(n) oligomers in a nondenaturing polyacrylamide gel, by UV-hyperchromicity of thermally denaturing oligomers, and by UV cross-linking of compact forms of d(CGG)(n) runs interspersed by thymidine clusters, That the compact d(CGG)(n) structures are unimolecular is suggested by their zero-order kinetics of formation, Diethyl pyrocarbonate modification reveals a single, 4-5 residue-long central or epicentral unpaired loop in folded d(CGG)(n) oligomers. The position of this loop remains unchanged by insertion of thymidine clusters into 15- or 33-mer d(CGG) tracts as indicated by KMnO4 probing of unpaired thymidines. The presence of a single loop in folded d(CGG)(n) oligomers and the accessibility of every guanine to dimethyl sulfate modification suggest that they are hairpin and not tetraplex structures, Modeling indicates that different d(CGG)(n) hairpins are stabilized by guanine-guanine Hoogsteen hydrogen bonds or by Hoogsteen and Watson-Crick bonds. If formed in vivo, d(CGG)(n) hairpins could entail slippage and trinucleotide expansion during replication and could obstruct FMR1 gene transcription and replication.	TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,BIOCHEM UNIT,IL-31096 HAIFA,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine								BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BURTON K, 1966, BIOCHEM J, V98, P70, DOI 10.1042/bj0980070; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; CHOI H, 1994, BIOCHIM BIOPHYS ACTA, V1217, P341; CHRISTIANSEN J, 1994, NUCLEIC ACIDS RES, V22, P5709, DOI 10.1093/nar/22.25.5709; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; FRIEDMANN T, 1978, NUCLEIC ACIDS RES, V5, P615, DOI 10.1093/nar/5.2.615; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; FURLONG JC, 1986, NUCLEIC ACIDS RES, V14, P3995, DOI 10.1093/nar/14.10.3995; GACY AM, 1995, CELL, V81, P533; GUO Q, 1993, BIOCHEMISTRY-US, V32, P3596, DOI 10.1021/bi00065a010; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; HUERTAS D, 1993, EMBO J, V12, P4029, DOI 10.1002/j.1460-2075.1993.tb06081.x; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LEE BL, 1992, NUCL ACIDS S SERIES, V29, P183; LUO S, 1993, SOMAT CELL MOLEC GEN, V9, P393; MURCHIE AIH, 1994, EMBO J, V13, P993, DOI 10.1002/j.1460-2075.1994.tb06344.x; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1992, TRENDS GENET, V8, P249, DOI 10.1016/0168-9525(92)90124-M; Sambrook J, 1989, MOL CLONING LABORATO; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SMITH SS, 1994, J MOL BIOL, V243, P143, DOI 10.1006/jmbi.1994.1640; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V369, P624; WEBB T, 1989, FRAGILE X SYNDROME, P50; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WILLIAMSON JR, 1992, CURR OPIN STRUC BIOL, V3, P357; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	46	95	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28970	28977		10.1074/jbc.270.48.28970	http://dx.doi.org/10.1074/jbc.270.48.28970			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499428	hybrid			2022-12-25	WOS:A1995TH05600072
J	PALSRYLAARSDAM, R; XU, YR; WITTENDERBY, P; BENOVIC, JL; HOSEY, MM				PALSRYLAARSDAM, R; XU, YR; WITTENDERBY, P; BENOVIC, JL; HOSEY, MM			DESENSITIZATION AND INTERNALIZATION OF THE M2 MUSCARINIC ACETYLCHOLINE-RECEPTOR ARE DIRECTED BY INDEPENDENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED PHOSPHORYLATION; CHOLINERGIC RECEPTORS; CHICK HEART; ADENYLYL CYCLASE; PROTEIN-KINASE; DIFFERENTIAL REGULATION; EXPRESSION; IDENTIFICATION; CLONING; CELLS	The phenomenon of acute desensitization of G-protein-coupled receptors has been associated with several events, including receptor phosphorylation, loss of high affinity agonist binding, receptor:G-protein uncoupling, and receptor internalization. However, the biochemical events underlying these processes are not fully understood, and their contributions to the loss of signaling remain correlative, In addition, the nature of the kinases and the receptor domains which are involved in modulation of activity have only begun to be investigated, In order to directly measure the role of G-protein-coupled receptor kinases (GRKs) in the desensitization of the m2 muscarinic acetylcholine receptor (m2 mAChR), a dominant-negative allele of GRK2 was used to inhibit receptor phosphorylation by endogenous GRK activity in a human embryonic kidney cell line. The dominant-negative GRK2K(220R) reduced agonist dependent phosphorylation of the m2 mAChR by similar to 50% and prevented acute desensitization of the receptor as measured by the ability of the m2 mAChR to attenuate adenylyl cyclase activity, In contrast, the agonist-induced internalization of the m2 mAChR was unaffected by the GRK2(K220R) construct. Further evidence linking receptor phosphorylation to acute receptor desensitization was obtained when two deletions of the third intracellular loop were made which created m2 mAChRs that did not become phosphorylated in an agonist dependent manner and did not desensitize. However, the mutant mAChRs retained the ability to internalize. These data provide the first direct evidence that GRK-mediated receptor phosphorylation is necessary for m2 mAChR desensitization; the likely sites of in vivo phosphorylation are in the central portion of the third intracellular loop (amino acids 282-323). These results also indicate that internalization of the m2 receptor is not a key event in desensitization and is mediated by mechanisms distinct from GRK phosphorylation of the receptor.	NORTHWESTERN UNIV, SCH MED, DEPT MOLEC PHARMACOL & BIOL CHEM, CHICAGO, IL 60611 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Northwestern University; Jefferson University				Witt-Enderby, Paula/0000-0002-1844-4457	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL050201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 50201] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM 44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P244; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HOSEY MM, 1994, REGULATION SIGNAL TR, P113; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; ISHII K, 1994, J BIOL CHEM, V269, P1125; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, MOL PHARMACOL, V35, P553; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEUTJE CW, 1987, BIOCHEMISTRY-US, V26, P6892; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LEVEY AI, 1995, J COMP NEUROL, V351, P339, DOI 10.1002/cne.903510303; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LIGGETT SB, 1994, REGULATION CELLULAR, P71; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MORO O, 1993, J BIOL CHEM, V268, P6862; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PETERSON GL, 1995, J BIOL CHEM, V270, P17808, DOI 10.1074/jbc.270.30.17808; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANKOPPEN CJ, 1994, EUR J BIOCHEM, V222, P525; VOGEL WK, 1995, J BIOL CHEM, V270, P15485, DOI 10.1074/jbc.270.26.15485; WEI HB, 1994, EUR J PHARM-MOLEC PH, V268, P381, DOI 10.1016/0922-4106(94)90063-9; WELLER M, 1975, P NATL ACAD SCI USA, V72, P381, DOI 10.1073/pnas.72.1.381; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YU SS, 1993, J BIOL CHEM, V268, P337	64	132	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29004	29011		10.1074/jbc.270.48.29004	http://dx.doi.org/10.1074/jbc.270.48.29004			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499433	hybrid			2022-12-25	WOS:A1995TH05600077
J	GILLESPIEBROWN, J; FULLER, SJ; BOGOYEVITCH, MA; COWLEY, S; SUGDEN, PH				GILLESPIEBROWN, J; FULLER, SJ; BOGOYEVITCH, MA; COWLEY, S; SUGDEN, PH			THE MITOGEN-ACTIVATED PROTEIN-KINASE KINASE MEK1 STIMULATES A PATTERN OF GENE-EXPRESSION TYPICAL OF THE HYPERTROPHIC PHENOTYPE IN RAT VENTRICULAR CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; SIGNAL TRANSDUCTION PATHWAYS; PHORBOL ESTER STIMULATION; ATRIAL-NATRIURETIC-FACTOR; MUSCLE-SPECIFIC GENES; CARDIAC MYOCYTES; ADRENERGIC-STIMULATION; MYOCARDIAL-CELLS; PHOSPHOINOSITIDE HYDROLYSIS; TRANSCRIPTIONAL ACTIVATION	Adult mammalian ventricular cardiomyocytes are terminally differentiated cells that enlarge adaptively by hypertrophy. In this situation, genes normally expressed in the fetal ventricular cardiomyocyte (e.g. atrial natriuretic factor (ANF), beta-myosin heavy chain (beta-MHC), and skeletal muscle (SkM) alpha-actin) are re-expressed, and there is transient expression of immediate early genes (e.g. c-fos), Using appropriate reporter plasmids, we studied the effects of transfection of the constitutively active or dominant negative mitogen-activated protein kinase kinase MEK1 on ANF, beta-MHC, and SkM alpha-actin promoter activities in cultured ventricular cardiomyocytes, ANF expression was stimulated (maximally 75-fold) by the hypertrophic agonist phenylephrine in a dose-dependent manner (EC(50), 10 mu M), and this stimulation was inhibited by dominant negative MEK1, Cotransfection of dominant negative MEK1 with a dominant negative mitogen-activated protein kinase (extracellular signal-regulated protein kinase (ERK2)) increased this inhibition. Transfection with constitutively active MEK1 constructs doubled ANF promoter activity, The additional cotransfection of wild-type ERK2 stimulated ANF promoter activity by about 5-fold. Expression of beta-MHC and SkM alpha-actin was also stimulated. Promoter activity regulated by activator protein-1 or c-fos serum response element consensus sequences was also increased, We conclude that the MEK1/ERK2 cascade may play a role in regulating gene expression during hypertrophy.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND; UNIV LONDON, INST CANC RES, CHESTER BEATTY LABS, CELL & MOLEC BIOL SECT, LONDON SW3 6JB, ENGLAND	Imperial College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Brown, Judith/0000-0003-4092-9685; Bogoyevitch, Marie/0000-0001-9745-3716; Cowley, Sally/0000-0003-0297-6675	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ADACHI S, 1994, J MOL CELL CARDIOL, V26, P789, DOI 10.1006/jmcc.1994.1096; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALLO SN, 1992, AM J PHYSIOL, V263, pC319, DOI 10.1152/ajpcell.1992.263.2.C319; ALLO SN, 1991, J BIOL CHEM, V266, P22003; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRAND T, 1993, J BIOL CHEM, V268, P11500; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLERK A, 1994, J BIOL CHEM, V269, P32848; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; GARDNER DG, 1991, AM J PHYSIOL, V261, pE177, DOI 10.1152/ajpendo.1991.261.2.E177; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LAZOU A, 1994, AM J PHYSIOL, V267, pH970, DOI 10.1152/ajpheart.1994.267.3.H970; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEEVERS SJ, 1993, THESIS U LONDON; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NEYSES L, 1991, BIOCHEM BIOPH RES CO, V181, P22, DOI 10.1016/S0006-291X(05)81376-2; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTANI H, 1988, CIRC RES, V62, P8, DOI 10.1161/01.RES.62.1.8; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; SUGDEN PH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P327, DOI 10.1016/0167-4889(93)90225-E; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	78	142	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28092	28096						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499296				2022-12-25	WOS:A1995TG21000021
J	HUMPHREYS, DP; WEIR, N; MOUNTAIN, A; LUND, PA				HUMPHREYS, DP; WEIR, N; MOUNTAIN, A; LUND, PA			HUMAN PROTEIN DISULFIDE-ISOMERASE FUNCTIONALLY COMPLEMENTS A DSBA MUTATION AND ENHANCES THE YIELD OF PECTATE-LYASE-C IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND FORMATION INVIVO; ENDOPLASMIC-RETICULUM; ALKALINE-PHOSPHATASE; IN-VIVO; GENE; IDENTIFICATION; MEMBRANE; RESIDENT; VECTORS; LUMEN	Human PDI was expressed to the Escherichia coli periplasm, by using a plasmid encoded ompA-PDI fusion under the control of the trp promoter, Periplasmic extracts were shown to contain active PDI using the scrambled ribonuclease assay, PDI activity was also demonstrated by complementation of two phenotypes associated with a dsbA mutation, Alkaline phosphatase activity, which is reduced in dsbA cells, was restored to wild type levels by PDI, PelC, a pectate lyase from Erwinia carotovora, was shown to be DsbA dependent in E. coli. PDI was able to restore its activity to that seen in wild type cells. Increased expression of PDI was found to increase the yield of active PelC above that seen in wild type cells, PDI also enhanced the yield of PelC in DsbA(-) cells but only in the presence of exogenous oxidized glutathione, PDI is thus able to functionally substitute for DsbA in the folding of disulfide-bonded proteins in the bacterial periplasm and to enhance the yield of highly expressed protein when the ability of the E. coli periplasm to fold protein may be saturated, However, our results suggest that the activities of DsbA and PDI in vivo may be different.	UNIV BIRMINGHAM, SCH BIOL SCI, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; CELLTECH LTD, SLOUGH SL1 4EN, BERKS, ENGLAND	University of Birmingham; Celltech Group Ltd			lund, peter a/N-9785-2018	Lund, Peter/0000-0002-6381-8526				BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; EMTAGE JS, 1983, P NATL ACAD SCI-BIOL, V80, P3671, DOI 10.1073/pnas.80.12.3671; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HALLEWELL RA, 1980, GENE, V9, P27, DOI 10.1016/0378-1119(80)90165-1; HINTON JCD, 1989, MOL MICROBIOL, V3, P1785, DOI 10.1111/j.1365-2958.1989.tb00164.x; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACOBDUBUISSON F, 1994, P NATL ACAD SCI USA, V91, P11552, DOI 10.1073/pnas.91.24.11552; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LILIE H, 1994, J BIOL CHEM, V269, P14290; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OSTERMEIER M, 1994, J BIOL CHEM, V269, P21072; OTSU M, 1994, J BIOL CHEM, V269, P6874; RAO NN, 1990, MOL MICROBIOL, V4, P1083, DOI 10.1111/j.1365-2958.1990.tb00682.x; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; Sambrook J, 1989, MOL CLONING LABORATO; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; STARR MP, 1977, J CLIN MICROBIOL, V6, P379; TANG B, 1994, BIOCHEM J, V301, P17, DOI 10.1042/bj3010017; TASANEN K, 1988, J BIOL CHEM, V263, P16218; TORRIANI AM, 1990, BIOESSAYS, V12, P371, DOI 10.1002/bies.950120804; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025	44	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28210	28215						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499315				2022-12-25	WOS:A1995TG21000040
J	LEE, CM; ROBINSON, LJ; MICHEL, T				LEE, CM; ROBINSON, LJ; MICHEL, T			OLIGOMERIZATION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE - EVIDENCE FOR A DOMINANT-NEGATIVE EFFECT OF TRUNCATION MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								Nitric oxide produced by the endothelial isoform of nitric oxide synthase (ecNOS) is a key determinant of vascular tone, In contrast to other nitric oxide synthase (NOS) isoforms, which have been characterized as soluble homodimeric enzymes, ecNOS is predominantly membrane-associated, a feature that has hindered direct biochemical analyses of its oligomeric structure, We investigated ecNOS oligomerization using co immunoprecipitation experiments in transiently transfected COS-7 cells. When COS-7 cells co transfected with constructs encoding wild-type ecNOS and an epitope-tagged myristoylation-deficient mutant were biosynthetically labeled with [H-3]myristate, the antibody to the epitope tag specifically immunoprecipitated H-3-labeled ecNOS, reflecting enzyme oligomerization, In COS-7 cells transfected with cDNAs encoding epitope-tagged truncation mutants and untagged full-length ecNOS, the wild-type enzyme could be immunoprecipitated by the antibody to the epitope tag, Co-immunoprecipitation of ecNOS with truncation mutants documented that both N- and C-terminal domains are involved in ecNOS oligomerization, When these truncation mutants are coexpressed with wild-type ecNOS, they exert a marked dominant negative effect on enzyme activity. Since NOS oligomerization itself may be subject to dynamic modulation, the regulation of ecNOS assembly may have implications for NO signaling in the vascular wall.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, R29HL046457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46457, HL09172] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin D J, 1994, Chem Biol, V1, P131, DOI 10.1016/1074-5521(94)90002-7; BAEK KJ, 1993, J BIOL CHEM, V268, P2120; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; NATHAN C, 1994, J BIOL CHEM, V269, P13725; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287	19	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27403	27406		10.1074/jbc.270.46.27403	http://dx.doi.org/10.1074/jbc.270.46.27403			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499193	hybrid			2022-12-25	WOS:A1995TE73600004
J	HUANG, LW; TURCK, CW; RAO, P; PETERS, KG				HUANG, LW; TURCK, CW; RAO, P; PETERS, KG			GRB2 AND SH-PTP2 - POTENTIALLY IMPORTANT ENDOTHELIAL SIGNALING MOLECULES DOWNSTREAM OF THE TEK/TIE2 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article						ENDOTHELIUM; GRB2; SH-PTP2; RECEPTOR TYROSINE KINASE	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; EXPRESSION CLONING; VASCULAR ENDOTHELIUM; SH3 DOMAINS; RAS; IDENTIFICATION; MORPHOGENESIS	TEK is a newly cloned receptor tyrosine kinase that is expressed predominantly in the endothelium of actively growing blood vessels. Disruption of TEK function in transgenic mice results in a profound defect in vascular development leading to embryonic lethality. These studies show that TEK signaling is indispensable for the development of the embryonic vasculature and suggest that TEK, signaling may also be required for the development of the tumor vasculature. Because the ligand for TEPC has not been identified, it has been difficult to study signal transduction by this important endothelial receptor. To circumvent this problem, a soluble TEK kinase domain (GTEKH) was developed which could be easily purified, autophosphorylated, and radiolabeled, Using the autophosphorylated, radiolabeled GTEKH to probe a mouse embryo expression library only two candidate signaling molecules were isolated, SH-PTP2 and GRB2. Autophosphorylated GTEKH associated with GRB2 and SH-PTP2 from endothelial lysates and not with PI3 kinase or PLC gamma. The association of GRB2 and SH-PTP2 with TEK was highly dependent on specific tyrosine residues in the TEK c-tail. These studies identify GRB2 and SH-PTP2 as potentially important mediators of TEK signaling that may trigger crucial endothelial responses during embryonic vascular development and during pathologic vascular growth.	DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOVASC, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	Duke University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BANNWARTH W, 1992, HELV CHIM ACTA, V75, P707, DOI 10.1002/hlca.19920750305; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASE RD, 1994, J BIOL CHEM, V269, P10467; COFFIN JD, 1988, DEVELOPMENT, V102, P735; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG FS, 1994, TIG, V10, P54; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PETERS KG, 1992, COLD SPRING HARB SYM, V57, P63, DOI 10.1101/SQB.1992.057.01.008; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SCHWARTZ SM, 1993, J CARDIOVASC PHARM, V21, pS31, DOI 10.1097/00005344-199321001-00007; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TURCK CW, 1992, PEPTIDE RES, V5, P156; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WELLBROCK C, 1995, ONCOGENE, V10, P2135; XIAO S, 1994, J BIOL CHEM, V269, P21244; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1993, ONCOGENE, V8, P663	62	73	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					2097	2103						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478529				2022-12-25	WOS:A1995TF29700020
J	ZORNIG, M; BUSCH, G; BENEKE, R; GULBINS, E; LANG, F; MA, A; KORSMEYER, S; MOROY, T				ZORNIG, M; BUSCH, G; BENEKE, R; GULBINS, E; LANG, F; MA, A; KORSMEYER, S; MOROY, T			SURVIVAL AND DEATH OF PRELYMPHOMATOUS B-CELLS FROM N-MYC/BCL-2 DOUBLE TRANSGENIC MICE CORRELATES WITH THE REGULATION OF INTRACELLULAR CA2+ FLUXES	ONCOGENE			English	Article						B-CELLS; N-MYC; BCL-2; TRANSGENIC MICE; APOPTOSIS; CALCIUM FLUX	HUMAN FOLLICULAR LYMPHOMA; C-MYC; PRE-B; BCL-2 GENE; N-MYC; FLOW-CYTOMETRY; APOPTOSIS; EXPRESSION; GENERATION; GROWTH	Coexpression of the proto-oncogenes c-myc and bcl-2 under the control of the immunoglobulin enhancer E mu provokes the rapid development of primitive lymphoid tumors in transgenic mice, In the present study we show that the myc family members N-myc and L-myc also cooperate with bcl-2 in oncogenesis and can provoke the development of more mature pre-B, B and T cell type lymphomas. The analysis of prelymphomatous B-cells from single E mu N-myc and bcl-2-Ig transgenic animals and from young, tumor free, double transgenic E mu N-myc/bcl-2-Ig mice revealed that E mu directed expression of N-myc leads to very rapid apoptosis after explantation and culturing compared to B-cells from normal mice. As expected, B-cells from bcl-2-Ig transgenics were protected to a certain degree from apoptosis, Strikingly however, B-cells from E mu N-myc/bcl-2-Ig double transgenic animals were found to be almost completely resistant towards a number of different apoptotic stimuli. Furthermore, after treatment with H2O2, which can trigger apoptosis, B-cells from E mu N-myc animals reach levels of intracellular free Ca2+ concentrations that are comparable to B-cells from normal mice, whereas B-cells from bcl-2-Ig or E mu N-myc/bcl-2-Ig double transgenic mice show no increase in intracellular Ca2+ concentrations after stimulation with H2O2. These findings suggest that the prevention of apoptosis conferred by bcl-2 correlates with the inhibition of intracellular Ca2+ fluxes whereas induction of apoptosis mediated by N-myc requires normal Ca2+ levels. We hypothesize therefore that the regulation of intracellular Ca2+ concentrations represent one important parameter in the oncogenic cooperation between bcl-2 and N-myc.	UNIV MARBURG,IMT,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; UNIV TUBINGEN,INST PHYSIOL 1,D-72076 TUBINGEN,GERMANY; HARVARD UNIV,CHILDRENS HOSP,SCH MED,CTR BLOOD RES,HOWARD HUGHES MED INST,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,ST LOUIS,MO 63110	Philipps University Marburg; Eberhard Karls University of Tubingen; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)			Moroy, Tarik/D-9923-2011; Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CHEN U, 1992, IMMUNOBIOLOGY, V185, P366, DOI 10.1016/S0171-2985(11)80653-4; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOGAN B, 1986, MANIPULATION MOUSE E; ISEKI R, 1993, J IMMUNOL, V151, P5198; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; NOWELL PC, 1987, DEV RECOGNITION TRAN; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PERRY RP, 1980, P NATL ACAD SCI-BIOL, V77, P1937, DOI 10.1073/pnas.77.4.1937; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7202; Sambrook J, 1989, MOL CLONING LABORATO; SENTMAN CL, 1992, CELL, V67, P879; SEYSCHAB H, 1989, EUR J IMMUNOL, V19, P1605, DOI 10.1002/eji.1830190913; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0; ZHING LT, 1993, P0 NATL ACAD SCI US, V90, P4533; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	45	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2165	2174						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478538				2022-12-25	WOS:A1995TF29700029
J	KEARSEY, JM; COATES, PJ; PRESCOTT, AR; WARBRICK, E; HALL, PA				KEARSEY, JM; COATES, PJ; PRESCOTT, AR; WARBRICK, E; HALL, PA			GADD45 IS A NUCLEAR-CELL CYCLE-REGULATED PROTEIN WHICH INTERACTS WITH P21(CIP1)	ONCOGENE			English	Article						GADD45; P21(CIP1); PCNA; P53; CELL CYCLE	IONIZING-RADIATION; P53 PROTEIN; DNA-BINDING; ANTIGEN; EXPRESSION; INDUCTION; SEQUENCE; REPAIR; GENE; IDENTIFICATION	GADD45 was originally identified as a cDNA clone induced by growth arrest and DNA damage. We show that Gadd45 is a nuclear protein, widely expressed in normal tissues, particularly in quiescent cellular populations. Using cell synchronisation methods we show that Gadd45 levels are highest in the G1 phase of the cell cycle, and are greatly reduced during S phase. Immunoprecipitation of Gadd45 from mammalian cells reveals that it is tightly associated with a protein which reacts with antibodies to the cyclin dependent kinase inhibitor p21(Cip1). Binding of recombinant Gadd45 protein to overlapping p21(Cip1) peptides in ELISA assays and use of the yeast two hybrid assay show that Gadd45 directly interacts with this cell cycle inhibitor. These data suggest that Gadd45 may act in the regulation of the cell cycle. It is postulated that the interactions of Gadd45 with both p21(Cip1) and PCNA are important for the modulation of cell cycles, and for the inhibition of DNA replication.	UNIV DUNDEE,DEPT PATHOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee; University of Dundee			Prescott, Alan/Y-5956-2018; Coates, Philip J/H-6854-2019; Warbrick, Emma/C-6424-2008	Prescott, Alan/0000-0002-0747-7317; Coates, Philip J/0000-0003-1518-6306; 				ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BAE IS, 1995, CANCER RES, V55, P2387; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHALUT C, 1994, BIOESSAYS, V16, P651, DOI 10.1002/bies.950160910; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREDERSDORF S, 1995, IN PRESS AM J PATHOL; FRIEDBERG EC, 1995, DNA REPAIR; GERDES J, 1984, J IMMUNOL, V133, P1710; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOUBIN F, 1995, ONCOGENE, V10, P2281; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HALL PA, 1995, ONCOGENE, V10, P2427; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JONES CJ, 1992, NUCLEIC ACIDS RES, V20, P991, DOI 10.1093/nar/20.5.991; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, IN PRESS SCI; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIURA M, 1992, J CELL PHYSIOL, V150, P370, DOI 10.1002/jcp.1041500221; MIYASHITA T, 1995, CELL, V80, P293; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PRICE BD, 1992, CANCER RES, V52, P3814; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAHN Q, 1995, INT J ONCOL, V6, P937; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	67	239	249	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1675	1683						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478594				2022-12-25	WOS:A1995TD09400001
J	NAYERI, S; DANIELSSON, C; KAHLEN, JP; SCHRADER, M; MATHIASEN, IS; BINDERUP, L; CARLBERG, C				NAYERI, S; DANIELSSON, C; KAHLEN, JP; SCHRADER, M; MATHIASEN, IS; BINDERUP, L; CARLBERG, C			THE ANTIPROLIFERATIVE EFFECT OF VITAMIN-D-3 ANALOGS IS NOT MEDIATED BY INHIBITION OF THE AP-1 PATHWAY, BUT MAY BE RELATED TO PROMOTER SELECTIVITY	ONCOGENE			English	Article						REGULATION OF TRANSCRIPTION; CONTROL OF PROLIFERATION; MCF-7 BREAST CANCER CELLS; RETINOID-X-RECEPTOR VITAMIN-D-3 RECEPTOR HETERODIMERS; VITAMIN-D-3 RESPONSE ELEMENTS	CANCER CELL-PROLIFERATION; RETINOIC ACID RECEPTORS; HUMAN OSTEOCALCIN GENE; GLUCOCORTICOID RECEPTOR; REGULATORY ELEMENTS; SIGNALING PATHWAYS; THYROID-HORMONE; C-JUN; DIFFERENTIATION; INVIVO	The hormone 1,25-dihydroxyvitamin D-3 (VD) is able to induce cellular differentiation and to inhibit cellular proliferation, which provides it with an interesting therapeutic potential in cancer. However, side effects of VD on homeostasis (eg hypercalcemia) had made the need for the development of VD analogues with low calcemic effect. On the human breast cancer cell line MCF-7 we obtained with the VD analogue EB1089 an about 100-fold higher anti-proliferative effect than with VD. We found that this difference in biological activity is neither related to increased functional affinity to the VD receptor nor to repression of AP-1 activity. The physiologically most prominent complex of the VD receptor is a heterodimer with the retinoid X receptor that binds VD response elements formed two hexameric core binding motifs being arranged either as direct repeats spaced by 3 nucleotides (DR3s) or as inverted palindromes spaced by 9 nucleotides (IP9s). We observed that EB1089 stimulates transcriptional activation from IP9-type elements at clearly lower concentrations than from DR3-type elements. It is possible that IP9-type response elements play an important role in or contribute to the control of cell proliferation, so that promoter-selectivity may explain the high anti-proliferative effect of EB1089.	HOP CANTONAL GENEVA,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND; LEO PHARMACEUT PROD,BIOL RES & DEV,DK-2750 BALLERUP,DENMARK	University of Geneva			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				BERG JP, 1994, J STEROID BIOCHEM, V50, P145, DOI 10.1016/0960-0760(94)90021-3; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BINDERUP L, 1992, BIOCHEM PHARMACOL, V43, P1885, DOI 10.1016/0006-2952(92)90630-2; BINDERUP L, 1992, REV CONTEMP PHARMACO, V3, P357; CARLBERG C, 1994, J STEROID BIOCHEM, V51, P137, DOI 10.1016/0960-0760(94)90086-8; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; COLSTON KW, 1989, LANCET, V1, P188; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P693, DOI 10.1016/0006-2952(92)90405-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; HAQ M, 1993, J CLIN INVEST, V91, P2416, DOI 10.1172/JCI116475; JAMES SY, 1994, J ENDOCRINOL, V141, P555, DOI 10.1677/joe.0.1410555; JIANG HP, 1994, ONCOGENE, V9, P3397; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KISSMEYER AM, 1995, ENDOCRINE, V3, P263, DOI 10.1007/BF03021403; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MATHIASEN IS, 1993, J STEROID BIOCHEM, V46, P365, DOI 10.1016/0960-0760(93)90226-M; McElwain Mariann C., 1995, Molecular and Cellular Differentiation, V3, P31; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; QUELO I, 1994, DNA CELL BIOL, V13, P1181, DOI 10.1089/dna.1994.13.1181; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STERN PH, 1981, CALCIFIED TISSUE INT, V33, P1, DOI 10.1007/BF02409404; VIETH R, 1990, BONE MINER, V11, P267, DOI 10.1016/0169-6009(90)90023-9; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZHANG Q, 1992, EUR J BIOCHEM, V207, P649, DOI 10.1111/j.1432-1033.1992.tb17092.x	49	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1853	1858						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478614				2022-12-25	WOS:A1995TD09400021
J	HABUCHI, T; DEVLIN, J; ELDER, PA; KNOWLES, MA				HABUCHI, T; DEVLIN, J; ELDER, PA; KNOWLES, MA			DETAILED DELETION MAPPING OF CHROMOSOME-9Q IN BLADDER-CANCER - EVIDENCE FOR 2 TUMOR-SUPPRESSOR LOCI	ONCOGENE			English	Note						BLADDER CANCER; CHROMOSOME 9; LOSS OF HETEROZYGOSITY; TUMOR SUPPRESSOR GENE	TRANSITIONAL-CELL CARCINOMA; GORLIN SYNDROME; GENE	Loss of heterozygosity (LOH) at loci on chromosome 9p and/or 9q is the most frequent genetic alteration in transitional cell carcinoma (TCC) of the bladder. However, localisation of the tumour suppressor locus or loci on 9q has been hampered by the relative infrequency of tumours with subchromosomal deletions. We have used 24 microsatellite markers to examine LOH in 70 new cases of TCC of the bladder and upper urinary tract. Forty tumours (57%) showed LOH at one or more loci on 9q and partial deletions were detected in five tumoms (7%). Combined data from the five cases with partial deletions place one tumour suppressor locus at 9q34 between D9S61 and D9S66 (an estimated distance of 13-14 cM). This region is frequently deleted in other sporadic tumours and encompasses one of the loci for tuberous sclerosis(TSC1). One tumour contained a distinct deletion between D9S153 and D9S109 (9q13-q31), which encompasses the locus for the familial nevoid basal cell carcinoma syndrome (Gorlin syndrome). This may indicate the presence of another tumour suppressor locus on 9q for TCC. Our findings significantly reduce the regions of 90 within which suppressor genes for TCC may reside. The possible involvement of two deletion targets on 90 in addition to the locus at 9p21 implicated in TCC may explain why LOH at all loci on chromosome 9 is frequent in TCC.	MARIE CURIE RES INST,MOLEC GENET LAB,OXTED RH8 0TL,SURREY,ENGLAND									AHSEE KW, 1994, CANCER RES, V54, P1617; BERNUES M, 1993, CANCER GENET CYTOGEN, V69, P76, DOI 10.1016/0165-4608(93)90120-B; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, CANCER RES, V55, P224; CAIRNS P, 1993, CANCER RES, V53, P1230; CARBONARA C, 1994, HUM MOL GENET, V3, P1829, DOI 10.1093/hmg/3.10.1829; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DEVLIN J, 1994, ONCOGENE, V9, P2757; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; GREEN AJ, 1994, HUM MOL GENET, V3, P1833, DOI 10.1093/hmg/3.10.1833; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAO CH, 1993, GENE CHROMOSOME CANC, V8, P155, DOI 10.1002/gcc.2870080304; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P531; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LOUGHRAN O, 1994, CANCER RES, V54, P5045; MERLO A, 1994, CANCER RES, V54, P2322; MIURA K, 1995, CANCER RES, V55, P1828; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLUMI AF, 1990, CANCER RES, V50, P7081; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; QUINN AG, 1994, GENE CHROMOSOME CANC, V11, P222, DOI 10.1002/gcc.2870110404; RUPPERT JM, 1993, CANCER RES, V53, P5093; SCHULTZ DC, 1995, CANCER RES, V55, P2150; SHANLEY SM, 1995, HUM MOL GENET, V4, P129; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STADLER WM, 1994, CANCER RES, V54, P2060; VANDERRIET P, 1994, CANCER RES, V54, P25; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8	37	106	115	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1671	1674						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478593				2022-12-25	WOS:A1995TC53500027
J	BERNINSONE, P; MIRET, JJ; HIRSCHBERG, CB				BERNINSONE, P; MIRET, JJ; HIRSCHBERG, CB			THE GOLGI GUANOSINE DIPHOSPHATASE IS REQUIRED FOR TRANSPORT OF GDP-MANNOSE INTO THE LUMEN OF SACCHAROMYCES-CEREVISIAE GOLGI VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SECRETORY VESICLES; NUCLEOSIDE-DIPHOSPHATASE; RAT-LIVER; YEAST; GLYCOSYLATION; MEMBRANE; BIOSYNTHESIS; APPARATUS; PROTEIN	The Saccharomyces cerevisiae Golgi lumenal guanosine diphosphatase is hypothesized to generate GMP which in turn allows entry of GDP-mannose into the lumen to serve as substrate for mannosylation of proteins and lipids. We have recently shown in studies in vivo that this GDPase is required for protein and sphingolipid mannosylation in the Golgi lumen of S. cerevisiae. We have now isolated Golgi-vesicles from wild type and gda1 null mutants (GDPase defective) and have found that the initial rate of GDP-mannose entry into mutant vesicles was 5-fold lower than into those of wild type. Because the concentration of GDP within vesicles is insufficient to inhibit Golgi lumenal mannosyltransferases and the null mutant vesicles are impaired in synthesis of Golgi mannoproteins, the above results demonstrate that the reduced availability of GDP-mannose in the null mutants is the cause for altered Golgi mannosylation of macromolecules.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester				Hirschberg, Carlos/0000-0003-2299-7721	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365, R01GM030365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; BRAELL WA, 1988, ANAL BIOCHEM, V170, P328, DOI 10.1016/0003-2697(88)90638-0; BRANDAN E, 1982, BIOCHEMISTRY-US, V21, P4640, DOI 10.1021/bi00262a019; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; KUHN NJ, 1977, BIOCHEM J, V168, P423, DOI 10.1042/bj1680423; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; PEREZ M, 1986, J BIOL CHEM, V261, P6822; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; SHERMAN F, 1986, METHODS YEAST GENETI, P20; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WICE BM, 1985, J BIOL CHEM, V260, P139	20	63	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					207	211						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506254				2022-12-25	WOS:A1994MR21900039
J	CAPPEL, RE; GILBERT, HF				CAPPEL, RE; GILBERT, HF			THIOL DISULFIDE EXCHANGE BETWEEN 3-HYDROXY-3-METHYGLUTARYL-COA REDUCTASE AND GLUTATHIONE - A THERMODYNAMICALLY FACILE DITHIOL OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											CAPPEL, RE (corresponding author), BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030, USA.				NHLBI NIH HHS [HL-01020, HL-28521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028521, K04HL001020] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERBOOM TPM, 1982, J BIOL CHEM, V257, P4248; ALPERT AJ, 1985, ANAL BIOCHEM, V144, P553, DOI 10.1016/0003-2697(85)90153-8; BALLARD FJ, 1976, BIOCHEM J, V154, P717, DOI 10.1042/bj1540717; BEG ZH, 1985, J BIOL CHEM, V260, P1682; BEG ZH, 1973, BIOCHEM BIOPH RES CO, V54, P1362, DOI 10.1016/0006-291X(73)91137-6; BOND JS, 1983, ARCH BIOCHEM BIOPHYS, V227, P367, DOI 10.1016/0003-9861(83)90465-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1979, J BIOL CHEM, V254, P5144; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V57, P209; CAPPEL RE, 1986, J BIOL CHEM, V261, P5378; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; CLINKENBEARD KD, 1973, J BIOL CHEM, V248, P2275; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOTAN I, 1985, J CELL PHYSIOL, V122, P14, DOI 10.1002/jcp.1041220104; DOTAN I, 1987, J BIOL CHEM, V262, P17058; DOTAN I, 1983, ARCH BIOCHEM BIOPHYS, V226, P401, DOI 10.1016/0003-9861(83)90308-9; EASOM RA, 1987, BIOCHEM J, V241, P183, DOI 10.1042/bj2410183; EDWARDS PA, 1972, J BIOL CHEM, V247, P1520; EDWARDS PA, 1977, J BIOL CHEM, V252, P1057; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAVATA MF, 1987, J BIOL CHEM, V262, P12254; GIBBONS GF, 1984, J BIOL CHEM, V259, P4399; GILBERT HF, 1981, J BIOL CHEM, V256, P1782; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; GUZMANBARRON ES, 1951, ADV ENZYMOL, V11, P201; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HULCHER FH, 1985, BIOCHEM INT, V10, P177; KATZ BA, 1986, J BIOL CHEM, V261, P5480; KNAPPE J, 1974, METHOD ENZYMAT AN, V4, P2026; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; LAUTERBURG BH, 1984, J CLIN INVEST, V73, P124, DOI 10.1172/JCI111182; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NESS GC, 1985, J BIOL CHEM, V260, P2391; NESS GC, 1986, BIOCHEM J, V233, P167, DOI 10.1042/bj2330167; NESS GC, 1985, J BIOL CHEM, V260, P6395; ORRENIUS S, 1984, TRENDS PHARMACOL SCI, V5, P432, DOI 10.1016/0165-6147(84)90495-4; PANINI SR, 1987, J BIOL CHEM, V262, P14435; PANINI SR, 1985, REGULATION HMG COA R, P149; PARKER RA, 1984, BIOCHEM BIOPH RES CO, V125, P629, DOI 10.1016/0006-291X(84)90585-0; PASSONNEAU JV, 1974, METHOD ENZYMAT AN, V4, P2059; ROITELMAN J, 1986, J LIPID RES, V27, P828; ROITELMAN J, 1986, J BIOL CHEM, V261, P5061; ROITELMAN J, 1984, J BIOL CHEM, V259, P870; ROITELMAN J, 1984, J BIOL CHEM, V259, P4029; SAMPLE CE, 1986, BIOCHEM BIOPH RES CO, V137, P201, DOI 10.1016/0006-291X(86)91196-4; SHAKED Z, 1980, BIOCHEMISTRY-US, V19, P4156, DOI 10.1021/bi00559a004; SIES H, 1983, FUNCTIONS GLUTATHION, P231; TAYLOR FR, 1986, J BIOL CHEM, V261, P5039; THOMAS JA, 1987, BIOCHIM BIOPHYS ACTA, V928, P121; TORMANEN CD, 1981, CIRCULATION, V64, P270; TRZASKOS JM, 1987, J BIOL CHEM, V262, P12261; Veloso D., 1971, REGULATION GLUCONEOG, P92; VINA J, 1978, BIOCHEM J, V170, P627, DOI 10.1042/bj1700627; WALTERS DW, 1986, J BIOL CHEM, V261, P5372; WALTERS DW, 1986, J BIOL CHEM, V261, P3135; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	58	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1988	263	25					12204	12212						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P8611	3410841				2022-12-25	WOS:A1988P861100011
J	BLAM, SB; MITCHELL, R; TISCHER, E; RUBIN, JS; SILVA, M; SILVER, S; FIDDES, JC; ABRAHAM, JA; AARONSON, SA				BLAM, SB; MITCHELL, R; TISCHER, E; RUBIN, JS; SILVA, M; SILVER, S; FIDDES, JC; ABRAHAM, JA; AARONSON, SA			ADDITION OF GROWTH-HORMONE SECRETION SIGNAL TO BASIC FIBROBLAST GROWTH-FACTOR RESULTS IN CELL-TRANSFORMATION AND SECRETION OF ABERRANT FORMS OF THE PROTEIN	ONCOGENE			English	Article									CALIF BIOTECHNOL INC,MT VIEW,CA 94043		BLAM, SB (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892, USA.				NATIONAL CANCER INSTITUTE [F32CA007843] Funding Source: NIH RePORTER; NCI NIH HHS [CA 07843-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ADELMAN JP, 1983, DNA-J MOLEC CELL BIO, V2, P183, DOI 10.1089/dna.1983.2.183; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CRABB JW, 1986, BIOCHEM BIOPH RES CO, V136, P1155, DOI 10.1016/0006-291X(86)90455-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOTTO GP, 1985, NATURE, V318, P472; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KARIN M, 1984, CELL, V36, P371, DOI 10.1016/0092-8674(84)90230-7; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STORY MT, 1987, BIOCHEM BIOPH RES CO, V142, P702, DOI 10.1016/0006-291X(87)91471-9; SUNG WL, 1986, P NATL ACAD SCI USA, V83, P561, DOI 10.1073/pnas.83.3.561; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; Tooze J, 1980, DNA TUMOR VIRUSES; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO N, 1986, BIOCHEM BIOPH RES CO, V138, P580, DOI 10.1016/S0006-291X(86)80536-8; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	55	100	104	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					129	136						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412772				2022-12-25	WOS:A1988Q053400001
J	HAMA, T; OGURA, A; OMORI, A; MURAYAMA, M; KUBOTA, M; SEKIGUCHI, M; ISHIGURO, M; MARUYAMA, M; HATANAKA, H; SATO, K				HAMA, T; OGURA, A; OMORI, A; MURAYAMA, M; KUBOTA, M; SEKIGUCHI, M; ISHIGURO, M; MARUYAMA, M; HATANAKA, H; SATO, K			A 13-MER PEPTIDE OF A BRAIN INJURY-DERIVED PROTEIN SUPPORTS NEURONAL SURVIVAL AND RESCUES NEURONS FROM INJURY CAUSED BY GLUTAMATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SEPTAL CHOLINERGIC NEURONS; NERVE GROWTH-FACTOR; ADULT-RAT BRAIN; NEURONOTROPHIC ACTIVITY; MESSENGER-RNA; CULTURED HIPPOCAMPAL; HYPOGLYCEMIC DAMAGE; LIMBIC SEIZURES; WOUND CAVITY; CA-2+	Neuronal survival is mediated by several kinds of proteins. Among these, neurotrophic factors play important roles in the nervous system by supporting neuronal activity and survival. It has been suggested recently that certain factors promote neuronal survival in the case of brain injury. To examine this possibility, we purified a novel neurotrophic factor from Gelfoam that was implanted at the site of injury caused in neonatal rats. During amino acid sequence analysis, we found that a fragmental peptide of this neurotrophic protein consisting of 13 amino acids showed neurotrophic activity. This 13-mer peptide promoted survival of septal cholinergic and mesencephalic dopaminergic neurons in culture and rescued hippocampal neurons from injury caused by glutamate in culture. This peptide rescued neurons from cell death caused by glutamate, even when added 4.5 h after glutamate exposure.			HAMA, T (corresponding author), MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN.							CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHENG B, 1992, J NEUROSCI, V12, P1558; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CHOI DW, 1987, J NEUROSCI, V7, P369; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; FRANDSEN A, 1989, J NEUROCHEM, V53, P297, DOI 10.1111/j.1471-4159.1989.tb07327.x; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; HATANAKA H, 1987, NEUROSCI LETT, V79, P85, DOI 10.1016/0304-3940(87)90676-8; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KUDO Y, 1990, BRAIN RES, V528, P48, DOI 10.1016/0006-8993(90)90193-F; MANTHORPE M, 1983, BRAIN RES, V267, P47, DOI 10.1016/0006-8993(83)91038-7; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MATTSON MP, 1990, SEMIN NEUROSCI, V5, P295; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; NIETOSAMPEDRO M, 1983, J NEUROSCI, V3, P2219; OGURA A, 1990, NEUROSCI RES, V9, P103, DOI 10.1016/0168-0102(90)90026-B; OGURA A, 1988, EXP BRAIN RES, V73, P447, DOI 10.1007/BF00406601; RICH KM, 1990, SCIENCE, V248, P1419, DOI 10.1126/science.2356470; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X	26	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29067	29070		10.1074/jbc.270.49.29067	http://dx.doi.org/10.1074/jbc.270.49.29067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493927				2022-12-25	WOS:A1995TJ22700008
J	XU, X; KITAMURA, K; LAU, KS; MUALLEM, S; MILLER, RT				XU, X; KITAMURA, K; LAU, KS; MUALLEM, S; MILLER, RT			DIFFERENTIAL REGULATION OF CA2+ RELEASE-ACTIVATED CA2+ INFLUX BY HETEROTRIMERIC G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM STORES; TYROSINE KINASE INHIBITORS; DIVALENT-CATION ENTRY; HUMAN-NEUTROPHILS; PANCREATIC ACINI; CYTOSOLIC CA-2+; MAST-CELLS; DEPLETION; CYTOCHROME-P-450; OSCILLATIONS	The least understood aspect of the agonist-induced Ca2+ signal is the activation and regulation of the Ca2+ release-activated Ca2+ influx (CRAC) across the plasma membrane. To explore the possible role of heterotrimeric G proteins in the various regulatory mechanisms of CRAC, continuous renal epithelial cell lines stably expressing alpha(13) and the constitutively active alpha(qQ209L) were isolated and used to measure CRAC activity by the Mn2+ quench technique. Release of intracellular Ca2+ by agonist stimulation or thapsigargin was required for activation of CRAC in all cells. Although the size of the internal stores was similar in all cells, CRAC was 2-3-fold higher in alpha 13- and alpha(qQ209L)-expressing cells. However, the channel was differentially regulated in the two cell types. Incubation at low [Ca2+](i), inhibition of the NOS pathway, or inhibition of tyrosine kinases inhibited CRAC activity in alpha(13) but not alpha(qQ209L) cells. Treatment with okadaic acid prevented inhibition of the channel by low [Ca2+], and the protein kinase inhibitors in alpha(13) cells. These results suggest that expression of alpha(qQ209L) dominantly activates CRAC by stabilizing a phosphorylated state, whereas expression of alpha(13) makes CRAC activation completely dependent on phosphomylation by several kinases. G proteins may also modulate CRAC activity independently of the phosphorylation/dephosphorylation state of the pathway to increase maximal CRAC activity. Furthermore, our results suggest a general mechanism for regulation of CRAC that depends on coupling of receptors to specific G proteins.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235; UNIV FLORIDA,DEPT MED & PHARMACOL,GAINESVILLE,FL 32610	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University System of Florida; University of Florida					NIDDK NIH HHS [DK 39839] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1995, NATURE, V373, P481, DOI 10.1038/373481b0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BIRD GS, 1992, NATURE, V352, P162; BISCHOF G, 1995, AM J PHYSIOL-CELL PH, V268, pC154, DOI 10.1152/ajpcell.1995.268.1.C154; BISCHOF G, 1995, CELL CALCIUM, V17, P250, DOI 10.1016/0143-4160(95)90071-3; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Furchgott RF, 1988, VASODILATATION VASCU, P410; GILON P, 1995, J BIOL CHEM, V270, P8050, DOI 10.1074/jbc.270.14.8050; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; HIRAMATSU Y, 1992, J MEMBRANE BIOL, V129, P277; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KALINEC G, 1992, MOL CELL BIOL, V12, P46867; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KITAMURA K, 1994, J CLIN INVEST, V94, P328, DOI 10.1172/JCI117325; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1993, BIOCHIM BIOPHYS ACTA, V1177, P127, DOI 10.1016/0167-4889(93)90031-J; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1992, ADV SEC MESS PHOSPH, P351; OFFERMANNS S, 1994, MOL CELL ENDOCRINOL, V100, P71, DOI 10.1016/0303-7207(94)90281-X; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PUTNEY JW, 1994, ENDOCR REV, V14, P610; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1991, PFLUG ARCH EUR J PHY, V417, P633, DOI 10.1007/BF00372962; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SINGER WD, 1994, J BIOL CHEM, V269, P19796; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; VOYNOYASENETSKA.T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKA.TA, 1994, ONCOGENE, V9, P2559; XU X, 1994, J BIOL CHEM, V269, P12645; YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P14967; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	52	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29169	29175		10.1074/jbc.270.49.29169	http://dx.doi.org/10.1074/jbc.270.49.29169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493943	hybrid			2022-12-25	WOS:A1995TJ22700024
J	HONORE, B; RASMUSSEN, HH; VORUM, H; DEJGAARD, K; LIU, XD; GROMOV, P; MADSEN, P; GESSER, B; TOMMERUP, N; CELIS, JE				HONORE, B; RASMUSSEN, HH; VORUM, H; DEJGAARD, K; LIU, XD; GROMOV, P; MADSEN, P; GESSER, B; TOMMERUP, N; CELIS, JE			HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-H, RIBONUCLEOPROTEIN-H', AND RIBONUCLEOPROTEIN-F ARE MEMBERS OF A UBIQUITOUSLY EXPRESSED SUBFAMILY OF RELATED BUT DISTINCT PROTEINS ENCODED BY GENES MAPPING TO DIFFERENT CHROMOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; HUMAN KERATINOCYTES; RNA RECOGNITION; SEQUENCE; BINDING; CELLS; PARTICLES; IDENTIFICATION; TRANSFORMATION; TRANSLATION	Molecular cDNA cloning, two-dimensional gel immunoblotting, and amino acid microsequencing identified three sequence-unique and distinct proteins that constitute a subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins corresponding to hnRNPs H, H', and F. These proteins share epitopes and sequence identity with two other proteins, isoelectric focusing sample spot numbers 2222 (37.6 kDa; pI 6.5) and 2326 (39.5 kDa; pI 6.6), indicating that the subfamily may contain additional members. The identity between hnRNPs H and H' is 96%, between H and F 78%, and between H' and F 75%, respectively. The three proteins contain three repeats, which we denote quasi-RRMs (qRRMs) since they have a remote similarity to the RNA recognition motif (RRM). The three qRRMs of hnRNP H, with a few additional NH2-terminal amino acids, were constructed by polymerase chain reaction amplification and used for ribohomopolymer binding studies, Each qRRM repeat bound poly(rG), while only the NH2-terminal qRRM bound poly(rC) and poly(rU). None of the repeats bound detectable amounts of poly(rA). The expression levels of hnRNPs H and F were differentially regulated in pairs of normal and transformed fibro blasts and keratinocytes, In normal human keratinocytes, the expression level of H was unaffected by treatment with several substances tested including two second messengers and seven cytokines, Likewise the expression level of F was independent of these substances, although it was strikingly down-regulated by long term treatment with 4 beta-phorbol 12-myristate 13-acetate, indicating that the protein kinase C signaling pathway regulates its expression. No effect of 4 beta-phorbol 12-myristate 13-acetate was observed on the expression of hnRNP H. The genes coding for hnRNPs H, H', and F were chromosome-mapped to 5q35.3 (HNRPH1), 6q25.3-q26, and/or Xq22 (HNRPH2) and 10q11.21-q11.22 (HNRPF), respectively.	AARHUS UNIV, DANISH CTR HUMAN GENOME RES, DK-8000 AARHUS C, DENMARK; JOHN F KENNEDY INST, DK-2600 GLOSTRUP, DENMARK	Aarhus University	HONORE, B (corresponding author), AARHUS UNIV, DEPT BIOCHEM MED, OLE WORMS ALLE, BLDG 170, DK-8000 AARHUS C, DENMARK.		Honoré, Bent/ABF-3650-2021; Tommerup, Niels/T-8776-2017	Madsen, Peder Sondergaard/0000-0002-8845-4802; Tommerup, Niels/0000-0003-2304-0112; Honore, Bent/0000-0002-3459-7429				BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRAVO R, 1982, J MOL BIOL, V154, P121, DOI 10.1016/0022-2836(82)90421-1; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; CELIS JE, 1986, FEBS LETT, V194, P101, DOI 10.1016/0014-5793(86)80059-X; CELIS JE, 1994, ELECTROPHORESIS, V15, P1349, DOI 10.1002/elps.11501501208; CELIS JE, 1994, ELECTROPHORESIS, V15, P309, DOI 10.1002/elps.1150150153; CELIS JE, 1994, CELL BIOL LABORATORY, V3, P222; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; DEJGAARD K, 1994, CELL BIOL LABORATORY, P339; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUZGUNES N, 1993, METHOD ENZYMOL, V221, P303, DOI 10.1016/0076-6879(93)21025-4; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORLACH M, 1994, J BIOL CHEM, V269, P23074; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; HONORE B, 1992, J BIOL CHEM, V267, P8485; HONORE B, 1993, J BIOCHEM BIOPH METH, V27, P39, DOI 10.1016/0165-022X(93)90066-W; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; JACOBS KA, 1988, NUCLEIC ACIDS RES, V16, P4637, DOI 10.1093/nar/16.10.4637; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; MCDONALD H, 1992, GENOMICS, V13, P344, DOI 10.1016/0888-7543(92)90251-M; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; QIAN ZW, 1994, NUCLEIC ACIDS RES, V22, P2334, DOI 10.1093/nar/22.12.2334; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RASMUSSEN HH, 1992, ELECTROPHORESIS, V13, P960, DOI 10.1002/elps.11501301199; Sambrook J, 1989, MOL CLONING LABORATO; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3; VANDEKERCKHOVE J, 1994, CELL BIOL LAB HDB, P359; VORECHOVSKY I, 1994, GENOMICS, V21, P517, DOI 10.1006/geno.1994.1310	48	97	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28780	28789						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499401				2022-12-25	WOS:A1995TH05600045
J	MINER, JH; LEWIS, RM; SANES, JR				MINER, JH; LEWIS, RM; SANES, JR			MOLECULAR-CLONING OF A NOVEL LAMININ CHAIN, ALPHA-5, AND WIDESPREAD EXPRESSION IN ADULT-MOUSE TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN S-LAMININ; A-CHAIN; NEUROMUSCULAR-JUNCTION; BASEMENT-MEMBRANES; SYNAPTIC CLEFT; B2 CHAIN; CELLS; SEQUENCE; GLYCOPROTEIN; DROSOPHILA	We have identified a fifth member of the alpha subfamily of vertebrate laminin chains. Sequence analysis revealed a close relationship of alpha 5 to the only known Drosophila alpha chain, suggesting that the ancestral alpha gene was more similar to alpha 5 than to alpha 1-4. Analysis of RNA expression showed that alpha 5 is widely expressed in adult tissues, with highest levels in lung, heart, and kidney. Our results suggest that alpha 5 may be a major laminin chain of adult basal laminae.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)								ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BROWN JC, 1994, J CELL SCI, V107, P329; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURHAM PL, 1995, DEV DYNAM, V203, P408, DOI 10.1002/aja.1002030404; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HENCHCLIFFE C, 1993, DEVELOPMENT, V118, P325; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KROLL TG, 1994, J BIOL CHEM, V269, P9270; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; MACKRELL AJ, 1993, FASEB J, V7, P375, DOI 10.1096/fasebj.7.2.8440414; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; RICHARDS AJ, 1994, GENOMICS, V22, P237, DOI 10.1006/geno.1994.1372; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SOLBERG S, 1992, Journal of Investigative Dermatology, V98, P864; SOROKIN L, 1994, EUR J BIOCHEM, V223, P603, DOI 10.1111/j.1432-1033.1994.tb19031.x; SOROKIN LM, 1992, EXP CELL RES, V201, P137, DOI 10.1016/0014-4827(92)90357-E; SUGIYAMA S, 1995, EUR J BIOCHEM, V228, P120, DOI 10.1111/j.1432-1033.1995.0120o.x; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VIRTANEN I, 1995, J HISTOCHEM CYTOCHEM, V43, P621, DOI 10.1177/43.6.7769233; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WEWER UM, 1994, METHOD ENZYMOL, V245, P85	44	227	232	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28523	28526		10.1074/jbc.270.48.28523	http://dx.doi.org/10.1074/jbc.270.48.28523			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499364	hybrid			2022-12-25	WOS:A1995TH05600008
J	YAO, M; KOW, YW				YAO, M; KOW, YW			INTERACTION OF DEOXYINOSINE 3'-ENDONUCLEASE FROM ESCHERICHIA-COLI WITH DNA CONTAINING DEOXYINOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR; HYPOXANTHINE; GLYCOSYLASE; COMPLEXES; EXCISION; RESIDUES; RELEASE; SITE; ION	By using a band mobility shift assay, deoxyinosine 3'-endonuclease, an Escherichia coli enzyme which recognizes deoxyinosine, AP site, urea residue, and base mismatches in DNA, was shown to bind tightly to deoxyinosine containing oligonucleotide duplexes, Two distinct protein-DNA complexes were observed, the faster migrating complex (complex I, K-d = 4 X 10(-9) M) contained one molecule of deoxyinosine 3'-endonuclease, while the slower migrating complex (complex II, K-d = 4 x 10(-7) M) contained two molecules of the protein bound to every molecule of duplex DNA, The endonucleolytic activity of deoxyinosine 3'-endonuclease paralleled the formation of the complex I, Interestingly, deoxyinosine 3'-endonuclease exhibited similar affinities for both the substrate and the nicked duplex product and thus remained bound to the DNA after the cleavage reaction, The formation of a stable complex required the presence of a duplex structure 5' to the deoxyinosine residue, DNase I footprinting revealed that deoxyinosine 3'-endonuclease protected 4-5 nucleotides 5' to the deoxyinosine, and when complex II was formed, at least 13 nucleotides 3' to deoxyinosine were protected. Based on these results, a model is proposed for the interaction of deoxyinosine 3'-endonuclease with DNA containing deoxyinosine.	UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405	University of Vermont								AU KG, 1992, J BIOL CHEM, V267, P12142; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; HAROSH I, 1988, J BIOL CHEM, V263, P3328; HILLPERKINS M, 1986, MUTAT RES, V162, P153, DOI 10.1016/0027-5107(86)90081-3; KARRAN P, 1980, BIOCHEMISTRY-US, V19, P6005, DOI 10.1021/bi00567a010; KARRAN P, 1978, J BIOL CHEM, V253, P5877; KLAND MJ, 1957, J AM CHEM SOC, V79, P6187, DOI 10.1021/ja01580a022; KUWABARA M, 1986, BIOCHEMISTRY-US, V25, P7401, DOI 10.1021/bi00371a023; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MYRNES B, 1982, NUCLEIC ACIDS RES, V10, P3693, DOI 10.1093/nar/10.12.3693; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PONNAMPERUMA C, 1961, SCIENCE, V134, P113, DOI 10.1126/science.134.3472.113; Roberts R, 1993, NUCLEASES, P35; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; YAO M, 1994, J BIOL CHEM, V269, P31390; YAO M, 1994, J BIOL CHEM, V269, P16260	23	43	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28609	28616		10.1074/jbc.270.48.28609	http://dx.doi.org/10.1074/jbc.270.48.28609			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499377	hybrid			2022-12-25	WOS:A1995TH05600021
J	FENG, JQ; CHEN, D; COONEY, AJ; TSAI, MJ; HARRIS, MA; TSAI, SY; FENG, M; MUNDY, GR; HARRIS, SE				FENG, JQ; CHEN, D; COONEY, AJ; TSAI, MJ; HARRIS, MA; TSAI, SY; FENG, M; MUNDY, GR; HARRIS, SE			THE MOUSE BONE MORPHOGENETIC PROTEIN-4 GENE - ANALYSIS OF PROMOTER UTILIZATION IN FETAL-RAT CALVARIAL OSTEOBLASTS AND REGULATION BY COUP-TFI ORPHAN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; INDUCTION; ELECTROPORATION; IDENTIFICATION; ORGANIZATION; ELEMENTS; PATHWAYS; FAMILY; BMP-4; CELL	Bone morphogenetic protein-4 (BMP-4) is one of a member of related polypeptides that are important in bone formation and other developmental processes, We isolated the BMP-4 gene from a mouse genomic library and characterized the exon-intron structure and one of the candidate promoters. Two alternative 5'-noncoding exons, 1A and 1B, were identified by reverse transcription polymerase chain reaction assays, Quantitative competitive polymerase chain reaction using Exon 1A, Exon 1B, and Exon 3 primers indicate the 1A-containing transcript is the primary BMP-4 mRNA expressed in bone cell cultures. Primer extension analysis supports that 1A is the major promoter utilized in bone cell cultures as well as in 9.5-day mouse embryos, 1A promoter activity indicate selective DNA regions functional in bone cells. We found potential regulatory response regions in the IA 5'-flanking region of the BMP-4 gene for the chicken ovalbumin upstream-transcription factor I (COUP TFI). Specific binding to the COUP-TFI response regions in the BMP-4 1A promoter was demonstrated, By co transfection of a COUP-TFI expression plasmid with the BMP-4 1A promoter in fetal rat calvarial osteoblasts, we demonstrated that COUP-TFI inhibits the BMP-4 promoter activity, This suggests that COUP-TFI could act as a silencer for BMP-4 transcription in vivo.	UNIV TEXAS, HLTH SCI CTR, DEPT MED ENDOCRINOL & METAB, SAN ANTONIO, TX 78284 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine					NCI NIH HHS [CA-40035] Funding Source: Medline; NIAMS NIH HHS [AR-39529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHEN D, 1993, BIOCHIM BIOPHYS ACTA, V1174, P289, DOI 10.1016/0167-4781(93)90200-W; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FENG JQ, 1995, BBA-GENE STRUCT EXPR, V1263, P163, DOI 10.1016/0167-4781(95)00106-Q; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GORMAN C, 1988, DNA CLONING PRACTICA, V2, P157; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HARRIS SE, 1994, J BONE MINER RES, V9, P855; HARRIS SE, 1994, J BONE MINER RES, V9, P389; JONES CM, 1991, DEVELOPMENT, V111, P531; JONES CM, 1992, DEVELOPMENT, V115, P639; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KURIHARA T, 1993, BIOCHEM BIOPH RES CO, V192, P1049, DOI 10.1006/bbrc.1993.1523; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NISHIMATSU SI, 1993, GROWTH FACTORS, V8, P173, DOI 10.3109/08977199309011020; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; POTTER H, 1988, ANAL BIOCHEM, V174, P361, DOI 10.1016/0003-2697(88)90035-8; ROUET P, 1992, BIOTECHNIQUES, V13, P700; Sambrook J, 1989, MOL CLONING LABORATO; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SHIMIZU K, 1994, CLIN ORTHOP RELAT R, P274; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; SUZUKI A, 1993, BIOCHEM J, V291, P413, DOI 10.1042/bj2910413; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212	37	90	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28364	28373						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499338	hybrid			2022-12-25	WOS:A1995TG21000063
J	SPIRO, C; BAZETTJONES, DP; WU, XL; MCMURRAY, CT				SPIRO, C; BAZETTJONES, DP; WU, XL; MCMURRAY, CT			DNA-STRUCTURE DETERMINES PROTEIN-BINDING AND TRANSCRIPTIONAL EFFICIENCY OF THE PROENKEPHALIN CAMP-RESPONSIVE ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; CYCLIC AMP; GENE; ELEMENT; PHOSPHORYLATION; POLYMERASE; INTERACTS; CELLS; SITES	Two precisely arranged proenkephalin cAMP response elements (CREs) behave as a single protein binding site, The experiments described support a model in which a secondary structural change creates a new binding site, which is made up of sequences from both of the CREs. The CRE-binding protein (CREB) binds CRE-1, but binding there is entirely dependent on the presence of CRE-2. Electron spectroscopic images show that a CREB dimer occupies twice as much DNA in the proenkephalin gene as in the prodynorphin gene, The enhancer region is sensitive to P-1 nuclease in a CREB concentration-dependent manner, and sensitivity is strand-specific, indicating protein-stabilized structural change. DNase I analysis shows that in the native proenkephalin gene, CREB binds both CRE-1 and CRE-2. In vivo, both CREs are occupied in the transcriptionally active proenkephalin gene, while neither is in the silent gene, Whereas CREB can bind CRE-2, mutation or elimination of either proenkephalin CRE alters response to second messengers and transcription factors. Thus, binding to CRE-2 alone is not sufficient. Specific and efficient transcription of the proenkephalin gene requires the presence of both CREs, precisely arranged to allow them to form a single protein binding site.	MAYO FDN & GRAD SCH,DEPT PHARMACOL,ROCHESTER,MN 55905; MAYO FDN & GRAD SCH,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,DEPT ANAT,CALGARY,AB T2N 4N1,CANADA	Mayo Clinic; Mayo Clinic; University of Calgary; University of Calgary								BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BAZETTJONES DP, 1989, MOL CELL BIOL, V9, P336, DOI 10.1128/MCB.9.1.336; BAZETTJONES DP, 1992, ELECTRON MICROSC REV, V5, P37, DOI 10.1016/0892-0354(92)90004-A; BORSOOK D, 1994, MOL ENDOCRINOL, V8, P240, DOI 10.1210/me.8.2.240; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COMB M, 1983, DNA-J MOLEC CELL BIO, V2, P213, DOI 10.1089/dna.1983.2.213; DOUGLASS J, 1994, MOL ENDOCRINOL, V8, P333, DOI 10.1210/me.8.3.333; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GACY AM, 1994, BIOCHEMISTRY-US, V33, P11951, DOI 10.1021/bi00205a034; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; JOSHI J, 1991, MOL ENDOCRINOL, V5, P1069, DOI 10.1210/mend-5-8-1069; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KONRADI C, 1994, J NEUROSCI, V14, P5623; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; LAFORGE KS, 1995, MOL CELL BIOL, V15, P2080; MATTES WB, 1986, BIOCHIM BIOPHYS ACTA, V868, P71, DOI 10.1016/0167-4781(86)90088-6; Maxam A M, 1980, Methods Enzymol, V65, P499; MCMURRAY CT, 1991, P NATL ACAD SCI USA, V88, P666, DOI 10.1073/pnas.88.2.666; MCMURRAY CT, 1994, BIOCHEMISTRY-US, V33, P11960, DOI 10.1021/bi00205a035; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER PR, 1992, CURRENT PROTOCOLS MO; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; OLSON GA, 1994, PEPTIDES, V15, P1513, DOI 10.1016/0196-9781(94)90131-7; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; POON D, 1993, J BIOL CHEM, V268, P5005; ROSEN H, 1984, J BIOL CHEM, V259, P4309; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; SHEEN JY, 1988, BIOTECHNIQUES, V6, P942; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TUGORES A, 1994, J BIOL CHEM, V269, P30789; WOHLRAB F, 1992, METHOD ENZYMOL, V212, P294; ZHU YS, 1994, DNA CELL BIOL, V13, P25, DOI 10.1089/dna.1994.13.25	43	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27702	27710		10.1074/jbc.270.46.27702	http://dx.doi.org/10.1074/jbc.270.46.27702			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499237	hybrid			2022-12-25	WOS:A1995TE73600048
J	CONG, JY; THOMPSON, VF; GOLL, DE				CONG, JY; THOMPSON, VF; GOLL, DE			EFFECT OF MONOCLONAL-ANTIBODIES SPECIFIC FOR THE 28-KDA SUBUNIT ON CATALYTIC PROPERTIES OF THE CALPAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; KINASE-C; CA-2+-DEPENDENT PROTEINASES; DROSOPHILA-MELANOGASTER; PROCOAGULANT ACTIVITY; HUMAN-NEUTROPHILS; MU-CALPAIN; CALCIUM; MEMBRANE; AUTOLYSIS	Nine monoclonal antibodies (mAbs) specific for the 28-kDa subunit common to mu- and m-calpains have been assayed for their effects on mu- and m-calpains. All nine react with the COOH-terminal part (domain VI) of the 28-kDa subunit, and all nine affect the Ca2+ concentration required for autolysis of m-calpain, but have little effect on the Ca2+ concentration required for autolysis of mu-calpain. None of the nine affect the specific proteolytic activity of mu- or m-calpain. Two of the mAbs, 5B9 and 5B3, were selected for further study. mAb 5B9 decreased the Ca2+ concentration required for autolysis to one-fifth of that required in its absence; sequencing of chymotryptic fragments showed that the epitope for mAb 5B9 is between amino acid residues 92 and 104 of the 28-kDa subunit. mAb 5B3 increased the Ca2+ concentration required for autolysis; the epitope for mAb 5B3 is located between amino acid residues 148 and 178 of the 28-kDa subunit, which is the region that contains the first EF-hand Ca2+-binding sequence in this subunit. Although it increases the Ca2+ concentration required for autolysis, mAb 5B3 has no effect on the Ca2+ concentration required for proteolytic activity of m-calpain, and unautolyzed m-calpain is not a proenzyme. That all nine mAbs react with domain VI and not with the NH2-terminal domain V of the 28-kDa subunit suggests that domain VI (and not domain V) is involved in autolysis, contrary to the view that phosphatidylinositol lowers the Ca2+ concentration required for autolysis by binding to domain V.	UNIV ARIZONA,MUSCLE BIOL GRP,TUCSON,AZ 85721	University of Arizona					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20984] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONG JY, 1989, J BIOL CHEM, V264, P10096; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; CORPS AN, 1989, CELL REGUL, V1, P75, DOI 10.1091/mbc.1.1.75; EDMUNDS T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P197, DOI 10.1016/0167-4838(91)90059-9; ELCE JS, 1989, BIOCHEM J, V261, P1039, DOI 10.1042/bj2611039; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1991, J BIOL CHEM, V266, P13289; GOLL D E, 1986, Ciencia Biologica Molecular and Cellular Biology, V11, P75; GOLL DE, 1964, J FOOD SCI, V29, P608, DOI 10.1111/j.1365-2621.1964.tb00418.x; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; HAYASHI M, 1992, BIOCHEM BIOPH RES CO, V182, P939, DOI 10.1016/0006-291X(92)91822-8; IMAJOH S, 1986, J BIOCHEM-TOKYO, V99, P1281, DOI 10.1093/oxfordjournals.jbchem.a135593; ISHII H, 1992, BIOCHIM BIOPHYS ACTA, V1175, P37, DOI 10.1016/0167-4889(92)90007-X; JI SQ, 1992, J ANIM SCI S1, V70, P208; KASAI Y, 1986, J BIOCHEM-TOKYO, V100, P183, DOI 10.1093/oxfordjournals.jbchem.a121691; KIKUCHI T, 1984, ARCH BIOCHEM BIOPHYS, V234, P639, DOI 10.1016/0003-9861(84)90314-X; KUBOKI M, 1987, BIOCHIM BIOPHYS ACTA, V929, P164, DOI 10.1016/0167-4889(87)90172-8; KUBOKI M, 1992, BIOCHEM BIOPH RES CO, V185, P1122, DOI 10.1016/0006-291X(92)91742-9; KUNIMATSU M, 1990, BIOCHEM BIOPH RES CO, V169, P1242, DOI 10.1016/0006-291X(90)92030-4; KUNIMATSU M, 1989, BIOCHEM BIOPH RES CO, V164, P875, DOI 10.1016/0006-291X(89)91540-4; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MELLGREN RL, 1988, BIOCHIM BIOPHYS ACTA, V954, P154, DOI 10.1016/0167-4838(88)90066-0; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; PINTER M, 1988, BIOCHEM J, V253, P467, DOI 10.1042/bj2530467; PINTER M, 1992, BIOCHEMISTRY-US, V31, P8201, DOI 10.1021/bi00150a012; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; PONTREMOLI S, 1985, BIOCHEM BIOPH RES CO, V129, P389, DOI 10.1016/0006-291X(85)90163-9; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; Suzuki K., 1990, INTRACELLULAR CALCIU, P25; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2; WOLFE FH, 1989, LIFE SCI, V45, P2093, DOI 10.1016/0024-3205(89)90074-X; WOLFE FH, 1989, BIOCHIM BIOPHYS ACTA, V998, P236, DOI 10.1016/0167-4838(89)90280-X; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H	46	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25740	25747						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503986				2022-12-25	WOS:A1993MK10000068
J	KLEINERT, H; GLADEN, A; GEISLER, M; BENECKE, BJ				KLEINERT, H; GLADEN, A; GEISLER, M; BENECKE, BJ			DIFFERENTIAL REGULATION OF TRANSCRIPTION OF HUMAN 7-S-K-RNA AND 7-S-L-RNA GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									RUHR UNIV BOCHUM,DEPT BIOCHEM,D-4630 BOCHUM 1,FED REP GER	Ruhr University Bochum			Geisler, Markus M/B-3921-2012; Kleinert, Hartmut/M-2988-2018	Geisler, Markus M/0000-0002-6641-5810; Kleinert, Hartmut/0000-0003-2202-3548; Elliott, Amy/0000-0003-0608-8931				BOGENHAGEN DF, 1980, CELL, V19, P27, DOI 10.1016/0092-8674(80)90385-2; DEFRANCO D, 1981, J BIOL CHEM, V256, P2424; DEFRANCO D, 1980, P NATL ACAD SCI-BIOL, V77, P3365, DOI 10.1073/pnas.77.6.3365; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; FOWLKES DM, 1980, CELL, V22, P405, DOI 10.1016/0092-8674(80)90351-7; FUHRMAN SA, 1981, NUCLEIC ACIDS RES, V9, P6439, DOI 10.1093/nar/9.23.6439; HOFSTETTER H, 1981, CELL, V24, P573, DOI 10.1016/0092-8674(81)90348-2; KLEINERT H, 1988, NUCLEIC ACIDS RES, V16, P1319, DOI 10.1093/nar/16.4.1319; KRUGER W, 1987, J MOL BIOL, V195, P31, DOI 10.1016/0022-2836(87)90325-1; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MURPHY S, 1986, NUCLEIC ACIDS RES, V14, P9243, DOI 10.1093/nar/14.23.9243; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; REDDY R, 1987, J BIOL CHEM, V262, P75; REICHEL R, 1980, NUCLEIC ACIDS RES, V8, P225, DOI 10.1093/nar/8.2.225; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SHARP S, 1983, J BIOL CHEM, V258, P2440; SOLLNERWEBB B, 1979, CELL, V18, P485, DOI 10.1016/0092-8674(79)90066-7; SPRAGUE KU, 1980, CELL, V22, P171, DOI 10.1016/0092-8674(80)90165-8; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; ULLU E, 1984, EMBO J, V3, P3303, DOI 10.1002/j.1460-2075.1984.tb02294.x; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WEINMANN R, 1976, CELL, V7, P557, DOI 10.1016/0092-8674(76)90206-3; WEINMANN R, 1974, P NATL ACAD SCI USA, V71, P1790, DOI 10.1073/pnas.71.5.1790; ZIEVE G, 1977, BIOCHEMISTRY-US, V16, P4520, DOI 10.1021/bi00639a029; ZOPHEL D, 1986, THESIS RUHR U BOCHUM	27	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1988	263	23					11511	11515						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P6713	3403542				2022-12-25	WOS:A1988P671300080
J	BRAZAS, RM; BHOITE, LT; MURPHY, MD; YU, YX; CHEN, YY; NEKLASON, DW; STILLMAN, DJ				BRAZAS, RM; BHOITE, LT; MURPHY, MD; YU, YX; CHEN, YY; NEKLASON, DW; STILLMAN, DJ			DETERMINING THE REQUIREMENTS FOR COOPERATIVE DNA-BINDING BY SWI5P AND PHO2P (GRF10P/BAS2P) AT THE HO PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA HOMEODOMAIN PROTEINS; NUCLEAR-MAGNETIC-RESONANCE; CELL-CYCLE CONTROL; ZINC-FINGER; CRYSTAL-STRUCTURE; SECONDARY STRUCTURE; HIS4 TRANSCRIPTION; HOMEO DOMAIN; YEAST; GENE	SW15 encodes a zinc finger DNA binding protein required for the transcription of the Saccharonyces cerevisiae HO gene, and PHO2 encodes a homeodomain DNA binding protein. In vitro biochemical studies using purified Swi5p and Pho2p proteins have demonstrated that Swi5p and Pho2p bind cooperatively to the HO promoter. in this report we investigate the regions of the Swi5p and Pho2p proteins required for cooperative DNA binding. The analysis of each protein gives a similar result: the zinc finger or homeodomain DNA binding domains are each sufficient for in vitro DNA binding, but additional regions of each protein are required for cooperative DNA binding. In vitro and in vivo experiments were conducted with promoters with altered spacing between the Pho2p and Swi5p binding sites. Mutations that increased the distance between the two binding sites had minimal effects on either in vitro cooperative DNA binding or in vivo upstream activating sequence activity. These observations suggest that the interaction domains of Swi5p and Pho2p are flexible and can tolerate an increase in distance between the two binding sites. The mechanism of the cooperative DNA binding by Swi5p and Pho2p is discussed.	UNIV UTAH,HLTH SCI CTR,DEPT ONCOL SCI,DIV MED & MOLEC GENET,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah				Stillman, David/0000-0002-5268-2416	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048624, R01GM039067] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA42014] Funding Source: Medline; NIGMS NIH HHS [GM39067, GM48624] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; BRAZAS RM, 1993, MOL CELL BIOL, V13, P5524, DOI 10.1128/MCB.13.9.5524; BRAZAS RM, 1993, P NATL ACAD SCI USA, V90, P11237, DOI 10.1073/pnas.90.23.11237; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CAMIER S, 1992, MOL CELL BIOL, V12, P5758, DOI 10.1128/MCB.12.12.5758; CHANG YC, 1993, GENETICS, V133, P29; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; GALANG CK, 1993, MOL CELL BIOL, V13, P4609, DOI 10.1128/MCB.13.8.4609; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, P949; JIANG YW, 1995, GENETICS, V140, P103; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; McKnight SL, 1993, TRANSCRIPTIONAL REGU; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; OSHIMA Y, 1981, MOL BIOL YEAST SACCH, P159; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MC, 1988, J BIOL CHEM, V263, P7211; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; [No title captured]	47	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29151	29161		10.1074/jbc.270.49.29151	http://dx.doi.org/10.1074/jbc.270.49.29151			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493941	hybrid			2022-12-25	WOS:A1995TJ22700022
J	GALLAGHER, PJ; GARCIA, JGN; HERRING, BP				GALLAGHER, PJ; GARCIA, JGN; HERRING, BP			EXPRESSION OF A NOVEL MYOSIN LIGHT-CHAIN KINASE IN EMBRYONIC-TISSUES AND CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; PROTEIN; ACTIN; BINDING; PHOSPHORYLATION; FIBROBLASTS; CONTRACTION; TELOKIN; GENE; CDNA	A novel, 208-kDa myosin light chain kinase (MLCK) distinct from smooth muscle and non-muscle MLCK has been identified by cross reaction to two antibodies raised against smooth muscle MLCK. Additional antibodies directed against the amino and carboxyl termini of the smooth muscle MLCK do not react with the 208-kDa MLCK, suggesting these regions are distinct. 208-kDa MLCK phosphorylates 20-kDa myosin light chains in a Ca2(+)/calmoduLin-dependent manner, consistent with it being a member of the MLCK family. Expression of 208-kDa MLCK and smooth muscle MLCK appears to be inversely regulated, with 208-kDa MLCK being most abundant during early development and declining at birth. In contrast, expression of smooth muscle MLCK is relatively low early during development and increases to become the predominant MLCK detected in all adult smooth and non-muscle tissues. The developmental expression pattern of the 208-kDa MLCK. suggests this form be named, embryonic MLCK.	INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	GALLAGHER, PJ (corresponding author), INDIANA UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, 635 BARNHILL DR, INDIANAPOLIS, IN 46202 USA.		Garcia, Joe GN/E-8862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL054118-03, R01 HL054118] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1975, NATURE, V256, P597, DOI 10.1038/256597a0; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; FAUX MC, 1993, MOL CELL BIOCHEM, V128, P81, DOI 10.1007/BF01076759; Gallagher P. J., 1994, Molecular Biology of the Cell, V5, p151A; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Gibson T J, 1993, DNA Seq, V3, P333, DOI 10.3109/10425179309020833; GIULIANO KA, 1992, MOL BIOL CELL, V3, P1037, DOI 10.1091/mbc.3.9.1037; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; KLINE RP, 1993, J CARDIOVASC ELECTR, V4, P642, DOI 10.1111/j.1540-8167.1993.tb01251.x; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; KOLEGA J, 1993, MOL BIOL CELL, V4, P819, DOI 10.1091/mbc.4.8.819; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481; RUMYANTSEV PP, 1991, GROWTH HYPERPLASIA C, P70; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16; YOSHIKAI S, 1992, ARCH BIOCHEM BIOPHYS, V299, P242, DOI 10.1016/0003-9861(92)90270-7	29	51	51	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29090	29095		10.1074/jbc.270.49.29090	http://dx.doi.org/10.1074/jbc.270.49.29090			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493932	Green Accepted, hybrid			2022-12-25	WOS:A1995TJ22700013
J	SEVERINOV, K; MUSTAEV, A; SEVERINOV, E; KOZLOV, M; DARST, SA; GOLDFARB, A				SEVERINOV, K; MUSTAEV, A; SEVERINOV, E; KOZLOV, M; DARST, SA; GOLDFARB, A			THE BETA-SUBUNIT RIF-CLUSTER-I IS ONLY ANGSTROMS AWAY FROM THE ACTIVE-CENTER OF ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL TOPOGRAPHY; RIFAMPICIN-RESISTANT; TERMINATION; CLEAVAGE; SITES	Ribonucleotide analogs bound in the initiating site of Escherichia coli RNA polymerase-promoter complex were cross-linked to the beta subunit. Using limited proteolysis and chemical degradation, the cross-link was mapped to a segment of beta between amino acids Val(516) and Arg(540). This region (Rif-cluster I) is known to harbor many rifampicin-resistant (Rif(R)) mutations. The results demonstrate that Rif-cluster I is part of the ''5'-face'' of the active center and provide structural basis for the long-known effects of Rif(R) mutations on transcription initiation, elongation, and termination.	PUBL HLTH RES INST,NEW YORK,NY 10016; ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University			Severinov, Konstantin/C-8545-2016; Kozlov, Maxim/GLN-3047-2022	Kozlov, Maxim/0000-0002-5994-9099	FIC NIH HHS [TW00258] Funding Source: Medline; NIGMS NIH HHS [GM49242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; HEUMANN H, 1987, BIOCHIM BIOPHYS ACTA, V909, P126, DOI 10.1016/0167-4781(87)90034-0; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JIN DJ, 1993, J MOL BIOL, V231, P1; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; MCCLURE WR, 1978, J BIOL CHEM, V253, P8949; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; Palenik B, 1992, CURR OPIN GENET DEV, V2, P931, DOI 10.1016/S0959-437X(05)80118-2; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1994, J BIOL CHEM, V269, P20826; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; WEHRLI W, 1977, EUR J BIOCHEM, V80, P325, DOI 10.1111/j.1432-1033.1977.tb11886.x	21	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29428	29432		10.1074/jbc.270.49.29428	http://dx.doi.org/10.1074/jbc.270.49.29428			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493980	hybrid			2022-12-25	WOS:A1995TJ22700061
J	SCHURMANN, A; BRAUERS, A; MASSMANN, S; BECKER, W; JOOST, HG				SCHURMANN, A; BRAUERS, A; MASSMANN, S; BECKER, W; JOOST, HG			CLONING OF A NOVEL FAMILY OF MAMMALIAN GTP-BINDING PROTEINS (RAGA, RAGB(S), RAGB(1)) WITH REMOTE SIMILARITY TO THE RAS-RELATED GTPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ADDITIONAL MEMBERS; ARF FAMILY; CELL-LINE; GENES; MEMBRANE; YEAST; SITE; IDENTIFICATION	cDNA clones of two novel Ras-related GTP-binding proteins (RagA and RagB) were isolated from rat and human cDNA libraries, Their deduced amino acid sequences comprise four of the six known conserved GTP-binding motifs (PM1, -2, -3, G1), the remaining two (G2, G3) being strikingly different from those of the Ras family, and an unusually large C-terminal domain (100 amino acids) presumably unrelated to GTP binding. RagA and RagB differ by seven conservative amino acid substitutions (98% identity), and by 33 additional residues at the N terminus of RagB, In addition, two isoforms of RagB (RagB(s) and RagB(l)) were found that differed only by an insertion of 28 codons between the GTP-binding motifs PM2 and PM3, apparently generated by alternative mRNA splicing, Polymerase chain reaction amplification with specific primers indicated that both long and short form of RagB transcripts were present in adrenal gland, thymus, spleen, and kidney, whereas in brain, only the long form RagB(1) was detected, A long splicing variant of RagA was not detected, Recombinant glutathione S-transferase (GST) fusion proteins of RagA and RagB(s) bound large amounts of radiolabeled GTP gamma S in a specific and saturable manner, In contrast, GTP gamma S binding of GST-RagB(l) hardly exceeded that of recombinant GST, GTP gamma S bound to recombinant RagA, and RagB(s) was rapidly exchangeable for GTP, whereas no intrinsic GTPase activity was detected. A multiple sequence alignment indicated that RagA and RagB cannot be assigned to any of the known subfamilies of Ras related GTPases but exhibit a 52% identity with a yeast protein (Gtr1) presumably involved in phosphate transport and/or cell growth. It is suggested that RagA and RagB are the mammalian homologues of Gtr1 and that they represent a novel subfamily of Ras-homologous GTP binding proteins.	RHEIN WESTFAL TH AACHEN, FAK MED, INST PHARMAKOL & TOXIKOL, D-52057 AACHEN, GERMANY	RWTH Aachen University			Becker, Walter/B-8889-2008; Joost, Hans-Georg/J-4462-2013	Becker, Walter/0000-0002-0347-4768; Joost, Hans-Georg/0000-0002-5860-606X; Schurmann, Annette/0000-0002-4113-4377				AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; DHAR R, 1984, NUCLEIC ACIDS RES, V12, P3611, DOI 10.1093/nar/12.8.3611; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MASANORI BY, 1992, MOL CELL BIOL, V12, P2958, DOI 10.1128/MCB.12.7.2958; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; TAN TJ, 1991, FEBS LETT, V291, P322, DOI 10.1016/0014-5793(91)81312-V; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WICHMANN H, 1989, NUCLEIC ACIDS RES, V17, P6737, DOI 10.1093/nar/17.16.6737; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	35	96	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28982	28988		10.1074/jbc.270.48.28982	http://dx.doi.org/10.1074/jbc.270.48.28982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499430	hybrid			2022-12-25	WOS:A1995TH05600074
J	SHORT, MK; JEFFREY, PD; KWONG, RF; MARGOLIES, MN				SHORT, MK; JEFFREY, PD; KWONG, RF; MARGOLIES, MN			CONTRIBUTION OF ANTIBODY HEAVY-CHAIN CDR1 TO DIGOXIN BINDING ANALYZED BY RANDOM MUTAGENESIS OF PHAGE-DISPLAYED FAB-26-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESHAPING HUMAN-ANTIBODIES; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; ANTIDIGOXIN ANTIBODIES; HYPERVARIABLE REGIONS; FV FRAGMENT; AFFINITY; SPECIFICITY; MUTATIONS; RECOGNITION	We constructed a bacteriophage-displayed library containing randomized mutations at H chain residues 30-35 of the anti-digoxin antibody 26-10 Fab to investigate sequence constraints necessary for high affinity binding in an antibody of known crystal structure. Phage were selected by panning against digoxin and three C-16-substituted analogues. All antigen-positive mutants selected using other analogues also bound digoxin. Among 73 antigen-positive clones, 26 different nucleotide sequences were found. The majority of Fabs had high affinity for digoxin (K-alpha 3.4 x 10(9) M(-1)) despite wide sequence diversity, Two mutants displayed affinities 2- and 4-fold higher than the parental antibody. Analysis of the statistical distribution of sequences showed that highest affinity binding occurred with a restricted set of amino acid substitutions at positions H33-35. All clones save two retained the parental Asn-H35, which contacts hapten and hydrogen bonds to other binding site residues in the parental structure, Positions H30-32 display remarkable diversity, with 10-14 different substitutions for each residue, consistent with high affinity binding. Thus complementarity can be retained and even improved despite diversity in the conformation of the N-terminal portion of the H-CDR1 loop.	MASSACHUSETTS GEN HOSP, DEPT SURG, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; MEM SLOAN KETTERING CANC CTR, DEPT CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center				Jeffrey, Philip/0000-0002-4351-5341	NHLBI NIH HHS [R01 HL47415] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047415] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; DAVIES DR, 1993, ACCOUNTS CHEM RES, V26, P421, DOI 10.1021/ar00032a005; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; JACKSON JR, 1995, J IMMUNOL, V154, P3310; JEFFREY PD, 1993, P NATL ACAD SCI USA, V90, P10310, DOI 10.1073/pnas.90.21.10310; Kabat EA, 1991, SEQUENCES PROTEINS I; MARSHAKROTHSTEIN A, 1980, P NATL ACAD SCI-BIOL, V77, P1120, DOI 10.1073/pnas.77.2.1120; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MUDGETTHUNTER M, 1982, J IMMUNOL, V129, P1165; NEAR RI, 1991, J IMMUNOL, V146, P627; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; OLSEN DB, 1993, METHOD ENZYMOL, V217, P189; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PANKA DJ, 1988, P NATL ACAD SCI USA, V85, P3080, DOI 10.1073/pnas.85.9.3080; PING J, 1993, J BIOL CHEM, V268, P23000; PLUCKTHUN A, 1989, METHOD ENZYMOL, V178, P497; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RIECHMANN L, 1993, BIOCHEMISTRY-US, V32, P8848, DOI 10.1021/bi00085a016; ROSE DR, 1983, J MOL BIOL, V165, P203, DOI 10.1016/S0022-2836(83)80252-6; SAMBROOK J, 1990, MOL CLONING LABORATO; SCHILDBACH JF, 1994, PROTEIN SCI, V3, P737; SCHILDBACH JF, 1993, PROTEIN SCI, V2, P206; SCHILDBACH JF, 1993, J BIOL CHEM, V268, P21739; SCHILDBACH JF, 1991, J BIOL CHEM, V266, P4640; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SMITH TW, 1970, BIOCHEMISTRY-US, V9, P331, DOI 10.1021/bi00804a020; THOMAS RE, 1992, MOL STRUCTURE BIOL A, P399; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; ZURAWSKI VR, 1978, J IMMUNOL, V121, P122	41	33	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28541	28550		10.1074/jbc.270.48.28541	http://dx.doi.org/10.1074/jbc.270.48.28541			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499368	hybrid			2022-12-25	WOS:A1995TH05600012
J	HWANG, A; MAITY, A; MCKENNA, WG; MUSCHEL, RJ				HWANG, A; MAITY, A; MCKENNA, WG; MUSCHEL, RJ			CELL CYCLE-DEPENDENT REGULATION OF THE CYCLIN B1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GENE-PRODUCT; PROTEIN; BINDING; PHASE; G2; PHOSPHORYLATION; INITIATION; EXPRESSION	Cyclin B1 mRNA expression varies through the cell cycle with its peak in G(2)/M. In cycling mammalian cells, its lowest level is in G(1) with a steady increase in S until a level 50-fold greater than that in G(1) is reached. In order to characterize the transcriptional component to this variation in expression, we cloned the upstream region 872 base pairs upstream from the start site of the cyclin B1 gene and have demonstrated that it confers cell cycle-dependent regulation onto two reporter genes, both chloramphenicol acetyltransferase and luciferase. Its activity was 25-fold greater in G(2)/M than in G(1) in HeLa cells with intermediate activity in S. This cyclical activity could be seen with sequences encompassing only 90 base pairs upstream from the start site. Protein binding to this region was demonstrated using electrophoretic mobility shift assays, and the binding profiles appeared to vary depending upon the phase of the cycle in which the extracts are made. Thus, transcriptional control plays an important role in determining cyclin B1 mRNA levels, and cell cycle-dependent activity is regulated through interactions with the region 90 bases upstream from the start site.	UNIV PENN, DEPT LAB MED & PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT RADIAT ONCOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania				Maity, Amit/0000-0001-7151-2845	NIGMS NIH HHS [GM 43759] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; HALL FL, 1993, ONCOGENE, V8, P1377; HATAKEYAMA M, 1994, COLD SPRING HARB SYM, V59, P1; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; KATO J, 1993, GENE DEV, V7, P331; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MARKIEWICZ DA, 1994, INT J RADIAT ONCOL, V28, P135, DOI 10.1016/0360-3016(94)90151-1; MEAD DA, 1991, BIO-TECHNOL, V9, P657, DOI 10.1038/nbt0791-657; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SALA A, 1994, CANCER RES, V54, P1402; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503	36	107	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28419	28424						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499347				2022-12-25	WOS:A1995TG21000072
J	WINSTON, BW; REMIGIO, LK; RICHES, DWH				WINSTON, BW; REMIGIO, LK; RICHES, DWH			PREFERENTIAL INVOLVEMENT OF MEK1 IN THE TUMOR NECROSIS FACTOR-ALPHA-INDUCED ACTIVATION OF P42(MAPK/ERK2) IN MOUSE MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; PHOSPHOLIPASE-C; GENE-PRODUCT; MAP KINASE; TYROSINE; PHOSPHORYLATION; EXPRESSION; THREONINE; CELLS	The pleiotropic cytokine tumor necrosis factor-alpha (TNF alpha) controls the expression of multiple gene products in macrophages and plays an important role in host defense, TNF alpha is recognized by the receptors, CD120a (p55) and CD120b (p75), Ligation of CD120a (p55) by TNF alpha or by anti-receptor agonistic antibodies initiates signal transduction leading to the activation of mitogen-activated protein kinases (MAPKs) (p42(mapk/erk2) and p44(mapk/erk1)). Phosphorylation and activation of MAPK are mediated by MAPK kinase (MEK), a family of Thr/Tyr kinases, In this study, we investigated the preferential involvement of the MEK isoforms MEK1 and MEK2 in the activation of p42(mapk/erk2) in mouse macrophages stimulated with TNF alpha. Exposure of macrophages to TNF alpha stimulated a time-dependent increase in the activity of MEK1 as measured by an in vitro kinase assay using kinase-inactive p42(mapk/erk2) (rMAPK(kd)) as substrate in the presence of gamma-[P-32]ATP. Maximal activation of MEK1 was detected at 10 min poststimulation and coincided with maximal transphosphorylation of Tyr and Thr residues of rMAPK(kd). By contrast, there was no evidence of MEK2 activation in macrophages in response to TNF alpha, These data suggest that MEK1 is the preferred substrate for MEK kinase, the upstream kinase implicated in activation of the MAPK pathway in macrophages by TNF alpha.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV PULM SCI,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027353] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27353] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DING AH, 1988, J IMMUNOL, V141, P2407; DULCOS B, 1991, METHOD ENZYMOL, V201, P10; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; HASLETT C, 1985, AM J PATHOL, V119, P101; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LAKE FR, 1994, J CLIN INVEST, V93, P1661, DOI 10.1172/JCI117148; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; PACE JL, 1985, J IMMUNOL, V134, P977; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RICHES DWH, 1991, J BIOL CHEM, V266, P24785; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SEGER R, 1992, J BIOL CHEM, V267, P14373; STEWART CC, 1981, METHODS STUDYING MON, P5; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UTSUNOMIYA Y, 1989, J IMMUNOL, V143, P2602; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WINSTON BW, 1995, J IMMUNOL, V155, P1525; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	30	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27391	27394		10.1074/jbc.270.46.27391	http://dx.doi.org/10.1074/jbc.270.46.27391			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499190	hybrid			2022-12-25	WOS:A1995TE73600001
J	GAO, X; CHEN, YQ; WU, N; GRIGNON, DJ; SAKR, W; PORTER, AT; HONN, KV				GAO, X; CHEN, YQ; WU, N; GRIGNON, DJ; SAKR, W; PORTER, AT; HONN, KV			SOMATIC MUTATIONS OF THE WAF1/CIP1 GENE IN PRIMARY PROSTATE-CANCER	ONCOGENE			English	Note						TUMOR SUPPRESSOR GENE; WAF1/CIP1; PROSTATIC ADENOCARCINOMA; MUTATION; POLYMERASE CHAIN REACTION	TUMOR; INHIBITOR; KINASES; P21	The WAF1/CIP1 gene, a potential tumor suppressor gene, has recently been cloned and identified as a p53 mediator and an inhibitor for G1 cyclin-dependent kinases (CDKs). We undertook this study to investigate the possible role of the WAF1/CIP1 gene in human prostatic carcinoma. Matched normal and cancer tissues from 18 patients with prostate cancer were screened for WAF1/CIP1 mutation by nested reverse transcription-polymerase chain reaction/single strand conformational polymorphism (RT-PCR/SSCP) and DNA sequencing. Shifted bands from three tumor, but not the matched normal specimens, were observed. Subsequent direct DNA sequencing of the PCR fragments identified four sequence alterations including a cytosine (C) to adenine (A) transversion and a guanine (G) to A transition and two A insertions. Our results demonstrated that mutations of the WAF1/CTP1 gene occur and may be important during the pathogenesis of human prostate cancer. This is the first report of WAF1/CIP1 mutation in a primary human cancer.	WAYNE STATE UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48202	Wayne State University; Wayne State University			Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708				BHATIA K, 1995, CANCER RES, V55, P1431; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHEN YQ, 1994, CANCER RES, V54, P1574; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; CHI SG, 1994, J NATL CANCER I, V86, P926, DOI 10.1093/jnci/86.12.926; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1995, INT J ONCOL, V6, P111; GAO X, 1993, CANCER RES, V53, P2723; GAO X, 1995, IN PRESS PATHOL ONCO; GAO X, 1995, CANCER MOL BIOL, V2, P475; GAO X, 1995, IN PRESS UROL; GAO X, 1994, CANCER MOL BIOL, V1, P297; GAO XA, 1994, ONCOGENE, V9, P2999; HAGMANN W, 1995, PROSTAGLANDINS, V49, P49, DOI 10.1016/0090-6980(94)00005-H; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LI YJ, 1995, ONCOGENE, V10, P599; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668; ZHOU XL, 1994, ONCOGENE, V9, P3737	39	109	116	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1395	1398						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478562				2022-12-25	WOS:A1995RY96700022
J	SCHOTT, AF; APEL, IJ; NUNEZ, G; CLARKE, MF				SCHOTT, AF; APEL, IJ; NUNEZ, G; CLARKE, MF			BCL-X(L) PROTECTS CANCER-CELLS FROM P53-MEDIATED APOPTOSIS	ONCOGENE			English	Article						BCL-X(L); P53; BREAST CANCER	BCL-2 PROTEIN; DEATH; GENE; MYC; P53; EXPRESSION; SURVIVAL; LINE	Oncogenesis is a process resulting from genetic events which cause loss of growth control or inhibition of appropriate cell death. The Bcl-x(L) protein is a recently discovered member of the bcl-2 family which has been shown to protect cells from some forms of programmed cell death, but has not yet been implicated in the genesis of human carcinomas. In this report we explore the role of Bcl-x(L) overexpression in protecting cancer cells from p53-mediated apoptosis. Increased levels of Bcl-x(L) were found in a subset of primary human breast carcinomas, as well as in the breast cancer line, T47D. T47D cells were then transfected with a temperature-sensitive mutant of the tumor suppressor p53 (p53ts). Although many tumor cell lines undergo apoptosis when p53 is expressed, the T47D transfectants remained viable at temperatures permitting wild-type p53 phenotype. This suggested that endogenous Bcl-x(L) could protect cancer cells from p53-mediated apoptosis. To test this hypothesis, murine erythroleukemia cells were transfected with bcl-x(L) and p53ts. While cell lines expressing p53 alone rapidly died, those cells co-expressing Bcl-x(L) survived. These results demonstrate that Bcl-x(L) is capable of protecting cells from p53-mediated apoptosis, and suggest a possible mechanism by which tumors expressing Bcl-x(L) are able to partly overcome the tumor suppressor functions of p53.	UNIV MICHIGAN,DEPT HEMATOL ONCOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014; Schott, Anne/AAD-1902-2019		NCI NIH HHS [CA-46657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BHARGAVA V, 1994, AM J PATHOL, V145, P535; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASTLE VP, 1993, AM J PATHOL, V143, P1543; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DOGLIONI C, 1994, VIRCHOWS ARCH, V424, P47; FUKUNAGAJOHNSON N, 1995, IN PRESS CARCINOGENE; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HALDAR S, 1994, CANCER RES, V54, P2095; IKEGAKI N, 1994, CANCER RES, V54, P6; JOENSUU H, 1994, AM J PATHOL, V145, P1191; KORSMEYER SJ, 1992, BLOOD, V880, P879; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; PIENTENPOL JA, 1993, NATURE, V365, P17; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1993, ONCOGENE, V8, P3427; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZUTTER M, 1991, BLOOD, V78, P1062	34	114	117	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1389	1394						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478561				2022-12-25	WOS:A1995RY96700021
J	YU, DH; MATIN, A; XIA, WY; SORGI, F; HUANG, L; HUNG, MC				YU, DH; MATIN, A; XIA, WY; SORGI, F; HUANG, L; HUNG, MC			LIPOSOME-MEDIATED IN-VIVO E1A GENE-TRANSFER SUPPRESSED DISSEMINATION OF OVARIAN-CANCER CELLS THAT OVEREXPRESS HER-2/NEU	ONCOGENE			English	Note						C-ERBB-2; CATIONIC LIPOSOME; TUMOR SUPPRESSION; ADENOVIRUS-5 E1A; ONCOGENE	NATURAL-KILLER CELLS; BREAST-CANCER; NEU GENE; EXPRESSION; ADENOVIRUS; ONCOGENE; PROTOONCOGENE; PRODUCTS; AMPLIFICATION; METASTASIS	The HER-2/neu proto-oncogene is frequently amplified or overexpressed in many different types of human cancers, a phenomenon that has been shown to correlate with shorter survival time and lower survival rate in ovarian cancer patients, We previously reported that increased HER-2/neu expression led to more severe malignancy and increased metastatic potential in animal models and that the adenovirus 5 E1A gene repressed HER-2/nue gene expression at transcriptional level and was able to suppress tumor growth when stably transfected into human ovarian cancer SKOV-3 cells which overexpress HER-2/neu. To investigate whether the E1A gene may be used as a therapeutic agent for HER-2/neu-overexpressing human cancers in living hosts, we first developed tumor-bearing mice by injecting SKOV-3 cells that overexpress HER-2/neu intraperitonealy into female nu/nu mice, Five days later, rye used cationic liposomes to directly deliver the E1A gene into adenocarcinomas that developed in the peritoneal cavity and an the mesentery of the mice that received the SKOV-3 cell injection, We found that liposome-mediated E1A gene transfer significantly inhibited growth and dissemination of ovarian cancer cells that overexpress HER-2/neu in the treated mice; about 70% of these mice survived at least 365 days, whereas all the control mice that did not receive the gene therapy developed severe tumor symptoms and died within 160 days, The results suggest that liposome-mediated E1A gene transfer may serve as an effective therapy for human ovarian cancers that overexpress HER-2/neu by directly targeting the HER-2/neu oncogene.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [CA64654, CA59327, CA60488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060488, R01CA064654, R29CA060488, P01CA059327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAHRS OH, 1992, MANUAL STAGING CANCE; BERCHUCK A, 1990, CANCER RES, V50, P4087; BERGMANN CI, 1986, NATURE, V319, P226; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; COOK JL, 1984, SCIENCE, V224, P612, DOI 10.1126/science.6710160; COOK JL, 1989, J IMMUNOL, V142, P4527; CREASMAN WT, 1991, AM J OBSTET GYNECOL, V165, P7, DOI 10.1016/0002-9378(91)90213-B; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HSU SM, 1982, J HISTOCHEM CYTOCHEM, V29, P577; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PIVER MS, 1991, SEMIN ONCOL, V18, P177; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEEG PS, 1988, CANCER RES, V48, P6550; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINER DB, 1990, CANCER RES, V50, P421; YAN DH, 1991, ONCOGENE, V6, P343; YU D, 1995, MOL BASIS ONCOLOGY, P131; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZHANG X, 1989, ONCOGENE, V4, P985	36	98	118	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1383	1388						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478560				2022-12-25	WOS:A1995RY96700020
J	NEWCOMB, R; FISHER, JM; SCHELLER, RH				NEWCOMB, R; FISHER, JM; SCHELLER, RH			PROCESSING OF THE EGG-LAYING HORMONE (ELH) PRECURSOR IN THE BAG CELL NEURONS OF APLYSIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											NEWCOMB, R (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.							ARCH S, 1977, BEHAV BIOL, V19, P45, DOI 10.1016/S0091-6773(77)91331-1; ARCH S, 1972, J GEN PHYSIOL, V60, P102, DOI 10.1085/jgp.60.1.102; BERRY RW, 1981, BIOCHEMISTRY-US, V20, P6200, DOI 10.1021/bi00524a045; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURFORD GD, 1973, BIOCHEM J, V136, P1047, DOI 10.1042/bj1361047; CAMPANELLI JT, 1987, J NEUROPHYSIOL, V57, P1201, DOI 10.1152/jn.1987.57.4.1201; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHIU AY, 1979, P NATL ACAD SCI USA, V76, P6656, DOI 10.1073/pnas.76.12.6656; FLEMINGER G, 1984, P NATL ACAD SCI-BIOL, V81, P3587, DOI 10.1073/pnas.81.11.3587; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HELLER E, 1980, P NATL ACAD SCI-BIOL, V77, P2328, DOI 10.1073/pnas.77.4.2328; KALDANY RRJ, 1986, J BIOL CHEM, V261, P5751; KUPFERMANN I, 1970, J NEUROPHYSIOL, V33, P877, DOI 10.1152/jn.1970.33.6.877; LEWIS RV, 1983, ANNU REV PHARMACOL, V23, P353, DOI 10.1146/annurev.pa.23.040183.002033; LOECHNER KJ, 1987, SOC NEUR ABSTR, V2, P1071; LOH YP, 1975, J COMP PHYSIOL, V100, P283; LORENZ RG, 1985, LIFE SCI, V37, P1523, DOI 10.1016/0024-3205(85)90184-5; MAHON AC, 1985, J NEUROSCI, V5, P1872; MAINS RE, 1977, P NATL ACAD SCI USA, V74, P3014, DOI 10.1073/pnas.74.7.3014; MAINS RE, 1981, J BIOL CHEM, V256, P5683; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1165, DOI 10.1152/jn.1979.42.4.1165; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1185, DOI 10.1152/jn.1979.42.4.1185; MAYERI E, 1982, NEUROSECRETION MOL C, P307; NAMBU JR, 1986, J NEUROSCI, V6, P2026; NEWCOMB R, 1987, J NEUROSCI, V7, P854; NEWCOMB R, 1985, AM ZOOL, V25, P157; NEWCOMB RW, 1987, NEUROCHEM INT, V11, P229, DOI 10.1016/0197-0186(87)90014-3; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHMAN BS, 1983, P NATL ACAD SCI-BIOL, V80, P5753, DOI 10.1073/pnas.80.18.5753; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHAPIRO AL, 1967, BIOCHEM BIOPH RES CO, V28, P815, DOI 10.1016/0006-291X(67)90391-9; SIGVARDT KA, 1986, J NEUROSCI, V6, P803; SOSSIN WS, 1987, J NEUROSCI, V7, P671; STUENKEL E, 1983, J COMP PHYSIOL B, V207, P191; TAUSSIG R, 1986, DNA-J MOLEC CELL BIO, V5, P453, DOI 10.1089/dna.1.1986.5.453	36	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1988	263	25					12514	12521						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P8611	3410850				2022-12-25	WOS:A1988P861100056
J	COHEN, N; SALZBERG, A; LEV, Z				COHEN, N; SALZBERG, A; LEV, Z			A BIDIRECTIONAL PROMOTER IS REGULATING THE DROSOPHILA-RAS2 GENE	ONCOGENE			English	Article									TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology			Salzberg, Adi/A-9986-2014; Salzberg, Adi/O-1198-2019	Salzberg, Adi/0000-0002-0427-9809; Salzberg, Adi/0000-0002-0427-9809				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROCK HW, 1987, GENE, V51, P129, DOI 10.1016/0378-1119(87)90301-5; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Elgin S.C.R., 1978, P112; FARNHAM PJ, 1985, P NATL ACAD SCI USA, V82, P3978, DOI 10.1073/pnas.82.12.3978; FURTH ME, 1987, ONCOGENE, V1, P47; GARABEDIAN MJ, 1985, P NATL ACAD SCI USA, V82, P1396, DOI 10.1073/pnas.82.5.1396; GARFINKEL MD, 1983, J MOL BIOL, V168, P765, DOI 10.1016/S0022-2836(83)80074-6; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; HU MCT, 1986, GENE, V42, P21; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; IATROU K, 1983, EMBO J, V2, P1431, DOI 10.1002/j.1460-2075.1983.tb01604.x; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; LEV Z, 1985, MOL CELL BIOL, V5, P1540, DOI 10.1128/MCB.5.6.1540; LEV Z, 1987, ANAL BIOCHEM, V160, P332, DOI 10.1016/0003-2697(87)90055-8; LEV Z, 1986, BIOCHIM BIOPHYS ACTA, V867, P144, DOI 10.1016/0167-4781(86)90074-6; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; MANIATIS T, 1982, LABORATORY MANUAL; MASTERS JN, 1985, MOL CELL BIOL, V5, P493, DOI 10.1128/MCB.5.3.493; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NEUMANSILBERBERG FS, 1984, CELL, V37, P1027; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NOTHIGER R, 1980, DROS INFOR SERVICE, V55, P162; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PAPAGEORGE AG, 1984, MOL CELL BIOL, V4, P23, DOI 10.1128/MCB.4.1.23; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SEGAL D, 1986, MOL CELL BIOL, V6, P2241, DOI 10.1128/MCB.6.6.2241; SEGEV O, 1988, IN PRESS ONCOGENE; SPANDIDOS DA, 1986, FEBS LETT, V203, P169, DOI 10.1016/0014-5793(86)80736-0; STELLER H, 1984, EMBO J, V3, P165, DOI 10.1002/j.1460-2075.1984.tb01778.x; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SWAROOP A, 1986, MOL CELL BIOL, V6, P833, DOI 10.1128/MCB.6.3.833; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WILLIAMS TJ, 1986, MOL CELL BIOL, V6, P4558, DOI 10.1128/MCB.6.12.4558	55	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					137	142						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412773				2022-12-25	WOS:A1988Q053400002
J	TAKAHASHI, H; NUKIWA, T; BASSET, P; CRYSTAL, RG				TAKAHASHI, H; NUKIWA, T; BASSET, P; CRYSTAL, RG			MYELOMONOCYTIC CELL LINEAGE EXPRESSION OF THE NEUTROPHIL ELASTASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									NHLBI, PULM BRANCH, BLDG 10, RM 6D03, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; Bieth JG, 1986, REGULATION MATRIX AC, P217; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; EID NS, 1987, J EXP MED, V165, P1448, DOI 10.1084/jem.165.5.1448; FLEUR ML, 1987, J BIOL CHEM, V262, P2111; GRANELLIPIPERNO A, 1979, J EXP MED, V149, P284, DOI 10.1084/jem.149.1.284; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HECK LW, 1985, ANAL BIOCHEM, V149, P153, DOI 10.1016/0003-2697(85)90488-9; JANOFF A, 1968, J EXP MED, V128, P1137, DOI 10.1084/jem.128.5.1137; JANOFF A, 1985, ANNU REV MED, V36, P207; KRAMPS JA, 1984, J HISTOCHEM CYTOCHEM, V32, P389, DOI 10.1177/32.4.6561228; MORNEX JF, 1986, J CLIN INVEST, V77, P1952, DOI 10.1172/JCI112524; Powers J ., 1980, CIBA FDN S, V75, P51; RODRIGUEZ RJ, 1977, SCIENCE, V198, P313, DOI 10.1126/science.910131; SENIOR RM, 1982, J CLIN INVEST, V69, P384, DOI 10.1172/JCI110462; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; YAMADA M, 1984, J BIOL CHEM, V259, P3021	18	116	118	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1988	263	5					2543	2547						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M1758	3422232				2022-12-25	WOS:A1988M175800067
J	BUCHLI, R; ALBERATIGIANI, D; MALHERBE, P; KOHLER, C; BROGER, C; CESURA, AM				BUCHLI, R; ALBERATIGIANI, D; MALHERBE, P; KOHLER, C; BROGER, C; CESURA, AM			CLONING AND FUNCTIONAL EXPRESSION OF A SOLUBLE FORM OF KYNURENINE ALPHA-AMINOADIPATE AMINOTRANSFERASE FROM RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN; PURIFICATION; MITOCHONDRIAL; IDENTITY; ACID	Several aminotransferases with kynurenine aminotransferase (KAT) activity are able to convert L-kynurenine into kynurenic acid, a putative endogenous modulator of glutamatergic neurotransmission. In the rat, one of the described KAT isoforms has been found to correspond to glutamine transaminase K. In addition, rat kidney alpha-aminoadipate aminotransferase (AadAT) also shows KAT activity. In this report, we describe the isolation of a cDNA clone encoding the soluble form of this aminotransferase isoenzyme from rat (KAT/AadAT). Degenerate oligonucleotides were designed from the amino acid sequences of rat kidney KAT/AadAT tryptic peptides for use as primers for reverse transcription-polymerase chain reaction of rat kidney RNA. The resulting polymerase chain reaction fragment was used to screen a rat kidney cDNA library and to isolate a cDNA clone encoding KAT/AadAT. Analysis of the combined DNA sequences indicated the presence of a single 1275-base pair open reading frame coding for a soluble protein of 425 amino acid residues. KAT/AadAT appears to be structurally homologous to aspartate aminotransferase in the pyridoxal 5'-phosphate binding domain. RNA blot analysis of rat tissues, including brain, revealed a single species of KAT/AadAT mRNA of similar to 2.1 kilobases. HEK-293 cells transfected with the KAT/AadAT cDNA exhibited both HAT and AadAT activities with enzymatic properties similar to those reported for the rat native protein.	F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,NERVOUS SYST DIS,CH-4002 BASEL,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,DEPT COMP CHEM,CH-4002 BASEL,SWITZERLAND	Roche Holding; Roche Holding								ALBERATIGIANI D, 1995, J NEUROCHEM, V64, P1448; BARAN H, 1994, J NEUROCHEM, V62, P730; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; CARPENEDO R, 1994, NEUROSCIENCE, V61, P237, DOI 10.1016/0306-4522(94)90227-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooper A J, 1994, Adv Pharmacol, V27, P71, DOI 10.1016/S1054-3589(08)61030-3; DESHMUKH DR, 1989, BIOCHEM J, V261, P761, DOI 10.1042/bj2610761; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; HARTLINE RA, 1985, METHOD ENZYMOL, V113, P664; HUCK S, 1984, J NEUROSCI, V4, P2650; HUYNH TV, 1984, DNA CLONING TECHNIQU, P49; JAEGER AU, 1994, J MOL BIOL, V239, P285; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MALHERBE P, 1995, FEBS LETT, V367, P141, DOI 10.1016/0014-5793(95)00546-L; MALHERBE P, 1994, J BIOL CHEM, V269, P13792; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MAWAL MR, 1991, BIOCHEM J, V279, P595, DOI 10.1042/bj2790595; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MOSCA M, 1994, FEBS LETT, V353, P21, DOI 10.1016/0014-5793(94)01003-X; NAKATANI Y, 1970, BIOCHIM BIOPHYS ACTA, V198, P219, DOI 10.1016/0005-2744(70)90054-9; OKUNO E, 1991, J NEUROCHEM, V57, P533, DOI 10.1111/j.1471-4159.1991.tb03783.x; OKUNO E, 1980, BIOCHEM J, V189, P581, DOI 10.1042/bj1890581; OKUNO E, 1991, BRAIN RES, V542, P307, DOI 10.1016/0006-8993(91)91583-M; OKUNO E, 1990, BRAIN RES, V534, P37, DOI 10.1016/0006-8993(90)90109-O; PERRY S, 1995, FEBS LETT, V360, P277, DOI 10.1016/0014-5793(95)00123-Q; PERRY SJ, 1993, MOL PHARMACOL, V43, P660; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT W, 1993, NEUROSCIENCE, V55, P177, DOI 10.1016/0306-4522(93)90464-Q; STONE TW, 1993, PHARMACOL REV, V45, P309; TAKEUCHI F, 1983, BIOCHIM BIOPHYS ACTA, V743, P323, DOI 10.1016/0167-4838(83)90389-8; TOBES MC, 1977, J BIOL CHEM, V252, P4591; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	34	68	73	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29330	29335		10.1074/jbc.270.49.29330	http://dx.doi.org/10.1074/jbc.270.49.29330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493966	hybrid			2022-12-25	WOS:A1995TJ22700047
J	RAY, A; GAO, XO; RAY, BK				RAY, A; GAO, XO; RAY, BK			ROLE OF A DISTAL ENHANCER CONTAINING A FUNCTIONAL NF-KAPPA-B-BINDING SITE IN LIPOPOLYSACCHARIDE-INDUCED EXPRESSION OF A NOVEL ALPHA(1)-ANTITRYPSIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTITRYPSIN GENE; ALPHA-1 PROTEINASE-INHIBITOR; LIVER-SPECIFIC TRANSCRIPTION; TRANSGENIC MICE; HUMAN-MONOCYTES; ELEMENTS; DNA; INTERLEUKIN-1-BETA; PURIFICATION; MACROPHAGES	alpha(1)-Antitrypsin (alpha(1)-AT) is one of the major proteinase inhibitors in serum. Its primary physiological function is to inhibit neutrophil elastase activity in lung, but it also inhibits other serine proteases including trypsin, chymotrypsin, thrombin, and cathepsin. We have previously reported a novel alpha(1)-AT, S-2 isoform, from rabbit that is induced up to 100-fold in the liver during acute inflammatory condition (Ray, B. K., Gao, X., and Ray, A. (1994) J. Biol. Chem. 269, 22080-22086). Here, we present evidence that the expression of this alpha 1-AT S-2 gene is also induced in lipopolysaccharide (LPS)-treated peripheral blood monocytes. From the cloned genomic DNA, we have identified a distal LPS-responsive enhancer located between -2438 and -1990 base pairs upstream of the transcription start site. In vitro DNA-binding studies demonstrated an interaction of an LPS-inducible NF-kappa B-like nuclear factor with a kappa B-element present in this enhancer region. Antibodies against p65 and p50 subunits of NP-kappa B supershifted the DNA-protein complex. A mutation of the NF-kappa B-binding element virtually abolished the LPS-responsive induction of the chimeric promoter in monocytic cells. Furthermore, overexpression of NF-kappa B induced the wild-type promoter activity. Taken together, these results demonstrated that during LPS-mediated inflammation, NF-kappa B/Rel family of transcription factors play a crucial role in the transcriptional induction of the inflammation responsive alpha(1)-AT gene.			RAY, A (corresponding author), UNIV MISSOURI, DEPT VET PATHOBIOL, COLUMBIA, MO 65211 USA.							ALLEN RC, 1974, AM J CLIN PATHOL, V62, P732; BARBEYMOREL C, 1987, J EXP MED, V166, P1041, DOI 10.1084/jem.166.4.1041; BENSI G, 1990, CELL GROWTH DIFFER, V1, P491; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; CHAO S, 1990, BIOCHEMISTRY-US, V29, P323, DOI 10.1021/bi00454a004; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CILIBERTO G, 1985, CELL, V41, P531, DOI 10.1016/S0092-8674(85)80026-X; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DESIMONE V, 1989, NUCLEIC ACIDS RES, V17, P9407, DOI 10.1093/nar/17.22.9407; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ERIKSSON S, 1964, ACTA MED SCAND, V175, P197; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GADEK JE, 1980, CLIN RES PROC, V16, P27; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GITLIN D, 1975, PLASMA PROTEINS, V2, P324; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAYSON DR, 1988, MOL CELL BIOL, V8, P1055, DOI 10.1128/MCB.8.3.1055; HAFEEZ W, 1992, J CLIN INVEST, V89, P1214, DOI 10.1172/JCI115705; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KELSEY GD, 1987, GENE DEV, V1, P161, DOI 10.1101/gad.1.2.161; KOOPMAN P, 1989, GENE DEV, V3, P16, DOI 10.1101/gad.3.1.16; KRAUTER KS, 1986, DNA-J MOLEC CELL BIO, V5, P29, DOI 10.1089/dna.1986.5.29; Laurell C., 1975, PLASMA PROTEINS, P229; LAURELL CB, 1979, J CLIN ENDOCR METAB, V49, P719, DOI 10.1210/jcem-49-5-719; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCKERROW JH, 1985, J BIOL CHEM, V260, P3703; MONTGOMERY KT, 1990, MOL CELL BIOL, V10, P2625, DOI 10.1128/MCB.10.6.2625; MUENSCH H, 1986, AM J HUM GENET, V38, P898; NUKIWA T, 1987, J BIOL CHEM, V262, P11999; OLSEN GN, 1975, J CLIN INVEST, V55, P427, DOI 10.1172/JCI107947; PERLMUTTER DH, 1985, P NATL ACAD SCI USA, V82, P795, DOI 10.1073/pnas.82.3.795; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P138, DOI 10.1172/JCI114133; RANGAN VS, 1990, J BIOL CHEM, V265, P8874; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RAY BK, 1994, J BIOL CHEM, V269, P22080; RAY BK, 1993, EUR J BIOCHEM, V216, P127, DOI 10.1111/j.1432-1033.1993.tb18124.x; RAY BK, 1991, BIOCHEM BIOPH RES CO, V178, P68, DOI 10.1016/0006-291X(91)91780-G; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHARP HL, 1969, J LAB CLIN MED, V73, P934; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WERB Z, 1982, J INVEST DERMATOL, V79, pS154, DOI 10.1111/1523-1747.ep12546056	61	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29201	29208		10.1074/jbc.270.49.29201	http://dx.doi.org/10.1074/jbc.270.49.29201			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493948				2022-12-25	WOS:A1995TJ22700029
J	SALGIA, R; UEMURA, N; OKUDA, K; LI, JL; PISICK, E; SATTLER, M; DEJONG, R; DRUKER, B; HEISTERKAMP, N; CHEN, LB; GROFFEN, J; GRIFFIN, JD				SALGIA, R; UEMURA, N; OKUDA, K; LI, JL; PISICK, E; SATTLER, M; DEJONG, R; DRUKER, B; HEISTERKAMP, N; CHEN, LB; GROFFEN, J; GRIFFIN, JD			CRKL LINKS P210(BCR/ABL) WITH PAXILLIN IN CHRONIC MYELOGENOUS LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; V-CRK; TRANSFORMATION; PROTEINS; ADHESION; STROMA; ABL	The Philadelphia chromosome translocation generates a chimeric oncogene, BCR/ABL, which causes chronic myelogenous leukemia (CML). In primary neutrophils from patients with CML, the major novel tyrosine-phosphorylated protein is CRKL, an SH2-SH3-SH3 linker protein which has an overall homology of 60% to CRK, the human homologue of the v-crk oncogene product. Anti-CRKL immunoprecipitates from CML cells, but not normal cells, were found to contain p210(BCR/ABL) and c-ABL. Several other phosphoproteins were also detected in anti-CRKL immunoprecipitates, one of which has been identified as paxillin, a 68-kDa focal adhesion protein which we have previously shown to be phosphorylated by p210(BCR/ABL). Using GST-CRKL fusion proteins, the SH3 domains of CRKL were found to bind c-ABL and p210(BCR/ABL), while the SH2 domain of CRKL bound to paxillin, suggesting that CRKL could physically Link p210(BCR/ABL) to paxillin. Paxillin contains three tyrosines in Tyr-X-X-Pro (Y-X-X-P) motifs consistent with amino acid sequences predicted to be optimal for binding to the CRKL-SH2 domain (at positions Tyr-31, Tyr-118, and Tyr-181). Each of these tyrosine residues was mutated to a phenylalanine residue, and in. vitro binding assays indicated that paxillin tyrosines at positions 31 and 118, but not 181, are likely to be involved in CRKL-SH2 binding. These results suggest that the p210(BCR/ABL) oncogene may be physically linked to the focal adhesion-associated protein paxillin in hematopoietic cells by CRKL. This interaction could contribute to the known adhesive defects of CML cells.	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, MOLEC CARCINOGENESIS SECT, LOS ANGELES, CA 90027 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Children's Hospital Los Angeles; Oregon Health & Science University			Heisterkamp, Nora/C-1698-2012; Li, Jian-Liang/AAE-9315-2019	Heisterkamp, Nora/0000-0003-2769-2273; Li, Jian-Liang/0000-0002-6487-081X; Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA60821, CA47456, CA36167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA060821, R55CA047456, R01CA036167, R37CA036167, R01CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; DRUKER B, 1992, BLOOD, V79, P2215; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SUGAHARA H, 1994, J EXP MED, V179, P1757, DOI 10.1084/jem.179.6.1757; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	37	126	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29145	29150		10.1074/jbc.270.49.29145	http://dx.doi.org/10.1074/jbc.270.49.29145			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493940	hybrid			2022-12-25	WOS:A1995TJ22700021
J	BALOW, JP; WEISSMAN, JD; KEARSE, KP				BALOW, JP; WEISSMAN, JD; KEARSE, KP			UNIQUE EXPRESSION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I PROTEINS IN THE ABSENCE OF GLUCOSE TRIMMING AND CALNEXIN ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL; INHIBITORS; MOLECULES; DEFICIENT; ANTIGENS; ER	Recent evidence indicates that efficient expression of major histocompatibility complex (MHC) complexes requires their interaction with the resident endoplasmic reticulum (ER) chaperone calnexin, which for certain proteins functions as a lectin specific for monoglucosylated glycans, In the current report, we studied the expression of MHC class I proteins in BW wild type thymoma cells (BW WT) and glucosidase II-deficient BW PHAR2.7 cells, Consistent with a requirement for glucose (Glc) trimming for interaction of class I proteins with calnexin, we found that nascent H-2K(k) proteins associated with calnexin in untreated BW WT cells, but not in BW WT cells treated with the glucosidase inhibitor castanospermine (cas), or in untreated glucosidase II-deficient BW PHAR2.7 cells, Suprisingly, we found that H-2K(k) expression occurred with similar efficiency in EW PHAR2.7 cells as in BW WT cells and that formation of nascent H-2K(k) complexes was perturbed by cas treatment in BW WT cells but not in BW PHAR2.7 cells, Finally, it was noted that expression of the molecular chaperone Rip was markedly increased in BW PHAR2.7 cells relative to EW WT cells, which is suggested to play a role in regulating the expression of H-2K(k) complexes in BW PHAR2.7 cells, The current study demonstrates that Glc trimming is required for efficient interaction of nascent H-2K(k) proteins with calnexin; that expression of MHC class I proteins can, under certain conditions, proceed effectively in the absence of Glc trimming and calnexin association; and that Bip expression is markedly increased under conditions where diglucosylated glycans persist on nascent glycoproteins within the ER, These data are consistent with the hypothesis that alternative oligomerization pathways exist for class I proteins within the quality control system of the ER that have differential requirements for removal of Glc residues from nascent glycan chains.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LOO TW, 1994, J BIOL CHEM, V269, P28683; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1994, J BIOL CHEM, V268, P3809; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; MORI K, 1993, CELL, V74, P743; NOBNER E, 1995, J EXP MED, V181, P327; OZATO K, 1980, J IMMUNOL, V124, P533; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; REITMAN ML, 1982, J BIOL CHEM, V257, P357; SCOTT JE, 1995, J IMMUNOL, V155, P143; SONG ES, 1994, J BIOL CHEM, V269, P7024; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	29	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29025	29029		10.1074/jbc.270.48.29025	http://dx.doi.org/10.1074/jbc.270.48.29025			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499436	hybrid			2022-12-25	WOS:A1995TH05600080
J	GOROVITS, BM; HOROWITZ, PM				GOROVITS, BM; HOROWITZ, PM			THE CHAPERONIN GROEL IS DESTABILIZED BY BINDING OF ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; ATP; HYDROLYSIS	The urea induced dissociation and subsequent conformational transitions of the nucleotide-bound form of GroEL were studied by light scattering, 4,4'-bis(1-anilino-8-naphthalenesulfonic acid) binding, and intrinsic tyrosine fluorescence. Magnesium ion alone (10 mM) stabilizes GroEL and leads to coordination of the structural transitions monitored by the different parameters. The midpoint of the light-scattering transition that monitored dissociation of the 14-mer with bound magnesium was raised to similar to 3 M, which is considerably higher than the ligand-free form of the protein, which exhibits a transition with a midpoint at similar to 2 M urea. Binding of ADP results in destabilization of the GroEL oligomeric structure, and complete dissociation of the 14-mer in the presence of 5 mM ADP occurs at about 2 M urea with the midpoint of the transition at similar to 1 M urea. The same destabilization by ADP and stabilization by Mg2+ were seen when the conformation was followed by the intrinsic fluorescence. Complexation with the nonhydrolyzable ATP analog, 5'-adenylimidodiphosphate gave an apparent stability of the quaternary structure that was between that observed with Mg2+ and that with ADP. The ADP-bound form of the protein demonstrated increased hydrophobic exposure at lower urea concentrations than the uncomplexed GroEL. In addition, the GroEL-ADP complex is more accessible for proteolytic digestion by chymotrypsin than the uncomplexed protein, consistent with a more open, flexible form of the protein. The implication of the conformational changes to the mechanism of the GroEL function is discussed.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ESO5729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; DIAMANT S, 1995, BIOCHEMISTRY-US, V34, P273, DOI 10.1021/bi00001a033; FISHER MT, 1994, J BIOL CHEM, V269, P13629; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GIBBONS DL, 1995, J BIOL CHEM, V270, P7335, DOI 10.1074/jbc.270.13.7335; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOROVITS B, 1995, J BIOL CHEM, V270, P2061, DOI 10.1074/jbc.270.5.2061; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, TRENDS BIOCHEM SCI, V217, P20; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11599; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LISSIN NM, 1995, FEBS LETT, V361, P55, DOI 10.1016/0014-5793(95)00151-X; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1995, BBA-PROTEIN STRUCT M, V1247, P209, DOI 10.1016/0167-4838(94)00231-5; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PRICE NC, 1993, BIOCHIM BIOPHYS ACTA, V1161, P52, DOI 10.1016/0167-4838(93)90195-W; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEAST RC, 1982, CRC HDB CHEM MOL BIO; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	37	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28551	28556		10.1074/jbc.270.48.28551	http://dx.doi.org/10.1074/jbc.270.48.28551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499369	hybrid			2022-12-25	WOS:A1995TH05600013
J	MARVIN, KW; FUJIMOTO, W; JETTEN, AM				MARVIN, KW; FUJIMOTO, W; JETTEN, AM			IDENTIFICATION AND CHARACTERIZATION OF A NOVEL SQUAMOUS CELL-ASSOCIATED GENE-RELATED TO PMP22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHEAL EPITHELIAL-CELLS; HUMAN EPIDERMAL KERATINOCYTE; RETINOIC ACID; GROWTH ARREST; L2/HNK-1 CARBOHYDRATE; MYELIN PROTEIN; DIFFERENTIATION; ADHESION; EXPRESSION; TRANSGLUTAMINASE	In this study, we identify and characterize a novel gene, CL-20, that encodes a 17.8-kDa protein with sequence and structural similarity to the growth arrest specific gene gas3/peripheral myelin protein gene PMP22. The CL-20 protein exhibits a 43% identity with PMP22. The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. The CL-20 gene is located on human chromosome 12 rather than 17 and encodes a 2.8-kilobase mRNA instead of 1.7-kilobase mRNA. These observations indicate that the CL-20 gene is related to but distinct from PMP22. In contrast to PMP22, CL-20 mRNA and protein are induced during squamous differentiation of rabbit tracheal epithelial cells in vitro, and Northern blot analysis and in situ hybridization demonstrated that CL-20 mRNA is most abundant in squamous epithelia. These results indicate that the high expression of CL-20 is closely correlated with squamous differentiation. The differences in tissue-specific expression and regulation between CL-20 and PMP22 suggest different roles for these two proteins. Retinoids, which inhibit squamous differentiation, repress the induction of CL-20. The retinoic acid receptor selective retinoid SRI-6751-84 is the most effective in suppressing CL-20, suggesting that the activation of the retinoic acid receptor signaling pathway is important in this suppression.			MARVIN, KW (corresponding author), NIEHS,PULM PATHOBIOL LAB,CELL BIOL SECT,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445				BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DELEON M, 1991, J NEUROSCI RES, V29, P437; DELEON M, 1994, J NEUROSCI RES, V38, P167, DOI 10.1002/jnr.490380207; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V2, P387; DUGAICZYK AD, 1983, BIOCHEMISTRY-US, V2, P1605; ECKERT RL, 1989, ENVIRON HEALTH PERSP, V80, P109, DOI 10.2307/3430736; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FIELD MC, 1992, J NEUROCHEM, V58, P993, DOI 10.1111/j.1471-4159.1992.tb09353.x; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUJIMOTO W, 1993, J INVEST DERMATOL, V101, P268, DOI 10.1111/1523-1747.ep12365200; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HAMMER JA, 1993, J NEUROSCI RES, V35, P546, DOI 10.1002/jnr.490350511; HARRIS CC, 1973, J NATL CANCER I, V48, P743; HOLBROOK KA, 1983, J INVEST DERMATOL, V81, P125; ILYAS AA, 1986, BRAIN RES, V385, P1, DOI 10.1016/0006-8993(86)91540-4; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1991, AM J PHYSIOL, V260, pL361, DOI 10.1152/ajplung.1991.260.6.L361; JETTEN AM, 1987, LAB INVEST, V56, P654; JETTEN AM, 1992, CELL GROWTH DIFFER, V3, P549; JETTEN AM, 1986, J BIOL CHEM, V261, P5097; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; Martinotti Alessia, 1992, Human Molecular Genetics, V1, P331, DOI 10.1093/hmg/1.5.331; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; PHELPS WC, 1987, J VIROL, V6, P1630; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; QUARLES RH, 1989, NEUROBIOLOGY GLYCOCO, P243; RAO BB, 1993, NAT GENET, V5, P269; REARICK JI, 1987, J BIOL CHEM, V262, P13069; RIOPELLE RJ, 1986, BRAIN RES, V367, P20, DOI 10.1016/0006-8993(86)91573-8; RUSSNAK R, 1990, GENE DEV, V4, P764, DOI 10.1101/gad.4.5.764; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; STELLMACH V M, 1989, New Biologist, V1, P305; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; SUTER U, 1992, NAT NEW GENET, V1, P159; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; VOLLBERG TM, 1992, MOL ENDOCRINOL, V6, P667, DOI 10.1210/mend.6.5.1318502; VOLLBERG TM, 1991, EXP CELL RES, V193, P93, DOI 10.1016/0014-4827(91)90542-3; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WONG YC, 1971, LAB INVEST, V24, P55	56	50	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28910	28916		10.1074/jbc.270.48.28910	http://dx.doi.org/10.1074/jbc.270.48.28910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499420	hybrid			2022-12-25	WOS:A1995TH05600064
J	TORRIGLIA, A; CHAUDUN, E; CHANYFOURNIER, F; JEANNY, JC; COURTOIS, Y; COUNIS, MF				TORRIGLIA, A; CHAUDUN, E; CHANYFOURNIER, F; JEANNY, JC; COURTOIS, Y; COUNIS, MF			INVOLVEMENT OF DNASE-II IN NUCLEAR DEGENERATION DURING LENS CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEASE-II; POLYACRYLAMIDE-GEL; APOPTOSIS; DEGRADATION; PROTEINS; DEATH; IDENTIFICATION; PURIFICATION; THYMOCYTES; ACTIVATION	The characterization of DNase II and DNase I activity was undertaken to discriminate their different roles in physiological nuclear degradation during lens fiber cell differentiation. The activity of both nucleases determined in a new assay allows to discriminate DNase II from DNase I in the same extract, In fibers, both types of nuclease activities are found and appear higher than in epithelial cells. Specific polyclonal antibodies directed against these two nucleases reveal by Western blot analysis the presence of various DNase isoforms, DNase II like-nuclease, present in fibers, is represented by three major bands (60, 23, and 18 kDa), which are not detected, at least for two of them (60 and 23 kDa), in epithelial cells, DNase I like nuclease pattern in fiber cells shows a single 32-kDa band, while several bands can be detected in epithelial cells, Immunocytochemistry studies show both nucleases present in lens cell sections, DNase II is, as usual, in cytoplasm of epithelial cells, but it appears strikingly concentrated in the nuclei of fibers, DNase I is always concentrated in nuclei of epithelial and fiber cells, DNA degradation observed in agarose gels shows that DNase II-activating medium cleaves the DNA from fiber cells more efficiently than DNase I-activating buffer, In addition, DNase II antibody is able to prevent this degradation, These results suggest a specific involvement of DNase II in nuclear degradation during lens cell differentiation.	ASSOC CLAUDE BERNARD,INSERM,XR118,F-75016 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Torriglia, Alicia/Q-3509-2019; Torriglia, Alicia/L-6957-2017	Torriglia, Alicia/0000-0003-1181-6710; 				APPLEBY DW, 1977, P NATL ACAD SCI USA, V74, P5579, DOI 10.1073/pnas.74.12.5579; Arruti C, 1995, Cell Death Differ, V2, P47; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Bernardi G., 1971, HYDROLYSIS, P271; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; CHAUDUN E, 1994, J CELL PHYSIOL, V158, P354, DOI 10.1002/jcp.1041580218; COUNIS MF, 1989, CELL DIFFER DEV, V27, P137, DOI 10.1016/0922-3371(89)90743-0; COUNIS MF, 1989, INT J BIOCHEM, V21, P235, DOI 10.1016/0020-711X(89)90181-X; COUNIS MF, 1977, DEV BIOL, V57, P47, DOI 10.1016/0012-1606(77)90353-0; Eastman A, 1994, Cell Death Differ, V1, P7; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; Hughes F M Jr, 1994, Cell Death Differ, V1, P11; KIM HS, 1982, ANAL BIOCHEM, V119, P96, DOI 10.1016/0003-2697(82)90671-6; LACKS SA, 1981, J BIOL CHEM, V256, P2644; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESCA P, 1968, NATURE, V220, P76, DOI 10.1038/220076a0; LIAO TH, 1989, BIOCHIM BIOPHYS ACTA, V1007, P15, DOI 10.1016/0167-4781(89)90124-3; LOCKSHIN RA, 1990, J GERONTOL, V45, P135; MANNHERZ HG, 1992, J BIOL CHEM, V267, P11661; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MODAK S. P., 1976, BIOL EPITHELIAL LENS, V60, P105; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; MOORE S, 1981, ENZYMES A, V14, P281; MUEL AS, 1986, J CELL PHYSIOL, V127, P167, DOI 10.1002/jcp.1041270120; Peitsch M C, 1994, Cell Death Differ, V1, P1; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PRICE PA, 1969, J BIOL CHEM, V244, P917; RAMOTAR D, 1987, J BIOL CHEM, V262, P425; ROCHE J, 1992, EXP EYE RES, V55, P183, DOI 10.1016/0014-4835(92)90107-4; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; SANWAL M, 1986, EXP CELL RES, V167, P429, DOI 10.1016/0014-4827(86)90183-7; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SLOR H, 1973, BIOCHEM BIOPH RES CO, V52, P556, DOI 10.1016/0006-291X(73)90748-1; SLOR H, 1971, BIOCHEM J, V123, P993, DOI 10.1042/bj1230993; SWANSON AA, 1966, EXP EYE RES, V5, P145, DOI 10.1016/S0014-4835(66)80030-1; TORRIGLIA A, 1994, NEUROSCIENCE, V60, P969, DOI 10.1016/0306-4522(94)90276-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YASUDA T, 1992, BIOCHIM BIOPHYS ACTA, V1119, P185, DOI 10.1016/0167-4838(92)90390-Y; ZOTIKOV L, 1970, J ULTRA MOL STRUCT R, V30, P642, DOI 10.1016/S0022-5320(70)90057-2	43	98	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28579	28585		10.1074/jbc.270.48.28579	http://dx.doi.org/10.1074/jbc.270.48.28579			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499373	hybrid			2022-12-25	WOS:A1995TH05600017
J	SINGH, K; BALLIGAND, JL; FISCHER, TA; SMITH, TW; KELLY, RA				SINGH, K; BALLIGAND, JL; FISCHER, TA; SMITH, TW; KELLY, RA			GLUCOCORTICOIDS INCREASE OSTEOPONTIN EXPRESSION IN CARDIAC MYOCYTES AND MICROVASCULAR ENDOTHELIAL-CELLS - ROLE IN REGULATION OF INDUCIBLE NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; RAT-KIDNEY CELLS; PHYSIOLOGICAL-PROPERTIES; NONPHOSPHORYLATED FORMS; MESSENGER-RNA; INDUCTION; BONE; GENE; GLYCOPROTEIN; PROMOTER	In heart muscle, the cytokine-inducible isoform of nitric oxide synthase (NOS2) is expressed in both cardiac myocytes and microvascular endothelial cells (CMEC). mRNA levels for both NOS2 and for osteopontin, a multifunctional extracellular matrix phosphoprotein containing an RGD integrin binding domain, are increased in cardiac muscle following intraperitoneal injection of adult rats with lipopolysaccharide. In vitro, interleukin- 1-beta and interferon-gamma increased osteopontin mRNA levels in CMEC as well as NOS2 expression in both CMEC and cardiac myocytes. However, osteopontin mRNA levels in heart muscle in vivo, and in cardiac myocytes and CMEC in vitro, also are increased 10-30-fold by the synthetic glucocorticoid dexamethasone, an agent that suppresses cytokine induction of NOS2 in both cell types. The hexapeptide GRGDSP, which interrupts binding of RGD-containing proteins to cell surface integrins, increased NOS2 mRNA, while a synthetic osteopontin peptide analogue decreased NOS2 mRNA and protein levels in both cytokine-pretreated cardiac myocytes and CMEC cultures. Also, transfection with a full-length antisense-osteopontin cDNA in cytokine-pretreated CMEC decreased endogenous osteopontin mRNA and increased NOS2 mRNA levels. These results suggest that osteopontin could regulate the location and extent of NOS2 induction in the heart. Increased expression of osteopontin also may be one mechanism by which glucocorticoids suppress NOS2 activity in cardiac myocytes and microvascular endothelial cells.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Balligand, Jean-Luc J/D-7543-2012	BALLIGAND, Jean-Luc/0000-0002-0522-4156	NHLBI NIH HHS [R37-HL36141, IP50-HL52320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141, P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLIGAND JL, 1995, AM J PHYSIOL-HEART C, V268, pH1293, DOI 10.1152/ajpheart.1995.268.3.H1293; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BENINATI S, 1993, J BIOCHEM-TOKYO, V114, P702; BERGER HJ, 1994, AM J PHYSIOL, V266, pH41; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; BUTTER WT, 1989, CONNECT TISSUE RES, V23, P123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GIACHELLI CM, 1995, TRENDS CARDIOVAS MED, V5, P88, DOI 10.1016/1050-1738(95)00005-T; HWANG S, 1994, J BIOL CHEM, V269, P711; JIN CH, 1990, MOL CELL ENDOCRINOL, V74, P221; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; MURRY CE, 1994, AM J PATHOL, V145, P1450; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; NODA M, 1988, J BIOL CHEM, V263, P13916; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PERRELLA MA, 1994, J BIOL CHEM, V269, P27045; PINSKY DJ, 1995, J CLIN INVEST, V95, P677, DOI 10.1172/JCI117713; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1992, J BIOL CHEM, V267, P23847; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P486, DOI 10.1161/01.RES.77.3.486; UNGUREANULONGROIS D, 1995, J MOL CELL CARDIOL, V27, P155, DOI 10.1016/S0022-2828(08)80015-6; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; WILLIAMS EB, 1995, CIRCULATION, V92, P705, DOI 10.1161/01.CIR.92.4.705; YANG XC, 1994, J CLIN INVEST, V94, P714, DOI 10.1172/JCI117390; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; ZHANG Q, 1992, EUR J BIOCHEM, V207, P649, DOI 10.1111/j.1432-1033.1992.tb17092.x	45	118	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28471	28478						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499354				2022-12-25	WOS:A1995TG21000079
J	SURREY, T; JAHNIG, F				SURREY, T; JAHNIG, F			KINETICS OF FOLDING AND MEMBRANE INSERTION OF A BETA-BARREL MEMBRANE-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECONSTITUTION; RENATURATION; INTERMEDIATE; OMPA	We have studied the kinetics of folding and membrane insertion of the outer membrane protein OmpA of Escherichia coli. In the native structure, its membrane-inserted domain forms a beta-barrel. The protein was unfolded in solubilized form in water/urea, and refolding was induced by dilution of urea and simultaneous addition of lipid vesicles, Three transitions along the folding pathway could be distinguished. Their characteristic times lie below a second, in the range of minutes, and in the range of an hour. The fast process corresponds to the transition from the unfolded state in water/urea to a misfolded state in water, the moderately slow process to a transition from the misfolded state to a partially folded state in the membrane, and the slow process to the transition from the partially folded to the native state. The partially folded state in the membrane is interpreted as the analogue of the molten globule state of soluble proteins.	MAX PLANCK INST BIOL, MEMBRANBIOCHEM ABT, D-72076 TUBINGEN, GERMANY	Max Planck Society			Surrey, Thomas/AAC-4608-2021	Surrey, Thomas/0000-0001-9082-1870				BOOTH PJ, 1995, NAT STRUCT BIOL, V2, P139, DOI 10.1038/nsb0295-139; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; DORNMAIR K, 1990, J BIOL CHEM, V265, P18907; EISELE JL, 1990, J BIOL CHEM, V265, P10217; Engelman DM, 1984, PROTEIN FOLDING PROB, P87; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FREUDL R, 1986, J BIOL CHEM, V261, P1355; Garel Jean-Renaud, 1992, P405; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HUANG KS, 1981, J BIOL CHEM, V256, P3802; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Schmid Franz X., 1992, P197; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; SCOTTO AW, 1985, BIOCHEMISTRY-US, V24, P4066, DOI 10.1021/bi00336a040; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WEI J, 1995, BIOCHEMISTRY-US, V34, P6408, DOI 10.1021/bi00019a021	20	102	103	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28199	28203						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499313				2022-12-25	WOS:A1995TG21000038
J	XIE, WL; HERSCHMAN, HR				XIE, WL; HERSCHMAN, HR			V-SRC INDUCES PROSTAGLANDIN SYNTHASE-2 GENE-EXPRESSION BY ACTIVATION OF THE C-JUN N-TERMINAL KINASE AND THE C-JUN TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE; SIGNAL-TRANSDUCTION; MESSENGER-RNA; SARCOMA VIRUS; PROTEIN; PHOSPHORYLATION; TYROSINE; FOS; CYCLOOXYGENASE; RECONSTITUTION	A consensus cyclic AMP response element (CRE) in the murine prostaglandin synthase-2 (PGS2) promoter is essential for pgs2 gene expression induced by pp60(v-src) the v-src oncogene product. In this study, we investigate (i) the transcription factors active at the PGS2 ''CRE site'' in response to v-src activation and (ii) the signal transduction pathways by which pp60(v-src) activates these transcription factors. Transient transfection assays with pgs2 promoter/luciferase reporter chimeric genes suggest that c-Jun mediates v-src-induced pgs2 gene expression. Antibody supershift experiments demonstrate that c-Jun can participate in a complex with the pgs2 promoter CRE site. Moreover, in vitro immunocomplex assays demonstrate that pp60(v-src) expression strongly activates c-Jun N-terminal kinase (JNK1) enzyme activity, Serines 63 and 73, the sites of c-Jun phosphorylation by JNK, are essential for v-src-induced, pgs2 promoter mediated luciferase expression. Cotransfection studies with plasmids expressing wild-type JNK, dominant-negative JNK, and dominant-negative MEKK-1 confirm that activation of the Ras/MEKK-1/JNK/c-Jun pathway is required for v-src-induced pgs2 gene expression. Overexpression of either wild type ERK-1 or ERK-2 proteins also potentiate v-src-mediated luciferase expression driven by the pgs2 promoter, and expression of dominant-negative mutants of ERK-1, ERK-2, or Raf-1 attenuate this response. Thus, in response to v-src expression, a Ras/MEKK-1/JNK signal transduction pathway activating c-Jun and a Ras/Raf-1/ERK pathway converge to mediate pgs2 gene expression via the CRE site in the pgs2 promoter.	UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT PHARMACOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BARKER K, 1989, J VIROL, V63, P2929, DOI 10.1128/JVI.63.7.2929-2935.1989; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; CAHILL MA, 1994, FEBS LETT, V344, P105, DOI 10.1016/0014-5793(94)00320-3; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOW KG, 1994, MOL CELL BIOL, V14, P4959; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEL AE, 1994, J IMMUNOL, V152, P4347; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531	45	289	300	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27622	27628		10.1074/jbc.270.46.27622	http://dx.doi.org/10.1074/jbc.270.46.27622			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499226	hybrid			2022-12-25	WOS:A1995TE73600037
J	YANG, Y; FRUH, K; AHN, K; PETERSON, PA				YANG, Y; FRUH, K; AHN, K; PETERSON, PA			IN-VIVO ASSEMBLY OF THE PROTEASOMAL COMPLEXES, IMPLICATIONS FOR ANTIGEN-PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; LINKED LMP GENE; MULTICATALYTIC PROTEINASE; HUMAN MHC; SUBUNITS; EXPRESSION; PHOSPHORYLATION; INTERFERON; REGION	The multicatalytic and multisubunit proteasomal complexes have been implicated in the processing of antigens to peptides presented by class I major histocompatibility complex molecules, Two structural complexes of this proteinase, 20 S and 26 S proteasomes, have been isolated from cells. Ey analyzing in vivo assembly of the proteasomal complexes we show that the 20 S proteasomal complexes are irreversibly assembled via 15 S assembly intermediates containing unprocessed beta-type subunits, The 20 S proteasomes further associate reversibly with proteasome activators PA28 or pre-existing ATPase complexes to form 26 S proteasomal complexes, Our findings that not all of the 20 S proteasomal complexes are assembled into 26 S proteasomal complexes within cells and that all of PA28 and ATPase complexes are associated with 20 S proteasomes strongly suggest that all proteasomal complexes coexist within cells, We further demonstrate that 26 S proteasomal complexes are predominantly present in the cytoplasm and a significant portion of the 20 S proteasomal complexes is associated with the endoplasmic reticulum membrane, Taken together, our findings suggest that depending upon their associated regulatory components, 26 S and 20 S-PA28 proteasomal complexes serve different housekeeping functions within the cells, while they degrade antigens in a cooperative manner in antigen processing.			YANG, Y (corresponding author), SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.			Frueh, Klaus/0000-0001-8014-3877				AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DEMARTINO GN, 1993, ENZYME PROTEIN, V47, P314, DOI 10.1159/000468689; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; ETLINGER JD, 1993, ENZYME PROTEIN, V47, P325, DOI 10.1159/000468690; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; FRUH K, 1992, J BIOL CHEM, V267, P22131; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; JACKSON MR, 1993, ANNU REV CELL BIOL, V9, P207, DOI 10.1146/annurev.cb.09.110193.001231; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MOTT JD, 1994, J BIOL CHEM, V269, P31466; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PATEL SD, 1994, P NATL ACAD SCI USA, V91, P296, DOI 10.1073/pnas.91.1.296; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1990, BIOCHEMISTRY-US, V29, P3777, DOI 10.1021/bi00467a026; TECTOR M, 1994, J BIOL CHEM, V269, P25816; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WOONGKYUNG S, 1994, SCIENCE, V264, P1322; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YANG Y, 1992, J BIOL CHEM, V267, P11669; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	46	174	176	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27687	27694		10.1074/jbc.270.46.27687	http://dx.doi.org/10.1074/jbc.270.46.27687			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499235	hybrid			2022-12-25	WOS:A1995TE73600046
J	BATTISTA, S; MARTELLI, ML; FEDELE, M; CHIAPPETTA, G; TRAPASSO, F; DEVITA, G; BATTAGLIA, C; SANTORO, M; VIGLIETTO, G; FAGIN, JA; FUSCO, A				BATTISTA, S; MARTELLI, ML; FEDELE, M; CHIAPPETTA, G; TRAPASSO, F; DEVITA, G; BATTAGLIA, C; SANTORO, M; VIGLIETTO, G; FAGIN, JA; FUSCO, A			A MUTATED P53 GENE ALTERS THYROID-CELL DIFFERENTIATION	ONCOGENE			English	Article						P53; THYROID; DIFFERENTIATION	WILD-TYPE P53; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; THYROGLOBULIN PROMOTER; THYROTROPIN RECEPTOR; MAMMALIAN-CELLS; MESSENGER-RNA; DNA-BINDING; EXPRESSION; MUTATIONS	p53 is the gene most frequently found mutated in human neoplasias. In the majority of tumors, p53 mutations contribute to the progression towards stages of increasing malignancy with the appearance of an undifferentiated phenotype. Also in thyroid cancerogenesis, p53 mutations correlate with the loss of the differentiated phenotype. The results presented here, suggest a direct involvement of p53 in the molecular mechanisms regulating cellular differentiation in thyroid since a mutated p53 gene markedly affects the growth potential and differentiated functions of the rat thyroid cell line PC Cl 3. Blockage in the expression of the PAX-8 transcription factor seems to be a key event in the loss of thyroid differentiated functions induced by the mutated p53 gene. Thyroid cells carrying a mutated p53 gene did not form colonies in soft agar or tumors in athymic mice, suggesting that a mutation of the p53 gene is not sufficient for the induction of the malignant phenotype and probably a cooperation with other oncogenes is necessary to accomplish full malignancy. No effect on either growth or differentiation of thyroid cells was exerted either by overexpression of the wild-type p53 gene, or by the vector alone.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; FDN PASCALE,IST NAZL TUMORI,I-80131 NAPLES,ITALY; UNIV NAPLES,FAC MED & CHIRURG NAPOLI,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV ENDOCRINOL,LOS ANGELES,CA 90048	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Fedele, Monica/C-1417-2015; Battista, Sabrina/AAY-2981-2020; De Vita, Gabriella/H-4422-2011; Viglietto, Giuseppe/AAC-2852-2019	Fedele, Monica/0000-0002-9171-1312; Battista, Sabrina/0000-0001-5899-9759; De Vita, Gabriella/0000-0002-7302-1174; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; AVVEDIMENTO VE, 1988, P NATL ACAD SCI USA, V85, P1744, DOI 10.1073/pnas.85.6.1744; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1990, ONCOGENE, V5, P893; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOBASHI Y, 1993, AM J SURG PATHOL, V14, P375; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; FUSCO A, 1981, CANCER RES, V42, P618; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ITO T, 1992, CANCER RES, V52, P1369; KERN SE, 1991, ONCOGENE, V6, P131; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LI FP, 1988, CANCER RES, V48, P5358; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; NAKAMURA T, 1992, JPN J CANCER RES, V83, P1293, DOI 10.1111/j.1349-7006.1992.tb02761.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J, 1989, MOL CLONING LABORATO; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WRIGHT PA, 1991, ONCOGENE, V6, P1693; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZARRILLI R, 1990, MOL ENDOCRINOL, V4, P39, DOI 10.1210/mend-4-1-39; ZHANG W, 1993, ONCOGENE, V8, P2555	55	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2029	2037						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478522				2022-12-25	WOS:A1995TF29700013
J	SOROKIN, A				SOROKIN, A			ACTIVATION OF THE EGF RECEPTOR BY INSERTIONAL MUTATIONS IN ITS JUXTAMEMBRANE REGIONS	ONCOGENE			English	Article						EGF RECEPTOR; DIMERIZATION; TRANSFORMATION	EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; TRANSMEMBRANE DOMAIN; EXTRACELLULAR DOMAIN; LIGAND-BINDING; SIGNAL TRANSDUCTION; NEU ONCOGENE; SURFACE-RECEPTORS; CARCINOMA-CELLS; POINT MUTATION	Ligand dependent activation of receptor tyrosine kinases is mediated by an allosteric dimerization process that is responsible for the stimulation of protein tyrosine kinase activity and receptor autophosphorylation. In order to gain further insight into the processes which control this process, we have generated EGF receptor mutants that contain inserts of 20-40 amino acids in their juxtamembrane regions, on each side of the receptor's single transmembrane domain. An EGF receptor mutant with an insertion on the cytoplasmic side of the transmembrane domain exhibited typical EGF binding characteristics, ligand-dependent tyrosine autophosphorylation, as web as ligand-induced DNA synthesis. However, an EGF receptor mutant with an insertion on both sides of the transmembrane domain was found to be constitutively activated. This mutant also exhibited dramatically reduced EGF binding, but dimerized and had enhanced tyrosine kinase activity even in the absence of ligand. Moreover, NIH3T3 cells expressing this mutant receptor formed colonies in soft agar in the absence of EGF. This represents a novel example of a constitutively activated receptor, and provides further support for receptor dimerization as a mechanism for activation of EGFR and other receptor tyrosine kinases.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University				Sorokin, Andrey/0000-0002-5660-0190				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; CAO HN, 1992, J BIOL CHEM, V267, P20489; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CARPENTER G, 1989, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COCHET C, 1988, J BIOL CHEM, V263, P3290; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; HALEY JD, 1989, ONCOGENE, V4, P273; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAZAN R, 1995, J CELL PHYSIOL, V162, P74, DOI 10.1002/jcp.1041620110; HILLMAN GM, 1982, BIOCHEMISTRY-US, V21, P1667, DOI 10.1021/bi00536a030; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1990, CELL REGUL, V1, P173, DOI 10.1091/mbc.1.2.173; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RIZZINO A, 1987, METHOD ENZYMOL, V146, P341; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SOROKIN AB, 1988, DOKL AKAD NAUK SSSR+, V300, P974; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAIMUN L, 1990, P NATL ACAD SCI USA, V87, P7270; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZIDOVETZKI R, 1981, P NATL ACAD SCI-BIOL, V78, P6981, DOI 10.1073/pnas.78.11.6981	54	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1531	1540						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478577				2022-12-25	WOS:A1995TC53500011
J	WU, LW; HACKETT, PB				WU, LW; HACKETT, PB			DEVELOPMENT OF CELLULAR-RESISTANCE TO PP60(V-SRC) KINASE-INDUCED CELL-DEATH	ONCOGENE			English	Article						CYTOTOXICITY; PP60(V-SRC) OVEREXPRESSION; TYROSINE KINASE	ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE PHOSPHATASES; HEAT-SHOCK; V-SRC; GENE-EXPRESSION; C-SRC; TRANSFORMING GENE; MAMMALIAN-CELLS; PHOSPHORYLATION; FIBROBLASTS	The v-src gene of Rous sarcoma virus (RSV) encodes pp60(v-src) a tyrosine kinase that can initiate cellular transformation. High levels of v-src gene expression can either be cytotoxic or the cause of altered expression of cellular genes, Examination of cytotoxic thresholds is difficult because cells expressing high levels of a cytotoxic oncogene will die. To evaluate quantitatively the cytotoxicity of pp60(v-src) on growth, we amplified two different v-src genes, under the control of the human hsp70B heat shock promoter to establish cell clones with varying copy numbers of the heat-inducible v-src gene. The viability of cell lines over a prolonged period of time depended on the particular src gene, the expression of v-src mRNA, synthesis of the pp60(v-src) protein and, most importantly, the tyrosine kinase activity of the pp60(v-src) protein. We found a relatively sharp threshold in v-src-encoded tyrosine kinase activity above which cell viability rapidly declines. However, over time, tyrosine kinase activity was exponentially suppressed at about a 10-fold higher rate than pp60(v-src) protein during passage. Our results indicate that homeostasis: of tyrosine phosphorylation is important for cell viability, that perturbation of this balance results in cell mortality, and that cells can evolve to accommodate overexpression of oncogene by downregulating the level of tyrosine kinase activity.	UNIV MINNESOTA, DEPT GENET & CELL BIOL, ST PAUL, MN 55108 USA; UNIV MINNESOTA, INST HUMAN GENET, ST PAUL, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [R01 CA 1983881] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELGHANY M, 1990, P NATL ACAD SCI USA, V87, P7061, DOI 10.1073/pnas.87.18.7061; ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BISHOP JM, 1982, RNA TUMOR VIRUS MOL, P1001; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEWEY WC, 1971, INT J RADIAT BIOL RE, V20, P505, DOI 10.1080/09553007114551421; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FORNACE AJ, 1989, EXP CELL RES, V182, P61, DOI 10.1016/0014-4827(89)90279-6; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOSKINS JM, 1956, EXP CELL RES, V11, P297, DOI 10.1016/0014-4827(56)90105-7; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKS CM, 1988, NUCLEIC ACIDS RES, V16, P10751, DOI 10.1093/nar/16.22.10751; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIU ZJ, 1989, NUCLEIC ACIDS RES, V17, P3986, DOI 10.1093/nar/17.10.3986; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MOUSTAKAS A, 1993, J VIROL, V67, P4337, DOI 10.1128/JVI.67.7.4337-4349.1993; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PETERSEN RB, 1989, J VIROL, V63, P4787, DOI 10.1128/JVI.63.11.4787-4796.1989; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SCHLESINGER MJ, 1989, STRESS INDUCED PROTE, P137; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STOLTZFUS CM, 1987, J VIROL, V61, P3401, DOI 10.1128/JVI.61.11.3401-3409.1987; TARPLEY WG, 1984, MOL CELL BIOL, V4, P2653, DOI 10.1128/MCB.4.12.2653; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VOELLMY R, 1985, P NATL ACAD SCI USA, V82, P4949, DOI 10.1073/pnas.82.15.4949; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; WU LW, 1993, THESIS U MINNESOTA; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	69	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1459	1468						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478570				2022-12-25	WOS:A1995TC53500004
J	MIYAMOTO, CM; BOYLAN, M; GRAHAM, AF; MEIGHEN, EA				MIYAMOTO, CM; BOYLAN, M; GRAHAM, AF; MEIGHEN, EA			ORGANIZATION OF THE LUX STRUCTURAL GENES OF VIBRIO-HARVEYI - EXPRESSION UNDER THE BACTERIOPHAGE-T7 PROMOTER, MESSENGER-RNA ANALYSIS, AND NUCLEOTIDE-SEQUENCE OF THE LUXD GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University								BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BELAS R, 1982, SCIENCE, V218, P791, DOI 10.1126/science.10636771; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLINE TW, 1972, BIOCHEMISTRY-US, V11, P3359, DOI 10.1021/bi00768a008; COHN DH, 1985, J BIOL CHEM, V260, P6139; COHN DH, 1983, P NATL ACAD SCI-BIOL, V80, P120, DOI 10.1073/pnas.80.1.120; ENGEBRECHT J, 1984, P NATL ACAD SCI-BIOL, V81, P4154, DOI 10.1073/pnas.81.13.4154; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1982, MOL CLONING LABORATO; McKenney K, 1981, Gene Amplif Anal, V2, P383; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIYAMOTO C, 1987, J BACTERIOL, V169, P247, DOI 10.1128/jb.169.1.247-253.1987; MIYAMOTO C, 1986, METHOD ENZYMOL, V133, P70; MIYAMOTO CM, 1985, J BACTERIOL, V161, P995, DOI 10.1128/JB.161.3.995-1001.1985; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; ULITZUR S, 1978, P NATL ACAD SCI USA, V75, P266, DOI 10.1073/pnas.75.1.266; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WALL LA, 1984, J BACTERIOL, V159, P720, DOI 10.1128/JB.159.2.720-724.1984	26	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13393	13399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417663				2022-12-25	WOS:A1988Q091700093
J	POTEMPA, J; DUBIN, A; KORZUS, G; TRAVIS, J				POTEMPA, J; DUBIN, A; KORZUS, G; TRAVIS, J			DEGRADATION OF ELASTIN BY A CYSTEINE PROTEINASE FROM STAPHYLOCOCCUS-AUREUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; JAGIELLONIAN UNIV, INST MOLEC BIOL, PL-31120 Krakow, POLAND	University System of Georgia; University of Georgia; Jagiellonian University								ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ARVIDSON S, 1973, BIOCHIM BIOPHYS ACTA, V302, P135, DOI 10.1016/0005-2744(73)90016-8; ARVIDSON SO, 1983, STAPHYLOCOCCI STAPHY, P745; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Bieth J., 1974, BAYER S, P463; BIETH JG, 1980, CLIN RES PROC, V16, P183; Bieth JG, 1986, REGULATION MATRIX AC, P217; BJORKLIND A, 1977, ACTA PATH MICRO IM B, V85, P277; DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720; DRAPEAU GR, 1978, J BACTERIOL, V136, P607, DOI 10.1128/JB.136.2.607-613.1978; DUBIN A, 1984, BIOCHEM INT, V8, P589; GOUNARIS AD, 1984, BIOCHEM J, V221, P445, DOI 10.1042/bj2210445; HARTMAN DP, 1977, INFECT IMMUN, V15, P59, DOI 10.1128/IAI.15.1.59-65.1977; HOWARD JB, 1983, ANN NY ACAD SCI, V421, P160, DOI 10.1111/j.1749-6632.1983.tb18106.x; HUMMEL BCW, 1959, CAN J BIOCHEM PHYS, V37, P1393, DOI 10.1139/o59-157; JANDA JM, 1986, J CLIN MICROBIOL, V24, P945, DOI 10.1128/JCM.24.6.945-946.1986; JANOFF A, 1977, AM REV RESPIR DIS, V116, P65; JANOFF A, 1985, ANNU REV MED, V36, P207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDL I, 1960, ARCH BIOCHEM BIOPHYS, V91, P47, DOI 10.1016/0003-9861(60)90453-7; MANDL I, 1962, P SOC EXP BIOL MED, V109, P923; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MIYAZAKI S, 1984, MICROBIOL IMMUNOL, V28, P1083, DOI 10.1111/j.1348-0421.1984.tb00765.x; MORIHARA K, 1967, ARCH BIOCHEM BIOPHYS, V120, P68, DOI 10.1016/0003-9861(67)90599-1; MURPHY RA, 1974, J DENT RES, V53, P832, DOI 10.1177/00220345740530041101; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; PAVLOVSKIS OR, 1979, INFECT IMMUN, V24, P181, DOI 10.1128/IAI.24.1.181-187.1979; POTEMPA J, 1986, J BIOL CHEM, V261, P14330; RIPPON JW, 1968, J INVEST DERMATOL, V50, P54, DOI 10.1038/jid.1968.8; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1368, DOI 10.1056/NEJM198405243102107; STEWART DJ, 1979, RES VET SCI, V27, P99, DOI 10.1016/S0034-5288(18)32866-2; SUEYOSHI T, 1985, FEBS LETT, V182, P193, DOI 10.1016/0014-5793(85)81182-0; TASHIRO M, 1987, VIROLOGY, V157, P421, DOI 10.1016/0042-6822(87)90284-4; TASHIRO M, 1987, NATURE, V325, P536, DOI 10.1038/325536a0; TWING SS, 1983, ANAL BIOCHEM, V143, P30; VARADI DP, 1970, BRIT J DERMATOL, V83, P143, DOI 10.1111/j.1365-2133.1970.tb12875.x; VARADI DP, 1968, NATURE, V218, P468, DOI 10.1038/218468a0; WERB Z, 1982, J INVEST DERMATOL, V79, pS154, DOI 10.1111/1523-1747.ep12546056; WOODS DE, 1982, INFECT IMMUN, V36, P1223, DOI 10.1128/IAI.36.3.1223-1228.1982	39	95	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1988	263	6					2664	2667						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M2161	3422637				2022-12-25	WOS:A1988M216100016
J	DALLMANN, HG; MCHENRY, CS				DALLMANN, HG; MCHENRY, CS			DNAX COMPLEX OF ESCHERICHIA-COLI DNA-POLYMERASE-III HOLOENZYME - PHYSICAL CHARACTERIZATION OF THE DNAX SUBUNITS AND COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEINS; GAMMA; TAU; PRODUCTS	A physical characterization of the tau and gamma subunits of the Escherichia coli DNA polymerase III holoenzyme and their complexes with the Delta, delta', chi, and psi subunits is presented, The native molecular mass of the tau and gamma subunits was determined to be 255,000 and 189,000 Da, respectively, by sedimentation equilibrium analytical ultracentrifugation. Bath values indicate a tetrameric quaternary structure. The tau and gamma complexes were reconstituted and purified using two different methods. Both complexes assembled readily and were reconstituted at subunit concentrations approaching physiological levels. The stoichiometries of the tau and gamma complexes, as determined by quantitative densitometry of SDS-polyacrylamide gels, were found to be tau(4) delta(1) delta'(1) chi(1) psi(1), and gamma(4) delta(1) delta'(1) chi(1) psi(1). BIAcore(TM) analysis demonstrated that the formation of large multiprotein complexes of holoenzyme subunits depends on the presence of the tau subunit; gamma could not substitute, We present a model for a gamma-less form of DNA polymerase III holoenzyme that has asymmetrical structural features that may be responsible for the functional asymmetry observed in holoenzyme, The stoichiometry of the reconstituted DNA polymerase III* component of holoenzyme in this model is (alpha epsilon theta)(2)DnaX(4) delta(1) delta'(1) chi(1) psi(1).	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOLEC BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FAY PJ, 1982, J BIOL CHEM, V257, P5692; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; INGRAHAM J, 1983, GROWTH BACTERIAL CEL, P269; MAKI S, 1988, J BIOL CHEM, V263, P6555; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; Malmqvist Magnus, 1994, Methods (Orlando), V6, P95, DOI 10.1006/meth.1994.1012; MCHENRY C, 1981, ENZYMES, V14, P39; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MINTON AP, 1990, ANAL BIOCHEM, V190, P1, DOI 10.1016/0003-2697(90)90125-S; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; ODONNELL M, 1994, ANN NY ACAD SCI, V726, P144, DOI 10.1111/j.1749-6632.1994.tb52806.x; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; SCHACHMAN HK, 1989, NATURE, V341, P259, DOI 10.1038/341259a0; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; XIAO H, 1993, J BIOL CHEM, V268, P11773; [No title captured]	27	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29563	29569		10.1074/jbc.270.49.29563	http://dx.doi.org/10.1074/jbc.270.49.29563			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493999	hybrid			2022-12-25	WOS:A1995TJ22700080
J	IKEZU, T; OKAMOTO, T; GIAMBARELLA, U; YOKOTA, T; NISHIMOTO, I				IKEZU, T; OKAMOTO, T; GIAMBARELLA, U; YOKOTA, T; NISHIMOTO, I			IN-VIVO COUPLING OF INSULIN-LIKE GROWTH-FACTOR-II MANNOSE 6-PHOSPHATE RECEPTOR TO HETEROMERIC G-PROTEINS - DISTINCT ROLES OF CYTOPLASMIC DOMAINS AND SIGNAL SEQUESTRATION BY THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BALB/C 3T3 CELLS; IGF-II; BINDING PROTEINS; ADENYLYL CYCLASE; ALPHA-SUBUNITS; MANNOSE-6-PHOSPHATE; TRANSDUCTION; EXPRESSION; LINKAGE	We examined the signaling function of the IGF-II/mannose 6-phosphate receptor (IGF-IIR) by transfecting IGF-IIR cDNAs into COS cells, where adenylyl cyclase (AC) was inhibited by transfection of constitutively activated G alpha(i), cDNA (G alpha(i2)Q205L). In cells transfected with IGF-IIR cDNA, IGF-II decreased cAMP accumulation promoted by cholera toxin or forskolin. This effect of IGF-II was not observed in untransfected cells or in cells transfected with IGF-IIRs lacking Arg(2410)-Lys(2423). Thus, IGF-IIR, through its cytoplasmic domain, mediates the G(i)-linked action of IGF-II in living cells. We also found that IGF-IIR truncated with C-terminal 28 residues after Ser(2424) caused G beta gamma-dominant response of AC in response to IGF-II by activating G(i). Comparison with the G alpha(i)-dominant response of AC by intact IGF-IIR suggests that the C-terminal 28-residue region inactivates G beta gamma. This study not only provides further evidence that IGF-IIR has IGF-II-dependent signaling function to interact with heteromeric G proteins with distinct roles by different cytoplasmic domains, it also suggests that IGF-IIR can separate and sequestrate the G alpha and G beta gamma signals following G(i) activation.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,CARDIOVASC RES CTR,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,SHRINERS HOSP CRIPPLED CHILDREN,DEPT ANESTHESIA,BOSTON,MA 02114; UNIV TOKYO,INST MED SCI,DEPT STEM CELL REGULAT,MINATO KU,TOKYO 108,JAPAN	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Tokyo			Yokota, Takashi/J-8483-2015	Ikezu, Tsuneya/0000-0002-3979-8596				BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; DAMKE H, 1994, MOL CELL ENDOCRINOL, V99, pR25, DOI 10.1016/0303-7207(94)90026-4; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; HARI J, 1987, EMBO J, V6, P3367, DOI 10.1002/j.1460-2075.1987.tb02658.x; IKEZU T, 1994, J BIOL CHEM, V269, P31955; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOJIMA I, 1988, BIOCHEM BIOPH RES CO, V154, P9, DOI 10.1016/0006-291X(88)90642-0; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MATHIEU M, 1990, MOL ENDOCRINOL, V4, P1327, DOI 10.1210/mend-4-9-1327; MATSUNAGA H, 1988, AM J PHYSIOL, V255, pC442, DOI 10.1152/ajpcell.1988.255.4.C442; MAYER BJ, 1993, CELL, V72, P629; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; MOHAN S, 1989, J CELL PHYSIOL, V140, P169, DOI 10.1002/jcp.1041400120; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NEER EJ, 1990, G PROTEINS, P41; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, P NATL ACAD SCI USA, V88, P8020; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROGERS SA, 1988, P NATL ACAD SCI USA, V85, P4037, DOI 10.1073/pnas.85.11.4037; ROGERS SA, 1989, J BIOL CHEM, V264, P7962; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; TAKAHASHI K, 1993, P NATL ACAD SCI USA, V90, P11772, DOI 10.1073/pnas.90.24.11772; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YASUDA K, 1992, J BIOL CHEM, V267, P20422	38	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29224	29228		10.1074/jbc.270.49.29224	http://dx.doi.org/10.1074/jbc.270.49.29224			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493951	hybrid			2022-12-25	WOS:A1995TJ22700032
J	RICCI, A; LANFRANCONE, L; CHIARI, R; BELARDO, G; PERTICA, C; NATALI, PG; PELICCI, PG; SEGATTO, O				RICCI, A; LANFRANCONE, L; CHIARI, R; BELARDO, G; PERTICA, C; NATALI, PG; PELICCI, PG; SEGATTO, O			ANALYSIS OF PROTEIN-PROTEIN INTERACTIONS INVOLVED IN THE ACTIVATION OF THE SHC/GRB-2 PATHWAY BY THE ERBB-2 KINASE	ONCOGENE			English	Article						ERBB-2; SHC; GRBB-2; SIGNAL TRANSDUCTION	RECEPTOR TYROSINE KINASES; SH3 DOMAINS; SIGNAL TRANSDUCTION; EGF RECEPTOR; NEU ONCOGENE; RAS; GRB2; GENE; AUTOPHOSPHORYLATION; PHOSPHORYLATION	In murine fibroblasts activation of the Shc/Grb-2 pathway by the ErbB-2 kinase involves tyrosine phosphorylation of She products and the formation of Shc/ErbB-2, Shc/Grb-2 and Grb-2/ErbB-2 complexes. Tyr 1139 of ErbB-2 bound to the Grb-2 SH2 domain in vitro as well as in intact cells. Tyr 1221 and 1248 are binding sites of gp185(ErbB-2) for Shc SH2 domain in vitro whereas Tyr 1196 and 1248 are major binding sites of ErbB-2 for She PTB domain. Inhibition of Shc/ErbB-2 complex formation in intact cells was obtained by simultaneous mutational inactivation of She SH2 and She PTB binding sites of gp185(Erb-2). Shc/ErbB-2 complexes are formed upon activation of the ErbB-2 kinase and tyrosine phosphorylation of She proteins; they are located in both cytosol and cellular membranes. ErbB-2 activation induces also translocation of Grb-2 from cytosol to membranes. This network of protein-protein interactions may reflect the ability of the Shc/Grb-2 pathway to act as a molecular snitch controlling different cellular functions regulated by RTK activation. In fact the Ras GDP exchanger mSOS was recruited in Grb-2/ErbB-2 complexes; furthermore besides mSOS, other polypeptides present in either cytosolic or membrane preparations were able to complex in vitro with Grb-2 SH3 domains.	REGINA ELENA INST CANC RES, IMMUNOL LAB, I-00156 ROME, ITALY; UNIV PERUGIA, IST CLIN MED, MOLEC BIOL LAB, I-06100 PERUGIA, ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Perugia			Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019	Lanfrancone, Luisa/0000-0002-4523-3815; Segatto, Oreste/0000-0003-2561-1142; chiari, rita/0000-0002-7649-273X				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V73, P611; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIESI G, 1992, HYBRIDOMA, V11, P519, DOI 10.1089/hyb.1992.11.519; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JANES PW, 1994, ONCOGENE, V9, P3601; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SEGATTO O, 1992, ONCOGENE, V7, P1339; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	60	61	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1519	1529						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478576				2022-12-25	WOS:A1995TC53500010
J	GENDLER, S; TAYLORPAPADIMITRIOU, J; DUHIG, T; ROTHBARD, J; BURCHELL, J				GENDLER, S; TAYLORPAPADIMITRIOU, J; DUHIG, T; ROTHBARD, J; BURCHELL, J			A HIGHLY IMMUNOGENIC REGION OF A HUMAN POLYMORPHIC EPITHELIAL MUCIN EXPRESSED BY CARCINOMAS IS MADE UP OF TANDEM REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note											GENDLER, S (corresponding author), IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Burchell, Joy/G-4560-2012					ABE M, 1986, J CELL PHYSIOL, V126, P126, DOI 10.1002/jcp.1041260117; AZEN E, 1984, P NATL ACAD SCI-BIOL, V81, P5561, DOI 10.1073/pnas.81.17.5561; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; BURCHELL J, 1984, INT J CANCER, V34, P763, DOI 10.1002/ijc.2910340605; ECKHERT RL, 1986, CELL, V46, P583; EPENETOS AA, 1982, LANCET, V2, P1004; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GENDLER S, 1988, IN PRESS BREAST CANC; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GRANOWSKA M, 1984, NUCL MED COMMUN, V5, P485, DOI 10.1097/00006231-198408000-00002; GRIFFITHS AB, 1987, INT J CANCER, V40, P319, DOI 10.1002/ijc.2910400307; HILKENS J, 1986, CANCER RES, V46, P2586; JOHNSON VG, 1986, CANCER RES, V46, P850; MANNING RF, 1980, J BIOL CHEM, V255, P9451; MUSKAVITCH MAT, 1982, CELL, V29, P1041, DOI 10.1016/0092-8674(82)90467-6; OZAKI LS, 1983, CELL, V34, P815, DOI 10.1016/0092-8674(83)90538-X; STAHL HD, 1985, P NATL ACAD SCI USA, V82, P543, DOI 10.1073/pnas.82.2.543; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TAYLORPAPADIMITRIOU J, 1981, INT J CANCER, V28, P17, DOI 10.1002/ijc.2910280104; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; 1984, LANCET, V2, P1441	26	573	608	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12820	12823						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417635				2022-12-25	WOS:A1988Q091700008
J	OGATA, N				OGATA, N			DEMONSTRATION OF PANCREATIC SECRETORY TRYPSIN-INHIBITOR IN SERUM-FREE CULTURE-MEDIUM CONDITIONED BY THE HUMAN PANCREATIC-CARCINOMA CELL-LINE CAPAN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											OGATA, N (corresponding author), NAGAYOSHI GEN HOSP,MOLEC ONCOL LAB,NAGAYOSHI 1-2-34,HIRANO KU,OSAKA 547,JAPAN.							BARTELT DC, 1977, ARCH BIOCHEM BIOPHYS, V179, P189, DOI 10.1016/0003-9861(77)90103-5; EDDELAND A, 1978, SCAND J CLIN LAB INV, V38, P261, DOI 10.3109/00365517809108421; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; FUKUOKA SI, 1986, BIOCHEM BIOPH RES CO, V139, P545, DOI 10.1016/S0006-291X(86)80025-0; Greene L J, 1976, Methods Enzymol, V45, P813; GREENE LJ, 1969, J BIOL CHEM, V244, P2646; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUHTALA ML, 1983, INT J CANCER, V31, P711, DOI 10.1002/ijc.2910310606; HUHTALA ML, 1982, J BIOL CHEM, V257, P13713; HUNT LT, 1974, BIOCHEM BIOPH RES CO, V60, P1020, DOI 10.1016/0006-291X(74)90415-X; IWAI K, 1987, J BIOL CHEM, V262, P8956; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; KIKUCHI N, 1985, J BIOCHEM-TOKYO, V98, P687, DOI 10.1093/oxfordjournals.jbchem.a135326; KITAHARA T, 1980, CLIN CHIM ACTA, V103, P135, DOI 10.1016/0009-8981(80)90205-3; LASSON A, 1986, CLIN CHIM ACTA, V161, P37, DOI 10.1016/0009-8981(86)90261-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDA K, 1983, RES COMMUN CHEM PATH, V40, P301; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NIINOBU T, 1986, RES COMMUN CHEM PATH, V53, P245; OGATA N, 1988, RES COMMUN CHEM PATH, V59, P233; OGATA N, 1980, J BIOL CHEM, V255, P7610; OGAWA M, 1985, RES COMMUN CHEM PATH, V50, P155; OGAWA M, 1987, RES COMMUN CHEM PATH, V55, P137; OGAWA M, 1980, TAN TO SUI, V1, P1631; PUBOLS MH, 1974, J BIOL CHEM, V249, P2235; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STENMAN UH, 1982, INT J CANCER, V30, P53, DOI 10.1002/ijc.2910300110; YAMAMOTO T, 1985, BIOCHEM BIOPH RES CO, V132, P605, DOI 10.1016/0006-291X(85)91176-3	29	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13427	13431						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417664				2022-12-25	WOS:A1988Q091700098
J	VANOMMEN, B; DENBESTEN, C; RUTTEN, ALM; PLOEMEN, JHTM; VOS, RME; MULLER, F; VANBLADEREN, PJ				VANOMMEN, B; DENBESTEN, C; RUTTEN, ALM; PLOEMEN, JHTM; VOS, RME; MULLER, F; VANBLADEREN, PJ			ACTIVE SITE-DIRECTED IRREVERSIBLE INHIBITION OF GLUTATHIONE S-TRANSFERASES BY THE GLUTATHIONE CONJUGATE OF TETRACHLORO-1,4-BENZOQUINONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									AGR UNIV WAGENINGEN,DEPT TOXICOL,6703 BC WAGENINGEN,NETHERLANDS; AGR UNIV WAGENINGEN,DEPT BIOCHEM,6703 BC WAGENINGEN,NETHERLANDS	Wageningen University & Research; Wageningen University & Research								ALIN P, 1986, EUR J BIOCHEM, V156, P343, DOI 10.1111/j.1432-1033.1986.tb09588.x; BHARGAVA MM, 1978, J BIOL CHEM, V253, P4112; CARNE T, 1979, BIOCHEM J, V177, P433, DOI 10.1042/bj1770433; DIERICKX PJ, 1983, RES COMMUN CHEM PATH, V41, P517; DIERICKX PJ, 1983, PHARMACOL RES COMMUN, V15, P581, DOI 10.1016/S0031-6989(83)80029-0; DING GJF, 1985, J BIOL CHEM, V260, P3268; GUTHENBERG C, 1979, BIOCHEM BIOPH RES CO, V86, P1304, DOI 10.1016/0006-291X(79)90258-4; HABIG WH, 1974, J BIOL CHEM, V249, P7130; IVANETICH KM, 1984, RES COMMUN CHEM PATH, V45, P233; KULKARNI AP, 1978, B ENVIRON CONTAM TOX, V20, P227, DOI 10.1007/BF01683513; LAI HCJ, 1984, J BIOL CHEM, V259, P5536; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MOSLEN MT, 1985, RES COMMUN CHEM PATH, V47, P59; Radola BJ, 1980, ELECTROPHORESIS, V1, P43, DOI DOI 10.1002/ELPS.1150010109; TELAKOWSKIHOPKINS CA, 1985, J BIOL CHEM, V260, P5820; VANOMMEN B, 1986, BIOCHEM PHARMACOL, V35, P3233, DOI 10.1016/0006-2952(86)90417-X; VOS RME, 1988, BIOCHEM PHARMACOL, V37, P1077, DOI 10.1016/0006-2952(88)90513-8; WILSON I, 1987, CHEM-BIOL INTERACT, V61, P229, DOI 10.1016/0009-2797(87)90003-2; YAMADA T, 1980, BIOCHEM PHARMACOL, V29, P1205, DOI 10.1016/0006-2952(80)90420-7	19	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12939	12942						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417644				2022-12-25	WOS:A1988Q091700028
J	SHEARES, BT				SHEARES, BT			SITE-SPECIFIC GLYCOSYLATION IN ANIMAL-CELLS - SUBSTITUTION OF GLUTAMINE FOR ASPARAGINE-293 IN CHICKEN OVALBUMIN DOES NOT ALLOW GLYCOSYLATION OF ASPARAGINE-312	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											SHEARES, BT (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [CA98765] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS SP, 1983, J AM CHEM SOC, V105, P661, DOI 10.1021/ja00341a078; Albein A. D., 1987, ANNU REV BIOCHEM, V56, P497; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; COLEMAN A, 1981, EUR J BIOCHEM, V113, P339; GLABE CG, 1980, J BIOL CHEM, V255, P9236; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HICKMAN S, 1977, J BIOL CHEM, V252, P4402; KALYAN NK, 1983, J BIOL CHEM, V258, P67; KELLER RK, 1978, BIOCHEM BIOPH RES CO, V85, P762, DOI 10.1016/0006-291X(78)91226-3; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRANITZKY W, 1985, INFECT IMMUN, V49, P336; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; OLDEN K, 1978, CELL, V13, P461, DOI 10.1016/0092-8674(78)90320-3; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; OLDEN K, 1985, TRENDS BIOCHEM SCI, V10, P78, DOI 10.1016/0968-0004(85)90238-5; POST LE, 1982, MOL CELL BIOL, V2, P233, DOI 10.1128/MCB.2.3.233; PRIVES JM, 1980, P NATL ACAD SCI-BIOL, V77, P5263, DOI 10.1073/pnas.77.9.5263; REBOIS RV, 1983, J BIOL CHEM, V258, P2775; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHEARES BT, 1986, P NATL ACAD SCI USA, V83, P1993, DOI 10.1073/pnas.83.7.1993; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOODS D, 1984, FOCUS, V6, P1; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	25	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1988	263	25					12778	12782						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P8611	3410855				2022-12-25	WOS:A1988P861100092
J	DECOTTIGNIES, P; SCHMITTER, JM; MIGINIACMASLOW, M; LEMARECHAL, P; JACQUOT, JP; GADAL, P				DECOTTIGNIES, P; SCHMITTER, JM; MIGINIACMASLOW, M; LEMARECHAL, P; JACQUOT, JP; GADAL, P			PRIMARY STRUCTURE OF THE LIGHT-DEPENDENT REGULATORY SITE OF CORN NADP-MALATE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									ECOLE POLYTECH, BIOCHIM LAB, F-91128 PALAISEAU, FRANCE	Institut Polytechnique de Paris	DECOTTIGNIES, P (corresponding author), UNIV PARIS 11, PHYSIOL VEGETALE MOLEC LAB, CNRS, UNITE 1128, F-91405 ORSAY, FRANCE.		Jacquot, Jean-Pierre/A-1571-2012	Jacquot, Jean-Pierre/0000-0003-4975-8587				ASHTON AR, 1983, BIOCHIM BIOPHYS ACTA, V749, P24, DOI 10.1016/0167-4838(83)90146-2; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; CLEMENTMETRAL JD, 1988, EUR J BIOCHEM, V172, P413, DOI 10.1111/j.1432-1033.1988.tb13902.x; CRAWFORD NA, 1986, ARCH BIOCHEM BIOPHYS, V244, P1, DOI 10.1016/0003-9861(86)90088-3; CRETIN C, 1987, THESIS U ORSAY FRANC; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V252, P426, DOI 10.1016/0003-9861(87)90049-X; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V256, P372, DOI 10.1016/0003-9861(87)90458-9; FERTE N, 1986, EUR J BIOCHEM, V154, P587, DOI 10.1111/j.1432-1033.1986.tb09439.x; FICKENSCHER K, 1987, EUR J BIOCHEM, V168, P653, DOI 10.1111/j.1432-1033.1987.tb13466.x; GLEASON FK, 1986, THIOREDOXIN GLUTARED, P21; JACQUOT JP, 1978, FEBS LETT, V96, P243, DOI 10.1016/0014-5793(78)80410-4; JACQUOT JP, 1984, PHYSIOL VEG, V22, P487; JACQUOT JP, 1976, FEBS LETT, V71, P223, DOI 10.1016/0014-5793(76)80937-4; JACQUOT JP, 1984, ARCH BIOCHEM BIOPHYS, V228, P170, DOI 10.1016/0003-9861(84)90058-4; JACQUOT JPP, 1981, PLANT PHYSIOL, V68, P300, DOI 10.1104/pp.68.2.300; JENKINS CLD, 1986, PLANT SCI, V45, P1, DOI 10.1016/0168-9452(86)90064-6; JOHNSON RS, 1987, BIOCHEMISTRY-US, V26, P1209, DOI 10.1021/bi00379a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTSPEICH F, 1985, J CHROMATOGR, V326, P321, DOI 10.1016/S0021-9673(01)87457-4; MAEDA K, 1986, EUR J BIOCHEM, V154, P197, DOI 10.1111/j.1432-1033.1986.tb09379.x; MARCUS F, 1987, BIOCHEMISTRY-US, V26, P7029, DOI 10.1021/bi00396a026; MATHEWS WR, 1987, J BIOL CHEM, V262, P7537; MATSUBARA H, 1967, P NATL ACAD SCI USA, V57, P439, DOI 10.1073/pnas.57.2.439; MAYHEW SG, 1971, ANAL BIOCHEM, V42, P191, DOI 10.1016/0003-2697(71)90025-X; MIGINIACMASLOW M, 1985, PHOTOSYNTH RES, V6, P201, DOI 10.1007/BF00049276; PORTER MA, 1986, ARCH BIOCHEM BIOPHYS, V245, P14, DOI 10.1016/0003-9861(86)90185-2; PORTER MA, 1988, J BIOL CHEM, V263, P123; PORTER MA, 1986, BIOCHEMISTRY-US, V25, P7314, DOI 10.1021/bi00371a011; SCHEIBE R, 1985, FEBS LETT, V180, P317, DOI 10.1016/0014-5793(85)81094-2; SCHEIBE R, 1986, BIOCHIM BIOPHYS ACTA, V870, P191, DOI 10.1016/0167-4838(86)90221-9; SCHURMANN P, 1979, BIOCHIM BIOPHYS ACTA, V569, P309, DOI 10.1016/0005-2744(79)90067-6; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; WOLOSIUK RA, 1977, FEBS LETT, V81, P253, DOI 10.1016/0014-5793(77)80529-2	33	68	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					11780	11785						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403553				2022-12-25	WOS:A1988P765000029
J	GARFIELD, JL; STOUT, CD				GARFIELD, JL; STOUT, CD			CRYSTALLIZATION AND PRELIMINARY-X-RAY DIFFRACTION STUDIES OF A TOXIC CRYSTAL PROTEIN FROM A SUBSPECIES OF BACILLUS-THURINGIENSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											GARFIELD, JL (corresponding author), SCRIPPS CLIN & RES FDN,RES INST,LA JOLLA,CA 92037, USA.							ARONSON AI, 1986, MICROBIOL REV, V50, P1; BERNHARD K, 1986, FEMS MICROBIOL LETT, V33, P261; KRIEG VA, 1983, Z ANGEW ENTOMOL, V96, P509; LI J, 1988, J MOL BIOL, V199, P543, DOI 10.1016/0022-2836(88)90625-0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1987, J MOL BIOL, V195, P755, DOI 10.1016/0022-2836(87)90197-5; MCPHERSON SA, 1988, BIO-TECHNOL, V6, P61, DOI 10.1038/nbt0188-61; THOMAS WE, 1983, FEBS LETT, V154, P362, DOI 10.1016/0014-5793(83)80183-5	8	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					11800	11801						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403554				2022-12-25	WOS:A1988P765000032
J	TAKAGI, T; KONISHI, K; MABUCHI, I				TAKAGI, T; KONISHI, K; MABUCHI, I			AMINO-ACID SEQUENCE OF STARFISH OOCYTE DEPACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									NATL INST BASIC BIOL,DEPT CELL BIOL,OKAZAKI,AICHI 444,JAPAN; UNIV TOKYO,COLL ARTS & SCI,DEPT BIOL,MEGURO KU,TOKYO 153,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); University of Tokyo	TAKAGI, T (corresponding author), TOHOKU UNIV,FAC SCI,INST BIOL,SENDAI,MIYAGI 980,JAPAN.							AMPE C, 1985, J BIOL CHEM, V260, P834; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; COOKE NE, 1986, J BIOL CHEM, V261, P3441; COOPER JA, 1986, J BIOL CHEM, V261, P477; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HOSOYA H, 1982, J BIOCHEM-TOKYO, V92, P1853, DOI 10.1093/oxfordjournals.jbchem.a134115; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MABUCHI I, 1982, J BIOCHEM-TOKYO, V92, P1439, DOI 10.1093/oxfordjournals.jbchem.a134068; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; MABUCHI I, 1981, J BIOCHEM-TOKYO, V89, P1341; NISHIDA E, 1984, J BIOCHEM-TOKYO, V95, P387, DOI 10.1093/oxfordjournals.jbchem.a134619; NYSTROM LE, 1979, FEBS LETT, V101, P161, DOI 10.1016/0014-5793(79)81317-4; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SHAH D M, 1983, Journal of Molecular and Applied Genetics, V2, P111; STONE D, 1978, J BIOL CHEM, V253, P1137; SUTOH K, 1984, BIOCHEMISTRY-US, V23, P6757, DOI 10.1021/bi00321a073; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P6186, DOI 10.1021/bi00368a053; TAKAGI T, 1984, J BIOCHEM-TOKYO, V96, P59, DOI 10.1093/oxfordjournals.jbchem.a134829; Tarr G E, 1977, Methods Enzymol, V47, P335; TSUGITA A, 1982, EUR J BIOCHEM, V124, P585, DOI 10.1111/j.1432-1033.1982.tb06634.x; TSUNASAWA S, 1985, J BIOCHEM-TOKYO, V97, P701, DOI 10.1093/oxfordjournals.jbchem.a135108	24	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1988	263	7					3097	3102						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M3259	3422641				2022-12-25	WOS:A1988M325900011
J	CHANG, CCY; CHEN, J; THOMAS, MA; CHENG, D; DELPRIORE, VA; NEWTON, RS; PAPE, ME; CHANG, TY				CHANG, CCY; CHEN, J; THOMAS, MA; CHENG, D; DELPRIORE, VA; NEWTON, RS; PAPE, ME; CHANG, TY			REGULATION AND IMMUNOLOCALIZATION OF ACYL-COENZYME A-CHOLESTEROL ACYLTRANSFERASE IN MAMMALIAN-CELLS AS STUDIED WITH SPECIFIC ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HAMSTER OVARY CELLS; RECEPTOR ACTIVITY; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; HUMAN FIBROBLASTS; DOWN-REGULATION; HEP-G2 CELLS; FATTY-ACIDS	Acyl-coenzyme A:cholesterol acyltransferase (ACAT) catalyzes the formation of intracellular cholesterol esters in various tissues. We recently reported the cloning and expression of human macrophage ACAT cDNA. In the current study, we report the production of specific polyclonal antibodies against ACAT by immunizing rabbits with the recombinant fusion protein composed of glutathione S-transferase and the first 131 amino acids of ACAT protein. Immunoblot analysis showed that the antibodies cross-reacted with a 50-kDa protein band from a variety of human cell lines. These antibodies immunodepleted more than 90% of detergent-solubilized ACAT activities from six different human cell types, demonstrating that the 50-kDa protein is the major ACAT catalytic component in these cells. In multiple human tissues examined, the antibodies recognized protein bands with various molecular weights. These antibodies also cross-reacted with the ACAT protein in Chinese hamster ovary cells. Immunoblot analysis showed that the ACAT protein contents in human fibroblast cells, HepG2 cells, or Chinese hamster ovary cells were not affected by sterol in the medium, demonstrating that the main mechanism for sterol-dependent regulation of ACAT activity in these cells is not change in ACAT protein content. As revealed by indirect immunofluorescent microscopy, the ACAT protein in tissue culture cells was located in the endoplasmic reticulum. This finding, along with earlier studies, suggests that cholesterol concentration in the endoplasmic reticulum may be the major determinant for regulating ACAT activity in the intact cells.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DIV THERAPEUT,ATHEROSCLEROSIS RES,ANN ARBOR,MI 48105	Dartmouth College; Pfizer				Chang, Ta-Yuan/0000-0002-3249-0468	NHLBI NIH HHS [HL 36709] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036709, R37HL036709] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1975, J BIOL CHEM, V250, P4025; CADIGAN KM, 1988, J LIPID RES, V29, P1683; CADIGAN KM, 1989, J CELL BIOL, V108, P2201, DOI 10.1083/jcb.108.6.2201; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; CHANG TY, 1994, TRENDS CARDIOVAS MED, V4, P223, DOI 10.1016/1050-1738(94)90038-8; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; CHIN J, 1981, J BIOL CHEM, V256, P6304; CORRELL CC, 1994, J BIOL CHEM, V269, P633; DAUMERIE CM, 1992, P NATL ACAD SCI USA, V89, P10797, DOI 10.1073/pnas.89.22.10797; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; FIELD FJ, 1995, J LIPID RES, V36, P1533; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1974, P NATL ACAD SCI USA, V71, P4288, DOI 10.1073/pnas.71.11.4288; GRAHAM FL, 1978, VIROLOGY, V86, P10, DOI 10.1016/0042-6822(78)90003-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HAVEKES LM, 1987, BIOCHEM J, V247, P739, DOI 10.1042/bj2470739; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; PAPE ME, 1995, J LIPID RES, V36, P823; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SALTER AM, 1989, BIOCHEM J, V263, P255, DOI 10.1042/bj2630255; Sambrook J, 1989, MOL CLONING LABORATO; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SHI SP, 1989, BIOCHIM BIOPHYS ACTA, V982, P187, DOI 10.1016/0005-2736(89)90054-0; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; STOSCHECK CM, 1983, J CELL BIOCHEM, V23, P191, DOI 10.1002/jcb.240230116; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1986, J BIOL CHEM, V261, P3147; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TROTTER PJ, 1993, J BIOL CHEM, V268, P10017; UELMEN PJ, 1995, IN PRESS J BIOL CHEM; VIA DP, 1989, J LIPID RES, V30, P1515	45	133	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29532	29540						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493995				2022-12-25	WOS:A1995TJ22700076
J	GUNTHERAUSBORN, S; PRAETOR, A; STEGMANN, T				GUNTHERAUSBORN, S; PRAETOR, A; STEGMANN, T			INHIBITION OF INFLUENZA-INDUCED MEMBRANE-FUSION BY LYSOPHOSPHATIDYLCHOLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-DEPENDENT FUSION; VIRUS HEMAGGLUTININ; BIOLOGICAL-MEMBRANES; VESICLES; LIPIDS; HEMOLYSIS; MODEL; STALK	Lysolipids have been reported to inhibit various membrane fusion events, and it was suggested that inhibition was due to their ''inverted cone'' shape, which hinders the formation of intermediate lipid structures required for fusion (Chernomordik, L. V., Vogel, S. S., Sokoloff, A., Onaran, H. O., Leikina, E. A., and Zimmerberg, J. (1993) FEBS Lett. 318, 71-76). Here, the effect of lysophosphatidylcholine (LPC) on fusion mediated by the hemagglutinin (HA) of influenza virus was investigated. Virus-liposome fusion was inhibited by LPC if the lysolipid was added to the membranes from an aqueous stock solution but not if LPC was symmetrically distributed over both leaflets of the liposomal bilayer. These findings would be consistent with an effect of LPC on lipid intermediate formation, but inhibition increased with increasing acyl chain length and thus a less pronounced inverted cone shape of the lysolipids suggesting that the mechanism of inhibition might be different. At low pH, due to the exposure of the fusion peptide of HA, followed by its insertion into the liposomal membrane, virus acquires the ability to bind to zwitterionic liposomes lacking receptors for HA. This type of binding was inhibited by LPC. Moreover, leakage of calcein from receptor-containing liposomes, induced by purified HA at low pH, was inhibited by LPC. Therefore, the inhibition of influenza-induced fusion by LPC was caused by the binding of LPC to fusion peptides, thereby preventing their interaction with the target membrane rather than an effect on intermediate lipid structures.	UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND; FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,D-14195 BERLIN,GERMANY	University of Basel; Free University of Berlin								Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHERNOMORDIK L, 1995, J VIROL, V69, P3049, DOI 10.1128/JVI.69.5.3049-3058.1995; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; CHERNOMORDIK LV, 1985, BIOCHIM BIOPHYS ACTA, V812, P643, DOI 10.1016/0005-2736(85)90257-3; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; CLAGUE MJ, 1993, VIRAL FUSION MECHANI, P113; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DEKRUYFF B, 1977, BIOCHIM BIOPHYS ACTA, V465, P443, DOI 10.1016/0005-2736(77)90263-2; DOMS RW, 1985, J BIOL CHEM, V260, P2973; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KOZLOV MM, 1989, EUR BIOPHYS J BIOPHY, V17, P121; MAEDA T, 1981, P NATL ACAD SCI-BIOL, V78, P4133, DOI 10.1073/pnas.78.7.4133; MANDERSLOOT JG, 1975, BIOCHIM BIOPHYS ACTA, V382, P22, DOI 10.1016/0005-2736(75)90368-5; Markin V, 1984, GEN PHYSL BIOPHYS, V5, P361; MARTIN I, 1993, FEBS LETT, V333, P325, DOI 10.1016/0014-5793(93)80680-S; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MONSMA SA, 1995, J VIROL, V69, P2583, DOI 10.1128/JVI.69.4.2583-2595.1995; NEBEL S, 1995, BIOCHEMISTRY-US, V34, P5705, DOI 10.1021/bi00017a001; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SATO SB, 1983, P NATL ACAD SCI-BIOL, V80, P3153, DOI 10.1073/pnas.80.11.3153; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; STAFFORD RE, 1989, BIOCHEMISTRY-US, V28, P5113, DOI 10.1021/bi00438a031; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1985, BIOCHEMISTRY-US, V24, P3107, DOI 10.1021/bi00334a006; STEGMANN T, 1995, BIOCHEMISTRY-US, V34, P1825, DOI 10.1021/bi00006a002; STEGMANN T, 1986, J BIOL CHEM, V261, P966; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; VANDENBESSELAAR AMHP, 1979, BIOCHIM BIOPHYS ACTA, V555, P193, DOI 10.1016/0005-2736(79)90159-7; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; WELTZIEN HU, 1977, BIOCHIM BIOPHYS ACTA, V466, P411, DOI 10.1016/0005-2736(77)90334-0; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSCHUT J, 1986, CHEM PHYS LIPIDS, V40, P145, DOI 10.1016/0009-3084(86)90068-X; WILSCHUT J, 1993, VIRAL FUSION MECHANI, P133; YEAGLE PL, 1994, BIOCHEMISTRY-US, V33, P1820, DOI 10.1021/bi00173a027; ZHANG ZM, 1994, AM J PHYSIOL, V267, pG80, DOI 10.1152/ajpgi.1994.267.1.G80	46	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29279	29285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493959				2022-12-25	WOS:A1995TJ22700040
J	KERSHAW, DB; THOMAS, PE; WHARRAM, BL; GOYAL, M; WIGGINS, JE; WHITESIDE, CI; WIGGINS, RC				KERSHAW, DB; THOMAS, PE; WHARRAM, BL; GOYAL, M; WIGGINS, JE; WHITESIDE, CI; WIGGINS, RC			MOLECULAR CLOTTING, EXPRESSION, AND CHARACTERIZATION OF PODOCALYXIN-LIKE PROTEIN-1 FROM RABBIT AS A TRANSMEMBRANE PROTEIN OF GLOMERULAR PODOCYTES AND VASCULAR ENDOTHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE DISEASE; GLUTATHIONE-S-TRANSFERASE; MAJOR SIALOPROTEIN; AMINONUCLEOSIDE NEPHROSIS; SULFATE PROTEOGLYCAN; EPITHELIAL-CELLS; ESCHERICHIA-COLI; MESSENGER-RNA; IDENTIFICATION; CLONING	Podocytes are responsible in part for maintaining the size and charge filtration characteristics of the glomerular filter. The major sialoprotein of the podocyte foot process glycocalyx is a 140-kDa sialoprotein named podocalyxin. Monoclonal antibodies raised against isolated rabbit glomeruli that recognized a podocalyxin-like protein based upon size, Alcian blue staining, wheat germ agglutinin binding, and distribution in renal cortex were used to expression clone cDNAs from a rabbit glomerular library. On Northern blot the cDNAs hybridized to a 5,5-kilobase pair transcript predominantly present in glomerulus. The overlapping cDNAs spanned 5,313 base pairs that contained an open reading frame of 1,653 base pairs and were not homologous with a previously described sequence. The deduced 551-amino acid protein contained a putative 21-residue N-terminal signal peptide and a 26-amino acid transmembrane region. The mature protein has a calculated molecular mass of 55 kDa, an extracellular domain that contains putative sites for N- and O-linked glycosylation, and a potential glycosaminoglycan attachment site. The intracellular domain contains potential sites for phosphorylation. Processing of the full-length coding region in COS-7 cells resulted in a 140-kDa band, suggesting that the 55-kDa core protein undergoes extensive post-translational modification. The relationship between the cloned molecule and the monoclonal antibodies used for cloning was confirmed by making a fusion protein that inhibited binding of the monoclonal antibodies to renal cortical tissue sections and then raising polyclonal antibodies against the PCLP1 fusion protein that also recognized glomerular podocytes and endothelial cells in tissue sections in a similar distribution to the monoclonal antibodies. We conclude that we have cloned and sequenced a novel transmembrane core glycoprotein from rabbit glomerulus, which has many of the characteristics of podocalyxin. We have named this protein podocalyxin-like protein 1.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109; UNIV TORONTO,DEPT MED,TORONTO,ON M5G 2C4,CANADA	University of Michigan System; University of Michigan; University of Toronto	KERSHAW, DB (corresponding author), UNIV MICHIGAN,MED CTR,DEPT PEDIAT,DIV NEPHROL,L2602 WOMENS,ANN ARBOR,MI 48109, USA.			Wiggins, Roger/0000-0002-1166-2849	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255, P01DK038149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39255, DK 38149, DK02264-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREWS PM, 1979, KIDNEY INT, V15, P376, DOI 10.1038/ki.1979.49; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEKAN G, 1990, AM J PATHOL, V137, P913; DEKAN G, 1991, P NATL ACAD SCI USA, V88, P5398, DOI 10.1073/pnas.88.12.5398; DOWNER G, 1988, J CLIN INVEST, V82, P998, DOI 10.1172/JCI113710; FLEIGEL L, 1987, P NATL ACAD SCI USA, V84, P1167; GEOHEGAN WD, 1977, J HISTOCHEM CYTOCHEM, V25, P1187; GOYAL M, 1991, J AM SOC NEPHROL, V1, P1334; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HORVAT R, 1986, J CELL BIOL, V102, P484, DOI 10.1083/jcb.102.2.484; HUBER S, 1988, J BIOL CHEM, V263, P752; KERJASCHKI D, 1985, AM J PATHOL, V118, P343; KERJASCHKI D, 1986, J CLIN INVEST, V78, P1142, DOI 10.1172/JCI112694; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LOGIN GR, 1987, LAB INVEST, V57, P585; MERRITT SE, 1990, LAB INVEST, V63, P762; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHNITZER JE, 1990, EUR J CELL BIOL, V52, P241; SEILER MW, 1977, LAB INVEST, V36, P48; SEILER MW, 1975, SCIENCE, V189, P390, DOI 10.1126/science.1145209; SETO D, 1990, NUCLEIC ACIDS RES, V18, P5905, DOI 10.1093/nar/18.19.5905; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITESIDE C, 1989, LAB INVEST, V61, P650; WHITESIDE CI, 1993, AM J PATHOL, V142, P1641; WOLFE SL, 1993, MOL CELL BIOL, P708; YOUNG RA, 1985, GENETIC ENG PRINCIPL, V7, P29	39	70	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29439	29446		10.1074/jbc.270.49.29439	http://dx.doi.org/10.1074/jbc.270.49.29439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493982	hybrid			2022-12-25	WOS:A1995TJ22700063
J	DENISON, SH; OREJAS, M; ARST, HN				DENISON, SH; OREJAS, M; ARST, HN			SIGNALING OF AMBIENT PH IN ASPERGILLUS INVOLVES A CYSTEINE PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTORS; NEUTRAL PROTEASE; NIDULANS; CALCIUM; CALPAIN; GENE; AUTOLYSIS; PROTEINS; CLONING; KINASE	In Aspergillus nidulans, the regulation of gene expression in response to changes in ambient pH is mediated by the PacC zinc finger transcriptional regulator, At alkaline ambient pH, PacC is proteolytically processed to a functional form serving as an activator of alkaline-expressed genes and a repressor of acid expressed genes. This activation of PacC occurs in response to a signal mediated by the products of the pal genes. Thus, the products of the palA, -B, -C, -F, -H, and -I genes constitute an alkaline ambient pH signal transduction pathway. How the pal signal transduction pathway senses ambient pH and transduces a signal to trigger PacC processing is a fascinating unresolved problem. We have cloned and sequenced the palB gene. The predicted palB gene product has similarity to the catalytic domain of the calpain family of calcium-activated cysteine proteases, We have shown, however, that the PalB protein does not catalyze the final step of proteolytic processing of PacC.	ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN	Imperial College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Orejas, Margarita/K-6821-2014	Orejas, Margarita/0000-0002-9974-8021				ARST HN, 1994, MOL GEN GENET, V245, P787, DOI 10.1007/BF00297286; BRODY H, 1991, NUCLEIC ACIDS RES, V19, P3105, DOI 10.1093/nar/19.11.3105; CADDICK MX, 1986, MOL GEN GENET, V203, P346, DOI 10.1007/BF00333978; CHUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M, V3; CLUTTERBUCK AJ, 1990, J GEN MICROBIOL, V136, P1731, DOI 10.1099/00221287-136-9-1731; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; DORN G, 1965, GENET RES, V6, P13, DOI 10.1017/S0016672300003943; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; JOHNSTONE IL, 1985, EMBO J, V4, P1307, DOI 10.1002/j.1460-2075.1985.tb03777.x; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; OREJAS M, 1995, GENE DEV, V9, P1622, DOI 10.1101/gad.9.13.1622; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROSSI A, 1990, FEMS MICROBIOL LETT, V66, P51, DOI 10.1016/0378-1097(90)90257-Q; SIMON J, 1995, FEBS LETT, V368, P397; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; THEOPOLD U, 1995, MOL CELL BIOL, V15, P824; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; ZIMMERMAN UJP, 1982, BIOCHEMISTRY-US, V21, P3977, DOI 10.1021/bi00260a012; 1991, PROGRAM MANUAL GCG P	26	119	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28519	28522		10.1074/jbc.270.48.28519	http://dx.doi.org/10.1074/jbc.270.48.28519			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499363	hybrid			2022-12-25	WOS:A1995TH05600007
J	HAAS, M; MCBRAYER, D; LYTLE, C				HAAS, M; MCBRAYER, D; LYTLE, C			[CL-](I)-DEPENDENT PHOSPHORYLATION OF THE NA-K-CL COTRANSPORT PROTEIN OF DOG TRACHEAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; CANINE AIRWAY EPITHELIA; H-3 BUMETANIDE BINDING; SQUID GIANT-AXON; ION-TRANSPORT; RED-CELLS; MECHANISM; SECRETION; VOLUME; STIMULATION	Basolateral Na-K-Cl cotransport activity in primary cultures of dog tracheal epithelial cells is stimulated by beta-adrenergic agents, such as isoproterenol, and by apical UTP, which acts through an apical P-2-purinergic receptor, While at least part of the stimulatory effect of isoproterenol appears to involve direct activation of the cotransporter via cAMP-dependent protein kinase, cotransport stimulation by apical UTP is entirely secondary to apical Cl- efflux and a resultant decrease in intracellular [Cl-] ([Cl-](i)) and/or cell shrinkage (Haas, M., and McBrayer, D. G. (1994) Am. J. Physiol. 266, C1440-C1452), In the secretory epithelia of the shark rectal gland and avian salt gland, Na-K-Cl cotransport activation by both cAMP dependent and cAMP-independent secretagogues has been shown to be accompanied by phosphorylation of the cotransport protein itself (Lytle, C., and Forbush, B., III (1992) J. Biol. Chem. 267, 25438-25443; Torchia, J., Lytle, C,, Pen, D. J., Forbush, B., III, and Sen, A. K. (1992) J. Biol. Chem. 267, 25444-25450). In the present study, we immunoprecipitate the similar to 170 kDa Na-K-Cl cotransport protein of dog tracheal epithelial cells with a monoclonal antibody against the cotransporter of the intestinal cell line T84. Incubation of confluent primary cultures of tracheal cells with isoproterenol and apical UTP increases basolateral-to-apical Cl-36(-) flux 3.4- and 2.6-fold, respectively, and produces similar increases (3.2- and 2.8-fold, respectively) in P-32 incorporation into the similar to 170-kDa cotransport protein. Decreasing [Cl-](i) (without concomitant cell shrinkage) by incubating cultures with apical nystatin and reduced apical [Cl-] ([Cl-](alpha)) likewise increases both cotransport activity and cotransport protein phosphorylation. These effects become more pronounced with greater reductions in [Cl-](alpha); after 20 min of incubation with nystatin and 32 mM [Cl-](alpha), cotransport activity and P-32 incorporation into the cotransport protein are increased 2.8- and 2.7-fold, respectively, similar to increases seen with apical UTP. 2-3-fold increases in cotransporter activity and phosphorylation are also seen in nystatin-treated cells under hypertonic conditions (50 mM sucrose added apically and basolaterally). These findings suggest a close correlation between Na-K-Cl cotransport activity and phosphorylation of the similar to 170-kDa cotransport protein. The latter is phosphorylated in response to both reduced [Cl-](i) and cell shrinkage, either or both of which are likely to be involved in secondary cotransport activation in response to apical UTP.	UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside	HAAS, M (corresponding author), UNIV CHICAGO, DEPT PATHOL, MC 6101, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.		Lytle, Christian/X-2836-2019	Lytle, Christian/0000-0001-5442-1546	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043967] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43967] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTAMIRANO AA, 1988, AM J PHYSIOL, V254, pC582, DOI 10.1152/ajpcell.1988.254.4.C582; BOUCHER RC, 1988, AM J PHYSIOL, V254, pC535, DOI 10.1152/ajpcell.1988.254.4.C535; BREITWIESER GE, 1990, AM J PHYSIOL, V258, pC749, DOI 10.1152/ajpcell.1990.258.4.C749; CASS A, 1973, NATURE-NEW BIOL, V244, P47, DOI 10.1038/newbio244047a0; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; FONG P, 1991, AM J PHYSIOL, V261, pL290, DOI 10.1152/ajplung.1991.261.4.L290; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; GREGER R, 1984, PFLUG ARCH EUR J PHY, V402, P376, DOI 10.1007/BF00583938; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1994, AM J PHYSIOL, V266, pC1440, DOI 10.1152/ajpcell.1994.266.5.C1440; HAAS M, 1982, J GEN PHYSIOL, V80, P125, DOI 10.1085/jgp.80.1.125; HAAS M, 1993, AM J PHYSIOL, V264, pC189, DOI 10.1152/ajpcell.1993.264.1.C189; HAAS M, 1990, AM J PHYSIOL, V259, pC557, DOI 10.1152/ajpcell.1990.259.4.C557; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HAAS M, 1991, AM J PHYSIOL, V260, pC791, DOI 10.1152/ajpcell.1991.260.4.C791; HAAS M, 1987, AM J PHYSIOL, V253, pC243, DOI 10.1152/ajpcell.1987.253.2.C243; HAAS M, 1995, FASEB J, V9, P599; KLEIN JD, 1993, J MEMBRANE BIOL, V132, P243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINSON C, 1990, BIOCHIM BIOPHYS ACTA, V1021, P1, DOI 10.1016/0005-2736(90)90375-X; LIEDTKE CM, 1992, AM J PHYSIOL, V262, pL621, DOI 10.1152/ajplung.1992.262.5.L621; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25438; LYTLE C, 1995, IN PRESS AM J PHYSL; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; NAKAHARI T, 1995, AM J PHYSIOL-RENAL, V268, pF64, DOI 10.1152/ajprenal.1995.268.1.F64; ONEILL WC, 1992, AM J PHYSIOL, V262, pC436, DOI 10.1152/ajpcell.1992.262.2.C436; PAULAIS M, 1992, J BIOL CHEM, V267, P21558; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; SHOROFSKY SR, 1984, J MEMBRANE BIOL, V81, P1, DOI 10.1007/BF01868804; SUN D, 1995, IN PRESS AM J PHYSL; TOHDA H, 1994, AM J PHYSIOL, V266, pC104, DOI 10.1152/ajpcell.1994.266.1.C104; TORCHIA J, 1992, J BIOL CHEM, V267, P25444; TORCHIA J, 1994, J BIOL CHEM, V269, P29778; TREHARNE KJ, 1994, AM J PHYSIOL-LUNG C, V267, pL592, DOI 10.1152/ajplung.1994.267.5.L592; VANSCOTT MR, 1988, AM J PHYSIOL, V255, pC237, DOI 10.1152/ajpcell.1988.255.2.C237; VIGNE P, 1994, J BIOL CHEM, V269, P19925; WELSH MJ, 1983, J CLIN INVEST, V71, P1392, DOI 10.1172/JCI110892	40	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28955	28961		10.1074/jbc.270.48.28955	http://dx.doi.org/10.1074/jbc.270.48.28955			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499426	hybrid			2022-12-25	WOS:A1995TH05600070
J	NODA, K; SAAD, Y; KARNIK, SS				NODA, K; SAAD, Y; KARNIK, SS			INTERACTION OF PHE(8) OF ANGIOTENSIN-II WITH LYS(199) AND HIS(256) OF AT(1) RECEPTOR IN AGONIST ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANALOGS	The acidic pharmacophores of selective ligands bind to Lys(199) and His(256) of the AT(1) receptor (Noda, K., Saad, Y., Kinoshita, A., Boyle, T. P., Graham, R. M., Husain, A., and Karnik, S. (1995) J. Biol. Chem. 270, 2284-2289). In this report we examine how interactions between these residues and agonists activate inositol phosphate production in transiently transfected COS-1 cells, [Sar(1)] angiotensin (Ang II) II and [Sar(1)]Ang II-amide stimulated a 5-fold inositol phosphate response from wild-type AT(1) receptor. The peptide antagonist [Sar(1),Ile(8)]Ang II and the non-peptide agonist L-162,313 produced a partial but saturating response. Stimulation of wild-type receptor by [Sar(1)]Ang II-amide and the mutant K199Q and K199A receptors by [Sar(1)]Ang II demonstrates that AT(1) receptor activation is not critically dependent on the ion-pairing of the alpha-COOH group of Ang II with Lys(199). The mutation of His(256) produced diminished inositol phosphate response without commensurate change in binding affinity of ligands. The His(256) Side chain is critical for maximal activation of the AT(1) receptor, although isosteric Gln substitution is sufficient for preserving the affinity for Phe(8)-substituted analogues of [Sar(1)]Ang II. Therefore, AT(1) receptor activation requires interaction of Phe(8) side chain of Ang II with His(256), which is achieved by docking the alpha-COOH group of Phe(8) to Lys(199). Furthermore, non-peptide agonists interact with Lys(199) and His(256) in a similar fashion.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NHLBI NIH HHS [HL33713, R01 HL057470] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUMELAS A, 1985, P NATL ACAD SCI USA, V82, P1881, DOI 10.1073/pnas.82.7.1881; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BUMPUS FM, 1977, HYPERTENSION PHYSIOP, P183; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HSIEH KH, 1986, J MED CHEM, V29, P1968, DOI 10.1021/jm00160a028; HUSAIN A, 1986, J PHARMACOL EXP THER, V239, P71; JI H, 1994, J BIOL CHEM, V269, P16533; KIVLIGHN SD, 1995, IN PRESS AM J PHARM; MARIE J, 1994, J BIOL CHEM, V269, P20815; NIKIFOROVICH GV, 1994, BIOCHEMISTRY-US, V33, P3591, DOI 10.1021/bi00178a016; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; NODA K, 1994, J BIOL CHEM, V269, P6743; PERLMAN S, 1995, J BIOL CHEM, V270, P1493, DOI 10.1074/jbc.270.4.1493; SCHAMBYE HT, 1995, MOL PHARMACOL, V47, P425; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205	20	111	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28511	28514		10.1074/jbc.270.48.28511	http://dx.doi.org/10.1074/jbc.270.48.28511			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499361	hybrid			2022-12-25	WOS:A1995TH05600005
J	SEKLER, I; LO, RS; KOPITO, RR				SEKLER, I; LO, RS; KOPITO, RR			A CONSERVED GLUTAMATE IS RESPONSIBLE FOR ION SELECTIVITY AND PH-DEPENDENCE OF THE MAMMALIAN ANION-EXCHANGERS AE1 AND AE2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RED-BLOOD-CELLS; SULFATE-BINDING PROTEIN; BAND-3 PROTEIN; INTRACELLULAR PH; IMPERMEANT CARBODIIMIDE; CHEMICAL MODIFICATION; PHOSPHATE-TRANSPORT; ACTIVE-TRANSPORT; MEMBRANE	The erythrocyte anion exchanger AE1 (band 3) serves as an important model for the study of the mechanism of ion transport. Chemical modification of human erythrocyte AE1 has previously suggested that glutamic acid residue 681 lies within the transport pathway and can cross the permeability barrier. This glutamate is conserved in all anion exchangers sequenced to date. We examined the effect on divalent (sulfate) and monovalent (chloride and bicarbonate) anion transport of mutating the corresponding glutamates in mouse AE1 and the closely related anion exchanger, AE2. Substitution of this conserved glutamate with uncharged or basic amino acids had a negligible effect on the maximal rate of sulfate-sulfate exchange in AE-reconstituted proteoliposomes, but largely abolished the steep pH dependence of sulfate transport observed in wild-type AE1 and AE2. In contrast, exchange of monovalent anions was undetectable in cells expressing these mutants. Replacement of the conserved glutamate with aspartate abolished both monovalent and divalent anion transport. These data suggest that the conserved glutamate residue plays a dual role in determining anion selectivity and in proton coupling to sulfate transport. A model explaining the role of the conserved glutamate in promoting ion selectivity and pH regulation is discussed.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM38543] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; BJERRUM PJ, 1989, J GEN PHYSIOL, V93, P813, DOI 10.1085/jgp.93.5.813; Brahm J, 1988, Soc Gen Physiol Ser, V43, P141; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CRAIK JD, 1985, J BIOL CHEM, V260, P2404; CREIGHTON TE, 1992, PROTEIN FOLDING; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; GASKO OD, 1976, ANAL BIOCHEM, V72, P57, DOI 10.1016/0003-2697(76)90506-6; Gunn RB, 1972, OXYGEN AFFINITY HEMO, P823; HE JJ, 1991, SCIENCE, V251, P1479, DOI 10.1126/science.1900953; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; JACOBSON BL, 1992, J MOL BIOL, V223, P27, DOI 10.1016/0022-2836(92)90712-S; JENNINGS ML, 1985, J BIOL CHEM, V260, P5472; JENNINGS ML, 1976, J MEMBRANE BIOL, V28, P187, DOI 10.1007/BF01869697; JENNINGS ML, 1987, J BIOL CHEM, V262, P1691; JENNINGS ML, 1988, J GEN PHYSIOL, V92, P161, DOI 10.1085/jgp.92.2.161; JENNINGS ML, 1992, J BIOL CHEM, V267, P13964; JENNINGS ML, 1989, ANN NY ACAD SCI, V274, P84; JULIEN T, 1988, J MEMBRANE BIOL, V102, P217, DOI 10.1007/BF01925715; KNAUF PA, 1986, PHYSL MEMBRANE DISOR, P191; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KRUPKA RM, 1989, J MEMBRANE BIOL, V109, P159, DOI 10.1007/BF01870855; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOWE AG, 1982, BIOCHIM BIOPHYS ACTA, V694, P353, DOI 10.1016/0304-4157(82)90002-8; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MACARA IG, 1983, CELL MEMBRANES METHO, P41; MILANICK MA, 1984, AM J PHYSIOL, V247, pC247, DOI 10.1152/ajpcell.1984.247.3.C247; PARADISO AM, 1987, NATURE, V325, P447, DOI 10.1038/325447a0; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; RESTREPO D, 1991, AM J PHYSIOL, V260, pC535, DOI 10.1152/ajpcell.1991.260.3.C535; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHNELL KF, 1977, J MEMBRANE BIOL, V30, P319; SEKLER I, 1995, J BIOL CHEM, V270, P11251, DOI 10.1074/jbc.270.19.11251; THOMAS HA, 1989, AM J PHYSIOL, V257, pC537, DOI 10.1152/ajpcell.1989.257.3.C537; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VAUGHANJONES RD, 1982, PHILOS T ROY SOC B, V299, P537, DOI 10.1098/rstb.1982.0150; VAUGHANJONES RD, 1979, J PHYSIOL-LONDON, V295, P111, DOI 10.1113/jphysiol.1979.sp012957; WARD CL, 1994, J BIOL CHEM, V269, P25710; WIETH JO, 1982, PHILOS T ROY SOC B, V299, P383, DOI 10.1098/rstb.1982.0139; WOOD PG, 1992, J MEMBRANE BIOL, V127, P139	48	47	47	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28751	28758		10.1074/jbc.270.48.28751	http://dx.doi.org/10.1074/jbc.270.48.28751			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499397	hybrid			2022-12-25	WOS:A1995TH05600041
J	TSUBAKI, M; HORI, H; MOGI, T; ANRAKU, Y				TSUBAKI, M; HORI, H; MOGI, T; ANRAKU, Y			CYANIDE-BINDING SITE OF BD-TYPE UBIQUINOL OXIDASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D TERMINAL OXIDASE; CYTOCHROME-C-OXIDASE; AEROBIC RESPIRATORY-CHAIN; ELECTRON-PARAMAGNETIC-RESONANCE; D COMPLEX; RAMAN-SPECTROSCOPY; BINUCLEAR CENTER; LIGAND-BINDING; IDENTIFICATION; PURIFICATION	We extended our investigation on the structure of the redox centers of bd-type ubiquinol oxidase from Escherichia coli using cyanide as a monitoring probe. We found that addition of cyanide to the air-oxidized O-2-bound enzyme caused appearance of an infrared C-N stretching band at 2161 cm(-1) and concomitant disappearance of the 647 nm absorption band of the cytochrome d (Fe2+)-O-2 species. Addition of cyanide to the air oxidized CO-bound enzyme also resulted in disappearance of the 635 nm absorption band and the 1983.4 cm(-1) C-O infrared band of the cytochrome d (Fe2+)-CO species. The resulting species had a derivative shaped electron paramagnetic resonance signal at g = 3.15. Upon partial reduction with sodium dithionite, this species was converted partly to a transient heme d (Fe3+)-C=N species having an electron paramagnetic resonance signal at g(z) = 2.96 and a C-N infrared band at 2138 cm(-1). These observations suggest that the active site of the enzyme has a heme-heme binuclear metal center distinct from that of the heme-copper terminal oxidase and that the treatment of the air-oxidized enzyme with cyanide resulted in a cyanide-bridging species with ''heme d(Fe3(+))-C=N-heme b(595)(Fe3+)'' structure.	OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN	Osaka University; University of Tokyo	TSUBAKI, M (corresponding author), HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN.							ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; ARGADE PV, 1984, SCIENCE, V225, P329, DOI 10.1126/science.6330890; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; GREEN GN, 1988, J BIOL CHEM, V263, P13138; GREEN GN, 1984, J BIOL CHEM, V259, P7994; GREEN GN, 1984, GENE, V32, P99, DOI 10.1016/0378-1119(84)90037-4; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HATATANAKA A, 1987, BIOCHIM BIOPHYS ACTA, V893, P289, DOI 10.1016/0005-2728(87)90050-8; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; HILL JJ, 1994, BIOPHYS J, V66, P367; INGLEDEW WJ, 1992, BIOCHEM J, V282, P255, DOI 10.1042/bj2820255; INGLEDEW WJ, 1993, EUR J BIOCHEM, V212, P657, DOI 10.1111/j.1432-1033.1993.tb17703.x; JIANG FS, 1993, J AM CHEM SOC, V115, P10293, DOI 10.1021/ja00075a052; JOHNSON MK, 1981, BIOCHEM J, V193, P699, DOI 10.1042/bj1930699; JUNEMANN S, 1995, J BIOL CHEM, V270, P16213, DOI 10.1074/jbc.270.27.16213; KAHLOW MA, 1991, BIOCHEMISTRY-US, V30, P11485, DOI 10.1021/bi00113a001; KAHLOW MA, 1993, J AM CHEM SOC, V115, P5845, DOI 10.1021/ja00066a071; KAUFFMAN HF, 1973, BIOCHIM BIOPHYS ACTA, V314, P276, DOI 10.1016/0005-2728(73)90112-6; KITA K, 1984, J BIOL CHEM, V259, P3375; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P1051, DOI 10.1021/bi00301a003; KONISHI K, 1986, J BIOCHEM, V99, P1227, DOI 10.1093/oxfordjournals.jbchem.a135586; KRASNOSELSKAYA I, 1993, FEBS LETT, V327, P279, DOI 10.1016/0014-5793(93)81004-J; LORENCE RM, 1986, BIOCHEMISTRY-US, V25, P2314, DOI 10.1021/bi00357a003; LORENCE RM, 1989, J BIOL CHEM, V264, P7135; MEINHARDT SW, 1989, BIOCHIM BIOPHYS ACTA, V975, P175, DOI 10.1016/S0005-2728(89)80216-6; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; PENG QY, 1994, FEBS LETT, V356, P159, DOI 10.1016/0014-5793(94)01253-9; POOLE RK, 1983, J GEN MICROBIOL, V129, P1335; POOLE RK, 1983, BIOCHIM BIOPHYS ACTA, V726, P205, DOI 10.1016/0304-4173(83)90006-X; PUDEK MR, 1974, ARCH BIOCHEM BIOPHYS, V164, P682, DOI 10.1016/0003-9861(74)90081-2; ROTHERY RA, 1989, BIOCHEM J, V261, P437, DOI 10.1042/bj2610437; SCOTT MJ, 1994, J AM CHEM SOC, V116, P11357, DOI 10.1021/ja00104a015; SPINNER F, 1995, BIOCHEM J, V308, P641, DOI 10.1042/bj3080641; TIMKOVICH R, 1985, J AM CHEM SOC, V107, P6069, DOI 10.1021/ja00307a041; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1132, DOI 10.1021/bi00535a004; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1992, BIOPHYS J, V63, P1564, DOI 10.1016/S0006-3495(92)81747-2; TSUBAKI M, 1993, FEBS LETT, V335, P13, DOI 10.1016/0014-5793(93)80430-3; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P164, DOI 10.1021/bi00052a022; UNO T, 1994, J BIOL CHEM, V269, P11912; UNO T, 1985, J BIOL CHEM, V260, P6755; YANG FD, 1986, J BIOL CHEM, V261, P4987; YOSHIKAWA S, 1985, J BIOL CHEM, V260, P3518; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412	44	66	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28565	28569		10.1074/jbc.270.48.28565	http://dx.doi.org/10.1074/jbc.270.48.28565			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499371	hybrid			2022-12-25	WOS:A1995TH05600015
J	WANG, XY; FUHRER, DK; MARSHALL, MS; YANG, YC				WANG, XY; FUHRER, DK; MARSHALL, MS; YANG, YC			INTERLEUKIN-11 INDUCES COMPLEX-FORMATION OF GRB2, FYN, AND JAK2 IN 3T3L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR TYROSINE KINASES; GTPASE-ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; SH3 DOMAIN; RAS; FAMILY	Previous studies suggested that interleukin-11 (IL-11) induces the activation of mitogen-activated protein kinase (MAPK) in mouse 3T3L1 cells. However, the mechanisms by which IL-11 activates MAPK remain elusive. Our present results show that IL-11 promotes the formation of the active GTP-bound form of Ras, suggesting that IL-11 actions may be transduced in part through the Ras/MAPK signaling pathway. By immunoblotting and immunoprecipitation, we further demonstrate the association of tyrosine phosphoproteins with Grb2, an adaptor protein serving as a key intermediate for Ras activation. These phosphotyrosine-containing proteins have been subsequently identified to be JAK2, Fyn, and Syp. JAK2 and Fyn are transiently associated with Grb2 upon stimulation with IL-11, suggesting that JAK2 and Fyn may be involved in transducing signals from the IL-11 receptor glycoprotein 130 to the Ras system through Grb2. Taken together, these results suggest that IL-11-induced interactions of JAK2, Fyn, and Grb2 may not only provide a novel mechanism for the activation of the Ras/MAPK system but also indicate cross-talk among diverse signaling pathways.	INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELLIS C, 1991, ONCOGENE, V6, P895; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; WEBB GC, 1993, GENOMICS, V18, P14, DOI 10.1006/geno.1993.1421; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1994, J BIOL CHEM, V269, P3731; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1994, EXP HEMATOL, V22, P467	31	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					27999	28002						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499280				2022-12-25	WOS:A1995TG21000005
J	KRAMER, RM; ROBERTS, EF; STRIFLER, BA; JOHNSTONE, EM				KRAMER, RM; ROBERTS, EF; STRIFLER, BA; JOHNSTONE, EM			THROMBIN INDUCES ACTIVATION OF P38 MAP KINASE IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHORYLATION; PROTEIN; CELLS	In human platelets a proline-directed kinase distinct from the ERK MAP kinases is stimulated by both thrombin and the thrombin receptor agonist peptide SFLLRN and may be involved in the activation of Ca2+-dependent cytosolic phospholipase Az (Kramer, R. M., Roberts, E. F., Hyslop, P. A., Utterback, B. G., Hui, K. Y., and Jakubowski, J. A. (1995) J. Biol. Chem. 270, 14816-14823). Here we show that this kinase is identical with or closely related to p38 (the mammalian homolog of HOG1 from yeast), a recently discovered protein kinase typically activated by inflammatory cytokines and environ mental stress. Further, we demonstrate that activation of this kinase by thrombin is transient (with maximal stimulation at 1 min), is accompanied by tyrosine phosphorylation, and precedes the activation of the ERK kinases, This is the first report to show that p38 kinase is activated by thrombin and to suggest a role for this MAP kinase in the thrombin-mediated signaling events during platelet activation.			KRAMER, RM (corresponding author), LILLY CORP CTR,LILLY RES LABS,CARDIOVASC RES,INDIANAPOLIS,IN 46285, USA.							BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COUGHLIN SR, 1994, SEMIN HEMATOL, V31, P270; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MINDEN A, 1995, CELL, P1147; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	20	186	191	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27395	27398		10.1074/jbc.270.46.27395	http://dx.doi.org/10.1074/jbc.270.46.27395			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499191	hybrid			2022-12-25	WOS:A1995TE73600002
J	NORGARDSUMNICHT, KE; ROUX, L; TOOMRE, DK; MANZI, A; FREEZE, HH; VARKI, A				NORGARDSUMNICHT, KE; ROUX, L; TOOMRE, DK; MANZI, A; FREEZE, HH; VARKI, A			UNUSUAL ANIONIC N-LINKED OLIGOSACCHARIDES FROM BOVINE LUNG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PULSED AMPEROMETRIC DETECTION; SIALIC ACIDS; DICTYOSTELIUM-DISCOIDEUM; EXCHANGE CHROMATOGRAPHY; STRUCTURAL-ANALYSIS; HNK-1 CARBOHYDRATE; MAMMALIAN-CELLS; KERATAN SULFATE; SUGAR CHAINS	We previously described a diverse family of sulfated anionic N-linked oligosaccharides released by peptide: N-glycosidase F (PNGaseF) from calf pulmonary artery endothelial (CPAE) cells (Roux, L., Holoyda, S,, Sundblad, G,, Freeze, H.H., and Varki, A, (1988) J. Biol. Chem. 263, 8879-8889), Since a major fraction of the intact lung consists of endothelial cells, we reasoned that bovine lung might be a rich source of similar molecules, Total N-linked oligosaccharides from bovine lung acetone powder were released by PNGaseF, labeled by [H-3]NaBH4 reduction, and the anionic fractions were studied with a variety of techniques, The sugar chains with lesser negative charge (designated Class I) share several properties of conventional multiantennary complex-type chains, However, unlike the case with CPAE cells, sialic acids account only for a minority of the anionic properties and only a small proportion carry sulfate esters, A variety of different treatments indicate that most of the unexplained negative charge is due to multiple carboxylic acid groups, Resistance to beta glucuronidase and alpha-iduronidase suggests that these may be previously undescribed modifications of mammalian oligosaccharides. The most highly charged N-linked chains (designated Class II) are more similar in general structure to the corresponding ones from CPAE cells, although relatively more abundant, Their high charge is primarily due to chondroitin sulfate, heparin/heparan sulfate, or keratan sulfate glycosaminoglycan chains, Sequential digestion studies suggest that a significant proportion of these molecules have more than one type of glycosaminoglycan chain associated with them, Compositional analysis indicates the presence of xylose residues in Class II, but not Class I molecules, However, unlike the case with conventional glycosaminoglycans, these residues are not at the reducing terminus. Most previously reported structures of complex-type N-linked oligosaccharides are derived from the glycoproteins of blood cells, plasma, or the secretions of cultured mammalian cells, This library of N-linked oligosaccharides from an intact mammalian organ (lung) contains a high proportion of novel anionic sugar chains whose structures are different from conventional complex-type sialylated chains and only partially related to those from CPAE cells, Further exploration of the N-linked chains of intact mammalian tissues seems warranted.	UNIV CALIF SAN DIEGO, SCH MED, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute				Freeze, Hudson/0000-0001-6316-0501	NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA38701] Funding Source: Medline; NHLBI NIH HHS [HL07107-19, P50 HL 23594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADACHE A, 1992, DEV NEUROSCI-BASEL, V14, P342, DOI 10.1159/000111681; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BRENNER W, 1995, ANAL BIOCHEM, V225, P213, DOI 10.1006/abio.1995.1146; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; EDGE ASB, 1984, J BIOL CHEM, V259, P4710; Evans MJ, 1989, LUNG CELL BIOL, P1; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GOWDA DC, 1989, BIOCHEMISTRY-US, V28, P4468, DOI 10.1021/bi00436a052; GREEN ED, 1988, J BIOL CHEM, V263, P25; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; HART GW, 1978, J BIOL CHEM, V253, P5795; HOFLACK B, 1982, EUR J BIOCHEM, V124, P527; KARLSSON NG, 1995, GLYCOCONJUGATE J, V12, P69, DOI 10.1007/BF00731871; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRESSE H, 1981, J BIOL CHEM, V256, P2926; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MOPPER K, 1973, ANAL BIOCHEM, V56, P440, DOI 10.1016/0003-2697(73)90210-8; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OKA S, 1992, J BIOL CHEM, V267, P22711; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; ROUX L, 1988, J BIOL CHEM, V263, P8879; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SILVESTRI LJ, 1982, ANAL BIOCHEM, V123, P303, DOI 10.1016/0003-2697(82)90450-X; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8890; TAKAHASHI N, 1990, J BIOL CHEM, V265, P7793; TAKAHASHI N, 1986, BIOCHEMISTRY-US, V25, P388, DOI 10.1021/bi00350a018; TAKASAKI S, 1974, J BIOCHEM-TOKYO, V76, P783; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1980, J BIOL CHEM, V255, P847; WAFFENSCHMIDT S, 1987, ANAL BIOCHEM, V165, P337, DOI 10.1016/0003-2697(87)90278-8; WEIBEL ER, 1976, LUNG CELLS DISEASE, P3; WING DR, 1992, GLYCOCONJUGATE J, V9, P293, DOI 10.1007/BF00731089; YAMASHITA K, 1983, J BIOL CHEM, V258, P4144	51	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27634	27645		10.1074/jbc.270.46.27634	http://dx.doi.org/10.1074/jbc.270.46.27634			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499228	hybrid			2022-12-25	WOS:A1995TE73600039
J	RAO, GN; DELAFONTAINE, P; RUNGE, MS				RAO, GN; DELAFONTAINE, P; RUNGE, MS			THROMBIN STIMULATES PHOSPHORYLATION OF INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR, INSULIN-RECEPTOR SUBSTRATE-1, AND PHOSPHOLIPASE C-GAMMA-1 IN RAT AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE-KINASE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; MOLECULAR-CLONING; ACTIVATION; INVITRO; MITOGENESIS; MECHANISM; SEVENLESS	It has recently been reported that protein-tyrosine kinase activity is required for thrombin-induced growth in vascular smooth muscle cells (VSMC). In the present study, we have identified several phosphoproteins that are tyrosine-phosphorylated in response to thrombin in quiescent VSMC. These proteins are insulin-like growth factor-1 receptor beta-subunit (IGF-IR beta), insulin receptor substrate-1 (IRS-1), and phospholipase C-gamma 1 (PLC-gamma 1). Thrombin-stimulated phosphorylation of these proteins was rapid; it was maximal at 1 min and reduced thereafter. Thrombin also activated mitogen-activated protein kinases (MAPK) in quiescent VSMC in a biphasic manner with a rapid and larger peak at 10 min (6-fold) followed by a sustained smaller second peak at 2 h (2-fold). Inhibition of protein-tyrosine kinase activity by the use of two structurally different protein-tyrosine kinase inhibitors, genistein and herbimycin A, significantly blocked the thrombin-induced tyrosine phosphorylation of IGF-1R beta, IRS-1, and PLC-gamma 1 and decreased thrombin-stimulated DNA synthesis. In contrast, however, inhibition of protein-tyrosine kinase activity had no effect on thrombin activation of MAPK. Collectively, these findings suggest a role for tyrosine phosphorylation of IGF-IR beta, IRS-1, and PLC-gamma 1 in thrombin-induced mitogenic signaling events in VSMC. Furthermore, while protein tyrosine phosphorylation is essential for thrombin-induced DNA synthesis, it is not required for thrombin-stimulated MAPK activation. Since thrombin rapidly activated Src in VSMC, Src may be involved in the cross-talk between the G-protein-coupled receptor agonist and a tyrosine kinase receptor such as IGF-1R.	EMORY UNIV,SCH MED,DIV CARDIOL,ATLANTA,GA 30322	Emory University	RAO, GN (corresponding author), UNIV TEXAS,MED BRANCH,DIV CARDIOL,9138 MED RES BLDG,RT 1064,301 UNIV BLVD,GALVESTON,TX 77555, USA.			Delafontaine, Patrice/0000-0003-3744-3617				ADAMO M, 1992, BIOFACTORS, V3, P151; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHUANG LM, 1994, J BIOL CHEM, V268, P27645; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FEINSTEIN MB, 1993, ADV EXP MED BIOL, V344, P129; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P318; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELZIG M, 1986, BIOMED BIOCHIM ACTA, V45, P1199; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAREMBOCK IJ, 1991, CIRCULATION, V84, P232, DOI 10.1161/01.CIR.84.1.232; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	49	132	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27871	27875		10.1074/jbc.270.46.27871	http://dx.doi.org/10.1074/jbc.270.46.27871			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499260	hybrid			2022-12-25	WOS:A1995TE73600071
J	SANCEAU, J; KAISHO, T; HIRANO, T; WIETZERBIN, J				SANCEAU, J; KAISHO, T; HIRANO, T; WIETZERBIN, J			TRIGGERING OF THE HUMAN INTERLEUKIN-6 GENE BY INTERFERON-GAMMA AND TUMOR-NECROSIS-FACTOR-ALPHA IN MONOCYTIC CELLS INVOLVES COOPERATION BETWEEN INTERFERON REGULATORY FACTOR-I, NF-KAPPA-B, AND SP1 TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; FACTOR-II; ACTIVATION; PROTEIN; EXPRESSION; BINDING; PROMOTER; ELEMENTS; IRF-1	We investigated the molecular basis of the synergistic induction by iterferon-gamma (IFN-gamma)/tumor necrosis factor-alpha (TNF-alpha) of human interleukin-6 (IL-6) gene in THP-1 monocytic cells, and compared it with the basis of this induction by lipopolysaccharide (LPS), Functional studies with IL-6 promoter demonstrated that three regions are the targets of the IFN-gamma and/or TNF-gamma action, whereas only one of these regions seemed to be implicated in LPS activation, The three regions concerned are: 1) a region between -73 and -36, which is the minimal element inducible by LPS or TNF-alpha; 2) an element located between -181 and -73, which appeared to regulate the response to IFN-gamma and TNF-alpha negatively; and 3) a distal element upstream of -224, which was inducible by IFN-gamma alone. LPS signaling was found to involve MF kappa B activation by the p50/p65 heterodimers. Synergis tic induction of the IL-6 gene by IFN-gamma and TNF-alpha, in monocytic cells, involved cooperation between the IRF-1 and NF kappa B p65 homodimers with concomitant removal of the negative effect of the retinoblastoma control element present in the IL-6 promoter. This removal occurred by activation of the constitutive Sp1 factor, whose increased binding activity and phosphorylation were mediated by IFN-gamma.	OSAKA UNIV, SCH MED, CTR BIOMED RES, DIV MOLEC ONCOL, SUITA, OSAKA 565, JAPAN	Osaka University	SANCEAU, J (corresponding author), INST CURIE, INSERM, U365, RECH SECT, 26 RUE ULM, F-75231 PARIS, FRANCE.		Kaisho, Tsuneyasu/B-4130-2012; Hirano, Toshio/C-8194-2009					BAGNARA GP, 1993, STEM CELLS, V11, P137; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOUTWOOD J, 1993, BLOOD, V82, P2611; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; EMILIE D, 1994, BLOOD, V84, P2472; EMILIE D, 1992, BLOOD, V80, P498; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; INOUE K, 1994, BLOOD, V84, P2672, DOI 10.1182/blood.V84.8.2672.bloodjournal8482672; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KERR IM, 1991, FEBS LETT, V285, P194, DOI 10.1016/0014-5793(91)80802-A; KIEHNTOPF M, 1995, J EXP MED, V181, P793, DOI 10.1084/jem.181.2.793; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LIN RT, 1994, J BIOL CHEM, V269, P17542; LIU JM, 1994, BLOOD, V84, P3995, DOI 10.1182/blood.V84.12.3995.bloodjournal84123995; MCGINLEY MD, 1995, J BIOL CHEM, V270, P5213, DOI 10.1074/jbc.270.10.5213; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MORI N, 1994, BLOOD, V84, P2904; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NICHOLS J, 1992, BLOOD, V80, P2953; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PORGADOR A, 1992, CANCER RES, V52, P3679; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; REIMANN T, 1994, J IMMUNOL, V153, P5740; REVEL M, 1989, EXPERIENTIA, V45, P549, DOI 10.1007/BF01990505; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSSELLI F, 1992, HUM GENET, V89, P42, DOI 10.1007/BF00207040; Sambrook J, 1989, MOL CLONING LABORATO; SANCEAU J, 1991, J IMMUNOL, V147, P2630; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCAMBIA G, 1995, BRIT J CANCER, V71, P354, DOI 10.1038/bjc.1995.71; SEHGAL PB, 1987, SCIENCE, V235, P731, DOI 10.1126/science.3492764; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SUZUKI T, 1990, JPN J CANCER RES, V81, P979, DOI 10.1111/j.1349-7006.1990.tb03335.x; TANABE O, 1988, J IMMUNOL, V141, P3875; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; UEDA A, 1994, J IMMUNOL, V153, P2052; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; WANLENG D, 1993, J IMMUNOL, V151, P322; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WIETZERBIN J, 1990, J LEUKOCYTE BIOL, V48, P149, DOI 10.1002/jlb.48.2.149; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x	81	187	191	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27920	27931		10.1074/jbc.270.46.27920	http://dx.doi.org/10.1074/jbc.270.46.27920			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499267	hybrid			2022-12-25	WOS:A1995TE73600078
J	TORTORELLA, D; SESARDIC, D; DAWES, CS; LONDON, E				TORTORELLA, D; SESARDIC, D; DAWES, CS; LONDON, E			IMMUNOCHEMICAL ANALYSIS OF THE STRUCTURE OF DIPHTHERIA-TOXIN SHOWS ALL 3 DOMAINS UNDERGO STRUCTURAL-CHANGES AT LOW PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY ANALYSIS; MODEL MEMBRANES; FRAGMENT-A; CONFORMATIONAL-CHANGES; BINDING DOMAIN; CELLS; TRANSLOCATION; LOCALIZATION; RECEPTOR; ENTRY	Diphtheria toxin is a bacterial protein that undergoes a physiologically critical conformational change at low pH, This change involves a partial unfolding event forming a molten globule-like structure, which exposes hydrophobic regions and which allows the toxin to insert into, and translocate across, membranes, In this report, antibody binding was used to examine the regions of the toxin that undergo structural changes at low pH. Monoclonal antibodies specific to the catalytic (C), transmembrane (T), and receptor-binding (R) domains of diphtheria toxin were prepared and isolated, In addition, the binding of anti-peptide antibodies raised against pep tides in the C and T domains to toxin was examined, Anti-C monoclonals and antipeptide antibodies were found to bind preferentially to low pH treated toxin relative to native toxin, Anti T and anti-R monoclonal binding ranged between preference for native toxin and preference for low pH-treated toxin, These results suggest that the C domain becomes more exposed to solution at low pH, and that both the T and R domains of the B chain undergo major conformational changes at low pH, Based on these results, a model in which low pH induces several coordinated changes in intra- and inter-domain interactions is suggested, The participation of the R domain in these changes is of particular significance because it suggests that the R domain plays a more important role in low pi-I-induced changes than previously realized.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; NATL INST BIOL STAND & CONTROLS,POTTERS BAR EN6 3QG,HERTS,ENGLAND	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institute for Biological Standards & Control				Tortorella, Domenico/0000-0003-0961-3535	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31986] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUTRAN B, 1987, IMMUNOLOGY, V60, P531; BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; BIGIO M, 1987, FEBS LETT, V218, P271, DOI 10.1016/0014-5793(87)81060-8; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CHUNG LA, 1988, BIOCHEMISTRY-US, V27, P1245, DOI 10.1021/bi00404a026; COLLIER RJ, 1982, ADP RIBOSYLATION REA, P573; COLLINS CM, 1987, UCLA S MOL CELL BIOL, V45, P41; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; ESBENSEN QY, 1993, BIOCHEM J, V294, P663, DOI 10.1042/bj2940663; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HAYAKAWA S, 1983, J BIOL CHEM, V258, P4311; HU VW, 1984, J BIOL CHEM, V259, P2226; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; JIANG JX, 1991, J BIOL CHEM, V266, P24003; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MONTECUCCO C, 1985, BIOCHEM J, V231, P123, DOI 10.1042/bj2310123; MURPHY JR, 1985, CURR TOP MICROBIOL, V118, P235; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OGATA M, 1991, INFECT IMMUN, V59, P407, DOI 10.1128/IAI.59.1.407-414.1991; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; PAPPENHEIMER AM, 1972, IMMUNOCHEMISTRY, V9, P891, DOI 10.1016/0019-2791(72)90163-2; ROLF JM, 1990, J BIOL CHEM, V265, P7331; ROLF JM, 1993, INFECT IMMUN, V61, P994, DOI 10.1128/IAI.61.3.994-1003.1993; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SESARDIC D, 1992, J GEN MICROBIOL, V138, P2197, DOI 10.1099/00221287-138-10-2197; TORTORELLA D, 1993, BIOCHEMISTRY-US, V32, P9181, DOI 10.1021/bi00086a025; TORTORELLA D, 1995, J BIOL CHEM, V270, P27446, DOI 10.1074/jbc.270.46.27446; WEISS MS, 1995, BIOCHEMISTRY-US, V34, P773, DOI 10.1021/bi00003a010; YOSHIMORI T, 1984, EXP CELL RES, V151, P344, DOI 10.1016/0014-4827(84)90385-9; ZALMAN LS, 1984, P NATL ACAD SCI-BIOL, V81, P3341, DOI 10.1073/pnas.81.11.3341; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZHAO JM, 1986, P NATL ACAD SCI USA, V83, P2002, DOI 10.1073/pnas.83.7.2002; ZHAO JM, 1988, J BIOL CHEM, V263, P15369; ZHAO JM, 1988, BIOCHEMISTRY-US, V27, P3398, DOI 10.1021/bi00409a041; ZUCKER DR, 1984, MOL IMMUNOL, V21, P795, DOI 10.1016/0161-5890(84)90166-4; ZUCKER DR, 1984, MOL IMMUNOL, V21, P785, DOI 10.1016/0161-5890(84)90165-2	39	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27439	27445		10.1074/jbc.270.46.27439	http://dx.doi.org/10.1074/jbc.270.46.27439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499200	hybrid			2022-12-25	WOS:A1995TE73600011
J	TORTORELLA, D; SESARDIC, D; DAWES, CS; LONDON, E				TORTORELLA, D; SESARDIC, D; DAWES, CS; LONDON, E			IMMUNOCHEMICAL ANALYSIS SHOWS ALL 3 DOMAINS OF DIPHTHERIA-TOXIN PENETRATE ACROSS MODEL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGMENT-B; LOW PH; TRANSLOCATION; INSERTION; BINDING; REDUCTION; DISULFIDE; CYTOSOL; ENTRY; CELLS	Diphtheria toxin undergoes membrane insertion and translocation across membranes when exposed to low pH, In this study, the translocation of the toxin has been investigated by the binding of antibodies to two preparations of model membrane-inserted toxin, In one prep aration, toxin was added externally to model membrane vesicles and then inserted by exposure to low pH, In the other preparation, toxin was entrapped in the vesicles at neutral pH, and then inserted by decreasing pH, At neutral pH, externally added antibodies could not bind to entrapped toxin, although they could bind to externally added native toxin, However, after low pH exposure, antibodies against all three toxin domains (catalytic (C), transmembrane (T), and receptor-binding (R)) could bind to entrapped toxin, and also to externally added membrane-inserted toxin, The binding to the entrapped toxin shows that all three domains of the toxin translocate to the trans face of the membrane after exposure to low pH, The observation that antibodies bind to both external and entrapped preparations of toxin after low pH exposure shows that toxin inserts in a mixed orientation. A difference in antibody binding to low pH-treated toxin in which the C domain is folded (Lr' conformation) or unfolded (Lr '' conformation) was also observed, An increase in antibody binding to C and T domains in the Lr '' conformation relative to binding to the Lr' conformation was found for entrapped toxin, suggesting that more of the C and T domains translocate across the bilayer in the Lr '' conformation. These results suggest all three toxin domains insert in the membrane bilayer and participate in translocation in vitro. The C and R domains lack classical transmembrane hydrophobic sequences, However, they possess sequences that have the potential to form membrane-inserting beta-sheets.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; NATL INST BIOL STAND & CONTROLS,POTTERS BAR EN6 3QG,HERTS,ENGLAND	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institute for Biological Standards & Control				Tortorella, Domenico/0000-0003-0961-3535	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31986] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; ESBENSEN QY, 1993, BIOCHEM J, V294, P663, DOI 10.1042/bj2940663; FALNES PO, 1993, J BIOL CHEM, V269, P8402; GONZALEZ JE, 1988, J BIOL CHEM, V263, P15257; HU VW, 1984, J BIOL CHEM, V259, P2226; IDZIOREK T, 1990, INFECT IMMUN, V58, P1415, DOI 10.1128/IAI.58.5.1415-1420.1990; JIANG GS, 1989, J BIOL CHEM, V264, P13424; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; JIANG JX, 1991, J BIOL CHEM, V266, P24003; JIN L, 1992, J MOL BIOL, V266, P851; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; LONDON E, 1992, MOL MICROBIOL, V6, P3277, DOI 10.1111/j.1365-2958.1992.tb02195.x; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; MADSHUS IH, 1994, J BIOL CHEM, V269, P17723; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; MONTECUCCO C, 1985, BIOCHEM J, V231, P123, DOI 10.1042/bj2310123; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; PAPINI E, 1993, J BIOL CHEM, V268, P1567; TORTORELLA D, 1993, BIOCHEMISTRY-US, V32, P9181, DOI 10.1021/bi00086a025; TORTORELLA D, 1995, J BIOL CHEM, V270, P27439, DOI 10.1074/jbc.270.46.27439; VANDERSPEK JC, 1993, J BIOL CHEM, V268, P12077; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WIEDLOCHA A, 1992, EMBO J, V13, P4835; ZALMAN LS, 1984, P NATL ACAD SCI-BIOL, V81, P3341, DOI 10.1073/pnas.81.11.3341; ZHAO JM, 1988, J BIOL CHEM, V263, P15369	30	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27446	27452		10.1074/jbc.270.46.27446	http://dx.doi.org/10.1074/jbc.270.46.27446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499201				2022-12-25	WOS:A1995TE73600012
J	TAMURA, T; AOYAMA, N; SAYA, H; HAGA, H; FUTAMI, S; MIYAMOTO, M; KOH, T; ARIYASU, T; TACHI, M; KASUGA, M; TAKAHASHI, R				TAMURA, T; AOYAMA, N; SAYA, H; HAGA, H; FUTAMI, S; MIYAMOTO, M; KOH, T; ARIYASU, T; TACHI, M; KASUGA, M; TAKAHASHI, R			INDUCTION OF FAS-MEDIATED APOPTOSIS IN P53-TRANSFECTED HUMAN COLON-CARCINOMA CELLS	ONCOGENE			English	Article						P53; FAS; APOPTOSIS; COLON CANCER	WILD-TYPE P53; TUMOR-NECROSIS-FACTOR; HUMAN GASTRIC-CANCER; SUPPRESSOR GENE; GROWTH; MUTATIONS; RECEPTOR; PROTEIN; LINE; DNA	To investigate the biological function of p53 in colon carcinoma cells, a wild-type p53 expression plasmid under the control of the human cytomegalovirus promoter was stably transfected into the human colon adenocarcinoma cell line WiDr, which carries a mutation of the p53 gene at codon 273. Exogenous wild-type p53 transcripts were detected at various expression levels in 8 of 117 G418-resistant clones. The growth rates of the wild-type p53+ clones in culture did not change significantly. The efficiency of colony formation in soft agar, however, was completely suppressed in two wild-type p53+ clones. This is the first to demonstrate the feasibility of stable transfection of the wild-type p53 gene under the control of non-inducible promoter in human colon cancer cells. The major alteration found was that wild-type p53+ cells which were incubated with anti-Fas IgM showed marked cytolysis,vith preferential overexpression of wild-type p53 accompanied by overexpression of a cyclin-dependent kinase inhibitor, WAF1, whereas the endogenous mutant p53 retained its expression level. The findings suggest that a Fas-initiated pathway is incidentally linked to a p53-dependent apoptotic pathway through the reconstituted wild-type p53 gene in WiDr cells. This model should help elucidating the additional role of the p53 tumor suppressor gene and the mechanism of apoptosis in colon carcinoma cells.	KYOTO UNIV,GRAD SCH MED,DEPT PATHOL & TUMOR BIOL,SAKYO KU,KYOTO 606,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT ONCOL,KUMAMOTO 860,JAPAN	Kyoto University; Kobe University; Kumamoto University			Saya, Hideyuki/J-4325-2013					BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CAJOT JF, 1992, CANCER RES, V52, P6956; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG JH, 1995, J IMMUNOL, V154, P1239; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FRITSCHE M, 1993, ONCOGENE, V8, P307; HABUCHI T, 1993, CANCER RES, V53, P3795; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HARPER JW, 1993, CELL, V75, P805; HOLSTEIN M, 1991, SCIENCE, V253, P49; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KYO E, 1993, INT J ONCOL, V3, P265; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATOZAKI T, 1992, CANCER RES, V52, P4335; MATOZAKI T, 1992, BIOCHEM BIOPH RES CO, V182, P215, DOI 10.1016/S0006-291X(05)80133-0; MERRITT AJ, 1994, CANCER RES, V54, P614; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; RIDGWAY PJ, 1993, ONCOGENE, V8, P1069; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEIN J, 1993, J GEN VIROL, V74, P2333, DOI 10.1099/0022-1317-74-11-2333; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1992, CANCER RES, V52, P2340; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; WONG GHW, 1994, J IMMUNOL, V152, P1951; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	44	93	93	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1939	1946						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478511				2022-12-25	WOS:A1995TF29700002
J	FOX, JEB; LIPFERT, L; CLARK, EA; REYNOLDS, CC; AUSTIN, CD; BRUGGE, JS				FOX, JEB; LIPFERT, L; CLARK, EA; REYNOLDS, CC; AUSTIN, CD; BRUGGE, JS			ON THE ROLE OF THE PLATELET MEMBRANE SKELETON IN MEDIATING SIGNAL-TRANSDUCTION - ASSOCIATION OF GP-IIB-IIIA, PP60(C-SRC), PP62(C-YES), AND THE P21(RAS) GTPASE-ACTIVATING PROTEIN WITH THE MEMBRANE SKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; INSOLUBLE CELLULAR MATRIX; GLYCOPROTEIN-IIB; TYROSINE PHOSPHORYLATION; ACTIN-FILAMENTS; PHOSPHOLIPASE-C; CYTOSKELETAL STRUCTURES; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS	The platelet plasma membrane is lined with a membrane skeleton composed of short actin filaments, actin-binding protein, spectrin, vinculin, and other unidentified proteins. It is connected to the outside of the cell through association with the cytoplasmic domains of transmembrane receptors. In detergent-lysed platelets, cytoplasmic actin filaments are sedimented by centrifugation at 15,600 X g, but the sedimentation of membrane skeleton fragments requires higher g-forces (100,000 X g). In the present study, we show that the major platelet integrin, glycoprotein (GP) IIb-IIIa, sediments from detergent-lysed platelets at 100,000 x g together with fragments of the membrane skeleton that contain the cytoskeletal proteins spectrin, vinculin, and talin. In addition, this cell fraction contained the tyrosine kinases pp60c-src and pp62c-yes and the p21ras GTPase-activating protein (GAP). After thrombin-induced platelet aggregation mediated by fibrinogen binding to GP IIb-IIIa on adjacent platelets, we detected a redistribution of spectrin, talin, vinculin, pp60c-src, and pp62c-yes to the fraction that sediments at 15,600 X g. The redistribution of these proteins from the high-speed detergent-insoluble fraction to the low-speed fraction correlated with the extent of aggregation and was not detected in aggregation-defective thrombasthenic platelets (which lack the GP IIb-IIIa complex). In addition, many of the proteins phosphorylated on tyrosine in activated platelets were present in detergent-insoluble fractions. These results are consistent with the possibilities that 1) GP IIb-IIIa, pp60c-src, pp62c-yes, and GAP associate with a membrane skeleton fraction that contains spectrin, vinculin, and talin, 2) the association of GP IIb-IIIa with adhesive ligand in a platelet aggregate causes components of the membrane skeleton to undergo altered association with cytoplasmic actin filaments, and 3) many of the proteins phosphorylated on tyrosine residues in activated platelets are components of the cytoskeleton. The results imply that the membrane skeleton may play an important role in binding signaling molecules at sites of integrin-cytoskeleton interactions and in mediating signal transduction events in platelets. Further, GP IIb-IIIa-induced redistribution of components of the membrane skeleton and associated signaling molecules may represent an important step in regulating integrin-induced motile events in platelets.	GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Takeda Pharmaceutical Company Ltd; Takeda Oncology; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	FOX, JEB (corresponding author), CHILDRENS HOSP,OAKLAND RES INST,747 52ND ST,OAKLAND,CA 94609, USA.				NCI NIH HHS [CA47572] Funding Source: Medline; NHLBI NIH HHS [HL30657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030657, R01HL030657, R37HL030657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASIJEE GM, 1990, EUR J BIOCHEM, V189, P131, DOI 10.1111/j.1432-1033.1990.tb15469.x; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BOYLES J, 1985, J CELL BIOL, V101, P1463, DOI 10.1083/jcb.101.4.1463; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1990, ONCOGENE, V5, P1033; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FOX JEB, 1984, J CELL BIOL, V98, P1985, DOI 10.1083/jcb.98.6.1985; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; FOX JEB, 1987, THROMB DIATH HAEMO, P175; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GARTNER TK, 1988, THROMB RES, V49, P43; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KARLSSON R, 1984, J CELL PHYSIOL, V121, P96, DOI 10.1002/jcp.1041210113; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; PHILLIPS DR, 1972, BIOCHEMISTRY-US, V11, P4582, DOI 10.1021/bi00774a025; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RESH MD, 1990, ONCOGENE, V5, P1437; RITTENHOUSE SE, 1983, P NATL ACAD SCI-BIOL, V80, P5417, DOI 10.1073/pnas.80.17.5417; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; TORI M, 1992, P NATL ACAD SCI USA, V89, P7796; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WEISS HJ, 1991, THROMB HAEMOSTASIS, V65, P202; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WHITE JG, 1984, AM J PATHOL, V117, P207; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; ZHANG J, 1992, J BIOL CHEM, V267, P4686	72	238	240	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25973	25984						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503992				2022-12-25	WOS:A1993MK10000098
J	GU, Y; HALL, ZW				GU, Y; HALL, ZW			CHARACTERIZATION OF ACETYLCHOLINE-RECEPTOR SUBUNITS IN DEVELOPING AND IN DENERVATED MAMMALIAN MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,DIV NEUROBIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BLACK R, 1987, J CELL BIOL, V105, P1329, DOI 10.1083/jcb.105.3.1329; BLOCH RJ, 1987, J CELL BIOL, V104, P645, DOI 10.1083/jcb.104.3.645; BOULTER J, 1985, J NEUROSCI, V5, P2545; BROCKES JP, 1975, BIOCHEMISTRY-US, V14, P2100, DOI 10.1021/bi00681a009; BROCKES JP, 1975, BIOCHEMISTRY-US, V14, P2092, DOI 10.1021/bi00681a008; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CLAUDIO T, 1987, SCIENCE, V238, P1688, DOI 10.1126/science.3686008; CONTITRONCONI BM, 1982, SCIENCE, V218, P1227, DOI 10.1126/science.7146904; DOWDING AJ, 1987, BIOCHEMISTRY-US, V26, P6372, DOI 10.1021/bi00394a010; EINARSON B, 1982, BIOCHEMISTRY-US, V21, P5295, DOI 10.1021/bi00264a027; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; FROEHNER SC, 1977, P NATL ACAD SCI USA, V74, P4685, DOI 10.1073/pnas.74.10.4685; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; KUBALEK E, 1987, J CELL BIOL, V105, P9, DOI 10.1083/jcb.105.1.9; KUBO T, 1985, EUR J BIOCHEM, V149, P5, DOI 10.1111/j.1432-1033.1985.tb08885.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LO MMS, 1981, EUR J BIOCHEM, V116, P155, DOI 10.1111/j.1432-1033.1981.tb05313.x; MCCARTHY MP, 1986, ANNU REV NEUROSCI, V9, P383; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MERLIE JP, 1981, J BIOL CHEM, V256, P6995; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NATHANSON NM, 1979, BIOCHEMISTRY-US, V18, P3392, DOI 10.1021/bi00582a028; NATHANSON NM, 1980, J BIOL CHEM, V255, P1698; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; NOMOTO H, 1986, EUR J BIOCHEM, V157, P233, DOI 10.1111/j.1432-1033.1986.tb09661.x; NUMA S, 1983, COLD SPRING HARB SYM, V48, P57, DOI 10.1101/SQB.1983.048.01.008; PATRICK J, 1983, COLD SPRING HARB SYM, V48, P71, DOI 10.1101/SQB.1983.048.01.009; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2633, DOI 10.1021/bi00357a052; ROLE LW, 1987, ANN REV NEUROSCI, V10, P403; SALPETER MM, 1987, VERTEBRATE NEUROMUSC, P55; SARGENT PB, 1984, J CELL BIOL, V98, P609, DOI 10.1083/jcb.98.2.609; SHIBAHARA S, 1985, EUR J BIOCHEM, V146, P15, DOI 10.1111/j.1432-1033.1985.tb08614.x; SHORR RG, 1981, EUR J BIOCHEM, V116, P143, DOI 10.1111/j.1432-1033.1981.tb05312.x; SMITH MM, 1987, J BIOL CHEM, V262, P4367; TAKAI T, 1984, EUR J BIOCHEM, V143, P109, DOI 10.1111/j.1432-1033.1984.tb08348.x; TAKAI T, 1985, NATURE, V315, P761, DOI 10.1038/315761a0; TANABE T, 1984, EUR J BIOCHEM, V144, P11, DOI 10.1111/j.1432-1033.1984.tb08424.x; Tarentino A L, 1978, Methods Enzymol, V50, P574; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; WITZEMANN V, 1987, FEBS LETT, V223, P104, DOI 10.1016/0014-5793(87)80518-5; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539	47	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12878	12885						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417640				2022-12-25	WOS:A1988Q091700019
J	METTERS, KM; ROSSIER, J; PAQUIN, J; CHRETIEN, M; SEIDAH, NG				METTERS, KM; ROSSIER, J; PAQUIN, J; CHRETIEN, M; SEIDAH, NG			SELECTIVE CLEAVAGE OF PROENKEPHALIN-DERIVED PEPTIDES (LESS-THAN-23,300 DALTONS) BY PLASMA KALLIKREIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									CNRS, PHYSIOL NERVEUSE LAB, F-91190 GIF SUR YVETTE, FRANCE; CLIN RES INST MONTREAL, JA DE SEVE LABS BIOCHEM & MOLEC NEUROENDOCRINOL, MONTREAL H2W 1R7, QUEBEC, CANADA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; CHRETIEN, Michel/0000-0002-8588-4460				BAIRD A, 1984, P SOC EXP BIOL MED, V175, P304; BEAUMONT A, 1985, J NEUROCHEM, V44, P934, DOI 10.1111/j.1471-4159.1985.tb12907.x; BLOCH KD, 1985, SCIENCE, V230, P1168, DOI 10.1126/science.2933808; BLOCH KD, 1987, J AM PHYSL, V252, pE147; BOARDER MR, 1982, J CLIN ENDOCR METAB, V54, P715, DOI 10.1210/jcem-54-4-715; CHAMINADE M, 1984, J PHYSIOL-LONDON, V353, P157, DOI 10.1113/jphysiol.1984.sp015329; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; CROMLISH JA, 1986, J BIOL CHEM, V261, P859; CROMLISH JA, 1986, J BIOL CHEM, V261, P850; CUPO A, 1984, NEUROPEPTIDES, V4, P389, DOI 10.1016/0143-4179(84)90114-8; DERKX FHM, 1987, J BIOL CHEM, V262, P2472; EDWARDS AV, 1986, J PHYSIOL-LONDON, V379, P1, DOI 10.1113/jphysiol.1986.sp016237; EVANGELISTA R, 1982, BIOCHEM BIOPH RES CO, V106, P895, DOI 10.1016/0006-291X(82)91795-8; EVANS SF, 1984, LIFE SCI, V34, P1481, DOI 10.1016/0024-3205(84)90063-8; GIBSON TR, 1987, ENDOCRINOLOGY, V120, P764, DOI 10.1210/endo-120-2-764; GIRAUD AS, 1984, NEUROSCI LETT, V46, P223, DOI 10.1016/0304-3940(84)90446-4; GLEMBOTSKI CC, 1985, BIOCHEM BIOPH RES CO, V132, P1008, DOI 10.1016/0006-291X(85)91907-2; GROS C, 1978, J NEUROCHEM, V31, P29, DOI 10.1111/j.1471-4159.1978.tb12429.x; HEXUM TD, 1980, NEUROPEPTIDES, V1, P137, DOI 10.1016/0143-4179(80)90016-5; JONES BN, 1982, P NATL ACAD SCI-BIOL, V79, P1313, DOI 10.1073/pnas.79.4.1313; KILPATRICK DL, 1981, P NATL ACAD SCI-BIOL, V78, P3265, DOI 10.1073/pnas.78.5.3265; KILPATRICK DL, 1981, BIOCHEM BIOPH RES CO, V103, P698, DOI 10.1016/0006-291X(81)90506-4; KILPATRICK DL, 1980, P NATL ACAD SCI-BIOL, V77, P7473, DOI 10.1073/pnas.77.12.7473; KIMURA S, 1980, P NATL ACAD SCI-BIOL, V77, P1681, DOI 10.1073/pnas.77.3.1681; KREAEMER WJ, 1985, P NATL ACAD SCI USA, V82, P6349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P287, DOI 10.1139/o83-039; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P501, DOI 10.1139/o83-066; LINDBERG I, 1984, J NEUROCHEM, V42, P1411, DOI 10.1111/j.1471-4159.1984.tb02802.x; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LISTON D, 1984, J NEUROCHEM, V43, P335, DOI 10.1111/j.1471-4159.1984.tb00905.x; LISTON DR, 1983, NATURE, V302, P62, DOI 10.1038/302062a0; LIVETT BG, 1981, NATURE, V289, P317, DOI 10.1038/289317a0; METTERS KM, 1985, NEUROPEPTIDES, V5, P521, DOI 10.1016/0143-4179(85)90069-1; METTERS KM, 1987, J NEUROCHEM, V49, P721, DOI 10.1111/j.1471-4159.1987.tb00953.x; MIZUNO K, 1985, BIOCHEM BIOPH RES CO, V128, P884, DOI 10.1016/0006-291X(85)90129-9; MIZUNO K, 1980, BIOCHEM BIOPH RES CO, V95, P1482, DOI 10.1016/S0006-291X(80)80064-7; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; PATEY G, 1984, FEBS LETT, V172, P303, DOI 10.1016/0014-5793(84)81146-1; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; ROSSIER J, 1987, IN PRESS 10TH P INT; SEIDAH NG, 1986, BIOSCIENCE REP, V6, P835, DOI 10.1007/BF01117107; SEIDAH NG, 1987, FEBS LETT, V211, P144, DOI 10.1016/0014-5793(87)81425-4; SEIDAH NG, 1988, BIOCHIMIE, V70, P33, DOI 10.1016/0300-9084(88)90156-3; STELL WK, 1987, IN PRESS J NEUROCHEM; STERN AS, 1979, P NATL ACAD SCI USA, V76, P6680, DOI 10.1073/pnas.76.12.6680; STERN AS, 1981, P NATL ACAD SCI-BIOL, V78, P1962, DOI 10.1073/pnas.78.3.1962; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROY CM, 1982, LIFE SCI, V31, P1717, DOI 10.1016/0024-3205(82)90193-X; WEBER E, 1983, P NATL ACAD SCI-BIOL, V80, P7362, DOI 10.1073/pnas.80.23.7362; ZARKADAS CG, 1987, ANAL BIOCHEM, V160, P251, DOI 10.1016/0003-2697(87)90045-5	52	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1988	263	25					12543	12553						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P8611	3410851				2022-12-25	WOS:A1988P861100060
J	CHEN, LM; YET, MG; SHAO, MC				CHEN, LM; YET, MG; SHAO, MC			NEW METHODS FOR RAPID SEPARATION AND DETECTION OF OLIGOSACCHARIDES FROM GLYCOPROTEINS	FASEB JOURNAL			English	Note									UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031305] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31305] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HARDY MR, 1988, P NATL ACAD SCI USA, V85, P3289, DOI 10.1073/pnas.85.10.3289; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; KOHNO M, 1972, METHOD ENZYMOL, V28, P786; OLECHNO JD, 1987, AM BIOTECHNOL LAB, V5, P38; RENDLEMAN JA, 1971, ADV CHEM SER, V117, P51; SHAO MC, 1987, J BIOL CHEM, V262, P2968; SHAO MC, 1987, J BIOL CHEM, V262, P2973; TAI T, 1977, J BIOL CHEM, V252, P6687; TAI T, 1975, J BIOL CHEM, V250, P8569; TOWNSEND RR, 1984, BIOCHEMISTRY-US, V23, P6389, DOI 10.1021/bi00321a016; YAMASHITA K, 1978, J BIOL CHEM, V253, P3862; YET MG, 1988, J BIOL CHEM, V263, P111	14	45	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1988	2	12					2819	2824		10.1096/fasebj.2.12.3410198	http://dx.doi.org/10.1096/fasebj.2.12.3410198			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	Q0229	3410198				2022-12-25	WOS:A1988Q022900012
J	ANDRAKE, MD; SKALKA, AM				ANDRAKE, MD; SKALKA, AM			MULTIMERIZATION DETERMINANTS RESIDE IN BOTH THE CATALYTIC CORE AND C-TERMINUS OF AVIAN-SARCOMA VIRUS INTEGRASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-PROTEIN INTERACTIONS; SITE-SPECIFIC RECOMBINATION; ESCHERICHIA-COLI; HIV-1 INTEGRASE; BINDING PROTEIN; DNA-BINDING; DOMAINS; INVITRO; IDENTIFICATION	We have shown previously that the active form of avian sarcoma virus integrase (ASV IN) is a multimer. In this report we investigate IN multimerization properties by a variety of methods that include size exclusion chromatography, chemical cross-linking, and protein overlay assays. We show that removal of the nonconserved C-terminal region of IN results in a reduced capacity for multimerization, whereas deletion of the first 38 amino acids has little effect on the oligomeric state. Binding of a full-length IN fusion protein to various IN fragments indicates that sequences in both the catalytic core (residues 50-207) and a C-terminal region (residues 201-240) contribute to IN self-association. We also observe that the isolated C-terminal fragment (residues 201-286) is capable of self-association. Finally, a single amino acid substitution in the core domain (S85G) produces a severe defect in multimerization. We conclude from these analyses that both the catalytic core and a region in the nonconserved C terminus are involved in ASV integrase multimerization. These results enhance our understanding of integrase self-association determinants and define a major role of the C-terminal region of Am integrase in this process.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [R35CA047486, P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008642] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47486, CA-06927] Funding Source: Medline; NIAID NIH HHS [5F32 AI08642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BROSIUS J, 1989, DNA-J MOLEC CELL BIO, V8, P759, DOI 10.1089/dna.1989.8.759; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; DONZELLA GA, 1993, J VIROL, V67, P7077, DOI 10.1128/JVI.67.12.7077-7087.1993; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; GRINDLEY NDF, 1993, SCIENCE, V262, P738, DOI 10.1126/science.8235593; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; HUGHES RE, 1993, EMBO J, V12, P1447, DOI 10.1002/j.1460-2075.1993.tb05788.x; JENKINS TM, 1995, P NATL ACAD SCI USA, V92, P6057, DOI 10.1073/pnas.92.13.6057; JONES KS, 1992, J BIOL CHEM, V267, P16037; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KALPANA GV, 1993, P NATL ACAD SCI USA, V90, P10593, DOI 10.1073/pnas.90.22.10593; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZ RA, 1994, ANN REV BIOCH, V61, P133; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KULKOSKY J, 1994, PHARMACOL THERAPEUT, V61, P185, DOI 10.1016/0163-7258(94)90062-0; KUNKEL GR, 1981, MOL CELL BIOCHEM, V34, P3, DOI 10.1007/BF02354846; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; PEERASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; RICE PA, 1994, EMBO J, V13, P1514, DOI 10.1002/j.1460-2075.1994.tb06413.x; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SCHMIDT TGM, 1994, J CHROMATOGR A, V676, P337, DOI 10.1016/0021-9673(94)80434-6; SEGALL AM, 1993, EMBO J, V12, P4567, DOI 10.1002/j.1460-2075.1993.tb06145.x; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; STEVENS FJ, 1989, BIOPHYS J, V55, P1155, DOI 10.1016/S0006-3495(89)82912-1; TERRY R, 1988, J VIROL, V62, P2358, DOI 10.1128/JVI.62.7.2358-2365.1988; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	49	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29299	29306		10.1074/jbc.270.49.29299	http://dx.doi.org/10.1074/jbc.270.49.29299			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493962				2022-12-25	WOS:A1995TJ22700043
J	KUHN, P; GUAN, C; CUI, T; TARENTINO, AL; PLUMMER, TH; VANROEY, P				KUHN, P; GUAN, C; CUI, T; TARENTINO, AL; PLUMMER, TH; VANROEY, P			ACTIVE-SITE AND OLIGOSACCHARIDE RECOGNITION RESIDUES OF PEPTIDE-N-4-(N-ACETYL-BETA-D-GLUCOSAMINYL)ASPARAGINE AMIDASE-F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCANS; N-GLYCOSIDASE-F; ENZYME; DEGLYCOSYLATION; REFINEMENT; PEPTIDE	Crystallographic analysis and site-directed mutagenesis have been used to identify the catalytic and oligosaccharide recognition residues of peptide-N-4-(N-acetyl-beta-D-glucosaminyl)asparagine amidase F (PNGase F), an amidohydrolase that removes intact asparagine-linked oligosaccharide chains from glycoproteins and glycopeptides. Mutagenesis has shown that three acidic residues, Asp-60, Glu-206, and Glu-118, that are located in a cleft at the interface between the two domains of the protein are essential for activity. The D60N mutant has no detectable activity, while E206Q and E118Q have less than 0.01 and 0.1% of the wild-type activity, respectively. Crystallographic analysis, at 2.0-Angstrom resolution, of the complex of the wild-type enzyme with the product, N,N'-diacetylchitobiose, shows that Asp-60 is in direct contact with the substrate at the cleavage site, while Glu-206 makes contact through a bridging water molecule. This indicates that Asp-60 is the primary catalytic residue, while Glu-206 probably is important for stabilization of reaction intermediates. Glu-118 forms a hydrogen bond with O-6 of the second N-acetylglucosamine residue of the substrate and the low activity of the E118Q mutant results from its reduced ability to bind the oligosaccharide. This analysis also suggests that the mechanism of action of PNGase F differs from those of L-asparaginase and glycosylasparaginase, which involve a threonine residue as the nucleophile.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA; SUNY ALBANY, DEPT PHYS, ALBANY, NY 12222 USA; NEW ENGLAND BIOLABS INC, BEVERLY, MA 01915 USA; SUNY ALBANY, SCH PUBL HLTH, DEPT BIOMED SCI, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany					NIGMS NIH HHS [GM-50431, GM-30471] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050431, R01GM030471] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEETHAM JC, 1992, J MOL BIOL, V224, P613, DOI 10.1016/0022-2836(92)90548-X; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HADFIELD AT, 1994, J MOL BIOL, V243, P856, DOI 10.1006/jmbi.1994.1688; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN P, 1994, BIOCHEMISTRY-US, V33, P11699, DOI 10.1021/bi00205a005; KUHN P, 1994, J MOL BIOL, V241, P622, DOI 10.1006/jmbi.1994.1536; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORRIS GE, 1994, STRUCTURE, V2, P1049, DOI 10.1016/S0969-2126(94)00108-1; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RASMUSSEN JR, 1992, J AM CHEM SOC, V114, P1124, DOI 10.1021/ja00029a071; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SWAIN AL, 1993, P NATL ACAD SCI USA, V90, P1474, DOI 10.1073/pnas.90.4.1474; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TARENTINO AL, 1993, BIOCHEM BIOPH RES CO, V197, P179, DOI 10.1006/bbrc.1993.2457; TARENTINO AL, 1993, TRENDS GLYCOSCI GLYC, V5, P163; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x	23	26	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29493	29497		10.1074/jbc.270.49.29493	http://dx.doi.org/10.1074/jbc.270.49.29493			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493989	hybrid			2022-12-25	WOS:A1995TJ22700070
J	FELSCHOW, DM; MACDIARMID, J; BARDOS, T; WU, RH; WOSTER, PM; PORTER, CW				FELSCHOW, DM; MACDIARMID, J; BARDOS, T; WU, RH; WOSTER, PM; PORTER, CW			PHOTOAFFINITY-LABELING OF A CELL-SURFACE POLYAMINE BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; L1210 LEUKEMIA-CELLS; HAMSTER OVARY CELLS; BIOLOGICAL PROPERTIES; TRANSPORT PROTEIN; SPERMIDINE; DERIVATIVES; DEFICIENT; RECEPTORS; ANALOGS	Intracellular polyamine pools are partially maintained by an active transport apparatus that is specific for and regulated by polyamines. Although mammalian transport activity has been characterized by kinetic studies, the actual protein itself has yet to be identified, purified, or cloned. As one approach to this problem, we attempted photoaffinity labeling of plasma membrane proteins using two specifically designed and synthesized polyamine conjugates as photoprobes. The first is a spermidine conjugate bearing the photoreactive moiety 4-azidosalicylic acid at the N-4 position via an alkyl linkage, and the second is a norspermine conjugate with 4 azidosalicylic acid at the N-1 position via an acyl linkage, Labeling of murine L1210 lymphocytic leukemia cells was carried out at 4 degrees C to promote selective alkylation of cell surface proteins, Separation of plasma membrane proteins from cells cross-linked with the N-4-spermidine conjugate by SDS-polyacrylamide gel electrophoresis revealed two heavily labeled proteins at similar to 118 and similar to 50 kDa (designated p118 and p50, respectively). Band p118 was more well defined and much more intensely labeled. Analogous proteins were also observed in human U937 lymphoma cells, Specificity of labeling was strongly suggested by competition with polyamines and analogs during labeling and further indicated by the nearly identical labeling of the same protein by the N-1-norspermine photoprobe but not by the unconjugated photoreagent. Neuraminidase pretreatment of L1210 cells increased mobility of the p118, suggesting that it was glycosylated and, thus, of plasma membrane origin. In transport deficient L1210 cells, p118 and p50 were found to have a slightly higher molecular mass and were accompanied by a less distinct protein band (similar to 100 kDa), These findings indicate the presence of a poly amine binding protein at the surface of murine and human leukemia cells, which could be directly or indirectly related to the polyamine transport apparatus.	ROSWELL PK CANC INST,GRACE CANC DRUG CTR,BUFFALO,NY 14263; SUNY BUFFALO,DEPT MED CHEM,BUFFALO,NY 14214; WAYNE STATE UNIV,COLL PHARM & ALLIED HLTH PROFESS,DEPT PHARMACEUT SCI,DETROIT,MI 48202	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Wayne State University			Woster, Patrick M/A-5604-2010	Woster, Patrick M/0000-0002-9471-1916	NCI NIH HHS [R01 CA22153, CA63552, CA01072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063552, R01CA022153] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; BERGERON RJ, 1984, SYNTHESIS-STUTTGART, P782; BERSE C, 1957, J ORG CHEM, V22, P805, DOI 10.1021/jo01358a024; BROWN PD, 1992, CELL BIOL, P77; BYERS TL, 1989, BIOCHEM J, V263, P745, DOI 10.1042/bj2630745; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; DAVE C, 1973, FED PROC, V32, P736; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FELSCHOW DM, 1995, P AM ASSOC CANC RES, V36, P507; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FINDLAY JBC, 1987, BIOL MEMBRANES PRACT, P197; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GAWELTHOMPSON K, 1988, J CELL PHYSIOL, V136, P237, DOI 10.1002/jcp.1041360205; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; JASYS VJ, 1992, J ORG CHEM, V57, P1814, DOI 10.1021/jo00032a039; JI TH, 1977, J BIOL CHEM, V252, P1566; KANKINUMA Y, 1988, EUR J BIOCHEM, V176, P409; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; Keller O., 1985, ORG SYNTH, V63, P160, DOI 10.1002/0471264180.OS063.19; KHAN NA, 1991, CELL BIOL INT REP, V15, P9, DOI 10.1016/0309-1651(91)90078-W; KRAMER DL, 1993, J CELL PHYSIOL, V155, P399, DOI 10.1002/jcp.1041550222; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; METTERS KM, 1993, J BIOL CHEM, V268, P6487; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P5095, DOI 10.1021/bi00438a029; PERSSON L, 1988, CANCER RES, V48, P4807; PORTER CW, 1985, CANCER RES, V45, P2050; PORTER CW, 1982, CANCER RES, V42, P4072; PORTER CW, 1983, SCIENCE, V219, P1083, DOI 10.1126/science.6823570; PRICE EM, 1987, BIOCHEMISTRY-US, V198, P4757; ROEMMELE RC, 1988, J ORG CHEM, V53, P2367, DOI 10.1021/jo00245a049; RYLANDER PN, 1985, HYDROGENATION METHOD, P163; SAAB NH, 1993, J MED CHEM, V36, P2998, DOI 10.1021/jm00072a020; SEILER N, 1990, INT J BIOCHEM, V22, P11; SHANAHAN MF, 1985, J BIOL CHEM, V260, P897; SIDDIQUI F, 1994, NEUROCHEM RES, V19, P1421, DOI 10.1007/BF00972471; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; STAROS JV, 1978, BIOCHEM BIOPH RES CO, V80, P568, DOI 10.1016/0006-291X(78)91606-6; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TAE HJ, 1982, ANAL BIOCHEM, V121, P286; THOM D, 1977, BIOCHEM J, V80, P649; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810	46	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28705	28711		10.1074/jbc.270.48.28705	http://dx.doi.org/10.1074/jbc.270.48.28705			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499391	hybrid			2022-12-25	WOS:A1995TH05600035
J	HE, YF; CHEN, H; QUON, MJ; REITMAN, M				HE, YF; CHEN, H; QUON, MJ; REITMAN, M			THE MOUSE OBESE GENE - GENOMIC ORGANIZATION, PROMOTER ACTIVITY, AND ACTIVATION BY CCAAT/ENHANCER-BINDING PROTEIN-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; DNA; TRANSFECTION; INSULIN; CELLS; C/EBP; RATS; SITE	The obese gene product, leptin, regulates adiposity. Mice homozygous for a nonfunctional obese gene become massively obese and develop diabetes mellitus due to overeating and increased metabolic efficiency. The cDNA sequence of obese was recently reported (Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J. L. (1994) Nature 372, 425-432; Correction: (1995 Nature 374, 479). We have determined the genomic organization of the 5' end of the mouse obese gene. The coding sequence is in exons 2 and 3, A single TATA-containing promoter was found upstream of exon 1. A minority (probably similar to 5%) of the obese mRNA contained an extra, untranslated exon between exons 1 and 2. Transcription of the obese gene was detected only in adipose cells. A 762 base pair obese gene promoter driving a luciferase gene yielded abundant activity in transiently transfected rat adipose cells in primary culture. The obese promoter was inactive in erythroid K562 cells. Deletion of bases from -762 downstream to -161 did not affect promoter activity in transfected adipose cells. The -161 minimal promoter contained consensus Spl and CCAAT/enhancer-binding protein (C/EBP) motifs. Cotransfection with C/EBP alpha (a transcription factor important in adipose cell differentiation) caused 23-fold activation. These data suggest that the obese promoter is a natural target of C/EBP alpha.	NIDDK, DIABET BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Quon, Michael/B-1970-2008; Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915				ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1994, PROGRAM MANUAL WISCO; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; FAUST IM, 1977, SCIENCE, V197, P393, DOI 10.1126/science.877564; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HARRIS RBS, 1986, J NUTR, V116, P2536, DOI 10.1093/jn/116.12.2536; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; Moore DD, 1995, GLOB MOB SURV; MOUTAID N, 1994, J BIOL CHEM, V269, P5629; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; RINK TJ, 1994, NATURE, V372, P406, DOI 10.1038/372406a0; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0	41	153	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28887	28891		10.1074/jbc.270.48.28887	http://dx.doi.org/10.1074/jbc.270.48.28887			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499416	hybrid			2022-12-25	WOS:A1995TH05600060
J	PARK, YW; KATZE, MG				PARK, YW; KATZE, MG			TRANSLATIONAL CONTROL BY INFLUENZA-VIRUS - IDENTIFICATION OF CIS-ACTING SEQUENCES AND TRANS-ACTING FACTORS WHICH MAY REGULATE SELECTIVE VIRAL MESSENGER-RNA TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA TRANSLATION; NS1 PROTEIN; CELLULAR PROTEIN; INFECTED-CELLS; POLIOVIRUS RNA; INITIATION; ADENOVIRUS; EXPRESSION; INHIBITION	We have shown that sequences contained within the viral mRNA 5'-untranslated region (UTR) played a critical role in directing selective influenza viral mRNA translation. We therefore attempted to identify transacting factors that may regulate viral mRNA translation through interactions with the 5'-UTR and at the same time map the precise sequences to which these factors bind. We can now demonstrate that multiple cellular proteins interact with influenza viral but not cellular 5'-UTRs using gel mobility shift and UV cross linking analyses. Gel supershift studies revealed that the La autoantigen was one of the cellular proteins that interacted with the viral 5'-UTR. Utilizing mutants of the viral mRNA 5' UTR, we have determined that sequences within the very 5'-conserved region and nucleotides immediately 3' are necessary but not always sufficient for binding certain cellular proteins. Northwestern analysis showed the binding of a distinct subset of cellular proteins to the viral 5'-UTR, but also demonstrated interactions of the viral nonstructural protein NS1. Gel shift analysis with purified recombinant NS1 confirmed the binding of the viral protein to a specific region of the viral 5'-UTRs. A model describing the possible role of these cellular and viral RNA-binding proteins in regulating influenza virus mRNA translation will be discussed.	UNIV WASHINGTON, SCH MED, DEPT MICROBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NCRR NIH HHS [RR 00166] Funding Source: Medline; NIAID NIH HHS [AI-22646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALONSOCAPLEN FV, 1992, GENE DEV, V6, P255, DOI 10.1101/gad.6.2.255; Ausubel FA, 1990, CURRENT PROTOCOLS MO; CHAN EKL, 1987, J EXP MED, V166, P1627, DOI 10.1084/jem.166.6.1627; DELALUNA S, 1995, J VIROL, V69, P2427, DOI 10.1128/JVI.69.4.2427-2433.1995; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; ENAMI K, 1994, J VIROL, V68, P1432, DOI 10.1128/JVI.68.3.1432-1437.1994; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FEIGENBLUM D, 1993, J VIROL, V67, P3027, DOI 10.1128/JVI.67.6.3027-3035.1993; Garfinkel Michele S., 1993, Gene Expression, V3, P109; GARFINKEL MS, 1993, J BIOL CHEM, V268, P22223; GARFINKEL MS, 1992, J BIOL CHEM, V267, P9383; GARFINKEL MS, 1994, SCI MED, V1, P64; HATADA E, 1992, J GEN VIROL, V73, P17, DOI 10.1099/0022-1317-73-1-17; HATADA E, 1992, J GEN VIROL, V73, P3325, DOI 10.1099/0022-1317-73-12-3325; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; KATZE MG, 1993, SEMIN VIROL, V4, P259, DOI 10.1006/smvy.1993.1022; KATZE MG, 1984, MOL CELL BIOL, V4, P2198, DOI 10.1128/MCB.4.10.2198; KATZE MG, 1986, J VIROL, V60, P1027, DOI 10.1128/JVI.60.3.1027-1039.1986; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; KRUG RM, 1973, VIROLOGY, V56, P334, DOI 10.1016/0042-6822(73)90310-3; KRUG RM, 1989, EXPRESSION REPLICATI, V2, P89; LU Y, 1994, GENE DEV, V8, P1817, DOI 10.1101/gad.8.15.1817; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; ONEILL RE, 1994, INFECT AGENT DIS, V3, P77; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; POGUE GP, 1993, J VIROL, V67, P7106, DOI 10.1128/JVI.67.12.7106-7117.1993; QIU Y, 1994, J VIROL, V68, P2425, DOI 10.1128/JVI.68.4.2425-2432.1994; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RILEY D, 1993, J VIROL, V67, P3586, DOI 10.1128/JVI.67.6.3586-3595.1993; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; SONENBERG N, 1990, ENZYME, V44, P278, DOI 10.1159/000468765; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; YAMANAKA K, 1991, ARCH VIROL, V120, P33, DOI 10.1007/BF01310947; YAMANAKA K, 1988, VIRUS GENES, V1, P19; YEN JH, 1995, VIROLOGY, V208, P723, DOI 10.1006/viro.1995.1204	41	97	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28433	28439						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499349				2022-12-25	WOS:A1995TG21000074
J	TODISCO, A; TAKEUCHI, Y; SEVA, C; DICKINSON, CJ; YAMADA, T				TODISCO, A; TAKEUCHI, Y; SEVA, C; DICKINSON, CJ; YAMADA, T			GASTRIN AND GLYCINE-EXTENDED PROGASTRIN PROCESSING INTERMEDIATES INDUCE DIFFERENT PROGRAMS OF EARLY GENE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH; IDENTIFICATION; MECHANISM; DOMAIN	We recently reported that gastrin and glycine-extended progastrin processing intermediates (G-Gly) exert growth promoting effects on AR4-2J cells (derived from rat pancreas) via interaction with distinct receptors, In this study we sought to investigate the mechanisms by which gastrin and G-Gly stimulate cell proliferation, While gastrin increased [Ca2+](i) in AR4-2J cells, G-Gly had no effect. Similarly, G-Gly had no effect either on basal and 10(-7) M vasoactive intestinal polypeptide-stimulated cAMP generation, although gastrin is known to inhibit cAMP generation, Gastrin dose dependently stimulated AR4-2J cell mRNA content of both c-fos and c-jun, two genes known to function in regulating cell proliferation, but G-Gly had no effect, Gastrin also induced the expression of luciferase in AR4-2J cells transfected with a construct consisting of a luciferase reporter gene coupled to the serum response element of the c-fos gene promoter, In similar fashion, gastrin stimulated the activity of mitogen-activated protein kinase, an enzyme known to mediate the induction of the c-fos serum response element in response to growth factor stimulation. Although G-Gly had none of these effects of gastrin in AR4-2J cells, it stimulated activity of c-Jun amino-terminal kinase, an enzyme known to phosphorylate and transcriptionally activate c-Jun. These data support the notion that gastrin stimulates cell proliferation by inducing c-fos and c-jun gene expression, while G-Gly acts by post-translationally regulating early gene transcriptional activation, Our studies represent a novel model in which both the precursor and the product of a key processing reaction, peptide alpha-amidation, act cooperatively to stimulate cell proliferation via distinct receptors linked to different signal transduction pathways.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PEDIAT, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; INSERM, U151, F-31054 TOULOUSE, FRANCE	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Institut National de la Sante et de la Recherche Medicale (Inserm)				Catherine, SEVA/0000-0002-4265-7372	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034306, P30DK034933] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK34306, P30DK34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; DELVALLE J, 1989, GASTROENTEROLOGY, V97, P1159, DOI 10.1016/0016-5085(89)91685-5; Edkins JS, 1906, J PHYSIOL-LONDON, V34, P133; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HILSTED L, 1991, REGUL PEPTIDES, V36, P323, DOI 10.1016/0167-0115(91)90067-Q; JOHNSON LR, 1977, ANNU REV PHYSIOL, V39, P135, DOI 10.1146/annurev.ph.39.030177.001031; KAISE M, 1995, J BIOL CHEM, V270, P11155, DOI 10.1074/jbc.270.19.11155; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARX JL, 1987, SCIENCE, V237, P854, DOI 10.1126/science.3039659; MATSUMOTO M, 1987, AM J PHYSIOL, V252, pG315, DOI 10.1152/ajpgi.1987.252.3.G315; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCEMAMA JL, 1988, FEBS LETT, V242, P61, DOI 10.1016/0014-5793(88)80985-2; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SINGH P, 1986, CANCER RES, V46, P1612; SMITH MJ, 1992, BLOOD, V79, P2107; SOLOMON TE, 1987, GASTROENTEROLOGY, V92, P429, DOI 10.1016/0016-5085(87)90138-7; SUGANO K, 1985, J BIOL CHEM, V260, P1724; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TODISCO A, 1994, AM J PHYSIOL, V267, pG245, DOI 10.1152/ajpgi.1994.267.2.G245; TODISCO A, 1995, AM J PHYSIOL, V268, pG160; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YOO OJ, 1982, P NATL ACAD SCI-BIOL, V79, P1049, DOI 10.1073/pnas.79.4.1049	33	84	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28337	28341						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499334				2022-12-25	WOS:A1995TG21000059
J	BARR, VA; SCOTT, LJ; HUBBARD, AL				BARR, VA; SCOTT, LJ; HUBBARD, AL			IMMUNOADSORPTION OF HEPATIC VESICLES CARRYING NEWLY SYNTHESIZED DIPEPTIDYL PEPTIDASE-IV AND POLYMERIC IGA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE PLASMA-MEMBRANE; CARBOHYDRATE RECOGNITION SYSTEMS; TRANS-CELLULAR TRANSPORT; RAT-LIVER; MEDIATED ENDOCYTOSIS; SUBCELLULAR FRACTIONATION; IMMUNOELECTRON MICROSCOPY; TRANSCYTOTIC VESICLES; ENDOPLASMIC-RETICULUM; SECRETORY COMPONENT	Hepatocytes must transport newly synthesized apical membrane proteins from the basolateral to the apical plasma membrane, Our earlier morphological study showed that the apical proteins share a late (subapical) part of the transcytotic pathway with the well characterized polymeric immunoglobulin A receptor (Barr, V. A., and Hubbard, A. L. (1993) Gastroenterology 105, 554-571), Starting with crude microsomes from the livers of [S-35]methionine-labeled rats, we sequentially immuno-adsorbed first vesicles containing the endocytic asialoglycoprotein receptor and then (from the depleted supernatant) vesicles containing the polymeric IgA receptor, Biochemical characterization indicated that early basolateral and late endosomes were present in the first population but not in the second. Neither Golgi, apical plasma membrane (PM)-, nor basolateral PM-derived vesicles were significant contaminants of either population. Both vesicle populations contained S-35-labeled receptor and S-35-labeled-dipeptidyl peptidase TV, Importantly, the elevated relative specific activity of the dipeptidyl peptidase (% of S-35-labeled/% immunoblotted) in the second population indicated that these vesicles must transport newly synthesized dipeptidyl peptidase IV. A distinct kind of vesicle was immunoadsorbed from a ''carrier-vesicle fraction''; surprisingly, these vesicles contained little S-35-receptor and virtually no dipeptidyl peptidase IV. These results, together with previous kinetic data from in vivo experiments, are consistent with a computer-generated model predicting that newly synthesized dipeptidyl peptidase IV is delivered to basolateral endosomes, which also contain newly synthesized polymeric immunoglobulin A receptor. The two proteins are then transcytosed together to the subapical region.	JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA; NIH, DIABET BRANCH, BETHESDA, MD 20892 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; University of Michigan System; University of Michigan								ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Barr V. A., 1994, Molecular Biology of the Cell, V5, p72A; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; BLEIL JD, 1982, EMBO J, V1, P351, DOI 10.1002/j.1460-2075.1982.tb01173.x; BRANCH WJ, 1987, BIOCHEM J, V244, P311, DOI 10.1042/bj2440311; BROWN WR, 1989, HEPATOLOGY, V9, P763, DOI 10.1002/hep.1840090518; CARIAPPA R, 1992, AM J PHYSIOL, V263, pE1021; Cariappa R., 1994, Molecular Biology of the Cell, V5, p72A; CASANOVA JE, 1992, ANN NY ACAD SCI, V664, P27, DOI 10.1111/j.1749-6632.1992.tb39746.x; CASCIOLAROSEN LA, 1992, J BIOL CHEM, V267, P11856; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COURTOY PJ, 1985, ENDOCYTOSIS, P163; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GURD JW, 1974, ARCH BIOCHEM BIOPHYS, V164, P305, DOI 10.1016/0003-9861(74)90035-6; HANDLER JS, 1989, ANNU REV PHYSIOL, V51, P729, DOI 10.1146/annurev.ph.51.030189.003501; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; HUBBARD AL, 1979, J CELL BIOL, V83, P65, DOI 10.1083/jcb.83.1.65; HUBBARD AL, 1979, J CELL BIOL, V83, P47, DOI 10.1083/jcb.83.1.47; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUBBARD AL, 1988, CELL FREE ANAL MEMBR, P115; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; Kraehenbuhl J P, 1992, Trends Cell Biol, V2, P170, DOI 10.1016/0962-8924(92)90036-M; KUHN LC, 1983, ANN NY ACAD SCI, V409, P751, DOI 10.1111/j.1749-6632.1983.tb26914.x; LARKIN JM, 1991, J CELL SCI, V98, P205; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; MAMADI Y, 1994, LIVER BIOL PATHOBIOL, P155; MAROUX S, 1983, BRUSH BORDER MEMBRAN, P34; MATLIN K S, 1992, Current Opinion in Cell Biology, V4, P623; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MAXFIELD FR, 1991, INTRACELLULAR TRAFFI; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; MULLOCK BM, 1978, BIOCHIM BIOPHYS ACTA, V543, P497, DOI 10.1016/0304-4165(78)90304-5; MULLOCK BM, 1980, FEBS LETT, V113, P201, DOI 10.1016/0014-5793(80)80591-6; MULLOCK BM, 1979, BIOCHIM BIOPHYS ACTA, V587, P381, DOI 10.1016/0304-4165(79)90442-2; MUSIL LS, 1988, J BIOL CHEM, V263, P15799; OGATA S, 1989, J BIOL CHEM, V264, P3596; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; RANK J, 1983, HEPATOLOGY, V3, P241; RENSTON RH, 1980, SCIENCE, V208, P1276, DOI 10.1126/science.7375938; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SANDVIG K, 1991, CELL BIOL INT REP, V15, P3, DOI 10.1016/0309-1651(91)90077-V; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SCOTT LJ, 1992, J BIOL CHEM, V267, P6099; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SZTUL E, 1993, J BIOL CHEM, V268, P1876; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; SZTUL ES, 1983, J CELL BIOL, V97, P1582, DOI 10.1083/jcb.97.5.1582; TAKAHASHI I, 1982, J IMMUNOL, V128, P1181; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WATTS C, 1992, J CELL SCI, V103, P1	74	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27834	27844		10.1074/jbc.270.46.27834	http://dx.doi.org/10.1074/jbc.270.46.27834			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499255	hybrid			2022-12-25	WOS:A1995TE73600066
J	UNSON, CG; CYPESS, AM; KIM, HN; GOLDSMITH, PK; CARRUTHERS, CJL; MERRIFIELD, RB; SAKMAR, TP				UNSON, CG; CYPESS, AM; KIM, HN; GOLDSMITH, PK; CARRUTHERS, CJL; MERRIFIELD, RB; SAKMAR, TP			CHARACTERIZATION OF DELETION AND TRUNCATION MUTANTS OF THE RAT GLUCAGON RECEPTOR - 7 TRANSMEMBRANE SEGMENTS ARE NECESSARY FOR RECEPTOR TRANSPORT TO THE PLASMA-MEMBRANE AND GLUCAGON BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; BETA-ADRENERGIC-RECEPTOR; HORMONE-RELATED PEPTIDE; EXPRESSION CLONING; BOVINE RHODOPSIN; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; PARATHYROID-HORMONE; ACTIVATION; GENE	Glucagon receptor mutants were characterized with the aim of elucidating minimal structural requirements for proper biosynthesis, ligand binding, and adenylyl cyclase coupling. One N-terminal deletion mutant and five truncation mutants with progressively shorter C termini were expressed in transiently transfected monkey kidney (COS-1) cells. Each truncation mutant was designed so that the truncated C-terminal tail would remain on the cytoplasmic surface of the receptor. In order to characterize the cellular location of the expressed receptor mutants, a highly specific, high affinity antipeptide antibody was prepared against the extracellular, N-terminal tail of the receptor, Immunoblot analysis and immunofluorescence microscopy showed that the presence of all seven putative transmembrane segments, but not an intact N-terminal tail, was required for cell surface expression of the receptor, Membranes from cells expressing receptor mutants lacking a large portion of the N-terminal tail or any of the seven putative transmembrane segments failed to bind glucagon. Membranes from cells expressing the C-terminal tail truncation mutants, which retained all seven transmembrane segments, bound glucagon with affinities similar to that of the native receptor and activated cellular adenylyl cyclase in response to glucagon. These results indicate that all seven helices are necessary for the proper folding and processing of the glucagon receptor, Glycosylation is not required for the receptor to reach the cell surface, and it may not be required for ligand binding, However, the N-terminal extracellular portion of the receptor is required for ligand binding, Most of the distal C-terminal tail is not necessary for ligand binding, and the absence of the tail may increase slightly the receptor binding affinity for glucagon. The C-terminal tail is also not necessary for adenylyl cyclase coupling and therefore does not play a direct role in G protein (G(s)) activation by the glucagon receptor.	ROCKEFELLER UNIV,NEW YORK,NY 10021; HOWARD HUGHES MED INST,MOLEC BIOL & BIOCHEM LAB,NEW YORK,NY 10021; NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BETHESDA,MD 20892	Rockefeller University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024039] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK24039] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ANUKANTH A, 1994, J BIOL CHEM, V269, P19738; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BERRIDGE MJ, 1985, NATURE, V312, P315; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; CARRUTHERS CJL, 1995, METH NEUROSCI, V25, P322; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHRISTOPHE J, 1995, BBA-REV BIOMEMBRANES, V1241, P45, DOI 10.1016/0304-4157(94)00015-6; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14397; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; IYENGAR R, 1988, J BIOL CHEM, V263, P15348; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUSUI T, 1994, BIOCHEMISTRY-US, V33, P12968, DOI 10.1021/bi00248a005; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SALESSE R, 1991, BIOCHIMIE, V73, P109, DOI 10.1016/0300-9084(91)90083-D; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRENGEL R, 1994, HDB RECEPTORS CHANNE, P153; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNSON CG, IN PRESS P NATL ACAD; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	54	93	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27720	27727		10.1074/jbc.270.46.27720	http://dx.doi.org/10.1074/jbc.270.46.27720			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499239	hybrid			2022-12-25	WOS:A1995TE73600050
J	UZAWA, N; YOSHIDA, MA; OSHIMURA, M; IKEUCHI, T				UZAWA, N; YOSHIDA, MA; OSHIMURA, M; IKEUCHI, T			SUPPRESSION OF TUMORIGENICITY IN 3 DIFFERENT CELL-LINES OF HUMAN ORAL SQUAMOUS-CELL CARCINOMA BY INTRODUCTION OF CHROMOSOME 3P VIA MICROCELL-MEDIATED CHROMOSOME TRANSFER	ONCOGENE			English	Article						CHROMOSOME 3; SQUAMOUS CELL CARCINOMA; MICROCELL FUSION; ORAL CANCER; TUMOR SUPPRESSOR GENE	SHORT ARM; LUNG-CANCER; RAS ONCOGENE; ALLELIC LOSS; HEAD; HETEROZYGOSITY; FREQUENCY; DELETION; REGIONS; TUMORS	It has been suggested that loss of the short arm of chromosome 3 is one of the most frequent abnormalities in human head and neck cancers including oral squamous cell carcinomas (SCC) and that one or more putative tumor suppressor gene(s) which may contribute to the initiation and/or progression of these tumors might be located on chromosome 3p. In this study, we examined the effects of introducing human chromosome 3 or 7 by microcell hybridization on the tumor-associated phenotypes of three different human oral SCC cell lines, HSC-2, HSC-3 and HSC-4. Transfer of a single chromosome 3p completely suppressed the tumorigenicity of all three parental cell lines, which showed a significant decrease in growth rate in vitro and morphological changes. In contrast, transfer of chromosome 7 had no effect on HSC-2 and HSC-4 cells, although it suppressed the tumorigenicity of HSC-3 cells without modifying their in vitro growth properties. Our findings provide additional confirmatory evidence that loss or inactivation of putative tumor suppressor gene(s) present on chromosome 3p might be primarily involved in the development of human oral SCC. The possibility that chromosome 7 may carry another tumor suppressor gene(s) is also discussed.	TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 1,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN	Tokyo Medical & Dental University (TMDU); Tottori University	UZAWA, N (corresponding author), TOKYO MED & DENT UNIV,MED RES INST,DEPT CYTOGENET,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							BERENSON JR, 1989, ONCOGENE, V4, P111; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CHANG SE, 1991, INT J CANCER, V48, P409, DOI 10.1002/ijc.2910480318; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EHLEN T, 1990, ONCOGENE, V5, P219; ELNAGGAR AK, 1993, CANCER, V72, P881, DOI 10.1002/1097-0142(19930801)72:3<881::AID-CNCR2820720337>3.0.CO;2-Q; FIELD JK, 1989, ONCOGENE, V4, P1463; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; HANSEN MF, 1987, CANCER RES, V47, P5518; HARRIS H, 1988, CANCER RES, V48, P3302; HEO DS, 1989, CANCER RES, V49, P5167; HIBI K, 1992, ONCOGENE, V7, P445; JIN YS, 1993, ORAL ONCOL, V29B, P257, DOI 10.1016/0964-1955(93)90045-G; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; LARGEY JS, 1994, ORAL SURG ORAL MED O, V77, P260, DOI 10.1016/0030-4220(94)90295-X; LATIF F, 1992, CANCER RES, V52, P1451; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MAESTRO R, 1993, CANCER RES, V53, P5775; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; MORITA R, 1991, CANCER RES, V51, P820; NAWROZ H, 1994, CANCER RES, V54, P1152; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; ONO T, 1993, JPN J GENET, V68, P617, DOI 10.1266/jjg.68.617; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SANDBERG AA, 1988, CANCER RES, V48, P1049; SARANATH D, 1991, BRIT J CANCER, V63, P573, DOI 10.1038/bjc.1991.133; SATO T, 1991, CANCER RES, V51, P5794; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SAXON PJ, 1986, EMBO J, V15, P3461; SHIMIZU M, 1990, ONCOGENE, V5, P185; SOMERS KD, 1990, ONCOGENE, V5, P915; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; TAKAHASHI E, 1992, GENOMICS, V13, P1047, DOI 10.1016/0888-7543(92)90018-N; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; UZAWA K, 1994, INT J CANCER, V58, P814, DOI 10.1002/ijc.2910580611; WU CL, 1994, CANCER RES, V54, P6484; YAMADA H, 1990, ONCOGENE, V5, P1141; YAMAMOTO T, 1986, CANCER RES, V46, P414; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOSHIDA MA, 1986, CANCER RES, V46, P2139; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	55	32	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1997	2004						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478518				2022-12-25	WOS:A1995TF29700009
J	JOHNSON, DG				JOHNSON, DG			REGULATION OF E2F-1 GENE-EXPRESSION BY P130 (RB2) AND D-TYPE CYCLIN KINASE-ACTIVITY	ONCOGENE			English	Article						E2F; D-TYPE CYCLIN; P130 (RB2); TRANSCRIPTIONAL REPRESSION	TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; GROWTH SUPPRESSION; BINDING PROTEIN; CELLULAR GENES; PRODUCT; CLONING; IDENTIFICATION; PROMOTER; FAMILY	Previous experiments have demonstrated that the regulation of E2F-1 transcription factor activity is critical for the maintenance of normal cell proliferation control. Regulation of E2F-1 is accomplished through at least two mechanisms: posttranslational regulation by binding proteins such as Rb and transcriptional regulation of the E2F-1 gene. The E2F-1 gene promoter has recently been isolated to examine this latter aspect of E2F-1 regulation. Preliminary studies demonstrate that the E2F-1 promoter is under E2F-dependent negative control during the cell growth response, being transcriptionally repressed through E2F sites in GO and early G1. We now demonstrate that the presence of an E2F DNA-binding complex containing the Rb-related p13O protein (Rb2) correlates with E2F-1 gene repression and that overexpression of p13O inhibits transcription from the E2F-1 promoter. Moreover, D-type cyclin-dependent kinase activity specifically activates the E2F-1 promoter by relieving E2F-mediated repression but is inhibited by coexpression of the cdk4 and cdk6 inhibitor p16 (CDKN2, MTS1, INK4). Taken together, these findings suggest that E2F-1 gene expression is controlled during cell cycle progression by a regulatory network involving at least one oncogene (cyclin D1) and several potential tumor suppressor genes.			JOHNSON, DG (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CARCINOGENESIS,DIV SCI PK RES,SMITHVILLE,TX 78957, USA.			Johnson, David/0000-0002-6223-1790				ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COLBRINIK D, 1993, GENE DEV, V7, P2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIAN KL, 1994, GENE DEV, V8, P2939; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1993, CELL, V70, P993; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYOL X, 1993, ONCOGENE, V8, P2561; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANIFUJITA N, 1994, ONCOGENE, V6, P1703; OSWALD F, 1994, ONCOGENE, V9, P2029; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAO A, 1995, ONCOGENE, V10, P221; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YEUNG RS, 1993, ONCOGENE, V8, P3465	64	83	84	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1685	1692						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478595				2022-12-25	WOS:A1995TD09400002
J	MILLER, ME; ENGEL, DA; SMITH, MM				MILLER, ME; ENGEL, DA; SMITH, MM			CYCLIC-AMP SIGNALING IS REQUIRED FOR FUNCTION OF THE N-TERMINAL AND CR-1 DOMAINS OF ADENOVIRUS E1A IN SACCHAROMYCES-CEREVISIAE	ONCOGENE			English	Article						GENE REGULATION; TRANSCRIPTION; YEAST; GENETICS	EARLY REGION-1A POLYPEPTIDES; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; DNA-BINDING ACTIVITY; FOS MESSENGER-RNA; ADENYLATE-CYCLASE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; CDC28 MUTATION; 1A PROTEINS	We have constructed yeast vectors in which derivatives of the adenovirus E1A gene are expressed from the GAL1 promoter. Cells expressing E1A(289) grow poorly and accumulate cells with a 1C DNA content. Using a series of E1A deletion mutants, we have identified three regions within the E1A protein that are necessary for the G(1) growth phenotype; each deletion partially relieves the growth defect. These deletions span residues 4-25, 38-60 and 140-186, which fall within the N-terminal, CR1 and CR3 domains of E1A respectively. Expression of the first 82 residues of E1A, spanning just the N-terminal and CR1 domains, strongly inhibits yeast cell growth in G(1) showing that these domains can function independently of other domains of E1A. Using this strong growth inhibition, we isolated a yeast mutant in the net1 gene that conferred resistance to the expression of E1A(1-82). The mutant was insensitive to expression of both E1A(1-82) and full length E1A, but remained sensitive to the toxicity caused by over-expression of a Ga14p-VP16 fusion. Finally, we found that the function of E1A in yeast depends on the cyclic AMP signaling pathway, providing a striking parallel with the action of E1A at the c-fos promoter in mammalian cells. These results suggest that a genetic analysis of the yeast model system will provide relevant new insights into mechanisms of gene regulation by E1A proteins.	UNIV VIRGINIA, SCH MED, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028920] Funding Source: NIH RePORTER; NCI NIH HHS [5T3 CA09109] Funding Source: Medline; NIGMS NIH HHS [GM28920] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTLETT R, 1990, BIOESSAYS, V12, P457, DOI 10.1002/bies.950121002; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Coulombe Benoit, 1992, Gene Expression, V2, P99; DYSON N, 1992, CANCER SURV, V12, P161; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ENGEL DA, 1991, P NATL ACAD SCI USA, V88, P3957, DOI 10.1073/pnas.88.9.3957; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GEDRICH RW, 1992, J VIROL, V66, P5849, DOI 10.1128/JVI.66.10.5849-5859.1992; GEDRICH RW, 1995, J VIROL, V69, P2333, DOI 10.1128/JVI.69.4.2333-2340.1995; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANDA H, 1987, GENE, V58, P127; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KORNUC M, 1988, MOL CELL BIOL, V8, P3717, DOI 10.1128/MCB.8.9.3717; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAI B, 1993, FEBS LETT, V321, P153, DOI 10.1016/0014-5793(93)80098-F; MALHOTRA P, 1993, J BIOL CHEM, V268, P20392; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; NEVINS JR, 1992, SCIENCE, V258, P424; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REED SI, 1992, CIBA F SYMP, V170, P7; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROWE DT, 1983, VIROLOGY, V127, P253, DOI 10.1016/0042-6822(83)90142-3; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYMOND BC, 1983, GENE, V25, P249, DOI 10.1016/0378-1119(83)90229-9; Sambrook J, 1989, MOL CLONING LABORATO; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; Sherman F., 1982, METHODS YEAST GENETI; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH MM, 1991, METHOD CELL BIOL, V35, P485; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; WADA T, 1990, BIOCHEM BIOPH RES CO, V170, P470, DOI 10.1016/0006-291X(90)92115-G; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE SP, 1983, J VIROL, V46, P1003, DOI 10.1128/JVI.46.3.1003-1013.1983; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	79	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1623	1630						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478587				2022-12-25	WOS:A1995TC53500021
J	BUDAY, L; WARNE, PH; DOWNWARD, J				BUDAY, L; WARNE, PH; DOWNWARD, J			DOWN-REGULATION OF THE RAS ACTIVATION PATHWAY BY MAP KINASE PHOSPHORYLATION OF SOS	ONCOGENE			English	Article						SOS; PAS; MAP KINASE; T CELL	NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; RECEPTOR; PROTEIN; GRB2; P21RAS; STIMULATION; COMPLEX; BINDS	Formation of a complex of the nucleotide exchange factor Sos, the SH2 and SH3 containing adaptor protein Grb2/Sem-5 and tyrosine phosphorylated EGF receptor and She has been implicated in the activation of Ras by epidermal growth factor (EGF) in fibroblasts: related mechanisms for activation of Ras operate in other cell types. An increase in the apparent molecular weight of Sos has been reported to occur after several minutes of receptor stimulation due to phosphorylation by mitogen-activated protein (MAP) kinases. We report here that treatment of human peripheral blood T lymphoblasts with phorbol esters causes a similar shift in mobility of Sos. This modification of Sos does not alter its ability to bind Grb2, but correlates with strong inhibition of the binding of the Sos/Grb2 complex to tyrosine phosphorylated sequences, either a tyrosine phosphopeptide in cell lysates or p36 in intact cells. This effect, along with the mobility shift of Sos, can be mimicked in vitro by phosphorylation of Sos by the mitogen-activated protein kinase, ERK1. A novel negative feedback mechanism therefore exists whereby activation of MAP kinases through Ras results in the uncoupling of the Sos/Grb2 complex from tyrosine kinase substrates without blocking the interaction of Sos with Grb2.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; SEMMELWEIS UNIV MED,SCH MED,INST BIOCHEM 1,H-1088 BUDAPEST,HUNGARY	Cancer Research UK; Semmelweis University				Downward, Julian/0000-0002-2331-4729				BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HALLBERG B, 1994, J BIOL CHEM, V270, P3913; HARLOW E, 1988, ANTIBODIES LABORATOR; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NEL AE, 1990, J IMMUNOL, V144, P2683; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; WATERS SB, 1995, MOL CELL BIOL, V15, P2791	21	103	104	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1327	1331						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478553				2022-12-25	WOS:A1995RY96700013
J	PERREM, K; RAYNER, J; VOSS, T; STURZBECHER, H; JACKSON, P; BRAITHWAITE, A				PERREM, K; RAYNER, J; VOSS, T; STURZBECHER, H; JACKSON, P; BRAITHWAITE, A			P53 REPRESSES SV40 TRANSCRIPTION BY PREVENTING FORMATION OF TRANSCRIPTION COMPLEXES	ONCOGENE			English	Article						P53; SV40; GENE REPRESSION	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN HSP70 PROMOTER; BINDING PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; NEGATIVE REGULATION; DNA-REPLICATION; MAMMALIAN-CELLS; GENE-PRODUCT; MUTANT P53	There is now much evidence to suggest that the p53 tumour suppressor protein functions to monitor the integrity of the genome. When DNA damage is detected, p53 suppresses cell growth to allow repair or directs the cell into apoptosis. The mechanism of action of p53 is as yet unclear but recent evidence has accumulated to suggest that p53 might act by regulating gene expression. Consistent with this model, p53 can both activate and repress a number of viral and cellular promoters. p53 has also been shown to bind to the CCAAT-binding Factor and TATA-binding protein (TBP), and there is direct evidence that p53 represses in vitro transcription by preventing TBP from binding DNA. We now provide evidence that p53 can repress transcription from the SV40 promoter by disrupting DNA/protein complexes involving transcription factor Sp1.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV CELL BIOL, CELL TRANSFORMAT GRP, CANBERRA, ACT 2601, AUSTRALIA; UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY	Australian National University; John Curtin School of Medical Research; Heinrich Pette Institute; University of Hamburg								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JACKSON P, 1993, ONCOGENE, V8, P589; JACKSON P, 1995, IN PRESS GENE EXPRES, V5; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIYASHITA T, 1994, CANCER RES, V54, P3131; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; PAULY M, 1992, NUCLEIC ACIDS RES, V20, P975, DOI 10.1093/nar/20.5.975; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, CANCER CELL, V6, P159; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TOOZE J, 1980, DNA TUMOR VIRUSES 2; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629	57	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1299	1307						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478550				2022-12-25	WOS:A1995RY96700010
J	HOKLAND, BM; SLOTTE, JP; BIERMAN, EL; ORAM, JF				HOKLAND, BM; SLOTTE, JP; BIERMAN, EL; ORAM, JF			CYCLIC-AMP STIMULATES EFFLUX OF INTRACELLULAR STEROL FROM CHOLESTEROL-LOADED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PROTEIN-KINASE-C; PLASMA-MEMBRANE; HUMAN FIBROBLASTS; ENDOPLASMIC-RETICULUM; BINDING; POOLS; TRANSLOCATION; MACROPHAGES; METABOLISM	The interaction of high density lipoprotein with its putative receptor stimulates translocation and efflux of intracellular sterols by a process involving activation of protein kinase C. This study shows that activation of cAMP-dependent protein kinase also stimulates efflux of intracellular sterols. When intracellular sterol pools of cholesterol-loaded cultured human skin fibroblasts and bovine aortic endothelial cells were radiolabeled with the biosynthetic precursor [H-3]mevalonolactone, high density lipoprotein3 (HDL3)-mediated H-3-sterol efflux was enhanced by addition of the adenylylcyclase activator forskolin, the phosphodiesterase inhibitors theophylline and 3-isobutyl-1-methylxanthine, and the cAMP analogues N-benzoyl-cAMP (N6-cAMP) and 8-thiomethyl-cAMP. The effect of N-cAMP was abolished by an inhibitor of cAMP-dependent protein kinase (H8). The enhanced sterol efflux was independent of receptor binding of HDL3, as similar effects were observed in the presence of tetranitromethane-modified HDL3, which lacks receptor binding activity. N6-cAMP stimulated efflux of several subspecies of newly synthesized sterols, including cholesterol. Elevation of cAMP levels increased the proportion of radiosterols that were accessible to treatment of cells with the enzyme cholesterol oxidase, suggesting that activation of cAMP-dependent protein kinase stimulates translocation of sterols from intracellular compartments to the plasma membrane where they desorb from the cell surface. Thus, at least two distinct protein kinase signalling pathways modulate transport of intracellular sterols in cholesterol-loaded cells.	UNIV WASHINGTON,DEPT MED,DIV METAB ENDOCRINOL & NUTR RG-26,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL31194, HL18645] Funding Source: Medline; NIDDK NIH HHS [DK-02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031194, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1986, METHOD ENZYMOL, V129, P691; AVIRAM M, 1989, J LIPID RES, V30, P65; BERNARD DW, 1991, J BIOL CHEM, V266, P710; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRINTON EA, 1985, ARTERIOSCLEROSIS, V5, P329, DOI 10.1161/01.ATV.5.4.329; BRINTON EA, 1986, J BIOL CHEM, V261, P495; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1991, J LIPID RES, V32, P329; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; Oram J F, 1986, Methods Enzymol, V129, P645; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; PINKERTON FD, 1982, J BIOL CHEM, V257, P1929; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; URBANI L, 1990, J BIOL CHEM, V265, P1919	27	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25343	25349						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503979				2022-12-25	WOS:A1993MK10000013
J	HIMES, SR; COLES, LS; KATSIKEROS, R; LANG, RK; SHANNON, MF				HIMES, SR; COLES, LS; KATSIKEROS, R; LANG, RK; SHANNON, MF			HTLV-1 TAX ACTIVATION OF THE GM-CSF AND G-CSF PROMOTERS REQUIRES THE INTERACTION OF NF-KB WITH OTHER TRANSCRIPTION FACTOR FAMILIES	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; COLONY-STIMULATING FACTOR; TUMOR NECROSIS FACTOR; LONG TERMINAL REPEAT; KAPPA-B; FACTOR GENE; TRANS-ACTIVATION; INTERLEUKIN-2 RECEPTOR; NUCLEAR FACTOR	The trans-activator protein, tax, from the human T leukemia virus type 1 (HTLV-1) trans-activates both viral and cellular genes. It has previously been shown that granulocyte macrophage-colony stimulating factor (GM-CSF) is constitutively expressed in HTLV-1 infected cells and in cells artificially expressing tax. We show here that the GM-CSF promoter is tax responsive in fibroblasts and T cells, whereas the granulocyte (G)-CSF promoter is tax responsive only in fibroblasts. The tax protein can activate cellular genes through at least two families of transcription factors; the NF-kB/rel and CREB/ATF families. We have used mutant tax proteins to show that the activation of NF-kB proteins is essential for tax trans-activation of both the GM-CSF and G-CSF promoters. The ability of tax to activate CREB/ATF proteins is also essential for GM-CSF trans-activation. We have identified a 44 bp region of the GM-CSF promoter that contains tax responsive elements. This region contains a classical NF-kB site, a CK-1 element that can bind the NF-kB p65 protein, as well as a putative ATF binding site. The tax response of the G-CSF promoter requires not only the conserved CK-1 sequence but also an adjacent NF-IL6 binding site that may explain the cell restricted function of the G-CSF promoter.	INST MED & VET SCI,HANSON CTR CANC RES,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; AZIZUKI S, 1987, LANCET, V1, P156; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KUCZEK ES, 1991, J IMMUNOL, V146, P2426; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NIMER SD, 1989, ONCOGENE, V4, P671; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PICCARDO P, 1988, ANN NEUROL S, V23, P156; ROONEY RJ, 1990, MOL CELL BIOL, V10, P5138, DOI 10.1128/MCB.10.10.5138; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; Shannon MF, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046923; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; WACHSMAN W, 1986, SEMIN HEMATOL, V23, P246; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P543; XU YL, 1990, J BIOL CHEM, V265, P20285; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	46	97	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3189	3197						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504230				2022-12-25	WOS:A1993MG78200001
J	CHANG, JH; DUMBAR, TS; OLSON, MOJ				CHANG, JH; DUMBAR, TS; OLSON, MOJ			CDNA AND DEDUCED PRIMARY STRUCTURE OF RAT PROTEIN-B23, A NUCLEOLAR PROTEIN CONTAINING HIGHLY CONSERVED SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note											CHANG, JH (corresponding author), UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216, USA.				NCRR NIH HHS [S07 RR05386, 1 S10 RR02745] Funding Source: Medline; NIGMS NIH HHS [5 R01 GM28349] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002745, S07RR005386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028349] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHUNG S Y, 1986, Proteins Structure Function and Genetics, V1, P195, DOI 10.1002/prot.340010302; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; ESCANDE ML, 1985, BIOL CELL, V53, P99, DOI 10.1111/j.1768-322X.1985.tb00359.x; FIELDS AP, 1986, EXP CELL RES, V164, P139, DOI 10.1016/0014-4827(86)90461-1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; JONES CE, 1981, BIOCHIM BIOPHYS ACTA, V667, P209, DOI 10.1016/0005-2795(81)90081-7; KALDERON D, 1984, CELL, V41, P615; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; LISCHWE MA, 1979, LIFE SCI, V25, P701, DOI 10.1016/0024-3205(79)90512-5; MAHONEY WC, 1980, J BIOL CHEM, V225, P11197; MAMRACK MD, 1979, BIOCHEMISTRY-US, V18, P3381, DOI 10.1021/bi00582a026; Maniatis T., 1982, MOL CLONING LABORATO, P76; MICHALIK J, 1981, LIFE SCI, V28, P1371, DOI 10.1016/0024-3205(81)90411-2; OCHS R, 1983, EXP CELL RES, V146, P139, DOI 10.1016/0014-4827(83)90332-4; PFEIFLE J, 1986, EXP CELL RES, V162, P11, DOI 10.1016/0014-4827(86)90422-2; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; RAO SVV, 1982, J BIOL CHEM, V257, P5035; SANGER F, 1977, P NATL ACAD SCI USA, V74, P560; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SINGH L, 1984, NUCLEIC ACIDS RES, V11, P6679; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8	34	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12824	12827						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417636				2022-12-25	WOS:A1988Q091700009
J	ECK, MJ; BEUTLER, B; KUO, G; MERRYWEATHER, JP; SPRANG, SR				ECK, MJ; BEUTLER, B; KUO, G; MERRYWEATHER, JP; SPRANG, SR			CRYSTALLIZATION OF TRIMERIC RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR (CACHECTIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; CHIRON RES LABS,EMERYVILLE,CA 94608	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008014] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM08014] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BUERGER MJ, 1960, CRYSTAL STRUCTURE AN; COHN EJ, 1953, PROTEINS CHEM BIOL A, P370; FISHER RG, 1980, ACTA CRYSTALLOGR A, V36, P755, DOI 10.1107/S0567739480001520; HAKOSHIMA T, 1988, J MOL BIOL, V201, P455, DOI 10.1016/0022-2836(88)90153-2; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; LEWITBENTLEY A, 1988, J MOL BIOL, V199, P389, DOI 10.1016/0022-2836(88)90323-3; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSSMAN MG, 1972, MOL REPLACEMENT METH; SMITH RA, 1987, J BIOL CHEM, V262, P6951; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; WESTBROOK EM, 1985, METHOD ENZYMOL, V114, P187	17	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12816	12819						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417634				2022-12-25	WOS:A1988Q091700007
J	HAAS, AL; BRIGHT, PM				HAAS, AL; BRIGHT, PM			THE RESOLUTION AND CHARACTERIZATION OF PUTATIVE UBIQUITIN CARRIER PROTEIN ISOZYMES FROM RABBIT RETICULOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											HAAS, AL (corresponding author), MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226, USA.				NIGMS NIH HHS [GM34009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARLSON N, 1987, J CELL BIOL, V104, P537, DOI 10.1083/jcb.104.3.537; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1984, J CELL BIOCHEM, V24, P27, DOI 10.1002/jcb.240240104; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GREGORI L, 1985, J BIOL CHEM, V260, P5232; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1983, BIOCHEMISTRY-US, V22, P4388, DOI 10.1021/bi00288a007; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, UBIQUITIN, P173; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HOUGH R, 1986, J BIOL CHEM, V261, P2400; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1986, BIOCHEMISTRY-US, V25, P3134, DOI 10.1021/bi00359a010; PICKART CM, 1985, J BIOL CHEM, V260, P1573; RABINOVITZ M, 1964, BIOCHIM BIOPHYS ACTA, V91, P313, DOI 10.1016/0926-6550(64)90255-5; RAVIV O, 1987, BIOCHEM BIOPH RES CO, V145, P658, DOI 10.1016/0006-291X(87)91015-1; ROSE IA, 1983, BIOCHEMISTRY-US, V22, P4234, DOI 10.1021/bi00287a012; WILKINSON KD, 1987, ANTI-CANCER DRUG DES, V2, P211; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	32	136	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13258	13267						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417657				2022-12-25	WOS:A1988Q091700075
J	STEWART, LC; KLINMAN, JP				STEWART, LC; KLINMAN, JP			BOVINE MEMBRANOUS DOPAMINE BETA-HYDROXYLASE IS NOT ANCHORED VIA COVALENTLY ATTACHED PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025765, R01GM025765] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25765] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1987, J BIOL CHEM, V262, P1485; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BJERRUM OJ, 1979, BIOCHEM J, V181, P231, DOI 10.1042/bj1810231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CRAINE JE, 1973, J BIOL CHEM, V248, P7838; DHAWAN S, 1987, J BIOL CHEM, V262, P1869; DUONG LT, 1985, J BIOL CHEM, V260, P2393; FISCHERCOLBRIE R, 1984, J NEUROCHEM, V42, P1008, DOI 10.1111/j.1471-4159.1984.tb12704.x; FOLDES A, 1972, BIOCHEM J, V126, P1209, DOI 10.1042/bj1261209; FUTERMAN AH, 1985, BIOCHEM BIOPH RES CO, V129, P312, DOI 10.1016/0006-291X(85)91439-1; GAVINE FS, 1984, J NEUROCHEM, V43, P1243, DOI 10.1111/j.1471-4159.1984.tb05379.x; HORTNAGL H, 1972, BIOCHEM J, V129, P187; KLINMAN JP, 1982, BIOCHEMISTRY-US, V21, P67, DOI 10.1021/bi00530a013; KUHN LJ, 1986, J BIOL CHEM, V261, P3816; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; Low M G, 1981, Methods Enzymol, V71 Pt C, P741; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; LOW MG, 1987, BIOCHEM J, V244, P1; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; MATSUDA Y, 1983, J BIOCHEM-TOKYO, V93, P1427, DOI 10.1093/oxfordjournals.jbchem.a134278; MCHUGH EM, 1985, J BIOL CHEM, V260, P4409; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; OLSON EN, 1986, J BIOL CHEM, V261, P2458; ROBERTS WL, 1986, FASEB J, V45, P1816; SABBAN EL, 1987, J NEUROSCI, V7, P192; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SCHMIDT MFG, 1983, CURR TOP MICROBIOL, V102, P101; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SHERMAN WR, 1970, ORG MASS SPECTROM, V3, P829, DOI 10.1002/oms.1210030702; SKOTLAND T, 1977, INT J PEPT PROT RES, V10, P311; SLATER EP, 1981, ARCH BIOCHEM BIOPHYS, V211, P288, DOI 10.1016/0003-9861(81)90456-2; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; SUPPATTAPONE S, 1984, J NEUROCHEM, V42, P1017; VANROMPUY L, 1982, J MOL BIOL, V161, P1, DOI 10.1016/0022-2836(82)90274-1; WALLACE EF, 1973, P NATL ACAD SCI USA, V70, P2253, DOI 10.1073/pnas.70.8.2253; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WINKLER H, 1982, SECRETORY GRANULE; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	43	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1988	263	25					12183	12186						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P8611	3410839				2022-12-25	WOS:A1988P861100006
J	BURBELO, PD; DRECHSEL, D; HALL, A				BURBELO, PD; DRECHSEL, D; HALL, A			A CONSERVED BINDING MOTIF DEFINES NUMEROUS CANDIDATE TARGET PROTEINS FOR BOTH CDC42 AND RAC GTPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR CHARACTERIZATION; CELL POLARITY; CLONING	Rho, Rac, and Cdc42 are small GTPases that regulate the formation of a variety of actin structures and the assembly of associated integrin complexes, but little is known about the target proteins that mediate their effects. Here we have used a motif-based search method to identify putative effector proteins for Rac and Cdc42. A search of the GenBank(TM) data base for similarity with the minimum Cdc42/Rac interactive binding (CRIB) region of a potential effector protein p65(PAK) has identified over 25 proteins containing a similar motif from a range of different species. These candidate Cdc42/Rac-binding proteins include family members of the mixed lineage kinases (MLK), a novel tyrosine kinase from Drosophila melanogaster (DPR2), a human protein MSE55, and several novel yeast and Caenorhabditis elegans proteins. Two murine p65(PAK) isoforms and a candidate protein from C. elegans, F09F7.5, interact strongly with the GTP form of both Cdc42 and Rac, but not Rho in a filter binding assay. Three additional candidate proteins, DPR2, MSE55, and MLK3 showed binding to the GTP form of Cdc42 and weaker binding with Rac, and again no interaction with Rho. These results indicate that proteins containing the CRIB motif bind to Cdc42 and/or Rac in a GTP-dependent manner, and they may, therefore, participate in downstream signaling.	UCL, MRC,MOLEC CELL BIOL LAB,CANC RES CAMPAIGN, ONCOGENE & SIGNAL TRANSDUCT GRP, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND	University of London; University College London; University of London; University College London			Burbelo, Peter D./B-1027-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAHOU WF, 1992, J BIOL CHEM, V267, P13986; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORROW DS, 1993, EUR J BIOCHEM, V213, P701; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EZOE K, 1994, ONCOGENE, V9, P935; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; ING YL, 1994, ONCOGENE, V9, P1745; ITO M, 1994, GENE, V139, P215; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATOH M, 1995, ONCOGENE, V10, P1447; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEPSENWOL S, 1989, J CELL BIOL, V108, P55, DOI 10.1083/jcb.108.1.55; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	38	541	560	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29071	29074		10.1074/jbc.270.49.29071	http://dx.doi.org/10.1074/jbc.270.49.29071			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493928	hybrid			2022-12-25	WOS:A1995TJ22700009
J	SPINK, J; COHEN, J; EVANS, TJ				SPINK, J; COHEN, J; EVANS, TJ			THE CYTOKINE RESPONSIVE VASCULAR SMOOTH-MUSCLE CELL ENHANCER OF INDUCIBLE NITRIC-OXIDE SYNTHASE - ACTIVATION BY NUCLEAR FACTOR-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; MOUSE MACROPHAGES; BINDING-PROTEIN; RELAXING FACTOR; SEPTIC SHOCK; LIPOPOLYSACCHARIDE; GENE; INDUCTION; IFN; TRANSCRIPTION	The production of inducible nitric oxide synthase (iNOS) within vascular smooth muscle (VSM) cells following exposure to proinflammatory cytokines is a major cause of the vasorelaxation and hypotension of septic shock. We have defined the cytokine-responsive element of the murine iNOS promoter, transfected into a VSM cell line, and the role of the NF-kappa B/Rel family of proteins in iNOS gene activation in these cells. The combination of interleukin-1, interferon-gamma, and tumor necrosis factor-alpha stimulates promoter activity by a factor of 8.1-fold; single cytokines show little activity, while pairs of cytokines produce an intermediate effect. Using a series of promoter deletion mutants, we have defined the cytokine-responsive element from position -890 to -1002; this region contains an NF-kappa B-binding site as well as a number of interferon response elements. Nuclear proteins from cytokine-stimulated VSM cells which bind to an oligonucleotide containing this kappa B Site are composed of p65 together with an unidentified protein of 50 kDa, which is not a known Rel family member. A promoter mutant with a S-base pair change within this kappa B site, which abolishes NF-kappa B binding, has an activity of only approximately 34% (S.E. +/- 1.5) of the wild-type promoter. In addition, protein binding to this site is abolished by a specific inhibitor of NF-kappa B activation, which also abrogates iNOS activity. Residual inducibility in such mutant promoters is attributable to the presence of an independently functioning downstream kappa B site (-85 to -75). The mechanism by which NF-kappa B activates the iNOS promoter in VSM cells in response to cytokines appears to be markedly different to that operative in macrophages in response to lipopolysaccharide.	ROYAL POSTGRAD MED SCH, DEPT INFECT DIS & BACTERIOL, LONDON W12 0NN, ENGLAND	Imperial College London								BEASLEY D, 1990, AM J PHYSIOL, V259, pR38, DOI 10.1152/ajpregu.1990.259.1.R38; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKAYAMA DK, 1992, AM J RESP CELL MOL, V7, P471, DOI 10.1165/ajrcmb/7.5.471; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; Sambrook J, 1989, MOL CLONING LABORATO; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	29	146	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29541	29547		10.1074/jbc.270.49.29541	http://dx.doi.org/10.1074/jbc.270.49.29541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493996				2022-12-25	WOS:A1995TJ22700077
J	SUN, ZM; MEANS, RL; LEMAGUERESSE, B; MEANS, AR				SUN, ZM; MEANS, RL; LEMAGUERESSE, B; MEANS, AR			ORGANIZATION AND ANALYSIS OF THE COMPLETE RAT CALMODULIN-DEPENDENT PROTEIN-KINASE-IV GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; DNA METHYLATION; BINDING PROTEIN; EXPRESSION; CREM; GR; SPERMATOGENESIS; CALSPERMIN; ACTIVATOR; SEQUENCE	A 42-kilobase pair region of rat DNA containing the Ca2+/calmodulin-dependent protein kinase IV (CaM kinase IV) gene has been cloned and characterized. The gene consists of 12 exons and 11 introns and is predicted to encode both beta and cy forms of CaM kinase IV as well as the testis-specific calmodulin-binding protein calspermin. The promoter utilized to generate the alpha-kinase isoform is located in intron 1, whereas the promoter utilized to produce the calspermin transcript is contained in intron 10. The calspermin promoter region which extends from -200 to +321 relative to the calspermin transcription initiation site that contains two cyclic AMP response elements (CRE) at -70 and -50 and has been shown previously to be inactive in NIH3T3 cells (Sun, Z., Sassone-Corsi, P., and Means, A. R. (1995) Mol. Cell. Biol. 15, 561-571) was ligated to the lacZ reporter gene and used to generate transgenic mice. The promoter was expressed exclusively in postmeiotic testis where beta-galactosidase was found predominantly in elongating spermatids. The cell and developmental specificity of transgene expression was very similar to the pattern shown by the endogenous gene. Although the transgene promoter was silent in somatic tissues, beta-galactosidase expression could be restored in primary cultures of skin fibroblasts by introduction of vectors encoding CREM tau and CaM kinase IV.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University			Le Magueresse-Battistoni, Brigitte/M-6927-2017; Le Magueresse-Battistoni, Brigitte/AAZ-5601-2021	Le Magueresse-Battistoni, Brigitte/0000-0002-7247-4403; Le Magueresse-Battistoni, Brigitte/0000-0002-7247-4403	NICHD NIH HHS [HD-07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARIEL M, 1991, P NATL ACAD SCI USA, V86, P2317; BELLVE AR, 1995, J CELL BIOL, V74, P68; BLAND MM, 1993, GENE, V137, P351, DOI 10.1016/0378-1119(93)90035-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHOI YC, 1991, J BIOL CHEM, V266, P20504; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GORAYA TY, 1995, J BIOL CHEM, V270, P19078, DOI 10.1074/jbc.270.32.19078; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; LARSON CA, 1995, 77TH P M END SOC WAS, P48; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; Means A R, 1976, Recent Prog Horm Res, V32, P477; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OLSON NJ, 1995, P NATL ACAD SCI USA, V92, P1659, DOI 10.1073/pnas.92.5.1659; ONO T, 1989, J BIOL CHEM, V264, P2081; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SIKELA JM, 1990, GENOMICS, V8, P579, DOI 10.1016/0888-7543(90)90048-Y; SIKELA JM, 1989, GENOMICS, V4, P21, DOI 10.1016/0888-7543(89)90309-1; SUN ZM, 1995, J BIOL CHEM, V270, P20962, DOI 10.1074/jbc.270.36.20962; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TRASLER JM, 1990, MOL CELL BIOL, V10, P1828, DOI 10.1128/MCB.10.4.1828	38	29	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29507	29514		10.1074/jbc.270.49.29507	http://dx.doi.org/10.1074/jbc.270.49.29507			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493991				2022-12-25	WOS:A1995TJ22700072
J	MATHER, MW; YU, L; YU, CA				MATHER, MW; YU, L; YU, CA			THE INVOLVEMENT OF THREONINE-160 OF CYTOCHROME-B OF RHODOBACTER-SPHAEROIDES CYTOCHROME BC(1) COMPLEX IN QUINONE BINDING AND INTERACTION WITH SUBUNIT-IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; IRON-SULFUR PROTEIN; RHODOPSEUDOMONAS-SPHAEROIDES; C OXIDOREDUCTASE; PHOTOSYNTHETIC GROWTH; RESPIRATORY-CHAIN; ELECTRON-TRANSFER; Q0 SITE; UBIQUINONE; MUTANTS	The cytochrome b subunit (subunit I) of the ubiquinolcytochrome c reductase (bc(1) complex) is thought to participate in the formation of two quinone/quinol reaction centers, an oxidizing center (Q(o)) and a reducing center, in accordance with the quinone cycle mechanism, Threonine 160 is a highly conserved residue in a segment of subunit I that was shown to bind quinone and is placed near the putative Q(o) site in current models of the bc(1) complex, Rhodobacter sphaeroides cells expressing bc(1) complexes with Ser or Tyr substituted for Thr(160) grow photosynthetically at a reduced rate, and cells expressing the mutated complexes produce an ''elevated' level of the bc(1) complex. The Ser substitution also affects the interaction of subunit IV with subunit I. Replacement of Thr(160) by Ser results in about a 70% loss of the activity in the purified complex, whereas substitution by Tyr lowers the activity by more than 80%. Both replacements lower the apparent K-m for ubiquinol. Electron paramagnetic resonance (EPR) spectroscopy shows that in the Ser substituted complex, the environments of the Rieske iron sulfur cluster in subunit III and the high potential cytochrome b (b(562)) in subunit I have been modified, The spectra of the Ser(160) and Tyr(160) iron-sulfur clusters have become redox-insensitive, with a line shape resembling that of the native complex in the fully reduced state, The EPR signal of b(562) in the Ser(160) complex is shifted from g = 3.50 to g = 3.52, but otherwise the line shape is very similar to the spectrum of the native complex. Most of these results are consistent with current ideas regarding the structure and function of Q(o) in the bc(1) complex, except for the alteration of the b(562) EPR feature, because this heme is not thought to be located in proximity to Q(o). Immunoblotting analysis showed that the Ser or Tyr substituted complex contained significantly less than a stoichiometric amount of subunit IV. The enzymatic activity of mutated bc(1) complex was found to be activable by the addition of purified subunit IV. These results indicate that Thr(160) plays an important role in the structure and/or function of the bc(1) complex.			MATHER, MW (corresponding author), OKLAHOMA STATE UNIV,OKLAHOMA AGR EXPT STN,DEPT BIOCHEM & MOLEC BIOL,246B NOBLE RES CTR,STILLWATER,OK 74078, USA.			Mather, Michael/0000-0002-1062-0137	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BOWYER JR, 1982, J BIOL CHEM, V257, P8321; BROSIUS J, 1989, DNA-J MOLEC CELL BIO, V8, P759, DOI 10.1089/dna.1989.8.759; CHEN YR, 1994, BIOCHEMISTRY-US, V33, P10207, DOI 10.1021/bi00199a050; CLAYTON RK, 1973, BIOCHIM BIOPHYS ACTA, V75, P312; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P211, DOI 10.1007/BF00762583; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; DU ZJ, 1993, METHOD ENZYMOL, V218, P104; Feher G., 1978, PHOTOSYNTHETIC BACTE, P349; GABELLINI N, 1982, EUR J BIOCHEM, V126, P105, DOI 10.1111/j.1432-1033.1982.tb06753.x; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; HALEY PE, 1986, J BIOL CHEM, V261, P4593; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P2155; HE DY, 1994, J BIOL CHEM, V269, P2292; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KHOSRAVI M, 1990, PLASMID, V23, P138, DOI 10.1016/0147-619X(90)90032-8; Kroger A, 1978, Methods Enzymol, V53, P579; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; NANO FE, 1984, J BACTERIOL, V158, P1094, DOI 10.1128/JB.158.3.1094-1103.1984; ORMEJOHNSON NR, 1974, BIOCHEM BIOPH RES CO, V45, P871; PEMBERTON JM, 1981, J BACTERIOL, V147, P110, DOI 10.1128/JB.147.1.110-117.1981; PURVIS DJ, 1990, J BIOL CHEM, V265, P1208; QIAN L, 1991, BIOTECHNIQUES, V10, P736; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; ROTT MA, 1993, J BACTERIOL, V175, P358, DOI 10.1128/JB.175.2.358-366.1993; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIDOW J, 1978, J BIOL CHEM, V253, P2392; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; TITUS DE, 1991, PROMEGA PROTOCOLS AP, P105; TRON T, 1991, EUR J BIOCHEM, V199, P753, DOI 10.1111/j.1432-1033.1991.tb16180.x; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TWOBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; VIEIRA J, 1983, GENE, V19, P254; WARD JM, 1982, PLASMID, V7, P239, DOI 10.1016/0147-619X(82)90005-1; YANG XH, 1986, J BIOL CHEM, V261, P2282; YU CA, 1993, J BIOENERG BIOMEMBR, V23, P259; YU L, 1984, J BIOL CHEM, V259, P5752; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x	58	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28668	28675		10.1074/jbc.270.48.28668	http://dx.doi.org/10.1074/jbc.270.48.28668			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499386	hybrid			2022-12-25	WOS:A1995TH05600030
J	PETROV, VV; SLAYMAN, CW				PETROV, VV; SLAYMAN, CW			SITE-DIRECTED MUTAGENESIS OF THE YEAST PMA1 H+-ATPASE - STRUCTURAL AND FUNCTIONAL-ROLE OF CYSTEINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; SARCOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SECRETORY VESICLES; NEUROSPORA-CRASSA; SENSORY RECEPTOR; CROSS-LINKING; CONSEQUENCES; CA-2+-ATPASE	The yeast plasma-membrane H+-ATPase contains nine cysteines, three in presumed transmembrane segments (Cys-148, Cys-312, and Cys-867) and the rest in hydrophilic regions thought to be exposed at the cytoplasmic surface (Cys-221, Cys-376, Cys-409, Cys-472, Cys-532, and Cys-569). To gather new functional and structural information, we have studied the yeast ATPase by cysteine mutagenesis. It proved possible to replace seven of the nine cysteines by alanine, one at a time, without any significant decrease in ATP hydrolysis or ATP-dependent proton pumping. In the remaining two cases (Cys-409 and Cys-472), there were small but reproducible effects; the results clearly indicated, however, that no single Cys is required for activity and that, if a disulfide bridge is formed in the yeast ATPase, it does not play an obligatory structural or functional role. Next, multiple mutants were constructed to ask how many Cys residues could be replaced simultaneously while leaving a fully functional enzyme. After substitution of all ''membrane'' Cys (Cys-148, Cys-312, and Cys-867) together with two non-conserved Cys located in hydrophilic regions (Cys-221 and Cys-569), there were no significant abnormalities in expression (87%) or activity (89% ATP hydrolysis/93% H+ pumping) of the mutant protein. Replacement of two additional cysteines (Cys-376 near the phosphorylation site and Cys-532, in or near the ATP-binding site) caused a drop in expression (to 54%), although the corrected hydrolytic and H+ pumping activities were still normal. When Cys-472 was also mutated, the corrected activity fell to 44% hydrolysis/47% pumping; finally, substitution of Cys-409 to give a ''cysteine-free'' ATPase led to a very poorly expressed and poorly active enzyme. Brief exposure of the ''one-cysteine'' and ''two-cysteine'' ATPases to trypsin revealed a normal pattern of degradation, but there was a slight impairment in the ability of vanadate to protect against proteolysis. Thus, although single Cys replacements are tolerated well by the yeast ATPase, multiple replacements are progressively more harmful, suggesting that they cause small but additive perturbations of protein folding.	YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	Yale University	PETROV, VV (corresponding author), YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KJ, 1994, BBA-BIOMEMBRANES, V1192, P53, DOI 10.1016/0005-2736(94)90142-2; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CAREAGA CL, 1992, BIOPHYS J, V62, P209, DOI 10.1016/S0006-3495(92)81806-4; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CORBALANGARCIA S, 1993, EUR J BIOCHEM, V217, P737, DOI 10.1111/j.1432-1033.1993.tb18300.x; DAIHO T, 1994, J BIOL CHEM, V269, P11060; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAGAN MJ, 1994, J MOL EVOL, V38, P57; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FENG Y, 1994, J BIOL CHEM, V269, P13224; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; GEORGOUSSI Z, 1985, BIOCHEM BIOPH RES CO, V126, P1196, DOI 10.1016/0006-291X(85)90312-2; GREEN NM, 1992, ANN NY ACAD SCI, V671, P104, DOI 10.1111/j.1749-6632.1992.tb43788.x; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; INESI G, 1994, BIOPHYS CHEM, V50, P129, DOI 10.1016/0301-4622(94)85025-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEE MH, 1994, J BACTERIOL, V176, P4825, DOI 10.1128/jb.176.16.4825-4837.1994; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MUTOH Y, 1992, SANGYO IKA DAIGAKU Z, V14, P253; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARDO JP, 1988, J BIOL CHEM, V263, P18664; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; PERLIN DS, 1992, ACTA PHYSIOL SCAND, V146, P183; PETROV VV, 1992, YEAST, V8, P589, DOI 10.1002/yea.320080803; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PRINZ C, 1992, YALE J BIOL MED, V65, P577; RAO R, 1993, J BIOL CHEM, V268, P6708; RAO R, 1989, ION TRANSPORT, P35; RAO R, 1995, IN PRESS MYCOTA, V4; RAO US, 1990, J BIOL CHEM, V265, P7227; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; Schekman R, 1982, MOL BIOL YEAST SACCH, VII, P361; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; THORLEYLAWSON DA, 1977, BIOCHEM J, V167, P739, DOI 10.1042/bj1670739; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; ULASZEWSKI S, 1983, EUR J BIOCHEM, V130, P235, DOI 10.1111/j.1432-1033.1983.tb07141.x; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P11814, DOI 10.1073/pnas.89.24.11814	52	40	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28535	28540		10.1074/jbc.270.48.28535	http://dx.doi.org/10.1074/jbc.270.48.28535			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499367	hybrid			2022-12-25	WOS:A1995TH05600011
J	TAIRA, E; NAGINO, T; TANIURA, H; TAKAHA, N; KIM, CH; KUO, CH; LI, BS; HIGUCHI, H; MIKI, N				TAIRA, E; NAGINO, T; TANIURA, H; TAKAHA, N; KIM, CH; KUO, CH; LI, BS; HIGUCHI, H; MIKI, N			EXPRESSION AND FUNCTIONAL-ANALYSIS OF A NOVEL ISOFORM OF GICERIN, AN IMMUNOGLOBULIN SUPERFAMILY CELL-ADHESION MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE OUTGROWTH FACTOR; MYELIN-ASSOCIATED GLYCOPROTEIN; GROWTH CONE GUIDANCE; NEURAL DEVELOPMENT; NERVOUS-SYSTEM; FASCICLIN-II; N-CAM; SURFACE; DROSOPHILA; PROTEINS	We have cloned a novel cDNA of gicerin, a cell adhesion molecule belonging to the immunoglobulin super-family. Both gicerin isoforms share the same extracellular domain, which has five immunoglobulin-like loop structures and a transmembrane domain as s-gicerin, but differ in the cytoplasmic tail domain. As the newly identified form has a larger cytoplasmic domain than the previously reported form, we refer to them as l-gicerin and s-gicerin, respectively, l-gicerin is transcribed from a distinct mRNA containing an inserted sequence not found in s-gicerin mRNA which caused a frameshift for the coding region for a cytoplasmic domain. Previous studies demonstrated that gicerin showed a doublet band of 82 and 90 kDa in chicken gizzard smooth muscle. We report that the 82-kDa protein corresponds to s-gicerin and the 90-kDa protein to l-gicerin. We also found that the two gicerin isoforms are expressed differentially in the developing nervous system, Functional analysis of these gicerin isoforms in stable transfectants revealed that they had differ in their homophilic adhesion properties, as well as in heterophilic cell adhesion assayed with neurite outgrowth factor. In addition, these isoforms have neurite-promoting activity by their homophilic adhesion, but differ in their ability to promote neurite outgrowth.			TAIRA, E (corresponding author), OSAKA UNIV, SCH MED, DEPT PHARMACOL 1, 2-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.			Kim, Cheol-Hee/0000-0002-3019-0699				ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DOHERTY P, 1992, J NEUROCHEM, V58, P2338, DOI 10.1111/j.1471-4159.1992.tb10984.x; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; DOHERTY P, 1991, J CELL SCI, P13; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; EDELMAN GM, 1986, ANNU REV PHYSIOL, V48, P417; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HASLER TH, 1993, EUR J BIOCHEM, V211, P329, DOI 10.1111/j.1432-1033.1993.tb19902.x; HAYASHI Y, 1985, J BIOL CHEM, V260, P4269; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KANIA A, 1993, NEURON, V11, P673, DOI 10.1016/0896-6273(93)90078-6; KATO S, 1992, NEUROSCI LETT, V140, P78, DOI 10.1016/0304-3940(92)90686-2; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; Maniatis T., 1982, MOL CLONING; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; NISHI R, 1979, NATURE, V277, P232, DOI 10.1038/277232a0; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHNER M, 1991, NEURAL RECOGNITION M; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; TAIRA E, 1994, NEURON, V12, P861, DOI 10.1016/0896-6273(94)90338-7; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TANIURA H, 1991, J CELL BIOL, V112, P313, DOI 10.1083/jcb.112.2.313; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; URUSHIHARA H, 1979, DEV BIOL, V70, P206, DOI 10.1016/0012-1606(79)90017-4	47	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28681	28687		10.1074/jbc.270.48.28681	http://dx.doi.org/10.1074/jbc.270.48.28681			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499388	hybrid			2022-12-25	WOS:A1995TH05600032
J	WELLS, NJ; FRY, AM; GUANO, F; NORBURY, C; HICKSON, ID				WELLS, NJ; FRY, AM; GUANO, F; NORBURY, C; HICKSON, ID			CELL-CYCLE PHASE-SPECIFIC PHOSPHORYLATION OF HUMAN TOPOISOMERASE II-ALPHA - EVIDENCE OF A ROLE FOR PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; DEPENDENT PHOSPHORYLATION; ATP HYDROLYSIS; LEUKEMIA-CELLS; PHORBOL ESTER; FISSION YEAST; MITOSIS; ENZYME; DIFFERENTIATION; PURIFICATION	Type II topoisomerases are essential for faithful cell division in all organisms. In human cells, the alpha isozyme of topoisomerase II has been implicated in catalyzing mitotic chromosome segregation via its action as a DNA unlinking enzyme. Here, we have shown that the enzymatic activity of topoisomerase II alpha protein purified from HeLa cell nuclei was strongly enhanced following phosphorylation by protein kinase C. We have investigated the possibility that this kinase is involved in cell cycle phase-specific phosphorylation of topoisomerase II alpha in HeLa cells. Two-dimensional tryptic phosphopeptide tide mapping revealed that topoisomerase II alpha protein immunoprecipitated from metabolically labeled HeLa cells was differentially phosphorylated during the G(2)/M phases of the cell cycle. To identify sites of phosphorylation and the kinase(s) responsible for this modification, oligohistidine-tagged recombinant domains of topoisomerase II alpha protein were overexpressed in Escherichia coli and purified by affinity chromatography. Phosphorylation of a short fragment of the N-terminal ATPase domain of topoisomerase II alpha by protein kinase C in vitro generated two phosphopeptides that co-migrated with prominent G(2)/M phase-specific phosphopeptides from the HeLa cell-derived topoisomerase II alpha protein. Site-directed mutagenesis studies indicated that phosphorylation of serine 29 generated both of these phosphopeptides. Our results implicate protein kinase C in the cell cycle phase-dependent modulation of topoisomerase II alpha enzymatic activity in human cells.	JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND	Cancer Research UK; University of Oxford			Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURDEN DA, 1994, BIOCHEMISTRY-US, V33, P14651, DOI 10.1021/bi00253a001; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CARDENAS ME, 1993, J CELL SCI, V104, P219; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARON PR, 1994, ADV PHARM DNA TOPOIS, P79; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; CLEMENS MJ, 1992, J CELL SCI, V103, P881; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; GANAPATHI R, 1993, BIOCHEM BIOPH RES CO, V192, P1274, DOI 10.1006/bbrc.1993.1554; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KIMURA K, 1994, J BIOL CHEM, V269, P24523; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1990, CELL, V62, P13; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROSE D, 1993, MOL CELL BIOL, V13, P3445, DOI 10.1128/MCB.13.6.3445; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SMITH PJ, 1989, CANCER RES, V49, P1118; SPELL RM, 1994, MOL CELL BIOL, V14, P1465, DOI 10.1128/MCB.14.2.1465; STRAUSFELD U, 1989, PREP BIOCHEM, V19, P37, DOI 10.1080/10826068908544895; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAN KB, 1992, CANCER RES, V52, P231; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714	60	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28357	28363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499337				2022-12-25	WOS:A1995TG21000062
J	LOHR, D; LOPEZ, J				LOHR, D; LOPEZ, J			GAL4/GAL80-DEPENDENT NUCLEOSOME DISRUPTION DEPOSITION ON THE UPSTREAM REGIONS OF THE YEAST GAL1-10 AND GAL80 GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; REGULATORY PROTEIN; DNA-BINDING; INVIVO; TRANSCRIPTION; ACTIVATION; ORGANIZATION; DISRUPTION; MECHANISM	Metabolic reactivation (incubating spheroplasts with galactose and casamino acids) causes disruption of nucleosomes from the upstream regions of the yeast GAL1, GAL10, and GAL80 genes, The disruption is specific. It depends on the transcription activator Gal4; it only occurs in galactose-reactivated chromatin from galactose-grown cells; it only affects upstream region, gene-proximal nucleosomes. Due to this specificity and because some of the same regions have shown induction-dependent changes by in vivo analyses, we suggest that the nucleosome-disrupted structure produced by reactivation is the authentic chromatin structure for these regions under conditions of galactose-induced GALI-10 and GAL80 expression. It is necessary to carry out a spheroplast reactivation treatment in order to observe this disrupted structure in nuclear chromatin because nucleosomes are redeposited onto these regions during the preliminary steps of nuclear isolation (cell harvest/ spheroplast preparation) probably in response to the nonphysiological conditions associated with these steps, However, during the same isolation procedures in cells lacking Gal80 protein, there is no nucleosome deposition on these regions, and the in vivo disrupted structure remains present in the nuclear chromatin, There fore, the nucleosome deposition process that operates in wild-type cells is dependent on Gal80 protein, defining another activity of this negative regulator.			LOHR, D (corresponding author), ARIZONA STATE UNIV,DEPT CHEM & BIOCHEM,TEMPE,AZ 85287, USA.				NATIONAL CANCER INSTITUTE [K04CA000911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037788] Funding Source: NIH RePORTER; NCI NIH HHS [CA00911] Funding Source: Medline; NIGMS NIH HHS [GM37788] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BELTZ W, 1977, THESIS FLORIDA STATE; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FEDOR M, 1988, MOL CELL BIOL, V9, P1721; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LIU L, 1987, P NATL ACAD SCI USA, V89, P7024; LOHR D, 1993, P NATL ACAD SCI USA, V90, P10628, DOI 10.1073/pnas.90.22.10628; LOHR D, 1987, J BIOL CHEM, V262, P15589; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; LOHR D, 1988, YEAST PRACTICAL APPR, P125; LOHR DE, 1981, BIOCHEMISTRY-US, V20, P5966, DOI 10.1021/bi00524a007; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; SHIMADA H, 1985, GENE, V39, P1; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	32	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27671	27678		10.1074/jbc.270.46.27671	http://dx.doi.org/10.1074/jbc.270.46.27671			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499233	hybrid			2022-12-25	WOS:A1995TE73600044
J	MUTHUSWAMY, SK; MULLER, WJ				MUTHUSWAMY, SK; MULLER, WJ			ACTIVATION OF SRC FAMILY KINASES IN NEU-INDUCED MAMMARY-TUMORS CORRELATES WITH THEIR ASSOCIATION WITH DISTINCT SETS OF TYROSINE-PHOSPHORYLATED PROTEINS IN-VIVO	ONCOGENE			English	Article						C-YES; FYN; TYROSINE PHOSPHORYLATION; MAMMARY TUMORS	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; HUMAN-BREAST-CANCER; MIDDLE-T-ANTIGEN; SIGNAL-TRANSDUCTION; METASTATIC DISEASE; SH3 DOMAINS; ONCOGENE; SUBSTRATE; MICE	Overexpression and amplification of the erbB-2 (nea) is thought to play a major role in mammary cancer. Although studies suggest that Neu is directly involved in the genesis of mammary tumors, the molecular mechanism by which Neu induces tumors is not well understood. Recently, we have demonstrated that the activity of c-Src tyrosine kinase is elevated in Neu-induced mammary tumors and this elevated activity correlates with its capacity to physically associate with Neu. To explore whether other members of the c-Src family are activated in these mammary tumors, we measured the in vitro kinase activity of the c-Yes and Fyn kinases in protein extracts derived from mammary tumor tissue and morphological normal adjacent tissue. These analyses revealed that c-Yes kinase activity was elevated in Neu-induced tumors by comparison to the adjacent tissue. By contrast, no significant activation of the Fyn kinase was noted in these tumors. Activation of c-Yes tyrosine kinase correlated with the capacity of c-Yes to associate with Neu in vivo in lysates derived from primary tumor samples. Studies with Rat.2 fibroblasts overexpressing activated Neu revealed that c-Src requires the presence of tyrosine phosphoryated Neu for its ability to interact with Neu in vivo. Moreover, analyses using radiolabeled c-Yes SH2 fusion protein revealed that this interaction is Likely occurring in a direct fashion. Although both c-Src and c-Yes kinase associate with Neu in vivo, a tyrosine phosphorylated protein of 89 kd (p89) was found associated with c-Src but not with c-Yes in cell lysates derived from mammary epithelial cells transformed by either Neu or PyV middle T antigen. Furthermore, this tyrosine phosphorylated protein was not detected in c-Src complexes derived from fibroblasts transformed by either Neu or PyV middle T. These observations suggest that p89 associates with c-Src only in mammary epithelial cells and not in fibroblasts.	MCMASTER UNIV, DEPT BIOL, HAMILTON, ON, CANADA; MCMASTER UNIV, INST MOLEC BIOL & BIOTECHNOL, DEPT PATHOL, CANC RES GRP, HAMILTON, ON, CANADA	McMaster University; McMaster University			Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JANES PW, 1994, ONCOGENE, V9, P3601; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KIEFER F, 1994, CURR BIOL, V4, P100, DOI 10.1016/S0960-9822(94)00025-4; KLAGES S, 1993, ONCOGENE, V8, P713; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK JS, 1993, ONCOGENE, V8, P2627; PATERSON MC, 1991, CANCER RES, V51, P556; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1992, ONCOGENE, V7, P1339; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; THOMAS JE, 1993, ONCOGENE, V8, P2521; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZHAN X, 1994, J BIOL CHEM, V269, P20221	58	80	87	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1801	1810						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478608				2022-12-25	WOS:A1995TD09400015
J	XU, L; MENG, Y; WALLEN, R; DEPINHO, RA				XU, L; MENG, Y; WALLEN, R; DEPINHO, RA			LOSS OF TRANSCRIPTIONAL ATTENUATION IN N-MYC IS ASSOCIATED WITH PROGRESSION TOWARDS A MORE MALIGNANT PHENOTYPE	ONCOGENE			English	Article						N-MYC PROTOONCOGENE; TRANSCRIPTIONAL ATTENUATION; MALIGNANT PROGRESSION	ZINC-FINGER PROTEIN; C-MYC; SEQUENCE REQUIREMENTS; GENE-EXPRESSION; 1ST EXON; CELLS; ELONGATION; FAMILY; BLOCK; PROMOTER	The modulation of RNA polymerase II processivity through the untranslated N-myc first exon represents an important mechanism governing N-myc mRNA levels during normal development. In this study, we employed the rat embryo fibroblast (REF) cooperation assay as a functional means to (i) map N-myc first exon sequences involved in the regulation of N-myc gene expression and specifically their contribution to controlling a block to transcriptional elongation and (ii) determine whether this transcriptional control mechanism plays a role in governing the oncogenic activity of N-myc. Transfection of N-myc expression constructs harboring various deletions within the untranslated first exon revealed that a region encoding a potential stem-loop structure followed by a thymine stretch (stem-loop/T region) was required for efficient transcriptional attenuation. The increase in transcriptional read-through associated with all deletions involving the stem-loop/T region also resulted in a more aggressive malignant phenotype as evidenced by a significant enhancement in the subcloning efficiency of N-myc/ras transformed foci. Most significantly, when cell lines generated from overexpression of the intact N-myc expression construct were selected for anchorage-independent growth, a strong block to transcriptional elongation was completely eliminated in all cases examined. Since the subcloning efficiency of transformed foci and the capacity of permanently established cell lines for anchorage-independent growth are direct correlates of more advanced stages of malignant transformation, our findings suggest that loss of transcriptional attenuation represents an important genetic event in the progression of N-myc-induced cellular transformation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X	NICHD NIH HHS [HD283117 2P30CA13330-20] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; XU L, 1993, ONCOGENE, V8, P2547; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	31	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1865	1872						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478616				2022-12-25	WOS:A1995TD09400023
J	FERRAO, P; MACMILLAN, EM; ASHMAN, LK; GONDA, TJ				FERRAO, P; MACMILLAN, EM; ASHMAN, LK; GONDA, TJ			ENFORCED EXPRESSION OF FULL-LENGTH C-MYB LEADS TO DENSITY-DEPENDENT TRANSFORMATION OF MURINE HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						MYB; TRANSFORMATION; FULL-LENGTH; DENSITY-DEPENDENCE; RETROVIRUS	AVIAN-MYELOBLASTOSIS VIRUS; PLASMACYTOID LYMPHOSARCOMAS; ERYTHROLEUKEMIA-CELLS; HEMATOPOIETIC-CELLS; PROTEIN TRUNCATION; ONCOGENE PRODUCT; COLON-CARCINOMA; DNA-BINDING; ACTIVATION; DIFFERENTIATION	The oncogenic activation of c-myb has been associated with structural alterations to the Myb protein. Although such alterations can increase the ability of Myb to transform haemopoietic cells, it has been unresolved whether over-expression of wild type (WT) c-Myb can lead to transformation. We show here that infection with a retrovirus that expresses WT i.e. full length c-Myb leads to transformation of primary haemopoietic cells (as indicated by clonogenic assays). The transformed cells are similar to those obtained with carboxyl-truncated (CT) c-Myb in that they show phenotypic and morphological characteristics of early myeloid cells and remain dependent on exogenous growth factors. Cells expressing WTMyb form lower numbers of colonies on average and have a greater tendency to spontaneously differentiate than those expressing truncated c-Myb. Additionally, our results show that transformation by both forms of Myb is dependent on the density at which the infected cells are cultured, and that low levels of transformation can be increased by addition of conditioned medium from myb transformed cells grown at high density. This implies that transformation can be enhanced by the effects of an autocrine growth factor. Moreover, the production of, or sensitivity to, such a factor may be influenced by Myb itself, since CT Myb-infected cells cultured at low densities show higher levels of transformation than WT Myb-infected cells.	INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,DIV HAEMATOL,LEUKAEMIA RES UNIT,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia			ASHMAN, LEONIE/G-7631-2013	ASHMAN, LEONIE/0000-0003-3559-3611				ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BARTELLA C, 1987, SCIENCE, V235, P1064; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1993, BLOOD, V82, P2813; GONDA TJ, 1991, SEMINARS VIROLOGY, V2, P351; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; MACMILLAN EM, 1994, BLOOD, V83, P209; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; METCALF D, 1982, INT J CANCER, V30, P773, DOI 10.1002/ijc.2910300616; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WINQVIST R, 1985, CANCER GENET CYTOGEN, V18, P251, DOI 10.1016/0165-4608(85)90090-1; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P3810	38	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1631	1638						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478588				2022-12-25	WOS:A1995TC53500022
J	HOLMES, CE; HECHT, SM				HOLMES, CE; HECHT, SM			FE-CENTER-DOT-BLEOMYCIN CLEAVES A TRANSFER-RNA PRECURSOR AND ITS TRANSFER DNA ANALOG AT THE SAME MAJOR SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC CLEAVAGE; STRAND SCISSION; DEOXYRIBONUCLEIC-ACID; ACTIVATED BLEOMYCIN; DEGRADATION; ANTIBIOTICS; TALISOMYCIN; CHEMISTRY	Previously, Fe.bleomycin (BLM) has been shown to mediate RNA cleavage in a fashion more highly selective than that of DNA. Because RNAs often assume secondary and tertiary structures not commonly encountered with DNAs, it was not clear whether the greater selectivity of RNA cleavage was a consequence of differences in the mononucleotide constituents of RNA and DNA, or of the three-dimensional structures of the individual substrates. Accordingly, we prepared a ''tDNA'' identical in sequence with Bacillus subtilis tRNA(His) precursor, the latter of which is known to be a good substrate for Fe(II).BLM A2 and which undergoes oxidative cleavage predominantly at U35. Remarkably, the tDNA underwent cleavage predominantly at T35. At higher concentrations of Fe(II).BLM A2, the tDNA was extensively degraded, while the tRNA(His) precursor was not. Competition experiments suggested that this was not due to more efficient binding of Fe.BLM to the tDNA; in fact the tRNA precursor appeared to be bound more efficiently. The lesser cleavage of the tRNA(His) may be due to limitations in the facility of chemical transformation following Fe.BLM binding, or else to the formation of RNA lesions that do not lead directly to RNA strand scission.	UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22901	University of Virginia; University of Virginia					NCI NIH HHS [CA53913] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA053913] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERRY DE, 1985, BIOCHEMISTRY-US, V24, P3207, DOI 10.1021/bi00334a020; CARTER BJ, 1990, J BIOL CHEM, V265, P7100; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; CARTER BJ, 1991, NUCLEOS NUCLEOT, V10, P215, DOI 10.1080/07328319108046448; CARTER BJ, 1991, TETRAHEDRON, V47, P2463, DOI 10.1016/S0040-4020(01)81781-6; CHIEN M, 1977, BIOCHEMISTRY-US, V16, P3641, DOI 10.1021/bi00635a021; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DUFF RJ, 1993, J AM CHEM SOC, V115, P3350, DOI 10.1021/ja00061a052; GOLD B, 1988, J AM CHEM SOC, V110, P2347, DOI 10.1021/ja00215a080; GREEN CJ, 1988, J BIOL CHEM, V263, P652; HAIDLE CW, 1979, BLEOMYCIN CHEM BIOCH, P222; HECHT SM, 1986, ACCOUNTS CHEM RES, V19, P383, DOI 10.1021/ar00132a002; HERTZBERG RP, 1988, BIOCHEMISTRY-US, V27, P3164, DOI 10.1021/bi00409a007; HERTZBERG RP, 1985, BIOCHEMISTRY-US, V24, P5285, DOI 10.1021/bi00341a001; HOLMES CE, 1993, BIOCHEMISTRY-US, V32, P4293, DOI 10.1021/bi00067a019; HUTTENHOFER A, 1992, J BIOL CHEM, V267, P24471; KAHN AS, 1988, SCIENCE, V241, P74; KROSS J, 1982, BIOCHEMISTRY-US, V21, P4310, DOI 10.1021/bi00261a021; LONG EC, 1990, J AM CHEM SOC, V112, P5272, DOI 10.1021/ja00169a040; MAGLIOZZO RS, 1989, MOL PHARMACOL, V35, P428; MASCHARAK PK, 1983, P NATL ACAD SCI-BIOL, V80, P6795, DOI 10.1073/pnas.80.22.6795; MIRABELLI CK, 1982, CANCER RES, V42, P2779; MIRABELLI CK, 1983, BIOCHEMISTRY-US, V22, P300, DOI 10.1021/bi00271a011; NAGAI K, 1991, J BIOL CHEM, V266, P23994; PAQUETTE J, 1990, EUR J BIOCHEM, V189, P259, DOI 10.1111/j.1432-1033.1990.tb15485.x; PERREAULT JP, 1989, EUR J BIOCHEM, V186, P87, DOI 10.1111/j.1432-1033.1989.tb15181.x; Sambrook J, 1989, MOL CLONING LABORATO; Slick B. I., 1985, BLEOMYCIN CHEMOTHERA; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIYAMA H, 1988, BIOCHEMISTRY-US, V27, P58, DOI 10.1021/bi00401a011; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; UEDA K, 1985, J BIOL CHEM, V260, P5804; WILLIAMS LD, 1988, BIOCHEMISTRY-US, V27, P3004, DOI 10.1021/bi00408a051	34	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25909	25913						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503991				2022-12-25	WOS:A1993MK10000089
J	IGARASHI, K; KANEDA, M; YAMAJI, A; SAIDO, TC; KIKKAWA, U; ONO, Y; INOUE, K; UMEDA, M				IGARASHI, K; KANEDA, M; YAMAJI, A; SAIDO, TC; KIKKAWA, U; ONO, Y; INOUE, K; UMEDA, M			A NOVEL PHOSPHATIDYLSERINE-BINDING PEPTIDE MOTIF DEFINED BY AN ANTIIDIOTYPIC MONOCLONAL-ANTIBODY - LOCALIZATION OF PHOSPHATIDYLSERINE-SPECIFIC BINDING-SITES ON PROTEIN-KINASE-C AND PHOSPHATIDYLSERINE DECARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA TOPOISOMERASE-II; ESCHERICHIA-COLI; CLONING; ACTIVATION; SEQUENCE; GENE; PHOSPHOLIPIDS; TRANSLOCATION; RECOGNITION; EXPRESSION	A monoclonal anti-idiotypic antibody, Id8F7, previously shown to bind to a phosphatidylserine (PS)-specific binding site on protein kinase C (PKC) has been used to identify a 12-amino acid consensus sequence shared by PKC and phosphatidylserine decarboxylase (PSD). The 14-amino acid synthetic peptide derived from the corresponding region of PSD (amino acids 351-364 of the enzyme from Chinese hamster ovary cells) bound effectively and specifically to PS, and that derived from rat PKC gamma (amino acids 227-240) bound weakly but specifically to PS. Analysis of binding of Id8F7 to various synthetic peptides revealed that the consensus sequence motif, FXFXLKXXXKXR, is responsible for the interaction with both Id8F7 and PS. The results suggest that the conserved amino acid residues represent a basic structural motif for the specific interaction with PS, and the corresponding regions of PKC and PSD form the PS-specific binding sites of these enzymes.	TOKYO METROPOLITAN INST MED SCI,DEPT INFLAMMAT RES,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN; KOBE UNIV,BIOSIGNAL RES CTR,NADA KU,KOBE 657,JAPAN; KOBE UNIV,FAC SCI,DEPT BIOL,KOBE 657,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Kobe University; Kobe University			Saido, Takaomi C/N-5472-2015; Igarashi, Koji/AAC-5332-2020; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Igarashi, Koji/0000-0002-5007-7079; Sado, Takaomi/0000-0003-1970-6903				ADACHI N, 1992, NUCLEIC ACIDS RES, V20, P5297, DOI 10.1093/nar/20.20.5297; BELL RM, 1991, J BIOL CHEM, V266, P4661; CALDERON C, 1994, J EXP MED, V180, P945, DOI 10.1084/jem.180.3.945; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COMFURIUS P, 1994, BIOCHEMISTRY-US, V33, P10319, DOI 10.1021/bi00200a012; CONNOR J, 1994, J BIOL CHEM, V269, P2399; CONSTANCE JC, 1993, J BIOL CHEM, V268, P24580; DOWHAN W, 1992, METHOD ENZYMOL, V209, P348; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; FADOK VA, 1993, J IMMUNOL, V151, P4274; FUJISAKU A, 1989, J BIOL CHEM, V264, P2118; GALINSKI MS, 1988, VIROLOGY, V165, P499, DOI 10.1016/0042-6822(88)90594-6; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; IGARASHI K, 1995, J BIOCHEM-TOKYO, V117, P452, DOI 10.1093/jb/117.2.452; KUGE O, 1991, J BIOL CHEM, V266, P6370; LEE MH, 1989, J BIOL CHEM, V264, P14797; LI QX, 1993, J BIOL CHEM, V263, P11516; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; ONO Y, 1994, P NATL ACAD SCI USA, V339, P229; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; OSATOMI K, 1990, VIROLOGY, V176, P643, DOI 10.1016/0042-6822(90)90037-R; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SAKANE F, 1991, J BIOL CHEM, V266, P7096; STEKHOVEN FMAHS, 1994, BBA-BIOMEMBRANES, V1194, P155; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; TUMA PL, 1993, J BIOL CHEM, V268, P17240; UMEDA M, 1989, J IMMUNOL, V143, P2273; UNTERMAN RD, 1981, P NATL ACAD SCI-BIOL, V78, P3478, DOI 10.1073/pnas.78.6.3478	36	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29075	29078		10.1074/jbc.270.49.29075	http://dx.doi.org/10.1074/jbc.270.49.29075			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493929	hybrid			2022-12-25	WOS:A1995TJ22700010
J	SUSULIC, VS; FREDERICH, RC; LAWITTS, J; TOZZO, E; KAHN, BB; HARPER, ME; HIMMSHAGEN, J; FLIER, JS; LOWELL, BB				SUSULIC, VS; FREDERICH, RC; LAWITTS, J; TOZZO, E; KAHN, BB; HARPER, ME; HIMMSHAGEN, J; FLIER, JS; LOWELL, BB			TARGETED DISRUPTION OF THE BETA(3)-ADRENERGIC RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-3-ADRENERGIC RECEPTOR; ATYPICAL BETA-ADRENOCEPTOR; BROWN ADIPOSE-TISSUE; RAT ADIPOCYTES; MOLECULAR CHARACTERIZATION; ADRENERGIC-RECEPTORS; ADENYLATE-CYCLASE; AGONIST EXPOSURE; TRANSGENIC MICE; UP-REGULATION	beta(3)-Adrenergic receptors (beta(3)-ARs) are expressed predominantly in white and brown adipose tissue, and beta(3)-selective agonists are potential anti-obesity drugs. However, the role of beta(3)-ARs in normal physiology is unknown. To address this issue, homologous recombination was used to generate mice that lack beta(3)-ARs. This was accomplished by direct injection of a DNA-targeting construct into mouse zygotes. Twenty-three transgenic mice were generated, of which two had targeted disruption of the beta(3)-AR gene. Mice that were homozygous for the disrupted allele had undetectable levels of intact beta(3)-AR mRNA, as assessed by RNase protection assay and Northern blotting, and lacked functional beta(3)-ARs, as demonstrated by complete loss of beta(3)-agonist (CL 316,243)-induced stimulation of adenylate cyclase activity and lipolysis. beta(3)-AR-deficient mice had modestly increased fat stores (females more than males), indicating that beta(3)-ARs play a role in regulating energy balance. Importantly, beta(1) but not beta(2)-AR mRNA levels up-regulated in white and brown adipose tissue of beta(3)-AR-deficient mice (brown more than white), strongly implying that beta(3)-ARs mediate physiologically relevant signaling under normal conditions and that ''cross-talk'' exists between beta(3)-ARs and beta(1)-AR gene expression. Finally, acute treatment of normal mice with CL 316,243 increased serum levels of free fatty acids (FFAs) (3.2-fold) and insulin (140-fold), increased energy expenditure (2-fold), and reduced food intake (by 45%). These effects were completely absent in beta(3)-AR-deficient mice, proving that the actions of CL are mediated exclusively by beta(3)-ARs. beta(3)-AR-deficient mice should be useful as a means to a better understanding of the physiology and pharmacology of beta(3)-ARs.	BETH ISRAEL HOSP, DEPT MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT PATHOL, BOSTON, MA 02215 USA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1H 8M5, CANADA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of Ottawa; Harvard University; Harvard Medical School			Flier, jeffrey/AAG-6223-2019	Harper, Mary-Ellen/0000-0003-3864-5886	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002119, R01DK049569, R01DK043051] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK4600, R01 DK043051, DK49569, DK02119] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; BIRNBAUMER L, 1969, J BIOL CHEM, V244, P3468; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; BOND RA, 1988, BRIT J PHARMACOL, V95, P723, DOI 10.1111/j.1476-5381.1988.tb11698.x; BOND RA, 1987, BRIT J PHARMACOL, V91, P683, DOI 10.1111/j.1476-5381.1987.tb11262.x; BRADLEY DC, 1989, ANAL BIOCHEM, V180, P11, DOI 10.1016/0003-2697(89)90081-X; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BRINSTER RL, 1989, P NATL ACAD SCI USA, V86, P7087, DOI 10.1073/pnas.86.18.7087; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; CARPENE C, 1993, J PHARMACOL EXP THER, V265, P237; CHAUDHRY A, 1991, AM J PHYSIOL, V261, pR403, DOI 10.1152/ajpregu.1991.261.2.R403; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; COHEN JA, 1993, DNA CELL BIOL, V12, P537, DOI 10.1089/dna.1993.12.537; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; CUSHMAN SW, 1978, J LIPID RES, V19, P269; EMORINE L, 1994, TRENDS PHARMACOL SCI, V15, P3, DOI 10.1016/0165-6147(94)90118-X; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; ESBENSHADE TA, 1994, NEUROPROTOCOLS, V4, P2; FAIN JN, 1973, MOL PHARMACOL, V9, P595; GRANNEMAN JG, 1992, J PHARMACOL EXP THER, V261, P638; GRANNEMAN JG, 1992, MOL PHARMACOL, V42, P964; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GREENBERG AS, 1987, J BIOL CHEM, V262, P4564; Hales C N, 1978, Biochem Soc Symp, P97; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HIMMSHAGEN J, 1992, AM J PHYSIOL, V266, pR1371; HIRSCH J, 1968, J LIPID RES, V9, P110; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLENGA C, 1989, BRIT J PHARMACOL, V98, P1420, DOI 10.1111/j.1476-5381.1989.tb12692.x; HOLLOWAY BR, 1992, AM J CLIN NUTR, V55, P262; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; JAKUBOWSKI M, 1992, J NEUROENDOCRINOL, V4, P79, DOI 10.1111/j.1365-2826.1992.tb00349.x; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NANTEL F, 1994, J BIOL CHEM, V269, P13148; NANTEL F, 1993, MOL PHARMACOL, V43, P548; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Robinson GA, 1971, CYCLIC AMP; RODBELL M, 1964, J BIOL CHEM, V239, P375; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SALMON DMW, 1985, INT J OBESITY, V9, P443; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SAMBROOK J, MOL CLONING LABORATO; SCHWABE U, 1973, N-S ARCH PHARMACOL, V276, P133, DOI 10.1007/BF00501186; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Steinberg D, 1976, Adv Cyclic Nucleotide Res, V7, P157; THOMAS RF, 1992, P NATL ACAD SCI USA, V89, P4490, DOI 10.1073/pnas.89.10.4490; TSUJII S, 1992, BRAIN RES, V587, P226, DOI 10.1016/0006-8993(92)91001-U; VANLIEFDE I, 1992, J PHARMACOL EXP THER, V262, P552; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; YOSHIDA T, 1992, AM J CLIN NUTR, V55, P237; ZAAGSMA J, 1990, TRENDS PHARMACOL SCI, V11, P3, DOI 10.1016/0165-6147(90)90032-4; ZHAO J, 1994, AM J PHYSIOL-CELL PH, V267, pC969, DOI 10.1152/ajpcell.1994.267.4.C969	67	388	400	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29483	29492		10.1074/jbc.270.49.29483	http://dx.doi.org/10.1074/jbc.270.49.29483			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493988	hybrid			2022-12-25	WOS:A1995TJ22700069
J	BELDENT, V; MICHAUD, A; BONNEFOY, C; CHAUVET, MT; CORVOL, P				BELDENT, V; MICHAUD, A; BONNEFOY, C; CHAUVET, MT; CORVOL, P			CELL-SURFACE LOCALIZATION OF PROTEOLYSIS OF HUMAN ENDOTHELIAL ANGIOTENSIN I-CONVERTING ENZYME - EFFECT OF THE AMINO-TERMINAL DOMAIN IN THE SOLUBILIZATION PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ANCHORED GROWTH-FACTORS; FACTOR TNF RECEPTOR; GOLGI-COMPLEX; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; FACTOR-ALPHA; BREFELDIN-A; CLEAVAGE; RELEASE	Angiotensin-converting enzyme (ACE) belongs to the type I class of ectoproteins and is solubilized by Chinese hamster ovary cells transfected with the full-length human ACE cDNA. ACE release in Chinese hamster ovary cells involves a proteolytic cleavage occurring in the carboxyl-terminal region, between Arg-1137 and Leu-1138, The subcellular localization of ACE proteolysis was established by pulse chase experiments, cell surface immunolabeling, and biotinylation of radiolabeled mature proteins, The proteolysis of ACE takes place primarily at the plasma membrane, The solubilization of ACE is less than 2% within 1 h, is increased 2.4-fold by phorbol esters, but is not influenced by ionophores. An ACE mutant lacking the transmembrane domain and the cytosolic part (ACE(Delta COOH)), is secreted at a faster rate without a carboxyl-terminal cleavage, and phorbol esters or ionophores have no effect on its rate of production in the medium, Therefore, the proteolysis of ACE is dependent on the presence of the membrane anchor and suggests that the secretase(s) involved is also membrane-associated, An ACE mutant lacking the aminoterminal domain (ACE(CF)) is secreted 10 fold faster compared with wild-type ACE, The solubilization of ACE(CF) occurs at the plasma membrane and is stimulated 2.7-fold by phorbol esters, and the cleavage site is localized between Arg-1227 and Val-1228. The amino-terminal domain of ACE slows down the proteolysis and seems to act as a ''conformational inhibitor'' of the proteolytic process, possibly via interactions with the ''stalk'' of ACE and the secretase(s) itself.	COLL FRANCE, INSERM, U36, F-75005 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France								ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BOSENBERG MW, 1992, CELL, V71, P117; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; EFTHIMIOPOULOS S, 1994, J NEUROSCI RES, V38, P81, DOI 10.1002/jnr.490380111; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EVIN G, 1994, INT J EXP CLIN INVES, V1, P263; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HARANO T, 1994, J BIOL CHEM, V269, P20305; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; HORIUCHI M, 1982, J CHROMATOGR, V233, P123, DOI 10.1016/S0378-4347(00)81738-7; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUBERT C, 1991, J BIOL CHEM, V266, P15377; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOTTAZ D, 1992, FEBS LETT, V313, P270, DOI 10.1016/0014-5793(92)81207-3; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PORTEU F, 1991, J BIOL CHEM, V266, P18846; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4450; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEN I, 1991, J BIOL CHEM, V266, P21985; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SKIDGEL RA, 1985, P NATL ACAD SCI USA, V82, P1025, DOI 10.1073/pnas.82.4.1025; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540	44	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28962	28969		10.1074/jbc.270.48.28962	http://dx.doi.org/10.1074/jbc.270.48.28962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499427	hybrid			2022-12-25	WOS:A1995TH05600071
J	KOHLHUBER, F; HERMEKING, H; GRAESSMANN, A; EICK, D				KOHLHUBER, F; HERMEKING, H; GRAESSMANN, A; EICK, D			INDUCTION OF APOPTOSIS BY THE C-MYC HELIX-LOOP HELIX/LEUCINE ZIPPER DOMAIN IN MOUSE 3T3-L1 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATION; CELL-GROWTH; MAX; PROTEIN; SEQUENCE; TRANSFORMATION; DIMERIZATION; GENE	The cellular proto-oncogene c-myc is involved in cell proliferation and transformation but is also implicated in the induction of programmed cell death (apoptosis). The c-Myc protein is a transcriptional activator with a carboxyl-terminal basic region/helix-loop-helix (HLH)/leucine zipper (LZ) domain. It forms heterodimers with the HLH/LZ protein Max and transactivates gene expression after binding DNA E-box elements. We have studied the phenotype of dominant negative mutants of c-Myc and Max in microinjection experiments. Max mutants with a deleted or mutated basic region inhibited DNA synthesis in serum stimulated 3T3-L1 mouse fibroblasts. In contrast, mutants of c-Myc expressing only the basic reson/HLH/LZ or HLH/LZ domains rapidly induced apoptosis at low and high serum levels. Co expression of the HLH/LZ domains of c-Myc and Max failed to do so. We suggest that the c-Myc HLH/LZ domain induces apoptosis by specific interaction with cellular factors different to Max.	GSF MUNICH, FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INST KLIN MOLEK BIOL & TUMORGENET, D-81377 MUNICH, GERMANY; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; FREE UNIV BERLIN, INST MOLEK BIOL & BIOCHEM, D-14195 BERLIN, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Cancer Research UK; Free University of Berlin								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COGLIATI T, 1993, ONCOGENE, V8, P1263; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEUSCHLE U, 1989, P NATL ACAD SCI USA, V86, P5400, DOI 10.1073/pnas.86.14.5400; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GREEN H, 1994, CELL, V74, P127; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; REDDY CD, 1992, ONCOGENE, V7, P2085; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAYLOR IM, 1990, MOL MICROBIOL, V4, P1259, DOI 10.1111/j.1365-2958.1990.tb00705.x; WYLLIE AH, 1987, ARCH TOXICOL, P3; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	55	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28797	28805		10.1074/jbc.270.48.28797	http://dx.doi.org/10.1074/jbc.270.48.28797			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499403	hybrid			2022-12-25	WOS:A1995TH05600047
J	HOWARD, MT; NELSON, WC; MATSON, SW				HOWARD, MT; NELSON, WC; MATSON, SW			STEPWISE ASSEMBLY OF A RELAXOSOME AT THE F PLASMID ORIGIN OF TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE-I; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; NICKING REACTION; GENE-PRODUCT; SEX FACTOR; ORIT; SITE; CONJUGATION; CATALYZES	A central step in the transfer of genetic information during bacterial conjugation of the Escherichia coli F plasmid involves the formation of a protein-DNA complex, called the relaxosome, at the origin of transfer. During conjugation, the relaxosome introduces a site- and strand-specific nick from which the physical transfer of a single strand of DNA is initiated. At least two F-encoded proteins, TraIp (tra gene product) and TraYp (traY gene product), and one host-encoded protein, integration host factor, are involved in this process. In this report, we use DNase I protection and electron microscopic techniques to investigate the mechanism of relaxosome formation. Our results show that TraYp and integration host factor form a protein-DNA complex that facilitates the binding of TraIp to assemble a relaxosome capable of introducing a site- and strand-specific nick at the origin of transfer. This nick is identical to that observed during conjugation.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Nelson, William C/E-9263-2016	Nelson, William C/0000-0002-1873-3929	NIGMS NIH HHS [GM16358, GM33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476, F32GM016358] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FU FYH, 1991, J BACTERIOL, V173, P1012; IPPENIHLER KA, 1986, ANNU REV GENET, V20, P593, DOI 10.1146/annurev.ge.20.120186.003113; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LAURENZIO LD, 1992, MOL MICROBIOL, V6, P2951; LUO Y, 1994, MOL MICROBIOL, V11, P459, DOI 10.1111/j.1365-2958.1994.tb00327.x; Maniatis T., 1982, MOL CLONING LABORATO, P86; MATSON SW, 1991, J BIOL CHEM, V266, P16232; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; NELSON WC, 1995, J BIOL CHEM, V270, P28374; NELSON WC, 1993, J BACTERIOL, V175, P2221, DOI 10.1128/JB.175.8.2221-2228.1993; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; THOMPSON R, 1984, EMBO J, V3, P1175, DOI 10.1002/j.1460-2075.1984.tb01947.x; THOMPSON TL, 1989, J MOL BIOL, V207, P505, DOI 10.1016/0022-2836(89)90460-9; TRAXLER BA, 1987, J BACTERIOL, V169, P3251, DOI 10.1128/jb.169.7.3251-3259.1987; TRAXLER BA, 1988, J MOL BIOL, V204, P205, DOI 10.1016/0022-2836(88)90609-2; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WILLETTS N, 1987, ESCHERICHIA COLI SAL, P1110	27	61	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28381	28386						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499340				2022-12-25	WOS:A1995TG21000065
J	JACKSON, CE; ONEILL, DO; BANK, A				JACKSON, CE; ONEILL, DO; BANK, A			NUCLEAR FACTOR-BINDING SITES IN HUMAN BETA-GLOBIN IVS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; HEMATOPOIETIC-CELL LINES; HIGH-LEVEL EXPRESSION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; RESTRICTED EXPRESSION; TRANSGENIC MICE; HOMEOBOX GENES; PROTEIN	The second intron of the human beta globin gene (beta IVS2) has been previously identified as a region required for proper expression of beta globin. To further characterize this region, we have footprinted the entire beta IVS2 and have analyzed regions of interest by electrophoretic mobility shift assay. Through these studies we have identified four utilized binding sites for the erythroid regulatory factor GATA-1, two sites bound by general transcription factor Oct-1, two sites bound by the nu clear matrix attachment DNA binding protein special A-T-rich binding protein 1, and a site bound by a potential homeobox protein. Additionally, we have found several factors displaying temporal or tissue specificity by electrophoretic mobility shift assay, which may be potentially involved in the regulation of beta globin expression. These proteins are not supershifted by antibodies to factors important in erythroid regulation such as GATA-1, NFE-2, or YY1, or by antibodies against more general transcription factors.	COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University					NHLBI NIH HHS [HL-28381, HL-48345] Funding Source: Medline; NIDDK NIH HHS [DK-25274] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048345, P60HL028381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025274, R01DK025274] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANTONIOU M, 1988, EMBO J, V7, P377, DOI 10.1002/j.1460-2075.1988.tb02824.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BEHRINGER RR, 1987, P NATL ACAD SCI USA, V84, P7056, DOI 10.1073/pnas.84.20.7056; BORTELL R, 1992, P NATL ACAD SCI USA, V89, P6119, DOI 10.1073/pnas.89.13.6119; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; CUNNINGHAM JM, 1994, BLOOD, V84, P1298; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DONOVANPELUSO M, 1987, J BIOL CHEM, V262, P17051; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GEY GO, 1952, CANCER RES, V12, P264; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LAFLAMME S, 1987, J BIOL CHEM, V262, P4819; LAVELLE D, 1991, P NATL ACAD SCI USA, V88, P7318, DOI 10.1073/pnas.88.16.7318; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LAWRENCE HJ, 1994, ANN NY ACAD SCI, V718, P165; LLOYD JA, 1994, J BIOL CHEM, V269, P19385; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATHEWS CHE, 1991, BLOOD, V78, P2248; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; ONEILL D, 1991, P NATL ACAD SCI USA, V88, P8953, DOI 10.1073/pnas.88.20.8953; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SENGUPTA PK, 1994, BLOOD, V83, P1420; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; SHEN WF, 1989, ADV EXP MED BIOL, V271, P211; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; SUN JM, 1994, J CELL BIOCHEM, V55, P252, DOI 10.1002/jcb.240550212; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VALLERGA A, 1991, BLOOD S, V78, P254; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WAITZ W, 1991, ONCOGENE, V6, P29; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; 1991, PROGRAM MANUAL GCG P	58	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28448	28456						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499351				2022-12-25	WOS:A1995TG21000076
J	FILPPULA, SA; SORMUNEN, RT; HARTIG, A; KUNAU, WH; HILTUNEN, JK				FILPPULA, SA; SORMUNEN, RT; HARTIG, A; KUNAU, WH; HILTUNEN, JK			CHANGING STEREOCHEMISTRY FOR A METABOLIC PATHWAY IN-VIVO - EXPERIMENTS WITH THE PEROXISOMAL BETA-OXIDATION IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENOYL-COA HYDRATASE; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; 3-HYDROXYACYL-COA DEHYDROGENASE; CATALASE-A; BIFUNCTIONAL ENZYME; MULTIENZYME COMPLEX; CANDIDA-TROPICALIS; MOLECULAR-CLONING; ESCHERICHIA-COLI	The biosphere is inherently built of chiral molecules, and once their metabolism is established, the stereochemical course of the reactions involved is seen to remain highly conserved, However, by replacing the yeast peroxisomal multifunctional enzyme (MFE), which catalyzes the second and third reactions of beta-oxidation of fatty acids via D-3-hydroxyacyl-CoA intermediates, with rat peroxisomal MFE, which catalyzes the same reactions via L-3-hydroxy intermediates, it was possible to change the chiralities of the intermediates in a major metabolic pathway in vivo. Both stereochemical alternatives allowed the yeast cells to grow on oleic acid, implying that when the beta-oxidation pathways evolved, the overall function was the determining factor for the ac quisition of MFEs and not the stereospecificities of the reactions themselves.	UNIV OULU,DEPT MED BIOCHEM,SF-90220 OULU,FINLAND; UNIV OULU,BIOCTR,SF-90220 OULU,FINLAND; UNIV OULU,DEPT PATHOL,SF-90220 OULU,FINLAND; BIOZENTRUM,INST BIOCHEM & MOLEK ZELLBIOL,A-1030 VIENNA,AUSTRIA; BIOZENTRUM,LUDWIG BOLTZMANN FORSCH STELLE BIOCHEM,A-1030 VIENNA,AUSTRIA; RUHR UNIV BOCHUM,FAK MED,ZELLBIOL ABT,INST PHYSIOL CHEM,W-4630 BOCHUM,GERMANY; UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,SF-70211 KUOPIO,FINLAND	University of Oulu; University of Oulu; University of Oulu; Ludwig Boltzmann Institute; Ruhr University Bochum; University of Eastern Finland				Hartig, Andreas/0000-0003-3334-2763				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEATTIE DS, 1968, BIOCHEM BIOPH RES CO, V30, P57, DOI 10.1016/0006-291X(68)90712-2; BEHRENDS W, 1988, ARCH BIOCHEM BIOPHYS, V263, P161, DOI 10.1016/0003-9861(88)90624-8; CHEN GL, 1991, BIOCHEM BIOPH RES CO, V178, P1084, DOI 10.1016/0006-291X(91)91003-U; COHEN G, 1988, EUR J BIOCHEM, V176, P159; COOPER TG, 1969, J BIOL CHEM, V244, P3514; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; DIRUSSO CC, 1990, J BACTERIOL, V172, P6459, DOI 10.1128/jb.172.11.6459-6468.1990; Goodridge A. G., 1985, BIOCH LIPIDS MEMBRAN, P143; GREEN DE, 1954, BIOL REV, V29, P330, DOI 10.1111/j.1469-185X.1954.tb00599.x; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; HOERTNER H, 1982, European Journal of Biochemistry, V128, P179; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KENNEDY EP, 1949, J BIOL CHEM, V179, P957; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LYNEN F, 1961, FED PROC, V20, P941; LYNEN F, 1953, BIOCHIM BIOPHYS ACTA, V12, P299, DOI 10.1016/0006-3002(53)90149-8; MALILA LH, 1993, J BIOL CHEM, V268, P21578; NADA MA, 1995, J BIOL CHEM, V270, P530, DOI 10.1074/jbc.270.2.530; NAGAHIGHASHI K, 1990, NUCLEIC ACIDS RES, V18, P4937; NUTTLEY WM, 1988, GENE, V69, P171, DOI 10.1016/0378-1119(88)90428-3; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; OSUMI T, 1985, J BIOL CHEM, V260, P8905; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PREISIGMULLER R, 1994, J BIOL CHEM, V269, P20475; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; SORMUNEN R, 1993, LAB INVEST, V68, P652; SRERE PA, 1994, BIOCHEM SOC T, V22, P446, DOI 10.1042/bst0220446; TANAKA A, 1982, ANN NY ACAD SCI, V386, P183, DOI 10.1111/j.1749-6632.1982.tb21416.x; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; VAGELOS PR, 1966, FED PROC, V25, P1485; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WAKIL SJ, 1961, J LIPID RES, V2, P1; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; YANG SY, 1983, J BIOL CHEM, V258, P9780	40	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27453	27457		10.1074/jbc.270.46.27453	http://dx.doi.org/10.1074/jbc.270.46.27453			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499202	hybrid			2022-12-25	WOS:A1995TE73600013
J	FOWLKES, JL; SERRA, DM; ROSENBERG, CK; THRAILKILL, KM				FOWLKES, JL; SERRA, DM; ROSENBERG, CK; THRAILKILL, KM			INSULIN-LIKE GROWTH-FACTOR (IGF)-BINDING PROTEIN-3 (IGFBP-3) FUNCTIONS AS AN IGF-REVERSIBLE INHIBITOR OF IGFBP-4 PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING-PROTEINS; TRANSFORMED HUMAN FIBROBLASTS; SECRETION; IDENTIFICATION; MECHANISM; CELLS; FORMS; RAT	Previous studies have shown that insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) is degraded only in the presence of exogenous IGFs; however, we found that cation-dependent proteinase activity present in conditioned medium of MC3T3-E1 osteoblasts degrades I-125-recombinant human (rh)IGFBP-4 in the absence of IGFs, Addition of IGF-I, IGF-II, or insulin to conditioned medium had little affect on I-125-rhIGFBP-4 proteolysis, while extraction of IGFs resulted in only a similar to 10% reduction in proteinase activity. Since factors other than IGFs appeared to be involved in regulating IGFBP-4 proteolysis, we hypothesized that IGFBP-3, an IGFBP produced by many cell lines, but not MC3T3-E1 cells, might function as an inhibitor of IGFBP-4 proteolysis, Addition of rhIGFBP-3 to conditioned media inhibited I-125-rhIGFBP-4 proteolysis by 90%, while IGF-I and IGF II reversed the inhibitory effects of rhIGFBP-3 in a dose-dependent manner, I-125-rhIGFBP-4 proteolysis was not inhibited by N-terminal rhIGEFBP-3 fragments that bind IGFs, but was inhibited by two synthetic peptides corresponding to sequences contained in the mid-region or C-terminal region of IGFBP-3, Both inhibitory peptides contain highly basic, putative heparin binding domains and heparin partially reversed the inhibitory effects of rhIGFBP-3 on I-125-rhIGFBP-4 proteolysis, These data demonstrate that rhIGFBP-3 inhibits IGFBP-4-degrading proteinase activity and binding of IGFs or glycosaminoglycans to IGFBP-3 may induce conformational changes in the binding protein, causing disinhibition of the proteinase.	DUKE UNIV, MED CTR, DIV ENDOCRINOL, DEPT PEDIAT, DURHAM, NC 27710 USA	Duke University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002276, R01DK055653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02276, R01 DK055653] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBISTON AL, 1995, ENDOCRINOLOGY, V136, P696, DOI 10.1210/en.136.2.696; AMARNANI S, 1993, J BONE MINER RES, V8, P157; ARAI T, 1994, ENDOCRINOLOGY, V135, P2358, DOI 10.1210/en.135.6.2358; ARAI T, 1994, J BIOL CHEM, V269, P20388; Bach LA, 1995, DIABETES REV, V3, P38; BAR RS, 1994, INT CONGR SER, V1056, P237; CAMACHOHUBNER C, 1991, J CELL PHYSIOL, V148, P281, DOI 10.1002/jcp.1041480214; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CEDA GP, 1991, ENDOCRINOLOGY, V128, P2815, DOI 10.1210/endo-128-6-2815; CLEMMONS DR, 1992, MODERN CONCEPTS INSU, P475; CONOVER CA, 1991, J CLIN INVEST, V88, P1354, DOI 10.1172/JCI115441; CONOVER CA, 1993, J CLIN INVEST, V91, P1129, DOI 10.1172/JCI116272; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; CONOVER CA, 1993, ENDOCRINOLOGY, V133, P1347, DOI 10.1210/en.133.3.1347; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DURHAM SK, 1995, J CLIN ENDOCR METAB, V80, P104, DOI 10.1210/jc.80.1.104; DURHAM SK, 1994, J BONE MINER RES, V9, P111; FOWLKES J, 1992, ENDOCRINOLOGY, V131, P2071, DOI 10.1210/en.131.5.2071; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3051, DOI 10.1210/en.131.6.3051; GOCKERMAN A, 1995, CIRC RES, V76, P514, DOI 10.1161/01.RES.76.4.514; HURLEY MM, 1995, J BONE MINER RES, V10, P222; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAMYAR A, 1994, CIRC RES, V74, P576, DOI 10.1161/01.RES.74.4.576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALPE R, 1992, 14TH ANN M AM SOC BO; MYERS SE, 1993, ENDOCRINOLOGY, V133, P1525, DOI 10.1210/en.133.4.1525; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; NEELY EK, 1992, ENDOCRINOLOGY, V130, P985, DOI 10.1210/en.130.2.985; QUARLES LD, 1991, ENDOCRINOLOGY, V128, P3144, DOI 10.1210/endo-128-6-3144; Rechler Matthew M., 1995, P155; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SHIMASAKI S, 1990, MOL ENDOCRINOL, V4, P1451, DOI 10.1210/mend-4-10-1451; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; THRAILKILL KM, 1995, BONE, V17, P307, DOI 10.1016/8756-3282(95)00223-Z; THRAILKILL KM, 1990, J CLIN INVEST, V86, P878, DOI 10.1172/JCI114788; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527	39	48	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27481	27488		10.1074/jbc.270.46.27481	http://dx.doi.org/10.1074/jbc.270.46.27481			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499205	hybrid			2022-12-25	WOS:A1995TE73600016
J	GARNOTEL, R; MONBOISSE, JC; RANDOUX, A; HAYE, B; BOREL, JP				GARNOTEL, R; MONBOISSE, JC; RANDOUX, A; HAYE, B; BOREL, JP			THE BINDING OF TYPE-I COLLAGEN TO LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN (LFA)-1 INTEGRIN TRIGGERS THE RESPIRATORY BURST OF HUMAN POLYMORPHONUCLEAR NEUTROPHILS - ROLE OF CALCIUM SIGNALING AND TYROSINE PHOSPHORYLATION OF LFA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CD11B/CD18 INTEGRIN; ADHESION; PROTEINS; ALPHA; ACTIVATION; SUBUNIT; TRISPHOSPHATE; TRANSDUCTION; MODULATION	Monoclonal antibodies to the alpha(L) beta(2) integrin inhibit the binding of type I collagen to PMN (polymorphonuclear neutrophil leukocytes) as well as the subsequent stimulation of superoxide production and enzyme secretion elicited by this collagen, Pepsinized collagen still binds PMN but no longer stimulates them, The I domain of the a chain of the integrin is involved in the binding, Two sequences of the alpha(1)(I) polypeptide chain of collagen participate in the process, Experiments of competitive inhibition by synthetic peptides showed that the sequence RGD (985-917) is used for binding to the cells and DGGRYY (1034-1039) serves to stimulate PMN, Experiments of radioactive labeling of the cells and affinity chromatography on Sepharose-collagen confirmed the presence in PMN extracts of two proteins, 95 and 185 kDa, respectively, corresponding to the molecular weights of the beta(2) and alpha(L) chains of the integrin and recognized by their specific monoclonal antibodies. The transduction pathways depending on the alpha(L) beta(2) integrin do not involve a G protein (ruled out by the use of cholera and pertussis toxins), whereas the cytoskeleton was found to participate in the process, as evidenced by inhibition by cytochalasin B. After collagen stimulation, cytoplasmic inositol trisphosphate and calcium ion increased sharply for less than 2 min, The use of the inhibitors staurosporine and calphostin C demonstrated that protein kinase C was involved, Evaluation of the activity of this enzyme showed that, upon stimulation of PMN with collagen I, it was translocated to plasma membrane. Acrylamide gel electrophoresis of the protein bands corresponding to the integrin alpha(L) beta(2), followed by immunoblotting using monoclonal antibodies to phosphotyrosine, permitted us to demonstrate that, prior to stimulation by type I collagen, there was no phos phorylation, whereas after stimulation, both cY,and beta(2) chains were stained by anti-phosphotyrosine antibodies, The adhesion of PMN to pepsinized type I collagen triggered tyrosine phosphorylation of the beta(2) chain of the integrin, without stimulating O-2radical anion production by these cells, whereas their stimulation by complete type I collagen induced the tyrosine phosphorylation of both alpha(L) and beta(2) subunits, The tyrosine phosphorylation of both integrin subunits during transduction of stimuli is a heretofore undescribed phenomenon that may correspond to a new system of transmembrane communication.	UNIV REIMS,FAC MED,BIOCHEM LAB,CNRS,EP 0089,F-51095 REIMS,FRANCE; UNIV REIMS,FAC SCI,BIOCHEM LAB,CNRS,EP 0089,F-50162 REIMS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne								AKIMARU K, 1992, ARCH BIOCHEM BIOPHYS, V298, P703, DOI 10.1016/0003-9861(92)90469-D; ALTIERI DC, 1992, BIOCHEM J, V288, P465, DOI 10.1042/bj2880465; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BUHL SN, 1978, CLIN CHEM, V24, P261; BUYON JP, 1990, J IMMUNOL, V144, P191; CARDARELLI PM, 1992, J BIOL CHEM, V267, P23159; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; ENGLISH D, 1981, J IMMUNOL, V126, P165; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KIKAWA U, 1983, METHOD ENZYMOL, V99, P288; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; LOFGREN R, 1993, J CELL BIOL, V123, P1597, DOI 10.1083/jcb.123.6.1597; LUNDGRENAKERLUND E, 1993, SCAND J IMMUNOL, V37, P569, DOI 10.1111/j.1365-3083.1993.tb02573.x; MONBOISSE JC, 1991, J LEUKOCYTE BIOL, V50, P373, DOI 10.1002/jlb.50.4.373; MONBOISSE JC, 1990, BIOCHEM J, V270, P459, DOI 10.1042/bj2700459; MONBOISSE JC, 1987, BIOCHEM J, V246, P599, DOI 10.1042/bj2460599; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NGSIKORSKI J, 1991, EXP CELL RES, V195, P504, DOI 10.1016/0014-4827(91)90402-G; NIEDBALSKI JS, 1986, ANAL BIOCHEM, V158, P138, DOI 10.1016/0003-2697(86)90601-9; PIEZ KA, 1963, BIOCHEMISTRY-US, V2, P58, DOI 10.1021/bi00901a012; RANDI AM, 1994, J BIOL CHEM, V269, P12395; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TROOST J, 1976, CLIN CHIM ACTA, V73, P329, DOI 10.1016/0009-8981(76)90180-7; WILKINSON MJ, 1990, ANAL BIOCHEM, V185, P294, DOI 10.1016/0003-2697(90)90295-K	34	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27495	27503		10.1074/jbc.270.46.27495	http://dx.doi.org/10.1074/jbc.270.46.27495			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499207	hybrid			2022-12-25	WOS:A1995TE73600018
J	ZHU, TH; BODEM, J; KEPPEL, E; PARO, R; ROYERPOKORA, B				ZHU, TH; BODEM, J; KEPPEL, E; PARO, R; ROYERPOKORA, B			A SINGLE ANCESTRAL GENE OF THE HUMAN LIM DOMAIN ONCOGENE FAMILY LMO IN DROSOPHILA - CHARACTERIZATION OF THE DROSOPHILA DLMO GENE	ONCOGENE			English	Article						TTG/RBTN T CELL ONCOGENES; LIM PROTEINS; STRUCTURAL CONSERVATION	CYSTEINE-RICH PROTEIN; 5' NONCODING REGION; MESSENGER-RNA; SECONDARY STRUCTURE; INSULIN GENE; CELL; MOTIF; TRANSLOCATIONS; MELANOGASTER; CHROMOSOME	Members of the human TTG/RBTN family, now renamed 'LMO' for LIM-only proteins, encode proteins with two tandem copies of a LIM motif. There are three members of this family, two have been isolated at the sites of chromosomal translocations in T-cell leukaemia. The function of the LIM motifs is at present unknown. We found that the LMO-2 gene is highly conserved between mammals, Drosophila and yeast. As a first step to obtain a model system for studying the function of the LIM motifs we have isolated the Drosophila homologue Dlmo. In contrast to mammals Drosophila appears to have only one lmo gene. A 2087 bp cDNA clone was isolated from a larval cDNA library, encoding a protein of 266 amino acids. A second transcript with an alternative 5' end was identified in RNA from embryos. The Drosophila Imo protein consists of two tandem copies of the conserved LIM domain characteristic of the human LMO family and an extended amino and carboxy terminus, which is not present in the human proteins. The amino acid sequence similarity with human LMO-1 and LMO-2 in LIM 1 is 79% and 69% and in LIM-2 90% and 60%, respectively. In addition a short stretch of 25 nucleotides with a homology of 83% between LMO-2 and Dlmo is found in the 3' UTR. Dlmo, like LMO-1, has an intron after the second LIM encoding region, which is not present in LMO-2. It is expressed maternally and at a high level in early embryogenesis as well as in adults. Interestingly we observed that the Dlmo protein is immunologically related to LMO-2 and can be detected by immunohistochemistry in early cellular blastoderm embryos. The gene was localised to a genetically well characterized region (17C on the X chromosome) opening the way for identification of mutations.	UNIV HEIDELBERG,INST HUMAN GENET,HEIDELBERG,GERMANY; UNIV HEIDELBERG,CTR MOLEC BIOL,W-6900 HEIDELBERG,GERMANY; NANKAI UNIV,INST MED,TIANJIN,PEOPLES R CHINA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Nankai University				Bodem, Jochen/0000-0003-1908-4091				Baptiste J, 1991, NUCLEIC ACIDS RES, V19, P5227; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; EBERL DF, 1992, GENETICS, V130, P569; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KIESS M, 1995, ONCOGENE, V10, P61; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MARIOL MC, 1987, MOL CELL BIOL, V7, P3244, DOI 10.1128/MCB.7.9.3244; MATTOX WW, 1984, MOL CELL BIOL, V4, P1343, DOI 10.1128/MCB.4.7.1343; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROYERPOKORA B, 1995, ONCOGENE, V10, P1353; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; 1994, DROSOPHILA GENETIC D	42	18	18	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1283	1290						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478548				2022-12-25	WOS:A1995RY96700008
J	JAYARAMAN, T; MARKS, AR				JAYARAMAN, T; MARKS, AR			RAPAMYCIN-FKBP12 BLOCKS PROLIFERATION, INDUCES DIFFERENTIATION, AND INHIBITS CDC2 KINASE-ACTIVITY IN A MYOGENIC CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; CYCLOSPORINE-A; RYANODINE RECEPTOR; GENE FAMILY; BC3H1 CELLS; ACTIVATION; FK506; TRANSCRIPTION; IMMUNOPHILIN; COMPLEXES	Rapamycin is a potent immunosuppressant that binds to the cytosolic protein, FKBP12, and blocks T cell activation. Here we report that rapamycin also blocks myogenic proliferation and induces differentiation, associated with a decrease in p34cdc2 activity and cyclin A levels. In yeast and mammals, rapamycin blocks cell cycle progression by causing G1 arrest, arguing for a conserved signaling pathway governing the G1 to S transition. p34cdc2 has been shown to play a role in both the transition from G1 to S and from G2 to M in yeast. In higher eukaryotes the role of p34cdc2 in G1 to S transition is less clear. Rapamycin and the structurally related macrolide antibiotic FK506 both bind to a cytosolic protein, the FK506-binding protein (FKBP12). We show that inhibition of myogenic proliferation is achieved at low doses of rapamycin (<1 ng/ml) and is competed by a molar excess of FK506, indicating specificity for FKBP12. The distinct FK506-calcineurin pathway did not affect myogenic proliferation, differentiation, or p34cdc2 kinase activity. Thus, the rapamycin-FKBP12 signaling pathway involves a specific and direct effect on p34cdc2 kinase activity at the G1 to S transition and identifies a regulatory step during myogenic differentiation.	CUNY MT SINAI SCH MED,MOLEC MED PROGRAM,BOX 1269,1 GUSTAVE L LEVY,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FORNWALD JA, 1982, NUCLEIC ACIDS RES, V10, P3861, DOI 10.1093/nar/10.13.3861; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MORICE WG, 1993, J BIOL CHEM, V268, P3734; MUNSON R, 1982, J CELL BIOL, V92, P350, DOI 10.1083/jcb.92.2.350; OLSON EN, 1983, J BIOL CHEM, V258, P2644; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; STRAUCH AR, 1986, J BIOL CHEM, V261, P849; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WICE B, 1987, J BIOL CHEM, V262, P1810	28	98	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25385	25388						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503980				2022-12-25	WOS:A1993MK10000019
J	ROYER, WE; HENDRICKSON, WA				ROYER, WE; HENDRICKSON, WA			MOLECULAR SYMMETRY OF LUMBRICUS ERYTHROCRUORIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											ROYER, WE (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							CREWE AV, 1984, ULTRAMICROSCOPY, V13, P365, DOI 10.1016/0304-3991(84)90002-0; CROWTHER RA, 1972, MOL REPLACEMENT METH, P174; FUSHITANI K, 1982, ARCH BIOCHEM BIOPHYS, V218, P540, DOI 10.1016/0003-9861(82)90378-2; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; Hendrickson W. A., 1983, LIFE CHEM REP S, V1, P167; HENDRICKSON WA, 1977, TRENDS BIOCHEM SCI, V2, P108, DOI 10.1016/0968-0004(77)90174-8; HENDRICKSON WA, 1976, ACTA CRYSTALLOGR A, V32, P778, DOI 10.1107/S0567739476001599; HENDRICKSON WA, 1986, BIOPHYS J, V49, P177, DOI 10.1016/S0006-3495(86)83633-5; LEVIN O, 1963, J MOL BIOL, V6, P95, DOI 10.1016/S0022-2836(63)80084-4; ROCHE J, 1960, BIOCHIM BIOPHYS ACTA, V41, P182, DOI 10.1016/0006-3002(60)90397-8; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P570, DOI 10.1107/S0021889879013273; Royer W.E. Jr, 1981, P337; ROYER WE, 1987, J MOL BIOL, V197, P149, DOI 10.1016/0022-2836(87)90618-8; SANTUCCI R, 1984, J MOL BIOL, V179, P713, DOI 10.1016/0022-2836(84)90163-3; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; SHLOM JM, 1973, J BIOL CHEM, V248, P7904; SUZUKI T, 1985, J BIOL CHEM, V260, P3145; SUZUKI T, 1986, J BIOL CHEM, V261, P9257; SUZUKI T, 1986, J MOL BIOL, V190, P119, DOI 10.1016/0022-2836(86)90081-1; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034	21	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13762	13765						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417678				2022-12-25	WOS:A1988Q159400047
J	CLEMENS, TL; MCGLADE, SA; GARRETT, KP; HORIUCHI, N; HENDY, GN				CLEMENS, TL; MCGLADE, SA; GARRETT, KP; HORIUCHI, N; HENDY, GN			TISSUE-SPECIFIC REGULATION OF AVIAN VITAMIN-D-DEPENDENT CALCIUM-BINDING PROTEIN-28-KDA MESSENGER-RNA BY 1,25-DIHYDROXYVITAMIN-D3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									ROYAL VICTORIA HOSP,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT CHEM,MONTREAL H3A 1A1,QUEBEC,CANADA; COLUMBIA UNIV,DEPT PATHOL,NEW YORK,NY 10023	McGill University; Royal Victoria Hospital; McGill University; Columbia University	CLEMENS, TL (corresponding author), HELEN HAYES HOSP,REG BONE CTR,ROUTE 9W,W HAVERSTRAW,NY 10993, USA.				NIAMS NIH HHS [AR 39191, AR 36446] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191, R23AR036446] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAUDIER J, 1985, J BIOL CHEM, V260, P662; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; BRUNS ME, 1986, J BIOL CHEM, V261, P7485; BRUNS MEH, 1978, J BIOL CHEM, V253, P3186; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTAKOS S, 1980, ARCH BIOCHEM BIOPHYS, V203, P809, DOI 10.1016/0003-9861(80)90242-8; CLEMENS TL, 1984, CALCIF TISSUE INT A, V63; CRAVISO GL, 1987, ENDOCRINOLOGY, V120, P894, DOI 10.1210/endo-120-3-894; DARWISH HM, 1987, P NATL ACAD SCI USA, V84, P6108, DOI 10.1073/pnas.84.17.6108; DELORME AC, 1983, J BIOL CHEM, V258, P1878; DESPLAN C, 1983, J BIOL CHEM, V258, P3502; DUPRET JM, 1987, J BIOL CHEM, V262, P16553; DUPRET JM, 1986, ENDOCRINOLOGY, V119, P2476, DOI 10.1210/endo-119-6-2476; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HENRY HL, 1974, J BIOL CHEM, V249, P7584; HOFMANN T, 1979, CAN J BIOCHEM CELL B, V57, P737, DOI 10.1139/o79-092; HUNZIKER W, 1986, P NATL ACAD SCI USA, V83, P7578, DOI 10.1073/pnas.83.20.7578; HUNZIKER W, 1983, P NATL ACAD SCI-BIOL, V80, P4228, DOI 10.1073/pnas.80.14.4228; JANDE SS, 1981, NATURE, V294, P765, DOI 10.1038/294765a0; KALLFELZ FA, 1967, P SOC EXP BIOL MED, V125, P54, DOI 10.3181/00379727-125-32011; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; PANSINI AR, 1984, J BIOL CHEM, V259, P9735; PERRET C, 1985, EUR J BIOCHEM, V150, P211, DOI 10.1111/j.1432-1033.1985.tb09009.x; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SONNENBERG J, 1984, ENDOCRINOLOGY, V115, P640, DOI 10.1210/endo-115-2-640; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUMPF WE, 1979, SCIENCE, V206, P1188, DOI 10.1126/science.505004; TANAKA Y, 1971, P NATL ACAD SCI US, V65, P605; TAYLOR AN, 1983, J HISTOCHEM CYTOCHEM, V31, P426, DOI 10.1177/31.3.6687473; TAYLOR AN, 1982, KIDNEY INT, V21, P765, DOI 10.1038/ki.1982.95; THEOFAN C, 1986, J BIOL CHEM, V261, P7311; THEOFAN G, 1985, VITAMIN D CHEM BIOCH, P332; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WASSERMA.RH, 1966, SCIENCE, V152, P791, DOI 10.1126/science.152.3723.791; Wasserman R. H., 1978, Vitamin D, P133; WILSON PW, 1985, NUCLEIC ACIDS RES, V13, P8867, DOI 10.1093/nar/13.24.8867; WOOD I, 1986, J BONE MIN RES, V1, pA433; [No title captured]	43	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13112	13116						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417652				2022-12-25	WOS:A1988Q091700054
J	CRUM, CJ; HU, J; HIDDINGA, HJ; ROTH, DA				CRUM, CJ; HU, J; HIDDINGA, HJ; ROTH, DA			TOBACCO MOSAIC-VIRUS INFECTION STIMULATES THE PHOSPHORYLATION OF A PLANT PROTEIN ASSOCIATED WITH DOUBLE-STRANDED RNA-DEPENDENT PROTEIN-KINASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV WYOMING,DEPT PLANT SOIL & INSECT SCI,POB 3354,LARAMIE,WY 82071	University of Wyoming								ANDREWS NC, 1985, J BIOL CHEM, V260, P7628; BAGLIONI C, 1979, CELL, V17, P255, DOI 10.1016/0092-8674(79)90151-X; BERRY MJ, 1985, BIOCHEM BIOPH RES CO, V133, P168, DOI 10.1016/0006-291X(85)91856-X; BISCHOFF JR, 1985, J BIOL CHEM, V260, P8237; DASGUPTA A, 1980, CELL, V19, P423, DOI 10.1016/0092-8674(80)90516-4; DEVASH Y, 1981, VIROLOGY, V111, P103, DOI 10.1016/0042-6822(81)90657-7; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EVANS RK, 1985, J BIOL CHEM, V260, P7800; FARRELL P, 1978, P NATL ACAD SCI US, V279, P523; FRASER RSS, 1980, J GEN VIROL, V46, P139, DOI 10.1099/0022-1317-46-1-139; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GOELET P, 1982, P NATL ACAD SCI-BIOL, V79, P5818, DOI 10.1073/pnas.79.19.5818; HALEY BE, 1983, FED PROC, V42, P2831; HIDDINGA HJ, 1988, SCIENCE, V241, P451, DOI 10.1126/science.3393910; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1975, J BIOL CHEM, V250, P409; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; MORROW CD, 1985, CELL, V40, P913, DOI 10.1016/0092-8674(85)90351-4; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; SAMUEL CE, 1977, VIROLOGY, V83, P56, DOI 10.1016/0042-6822(77)90210-0; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SCALLA R, 1978, VIROLOGY, V91, P183; SELA I, 1986, METHOD ENZYMOL, V119, P734; TUSCHALL DM, 1982, J VIROL, V44, P209, DOI 10.1128/JVI.44.1.209-216.1982	27	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13440	13443						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417665				2022-12-25	WOS:A1988Q091700100
J	DONAHUE, LM; STEIN, GH				DONAHUE, LM; STEIN, GH			HIGH-EFFICIENCY DNA-MEDIATED TRANSFORMATION OF HUMAN-DIPLOID FIBROBLASTS	ONCOGENE			English	Article											DONAHUE, LM (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309, USA.				NIA NIH HHS [AG00947] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELL E, 1978, SCIENCE, V202, P1158, DOI 10.1126/science.725592; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN S, 1987, J VIROL, V61, P3521, DOI 10.1128/JVI.61.11.3521-3527.1987; CORSARO CM, 1977, NATURE, V268, P737, DOI 10.1038/268737a0; CORSARO CM, 1977, P NATL ACAD SCI USA, V74, P4476, DOI 10.1073/pnas.74.10.4476; CORSARO CM, 1975, EXP CELL RES, V95, P39, DOI 10.1016/0014-4827(75)90606-0; DONIGER J, 1983, SCIENCE, V222, P114; FRY DG, 1986, J CELL PHYSIOL, V128, P313, DOI 10.1002/jcp.1041280225; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; GRODZICKER T, 1980, CELL, V21, P453, DOI 10.1016/0092-8674(80)90482-1; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HOEIJMAKERS JHJ, 1987, EXP CELL RES, V169, P111, DOI 10.1016/0014-4827(87)90230-8; Maniatis T., 1982, MOL CLONING; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; NICHOLS WW, 1977, SCIENCE, V196, P60, DOI 10.1126/science.841339; PALMER TD, 1987, MOL MECH REGULATION, P307; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUTHERLAND BM, 1985, P NATL ACAD SCI USA, V82, P2399, DOI 10.1073/pnas.82.8.2399; SUTHERLAND BM, 1984, CANCER RES, V44, P2769; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YANISHEVSKY R, 1974, J CELL PHYSIOL, V84, P165, DOI 10.1002/jcp.1040840202	23	15	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					221	224						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	3412775				2022-12-25	WOS:A1988Q053400014
J	SALEHI, Z; TAYLOR, JD; NIEDEL, JE				SALEHI, Z; TAYLOR, JD; NIEDEL, JE			DIOCTANOYLGLYCEROL AND PHORBOL ESTERS REGULATE TRANSCRIPTION OF C-MYC IN HUMAN PROMYELOCYTIC LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA	Duke University	SALEHI, Z (corresponding author), DUKE UNIV, MED CTR, DEPT PHARMACOL, DIV CLIN PHARMACOL, DURHAM, NC 27710 USA.				NATIONAL CANCER INSTITUTE [R01CA035680] Funding Source: NIH RePORTER; NCI NIH HHS [CA35680] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERENBLUM I, 1954, CANCER RES, V14, P471; BITTER GA, 1978, BIOCHEMISTRY-US, V17, P2198, DOI 10.1021/bi00604a028; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BRELVI ZS, 1986, J CELL BIOL, V102, P2234, DOI 10.1083/jcb.102.6.2234; BRESNICK EH, 1986, CANCER RES, V46, P4979; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COOPER RA, 1982, P NATL ACAD SCI-BIOL, V79, P2865, DOI 10.1073/pnas.79.9.2865; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DEBUSTROS A, 1985, J BIOL CHEM, V260, P98; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FAVERA R D, 1982, Nature (London), V299, P61, DOI 10.1038/299061a0; FLEMING WH, 1985, ENDOCRINOLOGY, V117, P2547, DOI 10.1210/endo-117-6-2547; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSSO LE, 1984, BIOCHEM BIOPH RES CO, V119, P473, DOI 10.1016/S0006-291X(84)80273-9; GROSSO LE, 1985, CANCER RES, V45, P847; HAYMAN MJ, 1981, J GEN VIROL, V52, P1, DOI 10.1099/0022-1317-52-1-1; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HOLT TJ, 1986, BLOOD S, V68, P89; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOLLER CA, 1985, J CLIN INVEST, V76, P365, DOI 10.1172/JCI111970; KOZBOR D, 1984, CANCER RES, V44, P438; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MCCACHREN SS, 1986, BLOOD, V68, P412; MITCHELL T, 1986, MOL PHARMACOL, V30, P398; NAKASATO F, 1984, GANN, V75, P737; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RABIN MS, 1986, P NATL ACAD SCI USA, V83, P357, DOI 10.1073/pnas.83.2.357; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SIENBENLIST U, 1984, CELL, V37, P381; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SLUNGAARD A, 1987, J CLIN INVEST, V79, P1542, DOI 10.1172/JCI112987; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TRAMONTANO D, 1986, J BIOL CHEM, V261, P3919; VANDENBARK GR, 1984, J CLIN INVEST, V73, P448, DOI 10.1172/JCI111231; VANDENBARK GR, 1984, J NATL CANCER I, V73, P1013; WATANABE T, 1985, BIOCHEM BIOPH RES CO, V126, P999, DOI 10.1016/0006-291X(85)90284-0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YAMAMOTO S, 1985, J BIOL CHEM, V260, P4230; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	64	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1988	263	4					1898	1903						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	L9227	3422230				2022-12-25	WOS:A1988L922700046
J	DUDEK, SM; SEMENKOVICH, CF				DUDEK, SM; SEMENKOVICH, CF			ESSENTIAL AMINO-ACIDS REGULATE FATTY-ACID SYNTHASE EXPRESSION THROUGH AN UNCHARGED TRANSFER RNA-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; MESSENGER-RNA; LIPOGENIC ENZYMES; GENE-EXPRESSION; HEPG2 CELLS; KINASE GCN2; TRANSCRIPTION; HEPATOCYTES; YEAST; TRIIODOTHYRONINE	To better understand the regulation of gene expression by amino acids, we studied the effects of these macronutrients on fatty acid synthase (FAS), an enzyme crucial for energy storage. When HepG2 cells were fed serum-free media selectively deficient in each amino acid, the omission of any single classic essential amino acid as well as Arg or His (essential in some rapidly growing cells) resulted in FAS mRNA levels that were about half of those in complete medium. Control message levels were unaffected and omission of nonessential amino acids did not alter FAS expression. FAS mRNA levels peaked 12-16 h after feeding complete and Ser (nonessential)-deficient media but did not increase in cells fed Lys (essential)-deficient medium. With Lys, FAS mRNA increased over the physiologic concentration range of 15-150 mu M, and low concentrations of lysine decreased FAS but not apoB protein mass. Transcription inhibitors mimicked treatment with Lys-deficient media, and nuclear run-off assays showed that Lys-deficient media abolished FAS but not apoB transcription. After treatment with Lys-deficient media, the intracellular Lys pool was rapidly depleted in association with an increase of uncharged (deacylated) tRNA(Lys) from <1 to 64% of available tRNA(Lys). Even in the presence of the essential amino acid His, increasing the levels of uncharged tRNA(His) with histidinol, a competitive inhibitor of the histidinyl-tRNA synthetase, blocked FAS expression. Tyrosinol treatment did not alter FAS mRNA levels. These results suggest that essential amino acids regulate FAS expression by altering uncharged tRNA levels, a novel mechanism for nutrient control of gene expression in mammalian cells.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV ATHEROSCLEROSIS NUTR & LIPID RES,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)				Semenkovich, Clay/0000-0003-1163-1871	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47436] Funding Source: Medline; NIDDK NIH HHS [5 P60 DK20579] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RE, 1969, BIOCHIM BIOPHYS ACTA, V190, P323, DOI 10.1016/0005-2787(69)90083-5; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BLAKE WL, 1991, J NUTR, V120, P1727; CALENDER R, 1966, PROCEDURES NUCLEIC A, V1, P384; CARLSON DP, 1986, MOL CELL BIOL, V6, P3278, DOI 10.1128/MCB.6.9.3278; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; EFRON ML, 1965, NEW ENGL J MED, V272, P1299, DOI 10.1056/NEJM196506242722501; FUKUDA H, 1987, BIOCHIM BIOPHYS ACTA, V920, P56, DOI 10.1016/0005-2760(87)90310-9; FUKUDA H, 1992, J BIOCHEM-TOKYO, V111, P25, DOI 10.1093/oxfordjournals.jbchem.a123713; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GRUNDY FJ, 1993, CELL, V74, P475, DOI 10.1016/0092-8674(93)80049-K; HANSEN BS, 1972, J BIOL CHEM, V247, P3854; HATLEN L, 1971, J MOL BIOL, V56, P535, DOI 10.1016/0022-2836(71)90400-1; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; IRWIN MI, 1971, J NUTR, V101, P539; JOYEUX C, 1989, MOL ENDOCRINOL, V4, P681; KATSURADA A, 1990, EUR J BIOCHEM, V190, P427, DOI 10.1111/j.1432-1033.1990.tb15592.x; LEVY R, 1992, J LIPID RES, V33, P1005; Lindner MC, 1991, NUTR BIOCH METABOLIS, V2nd, P87; MCCOY TA, 1959, P SOC EXP BIOL MED, V100, P115; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; NASS G, 1967, BIOCHIM BIOPHYS ACTA, V134, P347, DOI 10.1016/0005-2787(67)90012-3; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; PAO CI, 1993, MOL ENDOCRINOL, V7, P1561, DOI 10.1210/me.7.12.1561; PERSSON BC, 1993, MOL MICROBIOL, V8, P1011, DOI 10.1111/j.1365-2958.1993.tb01645.x; PILZ RB, 1987, J CLIN INVEST, V79, P1006, DOI 10.1172/JCI112867; PLAKIDOUDYMOCK S, 1993, BIOCHEM J, V295, P749, DOI 10.1042/bj2950749; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SARWAR G, 1991, J AM COLL NUTR, V10, P668; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SEMENKOVICH CF, 1987, BIOCHEMISTRY-US, V26, P4987, DOI 10.1021/bi00390a016; SEMENKOVICH CF, 1995, J LIPID RES, V36, P1507; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; STRAUSS AW, 1975, P NATL ACAD SCI USA, V72, P4366, DOI 10.1073/pnas.72.11.4366; THISSEN JP, 1994, ENDOCRINOLOGY, V134, P1570, DOI 10.1210/en.134.3.1570; TOMILIN NV, 1990, FEBS LETT, V263, P69, DOI 10.1016/0014-5793(90)80707-P; VAUGHAN MH, 1973, J BIOL CHEM, V248, P7087; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; YEGIAN CD, 1966, P NATL ACAD SCI USA, V55, P839, DOI 10.1073/pnas.55.4.839; ZHANG ZJ, 1993, J BIOL CHEM, V268, P26920	49	30	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29323	29329		10.1074/jbc.270.49.29323	http://dx.doi.org/10.1074/jbc.270.49.29323			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493965	hybrid			2022-12-25	WOS:A1995TJ22700046
J	FANUTTI, C; PONYI, T; BLACK, GW; HAZLEWOOD, GP; GILBERT, HJ				FANUTTI, C; PONYI, T; BLACK, GW; HAZLEWOOD, GP; GILBERT, HJ			THE CONSERVED NONCATALYTIC 40-RESIDUE SEQUENCE IN CELLULASES AND HEMICELLULASES FROM ANAEROBIC FUNGI FUNCTIONS AS A PROTEIN DOCKING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; NEOCALLIMASTIX-FRONTALIS; CLONING; XYLANASE; GENE; ENDOGLUCANASE; ENZYME; CELLULOSOME; COMPONENTS	Two cDNAs, designated xynA and manA, encoding xylanase A (XYLA) and mannanase A (MANA), respectively, were isolated from a cDNA Library derived from mRNA extracted from the anaerobic fungus, Piromyces. XYLA and MANA displayed properties typical of endo beta 1,4-xylanases and mannanases, respectively. Neither enzyme hydrolyzed cellulosic substrates. The nucleotide sequences of xynA and manA revealed open reading frames of 1875 and 1818 base pairs, respectively, coding for proteins of M(r) 68,049 (XYLA) and 68,055 (MANA). The deduced primary structure of MANA revealed a 458-amino acid sequence that exhibited identity with Bacillus and Pseudomonas fluorescens subsp, cellulosa mannanases belonging to glycosyl hydrolase Family 26. A 40-residue reiterated sequence, which was homologous to duplicated noncatalytic domains previously observed in Neocallimastix patriciarum xylanase A and endoglucanase B, was located at the C terminus of MANA. XYLA contained two regions that exhibited sequence identity with the catalytic domains of glycosyl hydrolase Family 11 xylanases and were separated by a duplicated 40-residue sequence that exhibited strong homology to the C terminus of MANA. Analysis of truncated derivatives of MANA confirmed that the N-terminal 458-residue sequence constituted the catalytic domain, while the C-terminal domain was not essential for the retention of catalytic activity. Similar deletion analysis of XYLA showed that the C-terminal catalytic domain homologue exhibited catalytic activity, but the corresponding putative N-terminal catalytic domain did not function as a xylanase. Fusion of the reiterated noncatalytic 40-residue sequence conserved in XYLA and MANA to glutathione S-transferase, generated a hybrid protein that did not associate with cellulose, but bound to 97- and 116-kDa polypeptides that are components of the multienzyme cellulase-hemicellulase complexes of Piromyces and Neocallimastix patriciarum, respectively. The role of this domain in the assembly of the enzyme complex is discussed.	BABRAHAM INST, DEPT CELLULAR PHYSIOL, CAMBRIDGE CB2 4AT, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT BIOL & NUTR SCI, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Newcastle University - UK				Black, Gary/0000-0003-3697-0714				AKINO T, 1989, APPL ENVIRON MICROB, V55, P3178, DOI 10.1128/AEM.55.12.3178-3183.1989; ALI BRS, 1995, FEMS MICROBIOL LETT, V125, P15, DOI 10.1016/0378-1097(94)00472-4; ARCHAND N, 1993, BIOCHEM J, V290, P857; BEGUIN P, 1994, FEMS MICROBIOL REV, V13, P25, DOI 10.1016/0168-6445(94)90099-X; BLACK GW, 1994, BIOCHEM J, V299, P381, DOI 10.1042/bj2990381; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; BRAITHWAITE KL, 1995, BIOCHEM J, V305, P1005, DOI 10.1042/bj3051005; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CHRISTGAU S, 1994, BIOCHEM MOL BIOL INT, V33, P917; COUGHLAN MP, 1993, PORT PR R M, V4, P53; FLINT HJ, 1993, J BACTERIOL, V175, P2943, DOI 10.1128/JB.175.10.2943-2951.1993; FONTES CMGA, 1995, APPL MICROBIOL BIOT, V43, P52, DOI 10.1007/BF00170622; FUJINO T, 1992, FEMS MICROBIOL LETT, V94, P165; GIBBS MD, 1992, APPL ENVIRON MICROB, V58, P3864, DOI 10.1128/AEM.58.12.3864-3867.1992; GILBERT HJ, 1992, MOL MICROBIOL, V6, P2065, DOI 10.1111/j.1365-2958.1992.tb01379.x; GILBERT HJ, 1993, J GEN MICROBIOL, V139, P187, DOI 10.1099/00221287-139-2-187; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HALL J, 1988, GENE, V69, P29, DOI 10.1016/0378-1119(88)90375-7; HAZLEWOOD GP, 1988, FEMS MICROBIOL LETT, V51, P231, DOI 10.1111/j.1574-6968.1988.tb03002.x; HAZLEWOOD GP, 1990, J GEN MICROBIOL, V136, P2089, DOI 10.1099/00221287-136-10-2089; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; KEMP P, 1984, J GEN MICROBIOL, V130, P27; KO EP, 1992, BIOCHEM J, V288, P117, DOI 10.1042/bj2880117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALBURG LM, 1993, CAN J MICROBIOL, V39, P882, DOI 10.1139/m93-132; MATSUSHITA O, 1990, J BACTERIOL, V172, P3620, DOI 10.1128/jb.172.7.3620-3630.1990; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; MILLWARDSADLER SJ, 1994, MOL MICROBIOL, V11, P375, DOI 10.1111/j.1365-2958.1994.tb00317.x; REYMOND P, 1992, GENE, V110, P57, DOI 10.1016/0378-1119(92)90444-T; Sambrook J, 1989, MOL CLONING LABORATO; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; TOKATLIDIS K, 1991, FEBS LETT, V291, P185, DOI 10.1016/0014-5793(91)81279-H; WILSON CA, 1992, ENZYME MICROB TECH, V14, P258, DOI 10.1016/0141-0229(92)90148-H; XUE GP, 1992, J GEN MICROBIOL, V138, P1413, DOI 10.1099/00221287-138-7-1413; ZHANG JX, 1992, MOL MICROBIOL, V6, P1013, DOI 10.1111/j.1365-2958.1992.tb02167.x; ZHOU LQ, 1994, BIOCHEM J, V297, P359, DOI 10.1042/bj2970359	38	124	142	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29314	29322		10.1074/jbc.270.49.29314	http://dx.doi.org/10.1074/jbc.270.49.29314			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493964	hybrid			2022-12-25	WOS:A1995TJ22700045
J	MERGAERT, P; DHAEZE, W; GEELEN, D; PROME, D; VANMONTAGU, M; GEREMIA, R; PROME, JC; HOLSTERS, M				MERGAERT, P; DHAEZE, W; GEELEN, D; PROME, D; VANMONTAGU, M; GEREMIA, R; PROME, JC; HOLSTERS, M			BIOSYNTHESIS OF AZORHIZOBIUM-CAULINODANS NOD FACTORS - STUDY OF THE ACTIVITY OF THE NODABCS PROTEINS BY EXPRESSION OF THE GENES IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROBACTERIAL COMMON ANTIGEN; CHITIN; IDENTIFICATION; STREPTOCOCCUS; NODULATION; SEQUENCE; LOCUS-1	By in vitro and in vivo studies with Escherichia coli expressing different combinations of the nodABCS genes of Azorhizobium caulinodans, Nod factor intermediates were identified and their structures determined using mass spectrometry. Substrate-product relationships were studied by time course experiments, and the Nod factor biosynthetic pathway was partially resolved. E. coli strains, harboring nodA and/or nocB, did not produce Nod metabolites, whereas the strain expressing nodC produced chitooligosaccharides. Thus, the first committed step was the production of the carbohydrate backbone. Bacitracin and tunicamycin did not affect this step, suggesting that undecaprenyl pyrophosphate-linked intermediates were not involved. The second step was the deacetylation of chitooligosaccharides by NodB since the E. coli strain expressing nodBC produced chitooligosaccharides, deacetylated at the non-reducing end and since the NodC products were precursors of the NodBC products. A strain expressing nodBCS produced N-methylated oligosaccharides, whereas a strain expressing nodCS produced unmethylated oligosaccharides. Time course experiments showed that methylation occurred after deacetylation. Thus, NodS acted after NodB. The NodBCS metabolites were partially converted to Lipo-chitooligosaccharides when the nodABCS genes were expressed, showing that NodA was involved in the acylation and acted after NodS.	STATE UNIV GHENT, GENET LAB, B-9000 GHENT, BELGIUM; CNRS, PHARMACOL & TOXICOL FONDAMENTALES LAB, F-31077 TOULOUSE, FRANCE; CNRS, CTR RECH MACROMOLEC VEGETALES, F-38041 GRENOBLE, FRANCE	Ghent University; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Mergaert, Peter/M-1265-2019; Geremia, Roberto A/A-7972-2010	Mergaert, Peter/0000-0002-5919-7317; 				ATKINSON EM, 1994, P NATL ACAD SCI USA, V91, P8418, DOI 10.1073/pnas.91.18.8418; BARR K, 1987, J BIOL CHEM, V262, P7142; BLOEMBERG GV, 1995, THESIS RIJKSUNIVERSI; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; BULAWA CE, 1991, NATURE, V353, P710, DOI 10.1038/353710b0; CARLSON RW, 1994, MOL PLANT MICROBE IN, V7, P684, DOI 10.1094/MPMI-7-0684; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DURAN A, 1978, J BIOL CHEM, V253, P4419; GEELEN D, 1995, MOL MICROBIOL, V17, P387, DOI 10.1111/j.1365-2958.1995.mmi_17020387.x; GEELEN D, 1993, MOL MICROBIOL, V9, P145, DOI 10.1111/j.1365-2958.1993.tb01676.x; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GOETHALS K, 1989, MOL GEN GENET, V219, P289, DOI 10.1007/BF00261190; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; ORLEAN P, 1987, J BIOL CHEM, V262, P5732; RICK PD, 1985, J BACTERIOL, V162, P494, DOI 10.1128/JB.162.2.494-503.1985; ROHRIG H, 1994, P NATL ACAD SCI USA, V91, P3122, DOI 10.1073/pnas.91.8.3122; Sambrook J, 1989, MOL CLONING LABORATO; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SCHULTZE M, 1995, P NATL ACAD SCI USA, V92, P2706, DOI 10.1073/pnas.92.7.2706; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; SPAINK HP, 1994, MOL MICROBIOL, V13, P821, DOI 10.1111/j.1365-2958.1994.tb00474.x; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252	24	43	49	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29217	29223		10.1074/jbc.270.49.29217	http://dx.doi.org/10.1074/jbc.270.49.29217			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493950	hybrid			2022-12-25	WOS:A1995TJ22700031
J	PALMER, TM; BENOVIC, JL; STILES, GL				PALMER, TM; BENOVIC, JL; STILES, GL			AGONIST-DEPENDENT PHOSPHORYLATION AND DESENSITIZATION OF THE RAT A(3) ADENOSINE RECEPTOR - EVIDENCE FOR A G-PROTEIN-COUPLED RECEPTOR KINASE-MEDIATED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION; RHODOPSIN; ACTIVATION; CELLS; ACIDS	A(3) adenosine receptor (A(3)AR) activation contributes to both the cardioprotective and antihypertensive effects of adenosine. To date, no studies have examined the mechanisms by which this receptor undergoes rapid homologous desensitization. Therefore, a functional hemagglutinin epitope-tagged A(3)AR has been stably expressed in Chinese hamster ovary cells, and its regulation by the AR agonist 5'-N-ethylcarboxamidoadenosine (NECA) has been studied. Cellular exposure to NECA induces rapid (t1/2 = similar to 1 min) A(3)AR phosphorylation on serine and threonine residues. This is associated with a functional desensitization and a 30-40% reduction in the number of high affinity agonist binding sites as determined by radioligand binding assays. Activation of second messenger-regulated kinases could not mimic the effect of NECA, suggesting a role for G-protein-coupled receptor kinases (GRKs). In vitro phosphorylation assays demonstrate that phosphorylation of agonist-occupied A(3)ARs is enhanced by GRK2 and that cellular pretreatment with NECA dramatically inhibits subsequent GRB2-mediated phosphorylation in vitro. Therefore, the A(3)AR is phosphorylated in situ by a kinase similar or identical to GRK2, and this may be involved in rapid functional desensitization of the A(3)AR.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Duke University; Duke University; Jefferson University			Palmer, Timothy/E-7290-2013; Palmer, Timothy/C-4975-2009	Palmer, Timothy/0000-0002-9803-7164; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035134, P50HL054314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL35134, P50HL54314] Funding Source: Medline; NIGMS NIH HHS [R01 GM44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1990, J BIOL CHEM, V265, P745; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; CHEN CY, 1993, J BIOL CHEM, V268, P7825; DELEAN A, 1982, MOL PHARMACOL, V22, P290; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; GALLORODRIGUEZ C, 1994, J MED CHEM, V37, P636, DOI 10.1021/jm00031a014; ISHII K, 1994, J BIOL CHEM, V269, P1125; KIM CM, 1993, RECEPTOR, V3, P39; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LINDEN J, 1994, TRENDS PHARMACOL SCI, V15, P298, DOI 10.1016/0165-6147(94)90011-6; LINDEN J, 1993, MOL PHARMACOL, V44, P524; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1994, MOL PHARMACOL, V45, P978; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALMER TM, 1995, J BIOL CHEM, V270, P16895, DOI 10.1074/jbc.270.28.16895; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	31	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29607	29613		10.1074/jbc.270.49.29607	http://dx.doi.org/10.1074/jbc.270.49.29607			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7494005	hybrid			2022-12-25	WOS:A1995TJ22700086
J	TONG, LA; PAV, S; LAMARRE, D; SIMONEAU, B; LAVALLEE, P; JUNG, G				TONG, LA; PAV, S; LAMARRE, D; SIMONEAU, B; LAVALLEE, P; JUNG, G			CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P-2-P-3 BUTANEDIAMIDE RENIN INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN RENIN	The binding modes of three peptidomimetic P-2-P-3 butanediamide renin inhibitors have been determined by x-ray crystallography. The inhibitors are bound with their backbones in an extended conformation, and their side chains occupying the S-5 to S-1' pockets. A (2-amino-4-thiazolyl)methyl side chain at the P-2 position shows stronger hydrogen-bonding and van der Waals interactions with renin than the His side chain, which is present in the natural substrate. The ACHPA-gamma-lactam transition state analog has similar interactions with renin as the dihydroxyethylene transition state analog.	BIOMEGA BOEHRINGER INGELHEIM RES INC,DEPT BIOCHEM,LAVAL,PQ H7S 2G5,CANADA; BIOMEGA BOEHRINGER INGELHEIM RES INC,DEPT CHEM,LAVAL,PQ H7S 2G5,CANADA	Boehringer Ingelheim; Boehringer Ingelheim	TONG, LA (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT INFLAMMATORY DIS,900 RIDGEBURY RD,POB 368,RIDGEFIELD,CT 06877, USA.			Tong, Liang/0000-0002-0563-6468				BRUNGER AT, 1992, X PLOR MANUAL VERSIO; DHANARAJ V, 1992, NATURE, V357, P466, DOI 10.1038/357466a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LIM LW, 1989, J MOL BIOL, V210, P239, DOI 10.1016/0022-2836(89)90305-7; LULY Jr, 1988, J MED CHEM, V31, P2264, DOI 10.1021/jm00120a005; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; OPIE LH, 1992, ANGIOTENSINOGEN CONV; PAV S, 1994, PROTEINS, V20, P98, DOI 10.1002/prot.340200110; PILOTE L, 1995, IN PRESS BIOCH CELL; RAHUEL J, 1991, J STRUCT BIOL, V107, P227, DOI 10.1016/1047-8477(91)90048-2; SALI A, 1992, PROTEINS, V12, P158, DOI 10.1002/prot.340120209; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; TONG L, 1995, J MOL BIOL, V250, P211, DOI 10.1006/jmbi.1995.0372; TONG L, 1993, J APPL CRYSTALLOGR, V26, P748, DOI 10.1107/S0021889893005631; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WILLIAMS PD, 1991, J MED CHEM, V34, P887, DOI 10.1021/jm00107a004	18	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29520	29524		10.1074/jbc.270.49.29520	http://dx.doi.org/10.1074/jbc.270.49.29520			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493993	hybrid			2022-12-25	WOS:A1995TJ22700074
J	ZHAO, XO; SIU, CH				ZHAO, XO; SIU, CH			COLOCALIZATION OF THE HOMOPHILIC FINDING SITE AND THE NEURITOGENIC ACTIVITY OF THE CELL-ADHESION MOLECULE L1 TO ITS 2ND IG-LIKE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX MOLECULES; DICTYOSTELIUM-DISCOIDEUM; HOMOPHILIC BINDING; NEURITE OUTGROWTH; IMMUNOGLOBULIN SUPERFAMILY; L1-LIKE MOLECULE; SCHWANN-CELLS; X-CHROMOSOME; N-CAM; GLYCOPROTEIN	The cell adhesion molecule L1 has been implicated in mediating cell-cell adhesion and in promoting neurite outgrowth. The extracellular region of L1 contains six immunoglobulin (Ig)-like domains in the amino-terminal region, followed by five fibronectin type III-like repeats. L1 is capable of undergoing homophilic binding as well as heterophilic interactions. To map the homophilic binding domain in L1, three glutathione S-transferase (GST) fusion proteins (GST-Ig1-2-3, GST-Ig4-5-6, and GST-Fn) were prepared and coupled to Covaspheres and their homophilic binding activity was determined using the Covasphere-to-substratum binding assay. Only GST-Ig1-2-3 was capable of homophilic binding. Next, His-tagged recombinant Ig-domain proteins (His-Ig1-2, His-Ig1, and His-Ig2) were expressed and subjected to similar assays. Only His-Ig1-2 and His-Ig2 were capable of homophilic interactions. Binding of His-Ig2-conjugated Covaspheres to substrate-coated His-Ig2 was inhibited by anti-Ig1-2-3 Fab and soluble His-Ig2. These results indicate that the L1 homophilic binding site resides within Ig2. To examine effects of these L1 recombinant proteins on neurite outgrowth, neural retinal cells were cultured on different substrate-coated fusion proteins. Both GST-Ig1-2-3 and His-Ig2 were potent inducers of neurite extension. These results thus indicate that the L1 Ig-like domain 2 alone is sufficient to mediate L1-L1 interaction and promote neurite outgrowth from retinal cells.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5G 1L6, CANADA	University of Toronto; University of Toronto								APPEL F, 1993, J NEUROSCI, V13, P4764; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BRUMMENDORF T, 1993, NEURON, V10, P711; BURGOON MP, 1995, J CELL BIOL, V130, P733, DOI 10.1083/jcb.130.3.733; CAMP GV, 1993, NAT GENET, V4, P421; CARPENTER EM, 1992, DEV BIOL, V150, P160, DOI 10.1016/0012-1606(92)90015-9; CHAPMAN VM, 1990, GENOMICS, V8, P113, DOI 10.1016/0888-7543(90)90232-J; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DJABALI M, 1990, GENOMICS, V7, P587, DOI 10.1016/0888-7543(90)90203-7; Doherty P, 1992, Curr Opin Neurobiol, V2, P595, DOI 10.1016/0959-4388(92)90024-F; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1993, CELL ADHES COMMUN, V1, P177, DOI 10.3109/15419069309095693; GRUMET M, 1984, P NATL ACAD SCI-BIOL, V81, P7989, DOI 10.1073/pnas.81.24.7989; GRUMET M, 1991, J CELL BIOL, V113, P1399, DOI 10.1083/jcb.113.6.1399; GRUMET M, 1982, NATURE, V295, P693, DOI 10.1038/295693a0; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; KOBOYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P238; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LEMMON V, 1986, J NEUROSCI, V6, P2987; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; MARTINI R, 1994, J NEUROCYTOL, V23, P1, DOI 10.1007/BF01189813; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; PECK D, 1993, J CELL BIOL, V123, P1587, DOI 10.1083/jcb.123.6.1587; PRINCE JT, 1991, J NEUROSCI RES, V30, P567, DOI 10.1002/jnr.490300315; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RAO Y, 1994, J BIOL CHEM, V269, P27540; Rathjen F. G, 1991, SEMIN NEUROSCI, V3, P297, DOI 10.1016/1044-5765(91)90047-R; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; SADOUL R, 1989, J NEUROCHEM, V53, P1471, DOI 10.1111/j.1471-4159.1989.tb08540.x; Sambrook J, 1989, MOL CLONING LABORATO; SANDIG M, 1994, J BIOL CHEM, V269, P14841; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	66	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29413	29421		10.1074/jbc.270.49.29413	http://dx.doi.org/10.1074/jbc.270.49.29413			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493978	hybrid			2022-12-25	WOS:A1995TJ22700059
J	GUDI, R; BOWKERKINLEY, MM; KEDISHVILI, NY; ZHAO, Y; POPOV, KM				GUDI, R; BOWKERKINLEY, MM; KEDISHVILI, NY; ZHAO, Y; POPOV, KM			DIVERSITY OF THE PYRUVATE-DEHYDROGENASE KINASE GENE FAMILY IN HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COENZYME-A; PURIFICATION; MECHANISM; KIDNEY; HEART; MICROCOMPUTER; PHOSPHATASE; STIMULATION; OXIDATION; COMPLEX	Recent evidence from this laboratory indicates that at least two isoenzymic forms of pyruvate dehydrogenase kinase (PDK1 and PDK2) may be involved in the regulation of enzymatic activity of mammalian pyruvate dehydrogenase complex by phosphorylation (Popov, K. M., Kedishvili, N, Y,, Zhao, Y,, Gudi, R,, and Harris, R. A. (1994) J. Biol. Chem, 269, 29720-29724), The present study was undertaken to further explore the diversity of the pyruvate dehydrogenase kinase gene family, Here we report the deduced amino acid sequences of three isoenzymic forms of PDK found in humans, In terms of their primary structures, two isoenzymes identified in humans correspond to rat PDK1 and PDK2, whereas a third gene (PDK3) encodes for a new isoenzyme that shares 68% and 67% of amino acid identities with PDK1 and PDK2, respectively, PDK3 cDNA expressed in Escherichia coli directs the synthesis of a polypeptide with a molecular mass of approximately 45,000 Da that possesses catalytic activity toward kinase-depleted pyruvate dehydrogenase. PDK3 appears to have the highest specific activity among the three isoenzymes tested as recombinant proteins, Tissue distribution of all three isoenzymes of human PDK was characterized by Northern blot analysis. The highest amount of PDK2 mRNA was found in heart and skeletal muscle, the lowest amount in placenta and lung, Brain, kidney, pancreas, and liver expressed an intermediate amount of PDK2 (brain > kidney = pancreas > liver), The tissue distribution of PDK1 mRNA differs markedly from PDK2, The message for PDK1 was ex pressed predominantly in heart with only modest levels of expression in other tissues (skeletal muscle > liver > pancreas > brain > placenta = lung > kidney), In contrast to PDK1 and PDK2, which are expressed in all tissues tested, the message for PDK3 was found almost exclusively in heart and skeletal muscle, indicating that PDK3 may serve specialized functions characteristic of muscle tissues, In all tissues tested thus far, the level of expression of PDK2 mRNA was essentially higher than that of PDK1 and PDK3, consistent with the idea that PDK2 is a major isoenzyme responsible for regulation of pyruvate dehydrogenase in human tissues.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Kedishvili, Natalia/0000-0001-6917-4891	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051262, R01GM051262] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47844] Funding Source: Medline; NIGMS NIH HHS [GM 51262] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHAL RH, 1993, ANNU REV NUTR, V13, P497, DOI 10.1146/annurev.nu.13.070193.002433; CATE RL, 1978, J BIOL CHEM, V253, P496; CATERSON ID, 1982, BIOCHEM J, V208, P53, DOI 10.1042/bj2080053; COOPER RH, 1974, BIOCHEM J, V143, P625, DOI 10.1042/bj1430625; DENTON RM, 1972, BIOCHEM J, V128, P161, DOI 10.1042/bj1280161; HANSFORD RG, 1976, J BIOL CHEM, V251, P5483; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LINN TC, 1969, P NATL ACAD SCI USA, V62, P227; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; POPOV KM, 1992, J BIOL CHEM, V267, P13129; PRATT ML, 1979, J BIOL CHEM, V254, P7191; PRIESTMAN DA, 1994, BIOCHEM J, V300, P659, DOI 10.1042/bj3000659; PRIESTMAN DA, 1992, FEBS LETT, V308, P83, DOI 10.1016/0014-5793(92)81056-R; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEPP LR, 1983, J BIOL CHEM, V258, P9454; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; WIRTZ E, 1991, MOL BIOCHEM PARASIT, V47, P119, DOI 10.1016/0166-6851(91)90154-X	26	209	224	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28989	28994		10.1074/jbc.270.48.28989	http://dx.doi.org/10.1074/jbc.270.48.28989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499431	hybrid			2022-12-25	WOS:A1995TH05600075
J	KEILER, KC; SAUER, RT				KEILER, KC; SAUER, RT			IDENTIFICATION OF ACTIVE-SITE RESIDUES OF THE TSP PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE	In a search for active-site residues of the Tsp protease, 20 positions were individually mutated to alanine, the mutant strains were assayed for growth defects in vivo, and the purified proteins were assayed for proteolytic activity in vitro. Alanine substitutions at three positions, Ser-430, Asp-441, and Lys-455, result in inactive proteases that have structures and substrate-binding properties similar to wild type, suggesting that the side chains at these positions participate in catalysis. Replacing Ser-430 with cysteine results in a partially active protease, which is inhibited by cysteine-modifying reagents. Replacing Asp-44l with asparagine does not significantly affect activity. However, other residues, including histidine and arginine, cannot functionally replace Lys-455. These data are consistent with a serine-lysine dyad mechanism, similar to those proposed for the LexA-like proteases, the type I signal peptidases, and the class A beta-lactamases.			KEILER, KC (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sauer, Robert/0000-0002-1719-5399; Keiler, Kenneth/0000-0001-8753-335X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015706, R01AI015706, R01AI016892] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16892, AI-15706] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Antonov V. K., 1993, CHEM PROTEOLYSIS; AZIZAN A, 1994, J BACTERIOL, V176, P6653, DOI 10.1128/JB.176.21.6653-6662.1994; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; HARA H, 1991, J BACTERIOL, V173, P4799, DOI 10.1128/jb.173.15.4799-4813.1991; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KEILER KC, 1995, PROTEIN SCI, V4, P1507, DOI 10.1002/pro.5560040808; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; NAKATSUKA T, 1987, J AM CHEM SOC, V109, P3808, DOI 10.1021/ja00246a064; SCHAGGER H, 1991, ANAL BIOCHEM, V166, P368; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SILBER KR, 1994, MOL GEN GENET, V242, P237, DOI 10.1007/BF00391018; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; 1991, PROGRAM MANUAL GCG P	21	62	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28864	28868		10.1074/jbc.270.48.28864	http://dx.doi.org/10.1074/jbc.270.48.28864			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499412	hybrid			2022-12-25	WOS:A1995TH05600056
J	NOESKEJUNGBLUT, C; HAENDLER, B; DONNER, P; ALAGON, A; POSSANI, L; SCHLEUNING, WD				NOESKEJUNGBLUT, C; HAENDLER, B; DONNER, P; ALAGON, A; POSSANI, L; SCHLEUNING, WD			TRIABIN, A HIGHLY POTENT EXOSITE INHIBITOR OF THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; HIRUDIN; PEPTIDE; THROMBOMODULIN; COAGULATION; KINETICS; BINDING; FORMS; VENOM	Triabin, a new thrombin inhibitor, has been purified from the saliva of Triatoma pallidipennis, a blood-sucking triatomine bug, It forms a noncovalent complex with thrombin at a molar ratio of 1:1, inhibits thrombin-induced platelet aggregation, and prolongs thrombin clotting time and activated partial thromboplastin time, However, it only minimally suppresses the amidolytic activity of thrombin, as measured by a chromogenic peptide substrate assay. It completely blocks trypsin-catalyzed cleavage of thrombin, probably via protection of the anion-binding exosite and inhibits the effect of thrombomodulin on thrombin in a dose-dependent fashion, These results indicate that the inhibitor is directed toward the anion-binding exosite of thrombin, The protein was partially sequenced and the information used to isolate cDNA clones from a T. pallidipennis salivary gland library. Four slightly polymorphic variants coding for mature proteins of 142 amino acids preceded by a putative leader sequence were obtained. The recombinant protein expressed in the periplasmic space of Escherichia coli has a biological activity similar to that of salivary triabin, as tested in a thrombin-induced platelet aggregation assay, In addition, recombinant triabin inhibits thrombin catalyzed hydrolysis of fibrinogen with a K-i of about 3 pM.	UNIV NACL AUTONOMA MEXICO,INST BIOTECHNOL,CUERNAVACA 62271,MORELOS,MEXICO	Universidad Nacional Autonoma de Mexico	NOESKEJUNGBLUT, C (corresponding author), SCHERING AG,RES LABS,MULLERSTR 170-178,D-13342 BERLIN,GERMANY.		Possani, Lourival D/J-2397-2013					BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN PJ, 1988, THROMB RES, V50, P273, DOI 10.1016/0049-3848(88)90228-9; CHURCH FC, 1991, J BIOL CHEM, V266, P11975; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; FENTON JW, 1989, SEMIN THROMB HEMOST, V15, P265, DOI 10.1055/s-2007-1002718; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; HAENDLER B, 1995, BIOCHEM J, V307, P465, DOI 10.1042/bj3070465; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HOLLEMAN WH, 1976, J BIOL CHEM, V251, P1663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MARKWARDT F, 1957, H-S Z PHYSIOL CHEM, V308, P147, DOI 10.1515/bchm2.1957.308.1.147; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MAURER HR, 1971, DISC ELECTROPHORESIS, P44; NOESKEJUNGBLUT C, 1994, J BIOL CHEM, V269, P5050; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TARR GE, 1986, METHODS PROTEIN MICR, P162; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; ZINGALI RB, 1993, BIOCHEMISTRY-US, V32, P10794, DOI 10.1021/bi00091a034	35	122	127	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28629	28634		10.1074/jbc.270.48.28629	http://dx.doi.org/10.1074/jbc.270.48.28629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499380	hybrid			2022-12-25	WOS:A1995TH05600024
J	ANAGUCHI, H; HIRAOKA, O; YAMASAKI, K; NAITO, S; OTA, Y				ANAGUCHI, H; HIRAOKA, O; YAMASAKI, K; NAITO, S; OTA, Y			LIGAND-BINDING CHARACTERISTICS OF THE CARBOXYL-TERMINAL DOMAIN OF THE CYTOKINE RECEPTOR HOMOLOGOUS REGION OF THE GRANULOCYTE-COLONY-STIMULATING FACTOR-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; SIGNAL TRANSDUCTION; EXTRACELLULAR DOMAIN; ESCHERICHIA-COLI; DRUG-THERAPY; PROTEIN; IDENTIFICATION; DETERMINANTS; DESIGN; MOTIF	The carboxyl-terminal domain (EC domain, roughly 100 amino acid residues) of the cytokine receptor homologous region in the receptor for murine granulocyte colony-stimulating factor was secreted as a maltose binding protein fusion into the Escherichia coli periplasm. The murine BC domain was prepared from the fusion protein by restriction protease factor Xa digestion and was purified to homogeneity. The purified BC domain specifically and stoichiometrically bound granulocyte colony-stimulating factor. This result indicates that the BC domain is also critical for ligand binding, as shown for the amino-terminal domain of the cytokine receptor homologous region (Hiraoka, O., Anaguchi, H., Yamasaki, K., Fukunaga, R., Nagata, S., and Ota, Y. (1994) J. Biol. Chem. 269, 22412-22419). The tertiary folding and the beta-sheet structure of the BC domain were confirmed by NMR spectroscopy. The disulfide bond pattern suggested from peptide mapping was Cys(224)-Cys(271) and Cys(242)-Cys(285). Disruption of the disulfide bonds suggested that both bonds are critical for maintaining the folding of the BC domain, although a BC domain lacking the second bond still retained ligand binding activity. Mutational analysis of the WSXWS sequence conserved in the cytokine receptor family suggested that this motif is critical for protein folding rather than for ligand binding.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN				Yamasaki, Kazuhiko/L-7108-2018	Yamasaki, Kazuhiko/0000-0003-0320-9697				ASAKURA A, 1994, BIOMED PHARMACOTHER, V48, P35, DOI 10.1016/0753-3322(94)90188-0; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMETRI GD, 1991, BLOOD, V78, P2791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; HIRAOKA H, 1995, IN PRESS J BIOL CHEM, V270; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; NAGATA S, 1990, HDB EXPT PHARM, V1, P699; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; SETO Y, 1992, J IMMUNOL, V148, P259; SOMERS W, 1994, NATURE, V327, P478; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P28; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619	30	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27845	27851		10.1074/jbc.270.46.27845	http://dx.doi.org/10.1074/jbc.270.46.27845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499256	hybrid			2022-12-25	WOS:A1995TE73600067
J	GU, J; DUBNER, R; FORNACE, AJ; IADAROLA, MJ				GU, J; DUBNER, R; FORNACE, AJ; IADAROLA, MJ			UREB1, A TYROSINE-PHOSPHORYLATED NUCLEAR-PROTEIN, INHIBITS P53 TRANSACTIVATION	ONCOGENE			English	Note						UREB1; P53; TRANSACTIVATION; SUPPRESSION; TUMOR SUPPRESSOR; TYROSINE PHOSPHORYLATION	WILD-TYPE; E6-AP; E6; UBIQUITINATION; TRANSFORMATION; EXPRESSION; COMPLEX; MUTANT; GROWTH; FORMS	Tumor suppressor p53 is a transcription activator that upregulates target genes containing the p53 binding site, UREB1, a DNA binding protein that is tyrosine phosphorylated in vivo, shares a significant homology with the human papilloma virus E6 associated protein (E6-AP). E6-AP forms a ternary complex with E6 and p53 and participates in the ubiquitination of p53. Based on the homology with E6-AP, but taking into account the nuclear localization of UREB1 and its smaller size, the present study used a transient transfection system to examine whether UREB1 influenced p53-stimulated transcription. Co-transfection of a vector expressing wildtype UREB1 with one expressing p53 into H1299, a p53 negative cell line, resulted in a pronounced suppression of p53 transactivation. The inhibitory effect was significantly attenuated by mutation of a tyrosine residue in the consensus tyrosine phosphorylation sequence of UREB1. These data suggest that optimal suppression of p53 transactivation requires tyrosine phosphorylated UREB1 and that tyrosine phosphorylation and dephosphorylation processes may be involved in the regulation of p53 transactivation.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	GU, J (corresponding author), NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BLDG 49,RM 1A11,49 CONVENT DR,MSC-4410,BETHESDA,MD 20892, USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				[Anonymous], 1994, PROGRAM MANUAL WISCO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CANTLEY LC, 1991, CELL, V25, P281; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; GU J, 1994, BIOTECHNIQUES, V17, P257; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MESSERSMITH DJ, 1994, MOL CELL NEUROSCI, V5, P238, DOI 10.1006/mcne.1994.1028; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1993, P NATL ACAD SCI USA, V91, P8797; SCHREIBER E, 1980, NUCLEIC ACIDS RES, V17, P6419; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOUNISHROUACH E, 1991, NATURE, V352, P345	27	20	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2175	2178						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478539				2022-12-25	WOS:A1995TF29700030
J	GARCIACALVO, M; KNAUS, HG; MCMANUS, OB; GIANGIACOMO, KM; KACZOROWSKI, GJ; GARCIA, ML				GARCIACALVO, M; KNAUS, HG; MCMANUS, OB; GIANGIACOMO, KM; KACZOROWSKI, GJ; GARCIA, ML			PURIFICATION AND RECONSTITUTION OF THE HIGH-CONDUCTANCE, CALCIUM-ACTIVATED POTASSIUM CHANNEL FROM TRACHEAL SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-ACTIVATED K+ CHANNEL; RAT-BRAIN; CHARYBDOTOXIN BLOCK; XENOPUS-OOCYTES; TEA BLOCKADE; BINDING-SITE; S4 REGION; VOLTAGE; PROTEIN; TETRAETHYLAMMONIUM	The high-conductance Ca2+-aetivated K+ (maxi-K) channel from bovine tracheal smooth muscle was purified to apparent homogeneity by a combination of conventional chromatographic techniques and sucrose density gradient centrifugation. Fractions with the highest specific activity for binding of monoiodotyrosine charybdotoxin, [I-125]ChTX, were enriched approximately 2000-fold over the initial digitonin-solubilized material up to a specific activity of 1 nmol/mg protein. Silver staining after SDS-polyacrylamide gel electrophoresis of the fractions from the last step of the purification indicates that binding activity is correlated with a major component of the preparation that displays an apparent molecular weight of 62,000. Labeling the same preparation with, I-125-Bolton-Hunter reagent reveals the existence of both 62 (alpha)- and 31 (beta)-kDa subunits, in an apparent stoichiometry of 1:1, comigrating with binding activity. The beta subunit is heavily glycosylated. Deglycosylation studies indicate that the beta subunit represents the protein to which [I-125]ChTX is covalently incorporated in the presence of the bifunctional cross-linking reagent disuccinimidyl suberate. Binding of [I-125]ChTX to the purified ChTX receptor displayed the same pharmacological profile that has been found previously for toxin binding to native membranes, including inhibition by iberiotoxin, limbatustoxin, tetraethylamonium, potassium, cesium, and barium. The purified preparation was reconstituted into liposomes which were then fused with artificial lipid bilayers. Single channels were readily observed with a conductance of 235 picosiemens in 150 mm KCl that displayed selectivity for potassium over chloride and that were blocked by ChTX. The open probability of these channels was increased by depolarizing membrane potentials and by raising the internal calcium concentration. These data suggest that the maxi-K channel purified from tracheal smooth muscle is composed of two subunits.	MERCK SHARP & DOHME LTD, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA	Merck & Company								ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; AUGUSTE P, 1989, FEBS LETT, V248, P150, DOI 10.1016/0014-5793(89)80451-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CECCHI X, 1987, BIOPHYS J, V52, P707, DOI 10.1016/S0006-3495(87)83265-4; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; FRANK RN, 1975, ARCH BIOCHEM BIOPHYS, V171, P1, DOI 10.1016/0003-9861(75)90001-6; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GARCIACALVO M, 1991, BIOCHEMISTRY-US, V30, P11157, DOI 10.1021/bi00110a020; GIANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719, DOI 10.1021/bi00144a011; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HUGUES M, 1982, BIOCHEM BIOPH RES CO, V107, P1577, DOI 10.1016/S0006-291X(82)80180-0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KNAUS HG, 1993, BIOPHYS J, V64, pA199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATORRE R, 1986, ION CHANNEL RECONSTI, P431; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MILLER C, 1988, NEURON, V1, P1003, DOI 10.1016/0896-6273(88)90157-2; MILLER C, 1987, BIOPHYS J, V52, P123, DOI 10.1016/S0006-3495(87)83196-X; NOVICK J, 1991, Biophysical Journal, V59, p78A; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCHMIDANTOMARCHI H, 1984, EUR J BIOCHEM, V142, P1, DOI 10.1111/j.1432-1033.1984.tb08242.x; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SEAGAR MJ, 1986, BIOCHEMISTRY-US, V25, P4051, DOI 10.1021/bi00362a010; SLAUGHTER RS, 1989, BIOCHEMISTRY-US, V28, P3995, DOI 10.1021/bi00435a055; SLAUGHTER RS, 1989, J CELL BIOL, V107, pA143; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	53	164	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					676	682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506261				2022-12-25	WOS:A1994MR21900106
J	OSIR, EO; RIDDIFORD, LM				OSIR, EO; RIDDIFORD, LM			NUCLEAR-BINDING SITES FOR JUVENILE-HORMONE AND ITS ANALOGS IN THE EPIDERMIS OF THE TOBACCO HORNWORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV WASHINGTON, DEPT ZOOL NJ15, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle								AJAMI AM, 1973, J INSECT PHYSIOL, V19, P635, DOI 10.1016/0022-1910(73)90072-3; ANDERSON J, 1972, BIOCHEM J, V126, P561, DOI 10.1042/bj1260561; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BOEHM MF, 1986, J ORG CHEM, V51, P5447, DOI 10.1021/jo00376a083; CHANG ES, 1980, P NATL ACAD SCI-BIOL, V77, P4657, DOI 10.1073/pnas.77.8.4657; CHANG ES, 1985, METHOD ENZYMOL, V111, P494; CHINZEI Y, 1982, CAN J BIOCHEM CELL B, V60, P243, DOI 10.1139/o82-029; CLARK JH, 1979, STEROID HORMONE RECE, V117, P17; ENG W, 1986, B SOC CHIM BELG, V95, P895; ENGELMANN F, 1981, MOL CELL ENDOCRINOL, V24, P103, DOI 10.1016/0303-7207(81)90082-4; ENGELMANN F, 1987, INSECT BIOCHEM, V17, P1045, DOI 10.1016/0020-1790(87)90118-1; Engelmann F., 1984, Advances in Invertebrate Reproduction, V3, P177; FAIN MJ, 1975, BIOL BULL-US, V149, P506, DOI 10.2307/1540383; GIESE C, 1977, Z NATURFORSCH C, V32, P158; GOODMAN W, 1978, GEN COMP ENDOCR, V35, P27, DOI 10.1016/0016-6480(78)90165-X; Goodman W.G., 1985, P491; GORSKI J, 1986, RECENT PROG HORM RES, V42, P297; HAGEDORN HH, 1979, ANNU REV ENTOMOL, V24, P475, DOI 10.1146/annurev.en.24.010179.002355; Hammock B.D., 1985, P431; ILENCHUK TT, 1987, INSECT BIOCHEM, V17, P1085, DOI 10.1016/0020-1790(87)90125-9; ILENCHUK TT, 1985, CAN J BIOCHEM CELL B, V63, P102, DOI 10.1139/o85-015; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; KATO Y, 1987, DEVELOPMENT, V99, P137; KLAGES G, 1980, NATURE, V286, P282, DOI 10.1038/286282a0; Koeppe J.K., 1985, P165; KOEPPE JK, 1986, BIOCHEM ACTION HORM, V13, P265; KOEPPE JK, 1981, JUVENILE HORMONE BIO, P215; KONIG R, 1985, INSECT BIOCHEM, V15, P735, DOI 10.1016/0020-1790(85)90102-7; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MITSUI T, 1979, INSECT BIOCHEM, V9, P637, DOI 10.1016/0020-1790(79)90103-3; MULVIHILL ER, 1977, J BIOL CHEM, V252, P2060; OSIR EO, 1986, ARCH INSECT BIOCHEM, V3, P513, DOI 10.1002/arch.940030603; PRESTWICH GD, 1987, INSECT BIOCHEM, V17, P1033, DOI 10.1016/0020-1790(87)90116-8; PRESTWICH GD, 1985, P NATL ACAD SCI USA, V82, P5290, DOI 10.1073/pnas.82.16.5290; Riddiford L.M., 1979, TCA (TISSUE CULTURE ASSOCIATION) MANUAL, V5, P975, DOI 10.1007/BF00919715; Riddiford L.M., 1985, P37; RIDDIFORD LM, 1986, ARCH INSECT BIOCHEM, P75, DOI 10.1002/arch.940030709; RIDDIFORD LM, 1987, INSECT BIOCHEM, V17, P1039, DOI 10.1016/0020-1790(87)90117-X; ROBERTS PE, 1983, MOL CELL ENDOCRINOL, V31, P53, DOI 10.1016/0303-7207(83)90030-8; ROBERTS PE, 1986, ARCH INSECT BIOCHEM, P7, DOI 10.1002/arch.940030704; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schooley DA, 1985, COMPREHENSIVE INSECT, P363; SPARKS TC, 1983, INSECT BIOCHEM, V13, P529, DOI 10.1016/0020-1790(83)90012-4; TATA JR, 1984, MOL CELL ENDOCRINOL, V36, P17, DOI 10.1016/0303-7207(84)90080-7; TATA JR, 1976, CELL, V9, P1, DOI 10.1016/0092-8674(76)90047-7; WEDER HG, 1974, EUR J BIOCHEM, V42, P475, DOI 10.1111/j.1432-1033.1974.tb03361.x; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YUND MA, 1985, COMPREHENSIVE INSECT, V7, P473	49	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13812	13818						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417679				2022-12-25	WOS:A1988Q159400056
J	ESSER, V; LIMBIRD, LE; BROWN, MS; GOLDSTEIN, JL; RUSSELL, DW				ESSER, V; LIMBIRD, LE; BROWN, MS; GOLDSTEIN, JL; RUSSELL, DW			MUTATIONAL ANALYSIS OF THE LIGAND-BINDING DOMAIN OF THE LOW-DENSITY LIPOPROTEIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV TEXAS, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas	ESSER, V (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.			Russell, David/0000-0002-0277-403X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016027] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL025182] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25182, HL 20948] Funding Source: Medline; NICHD NIH HHS [HD16027] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASU SK, 1977, J CELL BIOL, V74, P119, DOI 10.1083/jcb.74.1.119; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BROWN MS, 1978, J SUPRAMOL STR CELL, V8, P223, DOI 10.1002/jss.400080302; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOBBS HH, 1986, J BIOL CHEM, V261, P3114; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; MANIATIS T, 1982, MOL CLONING LABORATO; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCOTT J, 1987, BIOCHEM SOC SYMP, P155; STENFLO J, 1988, J BIOL CHEM, V263, P21; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; SUGO T, 1984, FEBS LETT, V165, P102, DOI 10.1016/0014-5793(84)80023-X; TOLLESHAUG H, 1983, CELL, V32, P941, DOI 10.1016/0092-8674(83)90079-X; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	40	265	279	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13282	13290						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417658				2022-12-25	WOS:A1988Q091700078
J	LAMBOOY, PK; KORN, ED				LAMBOOY, PK; KORN, ED			INHIBITION OF AN EARLY STAGE OF ACTIN POLYMERIZATION BY ACTOBINDIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											LAMBOOY, PK (corresponding author), NHLBI,CELL BIOL LAB,BETHESDA,MD 20892, USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ALBANESI JP, 1987, J BIOL CHEM, V262, P3404; CARLIER MF, 1985, J BIOL CHEM, V260, P6572; COOPER JA, 1986, J BIOL CHEM, V261, P477; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; EATON WA, 1978, P S CLIN BIOCH ASPEC, P443; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; GODDETTE DW, 1986, J BIOL CHEM, V261, P2605; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; HSU DS, 1980, J CHROMATOGR, V192, P193, DOI 10.1016/S0021-9673(00)81853-1; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL AA, 1984, J BIOL CHEM, V259, P3061; LAL AA, 1984, J BIOL CHEM, V259, P8794; LAL AA, 1985, J BIOL CHEM, V260, P132; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOZOVILLARIAS A, 1985, BIOCHEMISTRY-US, V24, P1544, DOI 10.1021/bi00327a038; NEWMAN J, 1985, BIOCHEMISTRY-US, V24, P1538, DOI 10.1021/bi00327a037; OOSAWA M, 1986, J BIOCHEM, V100, P1001, DOI 10.1093/oxfordjournals.jbchem.a121778; PANTALONI D, 1984, J BIOL CHEM, V259, P6274; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1986, J CELL BIOCHEM, V31, P87, DOI 10.1002/jcb.240310202; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; SONOBE S, 1986, J BIOL CHEM, V261, P4837; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TOBACMAN LS, 1983, J BIOL CHEM, V258, P8806; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; UENO T, 1986, J CELL BIOL, V103, P621, DOI 10.1083/jcb.103.2.621; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5	34	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12836	12843						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417638				2022-12-25	WOS:A1988Q091700012
J	BAENZIGER, JE; METHOT, N				BAENZIGER, JE; METHOT, N			FOURIER-TRANSFORM INFRARED AND HYDROGEN-DEUTERIUM EXCHANGE REVEAL AN EXCHANGE-RESISTANT CORE OF ALPHA-HELICAL PEPTIDE HYDROGENS IN THE NICOTINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; TORPEDO-CALIFORNICA; DIFFERENCE SPECTROSCOPY; CONFORMATIONAL-CHANGES; CHANNEL; MEMBRANES; PROTEINS; FTIR; BACTERIORHODOPSIN; LIPIDS	The structure of the nicotinic acetylcholine receptor (nAChR) has been studied using a novel combination of hydrogen/deuterium exchange and attenuated total reflectance Fourier transform infrared spectroscopy. Fourier transform infrared spectra show marked changes in both the amide I and amide II bands upon exposure of the nAChR to (H2O)-H-2. The substantial decrease in intensity of the amide II band reflects the exchange of roughly 30% of the peptide hydrogens within seconds of exposure to (H2O)-H-2, 50% after 30 min, 60% after 12 h, and 75% after prolonged exposure for several days at room temperature or lower temperatures. The 30% of peptide hydrogens that exchange within seconds is highly exposed to solvent and likely involved in random and turn conformations, whereas the 25% of exchange-resistant peptide hydrogens is relatively inaccessible to solvent and likely located in the transmembrane domains of the nAChR. Marked changes occur in the amide I contour within seconds of exposure of the nAChR to (H2O)-H-2 as a result of relatively large downshifts in the frequencies of amide I component bands assigned to turns and random structures. In contrast, only subtle changes occur in the amide I contour between 3 min and 12 h after exposure to (H2O)-H-2 as a result of slight downshifts in the frequencies of alpha-helix and beta-sheet vibrations. It is demonstrated that the time courses and relative magnitudes of the amide I component band shifts can be used both as an aid in the assignment of component bands to specific secondary structures and as a probe of the exchange rates of different types of secondary structures in the nAChR. Significantly, the intensities of the band shifts reflecting the exchange of alpha-helical secondary structures are relatively weak indicating that a large proportion of the 25% exchange resistant peptides adopt an alpha-helical conformation. Conversely, no evidence is found for the existence of a large number of exchange-resistant beta-strands. The exchange kinetics suggest a predominantly alpha-helical secondary structure for the transmembrane domains of the aAChR.			BAENZIGER, JE (corresponding author), UNIV OTTAWA,DEPT BIOCHEM,451 SMYTH RD,OTTAWA,ON K1H 8M5,CANADA.			Baenziger, John/0000-0002-2888-5328				AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BAENZIGER JE, 1992, BIOPHYS J, V61, P983, DOI 10.1016/S0006-3495(92)81905-7; BAENZIGER JE, 1992, BIOPHYS J, V62, P64, DOI 10.1016/S0006-3495(92)81780-0; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BUTLER DH, 1993, BIOCHIM BIOPHYS ACTA, V1150, P17, DOI 10.1016/0005-2736(93)90116-H; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CARRUTHERS A, 1983, BIOCHEMISTRY-US, V22, P5797, DOI 10.1021/bi00294a018; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; EARNEST TN, 1990, BIOPHYS J, V58, P1539, DOI 10.1016/S0006-3495(90)82498-X; ENGLANDER JJ, 1982, J BIOL CHEM, V257, P7982; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; FRINGELI UP, 1981, MEMBRANE SPECTROSCOP, P270; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GORNETSCHELNOKO.U, 1994, EMBO J, V13, P338; HE WZ, 1991, BIOCHEMISTRY-US, V30, P4552, DOI 10.1021/bi00232a027; HEIMBURG T, 1993, BIOPHYS J, V65, P2408, DOI 10.1016/S0006-3495(93)81299-2; HUCHO F, 1994, TRENDS BIOCHEM SCI, V19, P383, DOI 10.1016/0968-0004(94)90116-3; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; KONISHI T, 1977, FEBS LETT, V80, P455, DOI 10.1016/0014-5793(77)80496-1; KONISHI T, 1977, FEBS LETT, V80, P7982; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; MEILKE DL, 1988, J BIOL CHEM, V263, P3177; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; NABEDRYK E, 1988, NATO ASI SER A, V168, P237; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OSBORNE HB, 1977, FEBS LETT, V84, P217, DOI 10.1016/0014-5793(77)80691-1; SMITH ICP, 1984, MEMBRANE FLUIDITY, P133; SONVEAUX N, 1994, J BIOL CHEM, V269, P25637; SUSI H, 1967, J BIOL CHEM, V242, P5460; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; UNWIN N, 1996, NATURE, V373, P37; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; WU CSC, 1990, J PROTEIN CHEM, V9, P119, DOI 10.1007/BF01024993	44	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29129	29137		10.1074/jbc.270.49.29129	http://dx.doi.org/10.1074/jbc.270.49.29129			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493938	hybrid			2022-12-25	WOS:A1995TJ22700019
J	WU, DH; HERSH, LB				WU, DH; HERSH, LB			IDENTIFICATION OF AN ACTIVE-SITE ARGININE IN RAT CHOLINE-ACETYLTRANSFERASE BY ALANINE SCANNING MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; POLYACRYLAMIDE GELS; COMPLETE SEQUENCE; PROTEINS; CDNA; EXPRESSION; CLONING	Kinetic as well as chemical modification studies have implicated the presence of an active site arginine in choline acetyltransferase, whose function is to stabilize coenzyme binding by interacting with the 5'-phosphate of the coenzyme A substrate. In order to identify this residue seven conserved arginines in rat choline acetyltransferase were converted to alanine by site-directed mutagenesis, and the properties of these mutants were compared with the wild type enzyme. Substitution of arginine 452 with alanine resulted in a 7-12-fold increase in the K-m for both CoA and acetylcholine as well as K-cat with little change in the K-m for dephospho-CoA. Product inhibition studies showed choline to be a competitive inhibitor with respect to acetylcholine, indicating R452A follows the same Theorell-Chance kinetic mechanism as the wild type enzyme. Similar results were obtained with R452Q and R452E, with the latter showing the largest changes in kinetic parameters, These findings are consistent with Arg-452 mutations increasing the rate constant, k(5), for dissociation of the coenzyme from the enzyme. Direct evidence that arginine 452 is involved in coenzyme A binding was obtained by showing a 5-10-fold decrease in affinity of the R452A mutant for coenzyme A as determined by the ability to protect against phenylglyoxal inactivation as well as thermal inactivation.	UNIV KENTUCKY,CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky					NIA NIH HHS [AG 05893] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG005893, R55AG005893] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALFONSO A, 1994, J NEUROSCI, V14, P2290; BERRARD S, 1987, P NATL ACAD SCI USA, V84, P9280, DOI 10.1073/pnas.84.24.9280; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICE A, 1989, J NEUROSCI RES, V23, P266, DOI 10.1002/jnr.490230304; CARBINI L, 1990, BRAIN RES BULL, V24, P119, DOI 10.1016/0361-9230(90)90295-B; CARBINI LA, 1993, J NEUROCHEM, V61, P247, DOI 10.1111/j.1471-4159.1993.tb03561.x; CURRIER SF, 1974, P NATL ACAD SCI USA, V71, P3555; DRISKELL WJ, 1978, J NEUROCHEM, V30, P1135, DOI 10.1111/j.1471-4159.1978.tb12408.x; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; HERSH LB, 1979, J NEUROCHEM, V32, P991, DOI 10.1111/j.1471-4159.1979.tb04585.x; HERSH LB, 1978, J NEUROCHEM, V30, P1077, DOI 10.1111/j.1471-4159.1978.tb12401.x; HERSH LB, 1979, J BIOL CHEM, V254, P1988; HERSH LB, 1982, J BIOL CHEM, V257, P2820; HERSH LB, 1978, J NEUROCHEM, V30, P1087, DOI 10.1111/j.1471-4159.1978.tb12402.x; ISHII K, 1990, MOL BRAIN RES, V7, P151, DOI 10.1016/0169-328X(90)90092-R; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUTNER HG, 1981, P NATL ACAD SCI-BIOL, V78, P7449, DOI 10.1073/pnas.78.12.7449; REMINGTON S, 1982, J MOL BIOL, V172, P111; ROSKOSKI R, 1975, BIOCHEMISTRY-US, V14, P5105, DOI 10.1021/bi00694a013; ROSKOSKI R, 1974, J BIOL CHEM, V249, P2156; ROSSIER J, 1977, INT REV NEUROSCI, V20, P284; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCEK S, 1988, HDB EXPT PHARM, V86, P129; WU DH, 1995, J BIOL CHEM, V270, P19395, DOI 10.1074/jbc.270.33.19395; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	27	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29111	29116		10.1074/jbc.270.49.29111	http://dx.doi.org/10.1074/jbc.270.49.29111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493935	hybrid			2022-12-25	WOS:A1995TJ22700016
J	MAHON, TM; ONEILL, LAJ				MAHON, TM; ONEILL, LAJ			STUDIES INTO THE EFFECT OF THE TYROSINE KINASE INHIBITOR HERBIMYCIN-A ON NF-KAPPA-B ACTIVATION IN T-LYMPHOCYTES - EVIDENCE FOR COVALENT MODIFICATION OF THE P50 SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; PROTEIN; INTERLEUKIN-1; PHOSPHORYLATION; ALPHA; CELLS; MECHANISM; INVITRO	The tyrosine kinase inhibitor herbimycin A was found to block NF-kappa B stimulation in response to interleukin-1 and phorbol 12-myristate 13-acetate in EL4.NOB-1 thymoma cells and phorbol 12-myristate 13-acetate in Jurkat T lymphoma cells. The effect appeared not to involve inhibition of tyrosine kinase activation as neither interleukin-1 nor phorbol 12-myristate 13-acetate induced major changes in tyrosine phosphorylation in EL4.NOB-1 or Jurkat cells, respectively, Herbimycin A did not interfere with I kappa B-alpha degradation, and in unstimulated cells, it modified NF-kappa B prior to chemical dissociation with sodium deoxycholate. Because herbimycin A is thiol-reactive, we suspected that the target was the p50 subunit of NF-kappa B, which has a key thiol at cysteine 62, Herbimycin A inhibited DNA binding when added to nuclear extracts prepared from stimulated cells, which were shown to contain high levels of p50. Incubation of herbimycin A with a mercaptoethanol attenuated the effect, Herbimycin A was also shown to react directly with p50, blocking its ability to bind to the NF-kappa B consensus sequence. However, a mutant form of p50 in which cysteine 62 was mutated to serine was insensitive to herbimycin A. Finally, we demonstrated that the compound inhibited the expression of interleukin-2 (an NF-kappa B-regulated gene) in EL4.NOB-1 cells, These data therefore suggest that herbimycin A inhibits NF-kappa B by modifying the p50 subunit on cysteine 62 in the NF-kappa B complex, which blocks DNA binding and NF-kappa B driven gene expression. The results urge caution in the use of herbimycin A as a specific tyrosine kinase inhibitor and suggest that the development of agents that selectively modify p50 may have potential as a means of inhibiting NF-kappa B-dependent gene transcription.	TRINITY COLL DUBLIN, DEPT BIOCHEM, DUBLIN 2, IRELAND; TRINITY COLL DUBLIN, INST BIOTECHNOL, DUBLIN 2, IRELAND	Trinity College Dublin; Trinity College Dublin								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEG AA, 1993, GENE DEV, V7, P1564; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHOUCHI H, 1994, BIOCHEM J, V303, P499; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; EICHER DM, 1994, J IMMUNOL, V152, P2710; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GELFAND EW, 1985, NATURE, V315, P419, DOI 10.1038/315419a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HSI ED, 1989, J BIOL CHEM, V264, P10836; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KERR LD, 1991, J BIOL CHEM, V5, P1464; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, J BIOL CHEM, V267, P239; MARTIN M, 1989, EUR J BIOCHEM, V148, P1; MATHEWS JR, 1993, NUC ACID RES, V21, P1727; MIZEL S, 1990, IMMUNOL TODAY, V11, P357; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; ONEILL LAJ, 1992, KIDNEY INT, V41, P546, DOI 10.1038/ki.1992.78; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P390; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITZ LM, 1991, TRENDS CELL BIOL, V1, P130; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SONG L, 1993, IMMUNOLOGY, V80, P222; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STRICKER K, 1993, EUR J IMMUNOL, V23, P1475, DOI 10.1002/eji.1830230712; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521	54	122	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28557	28564		10.1074/jbc.270.48.28557	http://dx.doi.org/10.1074/jbc.270.48.28557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499370	Green Published, hybrid			2022-12-25	WOS:A1995TH05600014
J	OLSON, MW; WANG, YX; ELDER, RH; KAGUNI, LS				OLSON, MW; WANG, YX; ELDER, RH; KAGUNI, LS			SUBUNIT STRUCTURE OF MITOCHONDRIAL-DNA POLYMERASE FROM DROSOPHILA EMBRYOS - PHYSICAL AND IMMUNOLOGICAL STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'->5' EXONUCLEASE; SUBSTRATE-SPECIFICITY; CATALYTIC SUBUNIT; FUNCTIONAL ROLES; XENOPUS-LAEVIS; GAMMA; PROTEINS; POLYMERIZATION; IDENTIFICATION; MELANOGASTER	The subunit structure of mitochondrial DNA polymerase from Drosophila embryos has been examined by a combination of physical and immunological methods. A highly specific rabbit antiserum directed against the native enzyme was developed and found to recognize specifically its two subunits in immunoblot and immunoprecipitation analyses. That and the potent inhibition by the rabbit antiserum of the DNA polymerase and 3' --> 5' exonuclease activities of the nearly homogeneous mitochondrial DNA polymerase provide strong evidence for the physical association of the 3' --> 5' exonuclease with the two subunit enzyme. An immunoprecipitation analysis of crude enzyme fractions showed that the two subunits of Drosophila mitochondrial DNA polymerase are intact, and an in situ gel proteolysis analysis showed that they are structurally distinct. Template-primer DNA binding studies demonstrated formation of a stable and discrete enzyme DNA complex in the absence of accessory proteins. Photochemical cross-linking of the complexes by UV light indicated that the alpha but not the beta subunit of mitochondrial DNA polymerase makes close contact with DNA, and limited digestion of the native enzyme with trypsin showed that an similar to 65-kDa proteolytic fragment of the alpha subunit retains the DNA binding function.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM45295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; FOURY F, 1989, J BIOL CHEM, V264, P20552; FOURY F, 1989, EMBO J, V11, P2717; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; GRAY H, 1992, J BIOL CHEM, V267, P5835; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P2316, DOI 10.1073/pnas.76.5.2316; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; KAGUNI LS, 1988, CANC CELLS EUKARYOTI, P425; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; LISHWE MA, 1982, ANAL BIOCHEM, V127, P453; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; OLSON MW, 1992, J BIOL CHEM, V267, P23136; REEMS JA, 1994, J BIOL CHEM, V269, P33091; SANJANWALA B, 1989, P NATL ACAD SCI USA, V86, P4421, DOI 10.1073/pnas.86.12.4421; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WEISSBACH A, 1979, ARCH BIOCHEM BIOPHYS, V198, P386, DOI 10.1016/0003-9861(79)90511-3; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	31	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28932	28937		10.1074/jbc.270.48.28932	http://dx.doi.org/10.1074/jbc.270.48.28932			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499423	hybrid			2022-12-25	WOS:A1995TH05600067
J	QASIM, MA; RANJBAR, MR; WYNN, R; ANDERSON, S; LASKOWSKI, M				QASIM, MA; RANJBAR, MR; WYNN, R; ANDERSON, S; LASKOWSKI, M			IONIZABLE P-1 RESIDUES IN SERINE PROTEINASE-INHIBITORS UNDERGO LARGE PK SHIFTS ON COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OVOMUCOID 3RD DOMAINS; GRISEUS PROTEASE-B; REACTIVE-SITE; CRYSTAL-STRUCTURE; HYDROPHOBIC CORE; PEPTIDE-BOND; TURKEY; RESOLUTION; SEQUENCES; BINDING	The burial of charged residues in proteins is rare as it is thermodynamically strongly disfavored. However, in ''standard mechanism'' protein inhibitors of serine pro teinases, the P-1 residue, which is highly exposed, be comes buried in the S-1 specificity pocket of the enzyme. In many enzymes, such as Streptomyces griseus proteinase B (SGPB) the S-1 pocket is hydrophobic. We measured the pH dependence of the association equilibrium constant for the interaction of SGPB with turkey ovo mucoid third domain P-1 mutants, Glu(18) OMTKY3 and His(18) OMTKY3. In order to eliminate the effects of other ionizable groups on the enzyme and the inhibitor, we divided these pH dependences by the pH dependence of the association equilibrium constant for the Gln(18) OMTKY3 mutant. This yielded for Glu(18), pK(f) (free inhibitor) of 4.46 +/- 0.05 and pK(c) (complex) of 8.74 +/- 0.06. For His(18) the values are: pK(f) 6.63 +/- 0.08 and pK(c) 4.31 +/- 0.07. At low pH values Glu(18) variant is a relatively good inhibitor for SGPB. This may be biologically relevant.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; RUTGERS STATE UNIV, CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08854 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Rutgers State University New Brunswick					NATIONAL INSTITUTE ON AGING [R01AG011525, R01AG010462] Funding Source: NIH RePORTER; NIA NIH HHS [AG 11525, AG 10462] Funding Source: Medline; NIGMS NIH HHS [GM 10831] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APOSTOL I, 1993, J PROTEIN CHEM, V12, P419, DOI 10.1007/BF01025042; ARDELT W, 1985, BIOCHEMISTRY-US, V24, P5313, DOI 10.1021/bi00341a007; BIGLER TL, 1993, PROTEIN SCI, V2, P786, DOI 10.1002/pro.5560020509; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; Edsall JT, 1958, BIOPHYSICAL CHEM, P47; EMPIE MW, 1982, BIOCHEMISTRY-US, V21, P2274, DOI 10.1021/bi00539a002; FINKENSTADT WR, 1974, PROTEINASE INHIBITOR, P389; FIORETTI E, 1993, J ENZYM INHIB, V7, P57, DOI 10.3109/14756369309020189; FUJINAGA M, 1987, J MOL BIOL, V195, P397, DOI 10.1016/0022-2836(87)90659-0; FUJINAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P4868, DOI 10.1073/pnas.79.16.4868; GREEN NM, 1953, BIOCHEM J, V54, P347, DOI 10.1042/bj0540347; Halford J, 1933, J AM CHEM SOC, V55, P2272, DOI 10.1021/ja01333a011; HOMANDBERG GA, 1978, BIOCHEMISTRY-US, V17, P5220, DOI 10.1021/bi00617a023; Honig B., 1992, CURR OPIN STRUC BIOL, V2, P40; HUANG K, 1995, PROTEIN SCI, V4, P1985, DOI 10.1002/pro.5560041004; JURASEK L, 1971, CAN J BIOCHEM CELL B, V49, P1195, DOI 10.1139/o71-171; KOMIYAMA T, 1991, J BIOL CHEM, V266, P10727; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7609, DOI 10.1021/bi00244a033; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LASKOWSKI M, 1987, BIOCHEMISTRY-US, V26, P202, DOI 10.1021/bi00375a028; Laskowski M Jr, 1972, Methods Enzymol, V26, P193; LEATHERBARROW RJ, 1987, ENZFITTER VERSION 1; LEBOWITZ J, 1962, BIOCHEMISTRY-US, V1, P1044, DOI 10.1021/bi00912a015; LU W, 1993, PROTEIN SCI S, V2, P122; Lu W., 1994, THESIS PURDUE U; MATTIS JA, 1973, BIOCHEMISTRY-US, V12, P2239, DOI 10.1021/bi00736a009; Michaelis L, 1925, Z PHYS CHEM-STOCH VE, V116, P135; READ RJ, 1983, BIOCHEMISTRY-US, V22, P4420, DOI 10.1021/bi00288a012; READ RJ, 1986, PROTEINASE INHIBITOR, P301; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)90795-8; WILSON NA, 1995, BIOCHEMISTRY-US, V34, P8931, DOI 10.1021/bi00028a001; WYMAN J, 1990, BINDING LINKAGE FUNC, P33; [No title captured]; [No title captured]	38	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27419	27422		10.1074/jbc.270.46.27419	http://dx.doi.org/10.1074/jbc.270.46.27419			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499197	hybrid			2022-12-25	WOS:A1995TE73600008
J	SCHWORER, CM; COLBRAN, RJ; KEEFER, JR; SODERLING, TR				SCHWORER, CM; COLBRAN, RJ; KEEFER, JR; SODERLING, TR			CA-2+/CALMODULIN-DEPENDENT PROTEIN KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									VANDERBILT UNIV, MED CTR,SCH MED,HOWARD HUGHES MED INST, 702 LIGHT HALL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University			Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244				BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; COLBRAN RJ, 1988, FASEB J, V2, pA992; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Gracy R W, 1977, Methods Enzymol, V47, P195; GREENBERG H, 1965, J BIOL CHEM, V240, P1639; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; KURET J, 1985, J BIOL CHEM, V260, P6427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LAI Y, 1987, P NATL ACAD SCI USA, V84, P5710, DOI 10.1073/pnas.84.16.5710; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1988, FASEB J, V2, pA992; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SODERLING TR, 1982, J CHROMATOGR, V253, P243, DOI 10.1016/S0021-9673(01)88382-5; SODERLING TR, 1986, C INSERM, V139, P141; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x	24	188	189	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13486	13489						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417668				2022-12-25	WOS:A1988Q159400004
J	GOLDSTEIN, BJ; KAHN, CR				GOLDSTEIN, BJ; KAHN, CR			INITIAL PROCESSING OF THE INSULIN-RECEPTOR PRECURSOR INVIVO AND INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 33201, DK 31036] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031036, R37DK031036, R01DK033201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CLARK AJL, 1986, BIOCHIM BIOPHYS ACTA, V867, P244, DOI 10.1016/0167-4781(86)90040-0; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FORSAYETH J, 1986, DIABETES, V35, P837, DOI 10.2337/diabetes.35.7.837; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HEDO JA, 1985, BIOCHEM J, V232, P71, DOI 10.1042/bj2320071; HEDO JA, 1985, J CLIN INVEST, V76, P2355, DOI 10.1172/JCI112247; HEDO JA, 1987, J BIOL CHEM, V262, P954; HEDO JA, 1983, J BIOL CHEM, V258, P20; HEDO JA, 1985, HORM METAB RES, V17, P487, DOI 10.1055/s-2007-1013586; KAHN CR, 1985, ANNU REV MED, V36, P429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCDONALD AR, 1988, J CLIN INVEST, V81, P499, DOI 10.1172/JCI113347; MERLIE JP, 1984, CELL, V36, P573, DOI 10.1016/0092-8674(84)90335-0; OLSON TS, 1987, J BIOL CHEM, V262, P6816; REESJONES RW, 1983, BIOCHEM BIOPH RES CO, V116, P417, DOI 10.1016/0006-291X(83)90539-9; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; SALZMAN A, 1984, BIOCHEMISTRY-US, V23, P6555, DOI 10.1021/bi00321a043; SIMMEN FA, 1984, DNA-J MOLEC CELL BIO, V3, P393, DOI 10.1089/dna.1984.3.393; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WHITE MF, 1986, ENZYMES, V17, P247	28	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12809	12812						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417632				2022-12-25	WOS:A1988Q091700005
J	HUA, XX; SAKAI, J; HO, YK; GOLDSTEIN, JL; BROWN, MS				HUA, XX; SAKAI, J; HO, YK; GOLDSTEIN, JL; BROWN, MS			HAIRPIN ORIENTATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 IN CELL-MEMBRANES AS DETERMINED BY PROTEASE PROTECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; MONOCLONAL-ANTIBODIES; CULTURED-CELLS; TRANSCRIPTION; ENDOCYTOSIS	Sterol regulatory element-binding proteins (SREBP-1 and SREBP-2) are proteins of similar to 1150 amino acids each that are attached to membranes of the endoplasmic reticulum (ER). In sterol-depleted cells, a protease releases an NH2-terminal fragment of similar to 500 amino acids that contains a basic helix-loop-helix leucine zipper motif. This fragment enters the nucleus and stimulates transcription of genes encoding the low density lipoprotein receptor and enzymes of cholesterol biosynthesis. Prior evidence indicates that the SREBPs are attached to membranes by virtue of an 80-residue segment located similar to 80 amino acids to the COOH-terminal side of the leucine zipper. This segment-contains two long hydrophobic sequences separated by a short hydrophilic sequence of similar to 30 amino acids. We have proposed a hairpin model in which the two hydrophobic sequences span the membrane, separated by the short hydrophilic sequence which projects into the lumen of the ER (the ''lumenal loop''). The model predicts that the NH2- and COOH-terminal segments face the cytosol. To test this model, we constructed a cDNA encoding human SREBP-2 with epitope tags at the NH2 terminus and in the lumenal loop. The COOH-terminal region was visualized with a newly developed monoclonal antibody against this region. Sealed membrane vesicles were isolated from cells expressing the epitope-tagged version of SREBP-2. Trypsin treatment of these vesicles destroyed the NH2- and COOH-terminal segments and reduced the lumenal epitope to a size consistent with protection of the lumenal sequence plus the two membrane-spanning segments. The lumenal epitope tag contained two potential sites for N-linked glycosylation. The size of the trypsin-protected fragment was reduced by treatment with N-Glycanase(R) and endoglycosidase H, indicating that this segment was located in the lumen of the ER where it was glycosylated. These data provide strong support for the hairpin model.			HUA, XX (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Sakai, Juro/0000-0003-4043-1035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; Bollag D.M., 1991, PROTEIN METHODS; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; Sambrook J, 1989, MOL CLONING LABORATO; SATO R, 1994, J BIOL CHEM, V269, P17267; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	22	144	148	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29422	29427		10.1074/jbc.270.49.29422	http://dx.doi.org/10.1074/jbc.270.49.29422			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493979	hybrid			2022-12-25	WOS:A1995TJ22700060
J	KNEGTEL, RMK; STROKOPYTOV, B; PENNINGA, D; FABER, OG; ROZEBOOM, HJ; KALK, KH; DIJKHUIZEN, L; DIJKSTRA, BW				KNEGTEL, RMK; STROKOPYTOV, B; PENNINGA, D; FABER, OG; ROZEBOOM, HJ; KALK, KH; DIJKHUIZEN, L; DIJKSTRA, BW			CRYSTALLOGRAPHIC STUDIES OF THE INTERACTION OF CYCLODEXTRIN GLYCOSYLTRANSFERASE FROM BACILLUS-CIRCULANS STRAIN-251 WITH NATURAL SUBSTRATES AND PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CYCLOMALTODEXTRIN GLUCANOTRANSFERASE; MACROMOLECULAR STRUCTURES; SEQUENCE HOMOLOGY; BETA-CYCLODEXTRIN; TAKA-AMYLASE; PROTEIN; RESIDUES; BINDING; STEAROTHERMOPHILUS	Asp-229, Glu-257, and Asp-328 constitute the catalytic residues in cyclodextrin glycosyl transferase from Bacillus circulans strain 251. Via site-directed mutagenesis constructed D229N, E257Q, and D328N mutant proteins showed a 4,000-60,000 fold reduction of cyclization activity. A D229N/E257Q double mutant showed a 700,000-fold reduction and was crystallized for use in soaking experiments with alpha-cyclodextrin. Crystal structures were determined of wild type CGTase soaked at elevated pH with alpha cyclodextrin (resolution, 2.1 Angstrom) and maltoheptaose (2.4 Angstrom). In addition, structures at cryogenic temperature were solved of the unliganded enzyme (2.2 Angstrom) and of the D229N/E257Q mutant after soaking with alpha-cyclodextrin (2.6 Angstrom). In the crystals soaked in alpha-cyclodextrin and maltoheptaose, a maltotetraose molecule is observed to bind in the active site. Residue 229 is at hydrogen bonding distance from the C-6 hydroxyl group of the sugar, which after cleavage will contain the new reducing end. In the D229N/E257Q double mutant structure, two alpha-cyclodextrins are observed to replace two maltoses at the E-domain, thus providing structural information on product inhibition via binding to the enzyme's ram starch binding domain.	UNIV GRONINGEN,BIOSON RES INST,9747 AG GRONINGEN,NETHERLANDS; UNIV GRONINGEN,GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST,BIOPHYS CHEM LAB,9747 AG GRONINGEN,NETHERLANDS; UNIV GRONINGEN,GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS	University of Groningen; University of Groningen; University of Groningen			Dijkstra, Bauke W./H-4308-2019; Dijkhuizen, Lubbert/E-9454-2014; Dijkhuizen, Lubbert/K-3539-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Dijkhuizen, Lubbert/0000-0003-2312-7162; Rozeboom, Henriette/0000-0002-1656-6477				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BRON S, 1990, MODERN MICROBIOLOGIC, P146; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FRENCH D, 1957, ADV CARBOHYD CHEM, V12, P189; FUJIWARA S, 1992, J BACTERIOL, V174, P7478, DOI 10.1128/jb.174.22.7478-7481.1992; HADFIELD AT, 1994, J MOL BIOL, V243, P856, DOI 10.1006/jmbi.1994.1688; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KLEIN C, 1992, BIOCHEMISTRY-US, V31, P8740, DOI 10.1021/bi00152a009; KLEYWEGT GJ, 1994, JOINT CCP 4 ESF EACB, V30, P20; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON CL, 1994, J MOL BIOL, V236, P590, DOI 10.1006/jmbi.1994.1168; LAWSON CL, 1990, J MOL BIOL, V214, P807, DOI 10.1016/0022-2836(90)90335-J; MAKELA MJ, 1988, J BIOCHEM BIOPH METH, V15, P307, DOI 10.1016/0165-022X(88)90084-X; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MIKAMI B, 1993, BIOCHEMISTRY-US, V32, P6836, DOI 10.1021/bi00078a006; NAGASHIMA T, 1992, BIOSCI BIOTECH BIOCH, V56, P207, DOI 10.1271/bbb.56.207; NAKAMURA A, 1992, FEBS LETT, V296, P37, DOI 10.1016/0014-5793(92)80398-Z; PENNINGA D, 1995, BIOCHEMISTRY-US, V34, P3368, DOI 10.1021/bi00010a028; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sambrook J, 1989, MOL CLONING LABORATO; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SMITH H, 1988, GENE, V70, P351, DOI 10.1016/0378-1119(88)90207-7; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; SUNDBERG L, 1974, J CHROMATOGR, V90, P2234; SVENSSON B, 1989, BIOCHEM J, V264, P309, DOI 10.1042/bj2640309; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Vikmon M., 1982, 1ST P INT S CYCL BUD, P69; VILLETTE JR, 1992, BIOTECHNOL APPL BIOC, V16, P57	46	136	140	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29256	29264		10.1074/jbc.270.49.29256	http://dx.doi.org/10.1074/jbc.270.49.29256			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493956	hybrid, Green Published			2022-12-25	WOS:A1995TJ22700037
J	SEISER, C; POSCH, M; THOMPSON, N; KUHN, LC				SEISER, C; POSCH, M; THOMPSON, N; KUHN, LC			EFFECT OF TRANSCRIPTION INHIBITORS ON THE IRON-DEPENDENT DEGRADATION OF TRANSFERRIN RECEPTOR MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; FE-S CLUSTER; RESPONSIVE ELEMENT; NUCLEAR-RNA; CYTOSOLIC PROTEIN; C-FOS; FERRITIN; TRANSLATION	Transferrin receptor (TfR) mRNA expression is tightly linked to intracellular iron levels. Upon iron deprivation, the iron regulatory protein (IRP) stabilizes TfR mRNA by binding to stem-loop structures in its 3'-untranslated region, whereas increased iron levels result in inactivation of the mRNA-binding protein and rapid degradation of TfR mRNA. Although IRP and the regulation of its RNA binding activity have been studied intensively, little is known about the mechanism of TfR mRNA degradation. In order to get more information about factors involved in this process we investigated the in vivo IRP-RNA interaction and the effect of transcription inhibitors on the iron-dependent decay of TfR mRNA. Here we demonstrate that part of the active IRP co-localizes with TfR mRNA to the rough endoplasmic reticulum. High intracellular iron levels led to a drastic reduction of this active RNA-bound IRP in vivo, indicating that IRP dissociates prior to TfR mRNA decay. Furthermore, the transcription inhibitor actinomycin D and translation inhibitor cycloheximide suppressed TfR mRNA degradation but did not interfere with the IRP dissociation step. Other inhibitors of RNA polymerase II had no effect on iron-dependent degradation of TfR mRNA. However, high concentrations of alpha-amanitin known to block transcription by RNA polymerase III interfered with mRNA decay suggesting the involvement of polymerase III transcripts in the degradation pathway.	SWISS INST EXPTL CANC RES,GENET UNIT 155,CH-1066 EPALINGES,SWITZERLAND; UNIV VIENNA,VIENNA BIOCTR,INST MOLEC BIOL,A-1030 VIENNA,AUSTRIA	Swiss Institute Experimental Cancer Research; University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)				Seiser, Christian/0000-0002-7046-9352				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHAMBON P, 1975, ANNU REV BIOCHEM, V44, P613, DOI 10.1146/annurev.bi.44.070175.003145; CLEMENS MJ, 1987, CELL, V49, P157, DOI 10.1016/0092-8674(87)90553-8; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; ERNEST MJ, 1982, BIOCHEMISTRY-US, V21, P6761, DOI 10.1021/bi00269a022; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1993, BRIT J CANCER, V67, P99, DOI 10.1038/bjc.1993.16; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; KARWAN R, 1993, FEBS LETT, V319, P1, DOI 10.1016/0014-5793(93)80025-P; KNUTSEN HK, 1992, BIOCHEM BIOPH RES CO, V183, P632, DOI 10.1016/0006-291X(92)90529-T; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MATTAJ IW, 1993, FASEB J, V7, P47, DOI 10.1096/fasebj.7.1.8422974; MOWRY KL, 1987, SCIENCE, V238, P1682, DOI 10.1126/science.2825355; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SCHWARTZ ML, 1992, J BIOL CHEM, V267, P24596; SEISER C, 1993, J BIOL CHEM, V268, P13074; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; SOLDATI D, 1988, MOL CELL BIOL, V8, P1518, DOI 10.1128/MCB.8.4.1518; STEARNE PA, 1985, J IMMUNOL, V134, P3474; STRUB K, 1984, EMBO J, V3, P2801, DOI 10.1002/j.1460-2075.1984.tb02212.x; TANG CK, 1992, J BIOL CHEM, V267, P24466; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9; ZEEVI M, 1981, CELL, V26, P39, DOI 10.1016/0092-8674(81)90031-3; ZEZZA DJ, 1986, J BIOL CHEM, V261, P7455; ZEZZA DJ, 1986, J BIOL CHEM, V261, P7461	57	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29400	29406		10.1074/jbc.270.49.29400	http://dx.doi.org/10.1074/jbc.270.49.29400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493976	hybrid			2022-12-25	WOS:A1995TJ22700057
J	CARTER, MS; DOSKOW, J; MORRIS, P; LI, SL; NHIM, RP; SANDSTEDT, S; WILKINSON, MF				CARTER, MS; DOSKOW, J; MORRIS, P; LI, SL; NHIM, RP; SANDSTEDT, S; WILKINSON, MF			A REGULATORY MECHANISM THAT DETECTS PREMATURE NONSENSE CODONS IN T-CELL RECEPTOR TRANSCRIPTS IN-VIVO IS REVERSED BY PROTEIN-SYNTHESIS INHIBITORS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA MESSENGER-RNA; VARIABLE-REGION GENES; CHAIN GENES; TRANSLATION; MUTATIONS; EXPRESSION; STABILITY; ACCUMULATION; DIVERSITY; INDUCTION	Gene rearrangement during the ontogeny of T- and B-cells generates an enormous repertoire of T-cell receptor (TCR) and immunoglobulin (Ig) genes, Because of the error-prone nature of this rearrangement process, two thirds of rearranged TCR and Ig genes are expected to be out-of-frame and thus contain premature terminations codons (ptcs), We performed sequence analysis of reverse transcriptase-polymerase chain reaction products from fetal and adult thymus and found that newly transcribed TCR-beta pre-mRNAs (intron-bearing) are frequently derived from ptc-bearing genes but such transcripts rarely accumulate as mature (fully spliced) TCR-beta transcripts. Transfection studies in the SL12.4 T-cell line showed that the presence of a ptc in any of several TCR-beta exons triggered a decrease in mRNA levels, Ptc-bearing TCR-beta transcripts were selectively depressed in levels in a cell clone that contained both an in-frame and an out-of-frame gene, thus demonstrating the allelic specificity of this down-regulatory response, Protein synthesis inhibitors with different mechanism of action (anisomysin, cycloheximide, emetine, pactamycin, puromycin, and polio virus) all reversed the down-regulatory response, Ptc-bearing transcripts were induced within 0.5 h after cycloheximide treatment, The reversal by protein synthesis inhibitors was not restricted to lymphoid cells, as shown with TCR-beta and beta-globin constructs transfected in HeLa cells, Collectively, the data suggest that the ptc-mediated mRNA decay pathway requires an unstable protein, a ribosome, or a ribosome-like entity, Protein synthesis inhibitors may be useful tools toward elucidating the molecular mechanism of ptc-mediated mRNA decay, an enigmatic response that can occur in the nuclear fraction of mammalian cells.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030; OREGON HLTH SCI UNIV,MOLEC MICROBIOL & IMMUNOL GRAD PROGRAM,PORTLAND,OR 97201	University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University			Li, Shulin/D-6478-2011; Sandstedt, Sara A/A-3001-2010		NIGMS NIH HHS [GM39586] Funding Source: Medline; PHS HHS [T32 ML07781] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039586, R29GM039586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER GF, 1994, MOL CELL BIOL, V14, P1986, DOI 10.1128/MCB.14.3.1986; BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; BEHLKE MA, 1985, SCIENCE, V229, P566, DOI 10.1126/science.3875151; BELGRADER P, 1994, MOL CELL BIOL, V14, P6326, DOI 10.1128/MCB.14.9.6326; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; CHENG J, 1994, MOL CELL BIOL, V14, P6317, DOI 10.1128/MCB.14.9.6317; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; CHORNEY MJ, 1990, MOL CELL BIOL, V10, P243, DOI 10.1128/MCB.10.1.243; CHOU HS, 1987, P NATL ACAD SCI USA, V84, P1992, DOI 10.1073/pnas.84.7.1992; CONNOR A, 1994, J BIOL CHEM, V269, P25178; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FIELDS BN, 1991, FUNDAMENTAL VIROLOGY, P409; GASCOIGNE NRJ, 1990, J BIOL CHEM, V265, P9296; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; JACK HM, 1989, EUR J IMMUNOL, V19, P843, DOI 10.1002/eji.1830190510; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUGLER W, 1995, NUCLEIC ACIDS RES, V23, P413, DOI 10.1093/nar/23.3.413; LEE NE, 1988, J IMMUNOL, V140, P1665; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MACLEOD CL, 1984, CANCER RES, V44, P1784; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MAQUAT LE, 1995, RNA, V1, P453; MENON KP, 1994, CELL MOL BIOL, V40, P999; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; QIAN L, 1993, J IMMUNOL, V151, P6801; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; SINGER PA, 1986, P NATL ACAD SCI USA, V83, P7018, DOI 10.1073/pnas.83.18.7018; TUAILLON N, 1993, P NATL ACAD SCI USA, V90, P3720, DOI 10.1073/pnas.90.8.3720; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; WILKINSON M, 1990, NUCLEIC ACIDS RES, V19, P679; WILKINSON MF, 1988, EMBO J, V7, P101, DOI 10.1002/j.1460-2075.1988.tb02788.x; WILKINSON MF, 1988, EUR J IMMUNOL, V18, P873, DOI 10.1002/eji.1830180607; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796	53	253	259	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28995	29003		10.1074/jbc.270.48.28995	http://dx.doi.org/10.1074/jbc.270.48.28995			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499432	hybrid			2022-12-25	WOS:A1995TH05600076
J	CHUNG, CY; ZARDI, L; ERICKSON, HP				CHUNG, CY; ZARDI, L; ERICKSON, HP			BINDING OF TENASCIN-C TO SOLUBLE FIBRONECTIN AND MATRIX FIBRILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; HEXABRACHION TENASCIN; CELL-ADHESION; PROTEIN; LOCALIZATION; EXPRESSION; TISSUES; DOMAINS; TUMORS	The small splice variant of tenascin-C (TN) has eight fibronectin type III (FN3) domains. The major large splice variant has three (in chicken) or seven (in human) additional FN3 domains inserted between domains five and six, Chiquet-Ehrismann et al, (Chiquet-Ehrismann, R,, Matsuoka, Y,, Hofer, U,, Spring, J,, Bernasconi, C,, and Chiquet, M, (1991, Cell Regul. 2, 927-938) demonstrated that the small variant bound preferentially to fibronectin in enzyme-linked immunosorbent assay, and only the small variant was incorporated into the matrix by cultures of chicken fibroblasts. Here we have studied human TN, and confirmed that the small variant binds preferentially to purified fibronectin and to fibronectin-containing extracellular matrix. Thus this differential binding appears to be conserved across vertebrate species, Using bacterial expression proteins, we mapped the major binding site to the third FN3 domain of TN, Consistent with this mapping, a monoclonal antibody against an epitope in this domain did not stain TN segments bound to cell culture matrix fibrils, The enhanced binding of the small TN variant suggests the existence of another, weak binding site probably in FN3 domains 6-8, which is only positioned to bind fibronectin in the small splice variant. This binding of domains 6-8 may involve a third molecule present in matrix fibrils, as the enhanced binding of small TN was much more prominent to matrix fibrils than to purified fibronectin.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; IST NAZL RIC CANC,CELL BIOL LAB,I-16132 GENOA,ITALY	Duke University; University of Genoa; IRCCS AOU San Martino IST			Chung, Chang Y/G-7522-2012		NCI NIH HHS [R37 CA47056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKHIL I, 1993, J BIOL CHEM, V268, P2542; AUKHIL I, 1990, MATRIX, V10, P98, DOI 10.1016/S0934-8832(11)80176-9; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUETEHRISMAN.R, 1986, CELL, V47, P131; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHUANG CY, 1994, J CELL BIOL, V126, P539; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FAISSNER A, 1990, J NEUROCHEM, V54, P1004, DOI 10.1111/j.1471-4159.1990.tb02350.x; LIGHTNER VA, 1990, ANN NY ACAD SCI, V580, P260, DOI 10.1111/j.1749-6632.1990.tb17935.x; LIGHTNER VA, 1990, J CELL SCI, V95, P263; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; RIOU JF, 1990, DEV BIOL, V137, P305, DOI 10.1016/0012-1606(90)90256-I; RIOU JF, 1988, DEVELOPMENT, V104, P511; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	18	82	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29012	29017		10.1074/jbc.270.48.29012	http://dx.doi.org/10.1074/jbc.270.48.29012			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499434	hybrid			2022-12-25	WOS:A1995TH05600078
J	HUANG, WB; BATEMAN, E				HUANG, WB; BATEMAN, E			CLONING, EXPRESSION, AND CHARACTERIZATION OF THE TATA-BINDING PROTEIN (TBP) PROMOTER-BINDING FACTOR, A TRANSCRIPTION ACTIVATOR OF THE ACANTHAMOEBA TBP GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; III PROMOTERS; FACTOR-TFIIB; DNA; COMPLEX; CASTELLANII; SEQUENCE; DOMAINS; GCN4; COMPONENTS	TATA-binding protein (TBP) gene promoter binding factor (TPBF) is a transactivator which binds to the TBP promoter element (TPE) sequence of the Acanthamoeba TBP gene promoter and stimulates transcription in vitro. We have isolated a cDNA clone encoding TPBF. TPBF is a polypeptide of 327 amino acids with a calculated molecular mass of 37 kDa. The predicted amino acid sequence of TPBF shows no significant homology to other proteins. TPBF has two potential coiled-coil regions, a basic region, a proline-rich region, a histidine-rich N terminus, and a nuclear targeting sequence. The recombinant protein has an apparent molecular mass of 50 kDa, identical with that of TPBF purified from Acanthamoeba. Recombinant TPBF is able to bind DNA and activate transcription with the same specificity as natural Acanthamoeba TPBF, demonstrating the authenticity of the clone. Mobility shift assays of co-translated TPBF polypeptides and chemical cross-linking demonstrate that TPBF is tetrameric in solution and when bound to DNA. Analyses of TPBF mutants show that Coiled-coil II is essential for DNA binding, but Coiled coil I and the basic region are also involved. TPBF is thus a novel DNA-binding protein with functional similarity to the tumor suppressor protein p53.	UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405	University of Vermont					NEI NIH HHS [EY 08706] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY008706, R01EY008706] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOULIKAS T, 1995, J CELL BIOL, V55, P32; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CRAIG D, 1992, NUCLEIC ACIDS RES, V20, P4987, DOI 10.1093/nar/20.19.4987; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1994, J BIOL CHEM, V269, P18541; LIU F, 1993, NUCLEIC ACIDS RES, V21, P4321, DOI 10.1093/nar/21.18.4321; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARRY DAD, 1994, SCIENCE, V263, P488; PUGH BF, 1992, J BIOL CHEM, V267, P679; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WONG JM, 1992, GENE, V117, P91, DOI 10.1016/0378-1119(92)90494-A; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911	57	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28839	28847		10.1074/jbc.270.48.28839	http://dx.doi.org/10.1074/jbc.270.48.28839			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499409	hybrid			2022-12-25	WOS:A1995TH05600053
J	PFAFFINGER, PJ; DERUBEIS, D				PFAFFINGER, PJ; DERUBEIS, D			SHAKER K+ CHANNEL T1 DOMAIN SELF-TETRAMERIZES TO A STABLE STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL	The potassium channel T1 domain plays an important role in the regulated assembly of subunit proteins. We have examined the assembly properties of the Shaker channel T1 domain to determine if the domain can self-assemble, the number of subunits in a multimer, N-S and the mechanism of assembly, High pressure liquid chromatography (HPLC) size exclusion chromotography (SEC) separates T1 domain proteins into two peaks, By co-assembly assays, these peaks are identified to be a high molecular weight assembled form and a low molecular weight monomeric form, To determine the N, of the assembled protein peak on HPLC SEC, we first crosslinked the T1 domain proteins and then separated them on HPLC. Four evenly spaced bands co-migrate with the assembled protein peak; thus, the T1 domain assembles to form a tetramer, The absence of separate dimeric and trimeric peaks of assembled T1 domain protein suggests that the tetramer is the stable assembled state, most probably a closed ring structure.			PFAFFINGER, PJ (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031583] Funding Source: NIH RePORTER; NICHD NIH HHS [P30 HD31583] Funding Source: Medline; NINDS NIH HHS [R01 NS31583] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTALI B, 1993, J BIOL CHEM, V268, P24283; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0	15	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28595	28600		10.1074/jbc.270.48.28595	http://dx.doi.org/10.1074/jbc.270.48.28595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499375	hybrid			2022-12-25	WOS:A1995TH05600019
J	ANDRESS, DL				ANDRESS, DL			HEPARIN MODULATES THE BINDING OF INSULIN-LIKE GROWTH-FACTOR (IGF) BINDING PROTEIN-5 TO A MEMBRANE-PROTEIN IN OSTEOBLASTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RECEPTOR; BONE; IDENTIFICATION; MITOGENESIS; SURFACE	Osteoblast-like cells secrete insulin-like growth factor (IGF) binding protein-5 (IGFBP-5), which may act to enhance IGF-stimulated osteoblast function. We recently demonstrated that carboxyl-truncated IGFBP-5 (IGFBP-5(1-169)) binds to the osteoblast surface and stimulates mitogenesis by a pathway that is independent of IGF action, The present study was conducted to determine the mechanism of osteoblast binding of IGFBP-5, beginning with the assumption that cell surface glycosaminoglycans may mediate the binding of this heparin binding protein, Intact I-125-IGFBP-5 and I-125-IGFBP-5(1-169) exhibited one-site binding to mouse osteoblast monolayers with dissociation constants of 28 and 6 nM for intact I-125-IGFBP-5 and I-125-IGFBP-5(1-169), respectively. Osteoblast binding of intact I-125-IGFBP-5 was inhibited by low heparin concentrations, while I-125-IGFBP-5(1-169) binding was stimulated by heparin, Treatment of cells with heparinase or chlorate to decrease surface glycosaminoglycan density failed to reduce the binding of either form of IGFBP-5. In contrast, pretreatment of cells with IGFBP-5 caused down-regulation of I-125-IGFBP-5 binding. Cross-linking studies revealed that both intact I-125-IGFBP-5 and I-125-IGFBP-5(1-169) bind to proteins in Triton extracts of osteoblast membranes, which were absent in osteoblast derived matrix, Purification of membrane extracts by IGFBP-5 affinity chromatography revealed, 420-kDa band on reduced SDS-polyacrylamide gels, While the membrane protein internalized both forms of IGFBP-5,heparin treatment inhibited the internalization of intact I-125-IGFBP-5 but stimulated I-125-IGFBP-5(1-169) internalization. These data indicate that IGFBP-5 binds to and is internalized by an osteoblast membrane protein, which does not appear to be a proteoglycan. Glycosaminoglycans, however, modulate the binding and internalization of IGFBP-5 in a way that may preferentially favor the intracellular accumulation of the carboxyl-truncated form.	VET ADM MED CTR, RES SERV, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98493 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	ANDRESS, DL (corresponding author), VET ADM MED CTR, MED SERV, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.							ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; ARAI T, 1994, ENDOCRINOLOGY, V135, P2358, DOI 10.1210/en.135.6.2358; ARAI T, 1994, J BIOL CHEM, V269, P20388; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BAR RS, 1987, BIOCHEM BIOPH RES CO, V148, P734, DOI 10.1016/0006-291X(87)90937-5; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; FIELDER PJ, 1993, ENDOCRINOLOGY, V133, P415, DOI 10.1210/en.133.1.415; FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; KANZAKI S, 1994, ENDOCRINOLOGY, V134, P383, DOI 10.1210/en.134.1.383; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; LALOU C, 1994, ENDOCRINOLOGY, V135, P2318, DOI 10.1210/en.135.6.2318; LYLES KW, 1993, AM J PHYSIOL, V264, pE938, DOI 10.1152/ajpendo.1993.264.6.E938; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P143; MCCARTHY TL, 1994, J CELL PHYSIOL, V160, P163, DOI 10.1002/jcp.1041600119; MUELLER K, 1994, AM J PHYSIOL, V267, pE1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; OKAZAKI R, 1994, ENDOCRINOLOGY, V134, P126, DOI 10.1210/en.134.1.126; PFEILSCHIFTER J, 1990, ENDOCRINOLOGY, V126, P703, DOI 10.1210/endo-126-2-703; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROSENBERG RD, 1977, SEMIN HEMATOL, V14, P427; SCHMID C, 1994, AM J PHYSIOL, V267, pE226, DOI 10.1152/ajpendo.1994.267.2.E226; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	40	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28289	28296						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499327				2022-12-25	WOS:A1995TG21000052
J	LIN, RY; MOSS, SB; RUBIN, CS				LIN, RY; MOSS, SB; RUBIN, CS			CHARACTERIZATION OF S-AKAP84, A NOVEL DEVELOPMENTALLY-REGULATED A-KINASE ANCHOR PROTEIN OF MALE GERM-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; CAENORHABDITIS-ELEGANS; SPERMATOGENIC CELLS; LEUCINE ZIPPER; II-BETA; SUBUNIT; SPERM; EXPRESSION; CLONING; LOCALIZATION	In mammalian spermatozoa, most of the type II alpha isoform of cAMP-dependent protein kinase (PKAII alpha) is anchored at the cytoplasmic surface of a specialized array of mitochondria in the flagellar cytoskeleton. This places the catalytic subunits of PKAII alpha in proximity with potential target substrates in the cytoskeleton. The mechanism by which PKAII alpha is anchored at the outer surface of germ cell mitochondria has not been elucidated. We now report the cloning of a cDNA that encodes a novel, germ cell A kinase anchor protein (AKAP) designated S-AKAP84. S-AKAP84 comprises 593 amino acids and contains a centrally located domain that avidly binds regulatory subunits (RII alpha and RII beta) of PKAII alpha and PKAII beta. The 3.2-kilobase S-AKAP84 mRNA and the cognate S-AKAP84 RII binding protein are expressed principally in the male germ cell lineage. Expression of S-AKAP84 is tightly regulated during development. The protein accumulates as spermatids undergo nuclear condensation and tail elongation. The timing of S-AKAP84 expression is correlated with the de novo accumulation of RII alpha and RII beta subunits and the migration of mitochondria from the cytoplasm (round spermatids) to the cytoskeleton (midpiece in elongating spermatids). Residues 1-30 at the NH2 terminus of S-AKAP84 constitute a putative signal/anchor sequence that may target the protein to the outer mitochondrial membrane, Immunofluorescence analysis demonstrated that S-AKAP84 is co-localized with mitochondria in the flagellum.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	LIN, RY (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,ATRAN LABS,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NIGMS NIH HHS [GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; Clermont Y., 1993, FRONT ENDOCRINOL, P332; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Hecht N. B., 1993, CELL MOL BIOL TESTIS, P400; HIRSCH AH, 1993, J BIOL CHEM, V267, P2131; HOROWITZ JA, 1984, J BIOL CHEM, V259, P832; HOROWITZ JA, 1988, J BIOL CHEM, V263, P2098; HU ED, 1990, J BIOL CHEM, V265, P5072; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAND M, 1994, J BIOL CHEM, V269, P9234; LANDMARK BF, 1993, J REPROD FERTIL, V99, P323, DOI 10.1530/jrf.0.0990323; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LI Y, 1993, EXP CELL RES, V208, P170; LIEBERMAN SJ, 1988, J CELL BIOL, V107, P1809, DOI 10.1083/jcb.107.5.1809; LONNERBERG P, 1992, BIOL REPROD, V46, P1057, DOI 10.1095/biolreprod46.6.1057; LU XY, 1990, J BIOL CHEM, V265, P3293; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SUL HS, 1984, J BIOL CHEM, V259, P1201; TASH JS, 1982, BIOL REPROD, V26, P745, DOI 10.1095/biolreprod26.4.745; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	37	160	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27804	27811		10.1074/jbc.270.46.27804	http://dx.doi.org/10.1074/jbc.270.46.27804			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499250	hybrid			2022-12-25	WOS:A1995TE73600061
J	APPEL, K; WAGNER, P; BOLDYREFF, B; ISSINGER, OG; MONTENARH, M				APPEL, K; WAGNER, P; BOLDYREFF, B; ISSINGER, OG; MONTENARH, M			MAPPING OF THE INTERACTION SITES OF THE GROWTH SUPPRESSOR PROTEIN P53 WITH THE REGULATORY BETA-SUBUNIT OF PROTEIN-KINASE CK2	ONCOGENE			English	Article						P53; GROWTH SUPPRESSOR PROTEIN; PROTEIN KINASE; PHOSPHORYLATION	WILD-TYPE P53; DNA-BINDING FUNCTION; CELL-CYCLE CONTROL; CASEIN KINASE-2; T-ANTIGEN; TRANSFORMED-CELLS; TUMOR-ANTIGEN; PHOSPHORYLATION; DOMAIN; OLIGOMERIZATION	p53 plays an essential role in cellular growth control. Some of its distinct biological functions are regulated by interaction with cellular proteins. We have previously (Wagner et al., 1994) shown that p53 binds to the regulatory subunit of protein kinase CK2. Using C-terminal protein fragments of p53 we now demonstrate that the region between amino acids 287 and 340 on the polypeptide chain of p53 is critical for binding of p53 to the beta-subunit of CK2. Neither phosphorylation at the p34(cdc2) site (aa315) nor at the CK2 site (aa392) is necessary for binding of p53 to the beta-subunit of CK2. Using deletion mutants of the beta-subunit of CK2 we also show that an internal region between amino acids 72 and 149 of the beta-subunit of CK2 is necessary for binding to p53. Thus, this study defines new functional regions on the polypeptide chains of p53 and of protein kinase CK2.	UNIV SAARLAND,D-66421 HOMBURG,GERMANY	Saarland University			Montenarh, Mathias/AAB-6689-2020					ADDISON C, 1990, ONCOGENE, V5, P423; APPEL K, 1994, INT J ONCOL, V5, P667; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOLDYREFF B, 1994, CELL MOL BIOL RES, V40, P391; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; CHEN J, 1993, MOL CELL BIOL, V13, P4104; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1994, ONCOGENE, V9, P3249; GOTZ C, 1995, INT J ONCOL, V6, P1129; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; IWABUCHI K, 1993, ONCOGENE, V8, P1693; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1994, GASTROENTEROLOGY, V106, P1708, DOI 10.1016/0016-5085(94)90431-6; KRAISS S, 1990, ONCOGENE, V5, P845; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LORENZ A, 1992, INT J ONCOL, V1, P571; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; OROURKE RW, 1990, ONCOGENE, V5, P1829; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REIHSAUS E, 1990, ONCOGENE, V5, P137; REIHSAUS E, 1992, EXP CELL RES, V199, P10, DOI 10.1016/0014-4827(92)90456-I; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; SOUSSI T, 1990, ONCOGENE, V5, P945; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WAGNER P, 1994, INT J ONCOL, V4, P987; WAGNER P, 1994, INT J ONCOL, V4, P491; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	67	71	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1971	1978						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478515				2022-12-25	WOS:A1995TF29700006
J	KWON, TK; BUCHHOLZ, MA; GABRIELSON, EW; NORDIN, AA				KWON, TK; BUCHHOLZ, MA; GABRIELSON, EW; NORDIN, AA			A NOVEL CYTOPLASMIC SUBSTRATE FOR CDK4 AND CDK6 IN NORMAL AND MALIGNANT EPITHELIAL DERIVED CELLS	ONCOGENE			English	Article						CYCLIN-DEPENDENT KINASE; G1 CYCLINS; CELL CYCLE; BREAST CELL CARCINOMA; LUNG CELL CARCINOMA	RETINOBLASTOMA SUSCEPTIBILITY GENE; BREAST-CANCER; PROTEIN; EXPRESSION; CYCLINS; IDENTIFICATION; AMPLIFICATION	Cyclins and cyclin-dependent kinases (cdk) have been identified as important regulators of cell replication. Molecular alteration in the cdk pathways appear to be important in cancer with some cyclins (eg cyclin D and E) proposed to be oncogenes and some inhibitors of cdk (eg p16) proposed to be tumor suppressor genes, In human breast carcinoma cell line MDA361 both cyclin D and E are overexpressed and cdk 4 and 6 are the predominate kinases which phosphorylate retinoblastoma protein and to a greater extent a novel 88 kDa protein. This 88 kDa protein was detected as a significant substrate in five of seven breast carcinoma cell lines, three lung carcinoma cell lines as well as in primary breast and lung epithelium. Normal human and murine T lymphocytes and established lymphoid cell lines are devoid of this protein and minimal amounts were detected in normal human fibroblast. In contrast to retinoblastoma protein, the 88 kDa protein appears to be more prevalent in the cytosolic than the nuclear subfraction. The phosphorylation of this 88 kDa protein by the G(1) associated cdks suggest that this protein may represent another targeted substrate regulating the G(1) phase of the cell cycle.	NIA,GERONTOL RES CTR,CLIN IMMUNOL SECT,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University					NCI NIH HHS [P20 CA-ES 66204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA066204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HANNA Z, 1993, ONCOGENE, V8, P1661; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAMB A, 1994, SCIENCE, V246, P436; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIM YH, 1992, J IMMUNOL, V149, P17; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAN S, 1981, J SURG ONCOL, V18, P317, DOI 10.1002/jso.2930180313; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NOBORI T, 1994, SCIENCE, V264, P753; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PETERS G, 1994, J CELL SCI S, V18, P89; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERR CJ, 1993, CELL, V73, P1053	33	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2077	2083						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478527				2022-12-25	WOS:A1995TF29700018
J	CLARKE, AR; CUMMINGS, MC; HARRISON, DJ				CLARKE, AR; CUMMINGS, MC; HARRISON, DJ			INTERACTION BETWEEN MURINE GERMLINE MUTATIONS IN P53 AND APC PREDISPOSES TO PANCREATIC NEOPLASIA BUT NOT TO INCREASED INTESTINAL MALIGNANCY	ONCOGENE			English	Article						P53; APC; MIN; PANCREATIC CANCER; COLORECTAL CANCER	WILD-TYPE P53; P53-DEFICIENT MICE; CANCER; APOPTOSIS; TUMORS; MOUSE; GENE	Murine strains which bear constitutive inactivating mutations of either the APC or the p53 tumor suppressor genes are characterised by spontaneous tumors. APC mutated (Min) mice develop large and small bowel adenomas, a small proportion of which, in time, become malignant, p53 deficient mice develop predominantly lymphoma and sarcoma. By interbreeding these strains we have shown that there is cooperativity between these mutations, leading to a shift in phenotype. Most notably, this was characterised by a range of abnormalities of the exocrine pancreas in 83% of animals heterozygous for the APC mutation and constitutively null for functional p53, Dysplasia and preneoplastic foci were seen in 61% of these animals and pancreatic acinar cell adenocarcinoma in 22%. Analysis of these tumors showed them to have lost the remaining wild-type copy of APC. Similar loss of APC was not associated with the development of other extraintestinal tumors, Surprisingly, given the proposed role for loss of function mutations of the p53 gene in the development of human colorectal cancer, we have found no evidence for either an increase in the rate of adenoma formation in APC +/-, p53 -/- animals, or an increased rate of progression to malignancy compared with APC +/- p53 +/+ mice. These findings highlight striking tissue-specific differences in the tumor suppressor effects of p53.			CLARKE, AR (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014; Cummings, Margaret/B-5747-2011	Cummings, Margaret/0000-0002-7657-0240; Clarke, Alan/0000-0002-4281-426X				ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HAYES PC, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P441; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kaufman M.H., 1992, ATLAS MOUSE DEV; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KLOPPEL G, 1984, PANCREATIC PATHOLOGY, pCH7; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LONGNECKER DS, 1992, YALE J BIOL MED, V65, P457; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUONGO C, 1994, CANCER RES, V54, P5947; MALCOMSON RDG, IN PRESS BRIT J CANC; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; POWELL SM, 1992, NATURE, V59, P235; PURDIE CA, 1994, ONCOGENE, V9, P603; REDSTON MS, 1994, CANCER RES, V54, P3025; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YASHIMA K, 1994, INT J CANCER, V59, P43, DOI 10.1002/ijc.2910590110	36	87	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1913	1920						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478622				2022-12-25	WOS:A1995TD09400029
J	GLOVER, HR; BAKER, DA; CELETTI, A; DIBB, NJ				GLOVER, HR; BAKER, DA; CELETTI, A; DIBB, NJ			SELECTION OF ACTIVATING MUTATIONS OF C-FMS IN FDC-P1 CELLS	ONCOGENE			English	Article						C-FMS; C-KIT; FDC-P1; TYROSINE KINASE; ACTIVATING MUTATION	COLONY-STIMULATING FACTOR; DEPENDENT PROTEIN-KINASE; FACTOR-I CSF-1; OP OP MOUSE; V-FMS; ONCOGENE PRODUCT; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; SURFACE EXPRESSION; CATALYTIC SUBUNIT	FDC-P1 haemopoietic cells were used to select mutations of c-fms that constitutively activate the receptor for macrophage-colony stimulating factor (M-CSF or CSF-1), One mutation changed Ser 929 to Gly within a Ser/Gly rich region of the C-terminal tail and a second changed a nearby, highly conserved Leu 926 for Pro. A third mutation (D802V) changed Asp 802 to Val within the alpha L12/beta 9 region of the tyrosine kinase domain, so supporting the crystallographic evidence that this region triggers kinase activation, A c-kit mutation exactly equivalent to D802V was previously identified in a leukamic cell line and was demonstrated here to be transforming. Surprisingly, although D802V potently transformed FDC-P1 cells, it could not induce Rat-2 fibroblast foci, even in the presence of M-CSF. It is suggested that the accelerated receptor degradation induced by D802V may account for its cell specific effect.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London; Imperial College London			Celetti, Angela/AAY-7172-2020					BAKER DA, 1994, LEUKEMIA, V8, P141; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARUANA G, 1993, EXP HEMATOL, V21, P761; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HAPEL AJ, 1984, BLOOD, V64, P786; HUNTER T, 1992, COLD SPRING HARB SYM, V57, P25, DOI 10.1101/SQB.1992.057.01.005; KARN J, 1989, ONCOGENE, V4, P773; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MCDONOUGH SK, 1971, CANCER RES, V31, P953; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; POLLARD JW, 1991, DEV BIOL, V48, P273; QUI F, 1988, EMBO J, V7, P1003; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; WETTERS TV, 1992, EMBO J, V11, P551, DOI 10.1002/j.1460-2075.1992.tb05086.x; WIKTORJEDRZEJCZ.W, 1982, J EXP MED, V156, P1516; WIKTORJEDRZEJCZ.W, 1990, P NATL ACAD SCI USA, V87, P4828; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	52	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1347	1356						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478556				2022-12-25	WOS:A1995RY96700016
J	HERMEKING, H; FUNK, JO; REICHERT, M; ELLWART, JW; EICK, D				HERMEKING, H; FUNK, JO; REICHERT, M; ELLWART, JW; EICK, D			ABROGATION OF P53-INDUCED CELL-CYCLE ARREST BY C-MYC - EVIDENCE FOR AN INHIBITOR OF P21(WAF1/CIP1/SDI1)	ONCOGENE			English	Article						C-MYC; P53; P21; CDK2; CYCLINS; CELL CYCLE	PROTEIN; APOPTOSIS; TRANSCRIPTION; KINASES; GENE; P53	The tumour-suppressor p53 inhibits cell cycle progression by direct transactivation of the p21(WAF1/CIP1/SD11) gene, which encodes a universal inhibitor of cyclin dependent kinases (cdk). The proto-oncogene product c-Myc induces cell cycle progression and, in the absence of survival factors, apoptosis. However, a direct link between the cell cycle machinery and c-Myc has not yet been established, We show that c-Myc abrogates a p53-induced G1-arrest without elevating the expression of cdks or cyclins involved in the G1/S-transition, Instead, the results suggest that c-Myc interferes with the inhibitory action of p21 on cdk/cyclin-complexes by inducing a heat-labile inhibitor of p21, The inactivation of p21 and related cdk-inhibitors may explain several of the oncogenic actions of c-Myc, including the induction of proliferation, immortalisation and the inhibition of differentiation. Modulation of cdk activity by the induction of an inhibitor of cdk-inhibitors represents a novel mechanism of cell cycle regulation in mammalian cells.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH,INST EXPTL HAMATOL,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	HERMEKING, H (corresponding author), GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY.							ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELDEIRY WS, 1993, CELL, V75, P8817; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HHERMEKING H, 1994, SCIENCE, V265, P2091; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KIESER A, 1994, ONCOGENE, V9, P963; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, IN PRESS NATURE; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SAMBROCK J, 1989, MOL CLONING LABORATO; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WOLF DA, 1995, ONCOGENE, V10, P2067; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	39	95	96	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1409	1415						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478565				2022-12-25	WOS:A1995RY96700025
J	HUANG, L; YONEDA, M; KIMATA, K				HUANG, L; YONEDA, M; KIMATA, K			A SERUM-DERIVED HYALURONAN-ASSOCIATED PROTEIN (SHAP) IS THE HEAVY-CHAIN OF THE INTER-ALPHA-TRYPSIN INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; SEQUENCE; CD44; PROTEOGLYCAN; FAMILY; RECEPTOR; DOMAINS; PLASMA; ACID; MOLECULE	We showed previously that hyaluronan (HA) synthesized by cultured fibroblasts firmly bound 85-kDa proteins. The proteins were derived from serum used for the culture and appeared to be covalently linked to HA (Yoneda, M., Suzuki, S., and Kimata, K. (1990) J. Biol. Chem. 265, 5247-5257). In these regards, we named this molecule SHAP (serum-derived HA associated proteins). Incubation of serum with exogenous HA under physiological conditions enabled us to prepare SHAP.HA complex without cell cultivation. The complex thus obtained from bovine or human serum was served for the characterization of SHAP. Digestion with HA-lyase and subsequent separation on SDS-polyacrylamide gel electrophoresis yielded two components, X and Y. Because of the block of their NH2 termini, peptides were obtained by the digestion of X and Y with V8 protease, separated on SDS-polyacrylamide gel electrophoresis and then subjected to the anaylsis. Peptides from X and Y showed a high degree of sequence similarity to the two heavy chains, HC2 and HC1, of human inter-alpha-trypsin inhibitor (ITI), respectively (over 80% with bovine SHAP and essentially 100% with human SHAP). Cross-reactivity with antibodies against ITI supported the findings. Direct digestion of the complex with V8 protease and the subsequent purification of the HA-resistant fragment complex were performed to identify the HA-binding domains. NH2-terminal sequences of the fragments suggested the participation of the COOH-terminal half of ITI with an amphipathic alpha helix structure in the HA binding.			HUANG, L (corresponding author), AICHI MED UNIV, INST MOLEC SCI MED, YAZAKO, NAGAKUTE, AICHI 48011, JAPAN.							ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; BORK P, 1991, BIOCHEM J, V279, P908, DOI 10.1042/bj2790908; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1992, J BIOL CHEM, V267, P12380; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIARRAMEHRPOUR M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P114, DOI 10.1016/0167-4781(92)90065-8; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; GEBHARD W, 1988, BIOL CHEM H-S, V369, P19; GEBHARD W, 1988, FEBS LETT, V229, P63, DOI 10.1016/0014-5793(88)80798-1; GEBHARD W, 1986, PROTEINASE INHIBITOR, P375; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; KIMATA K, 1974, J BIOL CHEM, V249, P1646; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; ODUM L, 1990, INT J BIOCHEM, V22, P925, DOI 10.1016/0020-711X(90)90197-B; ODUM L, 1992, INT J BIOCHEM, V24, P215, DOI 10.1016/0020-711X(92)90249-Z; PRATT CW, 1986, ARCH BIOCHEM BIOPHYS, V248, P587, DOI 10.1016/0003-9861(86)90512-6; PRATT CW, 1987, ARCH BIOCHEM BIOPHYS, V258, P591, DOI 10.1016/0003-9861(87)90381-X; REISINGER P, 1985, BIOL CHEM H-S, V366, P479, DOI 10.1515/bchm3.1985.366.1.479; ROUET P, 1992, BIOL CHEM H-S, V373, P1019, DOI 10.1515/bchm3.1992.373.2.1019; SALIER JP, 1980, ANAL BIOCHEM, V109, P273, DOI 10.1016/0003-2697(80)90649-1; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALIER JP, 1987, P NATL ACAD SCI USA, V84, P8272, DOI 10.1073/pnas.84.23.8272; Sandson J, 1965, Trans Assoc Am Physicians, V78, P304; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHINOMURA T, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P35; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; UNDERHILL C, 1992, J CELL SCI, V103, P293; WANG HS, 1992, CONNECT TISSUE RES, V28, P29, DOI 10.3109/03008209209014226; WEIGEL PH, 1989, CIBA F SYMP, V143, P248; WEST DC, 1989, CIBA F SYMP, V143, P187; YONEDA M, 1990, J BIOL CHEM, V265, P5247; YONEDA M, 1991, CONNECT TISSUE, V22, P31; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	48	148	165	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26725	26730						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7504674				2022-12-25	WOS:A1993MK42500104
J	VINITSKY, A; GRUBMEYER, C				VINITSKY, A; GRUBMEYER, C			A NEW PARADIGM FOR BIOCHEMICAL ENERGY COUPLING - SALMONELLA-TYPHIMURIUM NICOTINATE PHOSPHORIBOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PNCB GENE; INTERMEDIATE; SYNTHETASE; MECHANISM; SEQUENCE; ATP	The pncB gene of Salmonella typhimurium was used to develop an overexpression system for nicotinate phosphoribosyltransferase (NAPRTase, EC 2.4.2.11), which forms nicotinate mononucleotide (NAMN) and PP(i) from nicotinate and alpha-D-5-phosphoribosyl-1-pyrophosphate (PRPP). NAPRTase hydrolyzes ATP in 1:1 molar stoichiometry to NAMN synthesis. Hydrolysis of ATP alters the ratio of products/substrates for the reaction nicotinate + PRPP half arrow right over half arrow left NAMN + PP(i) from its equilibrium value of 0.67 to a steady-state value of 1100. The energy for the maintenance of this ratio must come from ATP hydrolysis. However, in contrast to other ATP-utilizing enzymes, when all ATP is hydrolyzed the unfavorable product/substrate ratio collapses. ATP/ADP exchange results suggest that the overall reaction involves a phosphoenzyme (E-P) arising from E. ATP. K(m) values for nicotinate and PRPP each decreased by 200-fold when ATP was present to phosphorylate the enzyme. PP(i) stimulated the ATPase activity of the enzyme to V(max) values, suggesting that PP(i) formation during catalysis provides a trigger for cleavage of the putative E-P in the overall reaction and regenerates the low affinity form of the enzyme. A model is presented in which alternation of high and low affinity forms of NAPRTase provides a ''steady-state'' coupling between ATP hydrolysis and NAMN formation.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,3400 N BROAD ST,PHILADELPHIA,PA 19140; NYU,DEPT BIOL,NEW YORK,NY 10003	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; New York University								AMES GFL, 1990, BACTERIA, V12, P225; ARMON T, 1990, J BIOL CHEM, V265, P20723; BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; CULLIS PM, 1992, BIOCHEMISTRY-US, V31, P9642, DOI 10.1021/bi00155a017; Davis R., 1980, ADV BACTERIAL GENETI; FERRO AM, 1987, PYRIDINE NUCLEOTID B, V2, P25; HANNA LS, 1983, J BIOL CHEM, V258, P9745; HONJO T, 1966, BIOCHEM BIOPH RES CO, V25, P199, DOI 10.1016/0006-291X(66)90580-8; IMSANDE J, 1961, J BIOL CHEM, V236, P525; IMSANDE J, 1964, BIOCHIM BIOPHYS ACTA, V85, P255, DOI 10.1016/0926-6569(64)90246-9; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; KASAROV LB, 1973, BIOCHIM BIOPHYS ACTA, V320, P372, DOI 10.1016/0304-4165(73)90318-8; KOSAKA A, 1977, ARCH BIOCHEM BIOPHYS, V179, P334, DOI 10.1016/0003-9861(77)90119-9; KOSAKA A, 1971, J BIOL CHEM, V246, P3277; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MIDELFORT CF, 1976, J BIOL CHEM, V251, P5881; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; NIEDEL J, 1973, J BIOL CHEM, V248, P3500; OGASAWAR.N, 1966, BIOCHIM BIOPHYS ACTA, V118, P422, DOI 10.1016/S0926-6593(66)80052-8; PACKMAN PM, 1967, J BIOL CHEM, V242, P2075; PREISS J, 1958, J BIOL CHEM, V233, P492; PURICH DL, 1983, CONT ENZYME KINETICS, P403; SMITH LD, 1969, J BIOL CHEM, V244, P68; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STITT BL, 1988, J BIOL CHEM, V263, P11130; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; TREVORROW K, 1984, J BIOENERG BIOMEMBR, V16, P5359; VINITSKY A, 1991, J BACTERIOL, V173, P536, DOI 10.1128/jb.173.2.536-540.1991; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WUBBOLTS MG, 1990, J BIOL CHEM, V265, P17665	33	41	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					26004	26010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503993				2022-12-25	WOS:A1993MK10000101
J	BENNETT, JS; SHATTIL, SJ; POWER, JW; GARTNER, TK				BENNETT, JS; SHATTIL, SJ; POWER, JW; GARTNER, TK			INTERACTION OF FIBRINOGEN WITH ITS PLATELET RECEPTOR - DIFFERENTIAL-EFFECTS OF ALPHA-CHAIN AND GAMMA-CHAIN FIBRINOGEN PEPTIDES ON THE GLYCOPROTEIN-IIB-IIIA COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; MEMPHIS STATE UNIV,DEPT CHEM,MEMPHIS,TN 38152; MEMPHIS STATE UNIV,DEPT BIOL,MEMPHIS,TN 38152	University of Pennsylvania; University of Memphis; University of Memphis					NHLBI NIH HHS [HL26523, HL35586, HL23809] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL035586, R44HL123809, R01HL026523, R01HL023809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; FRELINGER AL, 1987, CLIN RES, V35, pA598; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; HAVERSTICK DM, 1985, BLOOD, V66, P946; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IZZO JL, 1964, J BIOL CHEM, V236, P3743; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; LAM SCT, 1987, J BIOL CHEM, V262, P947; NIIYA K, 1987, BLOOD, V70, P475; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PEERSCHKE EIB, 1987, BLOOD, V69, P950; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PYTELA R, 1986, SCIENCE, V231, P1159; RUGGERI ZM, 1982, P NATL ACAD SCI-BIOL, V79, P6038, DOI 10.1073/pnas.79.19.6038; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; Segel I. H, 1975, ENZYME KINETICS, P465; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; TOM JP, 1986, J AM CHEM SOC, V108, P5242; WILLIAMS S, 1987, THROMB RES, V46, P457, DOI 10.1016/0049-3848(87)90133-2; WOODS VL, 1986, J BIOL CHEM, V261, P5242; 1986, PEPTIDE SYNTHESIZER, V16	31	150	150	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12948	12953						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417645				2022-12-25	WOS:A1988Q091700030
J	MANICOURT, DH; PITA, JC; MCDEVITT, CA; HOWELL, DS				MANICOURT, DH; PITA, JC; MCDEVITT, CA; HOWELL, DS			SUPERFICIAL AND DEEPER LAYERS OF DOG NORMAL ARTICULAR-CARTILAGE - ROLE OF HYALURONATE AND LINK PROTEIN IN DETERMINING THE SEDIMENTATION COEFFICIENTS DISTRIBUTION OF THE NONDISSOCIATIVELY EXTRACTED PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									VET ADM MED CTR,MIAMI,FL 33125; CLEVELAND CLIN EDUC FDN,RES INST,DEPT MUSCULOSKELETAL RES,CLEVELAND,OH 44106	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cleveland Clinic Foundation	MANICOURT, DH (corresponding author), UNIV MIAMI,SCH MED,DEPT MED,DIV ARTHRITIS,POB 016960,R113,MIAMI,FL 33101, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM008662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038733] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM08662] Funding Source: Medline; NIAMS NIH HHS [AR38733] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aydelotte MB, 1986, ARTICULAR CARTILAGE, P235; BAYLISS MT, 1983, BIOCHEM J, V209, P387, DOI 10.1042/bj2090387; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BJELLE A, 1975, CONNECT TISSUE RES, V3, P141, DOI 10.3109/03008207509152172; BUCKWALTER JA, 1984, J BIOL CHEM, V259, P5361; CATERSON B, 1978, BIOCHIM BIOPHYS ACTA, V540, P412, DOI 10.1016/0304-4165(78)90171-X; CHRISTNER JE, 1978, ANAL BIOCHEM, V90, P22, DOI 10.1016/0003-2697(78)90004-0; CLELAND RL, 1979, BIOCHEM BIOPH RES CO, V87, P1140, DOI 10.1016/S0006-291X(79)80026-1; FALTZ LL, 1979, J BIOL CHEM, V254, P1381; FRANZEN A, 1981, BIOCHEM J, V195, P535, DOI 10.1042/bj1950535; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HARDINGHAM TE, 1987, J ORTHOP RES, V5, P36, DOI 10.1002/jor.1100050107; HEINEGARD D, 1972, BIOCHIM BIOPHYS ACTA, V285, P181, DOI 10.1016/0005-2795(72)90190-0; HJERPE A, 1980, J CHROMATOGR, V202, P458; KEMPSON GE, 1976, BIOCHIM BIOPHYS ACTA, V428, P741, DOI 10.1016/0304-4165(76)90205-1; KIMURA JH, 1979, J BIOL CHEM, V254, P2600; KIMURA JM, 1984, T ORTHOP RES SOC, V9, P12; KOSEKI M, 1978, J BIOCH TOKYO, V88, P553; MANICOURT DH, 1986, J BIOL CHEM, V261, P5426; MANICOURT DH, 1988, IN PRESS CONNECT TIS; Maroudas A, 1986, ARTICULAR CARTILAGE, P311; MASON RM, 1981, CONNECTIVE TISSUE RE, P87; Meachim G, 1979, ADULT ARTICULAR CART, P1; MERRIL CR, 1984, ELECTROPHORESIS, V5, P289, DOI 10.1002/elps.1150050509; Muir H., 1980, JOINTS SYNOVIAL FLUI, V2, P27; MULLER FJ, 1983, ANAL BIOCHEM, V135, P106, DOI 10.1016/0003-2697(83)90737-6; NIEDUSZYNSKI IA, 1980, BIOCHEM J, V185, P107, DOI 10.1042/bj1850107; NOLL H, 1967, NATURE, V215, P360, DOI 10.1038/215360a0; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; PITA JC, 1978, ARCH BIOCHEM BIOPHYS, V186, P66, DOI 10.1016/0003-9861(78)90464-2; PITA JC, 1985, BIOCHEMISTRY-US, V24, P4250, DOI 10.1021/bi00336a066; PITA JC, 1983, ANAL BIOCHEM, V133, P9, DOI 10.1016/0003-2697(83)90216-6; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; POOLE AR, 1982, J CELL BIOL, V93, P921, DOI 10.1083/jcb.93.3.921; POOLE AR, 1980, J HISTOCHEM CYTOCHEM, V28, P621, DOI 10.1177/28.7.6156200; POOLE CA, 1984, J ANAT, V138, P113; RATCLIFFE A, 1984, J HISTOCHEM CYTOCHEM, V32, P193, DOI 10.1177/32.2.6363519; SCHNEIDERMAN R, 1986, J ORTHOPAED RES, V4, P393, DOI 10.1002/jor.1100040402; STOCKWELL RA, 1983, J ANAT, V136, P425; TANG LH, 1979, J BIOL CHEM, V254, P523; URBAN JPG, 1979, BIORHEOLOGY, V16, P447; WEISS C, 1968, J BONE JOINT SURG AM, VA 50, P663, DOI 10.2106/00004623-196850040-00002	42	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13121	13129						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417653				2022-12-25	WOS:A1988Q091700056
J	PEARSON, WR; REINHART, J; SISK, SC; ANDERSON, KS; ADLER, PN				PEARSON, WR; REINHART, J; SISK, SC; ANDERSON, KS; ADLER, PN			TISSUE-SPECIFIC INDUCTION OF MURINE GLUTATHIONE TRANSFERASE MESSENGER-RNAS BY BUTYLATED HYDROXYANISOLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22908	University of Virginia	PEARSON, WR (corresponding author), UNIV VIRGINIA,DEPT BIOCHEM,BOX 440,JORDAN HALL,CHARLOTTESVILLE,VA 22908, USA.		Pearson, William/K-4908-2019	Pearson, William/0000-0002-0727-3680; Anderson, Karen/0000-0002-3870-5730	NICHD NIH HHS [KHDO-0361] Funding Source: Medline; NIEHS NIH HHS [ES-03607] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003607] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BENSON AM, 1984, CANCER RES, V44, P5256; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOARD PG, 1987, P NATL ACAD SCI USA, V84, P2377, DOI 10.1073/pnas.84.8.2377; CHA YN, 1979, BIOCHEM PHARMACOL, V28, P1917, DOI 10.1016/0006-2952(79)90645-2; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CZOSNEK H, 1984, NUCLEIC ACIDS RES, V12, P4825, DOI 10.1093/nar/12.12.4825; DANIEL V, 1987, DNA-J MOLEC CELL BIO, V6, P317, DOI 10.1089/dna.1987.6.317; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DING GJF, 1986, J BIOL CHEM, V261, P7952; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Ghosh P K, 1980, Methods Enzymol, V65, P580; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUBLER U, 1983, GENE, V25, P253; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HAYES JD, 1987, ARCH TOXICOL S, V10, P136; JAKOBY WB, 1984, BIOCHEM PHARMACOL, V33, P2539, DOI 10.1016/0006-2952(84)90621-X; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KALINYAK JE, 1982, J BIOL CHEM, V257, P523; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; LAI HCJ, 1984, J BIOL CHEM, V259, P5536; LAI HCJ, 1986, NUCLEIC ACIDS RES, V14, P6101, DOI 10.1093/nar/14.15.6101; LEE CY, 1981, J BIOL CHEM, V256, P8110; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; PARCHMENT RE, 1984, BIOCHEM BIOPH RES CO, V119, P1015, DOI 10.1016/0006-291X(84)90875-1; PEARSON WR, 1983, J BIOL CHEM, V258, P2052; PICKETT CB, 1984, J BIOL CHEM, V259, P5182; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; ROTHKOPF GS, 1986, BIOCHEMISTRY-US, V25, P993, DOI 10.1021/bi00353a007; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; TELAKOWSKIHOPKINS CA, 1985, J BIOL CHEM, V260, P5820; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; TU CPD, 1982, NUCLEIC ACIDS RES, V10, P5407, DOI 10.1093/nar/10.18.5407; TU CPD, 1984, J BIOL CHEM, V259, P9434; WARHOLM M, 1986, BIOCHEMISTRY-US, V25, P4119, DOI 10.1021/bi00362a020; Wattenberg L W, 1978, Adv Cancer Res, V26, P197, DOI 10.1016/S0065-230X(08)60088-3; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; 1984, USER B APPLIED BIOSY, V13	50	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13324	13332						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417659				2022-12-25	WOS:A1988Q091700084
J	BATEMAN, JF; LAMANDE, SR; DAHL, HHM; CHAN, D; COLE, WG				BATEMAN, JF; LAMANDE, SR; DAHL, HHM; CHAN, D; COLE, WG			SUBSTITUTION OF ARGININE FOR GLYCINE-664 IN THE COLLAGEN ALPHA-1(I) CHAIN IN LETHAL PERINATAL OSTEOGENESIS IMPERFECTA - DEMONSTRATION OF THE PEPTIDE DEFECT BY INVITRO EXPRESSION OF THE MUTANT CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									ROYAL CHILDRENS HOSP, MURDOCH INST, PARKVILLE, VIC 3052, AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	BATEMAN, JF (corresponding author), UNIV MELBOURNE, ROYAL CHILDRENS HOSP, DEPT PEDIAT, PARKVILLE, VIC 3052, AUSTRALIA.		Chan, Danny/C-4203-2009	Chan, Danny/0000-0003-3824-5778; Bateman, John/0000-0001-8542-0730; Lamande, Shireen/0000-0003-2938-2711				BARSH GS, 1981, P NATL ACAD SCI-BIOL, V78, P5142, DOI 10.1073/pnas.78.8.5142; BARSH GS, 1985, P NATL ACAD SCI USA, V82, P2870, DOI 10.1073/pnas.82.9.2870; BATEMAN JF, 1987, BIOCHEM J, V245, P393, DOI 10.1042/bj2450393; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BATEMAN JF, 1987, J BIOL CHEM, V262, P4445; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BATEMAN JF, 1987, J BIOL CHEM, V262, P7021; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BONADIO J, 1985, NATURE, V316, P363, DOI 10.1038/316363a0; CHEAH KSE, 1985, BIOCHEM J, V229, P287, DOI 10.1042/bj2290287; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1985, J BIOL CHEM, V260, P691; COHN DH, 1986, P NATL ACAD SCI USA, V83, P6045, DOI 10.1073/pnas.83.16.6045; DAHL HHM, 1986, J BIOL CHEM, V261, P4148; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; LUI CP, 1979, P NATL ACAD SCI USA, V76, P4503; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PROCKOP DJ, 1984, AM J HUM GENET, V36, P499; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILLENCE D, 1981, CLIN ORTHOP RELAT R, P11; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; STEINMANN B, 1984, J BIOL CHEM, V259, P1129; VOGEL BE, 1987, J BIOL CHEM, V262, P14737; WAKE SA, 1985, BIOCHEM J, V228, P425, DOI 10.1042/bj2280425; WILLIAMS CJ, 1983, J BIOL CHEM, V258, P5915	28	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					11627	11630						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403550				2022-12-25	WOS:A1988P765000006
J	GARLAND, F; GONSOULIN, F; CHEUNG, HC				GARLAND, F; GONSOULIN, F; CHEUNG, HC			THE MGADP-INDUCED DECREASE OF THE SH1-SH2 FLUORESCENCE RESONANCE ENERGY-TRANSFER DISTANCE OF MYOSIN SUBFRAGMENT-1 OCCURS IN 2 KINETIC STEPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV MICHIGAN,DEPT NAT SCI,DEARBORN,MI 48128	University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031239] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR31239] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGUIRRE R, 1986, BIOCHEMISTRY-US, V25, P6827, DOI 10.1021/bi00370a015; CHEUNG HC, 1985, BIOCHIM BIOPHYS ACTA, V832, P52, DOI 10.1016/0167-4838(85)90173-6; CHEUNG HC, 1983, J BIOL CHEM, V258, P5775; CHEUNG HC, 1987, BIOPHYS J, V51, pA86; DALBEY RE, 1983, BIOCHEMISTRY-US, V22, P4696, DOI 10.1021/bi00289a014; GARLAND F, 1979, BIOCHEMISTRY-US, V18, P5281, DOI 10.1021/bi00591a003; HIRATSUKA T, 1986, BIOCHEMISTRY-US, V25, P2101, DOI 10.1021/bi00356a039; HIRATSUKA T, 1987, BIOCHEMISTRY-US, V26, P3168, DOI 10.1021/bi00385a034; KATOH T, 1985, J BIOL CHEM, V260, P6723; LU RC, 1986, P NATL ACAD SCI USA, V83, P6392, DOI 10.1073/pnas.83.17.6392; MITCHELL EJ, 1986, EUR J BIOCHEM, V161, P25, DOI 10.1111/j.1432-1033.1986.tb10120.x; MORALES MF, 1982, ANNU REV PHYS CHEM, V33, P319, DOI 10.1146/annurev.pc.33.100182.001535; PERKINS WJ, 1984, J BIOL CHEM, V259, P8786; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1920; SUTOH K, 1987, BIOCHEMISTRY-US, V26, P4511, DOI 10.1021/bi00388a051; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P4800, DOI 10.1021/bi00262a043; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; TAO T, 1981, BIOCHEMISTRY-US, V20, P5051, DOI 10.1021/bi00520a035; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028	20	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					11621	11623						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403549				2022-12-25	WOS:A1988P765000004
J	KAMURA, T; TSUDA, H; YAE, Y; HATTORI, S; OHGA, S; SHIBATA, Y; KAWABATA, SI; HAMASAKI, N				KAMURA, T; TSUDA, H; YAE, Y; HATTORI, S; OHGA, S; SHIBATA, Y; KAWABATA, SI; HAMASAKI, N			AN ABNORMAL FIBRINOGEN FUKUOKA-II (GLY-B-BETA-15-]CYS) CHARACTERIZED BY DEFECTIVE FIBRIN LATERAL ASSOCIATION AND MIXED DISULFIDE FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; POLYMERIZATION SITE; BETA CHAIN; CLEAVAGE; PROTEINS; DNA	A dysfibrinogenemia was attributable to a single amino acid substitution from glycine to cysteine at residue 15 of the B beta chain in a fibrinogen molecule designated as fibrinogen Fukuoka II. The fibrinogen Fukuoka II showed prolonged thrombin and reptilase times and impaired fibrinopeptide B release by thrombin, resulting in abolition of fibrin monomer repolymerization under physiological conditions. Repolymerization of the des-(B beta 1-42)-fibrin monomers, however, was not distinguished from the normal pattern of des-(B beta 1-42)-fibrin monomers, suggesting that no other abnormality existed in fibrinogen Fukuoka II. Although an additional cysteine was substituted at residue 15 of the B beta chain, fibrinogen Fukuoka II had no free sulfhydryl group within the molecule. Instead, fibrinogen Fukuoka II formed a disulfide bond with cysteine, albumin, another mutated B beta chain within the same molecule, or intermolecular dimeric fibrinogen Fukuoka II. The mutation in fibrinogen Fukuoka II was the same as that in fibrinogen Ise published previously (Yoshida, N., Wada, H., Morita, K., Hirata, H., Matsuda, M., Yamazumi, K., Asakura, S., and Shirakawa, S. (1991) Blood 77, 1958-1963). Fibrinogen Ise, however, has been described as having prolonged thrombin time but normal reptilase time. Reasons for the discrepancy were not clear. Analysis of the B beta 1-42 fragment showed that fibrinogen was heterogeneous at position 31 of the B beta chain with respect to proline or hydroxyproline.	KYUSHU UNIV,FAC MED,DEPT CLIN CHEM & LAB MED,HIGASHI KU,FUKUOKA 81282,JAPAN	Kyushu University								ALMONDHIRY HAB, 1975, BLOOD, V45, P607; AUSTEN DEG, 1984, HUMAN BLOOD COAGULAT, P170; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BRANSON HE, 1983, ACTA HAEMATOL-BASEL, V70, P257, DOI 10.1159/000206737; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; Ebert RF, 1991, INDEX VARIANT HUMAN; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRALNICK HR, 1971, J CLIN INVEST, V50, P1819, DOI 10.1172/JCI106673; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN AH, 1993, THROMB HAEMOSTASIS, V70, P42; HOAR DI, 1987, CAN FAM PHYSICIAN, V33, P401; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; KAUDEWITZ H, 1986, FIBRINOGEN ITS DERIV, P31; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KEHL M, 1981, H-S Z PHYSIOL CHEM, V362, P1661; KOOPMAN J, 1992, P NATL ACAD SCI USA, V89, P3478, DOI 10.1073/pnas.89.8.3478; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKI K, 1951, ARCH BIOCHEM BIOPHYS, V32, P317, DOI 10.1016/0003-9861(51)90277-9; LIU CY, 1985, J BIOL CHEM, V260, P4390; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundblad R L, 1976, Methods Enzymol, V45, P156; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; MATSUDA M, 1983, J CLIN INVEST, V72, P1034, DOI 10.1172/JCI111027; MCDONAGH J, 1994, HEMOSTASIS THROMBOSI, P314; MOSESSON MW, 1974, J BIOL CHEM, V249, P4656; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; PANDY BV, 1991, BIOCHEMISTRY-US, V30, P162, DOI 10.1021/bi00215a024; PANDYA BV, 1984, BIOCHEMISTRY-US, V23, P460, DOI 10.1021/bi00298a010; PANDYA BV, 1985, J BIOL CHEM, V260, P2994; PIRKLE H, 1987, FIBRINOGEN, V2, P49; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBENLIST KR, 1993, BLOOD COAGUL FIBRIN, V4, P61, DOI 10.1097/00001721-199304010-00010; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOSHIDA N, 1991, BLOOD, V77, P1958; YU S, 1983, J BIOL CHEM, V258, P3407; ZHANG JZ, 1994, J BIOL CHEM, V269, P652	40	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29392	29399		10.1074/jbc.270.49.29392	http://dx.doi.org/10.1074/jbc.270.49.29392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493975	hybrid			2022-12-25	WOS:A1995TJ22700056
J	LUJAN, HD; MOWATT, MR; CONRAD, JT; BOWERS, B; NASH, TE				LUJAN, HD; MOWATT, MR; CONRAD, JT; BOWERS, B; NASH, TE			IDENTIFICATION OF A NOVEL GIARDIA-LAMBLIA CYST WALL PROTEIN WITH LEUCINE-RICH REPEATS - IMPLICATIONS FOR SECRETORY GRANULE FORMATION AND PREOTEIN ASSEMBLY INTO THE CYST WALL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; ANTIGENS; MURIS; GALACTOSAMINE; LOCALIZATION; CARBOHYDRATE; INHIBITOR; PATHWAY; INVITRO; KINASE	Giardia lamblia trophozoites, like most intestinal parasitic protozoa, undergo fundamental biological changes to survive outside the intestine of their mammalian host by differentiating into infective cysts. This complex process entails the coordinated production, processing, and transport of cyst wall constituents for assembly into a protective cyst wall. Yet, little is known about this process and the identity of cyst wall constituents. We previously identified a 26-kDa cyst wall protein, CWP1. In the present work, using monoclonal antibodies to cyst wall antigens, we cloned the gene that encodes a novel 39-kDa cyst wall protein, CWP2. Expression of CWP1 and CWP2 was induced during encystation with identical kinetics. Soon after synthesis, these two proteins combine to form a stable complex, which is concentrated within the encystation-specific secretory granules before incorporation into the cyst wall. Both proteins contain five tandem copies of a 24-residue leucine-rich repeat, a motif implicated in protein-protein interactions. Unlike CWP1, CWP2 has an extremely basic 121-residue COOH-terminal extension that might be involved in the sorting of these proteins to the secretory granules.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	LUJAN, HD (corresponding author), NIAID,PARASIT DIS LAB,BLDG 4,RM 126,,BETHESDA,MD 20892, USA.							ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMANTE L, 1972, Journal of Immunological Methods, V1, P289, DOI 10.1016/0022-1759(72)90006-3; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BOUCHER SEM, 1990, INFECT IMMUN, V58, P3516, DOI 10.1128/IAI.58.11.3516-3522.1990; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CAMPBELL JD, 1994, PARASITE IMMUNOL, V16, P211, DOI 10.1111/j.1365-3024.1994.tb00342.x; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; ERLANDSEN SL, 1989, J PARASITOL, V75, P787, DOI 10.2307/3283065; ERLANDSEN SL, 1990, J PARASITOL, V76, P267, DOI 10.2307/3283031; ERLANDSEN SL, 1990, J HISTOCHEM CYTOCHEM, V38, P625, DOI 10.1177/38.5.2332623; FEINBERG A, 1982, ANAL BIOCHEM, V132, P6; FILICE FRANCIS P., 1952, UNIV CALIFORNIA PUBL ZOOL, V57, P53; GILLIN FD, 1987, SCIENCE, V235, P1040, DOI 10.1126/science.3547646; GOZALBO D, 1993, PHARMACOL THERAPEUT, V60, P337, DOI 10.1016/0163-7258(93)90015-6; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; HASHIMOTO T, 1994, MOL BIOL EVOL, V11, P65; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HOOGENRAAD NJ, 1986, METHOD ENZYMOL, V121, P375; JARROLL EL, 1989, MOL BIOCHEM PARASIT, V32, P121, DOI 10.1016/0166-6851(89)90063-7; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kresse H, 1994, EXS, V70, P73; LECOMPTE MF, 1994, J BIOL CHEM, V269, P1905; LEVANONY H, 1992, J CELL BIOL, V119, P1117, DOI 10.1083/jcb.119.5.1117; LOHMAN KL, 1990, P NATL ACAD SCI USA, V87, P8393, DOI 10.1073/pnas.87.21.8393; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; LUJAN HD, 1995, J BIOL CHEM, V270, P13807, DOI 10.1074/jbc.270.23.13807; MACECHKO PT, 1992, MOL BIOCHEM PARASIT, V56, P301, DOI 10.1016/0166-6851(92)90179-N; MANNING P, 1992, J PROTOZOOL, V39, P290, DOI 10.1111/j.1550-7408.1992.tb01317.x; MANTEI N, 1992, ANAL SIGNALASE; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P236, DOI 10.1006/expr.1994.1087; MCKEARN TJ, 1980, MONOCLONAL ANTIBODIE, P368; Mehlotra R. K., 1993, Biological Memoirs, V19, P57; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; MOWATT MR, 1991, MOL BIOCHEM PARASIT, V49, P215, DOI 10.1016/0166-6851(91)90065-E; MURRAY PJ, 1991, J BIOL CHEM, V266, P24477; NASH TE, 1988, J IMMUNOL, V141, P636; REINER DS, 1990, EUR J CELL BIOL, V53, P142; REINER DS, 1989, INFECT IMMUN, V57, P963, DOI 10.1128/IAI.57.3.963-968.1989; RUBINSTEIN AL, 1995, P NATL ACAD SCI USA, V92, P3086, DOI 10.1073/pnas.92.8.3086; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STEINMAYR M, 1994, PLANT J, V5, P459, DOI 10.1046/j.1365-313X.1994.5040459.x; STENZEL DJ, 1991, INT J PARASITOL, V21, P613, DOI 10.1016/0020-7519(91)90069-J; STIBBS HH, 1989, J CLIN MICROBIOL, V27, P2582, DOI 10.1128/JCM.27.11.2582-2588.1989; STOTZ HU, 1993, PLANT PHYSIOL, V102, P133, DOI 10.1104/pp.102.1.133; STRATFORD M, 1994, YEAST, V10, P1741, DOI 10.1002/yea.320101307; THOMPSON RCA, 1993, ADV PARASIT, V32, P71, DOI 10.1016/S0065-308X(08)60207-9; TOOZE J, 1991, CELL BIOPHYS, V19, P117, DOI 10.1007/BF02989885; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WARD HD, 1990, MOL MICROBIOL, V4, P2095, DOI 10.1111/j.1365-2958.1990.tb00570.x; WARD HD, 1985, INFECT IMMUN, V49, P629, DOI 10.1128/IAI.49.3.629-634.1985	61	165	167	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29307	29313		10.1074/jbc.270.49.29307	http://dx.doi.org/10.1074/jbc.270.49.29307			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493963	hybrid			2022-12-25	WOS:A1995TJ22700044
J	PRIETO, PA; MUKERJI, P; KELDER, B; ERNEY, R; GONZALEZ, D; YUN, JS; SMITH, DF; MOREMEN, KW; NARDELLI, C; PIERCE, M; LI, YS; CHEN, X; WAGNER, TE; CUMMINGS, RD; KOPCHICK, JJ				PRIETO, PA; MUKERJI, P; KELDER, B; ERNEY, R; GONZALEZ, D; YUN, JS; SMITH, DF; MOREMEN, KW; NARDELLI, C; PIERCE, M; LI, YS; CHEN, X; WAGNER, TE; CUMMINGS, RD; KOPCHICK, JJ			REMODELING OF MOUSE MILK GLYCOCONJUGATES BY TRANSGENIC EXPRESSION OF A HUMAN GLYCOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; GDP-L-FUCOSE; 8-AMINONAPHTHALENE-1,3,6-TRISULFONIC ACID; LINKED OLIGOSACCHARIDES; ULEX-EUROPAEUS; GENE; CDNA; MICE; ATTACHMENT; RESOLUTION	The mammary gland is a unique biosynthetic tissue that produces a variety of species-specific glycoconjugates, but the factors regulating the production of specific glycoconjugates are not well understood. To explore the underlying regulation, a fusion gene containing a cDNA encoding the human alpha 1,S-fucosyltransferase (alpha 1,2FT), which generates the H-blood group antigen, flanked by the murine whey acidic protein promoter and a polyadenylation signal, was introduced into mice. Milk samples from transgenic animals contained soluble forms of the alpha 1,2FT, as revealed by Western blots of milk samples using an anti-alpha 1,2FT antiserum and by the demonstration of alpha 1,2FT enzyme activity. Milk from transgenic animals also contained large quantities of 2'-fucosyllactose (Fuc alpha 1-2Gal beta 1-4Glc) and modified glycoproteins containing the H-antigen, whereas milk from control animals lacked these glycoconjugates. Expression levels of 2'-fucosyllactose were high in most animals and represented 1/3 to nearly 1/2 of the total milk oligosaccharides. These results demonstrate that heterologous transgenic expression of a glycosyltransferase can result in the expression of both the transgene and its secondary gene products and that the structures of milk oligosaccharides can be remodeled depending on expression of the appropriate enzyme. Furthermore, these results suggest that the lactating mammary gland may be a unique biosynthetic reactor for the production of biologically active oligosaccharides and glycoconjugates.	ABBOTT LABS,ROSS PROD DIV,COLUMBUS,OH 43219; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; OHIO UNIV,EDISON ANIM BIOTECHNOL CTR,ATHENS,OH 45701; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104	Abbott Laboratories; University System of Georgia; University of Georgia; University System of Ohio; Ohio University; University of Oklahoma System; University of Oklahoma Health Sciences Center			Moremen, Kelley/AAD-4661-2019	Prieto, Pedro/0000-0001-9549-3730				ALLEN HJ, 1977, IMMUNOL COMMUN, V6, P585, DOI 10.3109/08820137709093469; ANDERSSON B, 1986, J INFECT DIS, V153, P232, DOI 10.1093/infdis/153.2.232; ARCHER JS, 1994, P NATL ACAD SCI USA, V91, P6840, DOI 10.1073/pnas.91.15.6840; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BAYNE ML, 1987, P NATL ACAD SCI USA, V84, P2638, DOI 10.1073/pnas.84.9.2638; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FIAT AM, 1989, MOL CELL BIOCHEM, V87, P5, DOI 10.1007/BF00421079; GINSBURG V, 1972, ADV ENZYMOL RAMB, V36, P131; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; HINDSGAUL O, 1982, CARBOHYD RES, V109, P109, DOI 10.1016/0008-6215(82)84034-2; JACKSON P, 1990, BIOCHEM J, V270, P705, DOI 10.1042/bj2700705; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KOBATA A, 1972, METHOD ENZYMOL, V28, P262; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEE EU, 1989, J BIOL CHEM, V264, P13848; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; PALEYANDA R, 1991, RECOMBINANT TECHNOLOGY IN HEMOSTASIS AND THROMBOSIS, P197; PATTON S, 1990, BIOCHIM BIOPHYS ACTA, V980, P333; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; REDDY GP, 1991, ANAL BIOCHEM, V198, P278, DOI 10.1016/0003-2697(91)90425-S; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SMITH DF, 1987, J BIOL CHEM, V262, P12040; STACK RJ, 1992, GLYCOBIOLOGY, V2, P85, DOI 10.1093/glycob/2.1.85; WILDE CJ, 1992, BIOCHEM J, V284, P717, DOI 10.1042/bj2840717	32	51	56	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29515	29519		10.1074/jbc.270.49.29515	http://dx.doi.org/10.1074/jbc.270.49.29515			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493992	hybrid			2022-12-25	WOS:A1995TJ22700073
J	ENGLISH, JM; VANDERBILT, CA; XU, SC; MARCUS, S; COBB, MH				ENGLISH, JM; VANDERBILT, CA; XU, SC; MARCUS, S; COBB, MH			ISOLATION OF MEK5 AND DIFFERENTIAL EXPRESSION OF ALTERNATIVELY SPLICED FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-KINASE; MAP KINASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SCHIZOSACCHAROMYCES-POMBE; INVITRO; YEAST; IDENTIFICATION; INSULIN; FAMILY	The prototype mitogen-activated protein (MAP) kinase module is a three-kinase cascade consisting of the MAP kinase, extracellular signal-regulated protein kinase (ERK) 1 or ERK2, the MAP/ERK kinase (MEK) MEK1 or MEK2, and the MEK kinase, Raf-1 or B-Raf. This and other MAP kinase modules are thought to be critical signal transducers in major cellular events including proliferation, differentiation, and stress responses. To identify novel mammalian MAP kinase modules, polymerase chain reaction was used to isolate a new MEK family member, MEK5, from the rat. MEK5 is more closely related to MEK1 and MEK2 than to the other known mammalian MEKs, MKK3 and MKK4. MEK5 is thought to lie in an uncharacterized MAP kinase pathway, because MEK5 does not phosphorylate the ERK/MAP kinase family members ERK1, ERK2, ERK3, JNK/SAPK, or p38/HOG1, nor will Raf-1, c-Mos, or MEKK1 highly phosphorylate it. Alternative splicing results in a 50-kDa alpha and a 40-kDa beta isoform of MEK5. MEK5 beta is ubiquitously distributed and primarily cytosolic. MEK5 alpha is expressed most highly in liver and brain and is particulate. The 23 amino acids encoded by the 5' exon in the larger alpha isoform are similar to a sequence found in certain proteins believed to associate with the actin cytoskeleton; this alternatively spliced modular domain may lead to the differential subcellular localization of MEK5 alpha.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	ENGLISH, JM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CAMPBELL JS, 1994, RECENT PROG HORM RES, V50, P131; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUND PK, 1986, J BIOL CHEM, V261, P12459; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; NADINDAVIS SA, 1990, MOL CELL BIOL, V10, P549, DOI 10.1128/MCB.10.2.549; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RACKER E, 1974, J BIOL CHEM, V249, P662; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGER F, 1977, P NATL ACAD SCI USA, V7, P5463; SEGER R, 1992, J BIOL CHEM, V267, P25628; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WARBRICK E, 1992, EMBO J, V10, P4291; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, NATURE, V372, P798; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHOU G, 1995, J BIOL CHEM, V270, P12664; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	66	185	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28897	28902		10.1074/jbc.270.48.28897	http://dx.doi.org/10.1074/jbc.270.48.28897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499418	hybrid			2022-12-25	WOS:A1995TH05600062
J	RUSTAEUS, S; LINDBERG, K; BOREN, J; OLOFSSON, SO				RUSTAEUS, S; LINDBERG, K; BOREN, J; OLOFSSON, SO			BREFELDIN-A REVERSIBLY INHIBITS THE ASSEMBLY OF APO-B CONTAINING LIPOPROTEINS IN MCA-RH7777 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; ADP-RIBOSYLATION FACTOR; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; GOLGI MEMBRANES; MESSENGER-RNA; INTRACELLULAR-TRANSPORT; SECRETORY PROTEINS; GUANINE-NUCLEOTIDE; RAT HEPATOCYTES	BFA inhibited in a dose dependent way the assembly of apoB-48 very low density lipoprotein (VLDL) but allowed a normal rate of biosynthesis of the apolipoprotein and of the assembly of the dense (''high density lipoprotein (HDL) like'') apoB-48 particle (apoB-48 HDL). The inhibition of the assembly of apoB-48 VLDL occurred at BFA levels that allowed a major secretion of both transferrin and apoB-48 HDL. The assembly of apoB-100 containing lipoproteins was also inhibited by BFA but could be reactivated by a 30-60 min chase in the absence of BFA, which agreed with the time that was estimated to be needed to restore the secretory pathway (approximately 60 min). Also the assembly of apoB-48 VLDL was reversible, Both apoB-48 and apoB-100 that was labeled in the presence of BFA assembled VLDL after removal of the BFA. Both apoB-100 and apoB-48 were associated with the membrane pellet of the microsomes. Virtually all (122 +/- 30%) of the membrane associated pulse-labeled apoB-48 remained in the membrane after a 180-min chase in the presence of BFA, compared to only 21 +/- 2% in normal cells (mean +/- S.D., n = 4). The corresponding figures for apoB-100 was 40 +/- 7% in BFA-treated cells and 9 +/- 7% in normal cells (mean +/- S.D., n = 4). Pulse-chase experiments with BFA offered conditions to selectively follow the turnover of membrane-associated apoB-100. Such experiments indicated that this apoB-100 pool is a precursor to VLDL.	GOTHENBURG UNIV,INST MED BIOCHEM & MICROBIOL,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,WALLENBERG LAB,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg				Andersson, Karin/0000-0002-9475-3040				ALEXANDER CA, 1973, J CELL BIOL, V69, P241; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1986, J BIOL CHEM, V83, P5296; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BRUNING A, 1992, J BIOL CHEM, V267, P7726; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DU EZ, 1994, J BIOL CHEM, V269, P24169; FAINARU M, 1977, METABOLISM, V26, P999, DOI 10.1016/0026-0495(77)90017-8; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GRETCH DG, 1995, FASEB J, V9, pA174; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAU PP, 1991, J BIOL CHEM, V266, P20550; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SCOTT J, 1989, MOL BIOL MED, V6, P65; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WINDMUELLER HG, 1985, J LIPID RES, V26, P70; YAN JP, 1994, J CELL BIOL, V126, P65, DOI 10.1083/jcb.126.1.65; YAO ZM, 1991, J BIOL CHEM, V266, P3300	43	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28879	28886		10.1074/jbc.270.48.28879	http://dx.doi.org/10.1074/jbc.270.48.28879			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499415	hybrid			2022-12-25	WOS:A1995TH05600059
J	TIKKANEN, K; HAATAJA, S; FRANCOISGERARD, C; FINNE, J				TIKKANEN, K; HAATAJA, S; FRANCOISGERARD, C; FINNE, J			PURIFICATION OF A GALACTOSYL-ALPHA-1-4-GALACTOSE-BINDING ADHESIN FROM THE GRAM-POSITIVE MENINGITIS-ASSOCIATED BACTERIUM STREPTOCOCCUS-SUIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIMBRIATED ESCHERICHIA-COLI; BINDING PROTEIN; POLYACRYLAMIDE GELS; GROUP-B; SPECIFICITY; STRAINS; PIGS; IDENTIFICATION; COAGGREGATION; ACTINOMYCES	Streptococcus suis causes meningitis, sepsis, and other serious infections in newborn and young pigs and in adult humans. The Gal alpha 1-4Gal-binding adhesin of S. suis was purified to homogeneity by ultrasonic treatment, fractional ammonium sulfate precipitation, and preparative polyacrylamide gel electrophoresis. Pigeon ovomucoid, a glycoprotein with Gal alpha 1-4Gal terminals, was used to detect the adhesin by blotting. The purified adhesin appeared as single band of an apparent size of 18 kDa and of a pI of 6.4; no disulfide bridges were present. The amount of adhesin as revealed by pigeon ovomucoid binding correlated with the hemagglutination activity of different S. suis strains. The purified adhesin bound to latex particles induced hemagglutination which was specifically inhibited with the same inhibitors as hemagglutination by the intact bacteria, thus demonstrating that the purified protein was the Gal alpha 1-4Gal-recognizing adhesin of S. suis. Two adhesin variants (P-N and P-O) with differing Gal alpha 1-4Gal binding specificity had the similar electrophoretic mobilities and the same N-terminal peptide sequences, indicating that they were closely related. This represents the first isolation of an adhesin with well defined cell surface carbohydrate binding activity from Gram-positive bacteria associated with meningitis.	UNIV KUOPIO, AI VIRTANEN INST, SF-70211 KUOPIO, FINLAND; UNIV TURKU, DEPT MED BIOCHEM, SF-20520 TURKU, FINLAND; CHU LIEGE, SERV IMMUNOHEMATOL, B-4000 LIEGE, BELGIUM	University of Eastern Finland; University of Turku; University of Liege	TIKKANEN, K (corresponding author), UNIV KUOPIO, DEPT BIOCHEM & BIOTECHNOL, POB 1627, SF-70211 KUOPIO, FINLAND.		Haataja, Sauli/AAR-5103-2020; Finne, Jukka/B-6881-2008	Finne, Jukka/0000-0002-8076-3344				ANDERSEN RN, 1993, INFECT IMMUN, V61, P981, DOI 10.1128/IAI.61.3.981-987.1993; ARENDS JP, 1988, REV INFECT DIS, V10, P131; BAGG J, 1982, J MED MICROBIOL, V15, P363, DOI 10.1099/00222615-15-3-363; Beachey, 1980, BACTERIAL ADHERENC B, V6, P1; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; BOYD B, 1993, J EXP MED, V177, P1745, DOI 10.1084/jem.177.6.1745; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CLIFTONHADLEY FA, 1983, AGR SOME DISEASES EM, P33; COLLETT MS, 1989, ADV VET SCI COMP MED, V33, P109; ELLIOTT SD, 1980, J HYG-CAMBRIDGE, V85, P275, DOI 10.1017/S0022172400063312; FRANCOISGERARD C, 1980, REV FR TRANSFUS IMMU, V23, P95, DOI 10.1016/S0338-4535(80)80050-X; FRANCOISGERARD C, 1979, BIOCHEM J, V177, P679, DOI 10.1042/bj1770679; GANESHKUMAR N, 1991, INFECT IMMUN, V59, P1093, DOI 10.1128/IAI.59.3.1093-1099.1991; GOLDHAR J, 1987, INFECT IMMUN, V55, P1837, DOI 10.1128/IAI.55.8.1837-1842.1987; HAATAJA S, 1993, J BIOL CHEM, V268, P4311; HAATAJA S, 1994, J BIOL CHEM, V269, P27466; HACKER J, 1993, INFECT IMMUN, V61, P544, DOI 10.1128/IAI.61.2.544-550.1993; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; KORHONEN TK, 1985, ENTEROBACTERIAL SURF, P301; KURL DN, 1989, INFECT IMMUN, V57, P384, DOI 10.1128/IAI.57.2.384-389.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1991, INFECT IMMUN, V59, P2677, DOI 10.1128/IAI.59.8.2677-2685.1991; LIUKKONEN J, 1992, J BIOL CHEM, V267, P21105; MOCH T, 1987, P NATL ACAD SCI USA, V84, P3462, DOI 10.1073/pnas.84.10.3462; MURRAY PA, 1986, INFECT IMMUN, V53, P359, DOI 10.1128/IAI.53.2.359-365.1986; NOWICKI B, 1986, MICROB PATHOGENESIS, V1, P335, DOI 10.1016/0882-4010(86)90066-5; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; PARKKINEN J, 1986, INFECT IMMUN, V54, P37, DOI 10.1128/IAI.54.1.37-42.1986; QUESSY S, 1995, INFECT IMMUN, V63, P1975, DOI 10.1128/IAI.63.5.1975-1979.1995; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; SANDFORD SE, 1992, DISEASES SWINE, P588; SIHVONEN L, 1988, ACTA VET SCAND, V29, P9; STINSON MW, 1982, INFECT IMMUN, V35, P335, DOI 10.1128/IAI.35.1.335-342.1982; TROTTIER S, 1991, REV INFECT DIS, V13, P1251; VAISANENRHEN V, 1984, INFECT IMMUN, V43, P149; VECHT U, 1985, VET QUART, V7, P315, DOI 10.1080/01652176.1985.9694005	41	27	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28874	28878		10.1074/jbc.270.48.28874	http://dx.doi.org/10.1074/jbc.270.48.28874			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499414	hybrid			2022-12-25	WOS:A1995TH05600058
J	VEYRUNE, JL; CARILLO, S; VIE, A; BLANCHARD, JM				VEYRUNE, JL; CARILLO, S; VIE, A; BLANCHARD, JM			C-FOS MESSENGER-RNA INSTABILITY DETERMINANTS PRESENT WITHIN BOTH THE CODING AND THE 3'-NON-CODING REGION LINK THE DEGRADATION OF THIS MESSENGER-RNA TO ITS TRANSLATION	ONCOGENE			English	Article						MESSENGER-RNA STABILITY; TRANSLATION; AU-RICH SEQUENCES; C-FOS	MESSENGER-RNA DEGRADATION; IRON-RESPONSIVE ELEMENTS; PROTEIN-SYNTHESIS INHIBITORS; UNTRANSLATED REGION; RICH SEQUENCES; TRANSFERRIN RECEPTOR; STABILITY INVITRO; GENE-EXPRESSION; BINDING-PROTEIN; GROWTH-FACTORS	The instability of oncogenic mRNA such as c-fos mRNA is controlled in cis by sequences present in both the coding and the 3' untranslated regions (3'UTR). The latter contains AU-rich elements (ARE) which, depending on the cellular context, mediate either their rapid degradation or inhibit their translation. These observations, along with the known increase of the Life spans of many unstable mRNA promoted by inhibitors of protein synthesis, raise the possibility that both processes are linked. To investigate further the putative involvement of translation in both coding region and ARE-mediated rapid decay of c-fos mRNA, we designed an expression vector based on the use of the ferritin mRNA iron regulatory element (IRE). The latter structure links translation to intracellular iron concentration when inserted at the proper location within the 5'UTR. Rapid degradation of a beta-globin/c-fos 3'UTR construct was prevented by Desferrioxamine, an iron chelator, and facilitated by ferric ammonium citrate or hemin, while stability of other mRNAs not containing the IRE or the ARE were unchanged. The same conclusion was reached when tbe stability of a c-fos mRNA devoid of ARE was assessed in function of iron availability.	INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE	Centre National de la Recherche Scientifique (CNRS)								AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BELASCO J, CONTROL MESSENGER RN; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1990, ONCOGENE, V5, P1585; BONNIEU A, 1989, ONCOGENE, V4, P881; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MATTIA E, 1989, P NATL ACAD SCI USA, V86, P1801, DOI 10.1073/pnas.86.6.1801; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEARNE PA, 1985, J IMMUNOL, V134, P3474; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	53	25	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2127	2134						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478533				2022-12-25	WOS:A1995TF29700024
J	FRANKLIN, GC; ADAM, GIR; MILLER, SJ; MONCRIEFF, CL; ULLERAS, E; OHLSSON, R				FRANKLIN, GC; ADAM, GIR; MILLER, SJ; MONCRIEFF, CL; ULLERAS, E; OHLSSON, R			AN INR-CONTAINING SEQUENCE FLANKING THE TATA BOX OF THE HUMAN C-SIS (PDGF-B) PROTOONCOGENE PROMOTER FUNCTIONS IN CIS AS A COACTIVATOR FOR ITS INTRONIC ENHANCER	ONCOGENE			English	Article						PDGF-B; C-SIS; INR; ENHANCER PROMOTER INTERACTIONS	GROWTH-FACTOR; CELL-LINES; TRANSCRIPTION INITIATION; REGULATORY ELEMENTS; MESSENGER-RNAS; 1ST INTRON; GENE; EXPRESSION; REGION; IDENTIFICATION	High-level activity of the human PDGF-B promoter in choriocarcinoma cell lines depends upon an atypical, intronic enhancer-like element which does not function with heterologous promoters tested. An extensive series of mutant PDGF-B promoter-driven constructs identified a sequence flanking the TATA box which is required specifically for enhancer-mediated transcription in human choriocarcinoma cell lines. This element, which we here term an enhancer-dependent cis co-activator (EDC) contains an Inr (initiator) consensus sequence upstream of the TATA box which is required, but not sufficient for its function. Requirement for the EDC is cell type-specific, since it was dispensable for enhancer-mediated transcription in a human breast cancer cell line. Although it lies within the region defined, the TATA box itself is not required for EDC function, or for basal promoter function which may derive from a second Inr-like sequence situated at the transcriptional start site. These observations indicate that interactions between some promoter and enhancer elements may be more complex than that generally described for 'classical' enhancer systems and may suggest an additional function for the initiator motif.			FRANKLIN, GC (corresponding author), UPPSALA UNIV,DEPT ANIM DEV & GENET,NORBYVAGEN 18A,S-75236 UPPSALA,SWEDEN.							BEHL C, 1993, NEUROSURGERY, V33, P697; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; FEN Z, 1991, ONCOGENE, V6, P953; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GARCIA JV, 1986, NATURE, V322, P383, DOI 10.1038/322383a0; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HOLMGREN L, 1993, CANCER RES, V53, P2927; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; Holmgren L, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026929; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG SW, 1995, J BIOL CHEM, V270, P3683, DOI 10.1074/jbc.270.8.3683; JIN HM, 1994, J BIOL CHEM, V269, P28648; KANEDA S, 1992, SOMAT CELL MOLEC GEN, V18, P409, DOI 10.1007/BF01233080; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KERMEKCHIEV M, 1991, GENE EXPRESSION, V1, P71; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LI XL, 1994, EMBO J, V13, P400, DOI 10.1002/j.1460-2075.1994.tb06274.x; MATSUOKA S, 1993, EUR J BIOCHEM, V218, P173, DOI 10.1111/j.1432-1033.1993.tb18363.x; NISTER M, 1988, CANCER RES, V48, P3910; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; PERES R, 1987, CANCER RES, V47, P3425; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; TIJAN R, 1994, CELL, V77, P5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0	44	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1873	1884						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478617				2022-12-25	WOS:A1995TD09400024
J	RONDINELLI, RH; HASLAM, SZ; FLUCK, MM				RONDINELLI, RH; HASLAM, SZ; FLUCK, MM			THE ROLE OF OVARIAN HORMONES, AGE AND MAMMARY-GLAND DEVELOPMENT IN POLYOMAVIRUS MAMMARY TUMORIGENESIS	ONCOGENE			English	Article						MAMMARY TUMOR DEVELOPMENT; OVARIAN HORMONES; AGE; POLYOMAVIRUS	VIRUS ONCOGENICITY; BREAST-CANCER; NUDE-MICE; CARCINOGENESIS; INDUCTION; ESTROGEN; DISEASE; TISSUE; TUMORS; RATS	Polyomavirus infection of adolescent athmyic female mice causes a high incidence of mammary adenocarcinomas, We have examined the role of ovarian hormones, age and mammary gland developmental stage at infection on subsequent tumor induction, viral replication and gene expression, Ovariectomy (OVX) of adolescent mice 1 week before infection decreased mammary tumor incidence and number, and significantly increased tumor latency. Reduction in tumorigenesis mas observed to a lesser degree if mice mere OVX at the time of or after infection, indicating that ovarian hormones are mainly required for tumor initiation. Tumor incidence was also reduced with increasing age; OVX prior to infection at older ages drastically reduced tumor development. Treatment of OVX adult mice with estrogen + progesterone for 1-3 weeks prior to infection was unable to restore tumorigenesis to the level observed in intact mice. Thus, in contrast to adolescent mice, the continued presence of ovarian hormones after infection was required for maximal tumorigenesis in adult mice. The decreased tumorigenesis observed in older animals is not likely due to increased differentiation since late pregnant mice with well differentiated mammary glands remained highly susceptible to tumorigenesis. At 10 days post infection, the levels of viral genomes were moderately high and similar in all experimental groups. Early viral protein and middle T-associated kinase levels were undetectable in infected tissues in all experimental conditions. However, high levels were found in tumors, perhaps reflecting a high dosage requirement for oncogenesis.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT PHYSIOL,CELL & MOLEC BIOL PROGRAM,E LANSING,MI 48824	Michigan State University; Michigan State University					NCI NIH HHS [5R01 CA58763, 5R01 CA40104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058763, R01CA040104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUZZI A, 1990, New Biologist, V2, P533; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BANERJEE M R, 1976, TCA (Tissue Culture Association) Manual, V2, P457, DOI 10.1007/BF00918341; BEREBBI M, 1988, ONCOGENE, V2, P149; BEREBBI M, 1990, ONCOGENE, V5, P505; BODIAN CA, 1993, CANCER, V71, P3896, DOI 10.1002/1097-0142(19930615)71:12<3896::AID-CNCR2820711217>3.0.CO;2-I; BOICE JD, 1977, J NATL CANCER I, V59, P823, DOI 10.1093/jnci/59.3.823; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHEN MC, 1995, J VIROL, V69, P326, DOI 10.1128/JVI.69.1.326-333.1995; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DAO TL, 1959, JNCI-J NATL CANCER I, V23, P567; DAO TL, 1962, CANCER RES, V22, P973; DAO TL, 1969, SCIENCE, V165, P810, DOI 10.1126/science.165.3895.810; DAO TL, 1960, J NATL CANCER I, V25, P991; DAWE CJ, 1987, AM J PATHOL, V127, P243; DIFRONZO G, 1990, ANTICANCER RES, V10, P1699; GRUBBS CJ, 1983, J NATL CANCER I, V70, P209; GRUBBS CJ, 1983, J NATL CANCER I, V71, P625; GULLINO PM, 1975, J NATL CANCER I, V54, P401; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HASLAM SZ, 1988, ENDOCRINOLOGY, V122, P464, DOI 10.1210/endo-122-2-464; HASLAM SZ, 1992, ONCOGENE, V7, P1295; HASLAM SZ, 1992, J STEROID BIOCHEM, V42, P589, DOI 10.1016/0960-0760(92)90449-S; HASLAM SZ, 1989, ENDOCRINOLOGY, V125, P2766, DOI 10.1210/endo-125-5-2766; HASLAM SZ, 1980, INT J CANCER, V26, P349, DOI 10.1002/ijc.2910260315; HASLAM SZ, 1993, J CELL PHYSIOL, V155, P72, DOI 10.1002/jcp.1041550110; HUGGINS C, 1959, J EXP MED, V109, P25, DOI 10.1084/jem.109.1.25; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KORFSMEIER KH, 1979, ANAT ANZEIGER, V145, P313; MERANZE DR, 1969, INT J CANCER, V4, P480, DOI 10.1002/ijc.2910040413; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NAGASAWA H, 1977, ACTA ENDOCRINOL-COP, V86, P794, DOI 10.1530/acta.0.0860794; NANDI S, 1958, J NATL CANCER I, V21, P1039; NERI C, 1990, CANCER RES, V50, P5892; RUSSO IH, 1990, BRIT J CANCER, V62, P243, DOI 10.1038/bjc.1990.268; RUSSO J, 1977, J NATL CANCER I, V59, P435, DOI 10.1093/jnci/59.2.435; RUSSO J, 1987, J NATL CANCER I, V78, P413; RUSSO J, 1979, AM J PATHOL, V96, P721; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; RUSSO J, 1978, J NATL CANCER I, V61, P1451; SHARKEY SM, 1986, CARCINOGENESIS, V7, P1991, DOI 10.1093/carcin/7.12.1991; SINHA DK, 1983, INT J CANCER, V31, P321, DOI 10.1002/ijc.2910310312; Swanson G M, 1994, J Natl Cancer Inst Monogr, P69; TOKUNAGA M, 1979, J NATL CANCER I, V62, P1347; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; VONDERHAAR BK, 1985, CONTROL CELL GROWTH, P11; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WIRTH JJ, 1992, J VIROL, V66, P3278, DOI 10.1128/JVI.66.6.3278-3286.1992	50	9	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1817	1827						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478610				2022-12-25	WOS:A1995TD09400017
J	ONODERA, M; KUNISADA, T; NISHIKAWA, S; SAKIYAMA, Y; MATSUMOTO, S; NISHIKAWA, S				ONODERA, M; KUNISADA, T; NISHIKAWA, S; SAKIYAMA, Y; MATSUMOTO, S; NISHIKAWA, S			OVEREXPRESSION OF RETINOIC ACID RECEPTOR-ALPHA SUPPRESSES MYELOID CELL-DIFFERENTIATION AT THE PROMYELOCYTE STAGE	ONCOGENE			English	Article						RAR-ALPHA; RETROVIRAL-MEDIATED GENE TRANSFER; BONE MARROW CELLS; MYELOID; APL	ZINC FINGER GENE; THYROID-HORMONE; RAR-ALPHA; ALL-TRANS; MONOCLONAL-ANTIBODIES; BINDING-PROPERTIES; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; DNA-BINDING; STEM-CELLS	Retinoic acid receptor (RAR) alpha is required to heterodimerize with retinoid X receptor (RXRs) in order to regulate myeloid differentiation. If so, it is expected that overexpression of normal RAR alpha may perturb the RAR alpha/ RXR heterodimer formation and also the differentiation of myeloid cells. We have described here the morphology and the RA response of human RAR alpha cDNA transduced murine bone marrow cells using a retroviral vector. Most of RAR alpha transduced cells displayed promyelocyte like morphology and their proportion of c-kit expressing population was increased remarkably compared with the control (Neo(r) gene transduced cells). Furthermore, this morphology was observed even after these cells were brought into the semisolid culture containing IL-3 alone. Interestingly, immature RAR alpha transduced cells differentiated into mature granulocytes under the condition of the high concentration of RA(10(-6)M). We did not observe any effect of RAR alpha on monocytes. These results indicate that overexpression of normal RAR alpha is sufficient for inducing maturation arrest of myeloid cell lineage that is similar to the phenotype found in the acute promyelocytic leukemia bearing PML-RAR alpha translocation.	KYOTO UNIV,FAC MED,DEPT MOLEC GENET,SAKYO KU,KYOTO 06001,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT PEDIAT,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Kyoto University; Hokkaido University								BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; Coffman R L, 1982, Immunol Rev, V69, P5; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAWSON MI, 1994, BLOOD, V84, P446; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KODAMA HA, 1982, J CELL PHYSIOL, V112, P89, DOI 10.1002/jcp.1041120114; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KRIEGLER M, 1990, LABORATORY MANUAL, P161; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROWLEY JD, 1987, LANCET, V5, P549; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TOHDA S, 1992, LEUKEMIA, V6, P656; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VARTDAL F, 1987, TRANSPLANTATION, V43, P366, DOI 10.1097/00007890-198703000-00010; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	53	21	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1291	1298						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478549				2022-12-25	WOS:A1995RY96700009
J	RODABAUGH, KJ; BIGGS, RB; QURESHI, JA; BARRETT, AJ; WELCH, WR; BELL, DA; BERKOWITZ, RS; MOK, SC				RODABAUGH, KJ; BIGGS, RB; QURESHI, JA; BARRETT, AJ; WELCH, WR; BELL, DA; BERKOWITZ, RS; MOK, SC			DETAILED DELETION MAPPING OF CHROMOSOME 9P AND P16 GENE ALTERATIONS IN HUMAN BORDERLINE AND INVASIVE EPITHELIAL OVARIAN-TUMORS	ONCOGENE			English	Article						BORDERLINE OVARIAN TUMOR; OVARIAN CANCER; CHROMOSOME 9P; LOSS OF HETEROZYGOSITY; P16 GENE	UNIFOCAL ORIGIN; CARCINOMAS; HETEROZYGOSITY; CANCER	We used PCR amplification of tandem repeats to study the pattern of allelic loss in borderline and invasive ovarian epithelial tumors using 12 primer pairs to generate a detailed deletion map of chromosome 9p. In the invasive ovarian carcinomas, there were three regions displaying high frequency of loss of heterozygosity (LOH) ranging from 31-38%. In contrast, LOH was a rare event among the borderline ovarian tumors, with one region revealing a rate of 20% and the remaining regions only 0-8% LOH. Therefore, allelic loss does not seem to be important for the development of borderline ovarian tumors. We also examined p16 gene expression and mutations in ovarian cancer cell lines and invasive and borderline ovarian tumor tissues. Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. However, the ovarian carcinoma cell lines showed a 50% homozygous deletion rate, SSCP analysis detected a mobility shift in only one (borderline) tumor. Since the primary invasive ovarian tumors did not show any deletions or mutations, it appears that p16 does not play a role in the pathogenesis of these tumors.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, DEPT OBSTET GYNECOL & REPROD BIOL, GYNECOL ONCOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; CAIRNS P, 1995, CANCER RES, V55, P224; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; CHENG JQ, 1994, CANCER RES, V54, P5547; EHLEN T, 1990, ONCOGENE, V5, P219; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; HUANG DP, 1994, CANCER RES, V54, P4003; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KRUK PA, 1990, LAB INVEST, V63, P132; LEE JH, 1990, CANCER RES, V50, P2724; MOK CH, 1992, CANCER RES, V52, P5119; MOK SC, 1995, GYNECOL ONCOL, V57, P299, DOI 10.1006/gyno.1995.1146; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; RUPPERT JM, 1993, CANCER RES, V53, P5093; SATO T, 1991, CANCER RES, V51, P5118; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; WERTHEIM I, 1995, P AM ASSOC CANC RES, V36, P545; XU L, 1994, CANCER RES, V54, P5262; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737; 1987, OBSTET GYNECOL, V156, P263	27	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1249	1254						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478544				2022-12-25	WOS:A1995RY96700004
J	LARSEN, J; MEYER, S; STEINLEIN, P; BEUG, H; HAYMAN, MJ				LARSEN, J; MEYER, S; STEINLEIN, P; BEUG, H; HAYMAN, MJ			TRANSFORMATION OF CHICKEN BONE-MARROW CELLS BY THE V-SKI ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; ERYTHROID-DIFFERENTIATION; LEUKEMIA-VIRUS; GROWTH-FACTOR; MIM-1 GENE; PHENOTYPE; MYB; INVITRO; EXPRESSION; MUSCLE	The effect of the v-ski oncogene on the transformation of chicken hematopoietic cells was examined. In initial experiments viruses encoding the v-ski oncoprotein did not transform chicken bone marrow cells. However, whereas viruses encoding the ts-v-sea oncoprotein transform solely erythroid cells, viruses encoding both the v-ski and the ts-v-sea oncogenes were found capable of transforming myeloid cells from the monocytic and/or granulocytic lineages in addition to erythroid cells. Analysis of cell clones transformed by the v-ski/ts-v-sea virus identified one clone that no longer expressed the v-sea protein, indicating that this protein was necessary for the initiation but not the maintenance of transformation. Subsequent experiments testing the effects of various growth factors on transformation of bone marrow cells by the v-ski oncogene product alone identified the avian c-kit ligand (stem cell factor; SCF) as being able to co-operate with the v-ski protein to cause transformation of chicken hematopoietic cells of both myeloid and erythroid lineages.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; BOYER PL, 1993, ONCOGENE, V8, P457; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DOMENGET C, 1992, ONCOGENE, V7, P2231; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1976, VIROLOGY, V71, P423, DOI 10.1016/0042-6822(76)90370-6; HAYMAN MJ, 1987, PATHOL IMMUNOPATH R, V6, P390, DOI 10.1159/000157065; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELLIHER MA, 1993, ONCOGENE, V8, P1249; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LARSEN J, 1992, ONCOGENE, V7, P1903; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; QUEVA C, 1992, DEVELOPMENT, V114, P125; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	40	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3221	3228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504231				2022-12-25	WOS:A1993MG78200004
J	SITTER, AJ; SHIFFLETT, JR; TERNER, J				SITTER, AJ; SHIFFLETT, JR; TERNER, J			RESONANCE RAMAN-SPECTROSCOPIC EVIDENCE FOR HEME IRON-HYDROXIDE LIGATION IN PEROXIDASE ALKALINE FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									VIRGINIA COMMONWEALTH UNIV,DEPT CHEM,RICHMOND,VA 23284	Virginia Commonwealth University					NCRR NIH HHS [RR02231] Funding Source: Medline; NIGMS NIH HHS [GM34443, GM39172] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034443, S15GM039172] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; ASHER SA, 1977, BIOCHEMISTRY-US, V16, P5849, DOI 10.1021/bi00645a032; ASHER SA, 1979, BIOCHEMISTRY-US, V18, P5377, DOI 10.1021/bi00591a019; ASHER SA, 1981, BIOCHEMISTRY-US, V20, P3339, DOI 10.1021/bi00515a004; BEETLESTONE J., 1964, BIO CHEMISTRY, V3, P707, DOI 10.1021/bi00893a019; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; CHOI S, 1982, J AM CHEM SOC, V104, P4327; CHOI SH, 1983, J AM CHEM SOC, V105, P3683, DOI 10.1021/ja00349a056; Coryell CD, 1937, J AM CHEM SOC, V59, P633, DOI 10.1021/ja01283a012; DEROPP JS, 1984, J AM CHEM SOC, V106, P4438, DOI 10.1021/ja00328a025; DESBOIS A, 1979, BIOCHEMISTRY-US, V18, P1510, DOI 10.1021/bi00575a019; DOEFF MM, 1983, INORG CHEM, V22, P851, DOI 10.1021/ic00147a035; Dollish F. R., 1974, CHARACTERISTIC RAMAN; ELLIS WD, 1969, ARCH BIOCHEM BIOPHYS, V133, P313, DOI 10.1016/0003-9861(69)90459-7; EPSTEIN N, 1972, FEBS LETT, V25, P46, DOI 10.1016/0014-5793(72)80450-2; EVANGELISTAKIRKUP R, 1985, FEBS LETT, V190, P221, DOI 10.1016/0014-5793(85)81288-6; GEORGE P, 1953, BIOCHEM J, V55, P236, DOI 10.1042/bj0550236; GEORGE P, 1964, REV MOD PHYS, V36, P441, DOI 10.1103/RevModPhys.36.441; GEORGE P, 1952, BIOCHEM J, V52, P517, DOI 10.1042/bj0520517; GEORGE P, 1961, HAEMATIN ENZYMES, P105; GONZALEZVERGARA E, 1985, BIOCHEMISTRY-US, V24, P6561, DOI 10.1021/bi00344a038; HARBURY HA, 1957, J BIOL CHEM, V225, P1009; HAYASHI Y, 1979, J BIOL CHEM, V254, P9101; HAYASHI Y, 1979, BIOCH CLIN ASPECTS O, P157; HENDRA PJ, 1968, CHEM IND-LONDON, P718; IIZUKA T, 1976, FEBS LETT, V64, P156, DOI 10.1016/0014-5793(76)80272-4; JOB D, 1977, ARCH BIOCHEM BIOPHYS, V179, P95, DOI 10.1016/0003-9861(77)90090-X; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; Keilin D, 1937, PROC R SOC SER B-BIO, V122, P119, DOI 10.1098/rspb.1937.0015; KOBAYASHI N, 1977, BIOCHIM BIOPHYS ACTA, V493, P340, DOI 10.1016/0005-2795(77)90190-8; LEE WA, 1985, P NATL ACAD SCI USA, V82, P4301, DOI 10.1073/pnas.82.13.4301; LOEHR TM, 1968, INORG CHEM, V7, P1708, DOI 10.1021/ic50067a004; MARKLUND S, 1974, BIOCHIM BIOPHYS ACTA, V350, P304, DOI 10.1016/0005-2744(74)90504-X; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; MAZZA G, 1968, BIOCHIM BIOPHYS ACTA, V167, P89, DOI 10.1016/0005-2744(68)90279-9; MORISHIMA I, 1977, BIOCHEMISTRY-US, V16, P5109, DOI 10.1021/bi00642a025; NOZAWA T, 1976, BIOCHIM BIOPHYS ACTA, V427, P652, DOI 10.1016/0005-2795(76)90209-9; OBRIEN P, 1985, INORG CHEM, V24, P1405, DOI 10.1021/ic00203a028; OZAKI Y, 1976, FEBS LETT, V62, P369, DOI 10.1016/0014-5793(76)80096-8; PHILLIPPI MA, 1982, J AM CHEM SOC, V104, P6026, DOI 10.1021/ja00386a031; QUINN R, 1984, J AM CHEM SOC, V106, P4136, DOI 10.1021/ja00327a012; RICARD J, 1972, EUR J BIOCHEM, V28, P566, DOI 10.1111/j.1432-1033.1972.tb01945.x; SAIGO S, 1981, BIOCHIM BIOPHYS ACTA, V669, P13, DOI 10.1016/0005-2795(81)90217-8; SCHONBAUM GR, 1979, BIOCH CLIN ASPECTS O, P195; SHANNON LM, 1966, J BIOL CHEM, V241, P2166; SHIEMKE AK, 1986, J AM CHEM SOC, V108, P2437, DOI 10.1021/ja00269a050; SHIEMKE AK, 1984, J AM CHEM SOC, V106, P4951, DOI 10.1021/ja00329a054; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SITTER AJ, 1985, BIOCHIM BIOPHYS ACTA, V828, P229, DOI 10.1016/0167-4838(85)90301-2; SJOBERG BM, 1987, BIOCHEMISTRY-US, V26, P4242; Smith D. W., 1970, STRUCT BOND, V7, P1, DOI 10.1007/BFb0118898; SMITH DW, 1978, CAN J BIOCH, V56, P702; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; STREKAS TC, 1974, BIOCHIM BIOPHYS ACTA, V351, P237, DOI 10.1016/0005-2795(74)90186-X; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TAMURA M, 1972, BIOCHIM BIOPHYS ACTA, V268, P292, DOI 10.1016/0005-2744(72)90324-5; TAMURA M, 1971, BIOCHIM BIOPHYS ACTA, V243, P249, DOI 10.1016/0005-2795(71)90082-1; TERNER J, 1985, BIOCHIM BIOPHYS ACTA, V828, P73, DOI 10.1016/0167-4838(85)90011-1; TERNER J, 1984, BIOCHIM BIOPHYS ACTA, V789, P80, DOI 10.1016/0167-4838(84)90064-5; TEROAKA J, 1981, J BIOL CHEM, V256, P3969; THEORELL H, 1951, ACTA CHEM SCAND, V5, P823, DOI 10.3891/acta.chem.scand.05-0823; Theorell H, 1941, J AM CHEM SOC, V63, P1804, DOI 10.1021/ja01852a005; THEORELL H, 1942, ARK KEMI MINERAL G A, V16, P1; TRAYLOR TG, 1984, J AM CHEM SOC, V106, P755, DOI 10.1021/ja00315a050; TRAYLOR TG, 1988, J AM CHEM SOC, V110, P239, DOI 10.1021/ja00209a039; WALKER FA, 1976, J AM CHEM SOC, V98, P5552, DOI 10.1021/ja00434a024; YAMADA H, 1974, ARCH BIOCHEM BIOPHYS, V165, P728, DOI 10.1016/0003-9861(74)90301-4; YAMAZAKI I, 1981, MOL CELL BIOCHEM, V40, P143; Yamazaki I, 1978, Adv Biophys, V11, P249; YONETANI T, 1971, J BIOL CHEM, V246, P7683; YU NT, 1980, J RAMAN SPECTROSC, V3, P166; [No title captured]	73	79	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13032	13038						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417650				2022-12-25	WOS:A1988Q091700043
J	SHIMAMURA, M; HAYASE, T; ITO, M; RASILO, ML; YAMAGATA, T				SHIMAMURA, M; HAYASE, T; ITO, M; RASILO, ML; YAMAGATA, T			CHARACTERIZATION OF A MAJOR NEUTRAL GLYCOLIPID IN PC12 CELLS AS III3GAL-ALPHA-GLOBOTRIAOSYLCERAMIDE BY THE METHOD FOR DETERMINING GLYCOSPHINGOLIPID SACCHARIDE SEQUENCE WITH ENDOGLYCOCERAMIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									MITSUBISHI KASEI RES CTR,MIDORI KU,YOKOHAMA 227,JAPAN		SHIMAMURA, M (corresponding author), MITSUBISHI KASEI INST LIFE SCI,GLYCOCONJUGATE RES LAB,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.			ito, Makoto/0000-0003-3159-7818				ANGSTROM J, 1982, ARCH BIOCHEM BIOPHYS, V213, P708, DOI 10.1016/0003-9861(82)90601-4; ARITA M, 1983, J BIOCHEM-TOKYO, V94, P249, DOI 10.1093/oxfordjournals.jbchem.a134336; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; FERRARI G, 1983, DEV BRAIN RES, V8, P215, DOI 10.1016/0165-3806(83)90006-8; GALILI U, 1987, J BIOL CHEM, V262, P4683; GASA S, 1983, J LIPID RES, V24, P174; GOODMAN R, 1978, P NATL ACAD SCI USA, V75, P4587, DOI 10.1073/pnas.75.9.4587; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAKOMORI S, 1986, SCI AM, V254, P32; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HANFLAND P, 1981, BIOCHEMISTRY-US, V20, P5310, DOI 10.1021/bi00521a034; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HATANAKA H, 1981, BRAIN RES, V222, P225, DOI 10.1016/0006-8993(81)91029-5; HONDA S, 1984, J CHROMATOGR, V299, P245, DOI 10.1016/S0021-9673(01)97836-7; ITO M, 1986, J BIOL CHEM, V261, P14278; KATOHSEMBA R, 1986, J NEUROCHEM, V46, P574, DOI 10.1111/j.1471-4159.1986.tb13006.x; KOIKE T, 1983, BIOCHIM BIOPHYS ACTA, V763, P258, DOI 10.1016/0167-4889(83)90133-7; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LEON A, 1982, MEMBRANE GROWTH DEV, P311; MARGOLIS RK, 1983, J BIOL CHEM, V258, P4110; MARGOLIS RU, 1984, FEBS LETT, V172, P339, DOI 10.1016/0014-5793(84)81153-9; RASILO ML, 1988, FEBS LETT, V227, P191, DOI 10.1016/0014-5793(88)80896-2; SCHWARTING GA, 1986, NEUROSCIENCE, V19, P647, DOI 10.1016/0306-4522(86)90287-3; SHIMAMURA M, 1987, 9TH P INT S GLYC, pA52; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5	26	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1988	263	24					12124	12128						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P7650	3403562				2022-12-25	WOS:A1988P765000078
J	BRANDAN, E; HIRSCHBERG, CB				BRANDAN, E; HIRSCHBERG, CB			PURIFICATION OF RAT-LIVER N-HEPARAN-SULFATE SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM,55 LAKE AVE N,WORCHESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester			; Brandan, Enrique/A-7063-2017	Hirschberg, Carlos/0000-0003-2299-7721; Brandan, Enrique/0000-0002-6820-5059	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BERG NB, 1971, J CELL BIOL, V50, P469, DOI 10.1083/jcb.50.2.469; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; DURANT GJ, 1962, ARCH BIOCHEM BIOPHYS, V99, P418, DOI 10.1016/0003-9861(62)90289-8; EDGE ASB, 1985, FED PROC, V44, P1789; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FLEISCHER B, 1974, J BIOL CHEM, V249, P5995; Fleischer S, 1974, Methods Enzymol, V31, P6; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GOHLER D, 1984, EUR J BIOCHEM, V138, P301, DOI 10.1111/j.1432-1033.1984.tb07915.x; GOODMAN GC, 1964, J CELL BIOL, V21, P353; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; HEINEGARD K, 1984, BIOCH EXTRACELLULAR, P277; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HORWITZ AL, 1968, J CELL BIOL, V38, P358, DOI 10.1083/jcb.38.2.358; INOUE H, 1986, J BIOL CHEM, V261, P4460; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; JOZIASSE DH, 1985, J BIOL CHEM, V260, P4941; KANTOR TG, 1956, J AM CHEM SOC, V79, P152; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KANWAR YS, 1984, P NATL ACAD SCI-BIOL, V81, P762, DOI 10.1073/pnas.81.3.762; KIMATA K, 1971, BIOCHIM BIOPHYS ACTA, V237, P606, DOI 10.1016/0304-4165(71)90282-0; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KJELLEN L, 1981, P NATL ACAD SCI-BIOL, V78, P5371, DOI 10.1073/pnas.78.9.5371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RIESENFELD J, 1982, J BIOL CHEM, V257, P7050; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WILLIAMS MP, 1983, BIOCHIM BIOPHYS ACTA, V756, P83, DOI 10.1016/0304-4165(83)90027-2; YOUNG RW, 1973, J CELL BIOL, V57, P175, DOI 10.1083/jcb.57.1.175	46	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1988	263	5					2417	2422						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M1758	3422231				2022-12-25	WOS:A1988M175800049
J	BLASCO, R; WITTICH, RM; MALLAVARAPU, M; TIMMIS, KN; PIEPER, DH				BLASCO, R; WITTICH, RM; MALLAVARAPU, M; TIMMIS, KN; PIEPER, DH			FROM XENOBIOTIC TO ANTIBIOTIC, FORMATION OF PROTOANEMONIN FROM 4-CHLOROCATECHOL BY ENZYMES OF THE 3-OXOADIPATE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOGENATED AROMATIC-COMPOUNDS; NUCLEOTIDE-SEQUENCE DETERMINATION; PSEUDOMONAS-PUTIDA; CHEMICAL-STRUCTURE; POLYCHLORINATED-BIPHENYLS; DEGRADING BACTERIUM; LACTONIZING ENZYME; MUCONIC ACIDS; DEGRADATION; BIODEGRADABILITY	Chloroaromatics, a major class of industrial pollutants, may be oxidatively metabolized to chlorocatechols by soil and water microorganisms that have evolved catabolic activities toward these xenobiotics. We show here that 4-chlorocatechol can be further transformed by enzymes of the ubiquitous 3-oxoadipate pathway. However, whereas chloromuconate cycloisomerases catalyze the dechlorination of 3-chloro-cis,cis-muconate to form cis-dienelactone, muconate cycloisomerases catalyze a novel reaction, i.e. the dechlorination and concomitant decarboxylation to form 4-methylenebut-2-en-4-olide (protoanemonin), an ordinarily plant-derived antibiotic that is toxic to microorganisms.	NATL RES CTR BIOTECHNOL, DIV MICROBIOL, D-38124 BRAUNSCHWEIG, GERMANY				Blasco, Rafael/E-6665-2015; Blasco, Rafael/O-6000-2019; Mallavarapu, Megharaj/D-3408-2011; Wittich, Regina-Michaela/L-3078-2014	Blasco, Rafael/0000-0003-3921-1553; Blasco, Rafael/0000-0003-3921-1553; Mallavarapu, Megharaj/0000-0002-6230-518X; Wittich, Regina-Michaela/0000-0002-5975-0944				ALDRICH TL, 1987, GENE, V52, P185, DOI 10.1016/0378-1119(87)90045-X; APAJALAHTI JHA, 1987, J BACTERIOL, V169, P675, DOI 10.1128/jb.169.2.675-681.1987; ASTURIAS JA, 1993, J BACTERIOL, V175, P4631, DOI 10.1128/JB.175.15.4631-4640.1993; BEDARD DL, 1987, APPL ENVIRON MICROB, V53, P1094, DOI 10.1128/AEM.53.5.1094-1102.1987; BOPP LH, 1986, J IND MICROBIOL, V1, P23, DOI 10.1007/BF01569413; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARI RVJ, 1987, J AM CHEM SOC, V109, P5514, DOI 10.1021/ja00252a034; DORN E, 1978, BIOCHEM J, V174, P85, DOI 10.1042/bj1740085; DORN E, 1978, BIOCHEM J, V174, P73, DOI 10.1042/bj1740073; DORN E, 1974, ARCH MICROBIOL, V99, P61, DOI 10.1007/BF00696222; EVANS WC, 1971, BIOCHEM J, V122, P509, DOI 10.1042/bj1220509; FETZNER S, 1992, J BACTERIOL, V174, P279, DOI 10.1128/jb.174.1.279-290.1992; FRANKLIN FCH, 1981, P NATL ACAD SCI-BIOL, V78, P7458, DOI 10.1073/pnas.78.12.7458; FRANTZ B, 1987, P NATL ACAD SCI USA, V84, P4460, DOI 10.1073/pnas.84.13.4460; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; GHOSAL D, 1989, GENE, V83, P225, DOI 10.1016/0378-1119(89)90108-X; GHOSAL D, 1988, MOL GEN GENET, V211, P113, DOI 10.1007/BF00338401; GOLDMAN A, 1987, J MOL BIOL, V194, P143, DOI 10.1016/0022-2836(87)90723-6; HAVEL J, 1992, APPL MICROBIOL BIOT, V38, P129, DOI 10.1007/BF00169432; HERNANDEZ BS, 1991, APPL ENVIRON MICROB, V57, P3361, DOI 10.1128/AEM.57.11.3361-3366.1991; HICKEY WJ, 1993, APPL ENVIRON MICROB, V59, P1194, DOI 10.1128/AEM.59.4.1194-1200.1993; HOIER H, 1994, ACTA CRYSTALLOGR D, V50, P75, DOI 10.1107/S090744499300900X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAZUR P, 1994, BIOCHEMISTRY-US, V33, P1961, DOI 10.1021/bi00173a045; NGAI KL, 1983, BIOCHEMISTRY-US, V22, P5231, DOI 10.1021/bi00291a025; PIEKEN WA, 1990, J ORG CHEM, V55, P3029, DOI 10.1021/jo00297a016; PIEPER DH, 1995, 1995 YEAR L PAST INT, P85; REINEKE W, 1984, APPL ENVIRON MICROB, V47, P395, DOI 10.1128/AEM.47.2.395-402.1984; REINEKE W, 1988, ANNU REV MICROBIOL, V42, P263, DOI 10.1146/annurev.mi.42.100188.001403; REINEKE W, 1984, MICROBIAL DEGRADATIO, P319; SANDER P, 1991, APPL ENVIRON MICROB, V57, P1430, DOI 10.1128/AEM.57.5.1430-1440.1991; SCHLOMANN M, 1990, J BACTERIOL, V172, P5119, DOI 10.1128/jb.172.9.5119-5129.1990; SCHLOMANN M, 1988, THESIS U STUTTGART G; SCHMIDT E, 1980, BIOCHEM J, V192, P339, DOI 10.1042/bj1920339; SCHMIDT E, 1980, BIOCHEM J, V192, P331, DOI 10.1042/bj1920331; SCHOLTEN JD, 1991, SCIENCE, V253, P182, DOI 10.1126/science.1853203; SCHREIBER A, 1980, APPL ENVIRON MICROB, V39, P58, DOI 10.1128/AEM.39.1.58-67.1980; SEEGAL BC, 1945, SCIENCE, V101, P413, DOI 10.1126/science.101.2625.413; SHAW E, 1946, J AM CHEM SOC, V68, P2510, DOI 10.1021/ja01216a024; SISTROM WR, 1954, J BIOL CHEM, V210, P821; SONDOSSI M, 1992, APPL ENVIRON MICROB, V58, P485, DOI 10.1128/AEM.58.2.485-495.1992; TAIRA K, 1988, BIOCHEMISTRY-US, V27, P3990, DOI 10.1021/bi00411a015; VOLLMER MD, 1994, J BACTERIOL, V176, P4366, DOI 10.1128/jb.176.14.4366-4375.1994; WITTICH RM, 1992, APPL ENVIRON MICROB, V58, P1005, DOI 10.1128/AEM.58.3.1005-1010.1992	44	96	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29229	29235		10.1074/jbc.270.49.29229	http://dx.doi.org/10.1074/jbc.270.49.29229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493952	hybrid			2022-12-25	WOS:A1995TJ22700033
J	BOESE, M; MORDVINTCEV, PI; VANIN, AF; BUSSE, R; MULSCH, A				BOESE, M; MORDVINTCEV, PI; VANIN, AF; BUSSE, R; MULSCH, A			S-NITROSATION OF SERUM-ALBUMIN BY DINITROSYL-IRON COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; ACTIVATED MACROPHAGES; CELLS; PEROXYNITRITE; SUPEROXIDE; OXIDATION; PROTEINS; RELEASE; ESTER	The objective of this study was to identify a potential mechanism for S-nitrosation of proteins. Therefore, we assessed S-nitrosation of bovine serum albumin by dinitrosyl-iron-di-L-cysteine complex [(NO)(2)Fe(L-cysteine)(2)], a compound similar to naturally occurring iron-nitrosyls. Within 5-10 min, (NO)(2)Fe(L-cysteine)(2) generated paramagnetic albumin-bound dinitrosyl-iron complex and S-nitrosoalbumin in a ratio of 4:1. Although S-nitroso-L-cysteine was concomitantly formed in low amounts, its concentration was not sufficient to account for formation of S-nitrosoalbumin via a trans-S-nitrosation reaction. Low oxygen tension did not affect S-nitrosation by the dinitrosyl-iron complex thus excluding the involvement of oxygenated NOx-species in the nitrosation reaction. Blockade of albumin histidine residues by pyrocarbonate, which prevented formation of dinitrosyl-iron-albumin complex, did not inhibit S-nitrosation of albumin. Thus, S-nitrosation of albumin by (NO)(2)Fe(L-cysteine), can proceed by direct attack of a nitrosyl moiety on the protein thiolate, without previous binding of the iron. We conclude that protein-bound dinitrosyl-iron complexes detected in high concentrations in certain tissues provide a reservoir of S-nitrosating species, e.g. low molecular dinitrosyl iron complexes.	UNIV FRANKFURT KLINIKUM, ZENTRUM PHYSIOL, D-60590 FRANKFURT, GERMANY	Goethe University Frankfurt; Goethe University Frankfurt Hospital			Shumaev, Konstantin/AAI-2362-2020; Vanin, Anatoly F/I-1069-2016	Vanin, Anatoly F/0000-0001-8392-4601				ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BARNETT DJ, 1994, J CHEM SOC PERK T 2, P1131, DOI 10.1039/p29940001131; BASTIAN NR, 1994, J BIOL CHEM, V269, P5127; BECKER K, 1995, IN PRESS EUR J BIOCH; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BONNETT R, 1977, HETEROCYCLES, V7, P637, DOI 10.3987/S-1977-01-0637; BOTTOMLEY F, 1978, ACCOUNTS CHEM RES, V11, P158, DOI 10.1021/ar50124a006; BRUNE B, 1994, LIFE SCI, V54, P61, DOI 10.1016/0024-3205(94)00775-6; BURBAEV DS, 1971, ZH STRUKT KHIM, V12, P252; BUTLER AR, 1988, ADV INORG CHEM, V32, P335, DOI 10.1016/S0898-8838(08)60235-4; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CROISY A, 1984, IARC SCI PUBL, V57, P327; CROISY AF, 1980, IARC SCI PUBL, V31, P83; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; HIBBS JB, 1990, INT CONGR SER, V897, P189; JOCELYN PC, 1972, BIOCH SH GROUP; Johnson B.F.G., 1966, PROG INORG CHEM, V7, P277; LANCASTER JR, 1994, FREE RADICAL BIO MED, V16, P869, DOI 10.1016/0891-5849(94)90206-2; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEE MH, 1994, BIOCHEMISTRY-US, V33, P3679, DOI 10.1021/bi00178a026; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LU SH, 1982, Z GASTROENTEROL, V20, P361; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; MULSCH A, 1993, BIOCHEM BIOPH RES CO, V196, P1303, DOI 10.1006/bbrc.1993.2394; Mulsch A., 1994, DRUG RES, V44, P408; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; RADI R, 1991, J BIOL CHEM, V266, P4244; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; VANIN AF, 1975, BIOFIZIKA+, V20, P1068; VANIN AF, 1993, BIOCHIM BIOPHYS ACTA, V1177, P37, DOI 10.1016/0167-4889(93)90154-H; VANIN AF, 1975, STUD BIOPHYS, V49, P13; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; WOOLUM JC, 1970, BIOCHIM BIOPHYS ACTA, V201, P131, DOI 10.1016/0304-4165(70)90018-8; ZHANG WX, 1983, CANCER RES, V43, P339	49	202	213	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29244	29249		10.1074/jbc.270.49.29244	http://dx.doi.org/10.1074/jbc.270.49.29244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493954	hybrid			2022-12-25	WOS:A1995TJ22700035
J	PIERRE, Y; BREYTON, C; KRAMER, D; POPOT, JL				PIERRE, Y; BREYTON, C; KRAMER, D; POPOT, JL			PURIFICATION AND CHARACTERIZATION OF THE CYTOCHROME B(6)F COMPLEX FROM CHLAMYDOMONAS-REINHARDTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; PHOTOSYSTEM-I; BF COMPLEX; SPINACH-CHLOROPLASTS; NUCLEOTIDE-SEQUENCE; MUTANT STRAINS; B6/F COMPLEX; B6-F COMPLEX; B/F COMPLEX; WILD-TYPE	A protocol has been developed for the purification of the cytochrome b(6)f complex from the unicellular alga Chlamydomonas reinhardtii. It is based on the use of the neutral detergent Hecameg (6-O-(N-heptylcarbamoyl) methyl-alpha-D-glycopyranoside) and comprises only three steps: selective solubilization from thylakoid membranes, sucrose gradient sedimentation, and hydroxylapatite chromatography. The purified complex contains two b hemes (alpha bands, 564 nm; E(m,8) = -84 and -158 mV) and one chlorophyll alpha (lambda(max) = 667-668 nm) per cytochrome f (alpha band, 554 nm; E(m,8) = +330 mV). It is highly active in transferring electrons from decylplastoquinol to oxidized plastocyanin (turnover number 250-300 s(-1)). The purified complex contains seven subunits, whose identity has been established by N-terminal sequencing and/or peptide-specific immunolabeling, namely four high molecular weight subunits (cytochrome f, Rieske iron-sulfur protein, cytochrome b(6), and subunit IV) and three similar to 4-kDa miniproteins (PetG, PetL, and PetX). Stoichiometry measurements are consistent with every subunit being present as two copies per b(6)f dimer.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE; COLL FRANCE,CNRS,URA 1187,F-75005 PARIS,FRANCE; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,URBANA,IL 61801	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; University of Illinois System; University of Illinois Urbana-Champaign			Kramer, David/B-9588-2016	Kramer, David/0000-0003-2181-6888				ADAM Z, 1987, FEBS LETT, V225, P67, DOI 10.1016/0014-5793(87)81132-8; ANDERSON MM, 1969, BIOCHIM BIOPHYS ACTA, V187, P193; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ATTEIA A, 1992, J BIOL CHEM, V267, P226; Bald D., 1992, P629; Barr R, 1971, METHOD ENZYMOL, V23, P372; BERTSCH J, 1991, PLANT MOL BIOL, V17, P131, DOI 10.1007/BF00036814; BLACK MT, 1987, ARCH BIOCHEM BIOPHYS, V252, P655, DOI 10.1016/0003-9861(87)90071-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER C, 1995, ANAL BIOCHEM, V224, P515, DOI 10.1006/abio.1995.1081; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BREYTON C, 1995, IN PRESS 10TH P INT; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; CRAMER WA, 1987, LIGHT REACTIONS, P447; Dawson R. M. C., 1986, DATA BIOCH RES, p[132, 138]; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; DEVITRY C, 1995, IN PRESS 10TH P INT; FRINDI M, 1992, J PHYS CHEM-US, V96, P8137, DOI 10.1021/j100199a058; GAL A, 1992, FEBS LETT, V298, P33, DOI 10.1016/0014-5793(92)80016-A; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HAUSKA G, 1986, METHOD ENZYMOL, V126, P271; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; HEINEMEYER W, 1984, CURR GENET, V8, P543, DOI 10.1007/BF00410442; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, EUR J BIOCHEM, V117, P591; HURT EC, 1983, FEBS LETT, V153, P413, DOI 10.1016/0014-5793(83)80655-3; JOLIOT P, 1986, BIOCHIM BIOPHYS ACTA, V849, P211, DOI 10.1016/0005-2728(86)90027-7; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; JOLIOT P, 1984, BIOCHIM BIOPHYS ACTA, V765, P210, DOI 10.1016/0005-2728(84)90015-X; KALYANASUNDARAM K, 1977, J AM CHEM SOC, V99, P2039, DOI 10.1021/ja00449a004; Kramer D. M., 1990, THESIS U ILLINOIS UR; KRAMER DM, 1993, BIOCHIM BIOPHYS ACTA, V1183, P72, DOI 10.1016/0005-2728(93)90006-2; KRAMER DM, 1994, BBA-BIOENERGETICS, V1184, P193, DOI 10.1016/0005-2728(94)90223-2; LAVERGNE J, 1984, PHOTOBIOCH PHOTOBIOP, V8, P207; LEE JW, 1995, J MOL BIOL, V252, P15, DOI 10.1006/jmbi.1994.0470; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; MATAGNE RF, 1989, J CELL BIOL, V108, P1221, DOI 10.1083/jcb.108.4.1221; MOSSER G, 1995, PHOTOSYNTH RES S, V1, P105; NITSCHKE W, 1987, FEBS LETT, V218, P283, DOI 10.1016/0014-5793(87)81062-1; ONDARROA M, 1994, EBEC SHORT REP, V8, P59; PICCIONI RG, 1981, EUR J BIOCHEM, V117, P93; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; PLUSQUELLEC D, 1989, ANAL BIOCHEM, V179, P145, DOI 10.1016/0003-2697(89)90215-7; POPOT JL, 1995, IN PRESS 10TH P INT; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RICH PR, 1987, BIOCHIM BIOPHYS ACTA, V892, P138, DOI 10.1016/0005-2728(87)90256-8; ROGNER M, 1990, J BIOL CHEM, V265, P6189; RUIZ MB, 1994, BBA-BIOMEMBRANES, V1193, P301, DOI 10.1016/0005-2736(94)90166-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT CL, 1993, PHOTOSYNTH RES, V38, P73, DOI 10.1007/BF00015063; TAE GS, 1993, PHOTOSYNTH RES, V36, P141, DOI 10.1007/BF00016278; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TAN S, 1989, BIOCHIM BIOPHYS ACTA, V973, P111, DOI 10.1016/S0005-2728(89)80410-4; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; WYNN RM, 1988, BIOCHIM BIOPHYS ACTA, V935, P115, DOI 10.1016/0005-2728(88)90208-3	66	151	164	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29342	29349		10.1074/jbc.270.49.29342	http://dx.doi.org/10.1074/jbc.270.49.29342			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493968	hybrid			2022-12-25	WOS:A1995TJ22700049
J	DATTO, MB; YU, Y; WANG, XF				DATTO, MB; YU, Y; WANG, XF			FUNCTIONAL-ANALYSIS OF THE TRANSFORMING GROWTH-FACTOR-BETA RESPONSIVE ELEMENTS IN THE WAF1/CIP1/P21 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; GENE-EXPRESSION; TGF-BETA; TRANSCRIPTION; KINASES; CLONING; FAMILY; INHIBITION; CYCLINS; PRODUCT	The transforming growth factor beta s (TGF-beta s) are a group of multifunctional growth factors that inhibit cell cycle progression in many cell types, The TGF-beta-induced cell cycle arrest has been partially attributed to the regulatory effects of TGF-beta on both the levels and activities of the G(1) cyclins and their cyclin-dependent kinase partners. The ability of TGF-beta to inhibit the activity of these kinase complexes derives in part from its regulatory effects on the cyclin-dependent kinase inhibitors, p21/WAF1/Cip1, p27(Kipl), and p15, Upon treatment of cells with TGF-beta, these three inhibitors bind to and block the activities of specific cyclin-cyclin-dependent kinase complexes to cause cell cycle arrest. Little is known, however, on the mechanism through which TGF-beta activates these cyclin dependent kinase inhibitors. In the case of p21, TGF-beta treatment leads to an increase in p21 mRNA. This increase in p21 mRNA is partly due to transcriptional activation of the p21 promoter by TGF-beta. To further define the signaling path ways through which TGF-beta induces p21, we have performed a detailed functional analysis on the p21 promoter. Through both deletion and mutation analysis of the p21 promoter, we have defined a 10-base pair sequence that is required for the activation of the p21 promoter by TGF-beta. In addition, this sequence is sufficient to drive TGF-beta-mediated transcription from a previously nonresponsive promoter. Preliminary gel shift assays demonstrate that this TGF-beta responsive element binds specifically to several proteins in vitro. Two of these proteins are the transcription factors Sp-1 and Sp-3. These studies represent the initial steps toward defining the signaling pathways involved in TGF-beta-mediated transcriptional activation of p21.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BAUKAMP P, 1988, J CELL BIOL, V106, P761; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU Y, 1993, NATURE, V336, P707; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NASMYTH K, 1994, NATURE, V336, P634; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	36	401	405	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28623	28628		10.1074/jbc.270.48.28623	http://dx.doi.org/10.1074/jbc.270.48.28623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499379	hybrid			2022-12-25	WOS:A1995TH05600023
J	MURTHY, YVSN; MASSEY, V				MURTHY, YVSN; MASSEY, V			CHEMICAL MODIFICATION OF THE N-10 RIBITYL SIDE-CHAIN OF FLAVINS - EFFECTS ON PROPERTIES OF FLAVOPROTEIN DISULFIDE OXIDOREDUCTASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART LIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; PIG-HEART; AZOTOBACTER-VINELANDII; RESOLUTION; RECONSTITUTION; BINDING; OXIDASE; ENZYME; NMR	Three flavin derivatives modified at the 2'-position of the flavin N-10 ribityl side chain were synthesized: arabinoflavin, 2'-F-2'-deoxyarabinoflavin, and 2'-deoxyriboflavin, These were converted to the FAD level with FAD synthetase, Apoproteins of lipoamide dehydrogenase, glutathione reductase, and mercuric reductase, a family of flavoprotein oxidoreductases, were reconstituted with these flavins. Significant reduction of the catalytic activities was observed with the modified enzymes, During anaerobic reduction of the modified enzymes with substrate or dithiothreitol, decreased thermodynamic stability of the two-electron reduced enzyme forms (EH(2)) and the accumulation of the four-electron reduced forms (EH(4)) noted. This effect was more pronounced in case of arabino-FAD-reconstituted enzymes than with the other two. It was found that NAD(+) binding influences the interaction between the flavin and the reduced disulfide in the 2'-F-arabino-FAD-lipoamide dehydrogenase, presumably by altering the relative oxidation-reduction potentials, F-19 NMR data were obtained for different forms of the 2'-F-arabino-FAD-lipoamide dehydrogenase, which suggest marked conformational changes from one form to the other, The F-19 NMR data for the oxidized forms of all three 2'-F-arabino-FAD proteins suggest that the fluorine experiences very similar chemical environments at the active sites.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECVAR J, 1982, J BIOL CHEM, V257, P5607; BRADY AH, 1971, J BIOL CHEM, V246, P5498; FOX B, 1982, J BIOL CHEM, V257, P2498; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; Ghisla S, 1994, FLAVINS AND FLAVOPROTEINS 1993, P283; GHISLA S, 1986, BIOCHEM J, V239, P1; GREIG JP, 1978, BIOL MAGN RESON, V1, P139; JARDETZKY O, 1981, NMR MOL BIOL, P52; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KELLOGG RM, 1992, TETRAHEDRON, V48, P4147, DOI 10.1016/S0040-4020(01)92193-3; KIM JJ, 1988, P NATL ACAD SCI USA, V18, P331; KIM JJP, 1992, PROG CLIN BIOL RES, V375, P111; LINDON JC, 1980, PROG NUCL MAG RES SP, V14, P27, DOI 10.1016/0079-6565(80)80002-1; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MASSEY V, 1962, J BIOL CHEM, V237, P2347; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MATTHEWS RG, 1979, J BIOL CHEM, V254, P4974; MATTHEWS RG, 1976, FLAVINS FLAVOPROTEIN, P464; MILES DW, 1968, BIOCHEMISTRY-US, V7, P2791, DOI 10.1021/bi00848a014; MILLER SM, 1995, BIOCHEMISTRY-US, V34, P13066, DOI 10.1021/bi00040a018; Miller SM, 1994, FLAVINS AND FLAVOPROTEINS 1993, P575; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; SHERRY B, 1985, BIOCHEMISTRY-US, V24, P2594, DOI 10.1021/bi00332a002; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; Sykes B D, 1978, Methods Enzymol, V49, P270; SYKES BD, 1980, MAGNETIC RESONANCE B, V1, P171; THORPE C, 1976, J BIOL CHEM, V251, P3553; TISHLER M, 1947, J AM CHEM SOC, V69, P1487, DOI 10.1021/ja01198a068; VANBERKEL WJH, 1991, EUR J BIOCHEM, V197, P769; VANBERKEL WJH, 1994, PROTEIN SCI, V3, P2245, DOI 10.1002/pro.5560031210; WEBER G, 1950, BIOCHEM J, V47, P114, DOI 10.1042/bj0470114; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; [No title captured]	39	17	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28586	28594		10.1074/jbc.270.48.28586	http://dx.doi.org/10.1074/jbc.270.48.28586			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499374	hybrid			2022-12-25	WOS:A1995TH05600018
J	UITTENBOGAARD, MN; GIEBLER, HA; REISMAN, D; NYBORG, JK				UITTENBOGAARD, MN; GIEBLER, HA; REISMAN, D; NYBORG, JK			TRANSCRIPTIONAL REPRESSION OF P53 BY HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I TAX PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HELIX-LOOP-HELIX; LONG TERMINAL REPEAT; WILD-TYPE P53; HTLV-I; DNA-SEQUENCES; GENE; EXPRESSION; LYMPHOMA; PROMOTER; BINDING	The human T-cell leukemia virus type I oncoprotein Tax transcriptionally deregulates a wide variety of viral and cellular genes. Tax deregulation of gene expression is mediated through interaction with a variety of structurally unrelated cellular transcription factors, as Tax does not bind DNA in a sequence-specific manner. Although most of these cellular transcription factors have been shown to mediate activation by Tax, we have recently demonstrated that members of the basic helix-loop-helix (bHLH) family of transcription factors, which play a critical role in progression through the cell cycle, mediate repression by Tax. In this report, we examined whether Tax might repress transcription of the tumor suppressor p53, as the p53 gene has recently been demonstrated to be regulated by the bHLH protein c-Myc. Furthermore, loss or inactivation of the p53 gene has been shown to be causally associated with oncogenic transformation. We show that Tax represses transcription of the p53 gene and that this repression is dependent upon the bHLH recognition element in the p53 promoter. Together, these results suggest that Tax may promote malignant transformation through repression of p53 transcription.	COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; UNIV S CAROLINA,DEPT BIOL SCI,COLUMBIA,SC 29208	Colorado State University; Colorado State University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia				Uittenbogaard, Martine/0000-0003-0371-3041	NCI NIH HHS [R01 CA55035, R29 CA59986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059986, R01CA055035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; BEIMLING P, 1988, ONCOGENE, V4, P511; BHATIA KG, 1992, CANCER RES, V52, P4273; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FREBOURG T, 1962, P NATL ACAD SCI USA, V89, P6413; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3551; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REID RL, 1993, ONCOGENE, V8, P3029; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; WIMAN KG, 1991, ONCOGENE, V6, P1633	36	78	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28503	28506		10.1074/jbc.270.48.28503	http://dx.doi.org/10.1074/jbc.270.48.28503			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499359	hybrid			2022-12-25	WOS:A1995TH05600003
J	MIYOSHI, E; IHARA, Y; HAYASHI, N; FUSAMOTO, H; KAMADA, T; TANIGUCHI, N				MIYOSHI, E; IHARA, Y; HAYASHI, N; FUSAMOTO, H; KAMADA, T; TANIGUCHI, N			TRANSFECTION OF N-ACETYLGLUCOSAMINYLTRANSFERASE-III GENE SUPPRESSES EXPRESSION OF HEPATITIS-B VIRUS IN A HUMAN HEPATOMA-CELL LINE, HB611	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN EXPRESSION; CDNA CLONING; HBV-DNA; PROTEIN; SURFACE; OLIGOSACCHARIDES; REPLICATION; INHIBITION; TISSUES; SYSTEM	beta-D-mannoside beta-1,4-N-acetylglucosaminyltransferase III (GnT-III) catalyzes the addition of N-acetylglucosamine in beta 1-4 linkage to the beta-linked mannose of the trimannosyl core of N-linked oligosaccharides and forms a bisecting GlcNAc structure. Although the biological meaning of the bisecting GlcNAc structure remains unclear, it is known that the attachment of a bisecting GlcNAc inhibits further processing of oligosaccharides by other glycosyltransferases. To investigate whether or not structural changes of oligosaccharides affect secretion and gene expression of hepatitis B virus (HBV), we introduced the GnT-III gene into a human hepatoma cell line, HB611, which secreted HBV-related proteins into the medium. Positive transfectants were cloned by hygromycin resistant selection. Three clones have high activities of GnT-III and secreted lower levels of HBV-related proteins into the medium in comparison with other clones, These clones showed marked suppression of HBV-related mRNAs and an increased binding with E-PHA as judged by lectin blot. Expression of beta actin, alpha fetoprotein, albumin, and prealubmin was not correlated with GnT-III activity in all the seven clones. Treatment of these cells with tunicamycin or swainsonine resulted in enhanced expression of HBV-related mRNA, These results indicate that some glycoproteins whose oligosaccharide structures are changed by overexpression of GnT-III suppress HBV gene expression.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 1, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				BLOCK TM, 1994, P NATL ACAD SCI USA, V91, P2235, DOI 10.1073/pnas.91.6.2235; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu CM, 1987, GASTROENTEROLOGY, V92, P220, DOI 10.1016/0016-5085(87)90863-8; DUDLEY FJ, 1971, LANCET, V2, P1; FARZA H, 1994, MOL CARCINOGEN, V9, P185, DOI 10.1002/mc.2940090402; FELKNER RH, 1992, J VIROL, V66, P4258, DOI 10.1128/JVI.66.7.4258-4264.1992; FLEET GWJ, 1988, FEBS LETT, V237, P128, DOI 10.1016/0014-5793(88)80185-6; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; KORCZAK B, 1993, INT J CANCER, V53, P634, DOI 10.1002/ijc.2910530418; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MIYOSHI E, 1994, CANCER RES, V54, P1854; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; MIYOSHI E, 1992, INT J CANCER, V52, P137, DOI 10.1002/ijc.2910520124; MIYOSHI E, 1993, CANCER RES, V53, P3899; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SHIRAKI K, 1992, J GEN VIROL, V73, P1401, DOI 10.1099/0022-1317-73-6-1401; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; TOWATA T, 1993, GASTROENTEROL JPN, V28, P242; TSURIMOTO T, 1987, P NATL ACAD SCI USA, V84, P444, DOI 10.1073/pnas.84.2.444; UEDA K, 1989, VIROLOGY, V169, P213, DOI 10.1016/0042-6822(89)90057-3; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; YOSHIMURA M, 1995, INT J CANCER, V60, P443, DOI 10.1002/ijc.2910600404	33	39	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28311	28315						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499330				2022-12-25	WOS:A1995TG21000055
J	SEGER, R; BIENER, Y; FEINSTEIN, R; HANOCH, T; GAZIT, A; ZICK, Y				SEGER, R; BIENER, Y; FEINSTEIN, R; HANOCH, T; GAZIT, A; ZICK, Y			DIFFERENTIAL ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE AND S6 KINASE SIGNALING PATHWAYS BY 12-O-TETRADECANOYLPHORBOL-13-ACETATE (TPA) AND INSULIN - EVIDENCE FOR INVOLVEMENT OF A TPA-STIMULATED PROTEIN-TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULINOMIMETIC AGENTS H2O2; RECEPTOR KINASE; INTACT-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; ANTIPROLIFERATIVE AGENTS; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORT; EGF RECEPTOR; MAP KINASE; PHOSPHORYLATION	AG-18, an inhibitor of protein-tyrosine kinases, was employed to study the role of tyrosine-phosphorylated proteins in insulin- and phorbol ester-induced signaling cascades. When incubated with Chinese hamster ovary cells overexpressing the insulin receptor, AG-18 reversibly inhibited insulin-induced tyrosine phosphorylation of insulin receptor substrate-1, with minimal effects either on receptor autophosphorylation or on phosphorylation of Shc64, Under these conditions, AG-18 inhibited insulin-stimulated phosphorylation of the ribosomal protein S6, while no inhibition of insulin-induced activation of mitogen-activated protein kinase (MAPK) kinase or MAPK was detected, In contrast, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced activation of MAPK kinase and MAPK and phosphorylation of S6 were inhibited by AG-18, This correlated with inhibition of TPA-stimulated tyrosine phosphorylation of several proteins, the most prominent ones being pp114 and pp120. We conclude that Tyr-phosphorylated insulin receptor substrate-1 is the main upstream regulator of insulin-induced S6 phosphorylation by p70(s6k), whereas MAPK signaling seems to be activated in these cells primarily through the adaptor molecule She. In contrast, TPA induced S6 phosphorylation is mediated by the MAPK/p90(rsk) cascade, A key element of this TPA-stimulated signaling pathway is an AG-18-sensitive protein-tyrosine kinase.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT MEMBRANE RES, IL-76100 REHOVOT, ISRAEL; HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem			Zick, Yehiel/K-1479-2012					AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; Holm-Hansen O., 1978, METHOD ENZYMOL, V57, P73, DOI [10.1016/0076-6879(78)57010-9, DOI 10.1016/0076-6879(78)57010-9]; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LEVITZKI A, 1990, BIOCHEM PHARMACOL, V40, P913, DOI 10.1016/0006-2952(90)90474-Y; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OFFERMANNS S, 1993, BIOCHEM J, V294, P545, DOI 10.1042/bj2940545; OGAWA W, 1994, J BIOL CHEM, V269, P29602; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PELECH SL, 1987, J BIOL CHEM, V262, P11598; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TERADA H, 1988, BIOCHIM BIOPHYS ACTA, V933, P193, DOI 10.1016/0005-2728(88)90070-9; THOMAS G, 1992, BIOCHEM SOC T, V20, P678, DOI 10.1042/bst0200678; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YANG YC, 1993, FEBS LETT, V333, P287, DOI 10.1016/0014-5793(93)80672-H; ZICK Y, 1983, J BIOL CHEM, V258, P75	66	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28325	28330						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499332				2022-12-25	WOS:A1995TG21000057
J	KIM, TJ; KIM, YT; PILLAI, S				KIM, TJ; KIM, YT; PILLAI, S			ASSOCIATION OF ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE WITH P120(CBL) IN ANTIGEN RECEPTOR-LIGATED B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; LYMPHOCYTES-B; KINASE LYN; IG-ALPHA; XID MICE; V-CBL; STIMULATION; IMMUNOGLOBULIN; ONCOGENE; SIGNAL	A 120-kDa protein that is tyrosine-phosphorylated upon antigen receptor ligation in B lymphocytes has been identified as the product of the c-cbl protooncogene. Tyrosine phosphorylation of Cbl depends on the efficient association of membrane immunoglobulin heavy chains with the Ig alpha/beta heterodimer but is unimpaired in splenic B cells from the Xid mouse. Crosslinking of membrane IgM and membrane IgG, but not of CD40, leads to the tyrosine phosphorylation of Cbl. In receptor-ligated B lymphocytes, p120(cbl) associates with an 85-kDa protein that has been identified as the 85-kDa subunit of phosphatidylinositol 3-kinase.			KIM, TJ (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, CTR CANC, CHARLESTOWN NAVY YARD, BOSTON, MA 02129 USA.		Kim, Tae Jin/D-6544-2011	Kim, Tae Jin/0000-0001-9802-0568	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033507] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 33507] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AOKI Y, 1995, J BIOL CHEM, V270, P15658, DOI 10.1074/jbc.270.26.15658; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P4204, DOI 10.1073/pnas.91.10.4204; BLAKE TJ, 1991, ONCOGENE, V6, P653; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1993, IMMUNOL REV, V132, P85, DOI 10.1111/j.1600-065X.1993.tb00838.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LALMANACHGIRARD AC, 1993, J EXP MED, V177, P1215, DOI 10.1084/jem.177.4.1215; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LINDSBERG ML, 1991, J IMMUNOL, V147, P3774; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SMIT L, 1994, J BIOL CHEM, V269, P20209; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	52	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27504	27509		10.1074/jbc.270.46.27504	http://dx.doi.org/10.1074/jbc.270.46.27504			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499208				2022-12-25	WOS:A1995TE73600019
J	KNARR, G; GETHING, MJ; MODROW, S; BUCHNER, J				KNARR, G; GETHING, MJ; MODROW, S; BUCHNER, J			BIP BINDING SEQUENCES IN ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE BIP; PEPTIDE-BINDING; HEAVY-CHAINS; LIGHT-CHAINS; PROTEIN; IMMUNOGLOBULIN; ASSOCIATION; SPECIFICITY; TRANSPORT; RELEASE	During the process of folding and assembly of antibody molecules in the endoplasmic reticulum, immunoglobulin heavy and light chains associate transiently with BiP, a resident endoplasmic reticulum protein that is a member of the Hsp70 family of molecular chaperones. Dip is thought to recognize unfolded or unassembled polypeptides by binding extended sequences of approximately seven amino acids that include bulky hydrophobic residues not normally exposed on the surface of native proteins. We used a computer algorithm developed to predict BiP binding sites within protein primary sequences to identify sites within immunoglobulin chains that might mediate their association with BiP. Very few of the sequential heptapeptides in the heavy or light chain sequences were potential Dip binding sites. Analysis of the ability of synthetic heptapeptides corresponding to 24 potential sites in heavy chains to stimulate the ATPase activity of BiP indicated that at least half of them were authentic Dip binding sequences. These sequences were not confined to a single domain of the heavy chain but were distributed within both the V-H and C-H domains. interestingly, when the BiP binding sequences were mapped onto the three dimensional structure of the Fd antibody fragment, the majority involve residues that participate in contact sites between the heavy and light chains. Therefore, we suggest that in. vivo BiP chaperones the folding and assembly of antibody molecules by binding to hydrophobic surface regions on the isolated immunoglobulin chains that subsequently participate in interchain contacts.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93040 REGENSBURG, GERMANY; UNIV MELBOURNE, DEPT BIOCHEM & MOLEC BIOL, PARKVILLE, VIC 3052, AUSTRALIA; UNIV REGENSBURG, INST MED MIKROBIOL & HYG, D-93042 REGENSBURG, GERMANY	University of Regensburg; University of Melbourne; University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				ATHERTON E, 1978, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39780000537; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P6922, DOI 10.1021/bi00242a016; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LILIE H, 1995, FEBS LETT, V362, P43, DOI 10.1016/0014-5793(95)00203-L; LILIE H, 1994, J BIOL CHEM, V269, P14290; LILIE H, 1993, PROTEIN SCI, V2, P1490, DOI 10.1002/pro.5560020913; LILIE H, 1995, PROTEIN SCI, V4, P917; LILIE H, 1995, J MOL BIOL, V248, P190, DOI 10.1006/jmbi.1995.0211; MA J, 1990, MOL IMMUNOL, V27, P623, DOI 10.1016/0161-5890(90)90004-J; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; [No title captured]	36	95	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27589	27594		10.1074/jbc.270.46.27589	http://dx.doi.org/10.1074/jbc.270.46.27589			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499221	hybrid			2022-12-25	WOS:A1995TE73600032
J	RUSCIANO, D; LORENZONI, P; BURGER, MM				RUSCIANO, D; LORENZONI, P; BURGER, MM			EXPRESSION OF CONSTITUTIVELY ACTIVATED HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR-RECEPTOR (C-MET) IN B16 MELANOMA-CELLS SELECTED FOR ENHANCED LIVER COLONIZATION	ONCOGENE			English	Article						B16 MELANOMA; C-MET; LIVER; METASTASIS	TYROSINE KINASE; B-16 MELANOMA; HOST ORGAN; PROTOONCOGENE; METASTASIS; MOTILITY; LINES	The murine melanoma B16-LS9 cell line was obtained after repeated passages in vivo through the liver of syngeneic mice, and shows an enhanced ability to colonize the liver after intravenous inoculation when compared to its parental, unselected counterpart B16-F1. We have previously shown that paracrine growth effects mainly account for better growth of B16-LS9 in the liver than at other sites, and more recently we reported hepatic transferrin as a factor contributing to efficient growth in the liver. Here we show that increased expression of constitutively activated c-met (the receptor for Hepatocyte Growth Factor/Scatter Factor) consistently occurs during selection of B16 cells through the liver. Constitutive activation of c-met seems to follow its own overexpression and not to depend on an autocrine mechanism. As a consequence, liver-selected B16 melanoma cells have higher tyrosine-kinase activity and higher amounts of tyrosine-phosphorylated proteins than parental B16-F1 or lung-specific B16-F10 cells. Overexpression of constitutively activated c-met enhances motility and invasiveness of B16-LS9 cells, presumably favoring their colonization efficiency in vivo. However, whether levels of c-met expression also determine the organ-specificity of B16 melanoma cells needs further clarification.			RUSCIANO, D (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.			RUSCIANO, DARIO/0000-0002-9577-2585				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRUNSON KW, 1979, J SUPRAMOL STR CELL, V11, P517, DOI 10.1002/jss.400110410; CHANG JH, 1993, ONCOGENE, V8, P959; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HALABAN R, 1992, ONCOGENE, V7, P2195; KOMADA M, 1993, ONCOGENE, V8, P2381; MINER KM, 1982, CANCER RES, V42, P4631; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; POSTE G, 1980, CANCER RES, V40, P1636; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUSCIANO D, 1994, INVAS METAST, V14, P349; RUSCIANO D, 1993, INVAS METAST, V13, P212; SARGENT NSE, 1988, P NATL ACAD SCI USA, V85, P7251, DOI 10.1073/pnas.85.19.7251; TAO T, 1979, INT J CANCER, V23, P854, DOI 10.1002/ijc.2910230618; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; YANAGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P802, DOI 10.1016/0006-291X(92)91803-X; ZHEN Z, 1994, ONCOGENE, V9, P1691	30	45	46	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					1979	1987						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478516				2022-12-25	WOS:A1995TF29700007
J	RUSSO, D; ARTURI, F; SCHLUMBERGER, M; CAILLOU, B; MONIER, R; FILETTI, S; SUAREZ, HG				RUSSO, D; ARTURI, F; SCHLUMBERGER, M; CAILLOU, B; MONIER, R; FILETTI, S; SUAREZ, HG			ACTIVATING MUTATIONS OF THE TSH RECEPTOR IN DIFFERENTIATED THYROID CARCINOMAS	ONCOGENE			English	Note						THYROTROPIN RECEPTOR; HYPERFUNCTIONING; ADENYLYL CYCLASE; CYCLIC AMP RAS ONCOGENE; GSP ONCOGENE	HUMAN THYROTROPIN RECEPTOR; HUMAN ENDOCRINE TUMORS; ALPHA-SUBUNIT; EXPRESSION; ONCOGENE; ADENOMAS; CLONING; GENE; RAS	A series of 14 thyroid carcinomas, characterized for their basal adenyl cyclase activity (ACA), was examined for the presence of activating point mutations in the TSH receptor (TSHR) gene, Sequencing of the carboxyl-part of this gene revealed the presence of a somatic and heterozygotic point mutation in codon 623 in three out of six tumors showing a constitutively enhanced ACA and a poor response to TSH stimulation. The mutation determines the substitution of a serine for an alanine in the third intracellular loop of the receptor, in a region critical for signal transduction. One tumor bearing a TSHR mutation presented also a N-ras point mutation. Both mutations were detected also in a lung metastasis of this tumor, Our data represent the first report of alterations in the TSHR gene in thyroid malign neoplasia, TSHR mutations may indeed participate, as web as the G alpha(s) protein (gsp oncogene), in the oncogenesis of some differentiated thyroid carcinomas presenting increased basal levels of cAMP and a poor response to TSH.	INST RECH SCI CANC,IFC 01,GENET MOLEC LAB,CNRS,UPR 42,F-94801 VILLEJUIF,FRANCE; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATTEDRA ENDOCRINOL,I-88100 CATANZARO,ITALY; UNIV REGGIO CALABRIA,FAC FARM,CATTEDRA FARMACOL,I-88100 CATANZARO,ITALY; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universita Mediterranea di Reggio Calabria; Universita Mediterranea di Reggio Calabria; UNICANCER; Gustave Roussy				ARTURI, Franco/0000-0002-1660-1228				AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; DEVRIES MV, 1986, GENE, V50, P313; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUMONT JE, 1989, METABOLIC BASIS INHE; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LIEBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUO K, 1993, J CLIN ENDOCR METAB, V76, P1446, DOI 10.1210/jc.76.6.1446; MAZZAFERRI EL, 1993, AM J MED, V97, P1446; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; THOMASMORVAN C, 1982, ACTA ENDOCRINOL-COP, V101, P25, DOI 10.1530/acta.0.1010025; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; YOSHIMOTO K, 1993, CANCER, V72, P1386, DOI 10.1002/1097-0142(19930815)72:4<1386::AID-CNCR2820720439>3.0.CO;2-J	30	112	119	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1907	1911						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478621				2022-12-25	WOS:A1995TD09400028
J	RAMOSMORALES, F; ROMERO, F; SCHWEIGHOFFER, F; BISMUTH, G; CAMONIS, J; TORTOLERO, M; FISCHER, S				RAMOSMORALES, F; ROMERO, F; SCHWEIGHOFFER, F; BISMUTH, G; CAMONIS, J; TORTOLERO, M; FISCHER, S			THE PROLINE-RICH REGION OF VAV BINDS TO GRB2, AND GRB3-3	ONCOGENE			English	Note						VAV; GRB2; GRB3-3; SH3; PROLINE-RICH; APOPTOSIS	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SH3 DOMAINS; RAS; PROTEIN; ACTIVATION; PROTOONCOGENE; ASSOCIATION; HOMOLOGY; GENE	Vav has structural features found in signaling proteins and is expressed only in hematopoietic cells. The recent development of mice Vav (-/-) has confirmed a major role of Vav in early blood cell development. We previously showed that Vav constitutively interacts with glutathione-S-transferase-Grb2. Coimmunoprecipitation experiments supported the idea of a complex formed by Vav-Grb2 in vivo. This complex is of potential interest in signaling of hematopoietic cells. In this work we localize the domains of Vav and Grb2 involved in this interaction. By the use of an in vivo genetic approach (the double hybrid system) and through in vitro experiments (glutathione-S-transferase fusion proteins) me furnish evidence that the interaction between Vav and Grb2 involves the C-SH3 domain of Grb2 and the proline-rich region located in the N-SH3 of Vav. Furthermore this was confirmed by the use of both Vav and Sos derived proline-rich peptides which blocked the binding. Tn addition me show that Vav also interacts with Grb3-3, a naturally occurring Grb2 isoform wich lacks functional SH2 domain.	UNIV SEVILLA,FAC BIOL,DEPT MICROBIOL,E-41080 SEVILLE,SPAIN; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY,FRANCE; CHU PITIE SALPETRIERE,CERVI,IMMUNOL CELLULARE & TISSULAIRE LAB,CNRS,URA 625,PARIS,FRANCE; INSERM,U248,F-75010 PARIS,FRANCE	University of Sevilla; Sanofi-Aventis; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	RAMOSMORALES, F (corresponding author), HOP COCHIN,INST COCHIN GENET MOLEC,INSERM,U363,27 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE.		Romero, Francisco/K-2101-2014; Tortolero, Maria/K-5744-2014; Ramos-Morales, Francisco/C-5734-2008	Romero, Francisco/0000-0002-9588-6881; Tortolero, Maria/0000-0003-1797-9940; Ramos-Morales, Francisco/0000-0002-1151-4547				ADAMS JM, 1992, ONCOGENE, V7, P611; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HOBERT O, 1994, J BIOL CHEM, V269, P20225; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P688; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MIKI H, 1994, J BIOL CHEM, V269, P5489; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sherman F., 1986, METHODS YEAST GENETI; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TOBE K, 1993, J BIOL CHEM, V268, P11167; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	41	50	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1665	1669						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478592				2022-12-25	WOS:A1995TC53500026
J	YAO, R; COOPER, GM				YAO, R; COOPER, GM			REGULATION OF THE RAS SIGNALING PATHWAY BY GTPASE-ACTIVATING PROTEIN IN PC12 CELLS	ONCOGENE			English	Article						RAS; GAP; PC12 CELLS	NERVE GROWTH-FACTOR; NIH 3T3 CELLS; MAP KINASE; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; THREONINE KINASE; MAMMALIAN-CELLS; FACTOR RECEPTOR; GENE-PRODUCT; HA-RAS	We have investigated the role of Pas GTPase-activating protein (GAP) in NGF-induced neuronal differentiation by overexpressing both wild-type and membrane-targeted GAP in PC12 cells. Extension of neurites in response to NGF was completely blocked in cells expressing the highest level of membrane-targeted GAP and significantly inhibited in cells expressing either wild-type GAP or lower levels of membrane-targeted GAP. Overexpression of membrane-targeted GAP similarly inhibited induction of differentiation by src, but not by ras or raf oncogenes, indicating that GAP inhibits differentiation of PC12 cells by downregulating Ras function. GAP overexpression also inhibited stimulation of mitogen-activated protein (MAP) kinase and induction of immediate-early genes in response to NGF. In cells expressing wild-type GAP or lower levels of membrane-targeted GAP, the initial activation of MAP kinase and immediate-early gene expression were only partially inhibited. However, GAP expression in these cells resulted in substantial inhibition of sustained MAP kinase activity following NGF treatment, consistent with the inhibition of neurite extension in these cell lines. These results indicate that GAP acts as a negative regulation, rather than an effector, of Ras signaling in PC12 cells.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALALAWI N, 1993, MOL CELL BIOL, V13, P2497, DOI 10.1128/MCB.13.4.2497; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	58	19	20	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1607	1614						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478585				2022-12-25	WOS:A1995TC53500019
J	ROZAKISADCOCK, M; VANDERGEER, P; MBAMALU, G; PAWSON, T				ROZAKISADCOCK, M; VANDERGEER, P; MBAMALU, G; PAWSON, T			MAP KINASE PHOSPHORYLATION OF MSOS1 PROMOTES DISSOCIATION OF MSOS1-SHC AND MSOS1-EGF RECEPTOR COMPLEXES	ONCOGENE			English	Article						MAP KINASE PHOSPHORYLATION; EXCHANGE FACTORS; MSOS1; SHC; EGF RECEPTOR	NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; RAS ACTIVATOR; GUANINE-NUCLEOTIDES; TYROSINE KINASES; ADAPTER PROTEIN; C-JUN; GRB2	The mouse protein mSos1 has a central Ras guanine nucleotide exchange domain, and a long proline-rich C-terminal tail which contains several potential binding sites for the SH3 domains of the adaptor protein, Grb2. In fibroblasts, growth factor stimulation results in the recruitment of Grb2-mSos1 into complexes with activated receptors and cytoplasmic phosphoproteins such as Shc, which are apparently involved in Ras activation, and subsequently to an increase in mSos1 phosphorylation on serine and threonine, The catalytic and C-terminal domains of mSos1 contain several potential sites for phosphorylation by mitogen-activated protein kinases. In vitro, purified p42/p44 MAP-kinase selectively phosphorylated the C-terminal tail of mSos1. Comparative tryptic phosphopeptide mapping of mSos1 phosphorylated in vitro by MAP kinase and of mSos1 immunoprecipitated from EGF-stimulated cells, revealed several phosphopeptides in common. These common phosphorylation sites have been mapped to a region encompassing the first three proline (pro)-rich motifs in the tail of mSos1. Furthermore, a region of mSos1 containing the first two pro-rich motifs could associate with MBP kinase activity in vitro. Phosphorylation of mSos1 did not affect binding of Grb2 to mSos1, but appeared to decrease binding of the mSos1-Grb2 complex to She and the EGF-receptor. These findings suggest a potential inhibitory role for MAP-kinase in attenuating nucleotide exchange on Ras, by uncoupling mSos1 from membrane-bound receptor complexes that lead to Ras activation.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOLEC BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON, 1995, CELL; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WANG W, 1995, IN PRESS NATURE GENE; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	41	76	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1417	1426						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478566				2022-12-25	WOS:A1995RY96700026
J	BEDI, GS; WILLIAMS, T				BEDI, GS; WILLIAMS, T			PURIFICATION AND CHARACTERIZATION OF A COLLAGEN-DEGRADING PROTEASE FROM PORPHYROMONAS-GINGIVALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLACK-PIGMENTED BACTEROIDES; TRYPSIN-LIKE PROTEASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; EXTRACELLULAR VESICLES; BACTERICIDAL ACTIVITY; DEGRADATION; IMMUNOGLOBULIN; STRAINS; W50	A trypsin-like protease was purified from spent culture medium of oral pathogen Porphyromonas gingivalis by chromatography on columns of DEAE-Sepharose, gel filtration on Sephadex G-100, and chromatofocusing on PBE-94. Purified enzyme showed a single band on SDS-polyacrylamide gel electrophoresis with an estimated molecular weight of 55,000. Purified protease hydrolyzed type I, III, IV, and V collagen from human placenta, and type I collagen from rat tail and calf skin, but did not hydrolyze type II collagen from chicken sternal cartilage. The purified enzyme also hydrolyzed the C3 component of complement, fibrinogen, fibronectin, alpha1-antitrypsin, alpha2-macroglobulin, apotransferrin, and human serum albumin. The hydrolytic activity of the purified enzyme on chromogenic substrates was limited to substrates with arginine in the P-1 position, although synthetic peptides were also cleaved at Lys-X linkage. The enzyme was activated by reducing agents dithiothreitol, L-Cysteine, and glutathione and inhibited by cysteine protease inhibitors N-ethylmaleimide, iodoacetic acid, and iodoacetamide. The enzyme was also inhibited by trans-epoxysuccinyl-L-leucylamido(4-guanidino) butane (E-64), leupeptin, antipain, salivary histidine-rich protein (HRP-5), soybean trypsin inhibitor, and EDTA. Since the protease is able to degrade the connective tissue components of periodontal tissue as well as components of host defense mechanism, this enzyme may be a potent virulence factor of P. gingivalis involved in invasion and tissue destruction.			BEDI, GS (corresponding author), MAGAININ PHARMACEUT INC,5110 CAMPUS DR,PLYMOUTH MEETING,PA 19462, USA.							BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; CARLSSON J, 1984, J MED MICROBIOL, V18, P39, DOI 10.1099/00222615-18-1-39; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; FRANDSEN EVG, 1987, INFECT IMMUN, V55, P631, DOI 10.1128/IAI.55.3.631-638.1987; FUZIMURA S, 1992, ORAL MICROBIOL IMMUN, V7, P212; GRENIER D, 1987, INFECT IMMUN, V55, P111, DOI 10.1128/IAI.55.1.111-117.1987; GRENIER D, 1992, INFECT IMMUN, V60, P1854, DOI 10.1128/IAI.60.5.1854-1857.1992; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGHON BE, 1982, J CLIN MICROBIOL, V15, P345, DOI 10.1128/JCM.15.2.345-346.1982; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYRAND D, 1988, MICROBIOL REV, V52, P134, DOI 10.1128/MMBR.52.1.134-152.1988; Miller EJ, 1984, EXTRACELLULAR MATRIX, P41; MORTENSEN SB, 1984, INFECT IMMUN, V45, P550, DOI 10.1128/IAI.45.3.550-557.1984; ODELL EW, 1992, ARCH ORAL BIOL, V37, P597, DOI 10.1016/0003-9969(92)90121-N; Ono M, 1987, Oral Microbiol Immunol, V2, P77, DOI 10.1111/j.1399-302X.1987.tb00294.x; ROBERTSON PB, 1982, J PERIODONTAL RES, V17, P275, DOI 10.1111/j.1600-0765.1982.tb01154.x; SATO M, 1987, ARCH ORAL BIOL, V32, P235, DOI 10.1016/0003-9969(87)90016-1; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SCRAGG MA, 1991, ARCH ORAL BIOL, V36, P709, DOI 10.1016/0003-9969(91)90037-U; SLOTS J, 1979, J CLIN PERIODONTOL, V6, P351, DOI 10.1111/j.1600-051X.1979.tb01935.x; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; SLOTS J, 1979, J CLIN MICROBIOL, V10, P371, DOI 10.1128/JCM.10.3.371-373.1979; SMALLEY JW, 1989, ARCH ORAL BIOL, V34, P579, DOI 10.1016/0003-9969(89)90098-8; SMALLEY JW, 1987, J GEN MICROBIOL, V133, P2883; SOJAR HT, 1993, INFECT IMMUN, V61, P2369, DOI 10.1128/IAI.61.6.2369-2376.1993; SORSA T, 1987, J PERIODONTAL RES, V22, P375, DOI 10.1111/j.1600-0765.1987.tb01602.x; SUNDQVIST G, 1985, J MED MICROBIOL, V19, P85, DOI 10.1099/00222615-19-1-85; TODA K, 1984, J PERIODONTAL RES, V19, P372, DOI 10.1111/j.1600-0765.1984.tb01010.x; TSUTSUI H, 1987, INFECT IMMUN, V55, P420, DOI 10.1128/IAI.55.2.420-427.1987; VANWINKELHOFF AJ, 1988, J CLIN PERIODONTOL, V15, P145; VANWINKELHOFF AJ, 1986, A VAN LEEUW J MICROB, V52, P163, DOI 10.1007/BF00429320; YONEDA M, 1990, INFECT IMMUN, V58, P406, DOI 10.1128/IAI.58.2.406-411.1990; YOSHIMURA F, 1984, ARCH ORAL BIOL, V29, P559, DOI 10.1016/0003-9969(84)90078-5	34	82	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					599	606						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506259				2022-12-25	WOS:A1994MR21900095
J	PARK, S; JOVE, R				PARK, S; JOVE, R			TYROSINE PHOSPHORYLATION OF RAS GTPASE-ACTIVATING PROTEIN STABILIZES ITS ASSOCIATION WITH P62 AT MEMBRANES OF V-SRC TRANSFORMED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; P21 GTPASE; SIGNAL TRANSDUCTION; FACTOR RECEPTORS; SH2 DOMAINS; GAP; BINDING; KINASES; STIMULATION; REQUIREMENT	Ras GTPase-activating protein (GAP) regulates the activity of Ras proteins, which have key roles in signal transduction pathways downstream of oncogenic and receptor tyrosine kinases. Previous studies indicated that Tyr-457 of bovine GAP (Tyr-460 of human GAP) is the major site of phosphorylation by viral Src (v-Src) kinase and epidermal growth factor receptor. The finding that Tyr-457 in GAP is located immediately adjacent to Src homology 2 (SH2) and 3 (SH3) domains led us to investigate the possibility that this specific phosphorylation regulates protein-protein interactions involving GAP. For this purpose, we constructed a full-length GAP mutant containing a substitution of Phe-457 in place of Tyr-457. Both wild-type GAP and mutant GAP(F457) were tagged with the KT3 epitope at the carboxyl terminus and were expressed in v-Src transformed rat fibroblasts. In vivo phosphorylation analyses established that GAP(F457) was weakly phosphorylated on tyrosine and, as expected, lacked the phosphopeptide containing Tyr-457. Analysis of GAP-associated proteins in anti-KT3 immunoprecipitates showed that GAP stably associated with two major phosphoproteins, p62 and p190, which have been previously described. Significantly, association of p62 with GAP(F457) was reduced approximately 3-fold compared with wild-type GAP. Subcellular fractionation experiments further demonstrated that Tyr-457 phosphorylation of GAP stabilized its association with p62 at cell membranes. Based on these findings, we propose that one role of tyrosine phosphorylation in GAP is to enhance its association with p62 at membranes, which in turn may contribute to regulation of Ras signal transduction pathways.	UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,DEPT MICROBIOL & IMMUNOL,6606 MED SCI 2,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan				Park, Soochul/0000-0002-7029-3414	NCI NIH HHS [CA55652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CHANG JH, 1993, ONCOGENE, V8, P959; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CORMACK B, 1988, CURRENT PROTOCOLS MO; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIBBS JB, 1990, ADP RIBOSYLATING TOX, P381; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HSIEH CL, 1989, SOMAT CELL MOLEC GEN, V15, P579, DOI 10.1007/BF01534919; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LUO K, 1990, ONCOGENE, V5, P921; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARK S, 1992, J BIOL CHEM, V267, P11612; PARK S, 1992, J BIOL CHEM, V267, P17194; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	51	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25728	25734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503985				2022-12-25	WOS:A1993MK10000066
J	PAVLIAK, V; NASHED, EM; POZSGAY, V; KOVAC, P; KARPAS, A; CHU, CY; SCHNEERSON, R; ROBBINS, JB; GLAUDEMANS, CPJ				PAVLIAK, V; NASHED, EM; POZSGAY, V; KOVAC, P; KARPAS, A; CHU, CY; SCHNEERSON, R; ROBBINS, JB; GLAUDEMANS, CPJ			BINDING OF THE O-ANTIGEN OF SHIGELLA-DYSENTERIAE TYPE-1 AND TYPE-26 RELATED SYNTHETIC FRAGMENTS TO A MONOCLONAL IGM ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PNEUMONIAE; ENTERIC INFECTIONS; RURAL BANGLADESH; POLYSACCHARIDE; LIGANDS; LIPOPOLYSACCHARIDE; SPECIFICITY; DEXTRAN; SHIGELLA-DYSENTERIAE-1; VIRULENCE	Shigella dysenteriae type 1 possesses an O-antigen whose repeating unit is -->3-alpha-L-Rhap-(1-->3)-alpha-L-Rhap-(1-->2)-alpha-D-Galp-(1-->3)-alpha-D-GlcpNAc-(1-->, where Rhap is rhamnopyranosyl, Galp is galactopyranosyl, and Glcp is glucopyranosyl. Using ligand-induced protein fluorescence change, we have measured the affinities of a monoclonal murine IgM for 26 fragments of, or related to, the structure of the O-polysaccharide and of the IgM Fab for the intact O-specific bacterial polysaccharide. Synthetic saccharides used were methyl glycosides to ensure an anomerically defined pyranosyl ring conformation. The galactosyl residue is the only monosaccharide of the antigenic epitope that shows quantifiable binding: approximately 3.0 kcal/mol of binding free energy, depending on the structure and conformation of the fragment it is a part of. Addition of an alpha-(1-->2)-linked rhamnosyl residue increases the free energy of binding significantly. We propose this rhamnopyranosyl-alpha-(1-->2)-galactopyranosyl disaccharide to be the basic determinant of the Shigella O-polysaccharide. Further extension (by linkages as in the natural antigen) of this oligosaccharidic ligand toward the upstream end (in an oligo- (or poly-)saccharide, such as A-->B-->C-->D-->E-->m, where A, B, C, D, and E are sugars and m is any moiety, such as methyl, we define A as the glycosyl- or upstream terminus, and E as the glycoside- or downstream terminus) by rhamnosyl and N-acetylglucosaminyl moieties improves the binding only minimally. The antibody is quite specific for the rhamnosyl-alpha-(1-->2)-galactosyl sequence but less so for the nature of the attachment to the galactosyl residue on the downstream side. Measurements using IgM Fab and the intact O-specific polysaccharide show that the antibody can bind internal segments on the antigen chain. The free energy of binding of this antibody for the disaccharide determinant varies from -DELTAG of 4.7 to 5.1 kcal/mol, depending on its flanking residues.	NIDDKD, BETHESDA, MD 20892 USA; US FDA, CTR BIOL RES & REVIEW, BETHESDA, MD 20892 USA; NICHHD, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BENNETT LG, 1979, BIOCHEMISTRY-US, V18, P3337, DOI 10.1021/bi00582a021; BENNETT LG, 1979, CARBOHYD RES, V72, P315, DOI 10.1016/S0008-6215(00)83958-0; BENNETT LG, 1979, J IMMUNOL, V122, P2356; BHATTACHARJEE AK, 1983, MOL IMMUNOL, V20, P351, DOI 10.1016/0161-5890(83)90016-0; BHATTACHARJEE AK, 1984, REV INFECT DIS, V6, P619; BIDLACK JM, 1986, J IMMUNOL METHODS, V91, P157, DOI 10.1016/0022-1759(86)90473-4; BINNS MM, 1985, ZBL BAKT MIK HYG B, V181, P197; BLACK RE, 1980, J INFECT DIS, V142, P660, DOI 10.1093/infdis/142.5.660; BLACK RE, 1984, PEDIATRICS, V73, P799; CHEN LC, 1980, INT J EPIDEMIOL, V9, P25, DOI 10.1093/ije/9.1.25; CHU CY, 1991, INFECT IMMUN, V59, P4450, DOI 10.1128/IAI.59.12.4450-4458.1991; CHU CY, 1983, INFECT IMMUN, V40, P245, DOI 10.1128/IAI.40.1.245-256.1983; CISAR J, 1975, J EXP MED, V142, P435, DOI 10.1084/jem.142.2.435; COHEN D, 1988, J INFECT DIS, V157, P1068, DOI 10.1093/infdis/157.5.1068; DAHMEN J, 1985, CARBOHYD RES, V138, P17, DOI 10.1016/0008-6215(85)85219-8; DAS MK, 1979, MOL IMMUNOL, V16, P97, DOI 10.1016/0161-5890(79)90050-6; DMITRIEV BA, 1976, EUR J BIOCHEM, V66, P559, DOI 10.1111/j.1432-1033.1976.tb10582.x; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; EVANS ME, 1968, J ORG CHEM, V33, P1074, DOI 10.1021/jo01267a028; FELSEN J, 1945, BACILLARY DYSENTERY; FORMAL SB, 1989, REV INFECT DIS, V11, pS547; GLAUDEMANS CPJ, 1993, ACS SYM SER, V519, P72; GLAUDEMANS CPJ, 1988, ACS SYM SER, V374, P78; GLAUDEMANS CPJ, 1989, CARBOHYD RES, V190, P267, DOI 10.1016/0008-6215(89)84130-8; GLAUDEMANS CPJ, 1991, CHEM REV, V91, P25, DOI 10.1021/cr00001a002; GLAUDEMANS CPJ, 1977, IMMUNOCHEMISTRY, V14, P675, DOI 10.1016/0019-2791(77)90140-9; Glaudemans CPJ, 1980, METHODS CARBOHYDR CH, V8, P145; GORDON JE, 1965, AM J TROP MED HYG, V14, P404, DOI 10.4269/ajtmh.1965.14.404; JOLLEY ME, 1974, CARBOHYD RES, V33, P377, DOI 10.1016/S0008-6215(00)82819-0; KOVAC P, 1992, J ORG CHEM, V57, P2455, DOI 10.1021/jo00034a047; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levene PA, 1934, J BIOL CHEM, V105, P431; LEVINE MM, 1973, J INFECT DIS, V127, P261, DOI 10.1093/infdis/127.3.261; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; LEVINE MM, 1990, LANCET, V335, P958, DOI 10.1016/0140-6736(90)91013-Z; LINDBERG AA, 1984, B WORLD HEALTH ORGAN, V62, P597; MATA LJ, 1967, TROP GEOGR MED, V19, P247; MICHON F, 1989, CARBOHYD RES, V194, P321, DOI 10.1016/0008-6215(89)85033-5; NASHED EM, 1990, J BIOL CHEM, V265, P20699; Orskov F., 1978, METHOD MICROBIOL, V2, P1; OUCHTERLONY O, 1968, HDB IMMUNODIFFUSION; PAVLIAK V, 1992, CARBOHYD RES, V229, P103, DOI 10.1016/S0008-6215(00)90483-X; POZSGAY V, 1987, CAN J CHEM, V65, P2764, DOI 10.1139/v87-459; POZSGAY V, 1992, BIOORG MED CHEM LETT, V2, P255; POZSGAY V, 1993, IN PRESS BIOORG MED; POZSGAY V, 1992, CARBOHYDRATES SYNTHE, P188; ROUSE DA, 1990, INFECT IMMUN, V58, P1445, DOI 10.1128/IAI.58.5.1445-1449.1990; SCRAGG JN, 1978, J PEDIATR-US, V93, P796, DOI 10.1016/S0022-3476(78)81081-6; SHARON J, 1982, MOL IMMUNOL, V19, P389, DOI 10.1016/0161-5890(82)90204-8; STANKER LH, 1985, J IMMUNOL METHODS, V76, P157, DOI 10.1016/0022-1759(85)90488-0; STOLL BJ, 1982, J INFECT DIS, V146, P177, DOI 10.1093/infdis/146.2.177; STREEFKERK DG, 1977, BIOCHEMISTRY-US, V16, P3760, DOI 10.1021/bi00636a005; STREEFKERK DG, 1977, J IMMUNOL, V120, P408; STURM S, 1986, MICROB PATHOGENESIS, V1, P307, DOI 10.1016/0882-4010(86)90056-2; TAYLOR DN, 1993, INFECT IMMUN, V61, P3678, DOI 10.1128/IAI.61.9.3678-3687.1993; WATANABE H, 1984, INFECT IMMUN, V43, P391, DOI 10.1128/IAI.43.1.391-396.1984; WATANABE H, 1984, INFECT IMMUN, V46, P55, DOI 10.1128/IAI.46.1.55-63.1984; ZIDOVETZKI R, 1980, BIOCHEMISTRY-US, V19, P2790, DOI 10.1021/bi00553a039; ZIEGLER T, 1990, CARBOHYD RES, V203, P253, DOI 10.1016/0008-6215(90)80022-U; ZIEGLER T, 1990, CARBOHYD RES, V204, P167, DOI 10.1016/0008-6215(90)84033-Q	60	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25797	25802						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503987				2022-12-25	WOS:A1993MK10000076
J	TSUKADA, T; TOMOOKA, Y; TAKAI, S; UEDA, Y; NISHIKAWA, S; YAGI, T; TOKUNAGA, T; TAKEDA, N; SUDA, Y; ABE, S; MATSUO, I; IKAWA, Y; AIZAWA, S				TSUKADA, T; TOMOOKA, Y; TAKAI, S; UEDA, Y; NISHIKAWA, S; YAGI, T; TOKUNAGA, T; TAKEDA, N; SUDA, Y; ABE, S; MATSUO, I; IKAWA, Y; AIZAWA, S			ENHANCED PROLIFERATIVE POTENTIAL IN CULTURE OF CELLS FROM P53-DEFICIENT MICE	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; EMBRYONIC STEM-CELLS; GERM-LINE CHIMERAS; WILD-TYPE P53; SPONTANEOUS IMMORTALIZATION; CYCLE CHECKPOINT; EPITHELIAL-CELLS; MESSENGER-RNA; GENE; FIBROBLASTS	Normal somatic cells are endowed with limited doubling potential in culture, and the process of immortalization is an inevitable step in neoplastic transformation of the cells. To examine the roles of p53 in this process, the cells of p53-deficient mice were examined for doubling potential. Fibroblast-like cells from a variety of tissues of these mice proliferated continuously without showing aging or crisis. The aneuploid cells overcome the population with passage, but cloning experiment indicated that chromosomal changes were not essential to this process. The enhanced proliferative potential in culture of cells from the p53-deficient mice was also observed in epithelial cells of lens, mammary glands and seminal vesicles and in neural precursor cells. Proliferation of bone marrow cells in response to stem cell factor was enhanced in long term culture, but not in in vitro colony assay; no permanent cell lines could be obtained. No effects of p53-deficiency were found in proliferation of cardiac muscle cells or hepatocytes.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC ONCOL LAB, TSUKUBA, IBARAKI 305, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, CELL BIOL LAB, TSUKUBA, IBARAKI 305, JAPAN; SAITAMA UNIV, FAC SCI, DEPT REGULAT BIOL, URAWA, SAITAMA 338, JAPAN; NATL MED CTR, CLIN RES INST, DIV GENET, SHINJUKU KU, TOKYO, TOKYO 162, JAPAN; SCI UNIV TOKYO, DEPT APPL BIOL SCI, NODA, CHIBA 278, JAPAN; KUMAMOTO UNIV, SCH MED, INST MOLEC EMBRYOL & GENET, MORPHOGENESIS LAB, KUMAMOTO, KUMAMOTO 860, JAPAN; TOKYO MED & DENT UNIV, SCH MED, DEPT BIOCHEM, TOKYO, TOKYO 113, JAPAN	RIKEN; RIKEN; Saitama University; Tokyo University of Science; Kumamoto University; Tokyo Medical & Dental University (TMDU)								AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; AIZAWA S, 1982, EXP CELL RES, V139, P416, DOI 10.1016/0014-4827(82)90269-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GOSHIMA K, 1976, J MOL CELL CARDIOL, V8, P217, DOI 10.1016/0022-2828(76)90038-9; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hogan B, 1986, MANIPULATING MOUSE E, P89; IMAGAWA W, 1982, P NATL ACAD SCI-BIOL, V79, P4074, DOI 10.1073/pnas.79.13.4074; IMAGAWA W, 1984, CELL CULTURE METHODS, V2, P127; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KITANI H, 1991, IN VITRO CELL DEV B, V27, P615; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUZAKI Y, 1992, J IMMUNOL, V149, P1069; MCKNIGHT GS, 1978, CELL, V14, P403; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NEMOTO N, 1993, JPN J CANCER RES, V84, P265, DOI 10.1111/j.1349-7006.1993.tb02866.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOGUCHI PD, 1978, J HISTOCHEM CYTOCHEM, V26, P761, DOI 10.1177/26.9.361885; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RITTLING SR, 1992, ONCOGENE, V7, P935; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROVINSKI B, 1988, ONCOGENE, V2, P445; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SAWADA N, 1987, IN VITRO CELL DEV B, V23, P267; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUDA T, 1989, BLOOD, V74, P1936; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; SUDA Y, 1987, J CELL PHYSIOL, V133, P197, DOI 10.1002/jcp.1041330127; SUDA Y, 1990, EMBO J, V9, P181, DOI 10.1002/j.1460-2075.1990.tb08094.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561; TOMOOKA Y, 1985, IN VITRO CELL DEV B, V21, P237, DOI 10.1007/BF02620935; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGI T, 1993, IN PRESS ANAL BIOCH; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	55	338	343	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3313	3322						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7504233				2022-12-25	WOS:A1993MG78200015
J	HANASH, SM; STRAHLER, JR; KUICK, R; CHU, EHY; NICHOLS, D				HANASH, SM; STRAHLER, JR; KUICK, R; CHU, EHY; NICHOLS, D			IDENTIFICATION OF A POLYPEPTIDE ASSOCIATED WITH THE MALIGNANT PHENOTYPE IN ACUTE-LEUKEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	HANASH, SM (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PEDIAT,R4451 KRESGE 1,BOX 0510,ANN ARBOR,MI 48109, USA.				NATIONAL CANCER INSTITUTE [R01CA032146] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 32146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREEFF M, 1986, SEMIN HEMATOL, V23, P300; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLICK M, 1984, BLOOD, V64, P1234; BOS JL, 1987, BLOOD, V69, P1237; CELIS JE, 1986, LEUKEMIA RES, V10, P237, DOI 10.1016/0145-2126(86)90021-4; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FRANSEN L, 1983, J BIOL CHEM, V258, P5276; GOLDSTEIN D, 1985, CANCER RES, V45, P5643; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; GREEN RJ, 1982, CANCER GENET CYTOGEN, V7, P247; HANASH SM, 1986, P NATL ACAD SCI USA, V83, P807, DOI 10.1073/pnas.83.3.807; HIRAI H, 1985, BLOOD, V66, P1371; JACOBSON BS, 1980, BIOCHIM BIOPHYS ACTA, V600, P769, DOI 10.1016/0005-2736(80)90479-4; Kessler S W, 1981, Methods Enzymol, V73, P442; KUICK RD, 1987, ELECTROPHORESIS, V8, P199, DOI 10.1002/elps.1150080405; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; STRAHLER JR, 1983, SCIENCE, V221, P860; TARR GE, 1986, MICROCHARACTERIZATIO, P155; THILLY WG, 1980, CHEM MUTAGENS, V6, P331; 1987, NBRF PIR PROTEIN SEQ	24	178	186	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12813	12815						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417633				2022-12-25	WOS:A1988Q091700006
J	LAGARIAS, JC; KLOTZ, AV; DALLAS, JL; GLAZER, AN; BISHOP, JE; OCONNELL, JF; RAPOPORT, H				LAGARIAS, JC; KLOTZ, AV; DALLAS, JL; GLAZER, AN; BISHOP, JE; OCONNELL, JF; RAPOPORT, H			EXCLUSIVE A-RING LINKAGE FOR SINGLY ATTACHED PHYCOCYANOBILINS AND PHYCOERYTHROBILINS IN PHYCOBILIPROTEINS - ABSENCE OF SINGLY D-RING-LINKED BILINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV CALIF BERKELEY,DEPT BIOCHEM & BIOPHYS,BERKELEY,CA 94720; UNIV CALIF DAVIS,DEPT BIOCHEM & BIOPHYS,DAVIS,CA 95616; GE,MED SYST GRP,FREMONT,CA 94539; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Davis; General Electric; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Lagarias, John Clark/L-3139-2013	Lagarias, John Clark/0000-0002-2093-0403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28994] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISHOP JE, 1986, J BIOL CHEM, V261, P6790; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; Glazer A. N., 1981, The biochemistry of plants. A comprehensive treatise. Volume 8. Photosynthesis., P51; GLAZER AN, 1973, J BIOL CHEM, V248, P659; GLAZER AN, 1979, ANAL BIOCHEM, V92, P489, DOI 10.1016/0003-2697(79)90689-4; GOSSAUER A, 1979, CHEM BER-RECL, V112, P2243, DOI 10.1002/cber.19791120631; GOSSAUER A, 1974, ANN CHEM J LIEBIGS, P1496; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KLOTZ AV, 1986, J BIOL CHEM, V261, P6797; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; KOEK JH, 1987, RECL TRAV CHIM PAY B, V106, P54; LAGARIAS JC, 1979, J AM CHEM SOC, V101, P5030, DOI 10.1021/ja00511a038; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; LUNDELL DJ, 1984, J BIOL CHEM, V259, P5472; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; NAGY JO, 1985, J BIOL CHEM, V260, P4864; NUT UH, 1985, 5TH INT S PHOT PROK, P304; OCARRA P, 1976, CHEM BIOCH PLANT PIG, P328; RUDIGER W, 1980, Z NATURFORSCH C, V35, P763; Scheer H., 1982, LIGHT REACTION PATH, P7; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SCHOENLEBER RW, 1984, J BIOL CHEM, V259, P5481; SCHOENLEBER RW, 1984, J BIOL CHEM, V259, P5485; SIDLER W, 1985, 5TH INT S PHOT PROK, P303; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; WILLIAMS VP, 1978, J BIOL CHEM, V253, P202	28	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12977	12985						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417648				2022-12-25	WOS:A1988Q091700035
J	REESE, RN; WINGE, DR				REESE, RN; WINGE, DR			SULFIDE STABILIZATION OF THE CADMIUM-GAMMA-GLUTAMYL PEPTIDE COMPLEX OF SCHIZOSACCHAROMYCES-POMBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV UTAH,MED CTR,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah	REESE, RN (corresponding author), UNIV UTAH,MED CTR,DEPT MED,SALT LAKE CITY,UT 84132, USA.				NIADDK NIH HHS [T32 AM07115] Funding Source: Medline; NIEHS NIH HHS [ES00147, ES03817] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817, K04ES000147] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON ME, 1986, P NATL ACAD SCI USA, V83, P5029, DOI 10.1073/pnas.83.14.5029; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; GRILL E, 1986, FEBS LETT, V197, P115, DOI 10.1016/0014-5793(86)80309-X; GRILL E, 1987, P NATL ACAD SCI USA, V84, P439, DOI 10.1073/pnas.84.2.439; HAYASHI Y, 1986, ENVIRON HEALTH PERSP, V65, P13, DOI 10.2307/3430156; KING T, 1957, METHOD ENZYMOL, V10, P634; KONDO N, 1984, TETRAHEDRON LETT, V25, P3869, DOI 10.1016/S0040-4039(01)91190-6; MEHRA RK, 1987, IN PRESS; MURASUGI A, 1984, J BIOCHEM-TOKYO, V96, P1375, DOI 10.1093/oxfordjournals.jbchem.a134965; MURASUGI A, 1983, J BIOCHEM-TOKYO, V93, P661, DOI 10.1093/oxfordjournals.jbchem.a134222; MUTCH N, 1988, BIOCHEM BIOPH RES CO, V151, P32; NOZIK AJ, 1985, J PHYS CHEM-US, V89, P397, DOI 10.1021/j100249a004; REESE RN, 1988, J BIOL CHEM, V263, P4186; REESE RN, 1987, BIOCHEM J, V241, P641, DOI 10.1042/bj2410641; ROSSETTI R, 1983, J CHEM PHYS, V79, P1086, DOI 10.1063/1.445834; ROSSETTI R, 1984, J CHEM PHYS, V80, P4464, DOI 10.1063/1.447228; STEFFENS JC, 1986, J BIOL CHEM, V261, P13879; WEBER DN, 1987, J BIOL CHEM, V262, P6962; 1976, STANDARD METHODS EXA, P499	20	139	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					12832	12835						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417637				2022-12-25	WOS:A1988Q091700011
J	ZOELLER, RA; MORAND, OH; RAETZ, CRH				ZOELLER, RA; MORAND, OH; RAETZ, CRH			A POSSIBLE ROLE FOR PLASMALOGENS IN PROTECTING ANIMAL-CELLS AGAINST PHOTOSENSITIZED KILLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Zoeller, Raphael/0000-0002-6560-0993	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021722] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21722] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN L H, 1987, Journal of Cell Biology, V105, p157A; BERGSTROM B, 1952, ACTA PHYSIOL SCAND, V25, P101; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; DAVIS PA, 1979, J BIOL CHEM, V254, P4760; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1978, P NATL ACAD SCI USA, V75, P1190, DOI 10.1073/pnas.75.3.1190; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FIBACH E, 1986, J CELL SCI, V85, P149; Foote C.S, 1976, FREE RADICALS BIOL, P85, DOI DOI 10.1016/B978-0-12-566502-5.50010-X; FOOTE CS, 1984, METHOD ENZYMOL, V105, P36; Frimer A. H., 1983, CHEM FUNCTIONAL GROU, P201; GATT S, 1988, BIOCHIM BIOPHYS ACTA, V958, P130, DOI 10.1016/0005-2760(88)90254-8; GOLDFINE H, 1987, BIOCHEMISTRY-US, V26, P2814, DOI 10.1021/bi00384a024; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; HAJRA AK, 1979, J BIOL CHEM, V254, P896; Horrocks L.A., 1982, NEW COMPR BIOCH, V4, P51, DOI [10.1016/s0167-7306(08)60006-x, DOI 10.1016/S0167-7306(08)60006-X]; KELLEY RI, 1986, AM J MED GENET, V23, P869, DOI 10.1002/ajmg.1320230404; KUGE O, 1986, J BIOL CHEM, V261, P5790; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGOLD HK, 1983, ETHER LIPIDS; MORAND O, 1982, BIOCHIM BIOPHYS ACTA, V711, P539, DOI 10.1016/0005-2760(82)90070-4; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MOSLEY ST, 1981, P NATL ACAD SCI-BIOL, V78, P5717, DOI 10.1073/pnas.78.9.5717; MUELLER HW, 1984, J LIPID RES, V25, P383; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; OWENS K, 1966, BIOCHEM J, V100, P354, DOI 10.1042/bj1000354; PAK JH, 1987, BIOCHEMISTRY-US, V26, P4824, DOI 10.1021/bi00389a033; PATTERSON MS, 1965, ANAL CHEM, V37, P854, DOI 10.1021/ac60226a017; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; ROTERING H, 1983, J BIOL CHEM, V258, P8068; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SCOTT TW, 1967, BIOCHEM J, V104, P1040, DOI 10.1042/bj1041040; SNYDER F, 1985, BIOCH LIPIDS MEMBRAN, P271; SUGIURA T, 1983, LIPIDS, V18, P125, DOI 10.1007/BF02536106; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1987, FASEB J, V46, P2112	39	305	313	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1988	263	23					11590	11596						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P6713	3403547				2022-12-25	WOS:A1988P671300093
J	LI, H; DEYRUP, A; MENSCH, JR; DOMOWICZ, M; KONSTANTINIDIS, AK; SCHWARTZ, NB				LI, H; DEYRUP, A; MENSCH, JR; DOMOWICZ, M; KONSTANTINIDIS, AK; SCHWARTZ, NB			THE ISOLATION AND CHARACTERIZATION OF CDNA-ENCODING THE MOUSE BIFUNCTIONAL ATP SULFURYLASE-ADENOSINE 5'-PHOSPHOSULFATE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATED ENZYME INTERMEDIATE; SULFATE ACTIVATION LOCUS; ADENOSINE-5'-PHOSPHOSULFATE KINASE; BRACHYMORPHIC MICE; ESCHERICHIA-COLI; PURIFICATION; SEQUENCE; IDENTIFICATION; CLONING; DEFECT	Biosynthesis of the activated sulfate donor, adenosine 3'-phosphate 5'-phosphosulfate, involves the sequential action of two enzyme activities: ATP sulfurylase, which catalyzes the formation of adenosine 5'-phosphosulfate (APS) from ATP and free sulfate, and APS kinase, which subsequently phosphorylates APS to produce adenosine 3'-phosphate 5'-phosphosulfate. Oligonucleotide primers were derived from a human infant brain-expressed sequence tag putatively encoding a portion of APS kinase. Using these primers, reverse transcriptase-polymerase chain reaction was performed on mRNA from neonatal normal mice resulting in amplification of a 127-bp DNA fragment. This fragment was subsequently used to screen a mouse brain lambda gt11 cDNA library, yielding a 2.2-kb clone. Primers were designed from the 5'-end of the 2.2-kb clone, and 5'-rapid amplification of cDNA ends was used to obtain the translation start site. Sequence from the overlapping clones was assembled into a 2475-bp composite sequence, which contains a single open reading frame that translates into a 624-deduced amino acid sequence. Northern blots of total RNA from neonatal mice yielded a single message species at approximately 3.3 kb. Southern blot of genomic DNA digested with several restriction enzymes suggested the gene is present as a single copy. Comparison against sequence data bases suggested the composite sequence was a fused sulfurylase-kinase product, since the deduced amino acid sequence showed extensive homology to known separate sequences of both ATP sulfurylase and APS kinase from several sources. The first 199 amino acids corresponded to APS kinase sequence, followed by 37 distinct amino acids, which did not match any known sequence, followed by 388 amino acids that are highly homologous to known ATP sulfurylase sequences. Finally, recombinant enzyme expressed in COS-1 cells exhibited both ATP sulfurylase and APS kinase activity.	UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago			Domowicz, Miriam/AAG-7886-2022; Domowicz, Miriam/AFL-7930-2022	Domowicz, Miriam/0000-0001-7860-4427; Domowicz, Miriam/0000-0001-7860-4427	NIAMS NIH HHS [AR-19622] Funding Source: Medline; NICHD NIH HHS [HD-17332, HD-09402] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332, P01HD009402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR019622, R01AR019622] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARZ HE, 1994, BBA-GENE STRUCT EXPR, V1218, P447, DOI 10.1016/0167-4781(94)90203-8; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GELLER DH, 1987, J BIOL CHEM, V262, P7374; JENDER HG, 1984, ARCH MICROBIOL, V138, P9, DOI 10.1007/BF00425399; LAUE BE, 1994, J BACTERIOL, V176, P3723, DOI 10.1128/JB.176.12.3723-3729.1994; LEUSTEK T, 1994, PLANT PHYSIOL, V105, P897, DOI 10.1104/pp.105.3.897; LEYH TS, 1988, J BIOL CHEM, V263, P2409; LEYH TS, 1992, J BIOL CHEM, V267, P542; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LI H, 1993, J BIOL CHEM, V268, P23504; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; LYLE S, 1994, BIOCHEM J, V301, P349, DOI 10.1042/bj3010349; LYLE S, 1994, BIOCHEMISTRY-US, V33, P6822, DOI 10.1021/bi00188a010; LYLE S, 1994, BIOCHEM J, V301, P355, DOI 10.1042/bj3010355; LYLE S, 1995, BIOCHEMISTRY-US, V34, P940, DOI 10.1021/bi00003a028; NOZAWA A, 1980, BIOCHIM BIOPHYS ACTA, V611, P309, DOI 10.1016/0005-2744(80)90066-2; ONAJOBI FD, 1973, PLANT PHYSIOL, V52, P580, DOI 10.1104/pp.52.6.580; OPPENHEIM DS, 1980, GENETICS, V95, P785; RENOSTO F, 1991, ARCH BIOCHEM BIOPHYS, V290, P66, DOI 10.1016/0003-9861(91)90592-7; RENOSTO F, 1990, J BIOL CHEM, V265, P10300; RENOSTO F, 1984, J BIOL CHEM, V259, P2113; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; SATISHCHANDRAN C, 1989, J BIOL CHEM, V264, P15012; SCHWEDOCK JS, 1994, J BACTERIOL, V176, P7055, DOI 10.1128/JB.176.22.7055-7064.1994; SCHWEDOCK JS, 1992, GENETICS, V132, P899; SERASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430; SEUBERT PA, 1980, CIBA F S, V72, P19; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; YATES JL, 1981, CELL, V21, P243	41	82	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29453	29459		10.1074/jbc.270.49.29453	http://dx.doi.org/10.1074/jbc.270.49.29453			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493984	hybrid			2022-12-25	WOS:A1995TJ22700065
J	CHA, MK; KIM, HK; KIM, IH				CHA, MK; KIM, HK; KIM, IH			THIOREDOXIN-LINKED THIOL PEROXIDASE FROM PERIPLASMIC SPACE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE DISMUTASE; ANTIOXIDANT PROTEIN; OXIDATIVE DAMAGE; DNA; GLUTATHIONE; OVOTHIOL	Three different molecular masses (24, 22, and 20 kDa) of antioxidant proteins were purified in Escherichia coli. These proteins exhibited the preventive effects against the inactivation of glutamine synthetase activity and the cleavage of DNA by a metal-catalyzed oxidation system capable of generating reactive oxygen species. Their antioxidant activities were supported by a thiol-reducing equivalent such as dithiothreitol. Analysis of the amino-terminal amino acid sequences and the immunoblots between 24 and 22-kDa proteins indicates that the 24-kDa protein is an intact form of the 22-kDa protein that was previously identified 22-kDa subunit (AhpC) of E. coli alkyl hydroperoxide reductase (AhpC/AhpF). We isolated and sequenced an E. coli genomic DNA fragment that encodes 20-kDa protein. Comparison of the deduced amino acid sequence of the 20-kDa protein with that of AhpC revealed no sequence homology. A search of a data bank showed that the 20-kDa protein is a new type of antioxidant enzyme. The synthesis of this novel 20-kDa protein was increased in response to oxygen stress during growth. The 20-kDa protein resides mainly in the periplasmic space of E. coli, whereas the 24-kDa AhpC resides mainly in the matrix. The 20-kDa protein was functionally linked to the thioredoxin as an in vivo thiol-regenerating system and exerted a peroxidase activity. This 20-kDa protein is thus named ''thiol peroxidase,'' which could act as an antioxidant enzyme removing peroxides or H2O2 within the catalase- and peroxidase-deficient periplasmic space of E. coli.	PAI CHAI UNIV,DEPT BIOCHEM,TAEJON 302735,SOUTH KOREA	Pai Chai University			Kim, Il-Han/W-1401-2019					BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, BIOFACTORS, V4, P177; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7072; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; CLAYCAMP HG, 1987, BIOCHEM BIOPH RES CO, V144, P432, DOI 10.1016/S0006-291X(87)80528-4; Crapo J D, 1978, Methods Enzymol, V53, P382; FRIDOVICH I, 1976, ANN REV BIOCH, V44, P147; GREGORY EM, 1973, J BACTERIOL, V115, P987, DOI 10.1128/JB.115.3.987-991.1973; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HASSAN HM, 1977, J BACTERIOL, V129, P1574, DOI 10.1128/JB.129.3.1574-1583.1977; HEPPEL LA, 1967, SCIENCE, V156, P1451, DOI 10.1126/science.156.3781.1451; HOLLER TP, 1988, J AM CHEM SOC, V110, P4837, DOI 10.1021/ja00222a057; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; MEAD JF, 1976, FREE RADICALS BIOLOG, V1, P51; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLIWKOWSKI MX, 1985, ANAL BIOCHEM, V147, P369, DOI 10.1016/0003-2697(85)90284-2; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Tappel A L, 1978, Methods Enzymol, V52, P506; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; TURNER E, 1988, SCIENCE, V242, P939, DOI 10.1126/science.3187533; YOST FJ, 1973, J BIOL CHEM, V248, P4905	32	126	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28635	28641		10.1074/jbc.270.48.28635	http://dx.doi.org/10.1074/jbc.270.48.28635			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499381	hybrid			2022-12-25	WOS:A1995TH05600025
J	KO, K; BUDD, D; WU, CB; SEIBERT, F; KOURTZ, L; KO, ZW				KO, K; BUDD, D; WU, CB; SEIBERT, F; KOURTZ, L; KO, ZW			ISOLATION AND CHARACTERIZATION OF A CDNA CLONE ENCODING A MEMBER OF THE COM44/CIM44 ENVELOPE COMPONENTS OF THE CHLOROPLAST PROTEIN IMPORT APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; TRANSIT PEPTIDE; SPINACH-CHLOROPLASTS; CONTACT SITES; IDENTIFICATION; POLYPEPTIDES; LOCALIZATION; INNER; TRANSLOCATION; PRECURSORS	Many of the proteins in the chloroplast envelope play an important role in facilitating the biochemical and transport processes of the compartment, For the transport of proteins into the chloroplast, we have recently identified at least three different envelope proteins (Com44/Cim44, Com70, and Cim97) in close physical proximity to a partially translocated chimeric precursor protein (Wu, C., Seibert, F. S., and Ko, K. (1994) J. Biol. Chem, 269, 32264-32271), In this study we report the characterization of a cDNA clone encoding a member of the Com44/Cim44 envelope proteins, The combined data from nucleotide sequencing, and RNA and protein blot analyses indicate the existence of multiple forms of the 44-kDa envelope protein, Depending on the plant species examined, immunologically-related protein bands with molecular masses of 42 to 46 kDa were observed, Organelle subfractionation, protease treatment, and immunomicroscopic studies together provide an indication that the immunologically-related proteins may be present in both the outer and inner envelope membranes, Go-migration of the product synthesized from the cDNA insert with a 44-kDa immunoreactive band of the chloroplast envelope, and the in vitro import results, together suggest that the in vitro synthesized 44-kDa protein is targeted to the envelope membrane without any further processing.			KO, K (corresponding author), QUEENS UNIV, DEPT BIOL, KINGSTON, ON K7L 3N6, CANADA.							ALEFSEN H, 1994, J PLANT PHYSIOL, V144, P339, DOI 10.1016/S0176-1617(11)81196-X; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CASHMORE AR, 1982, METHODS CHLOROPLAST, P387; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CLINE K, 1985, J BIOL CHEM, V260, P3691; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DRESESWERRINGLOER U, 1991, EUR J BIOCHEM, V195, P361, DOI 10.1111/j.1432-1033.1991.tb15714.x; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; GIULIANO G, 1988, EMBO J, V7, P3635, DOI 10.1002/j.1460-2075.1988.tb03244.x; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HINZ G, 1988, EUR J BIOCHEM, V175, P649, DOI 10.1111/j.1432-1033.1988.tb14241.x; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; HUNYH TV, 1985, DNA CLONING PRACTICA, V1, P49; JOYARD J, 1983, J BIOL CHEM, V258, P1; KADERBHAI MA, 1988, FEBS LETT, V232, P313, DOI 10.1016/0014-5793(88)80760-9; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KO K, 1994, PLANT PHYSIOL, V104, P1087, DOI 10.1104/pp.104.3.1087; KO K, 1992, J BIOL CHEM, V267, P2986; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; Maniatis T., 1982, MOL CLONING; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SEEDORF M, 1995, FEBS LETT, V367, P19, DOI 10.1016/0014-5793(95)00529-I; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SOLL J, 1992, PLANT J, V2, P253, DOI 10.1111/j.1365-313X.1992.00253.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WAN JX, 1995, J BIOL CHEM, V270, P16731, DOI 10.1074/jbc.270.28.16731; WU CB, 1993, J BIOL CHEM, V268, P19384; WU CB, 1994, J BIOL CHEM, V269, P32264	43	55	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28601	28608		10.1074/jbc.270.48.28601	http://dx.doi.org/10.1074/jbc.270.48.28601			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499376	hybrid			2022-12-25	WOS:A1995TH05600020
J	RIBAR, TJ; JAN, CR; AUGUSTINE, GJ; MEANS, AR				RIBAR, TJ; JAN, CR; AUGUSTINE, GJ; MEANS, AR			DEFECTIVE GLYCOLYSIS AND CALCIUM SIGNALING UNDERLIE IMPAIRED INSULIN-SECRETION IN A TRANSGENIC MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PATCH-CLAMP TECHNIQUES; ISLET CELLS; K+ CHANNELS; B-CELL; MICE; CALMODULIN; GLUCOSE; ELECTROPHYSIOLOGY; RELEASE	Pancreatic beta cells from mice that overexpress the Ca2+-binding protein calmodulin have a unique secretory defect that leads to chronic hyperglycemia. To further understand the molecular basis underlying this defect, we have studied signaling pathways in these beta cells, Measurements of cytosolic free Ca2+ concentration ([Ca2+](i)) using fura-2 or indo-1 revealed a markedly reduced response when glucose was the stimulant, However, eliciting membrane depolarization with 50 mM K+ or the addition of the ATP-sensitive K+ (K-ATP(+)) channel antagonist tolbutamide restored [Ca2+](i) transients to near normal levels. Electrophysiological analysis of the beta cell ion channels revealed that Ca2+ currents, delayed rectifier K+ currents, and K-ATP(+) channel currents were similar in transgenic and nontransgenic cells, suggesting that these ion channels were able to function normally. However, whereas K-ATP(+) channel currents in control cells were reduced by 50% by the presence of high glucose, those in transgenic cells were unaltered, Addition of tolbutamide inhibited this channel and enhanced the secretion of insulin in response to glucose for both control and transgenic cells, As these observations implicated a metabolic defect, glucose utilization, which is an indicator of glucose metabolism and ATP production in beta cells, was measured and found to be reduced by 40% in the transgenic cells. These data support the contention that excessive levels of calmodulin may compromise the ability of the beta cell. to metabolize glucose and to modulate the state of the K-ATP(+) channel, resulting in an inadequate control of the membrane potential, which collectively impair [Ca2+](i) and thus insulin secretion in response to glucose.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University; Duke University			Augustine, George James/J-9228-2013		NIDDK NIH HHS [DK-43017] Funding Source: Medline; NINDS NIH HHS [NS-21624] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021624] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; ASHCROFT FM, 1987, J PHYSIOL-LONDON, V385, P517, DOI 10.1113/jphysiol.1987.sp016505; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; DUKES ID, 1994, J BIOL CHEM, V269, P10979; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; EPSTEIN PN, 1992, ENDOCRINOLOGY, V130, P1387, DOI 10.1210/en.130.3.1387; GILON P, 1992, J BIOL CHEM, V267, P20713; GOROIX MH, 1990, DIABETOLOGIA, V33, P654; GRODSKY GM, 1966, DIABETES, V15, P910, DOI 10.2337/diab.15.12.910; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; JONES PM, 1992, BIOCHEM J, V285, P973, DOI 10.1042/bj2850973; MCDERMOTT AM, 1993, CELL SIGNAL, V5, P229, DOI 10.1016/0898-6568(93)90014-D; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MISLER S, 1989, DIABETES, V38, P422, DOI 10.2337/diabetes.38.4.422; MISLER S, 1992, DIABETES, V41, P662, DOI 10.2337/diabetes.41.6.662; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; NORLING LL, 1994, CELL CALCIUM, V16, P137, DOI 10.1016/0143-4160(94)90008-6; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RIBAR TJ, 1995, ENDOCRINOLOGY, V136, P106, DOI 10.1210/en.136.1.106; SAKMANN B, 1984, ANNU REV PHYSIOL, V46, P455, DOI 10.1146/annurev.ph.46.030184.002323; SENER A, 1987, BIOCHEM J, V246, P89, DOI 10.1042/bj2460089; SHIZURU JA, 1991, TRENDS ENDOCRIN MET, V2, P97, DOI 10.1016/S1043-2760(05)80004-9; SMOLEN P, 1993, BIOPHYS J, V64, P1668, DOI 10.1016/S0006-3495(93)81539-X; TAL M, 1992, P NATL ACAD SCI USA, V89, P5744, DOI 10.1073/pnas.89.13.5744; TSUURA Y, 1992, DIABETES, V41, P861, DOI 10.2337/diabetes.41.7.861; VALVERDE I, 1984, EXPERIENTIA, V40, P1061, DOI 10.1007/BF01971452; WOLLHEIM CB, 1987, BIOSCIENCE REP, V7, P443, DOI 10.1007/BF01362507	35	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28688	28695		10.1074/jbc.270.48.28688	http://dx.doi.org/10.1074/jbc.270.48.28688			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499389	hybrid			2022-12-25	WOS:A1995TH05600033
J	FUENTES, GM; RODRIGUEZRODRIGUEZ, L; FAY, PJ; BAMBARA, RA				FUENTES, GM; RODRIGUEZRODRIGUEZ, L; FAY, PJ; BAMBARA, RA			USE OF AN OLIGORIBONUCLEOTIDE CONTAINING THE POLYPURINE TRACT SEQUENCE AS A PRIMER BY HIV REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; PLUS-STRAND DNA; RNASE-H ACTIVITY; FEATURES IMPORTANT; INITIATION; INTEGRATION; REMOVAL	A primary site for initiation of plus strand DNA synthesis in human immunodeficiency virus (HIV) corresponds to a 19-nucleotide-long purine rich sequence located just upstream of the U3 region, designated the polypurine tract (PPT), The HIV reverse transcriptase (RT) uses its RNase H activity to cut the genomic RNA after minus strand DNA synthesis, A plus strand PPT primer is formed, extended, and then removed, In vitro, the HIV-RT recognizes this primer specifically, using it much more efficiently than other RNA primers, However, the PPT still primes significantly less efficiently than DNA primers, The 19-nucleotide PPT primer is partially resistant to degradation when compared with other oligoribonucleotides. Prior to initiation of DNA synthesis, several nucleotides are removed by the RT from the 3' ends of some of the PPT primers, Cleavage is enhanced in the absence of dNTPs. We suggest that DNA synthesis suppresses primer degradation, so that primer extension and cleavage occur in proper sequence, As a result of 3' end degradation, PPT elongation products contain 5'-RNA segments from 16 to 19 nucleotides in length, These shorter segments are also generated from a longer transcript containing the PPT sequence, indicating that they are not created as a result of binding of the RT to the 5' end of the PPT oligoribonucleotide. Full-length and shorter versions of the PPT primers are cleaved from the extended DNA by RT, These experiments show that HIV-RT has a specificity to generate a primer in the region of the PPT but that the ends of the primer are not well defined.	UNIV ROCHESTER, SCH MED & DENT, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NIAID NIH HHS [AI 01146] Funding Source: Medline; NIGMS NIH HHS [GM 49573, 1F 31 GM 17200-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573, F31GM017200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1994, BBA-GENE STRUCT EXPR, V1219, P380, DOI 10.1016/0167-4781(94)90062-0; FEDEROFF OY, 1993, J MOL BIOL, V233, P509; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HUBER HE, 1990, J BIOL CHEM, V265, P10565; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P739, DOI 10.1021/bi00054a002; Sambrook J, 1989, MOL CLONING LABORATO; SEN D, 1992, METHOD ENZYMOL, V211, P191; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WHORL B, 1990, BIOCHEMISTRY-US, V29, P10141	25	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28169	28176						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499308	hybrid			2022-12-25	WOS:A1995TG21000033
J	GUAGLIARDI, A; CERCHIA, L; ROSSI, M				GUAGLIARDI, A; CERCHIA, L; ROSSI, M			PREVENTION OF IN-VITRO PROTEIN THERMAL AGGREGATION BY THE SULFOLOBUS-SOLFATARICUS CHAPERONIN - EVIDENCE FOR NONEQUIVALENT BINDING SURFACES ON THE CHAPERONIN MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DENATURATION; COMPLEX; INVITRO; HSP60; GROEL; CELL	We have studied the effects of the Sulfolobus solfataricus chaperonin on the aggregation and inactivation upon heating of four model enzymes: chicken egg white lysozyme (one 14.4-kDa chain), yeast alpha-glucosidase (one 68.5-kDa chain), chicken liver malic enzyme (four 65-kDa subunits), and yeast alcohol dehydrogenase (four 37.5-kDa subunits). When the proteins were heated in the presence of an equimolar amount of chaperonin, 1) the aggregation was prevented in all solutions; 2) the inactivation profiles of the single-chain enzymes were comparable with those detected in the absence of the chaperonin, and enzyme activities were regained in the solutions heated in the presence of the chaperonin upon ATP hydrolysis (78 and 55% activity regains for lysozyme and alpha-glucosidase, respectively); 3) the inactivation of the tetrameric enzymes was completely prevented, whereas the activities decreased in the absence of the chaperonin. We demonstrate by gel filtration chromatography that the chaperonin interacted with the structures occurring during thermal denaturation of the model proteins and that the interaction with the single-chain proteins (but not that with the tetrameric proteins) was reversed upon ATP hydrolysis, The chaperonin had nonequivalent surfaces for the binding of the model proteins upon heating: the thermal denaturation intermediates of the single-chain proteins share Surfaces I, while the thermal denaturation intermediates of the tetrameric proteins share Surfaces II, ATP binding to the chaperonin induced a conformation that lacked Surfaces I and carried Surfaces II, These data support the concept that chaperonins protect native proteins against thermal aggregation by two mechanistically distinct strategies (an ATP-dependent strategy and an ATP-independent strategy), and provide the first evidence that a chaperonin molecule bears functionally specialized surfaces for the binding of the protein substrates.	CNR, IST BIOCHIM PROT & ENZIMOL, I-80125 NAPLES, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	GUAGLIARDI, A (corresponding author), UNIV NAPLES, DIPARTIMENTO CHIM ORGAN & BIOL, VIA MEZZOCANNONE 16, I-80134 NAPLES, ITALY.			Cerchia, Laura/0000-0002-7633-7932				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; DEMACARIO EC, 1994, TRENDS BIOTECHNOL, V12, P512, DOI 10.1016/0167-7799(94)90059-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Halvorson H., 1966, METHODS ENZYMOL, V8, P559, DOI [10.1016/0076-6879(66)08101-1, DOI 10.1016/0076-6879(66)08101-1]; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KNAPP S, 1994, J MOL BIOL, V242, P397; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCO S, 1994, FEBS LETT, V341, P152, DOI 10.1016/0014-5793(94)80447-8; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; NGUYEN VT, 1994, EUR J BIOCHEM, V220, P239; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; TSUGITA A, 1968, J BIOL CHEM, V243, P391; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	34	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28126	28132						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499301				2022-12-25	WOS:A1995TG21000026
J	CIOSSEK, T; LERCH, MM; ULLRICH, A				CIOSSEK, T; LERCH, MM; ULLRICH, A			CLONING, CHARACTERIZATION, AND DIFFERENTIAL EXPRESSION OF MDK2 AND MDK5, 2 NOVEL RECEPTOR TYROSINE KINASES OF THE ECK/EPH FAMILY	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; EPH/ECK FAMILY; EMBRYONIC DEVELOPMENT	GROWTH-FACTOR RECEPTOR; EPH GENE; MOUSE; DNA; SEQUENCES; CELLS; ELK	Using a polymerase chain reaction-based strategy for the cloning of developmentally regulated receptor tyrosine kinases, we identified two novel members of the eck/eph-related subfamily which, in analogy with the recently identified mouse developmental kinase 1 (MDK1), were designated MDK2 and MDK5. MDK2 is highly homologous to the mouse kinase Myk-1 and the human kinase Htk, whereas MDK5 represents the mouse homologue of human Hek2. Northern blot analyses of adult mouse tissues revealed a 4.7 kb transcript of MDK2 and a 4.8 kb transcript of MDK5 in various organ systems, including lung, liver, kidney, intestine, muscle, heart, and, in the case of MDK5, also the brain, In addition to the full-length transcripts, smaller fragments were identified that probably represent truncated receptors. Northern blot analysis and in situ hybridization of mouse embryos indicated abundant expression during embryonic development, with preferential involvement of tissues of epithelial and endothelial origin for both kinases and of the spinal cord gray matter for MDK5, Unlike most other members of the eck/eph-related subfamily, the expression of MDK2 and MDK5 is not primarily restricted to neuronal structures, and their abundant presence in various organ systems during embryonic development suggests an important role in gestational growth and differentiation.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BOHME B, 1993, ONCOGENE, V8, P2857; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIOSSEK T, 1995, ONCOGENE, V9, P97; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDLY BM, 1990, CANCER RES, V50, P1550; FLETCHER FA, 1994, ONCOGENE, V9, P3241; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; HANKS SK, 1988, SCIENCE, V241, P445; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1989, P NATL ACAD SCI USA, V88, P5449; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SDAMBROOK J, 1989, MOL CLONING LABORATO; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAYLOR V, 1994, ONCOGENE, V63, P163; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONDERGEER P, 1994, ANN REV CELL BIOL, V10, P251; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	56	58	64	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2085	2095						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478528				2022-12-25	WOS:A1995TF29700019
J	DESTEFANO, JJ; BAMBARA, RA; FAY, PJ				DESTEFANO, JJ; BAMBARA, RA; FAY, PJ			THE MECHANISM OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE TRANSCRIPTASE-CATALYZED STRAND TRANSFER FROM INTERNAL REGIONS OF HETEROPOLYMERIC RNA TEMPLATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-RECOMBINATION; RETROVIRAL RECOMBINATION; RIBONUCLEASE H; GENOMES; ENDONUCLEASE; DISPLAYS	The mechanism of human immunodeficiency virus reverse transcriptase-catalyzed strand transfer synthesis (i.e. switching of the primer to a new template) from internal regions of natural sequence RNA was investigated. The system consisted of a 142-nucleotide RNA template (donor) primed with a specific 20-nucleotide DNA oligonucleotide used to initiate synthesis. DNA oligonucleotides with homology to internal regions of the donor were used as acceptor templates. In reactions performed in the absence of acceptor template, a prominent DNA synthesis product 75 nucleotides in length resulting from pausing DNA synthesis within the homology zone was observed. Prominent donor RNA degradation products of 47 or 54 nucleotides were also observed, in reactions with 80 or 150 mM KCl, respectively. The lengths indicated a potential 13- or 20-nucleotide long, respectively, complementary region between the DNA and RNAs. The 54-, but not the 47-, nucleotide RNA was susceptible to Escherichia coli RNase H, indicating that the DNA was annealed only to the 54-mer. When acceptor was added, a portion of the 75-nucleotide DNA was chased into transfer product at both salt concentrations, and a portion of the 54-mer RNA became resistant to E. coli RNase H. Evidently, this donor RNA was annealed to the 75-nucleotide long DNA but could be actively displaced by the acceptor. Overall, these observations support two mechanisms for transfer. In one, the pause site-specific DNA dissociates from the donor template before transferring. In the other, the acceptor actively displaces the DNA from the donor.	UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hunter E, 1978, Curr Top Microbiol Immunol, V79, P295; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; STARNES MC, 1989, J BIOL CHEM, V264, P7073; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; VOGT PK, 1973, POSSIBLE EPISOMES EU, P35; VOLKMANN S, 1993, J BIOL CHEM, V268, P2674; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; ZHANG JY, 1993, SCIENCE, V259, P234, DOI 10.1126/science.8421784	21	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					161	168						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506252				2022-12-25	WOS:A1994MR21900033
J	BRADSHER, JN; TAN, SY; MCLAURY, HJ; CONAWAY, JW; CONAWAY, RC				BRADSHER, JN; TAN, SY; MCLAURY, HJ; CONAWAY, JW; CONAWAY, RC			RNA POLYMERASE-II TRANSCRIPTION FACTOR-SIII .2. FUNCTIONAL-PROPERTIES AND ROLE IN RNA CHAIN ELONGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR; FACTOR-EPSILON; FACTOR-DELTA; RAT-LIVER; PREINITIATION COMPLEX; FACTOR-ALPHA; CALF THYMUS; FACTOR-TAU; GENE; PURIFICATION	A novel transcription factor that stimulates synthesis of accurately initiated transcripts by mammalian RNA polymerase II has been identified and purified to apparent homogeneity from rat liver extracts (Bradsher, J. N., Jackson, K. W., Conaway, R. C., Conaway, J. W. (1993) J. Biol. Chem. 268, 25587-25593). This factor, which we designate SIII, has a native molecular mass of approximately 140 kDa and is composed of three polypeptides of 110, 18, and 15 kDa. In this report, we demonstrate that SIII stimulates promoter-specific transcription by increasing the overall rate of RNA chain elongation by RNA polymerase II. Results of pulse-chase experiments indicate that SIII does not need to be present during preinitiation complex formation or transcription initiation in order to stimulate promoter-specific transcription. In addition, SIII is able to stimulate the rate of RNA chain elongation by RNA polymerase II during transcription of double stranded oligo(dC)-tailed templates. Taken together, these findings indicate that the factor exerts its activity directly on the elongation complex.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; ERNST H, 1983, MOL CELL BIOL, V3, P2172, DOI 10.1128/MCB.3.12.2172; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	46	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25594	25603						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503981				2022-12-25	WOS:A1993MK10000048
J	GU, WG; POWELL, W; MOTE, J; REINES, D				GU, WG; POWELL, W; MOTE, J; REINES, D			NASCENT RNA CLEAVAGE BY ARRESTED RNA POLYMERASE-II DOES NOT REQUIRE UPSTREAM TRANSLOCATION OF THE ELONGATION COMPLEX ON DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-ALPHA; ESCHERICHIA-COLI; TRANSCRIPTION ELONGATION; TERNARY COMPLEXES; WHEAT-GERM; CALF THYMUS; FACTOR-SII; RAT-LIVER; AMANITIN; TERMINATION	Obstacles incurred by RNA polymerase II during primary transcript synthesis have been identified in vivo and in vitro. Transcription past these impediments requires SII, an RNA polymerase II-binding protein. SII also activates a nuclease in arrested elongation complexes and this nascent RNA shortening precedes transcriptional readthrough. Here we show that in the presence of SII and nucleotides, transcript cleavage is detected during SII-dependent elongation but not during SII-independent transcription. Thus, under typical transcription conditions, SII is necessary but insufficient to activate RNA cleavage. RNA cleavage could serve to move RNA polymerase II away from the transcriptional impediment and/or permit RNA polymerase II multiple attempts at RNA elongation. By mapping the positions of the 3'-ends of RNAs and the elongation complex on DNA, we demonstrate that upstream movement of RNA polymerase II is not required for limited RNA shortening (seven to nine nucleotides) and reactivation of an arrested complex. Arrested complexes become elongation competent after removal of no more than nine nucleotides from the nascent RNA's 3'-end. Further cleavage of nascent RNA, however, does result in ''backward'' translocation of the enzyme. We also show that one round of RNA cleavage is insufficient for full readthrough at an arrest site, consistent with a previously suggested mechanism of SII action.	EMORY UNIV,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243; Powell, Wade H./0000-0002-3727-2822	NIGMS NIH HHS [GM-46331, R01 GM046331, GM-08367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367, R01GM046331] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENGAL E, 1989, J BIOL CHEM, V264, P18926; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P1; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; EILAT D, 1984, J IMMUNOL, V133, P489; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; GARIGLIO P, 1974, FEBS LETT, V44, P330, DOI 10.1016/0014-5793(74)81170-1; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JOB C, 1992, BIOCHEM J, V285, P85, DOI 10.1042/bj2850085; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; Maxam A M, 1980, Methods Enzymol, V65, P499; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1993, IN PRESS TRANSCRIPTI; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RIVA M, 1987, J BIOL CHEM, V262, P14377; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPARKOWSKI J, 1992, GENETICS, V130, P411; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; VAISIUS AC, 1982, BIOCHEMISTRY-US, V21, P3097, DOI 10.1021/bi00256a010; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WIEST DK, 1992, J BIOL CHEM, V267, P7733	49	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25604	25616						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503982				2022-12-25	WOS:A1993MK10000049
J	GERTH, WA				GERTH, WA			NITROGEN BINDING TO DEOXYHEMOGLOBIN AT HIGH-PRESSURES AND ITS RELATION TO CHANGES IN HEMOGLOBIN-OXYGEN AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									DUKE UNIV, MED CTR, DEPT PHYSIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT ANESTHESIOL, DURHAM, NC 27710 USA	Duke University; Duke University	GERTH, WA (corresponding author), DUKE UNIV, MED CTR, FG HALL LAB ENVIRONM RES, DURHAM, NC 27710 USA.				NIGMS NIH HHS [GM-34600] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034600] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTINO R, 1968, J AM OIL CHEM SOC, V45, P830, DOI 10.1007/BF02540163; BROWN FF, 1976, PROC R SOC SER B-BIO, V193, P387, DOI 10.1098/rspb.1976.0053; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P13; CAREY FG, 1977, J BIOL CHEM, V252, P4102; DRAPER NR, 1966, APPLIED REGRESSION A; ENNS T, 1965, J PHYS CHEM-US, V69, P389, DOI 10.1021/j100886a005; EYRING H, 1973, ANESTHESIOLOGY, V38, P415, DOI 10.1097/00000542-197305000-00001; FEATHERSTONE RM, 1971, UNDERWATER PHYSL, P95; FRANKS NP, 1978, NATURE, V274, P339, DOI 10.1038/274339a0; GERTH WA, 1985, ARCH BIOCHEM BIOPHYS, V241, P187, DOI 10.1016/0003-9861(85)90375-3; Hawkins JA, 1936, J BIOL CHEM, V113, P273; KIESOW L A, 1974, Undersea Biomedical Research, V1, P29; KRETSINGER RH, 1968, J MOL BIOL, V31, P305, DOI 10.1016/0022-2836(68)90446-4; LAASBERG LH, 1971, J BIOL CHEM, V246, P4886; LAWRENCE JH, 1947, J PHYSIOL-LONDON, V105, P197; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILLAR RA, 1971, BRIT J ANAESTH, V43, P1003, DOI 10.1093/bja/43.11.1003; MILLER KW, 1973, MOL PHARMACOL, V9, P131; MORTIMER RG, 1960, J PHYS CHEM-US, V64, P387, DOI 10.1021/j100833a002; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; Prausnitz J.M., 1969, MOL THERMODYNAMICS F; Reid R., 1977, PROPERTIES GASES LIQ, V4th; ROSS PD, 1977, J MOL BIOL, V112, P437, DOI 10.1016/S0022-2836(77)80191-5; ROSS PD, 1978, BIOPOLYMERS, V17, P2285, DOI 10.1002/bip.1978.360170920; SCHOENBO.BP, 1967, NATURE, V214, P1120, DOI 10.1038/2141120a0; SCHOENBORN BP, 1969, J MOL BIOL, V45, P297, DOI 10.1016/0022-2836(69)90106-5; SCHOENBORN BP, 1965, NATURE, V208, P760, DOI 10.1038/208760a0; SCHOENBORN BP, 1966, MOL PHARMACOL, V2, P491; Steinhardt J., 1969, MULTIPLE EQUILIBRIA; STOLP BW, 1984, UNDERWATER PHYSL, V8, P315; Tanford Ch., 1973, HYDROPHOBIC EFFECT F; TAYLOR CD, 1978, ARCH BIOCHEM BIOPHYS, V191, P375, DOI 10.1016/0003-9861(78)90101-7; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TILTON RF, 1982, BIOCHEMISTRY-US, V21, P6850, DOI 10.1021/bi00269a035; Van Slyke DD, 1934, J BIOL CHEM, V105, P571; WELLS JM, 1974, UNDERWATER PHYSL, V5, P443; WELLS JM, 1969, THESIS U CALIFORNIA; WILHELM E, 1977, CHEM REV, V77, P219, DOI 10.1021/cr60306a003; WISHNIA A, 1964, BIOCHEMISTRY-US, V3, P1377, DOI 10.1021/bi00897a031; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5064, DOI 10.1021/bi00840a058; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5070, DOI 10.1021/bi00840a059	41	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1988	263	27					13515	13521						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q1594	3417671				2022-12-25	WOS:A1988Q159400012
J	SHEARER, G; KOHL, DH				SHEARER, G; KOHL, DH			NITROGEN ISOTOPIC FRACTIONATION AND O-18 EXCHANGE IN RELATION TO THE MECHANISM OF DENITRIFICATION OF NITRITE BY PSEUDOMONAS-STUTZERI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											SHEARER, G (corresponding author), WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130, USA.							AERSSENS E, 1986, J BIOL CHEM, V261, P9652; AVERILL BA, 1982, FEBS LETT, V138, P8, DOI 10.1016/0014-5793(82)80383-9; BARLEY MH, 1986, J AM CHEM SOC, V108, P5876, DOI 10.1021/ja00279a036; BOOGERD FC, 1980, FEBS LETT, V113, P279, DOI 10.1016/0014-5793(80)80609-0; Bryan B. A., 1981, Denitrification, nitrification and atmospheric nitrous oxide, P67; BRYAN BA, 1983, J BIOL CHEM, V258, P8613; BUNTON CA, 1959, J AM CHEM SOC, V81, P3466; CHIEN SH, 1977, SOIL SCI SOC AM J, V41, P63, DOI 10.2136/sssaj1977.03615995004100010021x; EATON SS, 1972, J ORGANOMET CHEM, V39, P179, DOI 10.1016/S0022-328X(00)88918-4; Fry A., 1970, ACS MONOGR SER, V167, P364; GARBER EAE, 1982, J BIOL CHEM, V257, P8091; GARBER EAE, 1983, J BIOL CHEM, V258, P3587; GARBER EAE, 1981, J BIOL CHEM, V256, P5459; GARBER EAE, 1982, J BIOL CHEM, V257, P4705; GORETSKI J, 1988, J BIOL CHEM, V263, P2316; GRANT MA, 1984, ARCH MICROBIOL, V140, P183, DOI 10.1007/BF00454923; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P488; HOGG JL, 1980, J AM CHEM SOC, V102, P79, DOI 10.1021/ja00521a014; KIM CH, 1984, J BIOL CHEM, V259, P2092; LAM Y, 1969, BIOCHIM BIOPHYS ACTA, V172, P450, DOI 10.1016/0005-2728(69)90141-8; LEIGHTON W, 1981, 1ST COURSE ORDINARY, P9; MARIOTTI A, 1981, PLANT SOIL, V62, P413, DOI 10.1007/BF02374138; MARIOTTI A, 1982, CAN J SOIL SCI, V62, P227, DOI 10.4141/cjss82-027; MORGENSTERN MA, 1985, THESIS U KANSAS LAWR; PAYNE WJ, 1981, DENITRIFICATION, P79; PICHINOTY F, 1977, ANN INST PASTEUR MIC, VA128, P75; SHEARER G, 1986, AUST J PLANT PHYSIOL, V13, P699, DOI 10.1071/PP9860699; STEIN RL, 1981, J ORG CHEM, V46, P3328, DOI 10.1021/jo00329a036; VARNER JE, 1953, ANAL CHEM, V25, P1528, DOI 10.1021/ac60082a031; WEEGAERSSENS E, 1987, J AM CHEM SOC, V109, P7214, DOI 10.1021/ja00257a065; WOOD ED, 1967, J MAR BIOL ASS UK, V47, P1331	31	42	44	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13231	13245						15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417655				2022-12-25	WOS:A1988Q091700072
J	WALDSCHMIDT, R; JAHN, D; SEIFART, KH				WALDSCHMIDT, R; JAHN, D; SEIFART, KH			PURIFICATION OF TRANSCRIPTION FACTOR-IIIB FROM HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											WALDSCHMIDT, R (corresponding author), INST MOLEK BIOL & TUMORFORSCH,KARL VON FRISCH STR,D-3550 MARBURG,FED REP GER.			Jahn, Dieter/0000-0002-4064-9205				BIEGER W, 1980, ANAL BIOCHEM, V109, P222, DOI 10.1016/0003-2697(80)90640-5; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE DJ, 1985, J BIOL CHEM, V260, P816; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CHAMBON P, 1975, ANNU REV BIOCHEM, V44, P613, DOI 10.1146/annurev.bi.44.070175.003145; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; GEIDUSCHEK EP, 1988, IN PRESS ANN REV BIO; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GRUISSEM W, 1981, EUR J BIOCHEM, V117, P407, DOI 10.1111/j.1432-1033.1981.tb06353.x; GUILFOYLE R, 1981, P NATL ACAD SCI US, V78, P3373; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HOFSTETTER H, 1981, CELL, V24, P573, DOI 10.1016/0092-8674(81)90348-2; HORCHER R, 1984, EUR J BIOCHEM, V139, P201, DOI 10.1111/j.1432-1033.1984.tb07995.x; JAHN D, 1987, J MOL BIOL, V193, P303, DOI 10.1016/0022-2836(87)90221-X; KLEKAMP MS, 1987, J BIOL CHEM, V262, P7878; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KRAUSE B, 1981, BIOCHEM INT, V2, P201; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; MAJOWSKI K, 1987, EMBO J, V6, P3057, DOI 10.1002/j.1460-2075.1987.tb02612.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SANTOS T, 1981, CELL, V23, P699, DOI 10.1016/0092-8674(81)90433-5; SCHWARTZ LB, 1974, J BIOL CHEM, V249, P5889; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHASTRY BS, 1984, J BIOL CHEM, V259, P1373; VANDYKE MW, 1987, NUCLEIC ACIDS RES, V15, P5031, DOI 10.1093/nar/15.13.5031; Wasylyk B, 1980, Nature, V285, P367, DOI 10.1038/285367a0; WEINMANN R, 1976, CELL, V7, P557, DOI 10.1016/0092-8674(76)90206-3; WINGENDER E, 1984, NUCLEIC ACIDS RES, V12, P8971, DOI 10.1093/nar/12.23.8971; WINGENDER E, 1988, GENE, V64, P77, DOI 10.1016/0378-1119(88)90482-9; WINGENDER E, 1984, EMBO J, V3, P1761, DOI 10.1002/j.1460-2075.1984.tb02043.x; WINGENDER E, 1986, J BIOL CHEM, V261, P1409	43	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1988	263	26					13350	13356						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	Q0917	3417660				2022-12-25	WOS:A1988Q091700087
J	BOHEN, SP				BOHEN, SP			HSP90 MUTANTS DISRUPT GLUCOCORTICOID RECEPTOR-LIGAND BINDING AND DESTABILIZE APORECEPTOR COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-RECEPTOR; DNA-BINDING; PROGESTERONE-RECEPTOR; DIOXIN RECEPTOR; YEAST; CYTOSOL; EXISTS; CELLS; COMPONENT	In order to attain competence to respond to hormone, certain steroid hormone receptors must be assembled into hetero-oligomeric aporeceptor complexes, containing Hsp90 and other proteins. Members of the Hsp90 gene family are highly conserved, strongly expressed, and required for viability in eukaryotic organisms. To elucidate the role of Hsp90 in the activity of steroid hormone receptors in vivo, four Hsp90 mutants, which cause defects in glucocorticoid receptor (GR) signaling, but support the viability of Saccharomyces cerevisiae, were previously isolated (Bohen, S. P., and Yamamoto, K. R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11424-11428). In this study, I characterize the effects of the Hsp90 mutants on GR ligand response, ligand binding activity, and aporeceptor complex stability. The mutants fall into two classes. Three of the Hsp90 mutants cause defects in GR ligand binding in vivo and form aporeceptor complexes that are unstable in vitro, relative to those containing wild-type Hsp90. The other mutant affects GR signaling, but aporeceptor complexes with this mutant are not defective for ligand binding or stability. These findings indicate that the binding of Hsp90 to GR in the aporeceptor complex is insufficient to induce a high ligand affinity conformation, rather the high ligand affinity of GR requires a specific interaction with Hsp90, which is altered by certain Hsp90 mutants.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,PROGRAM BIOL SCI BIOCHEM & MOLEC BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BOHEN SP, 1992, P NATL ACAD SCI USA, V90, P11424; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1989, CANCER RES, V49, pS2275; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HOLLEY SJ, 1995, IN PRESS MOL BIOL CE; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; INANOBE A, 1994, J BIOCHEM, V115, P486, DOI 10.1093/oxfordjournals.jbchem.a124363; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KAUFMANN SH, 1992, ENDOCRINOLOGY, V130, P3074, DOI 10.1210/en.130.5.3074; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; REXIN M, 1991, J BIOL CHEM, V266, P24601; ROUSSEAU GG, 1973, J MOL BIOL, V79, P539, DOI 10.1016/0022-2836(73)90405-1; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHULMAN G, 1992, BIOCHEMISTRY-US, V31, P1734, DOI 10.1021/bi00121a022; SHERMAN F, 1991, P3; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	47	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29433	29438		10.1074/jbc.270.49.29433	http://dx.doi.org/10.1074/jbc.270.49.29433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493981	hybrid			2022-12-25	WOS:A1995TJ22700062
J	JOSEPH, G; PICK, E				JOSEPH, G; PICK, E			PEPTIDE WALKING IS A NOVEL METHOD FOR MAPPING FUNCTIONAL DOMAINS IN PROTEINS - ITS APPLICATION TO THE RAC1-DEPENDENT ACTIVATION OF NADPH OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-FREE SYSTEM; DEPENDENT SUPEROXIDE PRODUCTION; SODIUM DODECYL-SULFATE; GUANINE-NUCLEOTIDES; RAS; MACROPHAGES; EFFECTOR; ACIDS; IDENTIFICATION; COMPONENT	Activation of the superoxide generating NADPH oxidase of phagocytes involves the assembly of a multimolecular complex and is dependent on the participation of the small molecular weight GTP-binding protein Rac (1 or 2). This model system was used for mapping functional domains in the primary sequence of Rad, based on assessing the inhibitory effect of 90 individual overlapping pentadecapeptides, spanning the entire length of Rad, on NADPH oxidase activation in two types of cell-free assay. Five functional domains mere identified, each consisting of a cluster of contiguous residues shared by members of five groups of overlapping inhibitory peptides. Four of the five domains are exposed on the molecular surface of Rad and were not identified previously by mutational analysis; the fifth corresponds to a polybasic motif near the carboxyl terminus, confirming earlier reports. Screening the entire linear sequence of a protein with a battery of overlapping peptides for interference with its ability to interact with upstream or downstream molecules should be of wide applicability as a reliable, fast, and economical method for mapping of functionally relevant domains.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,JULIUS FRIEDRICH COHNHEIM CTR PHAGOCYTE RES,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine			Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1992, J BIOL CHEM, V167, P16767; Barnard D, 1995, ONCOGENE, V10, P1283; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KRECK ML, 1995, FASEB J, V9, pA1413; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; MAEJI NJ, 1990, J IMMUNOL METHODS, V134, P23; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOORE I, 1995, TRENDS BIOCHEM SCI, V20, P10, DOI 10.1016/S0968-0004(00)88939-2; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; PICK E, 1989, J IMMUNOL, V143, P4180; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1992, INFLAMMATION BASIC P, P589; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SEIFERT R, 1986, FEBS LETT, V205, P161, DOI 10.1016/0014-5793(86)80886-9; SELF AJ, 1993, ONCOGENE, V8, P655; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VALERIO RM, 1991, ANAL BIOCHEM, V197, P168, DOI 10.1016/0003-2697(91)90374-3; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; XU XM, 1994, J BIOL CHEM, V269, P23569	44	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29079	29082		10.1074/jbc.270.49.29079	http://dx.doi.org/10.1074/jbc.270.49.29079			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493930	hybrid			2022-12-25	WOS:A1995TJ22700011
J	KUMAR, S; MCLAUGHLIN, MM; MCDONNELL, PC; LEE, JC; LIVI, GP; YOUNG, RR				KUMAR, S; MCLAUGHLIN, MM; MCDONNELL, PC; LEE, JC; LIVI, GP; YOUNG, RR			HUMAN MITOGEN-ACTIVATED PROTEIN-KINASE CSBP1, BUT NOT CSBP2, COMPLEMENTS A HOG1 DELETION IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL	CSBP1 and CSBP2 are human homologues of the Saccharomyces cerevisiae Hog1 mitogen-activated protein kinase which is required for growth in high osmolarity media. Expression of CSBP1, but not CSBP2, complemented a hog1 Delta phenotype. A CSBP2 mutant (A34V) that complements hog1 Delta was isolated and found to have similar to 3-fold lower kinase activity than the wild-type CSBP2. Further analysis revealed that both the kinase activity and tyrosine phosphorylation of CSBP1 and CSBP2 (A34V) is regulated by salt. In contrast, wild-type CSBP2 is constitutively active but dependent on the upstream kinase, Pbs2. Mutagenesis studies showed that reduction or elimination of CSBP2 kinase activity restores salt responsiveness as measured by tyrosine phosphorylation suggesting that too high a level of kinase activity can result in desensitization of the host cell and inability to grow in high salt.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CAMPBELL JS, 1994, RECENT PROG HORM RES, V50, P131; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HICKS JB, 1976, GENETICS, V83, P245; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376	18	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	1995	270	49					29043	29046		10.1074/jbc.270.49.29043	http://dx.doi.org/10.1074/jbc.270.49.29043			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TJ227	7493921	hybrid			2022-12-25	WOS:A1995TJ22700002
J	MAUPINFURLOW, JA; FERRY, JG				MAUPINFURLOW, JA; FERRY, JG			A PROTEASOME FROM THE METHANOGENIC ARCHAEON METHANOSARCINA-THERMOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPLASMA-ACIDOPHILUM PROTEASOMES; MULTICATALYTIC PROTEINASE; SEQUENCE-ANALYSIS; ALPHA-SUBUNIT; GENE; EXPRESSION; ALIGNMENT; CLONING; GROWTH; ACID	A 645-kDa proteasome was purified from Methanosarcina thermophila which had chymotrypsin like and peptidylglutamyl-peptide hydrolase activities and contained alpha (24-kDa) and beta (22-kDa) subunits. Processing of both subunits was suggested by comparison of N-terminal sequences with the sequences deduced from the alpha- and beta-encoding genes (psmA and psmB). Alignment of deduced sequences for the alpha and beta subunits revealed high similarity; however, the N-terminal sequence of the alpha subunit contained an additional 24 amino acids that were not present in the beta subunit. The alpha and beta subunits had high sequence identity with alpha- and beta-type subunits of proteasomes from eucaryotic organisms and the distantly related archaeon Thermoplasma acidophilum. The psmB gene was transcribed in vivo as a monocistronic message from a consensus archaeal promoter. The results suggest that proteasomes are more widespread in the Archaea than previously proposed. Southern blotting experiments suggested the presence of ubiquitin-like sequences in M. thermophila.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Maupin-Furlow, Julie/AAW-4035-2020	Maupin-Furlow, Julie/0000-0001-6105-0923	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044661, F32GM015877] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44661-02, 1F32GM15877-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARRIGO AP, 1987, J MOL EVOL, V25, P141, DOI 10.1007/BF02101756; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; COUX O, 1994, MOL GEN GENET, V245, P769, DOI 10.1007/BF00297284; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FERRY JG, 1992, CRIT REV BIOCHEM MOL, V27, P473, DOI 10.3109/10409239209082570; GENSCHIK P, 1992, FEBS LETT, V309, P311, DOI 10.1016/0014-5793(92)80796-J; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JABLONSKI PE, 1990, J BACTERIOL, V172, P1271, DOI 10.1128/jb.172.3.1271-1275.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1994, TRENDS BIOCHEM SCI, V19, P533, DOI 10.1016/0968-0004(94)90054-X; MARTINEK RG, 1964, CLIN CHEM, V10, P1087; NOTHWANG HG, 1994, BBA-GENE STRUCT EXPR, V1219, P361, DOI 10.1016/0167-4781(94)90060-4; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PHILIPPS G, 1993, EMBL Z26405 ACC; PUHLER G, 1994, SYST APPL MICROBIOL, V16, P734; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAYNAL M, 1994, EMBL Z29892 ACC; Reeve John N., 1993, P493; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SHIRATSUCHI A, 1993, EMBL X57210 ACC; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOWERS KR, 1984, CURR MICROBIOL, V11, P227, DOI 10.1007/BF01567165; SOWERS KR, 1988, J BACTERIOL, V170, P998, DOI 10.1128/jb.170.2.998-1002.1988; SOWERS KR, 1993, J BIOL CHEM, V268, P23172; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; WENZEL T, 1993, FEBS LETT, V326, P215, DOI 10.1016/0014-5793(93)81793-Y; WOLF S, 1993, FEBS LETT, V326, P42, DOI 10.1016/0014-5793(93)81757-Q; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004; ZWICKL P, 1994, STRUCT BIOL, V1, P765	48	60	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28617	28622		10.1074/jbc.270.48.28617	http://dx.doi.org/10.1074/jbc.270.48.28617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499378	hybrid			2022-12-25	WOS:A1995TH05600022
J	MIMNAUGH, EG; WORLAND, PJ; WHITESELL, L; NECKERS, LM				MIMNAUGH, EG; WORLAND, PJ; WHITESELL, L; NECKERS, LM			POSSIBLE ROLE FOR SERINE/THREONINE PHOSPHORYLATION IN THE REGULATION OF THE HETEROPROTEIN COMPLEX BETWEEN THE HSP90 STRESS PROTEIN AND THE PP60(V-SRC) TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; HEAT-SHOCK PROTEIN; RSV-TRANSFORMED CELLS; 2 CELLULAR PROTEINS; OKADAIC ACID; RETINOBLASTOMA PROTEIN; STEROID-RECEPTORS; TUMOR PROMOTER; CASEIN KINASE; PP60SRC	The abundant, cytoplasmic 90-kDa heat-shock protein associates transiently with the Rous sarcoma virus oncogenic protein tyrosine kinase, pp60(v-src), directs its cellular trafficking and negatively regulates its kinase activity, Here we report that the serine/threonine phosphatase inhibitor, okadaic acid, destabilized the heat-shock protein 90-pp60(v-src) chaperone complex in v-src-transfected cells. Concomitant with complex destabilization by okadaic acid, phosphoserine was doubled and phosphothreonine was increased 20-fold in the heat-shock protein 90. Although phosphorylation of the total pool of immunoprecipitable pp60(v-src) was unchanged, okadaic acid slightly increased phosphoserine and phosphothreonine levels specifically in pp60(v-src) bound to heat-shock protein 90. The low level of tyrosine phosphorylation in the pp60(v-src) complexed with heat-shock protein 90 was further decreased by okadaic acid. Interestingly, okadaic acid-stabilized hyperphosphorylation of the heat-shock protein 90-pp60(v-src) complex lowered the level of pp60(v-src) in cell membranes, the functional location for pp60(v-src). We suggest that serine/threonine phosphorylation of heat-shock protein 90 and/or pp60(v-src) functions as a regulatory molecular trigger to release pp60(v-src) from the chaperone complex at the inner surface of cell membranes.	NCI, BIOL CHEM LAB, BETHESDA, MD 20892 USA; UNIV ARIZONA, HLTH SCI CTR, STEELE MEM CHILDRENS RES CTR, TUCSON, AZ 85724 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Arizona; University of Arizona Health Sciences	MIMNAUGH, EG (corresponding author), NCI, CLIN PHARMACOL BRANCH, BLDG 10, ROOM 12N226, BETHESDA, MD 20892 USA.							Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GOTTESMAN MM, 1984, MOL CELL BIOL, V4, P2639, DOI 10.1128/MCB.4.12.2639; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GUPTA RW, 1993, BIOCHEM BIOPH RES CO, V196, P320, DOI 10.1006/bbrc.1993.2251; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OPPERMANN H, 1981, VIROLOGY, V113, P736, DOI 10.1016/0042-6822(81)90202-6; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; RESH MD, 1985, MOL CELL BIOL, V5, P916, DOI 10.1128/MCB.5.5.916; SARTOR O, 1992, J BIOL CHEM, V267, P21044; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SCHULTE TW, P AM ASSOC CANC RES, V36, P435; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YATSUNAMI J, 1993, CANCER RES, V53, P239	43	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28654	28659		10.1074/jbc.270.48.28654	http://dx.doi.org/10.1074/jbc.270.48.28654			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499384	hybrid			2022-12-25	WOS:A1995TH05600028
J	MORTIMER, BC; BEVERIDGE, DJ; MARTINS, IJ; REDGRAVE, TG				MORTIMER, BC; BEVERIDGE, DJ; MARTINS, IJ; REDGRAVE, TG			INTRACELLULAR-LOCALIZATION AND METABOLISM OF CHYLOMICRON REMNANTS IN THE LIVERS OF LOW-DENSITY-LIPOPROTEIN RECEPTOR-DEFICIENT MICE AND APOE-DEFICIENT MICE - EVIDENCE FOR SLOW METABOLISM VIA AN ALTERNATIVE APOE-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID EMULSION MODELS; APOLIPOPROTEIN-E; PLASMA-LIPOPROTEINS; TRANSGENIC MICE; LDL-RECEPTOR; PROTEIN; RATS; HYPERCHOLESTEROLEMIA; CLEARANCE; LACTOFERRIN	The metabolism of chylomicron remnants in mice deficient in low density lipoprotein receptor (LDLr) or apolipoprotein E (apoE) was compared with that of control C57BL/6J mice. Mice were injected intravenously with chylomicron-like emulsions labeled with radioactive lipids. Blood samples were taken at fixed time intervals from the retro-orbital sinus, and clearance rates of the lipoproteins were assessed from the decline in plasma radioactivities. To follow the intracellular pathway of remnants in the liver, emulsions labeled with a fluorescent cholesteryl ester (BODIPY) were injected, and liver sections were processed and assayed by laser confocal microscopy, Catabolism of remnant cholesteryl esters was assessed by injecting emulsions labeled with cholesteryl[1-C-14]oleate and measuring the expired CO2 from each animal. In apoE-deficient mice, remnant removal from plasma was totally impeded, while the clearance of remnants in LDLr-deficient mice was similar to that in C57BL/6J control mice, The confocal micrographs of livers 20 min after injection of fluorescent chylomicron-like emulsions showed evenly distributed fluorescent particles in the hepatocytes from control mice. In contrast, the fluorescent particles were mainly located in sinusoidal spaces in LDLr deficient mice, Three hours after injection the livers from control mice showed few fluorescent particles, indicating that remnants have been catabolized, while the sections from LDLr-deficient mice were still highly fluorescent, Micrographs from apoE deficient mice showed no fluorescent particles in the liver at any time after injection, Measurement of expired radioactive CO2 after injection of emulsions labeled in the fatty acid moiety of cholesteryl oleate indicated that remnant metabolism was slower in the LDLr-deficient mice and essentially nil in the apoE-deficient mice, Control mice had expired 50% of the injected label by 3 h after injection. We conclude that under normal circumstances, chylomicron remnants are rapidly internalized by LDLr and catabolized in hepatocytes, with a critical requirement for apoE, When LDLr is absent, remnants are taken up by a second apoE-dependent pathway, first to the sinusoidal space of the liver, with subsequent slow endocytosis and slow catabolism. Hepatic clearance via this second pathway is increased by heparin, inhibited by lactoferrin, heparinase, and suramin, and down-regulated by feeding a high fat diet.			MORTIMER, BC (corresponding author), UNIV WESTERN AUSTRALIA,DEPT PHYSIOL,NEDLANDS,WA 6907,AUSTRALIA.			Martins, Ian/0000-0002-2390-1501				CALLOW MJ, 1993, BIOCHEM MOL BIOL INT, V29, P913; CHANG SY, 1994, BBA-LIPID LIPID MET, V1215, P205, DOI 10.1016/0005-2760(94)90112-0; CHOI SY, 1993, J BIOL CHEM, V268, P15804; COLETTE C, 1994, DIABETES NUTR METAB, V7, P295; DESILVA HV, 1993, BIOCHEM SOC T, V21, P483, DOI 10.1042/bst0210483; DIARD P, 1994, BIOCHEM J, V299, P889, DOI 10.1042/bj2990889; GODFREY P, 1962, ANAL BIOCHEM, V4, P310, DOI 10.1016/0003-2697(62)90092-1; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; JI ZS, 1995, J LIPID RES, V36, P58; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KRASINSKI SD, 1990, METABOLISM, V39, P357, DOI 10.1016/0026-0495(90)90249-C; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; MOKUNO H, 1994, J BIOL CHEM, V69, P13238; MORTIMER BC, 1994, ARTERIOSCLER THROMB, V14, P1542, DOI 10.1161/01.ATV.14.10.1542; MORTIMER BC, 1990, BIOCHIM BIOPHYS ACTA, V1046, P46, DOI 10.1016/0005-2760(90)90093-D; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; REDGRAVE TG, 1983, INT REV PHYSIOL, V28, P103; REDGRAVE TG, 1990, METABOLISM, V39, P1, DOI 10.1016/0026-0495(90)90140-8; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; REDGRAVE TG, 1985, BIOCHIM BIOPHYS ACTA, V835, P104, DOI 10.1016/0005-2760(85)90036-0; REDGRAVE TG, 1995, IN PRESS J LIPID RES; SHAFI S, 1994, J LIPID RES, V35, P709; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SULTAN F, 1989, BIOCHEM J, V258, P587, DOI 10.1042/bj2580587; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1995, P NATL ACAD SCI USA, P4537; YEN FT, 1994, BIOCHEMISTRY-US, V33, P1172, DOI 10.1021/bi00171a017; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	39	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28767	28776		10.1074/jbc.270.48.28767	http://dx.doi.org/10.1074/jbc.270.48.28767			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499399	hybrid			2022-12-25	WOS:A1995TH05600043
J	SAVAGE, B; BOTTINI, E; RUGGERI, ZM				SAVAGE, B; BOTTINI, E; RUGGERI, ZM			INTERACTION OF INTEGRIN ALPHA(IIB)BETA(3) WITH MULTIPLE FIBRINOGEN DOMAINS DURING PLATELET-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; GAMMA-CHAIN; VONWILLEBRAND-FACTOR; GLANZMANN THROMBASTHENIA; STIMULATED PLATELETS; VITRONECTIN RECEPTOR; BINDING-SITE; ALPHA-CHAIN; AGGREGATION; COMPLEX	We have investigated how modulation of integrin alpha(IIb)beta(3) function influences the mechanisms that initiate platelet thrombus formation onto surface-bound fibrinogen and isolated fibrinogen domains, Under stationary conditions and with full activation of platelets blocked by prostaglandin E(1), the carboxyl-terminal gamma(400-411) sequence is necessary for establishing initial contact with the immobilized substrate. Molecules containing a single copy of this sequence, like the plasmin-generated fibrinogen fragment D, support platelet spreading, but the resulting attachment to the surface is loose and disrupted by minimal peeling force, In contrast, platelets adhere firmly to intact fibrinogen under the same conditions, suggesting that recognition of contact sites outside a single D domain can secure the firm interaction not supported by a single gamma(400-411) sequence. If platelets are activated, the gamma(400-411) sequence is no longer necessary to initiate the adhesion process but becomes sufficient, even as a single copy, to mediate stable surface attachment in the absence of shear stress, Under conditions of flow, however, intact fibrinogen but not fragment D can support adhesion, regardless of whether platelets have the potential to become activated or not, These results indicate the functional relevance of multiple fibrinogen domains during the initial stages of the platelet adhesion process.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-31950, HL-48728] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; ALEVRIADOU BR, 1993, BLOOD, V81, P1263; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; CHEN CS, 1988, BIOCHEMISTRY-US, V27, P6121, DOI 10.1021/bi00416a044; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COLLER BS, 1991, BLOOD, V78, P2603; COLLER BS, 1980, BLOOD, V55, P169; COLLER BS, 1991, BLOOD, V77, P75; DEMARCO L, 1986, J CLIN INVEST, V77, P1272, DOI 10.1172/JCI112430; DISE CA, 1982, J BIOL CHEM, V257, P4701; EDGECOMBE M, 1993, PLATELETS, V4, P141, DOI 10.3109/09537109309013210; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; GARTNER TK, 1993, THROMB RES, V71, P47; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GOGSTAD GO, 1982, BLOOD, V60, P663; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAM SCT, 1989, J BIOL CHEM, V264, P3742; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MASSINI P, 1971, THROMB DIATH HAEMOST, V25, P13, DOI 10.1055/s-0038-1654275; MUSTARD JF, 1978, BLOOD, V52, P453; NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448; NIIYA K, 1987, BLOOD, V70, P475; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PACKHAM MA, 1987, BLOOD, V70, P647; PLOW EF, 1980, J BIOL CHEM, V255, P971; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Ruggeri ZM, 1993, CURR OPIN CELL BIOL, V5, P898, DOI 10.1016/0955-0674(93)90041-N; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SMITH JW, 1990, J BIOL CHEM, V265, P12267	37	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28812	28817		10.1074/jbc.270.48.28812	http://dx.doi.org/10.1074/jbc.270.48.28812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499405	hybrid			2022-12-25	WOS:A1995TH05600049
J	BUSE, P; WOO, PL; ALEXANDER, DB; REZA, A; FIRESTONE, GL				BUSE, P; WOO, PL; ALEXANDER, DB; REZA, A; FIRESTONE, GL			GLUCOCORTICOID-INDUCED FUNCTIONAL POLARITY OF GROWTH-FACTOR RESPONSIVENESS REGULATES TIGHT JUNCTION DYNAMICS IN TRANSFORMED MAMMARY EPITHELIAL TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; SUPPRESSOR PROTEIN; TGF-ALPHA; INVITRO; ASSOCIATION; MECHANISMS; DROSOPHILA; EXPRESSION; CANCER; MICE	The synthetic glucocorticoid, dexamethasone, induces the ''normal-like'' differentiated property of tight junction formation and suppresses growth of the Con8 mammary epithelial tumor cell line, derived from a 7,12-dimethylbenz(alpha)anthracene-induced rat mammary adenocarcinoma. Characterization of the transepithelial electrical resistance of Con8 mammary tumor cells cultured on permeable supports revealed that a novel response to dexamethasone is the generation of a polarized cell monolayer with respect to epidermal growth factor receptor responsiveness, Administration of transforming growth factor-alpha (TGF-alpha) to the basolateral, but not the apical, plasma membrane compartment disrupted the glucocorticoid-stimulated tight junction barrier, Confocal immunofluorescence microscopy revealed that dexamethasone caused the ZO-1 tight junction-associated protein to localize exclusively to the apical border of laterally adjacent membranes of the cell periphery, whereas basolateral administration of TGF-alpha caused the redistribution of ZO-1 back to disorganized aggregates along the cell periphery, In contrast, TGF-alpha was able to exert its mitogenic effects equally on both sides of the cell monolayer independent of its polarized disruption of tight junction formation, Our results represent the first evidence for a functional polarization of the epidermal growth factor receptor and strongly implicate the glucocorticoid-regulated formation of tight junctions in policing the polarized responsiveness of mammary cells to growth factors.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NIDDK NIH HHS [DK-42799] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042799, R56DK042799] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABBOTT LA, 1992, MECH DEVELOP, V37, P43, DOI 10.1016/0925-4773(92)90014-B; ALEXANDER DB, 1993, CANCER RES, V53, P1808; Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; DEREN P, 1994, CARCINOGENESIS, V15, P1807; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GONZALEZ ML, 1990, AM J PHYSIOL, pC978; GOYA L, 1993, CANCER RES, V53, P1816; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; HSIEH JT, 1994, J BIOL CHEM, V269, P3711; IMAGAWA W, 1990, ENDOCR REV, V11, P494, DOI 10.1210/edrv-11-4-494; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; MADARA JL, 1988, CELL, V53, P497, DOI 10.1016/0092-8674(88)90562-4; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCROBERTS JA, 1992, AM J PHYSIOL, V262, pC207, DOI 10.1152/ajpcell.1992.262.1.C207; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARRY G, 1992, J CELL SCI, V101, P191; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; PITELKA DR, 1978, LACTATION COMPREHENS, P141; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Segaloff A, 1966, Recent Prog Horm Res, V22, P351; SINGER KL, 1994, J BIOL CHEM, V269, P16108; SJAASTAD MD, 1993, J CELL BIOL, V122, P589, DOI 10.1083/jcb.122.3.589; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; WEBSTER MK, 1991, CANCER RES, V51, P6031; WELSCH CW, 1985, CANCER RES, V45, P3415; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; ZHANG ZY, 1993, J BIOL CHEM, V268, P5557	44	46	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28223	28227						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499317				2022-12-25	WOS:A1995TG21000042
J	MIZUGUCHI, J; HU, CH; CAO, ZY; LOEB, KR; CHUNG, DW; DAVIE, EW				MIZUGUCHI, J; HU, CH; CAO, ZY; LOEB, KR; CHUNG, DW; DAVIE, EW			CHARACTERIZATION OF THE 5'-FLANKING REGION OF THE GENE FOR THE GAMMA-CHAIN OF HUMAN FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; EXPRESSION; PROTEINS; BINDING; ELEMENT; RAT; INTERLEUKIN-6; UPSTREAM	The 5'-flanking region of the gene coding for the gamma chain of human fibrinogen was characterized for its promoter activity, Reporter gene studies using chloramphenicol acetyltransferase as the indicator along with mutations in the DNA showed that a TATA-like sequence (-20 to -23 base pairs (bp)), a CAAT-like sequence (-54 to -57 bp), and an upstream stimulatory factor (USF) binding site (-66 to -77 bp) constitute a minimal promoter that mediates liver-specific expression of the gene. Electrophoretic gel mobility assays and antibody binding studies confirmed the interaction of USF with the binding site. An IL-6 responsive element with a sequence of CTGGAA located at -301 to -306 bp was shown to be a functional element in the IL-6 response. In contrast to the IL-6 responsive elements in the human alpha- and beta-fibrinogen genes, the element in the gene for the gamma chain of human fibrinogen was unaffected by the presence or elevated levels of the beta or delta isoforms of the CCAAT/enhancer binding proteins, A negative element with sequence homology to several silencer elements was also identified in the region of -348 to -390 bp of the gene for the gamma chain of human fibrinogen. A comparison of the regulatory elements in the genes coding for all three chains in fibrinogen is also presented.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056	NHLBI NIH HHS [HL16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haidaris P J, 1990, Blood Coagul Fibrinolysis, V1, P433, DOI 10.1097/00001721-199010000-00011; HANDAGAMA P, 1990, J CLIN INVEST, V86, P1364, DOI 10.1172/JCI114848; HANSEN LP, 1993, CURR OPIN GENET DEV, V3, P246, DOI 10.1016/0959-437X(93)90030-S; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HU CH, 1995, J BIOL CHEM, V270, P28342; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; MIAO CH, 1992, J BIOL CHEM, V267, P7395; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MOSESSON MW, 1972, J BIOL CHEM, V247, P5223; RIXON MW, 1985, BIOCHEMISTRY-US, V24, P2077, DOI 10.1021/bi00329a041; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1992, MOL CELL BIOL, V12, P2525, DOI 10.1128/MCB.12.6.2525; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STRAUB PW, 1963, J CLIN INVEST, V42, P130, DOI 10.1172/JCI104690; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WOLFENSTEINTODEL C, 1981, BIOCHEMISTRY-US, V20, P6146, DOI 10.1021/bi00524a036	30	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28350	28356						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499336				2022-12-25	WOS:A1995TG21000061
J	TAKAHASHI, S; NAKAGAWA, T; BANNO, T; WATANABE, T; MURAKAMI, K; NAKAYAMA, K				TAKAHASHI, S; NAKAGAWA, T; BANNO, T; WATANABE, T; MURAKAMI, K; NAKAYAMA, K			LOCALIZATION OF FURIN TO THE TRANS-GOLGI NETWORK AND RECYCLING FROM THE CELL-SURFACE INVOLVES SER AND TYR RESIDUES WITHIN THE CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; FACTOR-II RECEPTOR; BREFELDIN-A; COMPLEX; TGN38; SPECIFICITY; EXPRESSION; SEQUENCE; PROTEIN; INTERNALIZATION	Furin is a membrane-associated endoprotease that catalyzes cleavage of precursor proteins at Arg-X-Lys/Arg-Arg sites. Although, at steady state, furin is predominantly found in the trans-Golgi network (TGN), it also cycles between the TGN and the cell surface. Recently, the cytoplasmic tail of furin has been shown to be sufficient for its localization to the TGN. Within the cytoplasmic domain, there are Ser residues, which we now show are sites for phosphorylation by casein kinase II in vitro, and a Tyr-containing sequence, both of which have been shown to be important for other TGN proteins to localize to this compartment. In the present study, we show by site-directed mutagenesis that these residues are important for TGN localization and recycling of furin. Mutation of the Ser residues abrogated the TGN localization. By contrast, mutation of the Tyr residue did not affect the TGN localization but impaired the internalization from the plasma membrane. These observations suggest that distinct cytoplasmic determinants are responsible for retention in the TGN and retrieval from the cell surface of furin.	UNIV TSUKUBA, INST BIOL SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST BASIC MED SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, CTR GENE EXPT, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba			Nakayama, Kazuhisa/ABF-2924-2020	Watanabe, Tsuyoshi/0000-0002-6094-7728; Nakayama, Kazuhisa/0000-0001-7701-7183				Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; CONIBEAR E, 1994, J CELL SCI, V107, P923; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HALBAN PA, 1994, BIOCHEM J, V299, P1; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KORNER C, 1994, J BIOL CHEM, V269, P16529; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MAUXION F, 1995, EUR J CELL BIOL, V66, P119; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; Stanley Keith K., 1993, Trends in Cell Biology, V3, P252, DOI 10.1016/0962-8924(93)90046-4; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; WONG SH, 1993, J BIOL CHEM, V268, P22853	41	118	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28397	28401						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499343				2022-12-25	WOS:A1995TG21000068
J	GODDE, JS; WOLFFE, AP				GODDE, JS; WOLFFE, AP			DISRUPTION OF RECONSTITUTED NUCLEOSOMES - THE EFFECT OF PARTICLE CONCENTRATION, MGCL2 AND KCL CONCENTRATION, THE HISTONE TAILS, AND TEMPERATURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR ACCESS; CHROMATIN CORE PARTICLES; TUMOR VIRUS PROMOTER; RNA POLYMERASE-II; 5S RNA; IONIC-STRENGTH; TATA-BOX; DNA; BINDING; COMPLEX	We find that reconstituted nucleosome cores containing specific DNA sequences dissociate on dilution. This disruption of histone-DNA contacts leading to the re lease of free DNA is facilitated by the presence of the core histone tails, MgCl2 (5 mM), KCl (60 mM), and temperatures above 0 degrees C. Under reaction conditions that are commonly used to assess trans-acting factor access to nucleosomal DNA histone-DNA contacts are on the threshold of instability. We demonstrate how dilution of reconstituted nucleosomes containing a TATA box can facilitate TBP access to DNA.			GODDE, JS (corresponding author), NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892, USA.							ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; AUSIO J, 1984, J MOL BIOL, V177, P373, DOI 10.1016/0022-2836(84)90291-2; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURCH JBE, 1980, NUCLEIC ACIDS RES, V8, P4969, DOI 10.1093/nar/8.21.4969; BURTON DR, 1978, NUCLEIC ACIDS RES, V5, P3643, DOI 10.1093/nar/5.10.3643; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; COTTON RW, 1981, NUCLEIC ACIDS RES, V9, P445, DOI 10.1093/nar/9.2.445; EISENBERG H, 1981, J MOL BIOL, V150, P537, DOI 10.1016/0022-2836(81)90379-X; GORDON VC, 1979, NUCLEIC ACIDS RES, V6, P3845, DOI 10.1093/nar/6.12.3845; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HOFFMAN A, 1993, NUCLEIC ACIDS RES, V19, P6337; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI BY, 1994, J BIOL CHEM, V269, P7756; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LIBERTINI LJ, 1980, NUCLEIC ACIDS RES, V8, P3517, DOI 10.1093/nar/8.16.3517; LILLEY DMJ, 1979, NUCLEIC ACIDS RES, V7, P377, DOI 10.1093/nar/7.2.377; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RANJAN M, 1994, J BIOL CHEM, V269, P24699; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; STACKS PC, 1979, NUCLEIC ACIDS RES, V7, P2457, DOI 10.1093/nar/7.8.2457; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; van Holde K.E., 1988, CHROMATIN; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; WALKER IO, 1984, BIOCHIM BIOPHYS ACTA, V785, P97, DOI 10.1016/0167-4838(84)90132-8; WALKER IO, 1984, BIOCHEMISTRY-US, V23, P5622, DOI 10.1021/bi00318a037; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1993, METH MOL G, V2, P314; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YAGER TD, 1984, J BIOL CHEM, V259, P4212; ZAMA M, 1978, NUCLEIC ACIDS RES, V5, P3881, DOI 10.1093/nar/5.10.3881	43	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27399	27402		10.1074/jbc.270.46.27399	http://dx.doi.org/10.1074/jbc.270.46.27399			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499192				2022-12-25	WOS:A1995TE73600003
J	ISSE, N; OGAWA, Y; TAMURA, N; MASUZAKI, H; MORI, K; OKAZAKI, T; SATOH, N; SHIGEMOTO, M; YOSHIMASA, Y; NISHI, S; HOSODA, K; INAZAWA, J; NAKAO, K				ISSE, N; OGAWA, Y; TAMURA, N; MASUZAKI, H; MORI, K; OKAZAKI, T; SATOH, N; SHIGEMOTO, M; YOSHIMASA, Y; NISHI, S; HOSODA, K; INAZAWA, J; NAKAO, K			STRUCTURAL ORGANIZATION AND CHROMOSOMAL ASSIGNMENT OF THE HUMAN OBESE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; PROTEINS; MOUSE	The obese (ob) gene has been identified through a positional cloning approach; the mutation of this gene causes marked hereditary obesity and diabetes mellitus in mice, We report here the isolation and characterization of the human ob gene, Southern blot analysis demonstrated a single copy of the ob gene in the human genome, The human ob gene spanned similar to 20 kilobases (kb) and contained three exons separated by two introns, The first intron, similar to 10.6 kb in size, occurred in the 5'-untranslated region, 29 base pair (bp) upstream of the ATG start codon, The second intron of 2.3 kb in size was located at glutamine +49, By rapid amplification of 5'-cDNA ends, the transcription initiation sites were mapped 54 similar to 57 bp upstream of the ATG start codon, The 172-bp 5'-flanking region of the human ob gene contained a TATA box-like sequence and several cis-acting regulatory elements (three copies of GC boxes, an AP-2-binding site, and a CCAAT/enhancer-binding protein-binding site), By the fluorescence in situ hybridization technique, the ob gene was assigned to human chromosome 7q31.3. This study should establish the genetic basis for ob gene research in humans, thereby leading to the better understanding of the molecular mechanisms underlying the ob gene.	KYOTO UNIV, GRAD SCH MED, DEPT MED & CLIN SCI, SAKYO KU, KYOTO 606, JAPAN; KYOTO PREFECTURAL UNIV, DEPT HYG, KYOTO 606, JAPAN	Kyoto University; Kyoto Prefectural University			Mori, Kiyoshi/N-1267-2014	Mori, Kiyoshi/0000-0002-7285-8351; Okazaki, Taku/0000-0003-4790-1925				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ARIYAMA T, 1995, GENOMICS, V25, P114, DOI 10.1016/0888-7543(95)80116-4; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MASUZAKI H, 1995, P JPN ACAD B-PHYS, V71, P148, DOI 10.2183/pjab.71.148; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; OGAWA Y, 1994, J CLIN INVEST, V93, P1911, DOI 10.1172/JCI117182; OGAWA Y, 1995, GENOMICS, V27, P142, DOI 10.1006/geno.1995.1016; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAMURA N, 1994, J CLIN INVEST, V94, P1059, DOI 10.1172/JCI117420; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	135	165	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27728	27733		10.1074/jbc.270.46.27728	http://dx.doi.org/10.1074/jbc.270.46.27728			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499240	hybrid			2022-12-25	WOS:A1995TE73600051
J	JACOB, KK; OUYANG, LH; STANLEY, FM				JACOB, KK; OUYANG, LH; STANLEY, FM			A CONSENSUS INSULIN-RESPONSE ELEMENT IS ACTIVATED BY AN ETS-RELATED TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENTS; THYROID-HORMONE; PROLACTIN GENE; GROWTH-HORMONE; PROTEIN; BINDING; DNA; FOS; EXPRESSION; SRF	Insulin increases expression of somatostatin-chloramphenicol acetyltransferase (CAT) constructs 10-fold and thymidine kinase-CAT constructs 5-fold in GH4 cells. These responses are similar to our previously reported data on insulin-increased prolactin-CAT expression, They are also observed in HeLa cells and are thus not cell type specific, The evidence suggests that the insulin responsiveness of these genes is mediated by an Ets-related transcription factor, First, linker-scanning mutations and/or deletions of the prolactin, somatostatin, and thymidine kinase promoters suggest that their insulin responsiveness is mediated by the sequence CGGA, This sequence is identical with the response element of the Ets-related transcription factors, Second, CGGA-containing sequences placed at -88 in the Delta MTV-CAT reporter plasmid conferred insulin responsiveness to the mammary tumor virus promoter, Third, expression of the DNA-binding domain of c-Ets-a, which acts by blocking effects mediated by Ets-related transcription factors, inhibits the response of these promoters to insulin, Finally, the Ets-related proteins Sap and Elk-l bind to the prolactin, somatostatin, and thymidine kinase insulin response elements, An Ets-like element was found in all insulin-sensitive promoters examined and may serve a similar function in those promoters.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	JACOB, KK (corresponding author), NYU,MED CTR,DEPT MED,NEW YORK,NY 10016, USA.			Stanley, Frederick/0000-0002-3684-2168	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CADILLA C, 1992, GENE, V118, P223, DOI 10.1016/0378-1119(92)90192-R; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; FLUG F, 1987, J BIOL CHEM, V262, P6373; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; JACOB KK, 1994, J BIOL CHEM, V269, P25515; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JONG MTC, 1994, MOL ENDOCRINOL, V8, P1320, DOI 10.1210/me.8.10.1320; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; NAZRIN N, 1990, P NATL ACAD SCI USA, V87, P5273; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PRAGER D, 1988, ENDOCRINOLOGY, V122, P2946, DOI 10.1210/endo-122-6-2946; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY F, 1988, J BIOL CHEM, V263, P13443; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WEBER JL, 1984, MOL CELL BIOCHEM, V65, P171; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	30	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27773	27779		10.1074/jbc.270.46.27773	http://dx.doi.org/10.1074/jbc.270.46.27773			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499246	hybrid			2022-12-25	WOS:A1995TE73600057
J	SONODA, Y; YOSHIMOTO, T; SEKIYA, T				SONODA, Y; YOSHIMOTO, T; SEKIYA, T			HOMOZYGOUS DELETION OF THE MTS1/P16 AND MTS2/P15 GENES AND AMPLIFICATION OF THE CDK4 GENE IN GLIOMA	ONCOGENE			English	Article						GLIOMA; HOMOZYGOUS DELETION; MTS1/P16 GENE; MTS2/P15 GENE; CDK4 GENE	POLYMERASE CHAIN-REACTION; DINUCLEOTIDE REPEAT POLYMORPHISM; HUMAN BRAIN-TUMORS; MUTATIONS; DNA	Loci on chromosome 9p are frequently deleted in several malignant tumors, suggesting the presence of putative tumor suppressor genes. The MTS1/p16 and MTS2/p15 genes on 9p are considered to be candidates. Binding of p15 and p16 cell cycle-regulatory proteins to the cyclin dependent protein kinase CDK4 inhibits CDK4/cyclin D dependent phosphorylation of retinoblastoma protein. We analysed the DNAs from 37 gliomas of several grades of malignancy for allelic loss of chromosome 9p and abberations of the MTS1/p16 and MTS2/p15 genes. We detected losses of one allele and homozygous deletions at loci, including those of the MTS1/p16 and MTS2/p15 genes, in 10 and 3 tumors, respectively. However, we did not detect any tumor-specific mutation in the two genes. The CDK4 gene was amplified in two malignant gliomas without homozygous deletion of the MTS1/p16 and MTS2/p15 genes and one malignant glioma with an allelic loss of the genes. These data suggest that aberrations of the genes coding for components of the cell cycle-regulatory system occured in at least 15 of 37 gliomas.	NATL CANC CTR,RES INST,DIV ONCOGENE,CHUO KU,TOKYO 104,JAPAN; TOHOKU UNIV,SCH MED,DEPT NEUROSURG,AOBA KU,SENDAI,MIYAGI 980,JAPAN	National Cancer Center - Japan; Tohoku University				Sonoda, Yukihiko/0000-0001-7651-1374				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; COOLEMAN A, 1994, CANCER RES, V54, P344; FOUNTAIN JW, 1993, HUM MOL GENET, V2, P823, DOI 10.1093/hmg/2.6.823-a; FULTS D, 1992, GENOMICS, V14, P799, DOI 10.1016/S0888-7543(05)80191-0; FULTS D, 1990, CANCER RES, V50, P5784; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; KWIATKOWSKI DJ, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658-a; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; MAKINO R, 1990, Technique (Philadelphia), V2, P295; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; REY JA, 1993, CANCER GENET CYTOGEN, V66, P1, DOI 10.1016/0165-4608(93)90140-H; RUBIO MP, 1994, CANCER RES, V54, P4760; SCHMIDT EE, 1994, CANCER RES, V554, P6321; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; ZULCH KJ, 1979, WHO GENEVA	29	75	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2145	2149						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478535				2022-12-25	WOS:A1995TF29700026
J	JURDIC, P; TREILLEUX, I; VANDEL, L; TABONE, E; HUGUIER, S; SERGEANT, A; CASTELLAZZI, M				JURDIC, P; TREILLEUX, I; VANDEL, L; TABONE, E; HUGUIER, S; SERGEANT, A; CASTELLAZZI, M			TUMOR-INDUCTION BY V-JUN HOMODIMERS IN CHICKENS	ONCOGENE			English	Article						V-JUN; HOMODIMERS; VISCERAL TUMORS; LEIOMYOSARCOMA; IMMORTALIZATION; CHICKENS	DNA-BINDING ACTIVITY; AVIAN-SARCOMA VIRUS-17; C-JUN; EMBRYO FIBROBLASTS; TRANSCRIPTION FACTORS; CELL-TRANSFORMATION; TRANSGENIC MICE; PROTEIN-KINASE; FOS-GENE; ONCOGENE	To study the contribution of v-Jun homodimers to oncogenesis, me constructed artificial v-Jun derivatives in which the natural dimerization domain of v-Jun was replaced by an heterologous homodimerization domain from either the viral EB1 or the yeast GCN4 transcription factor. The resulting v-Jun chimeric proteins, called v-Jun(eb1) and v-Jun(gcn4), which can no longer dimerize with Jun or Fos, should only form homodimers in the cell. Helper-independent retroviruses expressing v-Jun, v-Jun(eb1) and v-Jun(gcn4) were generated. AU three viruses transformed primary cultures of chick embryo cells with the same high efficiency and promoted local tumor growth after subcutaneous injection of infected cells in young animals. In contrast, after intravenous injection of viral suspensions into chick embryos, only the chimeric proteins produced internal tumors that were lethal. These tumors were leiomyosarcomas located within the liver and along the digestive tract. Thus, in vivo, v-Jun(eb1) and v-Jun(gcn4) are more potent oncoproteins than v-Jun. These data demonstrate that when forced to accumulate, v-Jun homodimers can induce tumors efficiently. They also show that the oncogenic potential of v-Jun can be regulated through the properties of its dimerization domain.	ECOLE NORMALE SUPER LYON,INSERM,U412,UNITE VIROL HUMAINE,F-69364 LYON 07,FRANCE; CTR LEON BERARD,DEPT ANAT & CYTOL PATHOL,F-69373 LYON 08,FRANCE; LAB BIOL MOLEC & CELLULAIRE,CNRS,UMR 49,F-69373 LYON 08,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet				Vandel, Laurence/0000-0002-3692-2942				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1994, J BIOL CHEM, V269, P11186; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3241; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P269; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P491; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P8837, DOI 10.1073/pnas.90.19.8837; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GROSSI M, 1991, ONCOGENE, V6, P1767; HADMAN M, 1993, ONCOGENE, V8, P1895; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HARTL M, 1991, ONCOGENE, V6, P1623; HARVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL GM, 1992, VIROLOGY, V188, P373, DOI 10.1016/0042-6822(92)90768-K; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN IM, 1994, ONCOGENE, V9, P2793; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1982, ADV VIRAL ONCOL, V1, P82; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OEHLER T, 1993, ONCOGENE, V8, P1141; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; PURCHASE HG, 1977, INFECT IMMUN, V15, P423, DOI 10.1128/IAI.15.2.423-428.1977; SCHUH AC, 1992, ONCOGENE, V7, P667; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SHALABY F, 1994, ONCOGENE, V9, P2579; SU HY, 1991, ONCOGENE, V6, P1759; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; VANDEL L, 1995, ONCOGENE, V10, P495; VANHOEVEN KH, 1993, AM J SURG PATHOL, V17, P1176, DOI 10.1097/00000478-199311000-00011; VOGT, 1994, VOGT PK, P203; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	65	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1699	1709						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478597				2022-12-25	WOS:A1995TD09400004
J	SOLOMON, DLC; PHILIPP, A; LAND, H; EILERS, M				SOLOMON, DLC; PHILIPP, A; LAND, H; EILERS, M			EXPRESSION OF CYCLIN D1 MESSENGER-RNA IS NOT UP-REGULATED BY MYC IN RAT FIBROBLASTS	ONCOGENE			English	Note						CYCLIN D1; MYC; ESTROGEN RECEPTOR; TAMOXIFEN	HUMAN C-MYC; DNA-BINDING; ESTROGEN-RECEPTOR; STEROID BINDING; GENE-EXPRESSION; CELL-CYCLE; MAX; SEQUENCE; PROTEIN; DIMERIZATION	Conflicting results have been published regarding the regulation of cyclin D1 mRNA in rat fibroblasts expressing a hormone-regulated Myc protein, MycER. We confirm that activation of MycER with oestrogen rapidly induces cyclin D1 mRNA, even in the presence of cycloheximide. However, we show that this is an artefact resulting from an oestrogen-activated transcriptional activation domain in the oestrogen receptor part of the MycER chimaera. First, addition of 4-hydroxy-tamoxifen (4OHT), which does not activate this domain, allows association of MycER with Max and induces cell proliferation in serum-starved Rat-1-MycER cells without affecting cyclin D1 mRNA levels or the activity of D1 promoter-luciferase constructs. Second, Rat-1 cells expressing a mutant MycER with a hormone-binding domain that still binds 4OHT but no longer binds oestrogen, are driven into the cell cycle in response to 4OHT but fail to up-regulate cyclin D1 mRNA. Finally, Rat-1 cells in which wild-type human c-Myc expression can be induced, also progress into the cell cycle without increased D1 mRNA expression.	ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Ruprecht Karls University Heidelberg; Cancer Research UK				Eilers, Martin/0000-0002-0376-6533				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; GAUBATZ S, 1994, MOL CELL BIOL, V6, P3853; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HERBER B, 1994, ONCOGENE, V9, P1295; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOVEC H, 1994, ONCOGENE, V9, P323; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	44	42	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1893	1897						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478619				2022-12-25	WOS:A1995TD09400026
J	TAKITA, J; HAYASHI, Y; KOHNO, T; SHISEKI, M; YAMAGUCHI, N; HANADA, R; YAMAMOTO, K; YOKOTA, J				TAKITA, J; HAYASHI, Y; KOHNO, T; SHISEKI, M; YAMAGUCHI, N; HANADA, R; YAMAMOTO, K; YOKOTA, J			ALLELOTYPE OF NEUROBLASTOMA	ONCOGENE			English	Article						NEUROBLASTOMA; TUMOR SUPPRESSOR GENE; ALLELOTYPE; CHROMOSOME 9	N-MYC AMPLIFICATION; NEURO-BLASTOMA; GENE-MUTATIONS; HETEROZYGOSITY; RETINOBLASTOMA; CHROMOSOME-1; TUMOR; IDENTIFICATION; CARCINOMA; ONCOGENE	Although relatively high incidence of loss of heterozygosity (LOH) on chromosomes 1p, 11q, and 14q have been reported in neuroblastoma, it is still unclear whether or not LOH occurs specifically on these chromosome arms in neuroblastoma since only a few chromosomal arms have been examined for LOH in previous studies. Therefore, we screened 81 cases of tumors for LOH on all 22 autosomes and chromosome X using 35 restriction fragment length polymorphism markers and eight microsatellite markers. High incidence of LOH (>20%) was observed on six chromosome arms; 1p (26%), 2q (30%), 9p (36%), 11q (24%), 14q (22%), and 18q (31%), Frequencies of LOH on other chromosome arms were less than 13%. Patients with 9p LOH in the tumors showed statistically significant association with advanced stage of the disease and poor prognosis (P=0.037 and P=0.003, respectively) independently from N-myc amplification, while LOH on other chromosomes did not show association with stage, prognosis, and N-myc amplification. Thus, besides LOH on chromosomes 1p, 11q, and 14q, LOH on chromosomes 2q, 9p, and 18q also occurs relatively frequently in neuroblastoma, indicating the involvement of multiple tumor suppressor genes in the development of neuroblastoma. It is possible that there is a novel tumor suppressor gene on chromosome 9p which is involved in the progression of neuroblastoma.	NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; NATL CANC CTR,RES INST,DIV CANC INFORMAT & EPIDEMIOL,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,FAC MED,DEPT PEDIAT,BUNKYO KU,TOKYO 113,JAPAN; SAITAMA CHILDRENS MED CTR,DIV HEMATOL ONCOL,IWATSUKI,SAITAMA 339,JAPAN	National Cancer Center - Japan; National Cancer Center - Japan; University of Tokyo; Saitama Children's Medical Center								BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; IMAMURA J, 1993, CANCER RES, V53, P4053; JEN J, 1995, CANCER RES, V54, P6353; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOHNO T, 1994, ONCOGENE, V9, P103; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Maniatis T., 1982, MOL CLONING; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NAKAMURA T, 1991, JPN J CLIN ONCOL, V21, P325; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; TONINI GP, 1993, EUR J CANCER, V29A, P802, DOI 10.1016/S0959-8049(05)80412-5; TSUDA T, 1987, CANCER, V60, P820, DOI 10.1002/1097-0142(19870815)60:4<820::AID-CNCR2820600418>3.0.CO;2-Y; VOGAN K, 1993, CANCER RES, V53, P5269; WEINBERG RA, 1991, SCIENCE, V254, P138	35	90	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1829	1834						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478611				2022-12-25	WOS:A1995TD09400018
J	QUANG, CT; PIRONIN, M; VONLINDERN, M; BEUG, H; GHYSDAEL, J				QUANG, CT; PIRONIN, M; VONLINDERN, M; BEUG, H; GHYSDAEL, J			SPI-1 AND MUTANT P53 REGULATE DIFFERENT ASPECTS OF THE PROLIFERATION AND DIFFERENTIATION CONTROL OF PRIMARY ERYTHROID PROGENITORS	ONCOGENE			English	Article						LEUKEMIA; SPI-1; ETS PROTEINS; P53; ERYTHROID PROGENITORS	WILD-TYPE P53; VIRUS-INDUCED ERYTHROLEUKEMIA; AVIAN ERYTHROBLASTOSIS VIRUS; RAT EMBRYO FIBROBLASTS; GROWTH-FACTOR RECEPTOR; SEA ONCOGENE PRODUCT; ETS DOMAIN PROTEIN; V-ERBA; FRIEND-VIRUS; TRANSCRIPTIONAL ACTIVATION	The emergence of leukemic cells in Friend virus complex-induced erythroleukemia is associated with two recurrent genetic alterations, namely the inactivation of the p53 tumor suppressor gene and the overexpression of Spi-1, a member of the Ets family of transcriptional regulators. In order to determine the role of these genetic alterations on the proliferation and differentiation control of erythroblasts, we expressed Spi-1 and the temperature sensitive mutant p53(V135A) in avian primary erythroid progenitors. We show that enforced expression of Spi-1 in erythroblasts obtained from bone marrow cells by expression of the ts-Sea tyrosine kinase inhibits the execution of the differentiation program normally induced in these cells in response to Epo and insulin and following inactivation of ts-Sea function. In contrast, overexpression of p53(V135A) is without effect on the ability of these cells to differentiate into erythrocytes. However, expression of p53(V135A) in erythroid progenitors obtained from bone marrow cells in the presence of SCF, TGF alpha and estradiol, was found to relieve these cells from their absolute TGF alpha requirement for long term proliferation. This phenotype is dependent upon the expression of the mutant form of p53(V135A) as it is not observed at a temperature at which p53(V135A) regains wild type p53 function. Our results show that each of the genetic alterations which characterize Friend erythroleukemic cells affect in a distinct manner the proliferation and differentiation control of primary erythroid progenitors.	CTR UNIV ORSAY,INST CURIE,ONCOL VIRALE & CELLULAIRE LAB,CNRS,UMR 146,F-91405 ORSAY,FRANCE; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			QUANG, christine TRAN/G-7508-2016; von Lindern, Marieke/AAH-2350-2020; GHYSDAEL, Jacques/F-3377-2013					Andrews N C, 1994, Curr Opin Hematol, V1, P119; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BEUG H, 1992, NUCLEAR PROCESSES ON, P53; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELIYAHU D, 1988, ONCOGENE, V3, P313; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; FUHRMANN U, 1989, GENE DEV, V3, P2072, DOI 10.1101/gad.3.12b.2072; GANDRILLON O, 1994, ONCOGENE, V9, P749; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1992, CANCER SURV, V14, P169; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1988, ONCOGENE, V2, P317; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; Kowenz E, 1987, Haematol Blood Transfus, V31, P199; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEACOCK JW, 1990, ONCOGENE, V5, P1769; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROVINSKI B, 1988, ONCOGENE, V2, P445; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; WILLIAMS BP, 1988, ONCOGENE, V3, P345; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	80	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1229	1239						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478542				2022-12-25	WOS:A1995RY96700002
